Clinical trial NCT04936035
Conditions: Hypertension
Keywords: High blood pressure Hypertension Hypertensive siRNA Angiotensinogen AGT
Sponsor: Alnylam Pharmaceuticals
Start date: 2021-07-07; Completion date: 2024-12-05
Enrollment: 394 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.

Detailed description:
Participants will receive ALN-AGT01 or placebo for the first 6 months of the 12-month double-blind (DB) treatment period. Participants randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial ALN-AGT01 regimens until the end of the 12-month DB treatment period. Participants randomized to ALN-AGT01 regimens will remain on their originally assigned regimens through remainder of the study.

Arms: arm 1: Participants received zilebesiran matching placebo, subcutaneous (SC) injection, once every 3 months (Q3M), with re-randomization at Month 6 to 1 of the initial 4 zilebesiran regimens. Participants will continue their respective zilebesiran regimen up to Month 12 in the DB period and up to 24 additional months in the DB Extension period. Upon implementation of Amendment 6, the DB Extension period was closed. arm 2: Participants receive zilebesiran, 150 mg, SC injection, Q6M, during the 12-month DB period. Participants will continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Participants in this arm will receive a placebo during those dosing visits when they do not receive zilebesiran to maintain the blind. Upon implementation of Amendment 6, the DB Extension period was closed. arm 3: Participants receive zilebesiran, 300 mg, SC injection, Q6M, during the 12-month DB period. Participants will continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Participants in this arm will receive a placebo during those dosing visits when they do not receive zilebesiran to maintain the blind. Upon implementation of Amendment 6, the DB Extension period was closed. arm 4: Participants receive zilebesiran, 300 mg, SC injection, Q3M, during the 12-month DB period. Participants continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Upon implementation of Amendment 6, the DB Extension period was closed. arm 5: Participants receive zilebesiran, 600 mg, SC injection, Q6M, during the 12-month DB period. Participants will continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Participants in this arm will receive a placebo during those dosing visits when they do not receive zilebesiran to maintain the blind. Upon implementation of Amendment 6, the DB Extension period was closed.
Interventions: intervention 1: Placebo intervention 2: ALN-AGT01
Intervention descriptions: intervention 1: Placebo administered by SC injection intervention 2: ALN-AGT01 administered by SC injection

Protocol documents:
Prot_000.pdf: 
 
 
Official Title:  A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study 
to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients with Mild-to-Moderate 
Hypertension 
 
NCT Number:   
NCT04936035 
 
Document Date:   
Protocol , Version 6.0, 20 July 23  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
1 
 
CLINICAL STUDY PROTOCOL 
ALN-AGT01-002 
DATED 20 JULY 2023 
 
Protocol Title:  
A Randomized, Double-blind, Placebo-Controlled, 
Dose-Ranging Multicenter Study to Evaluate the 
Efficacy and Safety of ALN-AGT01 in Patients 
with Mild-to-Moderate Hypertension 
Short Title: 
A Study to Evaluate Efficacy and Safety of 
ALN-AGT01 in Patients with Mild-to-Moderate 
Hypertension (KARDIA-1) 
Study Drug: 
ALN-AGT01 (zilebesiran) 
EudraCT Number: 
2021-001248-82 
IND Number: 
143503 
Protocol Date: 
Original protocol, 09 April 2021 
Amendment 1, 20 April 2021 
Amendment 2, 09 June 2021 
Amendment 3, 09 December 2021 
Amendment 4, 22 March 2022 
Amendment 5, 04 November 2022 
Amendment 6, 20 July 2023 
Sponsor: 
Alnylam Pharmaceuticals, Inc. 
300 Third Street 
Cambridge, MA  02142 USA 
Telephone: +1-617-551-8200 
Sponsor Contact: 
 
 
The concepts and information contained in this document or generated during the study are considered 
proprietary and may not be disclosed in whole or in part without expressed written authorization of 
Alnylam Pharmaceuticals, Inc. 
 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
2 
SPONSOR PROTOCOL APPROVAL 
 
I have read this protocol and I approve the design of this study. 
 
 
 
___________________________________________  
 
 
Alnylam Pharmaceuticals, Inc. 
 
___________________________________________  
Date 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
3 
INVESTIGATOR’S AGREEMENT 
 
I have read the ALN-AGT01-002 protocol and agree to conduct the study in accordance with the 
protocol and all applicable regulations. I agree to maintain the confidentiality of all information 
received or developed in connection with this protocol. 
 
 
 
___________________________________________  
Printed Name of Investigator 
 
 
 
___________________________________________  
Signature of Investigator 
 
 
 
___________________________________________  
Date 






Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
6 
Study Design 
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study 
designed to evaluate the safety, efficacy, and pharmacodynamics (PD) of ALN-AGT01, 
administered subcutaneously (SC), in patients with mild-to-moderate hypertension. A schematic 
of the study design is provided in Figure 1. Before randomization, patients will discontinue prior 
antihypertensive medications (if taking) for a Washout period of at least 2 weeks (4 weeks of 
washout is required for long-acting antihypertensive medications, such as long-acting diuretics or 
calcium channel blockers). Patients who complete the Screening period and meet all 
inclusion/exclusion criteria for enrollment will receive ALN-AGT01 or placebo for the first 
6 months of the 12-month Double-blind (DB) treatment period.  
Starting at Month 3, conventional oral antihypertensives may be added per Investigator 
judgement for elevated blood pressure. Oral antihypertensives (if taking) will be temporarily 
held from Month 5 to Month 6 to assess the effect of ALN-AGT01 alone (vs placebo) at Month 6 
by ambulatory blood pressure monitoring (ABPM). During this 4-week period, blood pressure 
will be carefully monitored by home blood pressure monitoring and medications restarted if 
indicated. Patients may resume conventional oral antihypertensives at Month 6 per Investigator 
judgement. 
Patients randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial 
ALN-AGT01 regimens until the end of the DB period. Patients randomized to ALN-AGT01 
regimens will remain on their originally assigned regimens through Month 12. 
After the 12-month DB treatment period, patients may have been eligible to participate in an 
ALN-AGT01 open-label extension (OLE) study. If an individual patient reached Month 12 prior 
to availability of the OLE study, they may have continued their current blinded dosing in the DB 
Extension period for up to 24 additional months until the OLE study was open and then 
transition. Upon implementation of Amendment 6, the DB Extension period will be closed 
because a separate OLE study will not be conducted. Patients in the 12-month DB period will 
continue their planned dosing and assessments through the end of the 12-month DB period and 
then enter the Safety Follow-up period. Patients will not receive a dose of study drug at Month 
12. Patients in the DB Extension period will complete end of treatment (EOT) assessments at 
Month 18, 24, 30, or 36 (whichever visit comes first) and enter the Safety Follow-up period. 
Number of Planned Patients 
Approximately 375 patients will be enrolled in this study. 
Diagnosis and Main Eligibility Criteria 
This study will include adults (18 to 75 years, inclusive, at time of initial informed consent) with 
untreated hypertension or on stable therapy with up to 2 antihypertensive medications. Patients 
should have a daytime mean systolic blood pressure (SBP) ≥135 mmHg and ≤160 mmHg by 
ABPM after washout of background antihypertensive medication. Patients with secondary 
hypertension or orthostatic hypotension will be excluded. 
Study Drug, Dose, and Mode of Administration 
ALN-AGT01 is an SC administered N-acetylgalactosamine-conjugated small interfering RNA 
targeting liver-expressed messenger RNA for angiotensinogen (AGT). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
7 
Patients randomized to receive ALN-AGT01 will be administered 150 mg ALN-AGT01 SC once 
every 6 months, 300 mg ALN-AGT01 SC once every 6 months, 300 mg ALN-AGT01 SC once 
every 3 months, or 600 mg ALN-AGT01 SC once every 6 months during the 12-month DB 
period. Patients randomized to receive placebo will be randomized to 1 of the 4 initial dose 
regimens of ALN-AGT01 beginning at Month 6. 
Before Amendment 6, patients who entered the DB Extension period continued their current 
blinded dosing regimen from the 12-month DB period. Upon implementation of Amendment 6, 
the DB Extension period will be closed because a separate OLE study will not be conducted. 
Patients in the 12-month DB period will continue their planned dosing and assessments through 
the end of the 12-month DB period and then enter the Safety Follow-up period. Patients will not 
receive a dose of study drug at Month 12. For patients in the DB Extension period, patients will 
receive their last dose of study drug if their next visit is at Month 15, 21, 27, or 33 (whichever 
comes first). Patients will not receive study drug at other visits in the DB Extension period. 
Reference Treatment, Dose, and Mode of Administration 
Placebo (sodium chloride 0.9% w/v for SC administration) will be administered once every 3 
months and at the same volume as the study drug. Patients receiving once every 6 months 
ALN-AGT01 regimens will receive placebo SC at dosing visits at which they do not receive 
ALN-AGT01 to maintain the blind. 
Duration of Treatment and Study Participation 
The duration of treatment with ALN-AGT01 is up to 36 months. The estimated total time on 
study for each patient is up to 47 months, including up to 2 months of screening, followed by up 
to 36 months of treatment, and up to 12 months in the Follow-up period. 
Statistical Methods 
The planned enrollment for this study is 375 patients. Randomization will be stratified by race 
(black vs all other races) and by baseline blood pressure (mean 24-hour SBP < or ≥145 mmHg). 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline at Month 
3 in 24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 
375 patients (75 per treatment group) provides at least 84% power to detect a dose response 
signal in SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided significance 
level of 0.05. In addition, this sample size provides at least 80% power to detect a 10 mmHg 
difference between an individual ALN-AGT01 dose versus placebo with a 2-sided significance 
level of 0.05.  
The populations (analysis sets) are defined as follows:  
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• Pharmacokinetic (PK) Analysis Set: All patients who received at least 1 full dose of 
ALN-AGT01 and have at least 1 nonmissing postdose PK assessment. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
8 
• PD Analysis Set: All patients who received at least 1 full dose of study drug. All by-
treatment analyses based on the PD Analysis Set will be grouped according to the 
treatment actually received. 
• All ALN-AGT01 Treated Set: All patients who received any amount of 1 of the 4 
ALN-AGT01 dosing regimens, including patients who took ALN-AGT01 during the 
6-month placebo-controlled period and patients who initially took placebo and then 
switched to ALN-AGT01 after the Month 6 visit. 
For the primary analysis for the 6-month placebo-controlled DB period, the primary population 
used to evaluate efficacy will be the FAS. Safety will be analyzed using the Safety Analysis Set. 
The PK and PD Analysis Sets will be used to conduct PK and PD analyses, respectively. 
The All ALN-AGT01 Treated Set will be used to summarize the efficacy and safety of 
ALN-AGT01 throughout the entire DB period (including DB Extension period). 
To control the overall type I error, the primary and key secondary endpoints will be tested in 
hierarchical order. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
9 
Figure 1: 
Study Design 
 
Abbreviations: aHTN=antihypertensive medications; DB=double-blind; EOT=end of treatment; M=month; 
OLE=open-label extension; PBO=placebo; PO=per os (oral); Q3M=once every 3 months; Q6M=once every 6 
months; R=randomization; SC=subcutaneous; WO=washout. 
Note: Patients may have been eligible to participate in an ALN-AGT01 OLE study upon completion of the 
Month 12 predose assessments. If an individual patient reached Month 12 prior to availability of the OLE study, 
they may have continued their current blinded dosing in the DB Extension period for up to 24 additional months 
until the OLE study was open and then transition. Upon implementation of Amendment 6, the DB Extension period 
will be closed because a separate OLE study will not be conducted. Patients in the 12-month DB period will 
continue their planned dosing and assessments through the end of the 12-month DB period and then enter the Safety 
Follow-up period. Patients will not receive a dose of study drug at Month 12. Patients in the DB Extension period 
will complete all scheduled assessments and receive their planned dose of study drug if their next visit is at 
Month 15, 21, 27, or 33 and return to complete EOT assessments at their next scheduled visit (Month 18, 24, 30, or 
36) and then enter the Safety Follow-up period. If the next visit is Month 18, 24, 30, or 36, patients should complete 
EOT assessments and enter the Safety Follow-up period. Patients will not receive a dose of study drug at Month 18, 
24, 30, or 36. 
Note: Patients who were previously taking antihypertensives at screening should undergo a washout of these 
medications for at least 2 weeks during the Screening period (4 weeks of washout is required for long-acting 
antihypertensive medications, such as long-acting diuretics or calcium channel blockers). 
 










Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
14 
• 
Patients will be asked to perform Safety Follow-up visits q6M after the last dose of study drug as described in Section 3.1. During this Follow-up 
period, HBPM monitoring may continue at the discretion of the Investigator.  
• 
Patients who discontinue study drug prior to the Month 6 visit will be asked to complete the remainder of scheduled study visits and assessments (except 
for study drug administration) through Month 6. If a patient discontinues study drug after the Month 6 visit, EOT/ET assessments should be performed. 
See Section 4.3.1 for instructions for patients who discontinue study drug.  
Footnotes: 
a All assessments, except for postdose PK sample collection, are to be performed prior to dosing at dosing visits.  
b When applicable, pregnancy test results must be known prior to dosing.  
c Clinical laboratory assessments and blood pressure measurements taken for eligibility must be performed after at least 2 weeks of washout (4 weeks of washout 
is required for long-acting antihypertensive medications, such as long-acting diuretics or calcium channel blockers). 
d Office blood pressure must be measured before the patient takes oral antihypertensive medications.  
e ABPM recordings associated with dosing visits must be obtained within 2 weeks prior to randomization and within 7 days before dosing visits after Day 1 and 
results reviewed before dosing.  
f HBPM should be measured at least once per week in the morning upon waking. HBPM may be measured more frequently in some patients, per Investigator 
discretion, if more frequent measurement is warranted (eg, during screening if patients are undergoing washout and between Months 5 and 6 if oral 
antihypertensives are temporarily held). HBPM is not required at times when ABPM is being assessed. 
g ABPM and collection of RAAS biomarkers should only be performed as part of ET assessments if the patient discontinues the study prior to Month 12, and 
ABPM should only be performed at ET if the patient has not had an ABPM within the last 3 months. These assessments should not be performed at Month 36. 
h Fasting plasma laboratory samples should only be collected at Month 18. 
i The ADA sample should only be collected at the first Follow-up visit during the Follow-up period. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
15 
Table 2: 
PK Time Points 
Study Day 
Sampling Time 
(hh:mm) 
Plasma PK Sample 
Day 1  
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Day 169±7 
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Abbreviations: hh:mm=hour:minute; PK=pharmacokinetics. 
Notes:  
• 
The hour (±range) indicates sample collection timing relative to dosing. Precise PK sample times (hour and 
minute) are recorded. Refer to Section 6.4 for additional information on PK assessments. 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
16 
TABLE OF CONTENTS 
SPONSOR PROTOCOL APPROVAL ...........................................................................................2 
INVESTIGATOR’S AGREEMENT ...............................................................................................3 
PROTOCOL SYNOPSIS ................................................................................................................4 
TABLE OF CONTENTS ...............................................................................................................16 
LIST OF TABLES .........................................................................................................................20 
LIST OF FIGURES .......................................................................................................................20 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ................................................21 
1. 
INTRODUCTION ......................................................................................................23 
1.1. 
Study Rationale ...........................................................................................................23 
1.2. 
Background .................................................................................................................23 
1.3. 
Benefit-Risk Assessment ............................................................................................24 
2. 
OBJECTIVES AND ENDPOINTS ............................................................................25 
3. 
INVESTIGATIONAL PLAN .....................................................................................27 
3.1. 
Summary of Study Design ..........................................................................................27 
3.2. 
Scientific Rationale for Study Design ........................................................................29 
3.3. 
Justification for Dose ..................................................................................................30 
3.4. 
Method of Assigning Patients to Treatment Groups ..................................................31 
3.5. 
Blinding ......................................................................................................................32 
3.5.1. 
Emergency Unblinding ...............................................................................................32 
3.6. 
Data Monitoring Committee .......................................................................................32 
3.7. 
Clinical Event Adjudication Committees ...................................................................33 
3.8. 
Definition of End of Study for an Individual Patient .................................................33 
4. 
SELECTION AND REMOVAL OF PATIENTS ......................................................33 
4.1. 
Inclusion Criteria ........................................................................................................33 
4.2. 
Exclusion Criteria .......................................................................................................33 
4.3. 
Removal from Study Drug or Assessment .................................................................36 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments ......................36 
4.3.2. 
Stopping a Patient’s Study Participation ....................................................................37 
4.3.2.1. 
Patient Stops Participation in the Study ......................................................................37 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection 
to Process Patient’s Personal Data ..............................................................................38 
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study ........................38 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
17 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation ................................38 
4.3.3. 
Lost to Follow-Up.......................................................................................................39 
4.3.4. 
Replacement of Study Patients ...................................................................................39 
5. 
TREATMENTS AND OTHER REQUIREMENTS ..................................................39 
5.1. 
Treatments Administered ............................................................................................39 
5.2. 
Study Drug ..................................................................................................................39 
5.2.1. 
Description ..................................................................................................................39 
5.2.2. 
Dose and Administration ............................................................................................40 
5.2.3. 
Dose Modifications .....................................................................................................40 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping 
Study Drug Dosing .....................................................................................................41 
5.2.5. 
Neurological Criteria for Withholding, Monitoring, and Stopping Study 
Drug Dosing ................................................................................................................42 
5.2.6. 
Preparation, Handling, and Storage ............................................................................42 
5.2.7. 
Packaging and Labeling ..............................................................................................43 
5.2.8. 
Accountability .............................................................................................................43 
5.3. 
Clinical Product Complaints .......................................................................................43 
5.3.1. 
Definition ....................................................................................................................43 
5.3.2. 
Reporting ....................................................................................................................43 
5.4. 
Monitoring for Potential Clinical Events ....................................................................43 
5.4.1. 
Monitoring and Approach for Potential Hypotension ................................................43 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure 
Elevation .....................................................................................................................44 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction .......................................46 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia ..............................................47 
5.5. 
Concomitant Medications and Procedures .................................................................48 
5.5.1. 
Oral Antihypertensive Medication .............................................................................48 
5.5.2. 
Prohibited Concomitant Medication ...........................................................................49 
5.6. 
Treatment Compliance ................................................................................................49 
5.7. 
Other Requirements ....................................................................................................49 
5.7.1. 
Contraception ..............................................................................................................49 
5.7.2. 
Alcohol Restrictions ...................................................................................................50 
5.7.3. 
Tobacco and Nicotine Restrictions .............................................................................50 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
18 
5.7.4. 
Dietary Recommendations ..........................................................................................51 
5.7.5. 
Exercise .......................................................................................................................51 
6. 
STUDY ASSESSMENTS ..........................................................................................51 
6.1. 
Screening Assessments ...............................................................................................51 
6.1.1. 
Retesting .....................................................................................................................52 
6.1.2. 
Rescreening .................................................................................................................52 
6.2. 
Efficacy Assessments .................................................................................................52 
6.2.1. 
ABPM .........................................................................................................................52 
6.2.2. 
Office Blood Pressure .................................................................................................53 
6.2.3. 
HBPM .........................................................................................................................53 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment ....................................................53 
6.3. 
Pharmacodynamic Assessments .................................................................................53 
6.4. 
Pharmacokinetic Assessments ....................................................................................54 
6.5. 
Safety Assessments .....................................................................................................54 
6.5.1. 
Vital Signs ..................................................................................................................54 
6.5.2. 
Weight, Height, and Morphometrics ..........................................................................54 
6.5.3. 
Physical Examination .................................................................................................55 
6.5.4. 
Electrocardiogram .......................................................................................................55 
6.5.5. 
Clinical Laboratory Assessments ...............................................................................56 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments ........................................................58 
6.5.5.2. 
Immunogenicity ..........................................................................................................58 
6.5.5.3. 
Pregnancy Testing ......................................................................................................58 
6.5.5.4. 
Additional Liver Function Assessments .....................................................................58 
6.5.6. 
Adverse Events ...........................................................................................................59 
6.5.6.1. 
Definitions ..................................................................................................................59 
6.5.6.2. 
Eliciting and Recording Adverse Events ....................................................................61 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee .........................62 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee ...........62 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities .................................................62 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee ........................................................................63 
6.5.6.7. 
Pregnancy Reporting ..................................................................................................63 
6.5.6.8. 
Overdose and Other Special Situations Reporting .....................................................63 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
19 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository ...................................63 
7. 
STATISTICS ..............................................................................................................64 
7.1. 
Determination of Sample Size ....................................................................................64 
7.2. 
Statistical Methodology ..............................................................................................65 
7.2.1. 
Populations to be Analyzed ........................................................................................65 
7.2.2. 
Examination of Subgroups .........................................................................................65 
7.2.3. 
Handling of Missing Data ...........................................................................................65 
7.2.4. 
Baseline Evaluations ...................................................................................................65 
7.2.5. 
Efficacy Analyses .......................................................................................................66 
7.2.6. 
Pharmacodynamic Analysis........................................................................................66 
7.2.7. 
Pharmacokinetic Analysis ..........................................................................................66 
7.2.8. 
Safety Analyses ..........................................................................................................67 
7.2.9. 
Immunogenicity Analyses ..........................................................................................67 
7.2.10. 
Interim Analysis ..........................................................................................................67 
7.2.11. 
Optional Additional Research .....................................................................................67 
8. 
STUDY ADMINISTRATION ...................................................................................67 
8.1. 
Ethical and Regulatory Considerations ......................................................................67 
8.1.1. 
Informed Consent .......................................................................................................68 
8.1.2. 
Ethical Review ............................................................................................................68 
8.1.3. 
Serious Breach of Protocol .........................................................................................69 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention .................................69 
8.1.5. 
End of Study ...............................................................................................................69 
8.1.6. 
Termination of the Clinical Study or Site Closure .....................................................69 
8.2. 
Data Quality Control and Quality Assurance .............................................................70 
8.2.1. 
Data Handling .............................................................................................................70 
8.2.2. 
Study Monitoring ........................................................................................................70 
8.2.3. 
Audits and Inspections ................................................................................................70 
8.3. 
Publication Policy .......................................................................................................71 
9. 
LIST OF REFERENCES ............................................................................................72 
10. 
APPENDICES ............................................................................................................74 
10.1. 
Measurement of Blood Pressure .................................................................................74 
10.2. 
Procedures for Optional Home Healthcare Visits ......................................................76 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
20 
LIST OF TABLES 
Table 1: 
Schedule of Assessments ............................................................................................10 
Table 2: 
PK Time Points ...........................................................................................................15 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative 
Cause Identified ..........................................................................................................41 
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation ......................................................................................................45 
Table 5: 
Recommended Interventions for Hyperkalemia .........................................................47 
Table 6: 
Clinical Laboratory Assessments ...............................................................................57 
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases .............59 
 
LIST OF FIGURES 
Figure 1: 
Study Design .................................................................................................................9 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
21 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation  
Definition 
ABPM 
Ambulatory blood pressure monitoring 
ACE 
Angiotensin converting enzyme 
ADA 
Anti-drug antibody(ies) 
AE 
Adverse event 
AGT 
Angiotensinogen 
ALT 
Alanine aminotransferase 
AngI/II 
Angiotensin I/II 
ARB 
Angiotensin II-receptor blocker 
AST 
Aspartate aminotransferase 
CCB 
Calcium channel blocker 
CPC 
Clinical product complaint 
DB 
Double-blind 
DBP 
Diastolic blood pressure 
DMC 
Data Monitoring Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eGFR 
Estimated glomerular filtration rate 
EOT 
End of treatment 
ET 
Early termination 
FAS 
Full analysis set 
GalNAc 
N-acetylgalactosamine 
GCP 
Good Clinical Practice 
HbA1c 
Hemoglobin A1c 
HBPM 
Home blood pressure monitoring 
HCV 
Hepatitis C virus 
HDL-C 
High-density lipoprotein 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use 
IEC 
Independent Ethics Committee 
INR 
International normalized ratio 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
22 
Abbreviation  
Definition 
IRB 
Institutional Review Board 
IRT 
Interactive Response Technology 
ISR 
Injection site reaction 
LFT 
Liver function test 
MAO 
Monoamine oxidase 
MMRM 
Mixed model for repeated measurements 
mRNA 
Messenger RNA 
NSAID 
Nonsteroidal anti-inflammatory drug 
OLE 
Open-label extension 
PD 
Pharmacodynamic(s) 
PK 
Pharmacokinetic(s) 
PT 
Preferred term 
q3M 
Once every 3 months 
q6M 
Once every 6 months 
RAAS 
Renin-angiotensin-aldosterone system 
RNAi 
RNA interference 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SBP 
Systolic blood pressure 
SC 
Subcutaneous(ly) 
siRNA 
Small interfering RNA 
SGLT2 
Sodium-glucose co-transporter 2 
SOC 
System Organ Class 
ULN 
Upper limit of normal 
ZS-9 
Sodium zirconium cyclosilicate 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
23 
1. 
INTRODUCTION 
Alnylam Pharmaceuticals, Inc. (the Sponsor) is developing ALN-AGT01 (zilebesiran), a 
subcutaneously (SC) administered investigational agent comprised of a synthetic small 
interfering (siRNA) covalently linked to a triantennary N-acetylgalactosamine (GalNAc) ligand, 
which is designed to suppress liver production of angiotensinogen (AGT) and thereby reduce 
blood pressure in individuals with hypertension.  
1.1. 
Study Rationale 
Study ALN-AGT01-002 (KARDIA-1) is a randomized, double-blind, placebo-controlled, dose-
ranging, multicenter Phase 2 study designed to evaluate the safety, efficacy, and 
pharmacodynamics (PD) of ALN-AGT01, administered SC, in patients with mild-to-moderate 
hypertension. Patients will be randomized to 1 of 4 ALN-AGT01 treatment regimens or placebo 
for the first 6 months of the 12-month Double-blind (DB) period. After the first 6 months of the 
DB period, patients from the placebo arm will be re-randomized to 1 of the 4 initial 
ALN-AGT01 regimens for the remaining 6 months of the DB period, while patients randomized 
to ALN-AGT01 will remain on their originally assigned regimens. After completion of the 
12-month DB period, patients may have been eligible to participate in an ALN-AGT01 
open-label extension (OLE) study. If an individual patient reached Month 12 prior to availability 
of the OLE study, they may have continued their current blinded dosing in the DB Extension 
period for up to 24 additional months until the OLE study was open and then transition. Upon 
implementation of Amendment 6, the DB Extension period will be closed because a separate 
OLE study will not be conducted. Patients in the 12-month DB period will continue their planned 
dosing and assessments through the end of the 12-month DB period and then enter the Safety 
Follow-up period. Patients in the DB Extension period will complete end of treatment (EOT) 
assessments at Month 18, 24, 30, or 36 (whichever visit comes first) and enter the Safety Follow-
up period. 
The primary objective of the study is to evaluate the efficacy of ALN-AGT01 for the treatment 
of hypertension by evaluating the impact on systolic blood pressure (SBP) from baseline to 
Month 3, as assessed by ambulatory blood pressure monitoring (ABPM). Secondary and 
exploratory objectives of the study include evaluating the efficacy of ALN-AGT01 on other 
measures of blood pressure response and evaluating the PD effect of ALN-AGT01, including 
reduction in circulating AGT concentration. 
The full rationale for the study and design is presented in Section 3.2. 
1.2. 
Background 
Hypertension affects 30% to 45% of adults and is the strongest modifiable risk factor for 
cardiovascular disease, primarily strokes and myocardial infarction.[Olsen 2016; Williams 2018] 
The worldwide disease burden is profound, with a global prevalence of over 1 billion,[Kearney 
2005; NCD Risk Factor Collaboration 2017] and approximately 9 million deaths attributed to 
hypertension annually.[Angell 2015] 
Currently available pharmacologic therapies achieve target blood pressure in only a minority of 
patients, due in large part to physician inertia and patient nonadherence to daily oral 
medication.[Whelton 2018; Williams 2018] Low adherence to oral antihypertensives is 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
24 
associated with poor cardiovascular outcomes and is prevalent at all stages of disease.[Corrao 
2011; Peacock 2017; Schulz 2016; van der Laan 2017] Thus, despite the availability of multiple 
efficacious agents, current rates of control are low, and the global burden of death and disability-
adjusted life-years attributed to elevated blood pressure remains high.[Forouzanfar 2017; 
Muntner 2020] Development of new approaches to treat hypertension and to overcome the 
limitations of current therapies is a key unmet need.[Dzau 2019; McClellan 2019; Services 2020] 
The Sponsor is developing ALN-AGT01, a novel synthetic RNA interference (RNAi) 
therapeutic, for SC administration for the treatment of hypertension. RNAi is a naturally 
occurring cellular mechanism for regulation of gene expression, mediated through the binding of 
siRNA to its complementary messenger RNA (mRNA) sequence, leading to mRNA cleavage 
and subsequent suppression of the synthesis and levels of the target protein. ALN-AGT01 
contains an siRNA targeting AGT mRNA, conjugated to a GalNAc-containing ligand to facilitate 
delivery to the liver. Based on the mechanism of RNAi, ALN-AGT01 is specifically designed to 
reduce the hepatic synthesis of AGT protein, the first substrate in the renin-angiotensin-
aldosterone system (RAAS) and the sole precursor of vasoactive angiotensin peptides.[Khanna 
2017; Romero 2015] Because hepatocytes are the predominant source of circulating AGT, 
ALN-AGT01 has been developed to reduce blood pressure by decreasing circulating AGT levels 
and the downstream effects of angiotensin II (AngII). 
Preliminary data from Part A of the ongoing Phase 1 Study ALN-AGT01-001 (hereafter referred 
to as Study 001) in patients with hypertension have shown that single SC doses of ALN-AGT01 
lead to dose-dependent and durable reductions in circulating AGT, accompanied by clinically 
significant reductions in SBP and diastolic blood pressure (DBP). Reductions in AGT for up to 
6 months postdose were observed in the study.  
Most adverse events (AEs) have been mild or moderate in severity, and there have been no 
severe or serious adverse events (SAEs) related to study drug. There have been no clinically 
significant elevations in serum creatinine or serum potassium, and no patient has required 
intervention for low blood pressure. No clinically significant alanine aminotransferase (ALT) 
elevations have been observed in Part A patients who received ALN-AGT01 doses as high as 
800 mg. Injection site reactions (ISRs) were reported in a minority of patients and were all mild 
and transient events that resolved without intervention. 
This Phase 2 study will further quantify the antihypertensive effects of ALN-AGT01 across a 
range of doses (150 to 600 mg) and dose intervals (once every 3 months and once every 6 
months) to identify optimal treatment. The consistent and prolonged PD effect of ALN-AGT01 
is expected to achieve the unique benefit of continuous 24-hour blood pressure lowering with 
infrequent SC dosing.  
A detailed description of the chemistry, pharmacology, efficacy, and safety of ALN-AGT01 is 
provided in the Investigator’s Brochure. 
1.3. 
Benefit-Risk Assessment 
Clinical data available from Study 001 indicate that ALN-AGT01 may offer the benefit of blood 
pressure reduction to patients with hypertension. The mean SBP reduction observed after single 
ALN-AGT01 doses of 100 mg or higher exceeds 10 mmHg, which is comparable to the effect of 








Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
28 
monitoring [HBPM] SBP <135 mmHg, or daytime mean SBP <135 mmHg by 
ABPM).[Williams 2018] Oral antihypertensives (if taking) will be temporarily held from Month 
5 to Month 6 in appropriate patients (Month 5 office SBP <155 mmHg if taking 1 oral 
antihypertensive agent or office SBP <150 mmHg if taking 2 agents) to assess the effect of 
ALN-AGT01 alone (vs placebo) at Month 6 by ABPM. During this 4-week period, blood 
pressure will be carefully monitored by HBPM and oral antihypertensive medications restarted if 
confirmed office SBP >170 mmHg (or if confirmed office SBP >160 mmHg accompanied by 
symptoms). 
Patients may have been eligible to participate in a separate ALN-AGT01 OLE study upon 
completion of the Month 12 predose assessments. If an individual patient reached Month 12 
prior to availability of the OLE study, they may have continued their current blinded dosing in 
the DB Extension period for up to 24 additional months until the OLE study was open and then 
transition.  
In the DB Extension period, blood pressure will be closely monitored and individual 
modification of antihypertensive therapy will be allowed to maintain blood pressure in target 
range.  
Upon implementation of Amendment 6, the DB Extension period will be closed because a 
separate OLE study will not be conducted. Patients in the 12-month DB period will continue 
dosing and assessments as scheduled through Month 12. Upon completion of predose 
assessments at the Month 12 visit, patients will enter the Safety Follow-up period. Patients will 
not receive a dose of study drug at the Month 12 visit. For patients in the DB Extension period: 
• If the next visit upon implementation of Amendment 6 is Month 15, 21, 27, or 33, the 
patient should complete the scheduled assessments and receive the planned dose of 
study drug. Patients should return for their next scheduled visit (Month 18, 24, 30, or 
36) to complete EOT assessments and enter the Safety Follow-up period. Patients will 
not receive a dose of study drug at the Month 18, 24, 30, or 36 visit. 
• If the next visit upon implementation of Amendment 6 is Month 18, 24, 30, or 36, the 
patient should complete EOT assessments and enter the Safety Follow-up period. 
Patients will not receive a dose of study drug at the Month 18, 24, 30, or 36 visit. 
Patients will be considered as completing study drug if they received all planned doses during 
the 12-month DB period (Day 1 and Months 3, 6, and 9) and completed the Month 12 visit. 
Safety Follow-up Period 
Patients will be asked to complete Safety Follow-up visits once every 6 months after their last 
dose of study drug until serum AGT levels return to ≥50% of their individual mean baseline level 
(if known) or until 12 months after their last dose of study drug, whichever comes earlier. During 
the Safety Follow-up period, patients should return to their pre-study medical care (usual care). 
Patients who discontinue study drug prior to the Month 6 visit will be asked to complete the 
remainder of scheduled study visits and assessments (except for study drug administration) 
through Month 6. If a patient discontinues study drug after the Month 6 visit, EOT/early 
termination (ET) assessments should be performed. 
The planned enrollment for this study is approximately 375 patients (75 patients per group). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
29 
The duration of treatment with ALN-AGT01 is up to 36 months. The estimated total time on 
study for each patient is up to 47 months, including up to 2 months of screening, followed by up 
to 36 months of treatment, and up to 12 months in the Follow-up period. 
3.2. 
Scientific Rationale for Study Design 
This is a randomized, double-blind, placebo-controlled, dose-ranging, multicenter Phase 2 study 
designed to evaluate the safety, efficacy, and PD of ALN-AGT01, administered SC, in patients 
with mild-to-moderate hypertension. The primary objective of the study is to evaluate the 
efficacy of ALN-AGT01 by measuring the impact on SBP from baseline to Month 3, as assessed 
by ABPM.  
This study will quantify the antihypertensive effects of ALN-AGT01 across a range of doses and 
dose intervals to identify optimal treatment regimens for study in Phase 3. 
Patients will discontinue prior antihypertensive medications (if taking) for 2 to 4 weeks prior to 
study drug administration. During the study, blood pressure will be monitored with both 
outpatient 24-hour ABPM and automated office blood pressure measurements 
(EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical Investigation of Medicinal Products in 
the Treatment of Hypertension, 2016). The primary endpoint will be assessed by ABPM given its 
greater precision over office blood pressure measurements. In addition, 24-hour ABPM can 
assess short-term blood pressure variability and circadian patterns (including potential restoration 
of the normal nocturnal blood pressure dipping pattern that is lost in 21% to 35% of hypertensive 
patients).[de la Sierra 2009; White 1998] More frequent measurements will be collected through 
a third method, oscillometric HBPM, to assess long-term blood pressure variability and provide 
close safety monitoring for potential hypotension (or hypertension) while not in the clinic. 
As recommended by current guidance (International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use [ICH] Principles for Clinical Evaluation of 
New Antihypertensive Drugs, 2000 and EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical 
Investigation of Medicinal Products in the Treatment of Hypertension, 2016), the first 6 months 
of the DB period is designed as a randomized, placebo-controlled, parallel-group study. To 
adhere to best ethical standards for the treatment of patients with hypertension, individual 
modification of oral antihypertensive medications per Investigator judgement to maintain blood 
pressure within target is permitted starting at Month 3 and will continue throughout the study 
(except between Month 5 and Month 6 as described in Section 3.1). Separate from these treat-to-
target modifications, any confirmed event of severe hypertension (office SBP ≥180 mmHg or 
DBP ≥120 mmHg) will be appropriately treated regardless of its timing relative to study drug 
administration. 
If a patient requires treatment with a conventional oral antihypertensive before Month 6, a CCB 
and/or thiazide/thiazide-like diuretic may be added because there is extensive experience 
combining these classes with antihypertensive drugs that impact the RAAS. Additionally, their 
blood pressure effects are expected to washout within 2 to 4 weeks.  
Rigorous assessment of the antihypertensive effects of ALN-AGT01 at Month 6 (trough for the 
once every 6 month regimens) relative to placebo is critical to evaluate the feasibility of once 
every 6 month dosing regimens for future study in Phase 3. Accordingly, oral antihypertensives 
(if taking) will be temporarily held from Month 5 to the Month 6 ABPM assessment. For each 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
30 
patient, this limited interruption in oral antihypertensives will be contingent upon the patient’s 
Month 5 office SBP being adequately controlled (see Table 4) and the Investigator’s assessment 
that interruption can be safely performed and carefully monitored by HBPM measurements. Of 
note, a withdrawal period is a standard element in studies of oral antihypertensives that is often 
used to establish assay sensitivity, to demonstrate maintenance of efficacy, and to assess possible 
withdrawal effects (ICH E12A; Principles for Clinical Evaluation of New Antihypertensive 
Drugs, 2000). Outside of research studies, antihypertensives are temporarily discontinued in 
clinical practice for diagnostic purposes, and interruptions up to 6 weeks have been shown to be 
safe.[Beeftink 2017] In this study, the period of interruption is limited to 4 weeks, and most 
patients are expected to have continued antihypertensive effect from ALN-AGT01. If a clinically 
significant blood pressure elevation (confirmed SBP >170 mmHg; or SBP >160 mmHg 
accompanied by symptoms) occurs after the interruption of oral antihypertensives, Investigators 
will instruct the patient to promptly resume dosing with their existing supply of oral medication.  
After Month 6, other oral antihypertensives may be used at the discretion of the Investigator, 
following current care guidelines.[Whelton 2018; Williams 2018] Because ALN-AGT01 acts on 
the RAAS, the use of conventional RAAS inhibitors (angiotensin II-receptor blocker [ARB], 
angiotensin converting enzyme [ACE] inhibitors, or direct renin inhibitors) as rescue agents for 
high blood pressure will be avoided throughout this study. Blood pressure and pharmacokinetic 
(PK)/PD assessments will be collected through Month 12 to assess the effect of repeated dosing. 
While tissue specificity of ALN-AGT01 for the liver is hypothesized to improve tolerability 
relative to current oral antihypertensives,[Mullick 2017; Uijl 2019] the protocol’s monitoring 
plan is designed to meet the standards set by prior studies of conventional RAAS 
inhibitors,[McMurray 2016; Parving 2012] with improvements to include the use of the newer 
oral potassium binder patiromer (or with sodium zirconium cyclosilicate [ZS-9]), if available, for 
treatment of potential hyperkalemia.[Georgianos 2018; Weir 2015] The risk of renal safety 
events is further mitigated in this study by its eligibility criteria, which exclude patients who are 
at highest risk to have events (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73m2, 
baseline serum potassium >5 mEq/L, poorly controlled diabetes, or severely increased 
albuminuria) and those who may have decreased tolerance for renal safety events (patients with 
clinically significant heart failure, valvular heart disease, or recent history of cardiovascular 
event).  
3.3. 
Justification for Dose 
The doses of ALN-AGT01 in this study were selected on the basis of data from the Phase 1 
Study 001, in which single ALN-AGT01 doses up to 800 mg were found to have an acceptable 
safety profile, and clinically significant placebo-corrected reductions in mean SBP >10 mmHg 
by 24-hour ABPM were observed after doses as low as 100 mg. Dose selection was guided by 
the principle of evaluating doses that are well tolerated and predicted to result in a range of PD 
effects (ie, lowering of serum AGT) and antihypertensive responses. This is expected to enable 
development of population average dose-response relationships for PD and efficacy to guide 
identification of optimal treatment regimens (dose and dose frequency) for Phase 3.  
Preliminary PK/PD modeling based on serum AGT data from Study 001 indicates that 
ALN-AGT01 results in a dose-dependent lowering of serum AGT, with maximum reductions 
predicted to be achieved as early as 1 month postdose and significant reductions sustained for 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
31 
close to 6 months after dosing. Modeling of the relationship between serum AGT lowering and 
blood pressure suggests a log-linear relationship, with ≥92% reduction in serum AGT predicted 
to achieve median SBP reduction of ≥10 mmHg.  
Based on these, the once every 6 month doses of 150, 300, and 600 mg were selected to result in 
median serum AGT reductions of 81.9%, 89.4%, and 94.9%, respectively, at trough (Month 6), 
translating to median SBP reductions of 6.67 mmHg, 8.74 mmHg, and 11.6 mmHg, respectively. 
Thus, the selected doses will enable characterization of the dose-response relationships for serum 
AGT and blood pressure with the once every 6 month regimen. 
The selected doses also enable characterization of the dose-response relationships for serum 
AGT and blood pressure with once every 3 month regimens based on analysis of data from all 
arms at Month 3. This will provide support for development of a once every 3 month regimen, if 
desired. To this end, 300 mg once every 3 months will be evaluated to identify any cumulative 
effects. The 300 mg once every 3 months dose is predicted to result in median serum AGT 
reductions of >95% at trough (Month 3), translating to median SBP reductions of >10 mmHg.  
Thus, data from the current study will enable robust characterization of PD and efficacy of once 
every 3 month and once every 6 month regimens of ALN-AGT01 and guide further development 
of ALN-AGT01 as an antihypertensive therapeutic that results in reduction of blood pressure by 
≥10 mmHg throughout the dosing interval with infrequent administration. 
3.4. 
Method of Assigning Patients to Treatment Groups 
Using the Interactive Response Technology (IRT), patients will be randomized 1:1:1:1:1 to the 
following arms during the first 6 months of the 12-month DB period: 
• Placebo SC once every 3 months 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients initially randomized to placebo will be re-randomized 1:1:1:1 at Month 6 to 1 of the 4 
initial ALN-AGT01 regimens. 
Before Amendment 6, patients who entered the DB Extension period continued their current 
blinded dosing regimen from the DB period. Upon implementation of Amendment 6, patients in 
the 12-month DB period will continue their planned dosing and assessments through the end of 
the 12-month DB period but will not be eligible to enter the DB Extension period and receive a 
dose of study drug at Month 12. 
Randomization will be stratified by race (black vs all other races) and by baseline blood pressure 
(mean 24-hour SBP < or ≥145 mmHg). 
Each patient will be uniquely identified in the study by a combination of the site number and 
patient identification number. Upon signing the informed consent form (ICF), the patient will be 
assigned a patient identification number by the IRT system. The Investigator or his/her designee 
will randomize the patient in IRT after confirming that the patient fulfills all the inclusion criteria 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
32 
and none of the exclusion criteria. The Investigator or his/her designee will re-randomize the 
patient in IRT at Month 6 to assign placebo patients to 1 of the 4 initial ALN-AGT01 dose 
groups. 
3.5. 
Blinding 
The Sponsor, all site personnel (except for the site pharmacist or delegate), and patients will be 
blinded to study drug treatment through Month 6 of the 12-month DB period. During the course 
of the study, serum AGT, plasma PK, and treatment assignment using dummy IDs will be made 
available to a small, independent pharmacometrics team at the Sponsor that will not be involved 
in the conduct or oversight of the study. After the last patient completes the Month 3 visit and 
prior to the last patient’s Month 6 visit, a limited amount (ie, one-third) of SBP data will be made 
available to this small, independent pharmacometrics team for preliminary PK/PD modeling. 
After the database lock to support the analysis of Month 6 data is complete, all other Sponsor 
personnel will be unblinded to treatment assignment, but the site personnel (except for the site 
pharmacist) and patients will remain blinded to treatment assignment until after final database 
lock. The Sponsor and all site personnel will be blinded to serum AGT results until their 
respective unblinding. Serum AGT results will not be reported to site personnel until after the 
last patient completes the assessments at the Month 12 visit. 
Blinded doses of study drug will be administered under the supervision of the Investigator (see 
Section 5.2.2). All patients will receive the same volume and number of injections regardless of 
treatment assignment (patients receiving once every 6 month ALN-AGT01 regimens will receive 
placebo SC at dosing visits at which they do not receive ALN-AGT01 to maintain the blind). 
Because ALN-AGT01 may be slightly visually distinguishable from placebo, all blinded study 
drug doses will be prepared and the syringe(s) will be masked by a site pharmacist or delegate 
prior to administration by a blinded healthcare professional. See the Pharmacy Manual for 
additional details. 
3.5.1. 
Emergency Unblinding 
If the treating physician determines that the clinical management of the patient requires 
knowledge of the study drug assignment, the Investigator may break the blind, as necessary, in 
IRT. If time permits, clinical study center personnel should contact the Medical Monitor before 
unblinding to discuss the need to unblind the patient but must do so within 1 working day after 
the unblinding event. Unblinding information should be limited to the fewest number of people 
on a need-to-know basis. A record of when the blind was broken, who was unblinded, who broke 
the blind, and why it was broken, will be maintained in the electronic trial master file. 
Refer to the IRT instructions for details on emergency unblinding. 
3.6. 
Data Monitoring Committee 
An independent DMC will oversee the safety and overall conduct of this study. The DMC will 
operate under the rules of a charter that will be reviewed and approved at the organizational 
meeting of the DMC. Details are provided in the DMC Charter. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
33 
3.7. 
Clinical Event Adjudication Committees 
An independent Clinical Event Adjudication Committee of 2 or more nephrologists will review 
renal events blinded to treatment assignment to adjudicate whether they meet diagnostic criteria 
for acute kidney injury and, if so, their potential staging and contributing factors. Details are 
provided in the Renal Event Adjudication Committee charter. 
3.8. 
Definition of End of Study for an Individual Patient 
A patient is considered to have reached the end of the study if the patient has completed the 
Safety Follow-up visits as described in Section 3.1. 
A definition of the end of the overall study is provided in Section 8.1.5. 
4. 
SELECTION AND REMOVAL OF PATIENTS 
4.1. 
Inclusion Criteria 
Patients are eligible to be included in the study if all the following criteria apply: 
Age and Sex 
1. Age 18 to 75 years, inclusive, at time of initial informed consent 
2. Male or female 
Patient and Disease Characteristics 
3. Has untreated hypertension (not taking antihypertensive medication) or is on stable 
therapy with up to 2 antihypertensive medications. In general, stable therapy is defined as 
having no change in antihypertensive medication or dose within 30 days prior to 
screening.  
4. Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive 
medication. Patients previously taking medication for hypertension must be without 
antihypertensives for ≥2 weeks prior to this ABPM (4 weeks of washout is required for 
long-acting antihypertensive medications, such as long-acting diuretics [eg, 
chlorthalidone] or CCBs [eg, amlodipine]). 
Informed Consent 
5. Patient is able to understand and is willing and able to comply with the study 
requirements and to provide written informed consent. 
4.2. 
Exclusion Criteria 
Patients are excluded from the study if any of the following criteria apply: 
Disease-specific Conditions 
1. Secondary hypertension (including, but not limited to, renovascular hypertension, 
primary aldosteronism, pheochromocytoma, Cushing syndrome, aortic coarctation, or due 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
34 
to known history of moderate-to-severe obstructive sleep apnea not treated with 
continuous positive airway pressure therapy) 
2. Orthostatic hypotension (symptomatic or asymptomatic), defined as a fall of ≥20 mmHg 
SBP or ≥10 mmHg DBP within approximately 1 to 3 minutes of standing up from a 
seated position by office blood pressure. 
Laboratory Assessments 
3. Has any of the following laboratory parameter assessments after at least 2 to 4 weeks of 
washout:  
a. ALT or aspartate aminotransferase (AST) >2× upper limit of normal (ULN) 
b. Total bilirubin >1.5×ULN. Patients with elevated total bilirubin that is secondary to 
documented Gilbert’s syndrome are eligible if the total bilirubin is <2×ULN 
c. International normalized ratio (INR) >2.0 (patients on oral anticoagulant [eg, 
warfarin] with an INR <3.5 will be allowed) 
d. Elevated potassium >5 mEq/L  
e. eGFR of ≤30 mL/min/1.73m2 (calculation will be based on the Modification of Diet 
in Renal Disease formula)  
Prior/Concomitant Therapy 
4. Received an investigational agent within the last 30 days before randomization or are in 
follow-up of another clinical study prior to study enrollment. Any agent that has received 
health agency authorization (including for emergency use) by local or regional regulatory 
authorities is not considered investigational. Patients who are in follow-up for a 
coronavirus disease 2019 vaccine (authorized or investigational) study are allowed. 
5. Currently taking, taken within 30 days prior to randomization, or anticipated to receive 
during the study treatment period any medication or herbal supplement known to 
significantly affect blood pressure (with the exception of medications for the treatment of 
essential hypertension). Patients who require medications such as monoamine oxidase 
(MAO) inhibitors that are associated with hypertensive crisis should be 
excluded.[Whelton 2018]  
6. Currently taking beta blockers and unable to undergo a washout at least 2 weeks prior to 
randomization 
7. Changes, such as initiation or discontinuation, of sodium-glucose co-transporter 2 
(SGLT2) inhibitor therapy within 30 days prior to screening. Patients on a stable dose of 
SGLT2 therapy for at least 30 days prior to screening with no anticipated changes during 
the study treatment period are permitted. 
8. Prescription nonsteroidal anti-inflammatory drugs (NSAIDs) are not permitted. Patients 
receiving low-dose aspirin (defined as ≤100 mg per day) for at least 30 days prior to 
screening are permitted. Paracetamol/acetaminophen for analgesia will be allowed.  
9. Anticipates using organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, 
isosorbide dinitrate, pentaerythritol) during the study treatment period 
10. Currently taking, taken within 6 months prior to randomization, or anticipated to receive 
an RNAi therapeutic (approved or investigational) during the study 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
35 
Medical Conditions 
11. Current or prior history of intolerance to an ARB, ACE inhibitor (other than cough), or 
direct renin inhibitor 
12. Medical condition, other than hypertension, that requires treatment with a RAAS 
inhibitor 
13. History of multiple drug allergies or history of allergic reaction to an oligonucleotide or 
to GalNAc 
14. Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus (hemoglobin A1c 
[HbA1c] >9.0%), or laboratory evidence of diabetes during screening (HbA1c ≥7.0%) 
without known diagnosis of diabetes 
15. History of severely increased albuminuria (urine albumin:creatinine ratio >300 mg/g or 
>300 mg/day) or laboratory results consistent with this diagnosis upon screening  
16. Has known human immunodeficiency virus or known current or chronic hepatitis C virus 
(HCV) or hepatitis B virus infection 
17. History of any cardiovascular event (eg, stroke, transient ischemic attack, myocardial 
infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary 
intervention, hospitalization due to heart failure) within 6 months prior to randomization 
18. Clinically significant valvular heart disease 
19. New York Heart Association II to IV heart failure 
20. Uncontrolled serious cardiac arrhythmia, defined as recurrent and highly symptomatic 
ventricular tachycardia, atrial fibrillation with rapid ventricular response, or 
supraventricular tachycardia in the 3 months prior to randomization 
21. Has undergone liver transplantation or is anticipated to be on an active liver 
transplantation waiting list during the study treatment period 
22. History of renal transplantation or under immunosuppressive therapy 
23. Has other medical conditions or comorbidities which, in the opinion of the Investigator, 
would interfere with study compliance or data interpretation; or, in the opinion of the 
Investigator, taking part in the study would jeopardize the safety of the patient 
24. Clinically significant illness, in the opinion of the Investigator, within 7 days prior to 
randomization 
25. History of intolerance to SC injection(s) that could potentially hinder study drug 
administration or evaluation of local tolerability 
26. Has planned major surgery or general anesthesia during the study 
Contraception, Pregnancy, and Breastfeeding 
27. Is not willing to comply with the contraceptive requirements during the study period, as 
described in Section 5.7.1 
28. Female patient is pregnant, planning a pregnancy, or breast-feeding. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
36 
Alcohol or Nicotine Use and Substance Abuse 
29. Unwilling or unable to limit alcohol consumption throughout the course of the study. 
Alcohol intake of >2 units/day is excluded during the study (unit: 1 glass of wine 
[approximately 125 mL] = 1 measure of spirits [approximately 1 fluid ounce] = ½ pint of 
beer [approximately 284 mL]). 
30. History of alcohol or substance abuse (licit or illicit drugs) within the last 12 months 
before screening, in the opinion of the Investigator 
31. Unwilling or unable to abstain from use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine 
patches, or e-cigarettes) within 30 minutes prior to office blood pressure measurements  
Other Restrictions 
32. Third shift or night shift workers 
33. Arm circumference exceeds the maximum cuff size of any of the blood pressure 
instruments provided by the Sponsor 
34. Placed in an institution on the basis of an official or court order 
4.3. 
Removal from Study Drug or Assessment 
Patients are free to discontinue study drug and/or stop protocol procedural assessments, or 
participation in the study as a whole at any time and for any reason, without penalty to their 
continuing medical care. The Investigator or the Sponsor may discontinue study drug or stop a 
patient’s participation in the study at any time if this is considered to be in the patient’s best 
interest. Any discontinuation of treatment or the stopping of the patient’s participation in the 
study must be fully documented in the electronic case report form (eCRF) and should be 
followed up by the Investigator. 
Discontinuation of study drug or declining procedural assessments is described in Section 4.3.1, 
while the stopping of a patient’s participation in the study is detailed in Section 4.3.2. 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments 
Reasons for discontinuation of study drug include any of the following: 
• Significant protocol deviation; which includes required treatment with prohibited 
medication (as defined in Section 5.5.2) per Investigator discretion 
• AE 
• Non-adherence to treatment regimen 
• Pregnancy 
• Lost to follow-up 
• Other reason (non-AE) 
• Or, study is terminated by the Sponsor 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
37 
If possible, the Investigator will confer with the Sponsor or Medical Monitor before 
discontinuing dosing in the patient. Patients who are pregnant will be discontinued from study 
drug dosing immediately (see Section 6.5.6.7 for reporting and follow-up of pregnancy). A 
positive urine pregnancy test should be confirmed by a serum pregnancy test prior to 
discontinuing the study drug. 
Patients who discontinue study drug and/or decline procedural assessments should not be 
automatically removed from study. In general, patients who discontinue study drug dosing for 
any reason will be encouraged to remain on the study to complete the remaining assessments and 
study visits so that their experience is captured in the final analyses.  
If this occurs, the Investigator is to discuss with the patient the appropriate processes for 
discontinuation from study drug and must discuss with the patient the options for continuation of 
the Schedule of Assessments (Table 1), including different options for follow-up and collection 
of data (eg, in person, by phone, by mail, through family or friends, or from options not 
involving patient contact, such as communication with other treating physicians or from review 
of medical records), including endpoints and AEs, and must document this decision in the 
patient’s medical records. 
If a patient discontinues dosing due to an AE, including SAEs, the event should be followed as 
described in Section 6.5.6. When a patient discontinues study drug dosing, the primary reason 
must be recorded in the eCRF. Patients who discontinue study drug and remain on study may 
receive treatment consistent with local standard practice for their disease per Investigator 
judgement, as applicable. 
Patients who discontinue from study drug before Month 6 will be encouraged to remain on the 
study and complete assessments (except study drug administration) through Month 6. They will 
also be asked to complete Safety Follow-up visits once every 6 months after the last dose of 
study drug per the safety follow-up schedule (see Table 1) until PD recovery or 12 months after 
the last dose of study drug (whichever is earlier); see Section 3.1. 
Patients who discontinue study drug after the Month 6 visit will be asked to return for their next 
scheduled visit to complete EOT/ET assessments and complete Safety Follow-up visits once 
every 6 months after the last dose of study drug per the safety follow-up schedule (see Table 1) 
until PD recovery or 12 months after the last dose of study drug (whichever is earlier); see 
Section 3.1. 
4.3.2. 
Stopping a Patient’s Study Participation 
4.3.2.1. 
Patient Stops Participation in the Study 
A patient may stop participation in the study at any time. A patient considering stopping 
participation in the study before Month 6 should be informed that the patient can discontinue 
study drug and/or decline procedural assessments and remain in the study to complete their study 
assessments through the Month 6 visit and complete Safety Follow-up visits as described in 
Section 4.3.1, or alternatively may complete any minimal assessments for which the patient 
consents. If a patient still chooses to discontinue study drug and stop participation in all follow-
up prior to the completion of the Month 6 visit, every effort should be made to conduct the 
Month 6 visit assessments at an earlier time (Table 1). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
38 
A patient considering stopping participation in the study after the Month 6 visit should be 
informed that the patient can discontinue study drug and/or decline procedural assessments and 
remain in the study to complete the assessments scheduled for the EOT/ET visit and complete 
Safety Follow-up visits as described in Section 4.3.1, or alternatively may complete any minimal 
assessments for which the patient consents. 
If the patient does not wish to or is unable to continue further study participation, the Investigator 
is to discuss with the patient appropriate procedures for stopping participation in the study. Data 
collected from the patient can continue to be used. 
Note, in countries where the collection and processing of the patient’s personal data is based on 
consent, if a patient withdraws consent to collect and process his/her personal data (see 
Section 4.3.2.2), as applicable, personal data up to the withdrawal of consent will be included in 
the analysis of the study. In addition, where permitted, publicly available data (such as 
appropriate national or regional vital status registry or other relevant databases) can be included 
after withdrawal of consent, where available and allowable by local law. 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection to 
Process Patient’s Personal Data 
Where allowed by local law, the patient may decide to withdraw consent to collect, store, and 
use biological samples and, as applicable, other personal data, informing the study doctor at any 
time in writing or in any other form that may be locally required. Also, where allowed by local 
law, the patient may object to the collection, storage, and use of his/her personal data, informing 
the study doctor at any time in writing or in any other form that may be locally required. In both 
cases, the Sponsor will continue to keep and use the patient’s study information (including any 
data resulting from the analysis of the patient’s biological samples until the time of 
withdrawal/objection) according to applicable law. The process for the storage and, as 
applicable, further use of remaining samples will be followed per local requirements.  
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study 
The Investigator or Sponsor may stop the participation of a patient in the study at any time if this 
is considered to be in the patient’s best interest. However, study integrity and interpretation are 
best maintained if all enrolled patients continue study assessments and follow-up even if study 
drug is discontinued. 
Termination of the clinical study and site closure are described in Section 8.1.6. 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation 
The primary reason that a patient’s study participation is stopped must be recorded in the 
appropriate section of the eCRF and all efforts will be made to complete and report the 
observations as thoroughly as possible. If a patient’s study participation is stopped due to an AE, 
including SAEs, the event should be followed as described in Section 6.5.6. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
39 
4.3.3. 
Lost to Follow-Up 
A patient will be considered lost to follow-up if the patient repeatedly fails to return for 
scheduled visits and is unable to be contacted by the clinical study center. The following actions 
must be taken if a patient fails to return to the clinic for a required study visit: 
• The site must attempt to contact the patient and reschedule the missed visit as soon as 
possible and counsel the patient on the importance of maintaining the assigned visit 
schedule and ascertain if the patient wishes to continue in the study, and/or should 
continue in the study. 
• Before a patient is deemed lost to follow up, the Investigator or designee must make 
every effort to regain contact with the patient (where possible, 3 telephone calls and, 
if necessary, a certified letter to the patient’s last known mailing address or local 
equivalent methods). These contact attempts should be documented in the patient’s 
medical record. 
• Should the patient continue to be unreachable, the patient will be considered to have 
stopped participation in the study. 
• For patients who are lost to follow-up, the Investigator can search publicly available 
records (where permitted and allowed by local law) to ascertain survival status. This 
ensures that the outcome of the study is as comprehensive as possible. 
4.3.4. 
Replacement of Study Patients 
No additional patients may be enrolled to mitigate the impact of patients who discontinue the 
study drug or stop participation in the study.  
5. 
TREATMENTS AND OTHER REQUIREMENTS 
5.1. 
Treatments Administered 
Study drug supplied for this study must not be used for any purpose other than the present study 
and must not be administered to any person not enrolled in the study. Study drug that has been 
dispensed and returned unused must not be re-dispensed. 
5.2. 
Study Drug 
Detailed information describing the preparation, administration, and storage of ALN-AGT01 SC 
and placebo SC is provided in the Pharmacy Manual. 
5.2.1. 
Description 
ALN-AGT01 will be supplied as a sterile solution for SC injection. See the Pharmacy Manual 
for further details of solution concentration and fill volume. 
The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC 
administration).  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
40 
5.2.2. 
Dose and Administration 
During the 12-month DB period, patients will be administered ALN-AGT01 or placebo, at the 
same volume and number of SC injections regardless of treatment assignment, once every 3 
months. The ALN-AGT01 and placebo groups are below: 
• Placebo SC once every 3 months, with re-randomization (1:1:1:1) at Month 6 to 1 of 
the initial 4 ALN-AGT01 regimens 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Before Amendment 6, patients who entered the DB Extension period continued their current 
blinded dosing regimen from the DB period. Upon implementation of Amendment 6, patients in 
the 12-month DB period will continue their planned dosing and assessments through the end of 
the 12-month DB period but will not be eligible to enter the DB Extension period and receive a 
dose of study drug at Month 12. For patients in the DB Extension period, patients will receive 
their last dose of study drug if their next visit is at Month 15, 21, 27, or 33. Patients will not 
receive study drug at other visits in the DB Extension period. 
Patients receiving once every 6 month ALN-AGT01 regimens will receive placebo SC at dosing 
visits at which they do not receive ALN-AGT01 to maintain the blind. 
Study drug injections will be administered under the supervision of the Investigator or healthcare 
professional. To maintain the blind, the doses are to be prepared by and syringes are to be 
masked by an unblinded site pharmacist or designee prior to study drug administration. A full 
description of the blinding procedure is included in the Pharmacy Manual. The injection site may 
be marked and mapped for later observation. Injections may be administered in the abdomen, 
thigh, or the side or back of the upper arms. The rotation of sites is recommended. If a local 
reaction around the injection site occurs, photographs may be obtained. Detailed instructions for 
study drug administration are found in the Pharmacy Manual. 
If a patient does not receive a dose of study drug within the specified visit window, the 
Investigator should contact the Medical Monitor. After such consultation, the dose may be 
administered up to 42 days before the next scheduled dose. Thereafter, the dose will be 
considered missed and not administered. 
Patients will be permitted to miss an occasional dose of study drug. However, if a patient misses 
2 consecutive doses, the Investigator, in consultation with the Medical Monitor, will discuss 
whether the patient will be able to continue the study (see also Section 4.3). 
Additional details can be found in the Pharmacy Manual. 
The definition of study drug overdose, follow-up procedures, and reporting requirements are 
provided Section 6.5.6.8. 
5.2.3. 
Dose Modifications 
Dose modifications are not permitted. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
41 
If a study drug-related AE occurs in a patient that the Investigator judges as presenting a 
potential risk to the patient for further dosing, the study drug dose may be held at the discretion 
of the Investigator and the Medical Monitor should be contacted. 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping Study 
Drug Dosing  
1. Dosing decisions may be made based on the most recently available liver function test 
(LFT) results from a central laboratory (Table 6). 
2. For any ALT or AST elevation >3×ULN, central laboratory results should be used to 
guide subsequent monitoring as detailed in Table 3. 
3. For any ALT or AST elevation >3×ULN: 
a. If local laboratory results are obtained, confirm with a central laboratory as soon as 
possible, ideally within 2 to 3 days, but no later than 7 days. 
b. If an alternative cause is found, provide appropriate care. 
c. If an alternative cause is not found, perform assessments per Table 6 and Table 7. 
4. For any ALT or AST elevation >3×ULN without alternative cause that is accompanied 
by clinical symptoms consistent with liver injury (eg, nausea, right upper quadrant 
abdominal pain, jaundice) or elevated bilirubin to ≥2×ULN or INR ≥1.5, permanently 
discontinue dosing. 
5. For confirmed ALT or AST elevations >3×ULN without alternative cause and not 
accompanied by symptoms or elevated bilirubin ≥2×ULN or INR ≥1.5, see Table 3. 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative Cause 
Identified 
Transaminase Level 
Action 
>3× to 5×ULN 
• 
May continue study drug dosing 
• 
Evaluate the initial elevation in LFT per the following assessments: 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6  
• 
Monitor at least every 2 weeks (LFT and coagulation per Table 6)  
• 
If elevation persists for ≥2 months, must discuss with the Medical Monitor 
before continuing dosing 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
42 
Transaminase Level 
Action 
>5× to 8×ULN 
• 
Hold study drug dosing until recovery to ≤1.5×ULN or baseline; may 
resume dosing after discussion with the Medical Monitor 
• 
Evaluate the initial elevation in LFT per the following assessments 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6 
• 
Monitor at least weekly: LFT and coagulation per Table 6 until ALT and/or 
AST is declining on 2 consecutive draws, then may decrease monitoring to 
biweekly 
• 
If ALT or AST rises to >5×ULN following resumption of dosing, 
permanently discontinue dosing 
>8×ULN 
Permanently discontinue study drug dosing after confirmation of the 
transaminase value at the central laboratory. 
Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; INR=international normalized 
ratio; LFT=liver function test(s); ULN=upper limit of normal. 
Notes: In addition to these criteria, other assessments or evaluations may be performed per Investigator discretion, 
as appropriate. 
5.2.5. 
Neurological Criteria for Withholding, Monitoring, and Stopping Study Drug 
Dosing 
Clinically significant events that may be consistent with potential decreased proprioception 
(including but not limited to unusual clumsiness, gait abnormalities, and unexplained 
balance/coordination issues that are either absent at or worsening from the baseline) should be 
reported as an AE. If the treatment-emergent AE is persistent and considered related to study 
drug, specialty consultation with a neurologist should be considered. However, if such a 
treatment-emergent AE is serious or severe (regardless of the Investigator’s assessment of 
relatedness), the patient must be referred for neurologist consultation, and study drug dosing 
must be held until that consultation is complete. Resumption of dosing must be approved by the 
Medical Monitor. 
5.2.6. 
Preparation, Handling, and Storage 
Staff at each clinical study center will be responsible for preparation of ALN-AGT01 or placebo 
doses according to procedures detailed in the Pharmacy Manual. No special procedures for the 
safe handling of study drug are required. 
ALN-AGT01 will be stored at approximately 2 to 30°C until dose preparation. Deviations from 
the recommended storage conditions should be reported to the Sponsor and use of ALN-AGT01 
halted until authorization for its continued use has been provided by the Sponsor or designee, as 
described in the Pharmacy Manual. 
A Sponsor representative or designee will be permitted, upon request, to audit the supplies, 
storage, dispensing procedures, and records. 
Instructions specific to unused study drug and additional storage will be provided in the 
Pharmacy Manual. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
43 
5.2.7. 
Packaging and Labeling 
All packaging, labeling, and production of study drug will be in compliance with current Good 
Manufacturing Practice specifications, as well as applicable local regulations. Study drug labels 
and external packaging will include all appropriate information as per local labeling 
requirements. Additional details will be available in the Pharmacy Manual. 
5.2.8. 
Accountability 
The Investigator or designee will maintain accurate records of receipt and the condition of 
ALN-AGT01 supplied for this study, including dates of receipt. In addition, accurate records will 
be kept of when and how much ALN-AGT01 is dispensed and administered to each patient in 
the study. Any reasons for departure from the protocol dispensing regimen must also be 
recorded. 
At the completion of the study, there will be a final reconciliation of all ALN-AGT01. Used, 
partially used, and unused ALN-AGT01 will be returned to the Sponsor (or designee) or 
destroyed at the clinical study center according to applicable regulations. 
Further instructions about drug accountability will be detailed in the Pharmacy Manual. 
5.3. 
Clinical Product Complaints 
5.3.1. 
Definition 
A clinical product complaint (CPC) is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of the study drug and its packaging after it is released for distribution to the site at 
which study drug will be administered. 
A CPC may be detected prior to use of study drug, during use, or after use. A CPC is typically 
nonmedical in nature; however, it is possible that study drug complaints could be associated with 
an AE. Examples of a CPC include, but are not limited to: illegible clinical label, missing clinical 
label, damaged vial, empty vial, and contamination of study drug. 
5.3.2. 
Reporting 
For product complaints, the Sponsor or its designee should be notified within 24 hours using the 
process outlined in the Pharmacy Manual. CPCs that may be associated with an AE must be 
evaluated and reported as indicated in Section 6.5.6. Detailed instructions on reporting CPCs will 
be provided in the Pharmacy Manual. 
5.4. 
Monitoring for Potential Clinical Events 
5.4.1. 
Monitoring and Approach for Potential Hypotension 
Hypotension is an obligate risk of antihypertensive medications. In addition to office blood 
pressure monitoring, outpatient blood pressure should be monitored weekly with HBPM to 
ensure the early detection of potential hypotension. Whenever possible, management decisions 
will be based on blood pressure measurements confirmed by office blood pressure. 
The following management recommendations for hypotension are provided: 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
44 
• Low blood pressure that is associated with symptoms should promptly be evaluated at 
the clinical study site or another hospital setting. Clinical study site evaluation for low 
blood pressure should include the assessment of orthostatic blood pressure (eg, supine 
to standing).  
• The Investigator should consider downtitration, interruption, or discontinuation of 
oral antihypertensives (if taking) if confirmed office SBP <90 mmHg or if clinical 
symptoms, such as lightheadedness or dizziness, develop coupled with a significantly 
lower SBP compared to prior visits (ie, SBP <100 mmHg). 
• Clinically significant events discovered during the course of a patient’s general 
medical care should be promptly communicated to the site and evaluated by the 
Investigator, especially if hypotension is noted. Patients will carry Independent Ethics 
Committee (IEC)-approved patient cards to facilitate this physician-to-physician 
communication.  
• If hypotension is confirmed, serum electrolytes and creatinine should be measured 
and any oral antihypertensive(s) previously started for hypertensive escape should be 
down-titrated, interrupted, or discontinued per Investigator judgement.  
• The frequency of blood pressure and biochemical monitoring (serum electrolytes and 
creatinine) should be increased during intercurrent illnesses that predispose patients to 
dehydration (eg, vomiting or diarrhea that persists for more than 24 hours) or when 
symptoms consistent with decreased effective circulating volume (eg, presyncopal 
symptoms, unexplained falls, decreased urine output) manifest, even if a patient’s 
recent blood pressure measurements have been normal. 
• Hypotension that warrants direct evaluation at the site should be communicated to the 
Medical Monitor within 24 hours. In addition, other clinical events consistent with 
potential hypotension (eg, unexplained presyncope, syncope, or falls) should be 
communicated to the Medical Monitor within 24 hours of the site being notified. 
• Management of persistent hypotension may include increased salt intake or, if 
unresponsive, standard treatments for orthostatic intolerance syndromes such as 
fludrocortisone or midodrine. 
• Low blood pressure that requires medical treatment (including intravenous fluid 
support) or other clinical events consistent with potential hypotension (see above) 
should be recorded as AEs. 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure Elevation 
In addition to office blood pressure monitoring, outpatient blood pressure will be monitored 
frequently with HBPM to ensure the early detection of potential significant elevations. Whenever 
possible, management decisions will be based on blood pressure measurements confirmed by 
office blood pressure. The recommended interventions for potentially clinically significant blood 
pressure elevation are presented in Table 4.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
45 
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation 
Study Period 
Intervention 
Throughout Study 
• 
Whenever possible, management decisions should be based on blood 
pressure measurements confirmed by office blood pressure. 
• 
Any confirmed event of severe hypertension (office SBP ≥180 mmHg 
and/or office DBP ≥120 mmHg) should be appropriately treated regardless 
of its timing relative to study drug administration.  
• 
Because ALN-AGT01 acts on the RAAS, the use of conventional RAAS 
inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors) as rescue 
agents for high blood pressure will be avoided throughout this study.  
• 
If added, oral antihypertensives must be used per their labeled instructions 
and in accordance with current care guidelines.[Whelton 2018; Williams 
2018] 
Day 1 to Month 3 
Intervene if clinically significant blood pressure elevation: 
• 
Because of the gradual onset of effects of ALN-AGT01, interventions for 
asymptomatic hypertension should be avoided in the first 6 weeks after the 
patient’s first administration of study drug.  
• 
After Week 6, patients who develop office SBP >160 mmHg and increased 
>10 mmHg from their baseline office SBP that persists for ≥24 hours on 2 
consecutive measurements or that is accompanied by hypertensive 
symptoms should be evaluated by the clinical study site. Severely 
symptomatic patients should be evaluated at the clinical study site or 
another hospital setting within 24 hours. 
• 
If persistent hypertension is confirmed (without the identification of a 
specific treatable cause) and the Investigator deems it to be a clinically 
significant change, treatment may be initiated at the medical discretion of 
the Investigator using a CCB and/or a thiazide/thiazide-like diuretic. 
Investigators should avoid long-acting agents that may not fully washout 
between Month 5 and Month 6. 
Months 3 to 6 
Treat to target blood pressure using a CCB and/or thiazide/thiazide-like diuretic: 
• 
At Month 3, a CCB and/or a thiazide/thiazide-like diuretic may be added if 
the daytime mean SBP is ≥135 mmHg by ABPM. If the Investigator feels 
there is a compelling clinical reason to wait, the rationale for exception 
should be documented in the eCRF. 
• 
After Month 3, oral antihypertensive medications may also be added per 
Investigator judgement for persistent elevations in blood pressure above 
recommended target per treatment guidelines (eg, office SBP <140 mmHg, 
HBPM SBP <135 mmHg, or daytime mean SBP by ABPM <135 
mmHg).[Williams 2018] 
• 
A temporary hold of oral antihypertensives (if taking) will be performed in 
appropriate patients (below) from Month 5 to Month 6: 
- Month 5 office SBP <160 mmHg if taking no oral antihypertensive 
agents 
- Month 5 office SBP <155 mmHg if taking 1 oral antihypertensive agent 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
46 
Study Period 
Intervention 
- Month 5 office SBP <150 mmHg if taking 2 oral antihypertensive 
agents. 
• 
During this 4-week period, blood pressure will be carefully monitored by 
HBPM and oral antihypertensive medications restarted if confirmed office 
SBP >170 mmHg (or if confirmed office SBP >160 mmHg accompanied by 
symptoms) 
Month 6 to End of 
Study 
Treat to target blood pressure using Investigator’s choice of oral 
antihypertensive(s). 
• 
At Month 6, prior oral antihypertensive may be restarted per Investigator 
judgement if daytime mean SBP is ≥135 mmHg by ABPM. 
• 
Oral antihypertensive medications may also be added per Investigator 
judgement for persistent elevations in blood pressure above recommended 
target per treatment guidelines (eg, office SBP <140 mmHg; HBPM SBP 
<135 mmHg; daytime mean SBP by ABPM <135 mmHg).[Whelton 2018; 
Williams 2018] 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of eGFR 
through the anticipated onset of initial ALN-AGT01 PD. Based upon the renal dysfunction 
associated with conventional RAAS inhibitors,[McMurray 2016; Parving 2012] the following 
guidelines apply throughout the study: 
• If an individual patient experiences a decrease in eGFR by ≥30% from baseline or to 
≤30 mL/min/1.73m2, the Investigator should obtain confirmatory repeat tests, contact 
the Sponsor, and look for potentially reversible causes of renal dysfunction such as: 
− NSAIDs, antibiotics, or other treatments known to impair renal function 
− Recent exposure to intravenous contrast agents 
− Hypotension 
− Hypovolemia 
− Urinary infection 
− Urinary tract obstruction 
• If an individual patient experiences a decrease in eGFR by ≥40% from baseline or to 
≤25 mL/min/1.73m2, the Investigator should obtain confirmatory repeat tests, look for 
potentially reversible causes of renal dysfunction, and contact the Sponsor to discuss 
the potential interruption of study drug. Serum creatinine should be monitored at least 
weekly until improving.  
• If a patient is on additional oral antihypertensive agents, the Investigator should 
consider whether these agents should be interrupted, especially during intercurrent 
illness or volume depletion 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
47 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of serum 
electrolytes (at least monthly through the anticipated onset of ALN-AGT01 PD). The following 
guidelines apply for potassium elevations detected by laboratory monitoring.[McMurray 2016; 
Parving 2012] 
Table 5: 
Recommended Interventions for Hyperkalemia 
Serum K+ >5.2 and <5.5 mmol/L 
Serum K+ ≥5.5 and <6.0 mmol/L 
Serum K+ ≥6.0 mmol/L 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample. 
• 
Reinforce low-potassium diet 
and restriction of food/drinks 
with high potassium content  
• 
Review medical regimen 
(including dietary supplements 
and over-the-counter 
medications) for agents known 
to cause hyperkalemiaa. 
Consider reduction in dose or 
discontinuation of these agents. 
• 
Repeat K+ measurement within 
3 to 5 days. 
• 
If K+ remains >5.2 and <5.5 
mmol/L, regularly monitor K+ 
levels to ensure stability (at 
least weekly if in the first 6 
weeks of treatment or at least 
once monthly afterwards) 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample 
• 
Consider interruption or delay 
of study drug, according to 
Investigator medical judgment  
• 
Apply all measures outlined for 
serum K+ >5.2 and <5.5 
mmol/L 
• 
Repeat K+ measurement after 2 
to 3 days 
• 
If K+ <5.5 mmol/L, consider 
resumption of study drug (if 
interrupted) with repeat 
potassium within 5 days 
• 
If K+ persistently elevated ≥5.5 
mmol/L, consider treatment 
with patiromer (or with sodium 
zirconium cyclosilicate), if 
available 
• 
Immediately interrupt 
study drug 
• 
Confirm potassium 
concentration in a 
non-hemolyzed 
sample 
• 
Urgently evaluate 
patient and treat 
hyperkalemia as 
clinically indicated. 
After urgent 
treatment, consider 
treatment with 
patiromer (or with 
sodium zirconium 
cyclosilicate), if 
available 
• 
Apply all measures 
outlined for serum K+ 
≥5.5 and <6.0 
mmol/L 
• 
No resumption of 
study drug without 
individualized case 
discussion with and 
permission from 
Alnylam Medical 
Monitor 
Abbreviations: NSAID=nonsteroidal anti-inflammatory drug. 
a This list is not meant to be exhaustive: potassium-sparing diuretics (eg, amiloride and triamterene), potassium 
supplements (eg potassium chloride), salt substitutes, NSAIDs, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, herbal supplements (eg, Noni juice, alfalfa [Medicago sativa], 
dandelion [Taraxacum officinale], horsetail [Equisetum arvense], nettle [Urtica dioica], milkweed, lily of the 
valley, Siberian ginseng, hawthorn berries). 
The availability of patiromer or ZS-9 will be assessed at participating study sites. These 
potassium-binding drugs are indicated for the treatment of hyperkalemia and have been shown to 
safely reduce serum potassium levels and to maintain long-term normokalemia in chronic kidney 
disease patients receiving background conventional RAAS inhibitor therapy.[Georgianos 2018; 
Weir 2015] 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
48 
5.5. 
Concomitant Medications and Procedures 
Use of concomitant medications and procedures will be recorded on the patient’s eCRF as 
specified in the Schedule of Assessments (see Table 1). Concomitant medications include all 
prescription medications, herbal preparations, over the counter medications, vitamins, and 
minerals. Any changes in medications during the study will also be recorded on the eCRF. 
Standard vitamins and topical medications are permitted. However, topical steroids must not be 
applied anywhere near the injection site(s) unless medically indicated. For permitted concomitant 
medications administered SC, do not administer in same injection site area as the study drug for 
4 days after the last dose of study drug. 
Patients receiving low-dose aspirin (defined as ≤100 mg per day) for at least 30 days prior to 
screening and during the study treatment period are allowed. Occasional use of other over-the-
counter systemic NSAIDs is allowed. However, given their association with increased blood 
pressure, they should be avoided when possible and for at least 2 days prior to ABPM and office 
blood pressure measurements, and alternative analgesics (acetaminophen, topical NSAIDs) 
should be considered.[Whelton 2018] When used, the dosing of systemic NSAIDs should be at 
the lower end of the labeled range and for the shortest duration possible.  
Patients receiving SGLT2 inhibitors (eg, empagliflozin, canagliflozin, and dapagliflozin) should 
be on a stable dose for at least 30 days prior to screening and during the study treatment period. 
These medications should not be initiated or discontinued, if possible, during the study treatment 
period.  
Patients will be allowed to receive vaccines (eg, for SARS-CoV-2) that have received health 
agency authorization (including for emergency use) by local or regional regulatory authorities. 
Any concomitant medication that is required for the patient’s welfare may be administered by the 
Investigator, except as described in Section 5.5.2. However, it is the responsibility of the 
Investigator to ensure that details regarding the medication are recorded on the eCRF. 
Concomitant medication will be coded using an internationally recognized and accepted coding 
dictionary. 
5.5.1. 
Oral Antihypertensive Medication  
Individual initiation and modification of oral antihypertensive medications per Investigator 
judgement are permitted throughout the study if required to treat clinically significant blood 
pressure elevation (Section 5.4.2). In addition, after a patient completes the placebo-controlled 
primary endpoint at Month 3, oral antihypertensive medications may also be added per 
Investigator judgment for persistent elevations in blood pressure above recommended target per 
treatment guidelines (eg, office SBP <140 mmHg, HBPM SBP <135 mmHg, or daytime mean 
SBP by ABPM <135 mmHg).[Williams 2018] All oral antihypertensive medication that are 
dosed once daily should be taken in the morning. 
Serum electrolytes and creatinine should be measured at a central or local laboratory 
approximately 2 weeks after any antihypertensive addition or dose titration. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
49 
5.5.2. 
Prohibited Concomitant Medication 
The following medications, treatments, and supplements are prohibited throughout the study 
treatment period (until the EOT visit): 
• Conventional RAAS inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors)  
• Prescription NSAIDs  
• Organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, isosorbide 
dinitrate, pentaerythritol) 
• An RNAi therapeutic (other than ALN-AGT01) 
• Medications, herbal supplements (including Ma Huang and St. John’s wort), or other 
substances (such as licorice) that are associated with increases in LFT abnormalities 
or with blood pressure abnormalities are prohibited. This includes certain stimulants 
(eg, amphetamine, methylphenidate dexmethylphenidate, dextroamphetamine), MAO 
inhibitors, atypical antipsychotics (eg, clozapine, olanzapine), diet pills (eg, 
phenylpropanolamine, sibutramine), and nasal decongestants (eg, phenylephrine 
hydrochloride, pseudoephedrine, naphazoline hydrochloride), unless individually 
approved by both the Investigator and the Medical Monitor. 
• Medications, herbal medicines, over-the-counter medications, or supplements known 
to cause hyperkalemia are prohibited unless individually approved by both the 
Investigator and the Medical Monitor. This includes potassium-sparing diuretics, 
potassium supplements, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, mineralocorticoid receptor 
antagonists, Noni juice, alfalfa, dandelion, horsetail, nettle, milkweed, lily of the 
valley, Siberian ginseng, and hawthorn berries. 
All concomitant medications must be reviewed and approved by the Investigator, with particular 
attention to avoiding drugs that may affect blood pressure. 
5.6. 
Treatment Compliance 
Compliance with study drug administration will be verified through observation by study staff. 
5.7. 
Other Requirements 
5.7.1. 
Contraception 
Females of child-bearing potential must be willing to use a highly effective method of 
contraception from 14 days before first dose, throughout study participation, and through safety 
follow-up (if applicable; see Section 3.1).  
Birth control methods which are considered highly effective include: 
• Placement of an intrauterine device. 
• Placement of an intrauterine hormone-releasing system. 
• Bilateral tubal occlusion. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
50 
• Surgical sterilization of male partner (with the appropriate post-vasectomy 
documentation of the absence of sperm in the ejaculate; for female patients on the 
study, the vasectomized male partner should be the sole partner for that patient). 
• Established use of oral (except low-dose gestagens), implantable, injectable, or 
transdermal hormonal methods of contraception associated with the inhibition of 
ovulation. 
• True sexual abstinence, when in line with the preferred and usual lifestyle of the 
patient. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception. Abstinent 
patients must agree to use one of the above-mentioned contraceptive methods if they 
start heterosexual relationships during the study and through safety follow-up (if 
applicable; Section 3.1). 
Investigators should advise females of childbearing potential of the most appropriate birth 
control method available within their country taking into account local medical practice. 
Females of child-bearing potential include female patients who have experienced menarche (or 
begin menarche over the course of the study), and who are not postmenopausal or permanently 
sterilized (eg, bilateral oophorectomy, hysterectomy, or bilateral salpingectomy). A 
postmenopausal state is defined as the absence of menses for 12 months without an alternative 
medical cause, confirmed by follicle stimulating hormone level within the postmenopausal 
range.  
For male patients, no contraception is required. However, use by males of contraception 
(condom) may be required in some countries, eg, France, in order to comply with local 
requirements as described in the corresponding patient ICFs.  
Compliance with contraception requirements will be assessed on a regular basis by the 
Investigator throughout the course of the study (see Section 6.5.5.3). Pregnancy testing will be 
performed before every dose for postmenarcheal females throughout the course of the study (see 
Section 6.5.5.3). 
5.7.2. 
Alcohol Restrictions 
Patients should limit alcohol consumption throughout the course of the study. Alcohol is limited 
to no more than 2 units per day (unit: 1 glass of wine [approximately 125 mL] =1 measure of 
spirits [approximately 1 fluid ounce] =½ pint of beer [approximately 284 mL]) for the duration 
of the study. Compliance with alcohol restrictions should be assessed on a regular basis by the 
Investigator throughout the course of the study. 
5.7.3. 
Tobacco and Nicotine Restrictions 
Use of nicotine or tobacco-containing products (including but not limited to snuff, chewing 
tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) must be avoided within 30 
minutes prior to blood pressure measurements. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
51 
5.7.4. 
Dietary Recommendations  
All patients will receive educational materials on diet with recommendations to limit sodium 
consumption to approximately 2.0 g per day from screening through the end of the Treatment 
period. This direction should be provided at the start of the Screening period, and treatment-
naïve patients should follow these recommendations for at least 1 week prior to screening 
assessments of blood pressure. Of note, this is the sodium intake recommended in the 2018 
European Society of Cardiology/European Society of Hypertension Guidelines for both 
hypertensive patients and for the general population.[Williams 2018]  
On days on which samples for fasting lipid panel and glycemic assessments are collected, 
patients are required to fast for ≥10 hours before sample collection (Section 6.5.5.1). 
5.7.5. 
Exercise 
Patients should abstain from strenuous exercise for 48 hours before each blood collection for 
clinical laboratory tests and from any exercise for 30 minutes prior to office blood pressure 
measurements. 
6. 
STUDY ASSESSMENTS 
The Schedule of Assessments is provided in Table 1. Study visits should be scheduled for the 
morning. All assessments, except for postdose PK sample collection, are to be performed prior to 
dosing at dosing visits. Additional information on the collection of study assessments will be 
detailed in the study manuals. 
Where applicable country and local regulations and infrastructure for home healthcare allow, 
home healthcare may take place at a location other than the clinical study site to perform study 
assessments, which may include collection of blood and urine samples and measurement of vital 
signs (including blood pressure assessments) and weight (at the discretion of the Investigator). 
See further details in Section 10.2. 
6.1. 
Screening Assessments 
An ICF that has been approved by the appropriate Institutional Review Board (IRB)/IEC must be 
signed (in paper or electronic format per local regulations and institutional standards) by the 
patient before the screening procedures are initiated. All patients will be given a copy of the 
signed and dated ICF. 
Patients will be screened to ensure that they meet all the inclusion criteria and none of the 
exclusion criteria. Rescreening of patients is permitted with consultation of the Medical Monitor 
(see Section 6.1.2). 
Patient demographic data and medical history/disease history will be obtained. Any changes to 
medical history occurring between the screening assessment and Day 1 will be updated prior to 
study drug administration. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
52 
6.1.1. 
Retesting  
If in the Investigator’s judgement, the screening laboratory abnormalities are likely to be 
transient, then laboratory tests may be repeated. The Investigator’s rationale should be 
documented. Laboratory values can be retested once during screening provided that the patient 
can be evaluated for eligibility after at least 2 to 4 weeks of washout (as applicable) and 
randomized within the allowed Screening period. Retesting of screening ABPM is permitted 
once if the first screening ABPM is invalid. A valid screening ABPM recording must be obtained 
within 2 weeks prior to randomization for all patients. In circumstances where it is not possible 
to randomize an eligible patient within the 2-week window following a valid screening ABPM 
result that met the inclusion criterion, a single additional ABPM assessment is permitted, with no 
option for retesting in case of an invalid reading. Eligibility is assessed by the most recent 
ABPM result obtained. If a valid ABPM reading that meets the inclusion criterion is unable to be 
obtained within 2 weeks prior to randomization, the patient is a screen failure. 
6.1.2. 
Rescreening 
A patient who does not meet all study eligibility criteria due to a transient condition observed at 
screening (eg, prohibited medications that were subsequently discontinued) will be allowed to 
return once for rescreening. A patient will be re-consented if rescreening occurs outside of the 
60-day screening window. In this case, all screening procedures must be repeated. 
6.2. 
Efficacy Assessments 
All blood pressure measurements (ABPM, office, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in 
Section 10.1.  
In patients taking oral antihypertensives, a washout of at least 2 to 4 weeks (as applicable) must 
be completed prior to measurement of the baseline ABPM (for eligibility) and baseline office 
blood pressure. The baseline ABPM and office blood pressure must be measured within 2 weeks 
before randomization. An HBPM unit will be provided during the Screening period to facilitate 
monitoring during the washout of prior oral antihypertensives (if taking) and to establish the 
HBPM baseline prior to randomization. To establish baseline, 3 recordings should be collected 
during the last week immediately prior to randomization. 
ABPM placement may be performed at home by appropriately trained individuals, as detailed in 
the ABPM Investigator Manual. If a patient is unable to report to the site for an office blood 
pressure assessment, a substitute “remote visit blood pressure measurement” may be obtained 
remotely using the methods described in Section 10.1. 
Recommendations for approach and monitoring of low blood pressure/hypotension and 
hypertensive escape are provided in Section 5.4.1 and Section 5.4.2, respectively. 
6.2.1. 
ABPM 
In patients taking oral antihypertensives (including those initiated as rescue medication), ABPM 
should be started prior to the morning dose of antihypertensive medication.  
Validity will be assessed for all ABPMs. If the ABPM recording is invalid at any point during 
the study, the patient will be provided 1 opportunity to repeat the recording.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
53 
In circumstances where it is not possible to randomize a patient within the 2-week window 
following a valid ABPM recording that met the inclusion criterion, a single additional ABPM 
recording is permitted, with no option for retesting in case of an invalid recording. Eligibility is 
assessed by the most recent ABPM recording obtained. If a valid ABPM recording that meets the 
inclusion criterion is unable to be obtained within 2 weeks prior to randomization, the patient is a 
screen failure.  
See further details in Section 10.1 and the ABPM Investigator Manual. 
6.2.2. 
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor at trough (prior to taking oral antihypertensives) and at approximately the same time 
each day; therefore, visits should be scheduled at approximately the same time of day, whenever 
possible. Office blood pressure must include orthostatic measurements (seated and standing).  
Exercise, caffeine, alcohol consumption, and use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or 
e-cigarettes) must be avoided within 30 minutes prior to blood pressure measurements. The use 
of inhaled short-acting beta agonists should be avoided within 6 hours prior to measuring blood 
pressure and/or heart rate. The use of phosphodiesterase type 5 inhibitors (eg, sildenafil, 
tadalafil, vardenafil, avanafil) should be avoided within 48 hours prior to measuring blood 
pressure. 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the HBPM and OBPM Investigator Manual.  
6.2.3. 
HBPM 
The HBPM should be measured in the morning upon waking, prior to breakfast/caffeine or 
taking morning oral medications. HBPM is not required on days when ABPM is being assessed. 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the HBPM and OBPM Investigator Manual. 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment 
Up to 100 patients at select sites will be given the option of using a wearable blood pressure 
sensor for 2 periods of 2 to 4 weeks each according to the Schedule of Assessments (Table 1). 
Wearable blood pressure assessments performed during screening should be obtained during the 
last 2 to 4 weeks before Day 1. The second period of assessment should be obtained 2 to 4 weeks 
prior to the Month 3 visit. Participation will be contingent upon individual patient consent. These 
noninvasive, cuffless devices are worn on the finger or wrist as described in the Biobeat 
Investigator Manual, using the opposite arm as that used for ABPM. 
6.3. 
Pharmacodynamic Assessments 
Blood samples for determination of AGT and RAAS biomarkers (plasma renin concentration, 
AngI, AngII, and aldosterone) will be collected according to the Schedule of Assessments 
(Table 1). Blood samples for PD assessments must be collected before study drug administration 
(on days when study drug is to be dosed) or at a time point corresponding to the time of study 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
54 
drug dosing (on other days). Blood AGT levels will be analyzed at a central laboratory by 
enzyme-linked immunosorbent assay for measurement of PD effect. These biomarkers may be 
analyzed using validated assays. Details regarding the collection, processing, shipping, and 
storage of the samples will be provided in the Laboratory Manual.  
Results will not be used to adjust dosing of ALN-AGT01 or guide clinical management and will 
not be shared with sites until after the last patient completes Month 12. If clinical circumstances 
arise for which such information is required to guide patient care, local laboratory assessments 
should be drawn. 
6.4. 
Pharmacokinetic Assessments 
Blood samples will be collected for the assessment of plasma concentrations of ALN-AGT01 
and its primary metabolite AS(N-1)3′ ALN-AGT01 at the time points indicated in the Schedule 
of Assessments (Table 1). A detailed schedule of time points for the collection of blood samples 
for PK analysis is in Table 2. 
Plasma concentrations of ALN-AGT01 and AS(N-1)3′ ALN-AGT01 will be determined using a 
validated assay. Details regarding sample volumes to be collected, and the processing, shipping, 
and analysis of the samples will be provided in the Laboratory Manual. 
6.5. 
Safety Assessments 
The assessment of safety during the study will consist of the surveillance and recording of AEs, 
including SAEs, recording of concomitant medication and measurements of vital signs, weight, 
electrocardiogram (ECG) findings, and laboratory tests. Clinically significant abnormalities 
observed during the physical examination are recorded. 
6.5.1. 
Vital Signs 
Vital signs will be measured as specified in the Schedule of Assessments (Table 1) and include 
office blood pressure, heart rate, body temperature, and respiratory rate. When vital signs and 
blood sample collection occur at the same time, vital signs should be performed before blood 
samples are drawn, where possible. Vital signs should be measured predose in the seated 
position, after the patient has rested comfortably for approximately 5 minutes. Body temperature 
in degrees Celsius will be obtained via oral, tympanic, forehead, or axillary methods. Heart rate 
will be counted for a full minute and recorded in beats per minute, and respiration rate will be 
counted for a full minute and recorded in breaths per minute. Blood pressure is described in 
Section 6.2.  
Additional vital sign assessments, as medially indicated, may be added at the discretion of the 
Investigator, or as per DMC advice. 
Vital signs results will be recorded in the eCRF. 
6.5.2. 
Weight, Height, and Morphometrics 
Height and body weight measurements will be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded in the eCRF. Height will be measured at screening 
only. Height will be measured in centimeters. Body weight should be measured in kilograms to 
the first decimal point in patients wearing light clothing and without shoes.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
55 
Waist circumference and waist-to-hip-ratio will also be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded on the eCRF. For waist circumference and waist-to-
hip ratio, patients should wear minimal clothing to ensure that the measuring tape is correctly 
positioned. Patients should stand erect with the abdomen relaxed, arms at the sides, feet together 
and with their weight equally divided over both legs. To perform the waist measurement, the 
lowest rib margin is first located and marked with a pen. The iliac crest is then palpated in the 
midaxillary line, and also marked. It is recommended to apply an elastic tape horizontally 
midway between the lowest rib margin and the iliac crest, and tie firmly so that it stays in 
position around the abdomen about the level of the umbilicus. The elastic tape thus defines the 
level of the waist circumference, which can then be measured by positioning the measuring tape 
over the elastic tape. Hip circumference measurement should be taken around the widest portion 
of the buttocks. Patients are asked to breathe normally, and to breathe out gently at the time of 
the measurement to prevent them from contracting their muscles or from holding their breath. A 
stretch-resistant tape that provides a constant 100 g of tension is recommended. Measurements 
should be obtained with the tape positioned parallel to the floor and performed using the same 
procedure throughout the study. 
The reading is taken to the nearest centimeter and entered in the source document. Each 
measurement should be repeated twice; if the measurements are within 1 cm of each other, the 
average should be calculated. If the difference between the 2 measurements exceeds 1 cm, the 2 
measurements should be repeated.  
6.5.3. 
Physical Examination 
Full and symptom-directed physical examinations will be conducted according to the Schedule 
of Assessments (Table 1); if a physical examination is scheduled for a dosing visit, it should be 
conducted prior to dosing. Full physical examinations will include the examination of the 
following: general appearance; head, eyes, ears, nose and throat; respiratory, cardiovascular, 
gastrointestinal, musculoskeletal, and dermatological systems; thyroid; lymph nodes; and 
neurological status (see the Recommended Neurological Assessments for All Physical 
Examinations document for further details on the assessments to be performed as part of the 
neurological evaluation). 
Symptom-directed physical examinations will be guided by evaluation of changes in symptoms, 
or the onset of new symptoms, since the last visit. Neurological evaluation should be performed 
during all symptom-directed physical examinations regardless of whether neurological 
symptoms have been experienced by the patient.  
Clinically significant abnormalities observed during the physical examination are recorded on 
the medical history or AE eCRF. 
6.5.4. 
Electrocardiogram 
The 12-lead ECGs reporting rhythm, ventricular rate, RR interval, PR interval, QRS duration, 
and QT interval and Fridericia-corrected QT interval will be obtained using a local machine, as 
specified in the Schedule of Assessments (Table 1). Patients should be supine for at least 10 
minutes before each ECG is obtained. The Investigator or qualified designee will review all 
single 12-lead ECGs to assess whether the results have changed since the Baseline visit and to 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
56 
determine the clinical significance of the results. These assessments will be recorded in the 
eCRF.  
When ECG and blood sample collection for RAAS biomarkers (renin, aldosterone, and Ang I/II) 
occur at the same visit, and where feasible, blood sample collection should occur first. ECGs 
should be performed at least 30 minutes after phlebotomy or other stressful assessments. 
The Investigator or qualified designee will review all ECGs to assess whether the results have 
changed since the baseline visit and to determine the clinical significance of the results. These 
assessments will be recorded in the eCRF. Additional ECGs may be collected at the discretion of 
the Investigator, or as per DMC advice.  
6.5.5. 
Clinical Laboratory Assessments 
The following clinical laboratory tests will be evaluated by a central laboratory. Specific 
instructions for transaminase elevations are provided in Section 6.5.6.4. For any other 
unexplained clinically relevant abnormal laboratory test occurring after study drug 
administration, the test should be repeated and followed up at the discretion of the Investigator, 
or as per DMC advice, until it has returned to the normal range or stabilized, and/or a diagnosis 
is made to adequately explain the abnormality. Additional safety laboratories and assessments as 
indicated by the clinical situation may be requested. Clinical laboratory assessments are listed in 
Table 6 and will be assessed as specified in the Schedule of Assessments (Table 1).  
While local laboratory results may be used for urgent clinical decisions, on the day of the 
assessments all laboratory assessments specified in Table 6 which are performed at the clinic 
should also be sent in parallel to the central laboratory. In the case of discrepant local and central 
laboratory results on samples drawn on the same day, central laboratory results will be relied 
upon for clinical decisions. 
Clinical laboratory assessments may be collected at the clinical study center or at home by a 
trained healthcare professional. Blood samples collected for RAAS biomarkers should be 
collected in the morning and in the seated/upright position (after blood pressure measurements 
and before any assessments collected in the supine position). 
Spot urine collections for albumin and creatinine should be obtained in the morning.  
For any safety event or laboratory abnormality, additional laboratory assessments, imaging, and 
consultation may be performed for clinical evaluation and/or in consultation with the Medical 
Monitor; results may be collected and should be included in the clinical database. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
57 
Table 6: 
Clinical Laboratory Assessments  
Hematology 
Complete blood count with differential 
 
Serum Chemistry 
Sodium 
Potassium 
BUN 
Phosphate 
Uric acid 
Albumin 
Total protein 
Calcium 
Glucose 
Bicarbonate 
Creatinine and eGFR 
Chloride 
Liver Function Tests 
 
AST 
ALP 
ALT 
Bilirubin (total and direct) 
GGT 
 
Urinalysis 
Visual inspection for appearance and color 
Bilirubin 
pH (dipstick) 
Nitrite 
Specific gravity 
RBCs 
Ketones 
Urobilinogen 
Protein  
Leukocyte esterase 
Glucose 
Microscopy (if clinically indicated) 
Coagulation  
Prothrombin time 
International normalized ratio 
Partial thromboplastin time  
 
Fasting Lipid Panel and Glycemic Assessments (see Section 6.5.5.1) 
Lipid panel, including 
HDL-C, non-HDL-C, LDL-C, apolipoprotein A1, 
triglycerides, total cholesterol  
Insulin 
Fasting plasma glucose 
HbA1c 
Immunogenicity (see Section 6.5.5.2) 
ADA 
 
Pregnancy Testing/FSH Screening (see Section 6.5.5.3) 
β-human chorionic gonadotropin (females of 
child-bearing potential only) 
Follicle-stimulating hormone (postmenopausal 
women only) 
Abbreviations: ADA=anti-drug antibodies; ALP=alkaline phosphatase; ALT=alanine aminotransferase; 
AST=aspartate aminotransferase; BUN=blood urea nitrogen; eGFR=estimated glomerular filtration rate; 
FSH=follicle-stimulating hormone; GGT=gamma glutamyl transferase; HbA1c=hemoglobin A1c; HDL-C=high-
density lipoprotein; LDL-C=low-density lipoprotein; RBCs=red blood cells. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
58 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments 
Blood samples for fasting plasma glucose, insulin, lipid panel (including total cholesterol, high-
density lipoprotein [HDL-C], non-HDL-C, low-density lipoprotein, apolipoprotein A1, and 
triglycerides), and HbA1c will be collected at the time points listed in the Schedule of 
Assessments (Table 1). Patients are required to fast for ≥10 hours before sample collection for 
fasting plasma glucose, insulin, lipid panel, and HbA1c. Samples should be collected at 
approximately the same time of day (±2 hours). 
6.5.5.2. 
Immunogenicity 
Blood samples will be collected to evaluate anti-drug antibodies (ADA). Blood samples for ADA 
testing must be collected before study drug administration (on days when study drug is to be 
dosed) or at a time point corresponding to the time of study drug dosing (on other days) as 
specified in the Schedule of Assessments (Table 1). A blood sample to evaluate ADA will be 
collected at the ET visit, if applicable. Blood samples for ADA will be analyzed at a central 
laboratory. 
Details regarding the processing, shipping, and analysis of the samples will be provided in the 
Laboratory Manual. 
6.5.5.3. 
Pregnancy Testing 
A pregnancy test will be performed for females of child-bearing potential. A serum pregnancy 
test will be performed at screening, and urine pregnancy tests will be performed thereafter per 
the Schedule of Assessments and any time pregnancy is suspected. More frequent pregnancy 
testing may be performed where required per local requirements. The results of the pregnancy 
test must be known before study drug administration. Patients who are pregnant at screening are 
not eligible for study participation. Any woman with a positive urine pregnancy test, 
subsequently confirmed by a positive serum pregnancy test, during the study will be 
discontinued from study drug but will continue to be followed for safety. Patients determined to 
be pregnant while on study will be followed at least until the pregnancy outcome is known (see 
Section 6.5.6.7 for follow-up instructions). 
A blood sample will be drawn at screening to measure the levels of follicle stimulating hormone 
in order to confirm postmenopausal status in all women suspected to be postmenopausal (see 
Section 5.7.1 for definition of postmenopausal state). 
6.5.5.4. 
Additional Liver Function Assessments 
Additional laboratory assessments will be performed in patients who experience any LFT 
abnormalities as outlined in Section 5.2.4. Following the occurrence of elevated liver 
transaminases or other LFT abnormalities per central laboratory, all assessments in Table 7 will 
be performed 1 time, as well as hematology, serum chemistry, LFT, and coagulation assessments 
from Table 6, and other assessments or evaluations per Investigator discretion, as appropriate.  
Monitoring, including criteria for dose modification or withholding the study drug, is described 
in Section 5.2.4.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
59 
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases 
Extended Hepatic Panel 
HBsAg, HBc antibody IgM  
Parvovirus B19 DNA – quantitative 
HAV antibody IgM 
HHV-6 DNA viral load – quantitative 
HCV antibody 
Anti-nuclear antibodies 
HCV RNA PCR – quantitative 
Anti-smooth muscle antibodies 
HEV antibody IgM 
Anti-LKM1 antibody 
Herpes Simplex Virus 1 and 2 antibody IgM, IgG 
Anti-mitochondrial antibodies 
Herpes Zoster Virus IgM, IgG 
Anti-SLA 
Epstein-Barr Virus antibodies, IgM, and IgG 
Ferritin 
Cytomegalovirus antibodies, IgM, IgG 
Ceruloplasmin 
Imaging 
Abdominal ultrasound with Doppler flow (or CT or MRI) including right upper quadrant 
Focused Medical and Travel History 
Use of any potentially hepatotoxic concomitant 
medications, including over the counter medications 
and herbal remedies 
Alcohol consumption and drugs of abuse 
Other potentially hepatotoxic agents including any 
work-related exposures 
Recent travels to areas where hepatitis A or E 
is endemic 
Abbreviations: CT=computed tomography; HAV=hepatitis A virus; HBc=hepatitis B core; HBsAg=hepatitis B virus 
surface antigen; HCV=hepatitis C virus; HEV=hepatitis E virus; HHV-6=human herpesvirus 6; 
IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; LKM1=liver/kidney microsome-1 antibody; 
MRI=magnetic resonance imagery; PCR=polymerase chain reaction; RNA=ribonucleic acid; SLA=soluble liver 
antigen 
Note: 
• 
All laboratory assessments will be measured in a central laboratory. The full panel of assessments should only 
be performed once; individual assessments may be repeated, as needed. 
6.5.6. 
Adverse Events 
6.5.6.1. 
Definitions 
Adverse Event 
According to the ICH E2A guideline Definitions and Standards for Expedited Reporting, and 21 
Code of Federal Regulations 312.32, Investigational New Drug Safety Reporting, an AE is any 
untoward medical occurrence in a patient or clinical investigational subject administered a 
medicinal product and which does not necessarily have a causal relationship with this treatment. 
Serious Adverse Event 
An SAE is any untoward medical occurrence that at any dose: 
• Results in death 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
60 
• Is life-threatening (an event which places the patient at immediate risk of death from 
the event as it occurred. It does not include an event that had it occurred in a more 
severe form might have caused death) 
• Requires inpatient hospitalization or prolongation of existing hospitalization 
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly or birth defect 
• Is an important medical event that may not be immediately life-threatening or result 
in death or hospitalization but may jeopardize the patient and may require 
intervention to prevent one of the other outcomes listed in the definition above (eg, 
events include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home, blood dyscrasias, convulsions, or the development of drug 
dependency or abuse). 
Adverse Events of Clinical Interest 
The following are considered to be AEs of clinical interest: 
• ALT or AST >3×ULN 
• Severe or serious ISRs; ISRs that are associated with a recall phenomenon (reaction 
at the site of a prior injection with subsequent injections), or those that lead to 
temporary dose interruption or permanent discontinuation of ALN-AGT01. 
An ISR is defined as a local reaction at or near the site of injection. “At or near” the 
injection site includes reactions at the injection site, adjacent to the injection site, or a 
reaction which may shift slightly away from the injection site due to gravity (eg, as 
may occur with swelling or hematoma). A systemic reaction which includes the 
injection site, eg, generalized urticaria, other distinct entities or conditions like 
lymphadenopathy that may be near the injection site is not considered an ISR. 
For information on recording and reporting of AEs of clinical interest, see Section 6.5.6.2 and 
Section 6.5.6.3, respectively. 
Adverse Event Severity 
Adverse events are to be graded according to the categories detailed below: 
Mild: 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
Moderate: Moderate; minimal, local, or noninvasive intervention indicated; limiting age 
appropriate instrumental activities of daily living (eg, preparing meals, shopping 
for groceries or clothes, using the telephone, managing money). 
Severe: 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting 
self-care activities of daily living (ie, bathing, dressing and undressing, feeding 
self, using the toilet, taking medications, and not bedridden); OR life-threatening 
consequences; urgent intervention indicated; OR death related to an adverse event. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
61 
Changes in severity should be documented in the medical record to allow assessment of the 
duration of the event at each level of severity. Adverse events characterized as intermittent 
require documentation of the start and stop of each incidence. When changes in the severity of an 
AE occur more frequently than once a day, the maximum severity for the experience that day 
should be noted. If the severity category changes over a number of days, then those changes 
should be recorded separately (with distinct onset dates). 
Adverse event severity and seriousness are assessed independently. ‘Severity’ characterizes the 
intensity of an AE. ‘Serious’ is a regulatory definition and serves as a guide to the Sponsor for 
defining regulatory reporting obligations (see definition for SAE). 
Relationship of the Adverse Event to Study Drug 
The relationship of each AE to study drug should be evaluated by the Investigator by a “yes” or 
“no” response to the question: “Is there a reasonable possibility that the event may have been 
caused by the study drug?” A “yes” response indicates that the event is considered as related to 
the study drug. 
6.5.6.2. 
Eliciting and Recording Adverse Events 
Eliciting Adverse Events 
The patient should be asked about medically relevant changes in the patient’s health since the 
last visit. The patient should also be asked if the patient has been hospitalized, had any accidents, 
used any new medications, or changed concomitant medication routines (both prescription and 
over-the-counter). In addition to patient observations, AEs will be documented from any 
clinically relevant laboratory findings, physical examination findings, ECG changes, or other 
findings that are relevant to patient safety. 
Recording Adverse Events 
The Investigator is responsible for recording non-serious AEs that are observed or reported by 
the patient after administration of the first dose of study drug regardless of their relationship to 
study drug through the end of study. Non-serious AEs will be followed until the end of study. 
Events occurring after signing of the ICF and before study drug administration will be captured 
as medical history (see Section 6.1), while AEs that occur after study drug administration, and 
baseline events that worsen after study drug administration, must be recorded as AEs.  
The Investigator is responsible for recording SAEs that are observed or reported by the patient 
after the time when the informed consent is signed regardless of their relationship to study drug 
through the end of study. SAEs will be followed until satisfactory resolution, until baseline level 
is reached, or until the SAE is considered by the Investigator to be chronic or the patient is 
stable, as appropriate. 
All AEs must be recorded in the source records for the clinical study center and in the eCRF for 
the patient, whether or not they are considered to be drug-related. Each AE must be described in 
detail: onset time and date, description of event, severity, relationship to study drug, action taken, 
and outcome (including time and date of resolution, if applicable). 
For SAEs, record the event(s) in the eCRF and, as applicable, the SAE form. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
62 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the supplemental AEs of 
Clinical Interest eCRF should be completed. Additional clinical and laboratory information may 
be collected. Refer to CRF completion guidelines for details on reporting events in the 
supplemental AEs of Clinical Interest eCRF. 
For all ISRs, the Investigator, or delegate, should submit an Injection Site Reaction Signs or 
Symptoms eCRF, recording additional information regarding each injection site reaction that is 
entered on the AE eCRF (eg, symptom(s), injection site location, follow-up actions taken, etc). 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the Sponsor or its designee 
should be notified within 24 hours using the appropriate eCRF. 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee 
An assessment of the seriousness of each AE will be made by the Investigator. Any AE and 
laboratory abnormality that meets the SAE criteria in Section 6.5.6.1 must be reported to the 
Sponsor or designee immediately and no later than 24 hours from the time that clinical study 
center staff first learns of the event. All SAEs must be reported regardless of the relationship to 
study drug. 
The initial report should include at least the following information: 
• Patient’s study number 
• Description and date of onset of the event 
• Criterion for serious 
• Preliminary assignment of relationship to study drug, and 
• Investigator/site information 
To report the SAE, complete the eCRF and, as applicable, the SAE form. Immediately and no 
later than 24 hours of receipt of follow-up information, the Investigator must update the eCRF 
and, as applicable, the SAE form.  
Appropriate remedial measures should be taken by the Investigator using his/her best medical 
judgment to treat the SAE. These measures and the patient’s response to these measures should 
be recorded. All SAEs, regardless of relationship to study drug, will be followed by the 
Investigator until satisfactory resolution or the Investigator deems the SAE to be chronic or 
stable. Clinical, laboratory, and diagnostic measures should be employed by the Investigator as 
needed to adequately determine the etiology of the event. 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities 
The Sponsor or its representative will report certain study events in an expedited manner to the 
Food and Drug Administration, the European Medicines Agency’s EudraVigilance electronic 
system according to Directive 2001/20/EC, and to all country Regulatory Authorities where the 
study is being conducted, according to local applicable regulations. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
63 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee 
Suspected unexpected serious adverse reactions will be reported to the IRB/IEC per their 
institutional policy by the Investigator or Sponsor (or Sponsor designee) according to country 
requirements. Copies of each report and documentation of IRB/IEC notification and 
acknowledgement of receipt will be kept in the Investigator’s study file. 
6.5.6.7. 
Pregnancy Reporting 
If a female patient becomes pregnant during the study through safety follow-up (Section 3.1), the 
Investigator must report the pregnancy to the Sponsor or designee within 24 hours of being 
notified of the pregnancy. Details of the pregnancy will be recorded on the pregnancy reporting 
form. The patient should receive any necessary counseling regarding the risks of continuing the 
pregnancy, the possible effects on the fetus, and be counseled not to breastfeed for 90 days after 
the last dose of study drug. 
The pregnancy should be followed by the Investigator until completion. At the completion of the 
pregnancy, the Investigator will document the outcome of the pregnancy. If the outcome of the 
pregnancy results in a postpartum complication, spontaneous abortion, stillbirth, neonatal death, 
or congenital anomaly, then the Investigator should follow the procedures for reporting an SAE 
as outlined in Section 6.5.6.4. 
6.5.6.8. 
Overdose and Other Special Situations Reporting 
An overdose is defined as any dose of study drug administered to the participant or taken by the 
participant that is >2× the assigned dose during a single administration and/or ≥2 doses within ½ 
the intended dosing interval. 
The Sponsor does not recommend specific treatment for an overdose.  
In an event of an overdose or other special situations (eg, medication error, abuse, misuse, CPC 
associated with an AE), the Investigator should: 
• Contact the Medical Monitor within 24 hours  
• Submit the special situations reporting form within 24 hours using the contact 
information in the Pharmacy Manual 
• Closely monitor the participant for any AE/SAE and laboratory abnormalities 
• Document the amount of study drug given  
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or 
a concomitant medication will be considered AEs/SAEs.  
Full details of overdose and other special situations reporting instructions will be outlined in the 
Pharmacy Manual. 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository 
Alnylam’s RNAi therapeutics platform permits the highly specific targeting of investigational 
therapies based on genetic sequence. It is possible that variations in the target genetic sequence 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
64 
will result in variations in drug effect. More generally, genetic variations may account for the 
well-described heterogeneous manifestations of disease in patients with hypertension, as well as 
their responses to treatment. 
Where allowed per local regulations, ethics committee (IRB/IEC) approval, and patient consent, 
samples will be collected as part of this study to permit exploratory investigations and the 
application of novel approaches to bioanalyses that may further elucidate the outcomes of this 
study, or potentially advance understanding of the safety, mechanism of action, and/or efficacy 
of ALN-AGT01. 
Biological specimens will be collected at the intervals indicated in the Schedule of Assessments 
(Table 1). These specimens will be analyzed at a central laboratory. Potential exploratory 
investigations may include DNA, RNA, or biochemical metabolite assessments as they relate to 
disease progression, efficacy, or safety. 
The biospecimen repository will also include residual material from routine samples (safety 
laboratory samples, PK samples, etc) that are obtained during the study. 
These specimens will be securely stored in a central biorepository for up to 10 years following 
the completion of this clinical study (ie, last patient last visit), or as per local regulations. After 
10 years have elapsed, samples will be destroyed. 
Details regarding the collection, processing, storage, and shipping of the samples will be 
provided in the Laboratory Manual. 
Exploratory analysis of these biospecimens will be performed by Alnylam Pharmaceuticals or its 
designees. 
When biobanking is permitted by local regulation, study participants will be advised during the 
informed consent process of these biobanking details and the potential for exploratory 
investigation of their samples. 
7. 
STATISTICS 
A Statistical Analysis Plan (SAP) will be finalized before database lock and unblinding for the 
primary analysis. The plan will detail the implementation of the statistical analyses in accordance 
with the principle features stated in the protocol. 
7.1. 
Determination of Sample Size 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline at Month 
3 in 24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 375 
patients (75 per treatment group) provides at least 84% power to detect a dose response signal in 
SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided significance level of 
0.05. In addition, this sample size provides at least 80% power to detect a 10 mmHg difference 
between an individual ALN-AGT01 dose versus placebo with a 2-sided significance level of 
0.05. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
65 
7.2. 
Statistical Methodology 
The statistical and analytical plans presented below are brief summaries of planned analyses. 
More complete plans will be detailed in the SAP. Changes to the methods described in the final 
SAP will be described and justified as needed in the clinical study report. For information on 
study endpoints, see Section 2. 
7.2.1. 
Populations to be Analyzed 
The populations (analysis sets) are defined as follows: 
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• PK Analysis Set: All patients who received at least 1 full dose of ALN-AGT01 and 
have at least 1 nonmissing postdose PK assessment. 
• PD Analysis Set: All patients who received at least 1 full dose of study drug. All by-
treatment analyses based on the PD Analysis Set will be grouped according to the 
treatment actually received. 
• All ALN-AGT01 Treated Set: All patients who received any amount of 1 of the 4 
ALN-AGT01 dosing regimens, including patients who took ALN-AGT01 during the 
6-month placebo-controlled period and patients who initially took placebo and then 
switched to ALN-AGT01 after the Month 6 visit. 
For the primary analysis for the 6-month placebo-controlled DB period, the primary population 
used to evaluate efficacy will be the FAS. Safety will be analyzed using the Safety Analysis Set. 
The PK and PD Analysis Sets will be used to conduct PK and PD analyses, respectively. 
The All ALN-AGT01 Treated Set will be used to summarize the efficacy and safety of 
ALN-AGT01 throughout the entire DB period (including DB Extension period). 
7.2.2. 
Examination of Subgroups 
Subgroup analyses will be conducted for selected endpoints. Subgroup categories and detailed 
methodology will be provided in the SAP. 
7.2.3. 
Handling of Missing Data 
Handling of missing data will be described in the SAP. 
7.2.4. 
Baseline Evaluations 
Demographics and other disease-specific baseline characteristics will be summarized. 
In general, baseline will be defined as the average of all assessments, including unscheduled 
assessments, prior to the first dose of study drug. Details of the definition will be specified in the 
SAP. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
66 
7.2.5. 
Efficacy Analyses 
The primary endpoint is the change from baseline at Month 3 in 24-hour mean SBP assessed by 
ABPM. The hypothesis of the dose response signal for the primary endpoint across ALN-AGT01 
doses and placebo will be tested using Dunnett’s procedure based on mixed model for repeated 
measurements (MMRM). The MMRM model will include treatment, visit, treatment-by-visit 
interaction, and race (black; all other races) as fixed factors and baseline 24-hour mean SBP 
assessed by ABPM as a covariate. An unstructured covariance matrix will be used. 
The key secondary endpoints are: 
• Change from baseline at Month 3 in office SBP 
• Change from baseline at Month 6 in 24-hour mean SBP assessed by ABPM 
• Change from baseline at Month 6 in office SBP 
• Proportion of patients with 24-hour mean SBP assessed by ABPM <130 mmHg 
and/or reduction ≥20 mmHg without additional antihypertensive medications at 
Month 6 
To control the overall type I error, the primary and key secondary endpoints will be tested in 
hierarchical order. 
Details of the analysis method for primary, secondary, and exploratory endpoints will be 
described in the SAP. 
7.2.6. 
Pharmacodynamic Analysis 
Pharmacodynamic analyses will include the evaluation of changes in levels of serum AGT and 
other exploratory biomarkers of the RAAS pathway. Descriptive statistics for observed levels 
and the relative change from baseline for all measured biomarkers will be presented for each of 
the postdose time points. 
Statistical comparison of the biomarker levels (absolute and/or change from baseline) across 
treatment groups may be explored. Details of the analysis will be specified in the SAP.  
Population PK/PD analysis may be conducted to evaluate the dose-response relationships for PD 
lowering after ALN-AGT01 treatment. Additionally, the relationship between lowering of serum 
AGT and blood pressure may be explored within a modeling framework. If conducted, these 
analyses will be described in a pharmacometrics analysis plan and results will be presented in a 
separate report. 
7.2.7. 
Pharmacokinetic Analysis 
Plasma concentrations of ALN-AGT01 and its metabolite AS(N-1)3′ ALN-AGT01 will be 
summarized using descriptive statistics. 
Population PK analysis may be conducted on the PK data from this study. If conducted, the 
analysis methods will be described in a pharmacometrics analysis plan and results will be 
presented in a separate report. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
67 
7.2.8. 
Safety Analyses 
The primary parameter is the frequency of treatment-emergent AEs (hereafter referred to simply 
as AEs). Safety parameters also include vital signs, ECGs, and clinical laboratory assessments. 
Extent of exposure will be summarized.  
Prior and concomitant medications will be coded using the World Health Organization Drug 
Dictionary. Results will be tabulated by Anatomical Therapeutic Chemical Classification System 
and Preferred Term (PT). 
Adverse events will be classified according to the Medical Dictionary for Regulatory Activities 
(MedDRA) System Organ Class (SOC) and PT. Adverse events, SAEs, related AEs, AEs leading 
to discontinuation of study drug, and AEs leading to death will be summarized by SOC and PT 
for each treatment arm. By-patient listings will be provided for deaths, SAEs, and AEs leading to 
discontinuation of study drug.  
Descriptive statistics will be provided for clinical laboratory parameters, ECG, and vital signs 
summarizing the observed values and changes from baseline over time. Laboratory shift tables 
from baseline grade (or category) to worst post-baseline grade (or category) will be presented for 
laboratory parameters that are graded or categorized. Abnormal physical exam findings will be 
presented in listings. 
Other safety summaries will be presented as appropriate. Further details will be specified in the 
SAP. 
7.2.9. 
Immunogenicity Analyses 
The frequency and percentage of patients with confirmed positive ADA assay at any time during 
the study as well as at each scheduled visit will be summarized. The titer results for patients with 
confirmed positive ADA results will be summarized. 
7.2.10. 
Interim Analysis 
No formal interim analysis is planned before the primary analysis.  
7.2.11. 
Optional Additional Research 
Optional additional research may be conducted in the future on the biological samples and/or 
data collected during the study in accordance with the strict terms of the ICF (see Section 4.3.2). 
8. 
STUDY ADMINISTRATION 
8.1. 
Ethical and Regulatory Considerations 
This study will be conducted in accordance with the protocol, all applicable regulatory 
requirements, and the current guidelines of Good Clinical Practice (GCP). Compliance with GCP 
provides public assurance that the rights, safety, and well-being of study patients are protected 
consistent with the principles that have their origin in the Declaration of Helsinki. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
68 
8.1.1. 
Informed Consent 
The Investigator will ensure that the patient is given full and adequate oral and written 
information about the nature, purpose, possible risk, and benefit of the study. Patients must also 
be notified that they are free to discontinue from the study at any time. The patient should be 
given the opportunity to ask questions and allowed time to consider the information provided. 
The Investigator will inform the patient if new information becomes available that may be 
relevant to the patient’s willingness to continue participation in the study. Communication of this 
information should be documented. 
The patient’s signed and dated informed consent (in paper or electronic format per local 
regulations and institutional standards) must be obtained before conducting any study tests or 
procedures that are not part of routine care. 
The Investigator must maintain the original, signed ICF. A copy of the signed ICF must be given 
to the patient. 
8.1.2. 
Ethical Review 
The study protocol, including the ICF, must be approved or given a favorable opinion in writing 
by an IRB or IEC, as appropriate. The Investigator must submit written approval before he or she 
can enroll any patient into the study. 
The Investigator is responsible for informing the IRB or IEC of any amendment to the protocol 
in accordance with local requirements. In addition, the IRB or IEC must approve all patient 
materials for the study. The protocol must be reapproved by the IRB or IEC upon receipt of 
amendments and annually, as local regulations require. 
Initial IRB or IEC approval of the protocol, and all materials approved by the IRB or IEC for this 
study including the patient consent form and recruitment materials must be maintained by the 
Investigator and made available for inspection. 
The Investigator will submit reports of SAEs as outlined in Section 6.5.6. In addition, the 
Investigator agrees to submit progress reports to the IRB or IEC per their local reporting 
requirements, or at least annually and at the conclusion of the study. The reports will be made 
available to the Sponsor or designee. 
Any communications from regulatory agencies, IRBs, or IECs in regard to inspections, other 
studies that impact this protocol or the qualifications of study personnel should be promptly 
reported to the Sponsor or its designee. 
The Investigator is also responsible for providing the IRB or IEC with reports of any reportable 
serious adverse drug reactions from any other study conducted with the study drug. The Sponsor 
or designee will provide this information to the Investigator. 
Major changes in this research activity, except those to remove an apparent immediate hazard to 
the patient, must be reviewed and approved by the Sponsor and the IRB or IEC that approved the 
study. Amendments to the protocol must be submitted in writing to the Investigator’s IRB or IEC 
and the Regulatory Authority for approval before patients are enrolled under the amended 
protocol, and patients must be re-consented to the most current version of the ICF.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
69 
8.1.3. 
Serious Breach of Protocol 
Investigators must notify the Medical Monitor within 24 hours of becoming aware of a potential 
serious breach of the protocol. A serious breach is a breach that is likely to affect to a significant 
degree the safety and rights of a study participant or the reliability and robustness of the data 
generated in the clinical study. 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention 
All documentation (including personal data) relating to the study should be retained for 2 years 
after the last approval in an ICH territory or as required by local laws and regulations, whichever 
is longer. 
If it becomes necessary for the Sponsor, the Sponsor’s designee, applicable IRB/IEC, or 
applicable regulatory authorities to review or audit any documentation relating to the study, the 
Investigator must permit direct access to all source documents/data. Records will not be 
destroyed without informing the Sponsor in writing and giving the Sponsor the opportunity to 
store the records for a longer period of time at the Sponsor’s expense. 
The Investigator must ensure that the patients’ confidentiality will be maintained. On the eCRFs 
or other documents submitted to the Sponsor or designees, patients should not be identified by 
their names, but by the assigned patient number or code. If patient names are included on copies 
of documents to be submitted to the Sponsor or designees, the names will be obliterated, and the 
assigned patient number added to the document, before sending to the Sponsor. Documents not 
for submission to the Sponsor (eg, signed ICFs) should be maintained by the Investigator in strict 
confidence. 
The Investigator must treat all of the information related to the study and the compiled data as 
confidential, whose use is for the purpose of conducting the study. The Sponsor must approve 
any transfer of information not directly involved in the study. 
To comply with local and/or regional regulations, this clinical study may be registered, and study 
results may be posted on public registries, such as ClinicalTrials.gov. 
8.1.5. 
End of Study 
The end of study is defined as the last patient last visit. 
8.1.6. 
Termination of the Clinical Study or Site Closure 
The Sponsor, or designee, reserves the right to terminate the study or a clinical study site at any 
time. Conditions that may warrant this action may include, but are not limited to: 
• The discovery of an unexpected, serious, or unacceptable risk to patients participating 
in the study 
• Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of participants by the Investigator 
• The decision on the part of the Sponsor to suspend or discontinue treatment with the 
study drug 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
70 
Should the study be terminated, and/or the site closed for whatever reason, all documentation and 
study drug pertaining to the study must be returned to the Sponsor or its representative, and the 
Investigators, IRB/IEC and Regulatory Authorities will be promptly informed of the termination 
and the reason for the decision. The Investigator should promptly inform the patients and assure 
appropriate therapy and follow-up. 
8.2. 
Data Quality Control and Quality Assurance 
8.2.1. 
Data Handling 
Study data must be recorded on CRFs (paper and/or electronic) provided by the Sponsor or 
designee on behalf of the Sponsor. Case report forms must be completed only by persons 
designated by the Investigator. If eCRFs are used, study data must be entered by trained site 
personnel with access to a valid and secure eCRF system. All data entered into the eCRF must 
also be available in the source documents. Corrections on paper CRFs must be made so as to not 
obliterate the original data and must be initialed and dated by the person who made the 
correction. 
8.2.2. 
Study Monitoring 
The Monitor, as a representative of the Sponsor, has an obligation to closely follow the study 
conduct at the site. The Monitor will visit the Investigator and clinical study center periodically 
and will maintain frequent telephone and written contact. The Monitor will maintain current 
personal knowledge of the study through observation, review of study records and source 
documentation, and discussion of the conduct of the study with the Investigator and staff. 
The Monitor will review source documents, systems and CRFs to ensure overall quality and 
completeness of the data and to confirm study procedures are complied with the requirements in 
the study protocol accurately. The Sponsor, or its designee, will be allowed to conduct site visits 
to the investigation facilities for the purpose of monitoring any aspect of the study. The 
Investigator agrees to allow the Monitor to inspect the drug storage area, study drug stocks, drug 
accountability records, patient charts and study source documents, site standard operating 
procedures and training records, and other records relative to study conduct. 
Where local regulations allow, the Monitor may request remote access to source documents and 
systems. Should this take place, it will be done in a manner that protects the confidentiality of the 
data. 
8.2.3. 
Audits and Inspections 
Periodically, the Sponsor or its authorized representatives audit clinical investigative sites as an 
independent review of core study processes and documents to determine whether these activities 
were conducted, and data were recorded, analyzed, and accurately reported according to the 
protocol, GCP guidelines of the ICH, and any applicable regulatory requirements. A regulatory 
authority, an IEC or an IRB may visit the site to perform audits or inspections, including source 
data verification. The Investigator should contact the Sponsor and designee immediately if 
contacted by a regulatory agency, an IEC, or an IRB about an inspection. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
71 
8.3. 
Publication Policy 
It is intended that after completion of the study, the data are to be submitted for publication in a 
scientific journal and/or for reporting at a scientific meeting. A copy of any proposed publication 
(eg, manuscript, abstracts, oral/slide presentations, book chapters) based on this study, must be 
provided and confirmed received at the Sponsor at least 30 days before its submission. The 
Clinical Trial Agreement will detail the procedures for publications. 
Authorship of any publications resulting from this study will be determined on the basis of the 
Uniform Requirement for Manuscripts Submitted to Biomedical Journals (International 
Committee of Medical Journal Editors). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
72 
9. 
LIST OF REFERENCES 
Angell SY, De Cock KM, Frieden TR. A public health approach to global management of 
hypertension. Lancet. 2015 Feb 28;385(9970):825-7. 
Beeftink MM, van der Sande NG, Bots ML, Doevendans PA, Blankestijn PJ, Visseren FL, et al. 
Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-
to-Control Hypertension. Hypertension. 2017 May;69(5):927-32. 
Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to 
antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011 Mar;29(3):610-8. 
de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M, et al. Prevalence and 
factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension. 
2009 Mar;53(3):466-72. 
Dzau VJ, Balatbat CA. Future of Hypertension. Hypertension. 2019 Sep;74(3):450-7. 
Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of 
Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 
2017 Jan 10;317(2):165-82. 
Georgianos PI, Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding 
drugs. Kidney Int. 2018 Feb;93(2):325-34. 
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of 
hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23. 
Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the 
Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-30. 
McClellan M, Brown N, Califf RM, Warner JJ. Call to Action: Urgent Challenges in 
Cardiovascular Disease: A Presidential Advisory From the American Heart Association. 
Circulation. 2019 Feb 26;139(9):e44-e54. 
McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, et al. Aliskiren, 
Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016 Apr 21;374(16):1521-
32. 
Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP, Crooke RM. Blood Pressure 
Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of 
Hypertension and Kidney Injury. Hypertension. 2017 Sep;70(3):566-76. 
Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, et al. Trends in Blood 
Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020 
Sep 22;324(12):1190-200. 
NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a 
pooled analysis of 1479 population-based measurement studies with 19.1 million participants. 
Lancet. 2017 Jan 7;389(10064):37-55. 
Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and 
a lifecourse strategy to address the global burden of raised blood pressure on current and future 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
73 
generations: the Lancet Commission on hypertension. Lancet. 2016 Nov 26;388(10060):2665-
712. 
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. 
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 
6;367(23):2204-13. 
Peacock E, Krousel-Wood M. Adherence to Antihypertensive Therapy. Med Clin North Am. 
2017 Jan;101(1):229-45. 
Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications 
and controversies. Nat Rev Endocrinol. 2015 Apr;11(4):242-52. 
Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE, et al. Medication 
adherence and persistence according to different antihypertensive drug classes: A retrospective 
cohort study of 255,500 patients. Int J Cardiol. 2016 Oct 1;220:668-76. 
Services UDoHaH. The Surgeon General's Call to Action to Control Hypertension. 2020 October 
2020:1-50. 
Uijl E, Mirabito Colafella KM, Sun Y, Ren L, van Veghel R, Garrelds IM, et al. Strong and 
Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen. 
Hypertension. 2019 Jun;73(6):1249-57. 
van der Laan DM, Elders PJM, Boons C, Beckeringh JJ, Nijpels G, Hugtenburg JG. Factors 
associated with antihypertensive medication non-adherence: a systematic review. J Hum 
Hypertens. 2017 Nov;31(11):687-94. 
Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients 
with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 
15;372(3):211-21. 
Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report 
of the American College of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115. 
White WB, Mansoor GA, Tendler BE, Anwar YA. Nocturnal blood pressure epidemiology, 
determinants, and effects of antihypertensive therapy. Blood Press Monit. 1998 Feb;3(1):43-51. 
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH 
Guidelines for the management of arterial hypertension: The Task Force for the management of 
arterial hypertension of the European Society of Cardiology and the European Society of 
Hypertension: The Task Force for the management of arterial hypertension of the European 
Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 
Oct;36(10):1953-2041. 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
74 
10. 
APPENDICES 
10.1. 
Measurement of Blood Pressure 
All blood pressure measurements (office, ABPM, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in the 
relevant user manuals.  
The appropriately sized cuff for each modality must be used for all assessments. The arm’s 
circumference at midpoint (halfway between the acromion and olecranon) should be determined 
at screening with a metric tape measure and used to select the appropriately sized blood pressure 
cuff/bladder for each instrument as described in the ABPM Investigator Manual and the HBPM 
and OBPM Investigator Manual. Unless significant weight loss or gain occurs between visits, the 
patient should use the same cuff/bladder size throughout the study. 
At the first Screening visit only, office blood pressure will be measured in both arms to select the 
appropriate arm to use for office blood pressure and HBPM measurements. Unless a concomitant 
condition favors the use of a specific arm, the arm with the higher office SBP should be used for 
all subsequent office blood pressure and HBPM readings. The ABPM should be measured using 
the patient’s nondominant arm. If the patient is ambidextrous, the same arm used for office blood 
pressure and HBPM readings should be used. 
ABPM 
The appropriately sized cuff should be placed on the correct arm following the instructions in the 
ABPM Investigator Manual. In patients taking oral antihypertensives (including those initiated as 
rescue medication), ABPM should be started prior to the morning dose of antihypertensive 
medication. All ABPM collections must be in the outpatient/ambulatory state. During screening, 
ABPM recording must be obtained within 2 weeks prior to randomization. ABPM recordings 
that are associated with dosing visits after Day 1 must be obtained in advance of the visit (within 
7 days before the corresponding dosing visit) and the results reviewed prior to dosing. 
During the 24-hour monitoring period, patients must avoid strenuous exercise but should 
otherwise maintain their usual level of physical activity. The ABPM is programmed to take 
readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the 
night (10 pm to 5:59 am). While awake, the patient should hold their arm still by their side while 
the device is inflating for a reading. Patients must record the timing of going to sleep, waking up, 
and any oral medications taken during the ABPM, and these responses must be entered into the 
eCRF. 
After the monitoring period is complete, upload the ABPM data to receive a report with validity 
assessment. An ABPM will be considered valid if (1) the number of successful daytime readings 
is ≥33, (2) the number of successful nighttime readings is ≥11, and (3) no more than 3 hours are 
not represented (ie, 3 sections of 60 minutes where 0 valid readings were obtained). If the ABPM 
recording is invalid at any point during the study, the patient will be provided 1 opportunity to 
repeat the recording within 7 days from the end time of the invalid ABPM.  
In circumstances where it is not possible to randomize a patient within the 2-week window 
following a valid ABPM recording that met the inclusion criterion, a single additional ABPM 
recording is permitted, with no option for retesting in case of an invalid recording. Eligibility is 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
75 
assessed by the most recent ABPM recording obtained. If a valid ABPM recording that meets the 
inclusion criterion is unable to be obtained within 2 weeks prior to randomization, the patient is a 
screen failure.  
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor and the arm selected during screening. 
Office blood pressure should be measured early in the visit prior to the morning dose of 
antihypertensive medication, before phlebotomy or other potentially stressful assessments. To 
minimize confounding by circadian changes, study visits should be scheduled for a consistent 
timeframe of the day. The use of inhaled short-acting beta agonists should be avoided within 6 
hours prior to measuring blood pressure and/or heart rate. The use of phosphodiesterase type 5 
inhibitors (eg, sildenafil, tadalafil, vardenafil, avanafil) should be avoided within 48 hours prior 
to measuring blood pressure. 
Before measuring blood pressure, confirm that there has been no exercise or use of caffeine or 
nicotine- or tobacco-containing products (including but not limited to snuff, chewing tobacco, 
cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) within the last 30 minutes. If necessary, 
delay blood pressure assessment to meet these requirements. Because a full bladder can impact 
blood pressure measurements, ask the patient to use the bathroom before the assessment. 
All office blood pressure assessments will include both seated and standing measurements.  
Seated Office Blood Pressure Measurement: For seated measurements, the patient should be in a 
comfortable resting position in a chair with their back supported and their feet flat on the floor. 
• Place the appropriately sized cuff on the correct arm with no clothing between the 
patient’s arm and the cuff and with the midpoint of the bladder length positioned over 
the brachial artery (located by palpation). The arm should be supported on an armrest 
or table with mid-cuff at heart level and the palm facing the ceiling. 
• Follow the HBPM and OBPM Investigator Manual to initiate the automated blood 
pressure device’s seated measurement protocol. This program includes a 5-minute 
period of rest, followed by 4 sequential blood pressure measurements at 1-minute 
intervals. The seated blood pressure for the visit will be defined by the average of the 
last 3 individual measurements. 
• During the device’s seated measurement protocol, the staff member should leave the 
room and the patient should remain at rest without distraction (avoid mobile phones). 
The following script may be used: “The blood pressure device works best when you 
are at rest and without any distraction. If you agree, I would like to leave the room for 
the next 10 to 15 minutes while it is recording. This will include a 5-minute period of 
rest, followed by about 5 minutes of the device inflating to measure your blood 
pressure”. 
Standing Office Blood Pressure Measurement: A standing measurement should be obtained 
immediately after collection of the seated measurements. 
• Being careful to maintain the cuff’s position, ask the patient to stand with the cuffed 
arm bent slightly and the hand of the cuffed arm supported at heart level.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
76 
• Using a stopwatch or watch, measure standing blood pressure 1 minute after standing 
by using the automated blood pressure device’s single measurement protocol.  
• After the standing measurement, ask the patient if they experienced dizziness or light-
headedness when standing and enter their response in the eCRF. 
If a patient is unable to report to the site for an office blood pressure assessment, a substitute 
“remote visit blood pressure measurement” may be obtained remotely by a visiting nurse or other 
appropriately trained personnel who will bring an office blood pressure instrument to the 
patient’s location and follow the same procedure performed at the site. If a home visit is not 
possible, a “remote visit blood pressure measurement” should instead be obtained using the 
patient’s HBPM instrument under direct supervision (phone call or teleconferencing) by 
appropriately trained study staff, following the instructions detailed in the HBPM and OBPM 
Investigator Manual. Results and the remote method used should be entered into the eCRF. 
HBPM 
Patients should measure HBPM in the morning, prior to breakfast/caffeine or taking morning 
oral medications. HBPM is not required on days when ABPM is being assessed. The HBPM 
measurement should be obtained in a room without distractions, seated comfortably with the 
back supported and feet flat on the floor. The patient will initiate the automated blood pressure 
program on their HBPM device. This program includes a 5-minute period of rest, followed by 4 
sequential blood pressure measurements at 1-minute intervals. The seated blood pressure for the 
visit will be defined by the average of the last 3 individual measurements.  
To establish baseline, each patient should measure HBPM during the week (with at least 3 
successful readings) immediately prior to randomization. 
After Day 1, HBPM should be measured at least once per week. Patients may select the day of 
the week that is most convenient for their personal schedule. The frequency of HBPM may be 
increased in some patients, per Investigator discretion, if more frequent measurement is 
warranted (eg, during screening if patients are undergoing washout and during the temporary 
hold of oral antihypertensives performed from Month 5 to Month 6). 
10.2. 
Procedures for Optional Home Healthcare Visits 
Home healthcare may be allowed where applicable country and local regulations and 
infrastructure for home healthcare allow and will follow procedures that are in compliance with 
relevant local regulations and guidelines (eg, General Data Protection Regulation [EU (European 
Union) no 2016/679], ICH E6[R2], and the Declaration of Helsinki). The use of home healthcare 
is optional and will not be utilized for visits at which study drug is administered or at visits that 
are required to be performed at the site (see Table 1).  
The option for home healthcare aims to improve patient diversity, participation, engagement, and 
retention in the study by reducing patient burden and minimizing study-related travel to the site, 
allowing flexibility in the study visit schedule. 
For clinical study sites where home healthcare is utilized, the Investigator will retain 
responsibility for oversight, patient safety, and conduct of the trial, and will be responsible for 
reviewing the qualifications of and approving each home healthcare professional, delegating 
responsibilities to the home healthcare professional in the site delegation log, providing 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 6, 20 July 2023 
Alnylam Pharmaceuticals 
Confidential 
77 
instructions for home healthcare visits, communicating with the home healthcare professional at 
home visits as needed, and reviewing the source data files collected during the home healthcare 
visit. The home healthcare professional will be trained on the protocol and other relevant study 
documents and procedures and will be responsible for conducting vital sign assessments 
(including blood pressure assessments), collecting blood and urine samples, collecting weight, 
and documenting and notifying the site study team of any suspected or potential AE symptoms 
or changes to concomitant medications. The home healthcare professional will be responsible for 
providing source documentation of the visit to the study site. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
1 
 
CLINICAL STUDY PROTOCOL 
ALN-AGT01-002 
DATED 04 NOVEMBER 2022 
 
Protocol Title:  
A Randomized, Double-blind, Placebo-Controlled, 
Dose-Ranging Multicenter Study to Evaluate the 
Efficacy and Safety of ALN-AGT01 in Patients 
with Mild-to-Moderate Hypertension 
Short Title: 
A Study to Evaluate Efficacy and Safety of 
ALN-AGT01 in Patients with Mild-to-Moderate 
Hypertension (KARDIA-1) 
Study Drug: 
ALN-AGT01 (zilebesiran) 
EudraCT Number: 
2021-001248-82 
IND Number: 
143503 
Protocol Date: 
Original protocol, 09 April 2021 
Amendment 1, 20 April 2021 
Amendment 2, 09 June 2021 
Amendment 3, 09 December 2021 
Amendment 4, 22 March 2022 
Amendment 5, 04 November 2022 
Sponsor: 
Alnylam Pharmaceuticals, Inc. 
300 Third Street 
Cambridge, MA  02142 USA 
Telephone: +1-617-551-8200 
Sponsor Contact: 
 
 
The concepts and information contained in this document or generated during the study are considered 
proprietary and may not be disclosed in whole or in part without expressed written authorization of 
Alnylam Pharmaceuticals, Inc. 
 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
2 
SPONSOR PROTOCOL APPROVAL 
 
I have read this protocol and I approve the design of this study. 
 
 
 
___________________________________________  
 
 
Alnylam Pharmaceuticals, Inc. 
 
___________________________________________  
Date 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
3 
INVESTIGATOR’S AGREEMENT 
 
I have read the ALN-AGT01-002 protocol and agree to conduct the study in accordance with the 
protocol and all applicable regulations. I agree to maintain the confidentiality of all information 
received or developed in connection with this protocol. 
 
 
 
___________________________________________  
Printed Name of Investigator 
 
 
 
___________________________________________  
Signature of Investigator 
 
 
 
___________________________________________  
Date 








Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
7 
should have a daytime mean systolic blood pressure (SBP) ≥135 mmHg and ≤160 mmHg by 
ABPM after washout of background antihypertensive medication. Patients with secondary 
hypertension or orthostatic hypotension will be excluded. 
Study Drug, Dose, and Mode of Administration 
ALN-AGT01 is an SC administered N-acetylgalactosamine-conjugated small interfering RNA 
targeting liver-expressed messenger RNA for angiotensinogen (AGT). 
Patients randomized to receive ALN-AGT01 will be administered 150 mg ALN-AGT01 SC once 
every 6 months, 300 mg ALN-AGT01 SC once every 6 months, 300 mg ALN-AGT01 SC once 
every 3 months, or 600 mg ALN-AGT01 SC once every 6 months during the 12-month DB 
period and DB Extension period. Patients randomized to receive placebo will be randomized to 1 
of the 4 initial dose regimens of ALN-AGT01 beginning at Month 6.  
Reference Treatment, Dose, and Mode of Administration 
Placebo (sodium chloride 0.9% w/v for SC administration) will be administered once every 3 
months and at the same volume as the study drug. Patients receiving once every 6 months 
ALN-AGT01 regimens will receive placebo SC at dosing visits at which they do not receive 
ALN-AGT01 to maintain the blind. 
Duration of Treatment and Study Participation 
The duration of treatment with ALN-AGT01 is up to 36 months. The estimated total time on 
study for each patient is up to 47 months, including up to 2 months of screening, followed by up 
to 36 months of treatment, and up to 12 months in the Follow-up period. 
Statistical Methods 
The planned enrollment for this study is 375 patients. Randomization will be stratified by race 
(black vs all other races) and by baseline blood pressure (mean 24-hour SBP < or ≥145 mmHg). 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline at Month 
3 in 24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 
375 patients (75 per treatment group) provides at least 84% power to detect a dose response 
signal in SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided significance 
level of 0.05. In addition, this sample size provides at least 80% power to detect a 10 mmHg 
difference between an individual ALN-AGT01 dose versus placebo with a 2-sided significance 
level of 0.05.  
The populations (analysis sets) are defined as follows:  
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• Pharmacokinetic (PK) Analysis Set: All patients who received at least 1 full dose of 
ALN-AGT01 and have at least 1 nonmissing postdose PK assessment. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
8 
• PD Analysis Set: All patients who received at least 1 full dose of study drug. All by-
treatment analyses based on the PD Analysis Set will be grouped according to the 
treatment actually received. 
• All ALN-AGT01 Treated Set: All patients who received any amount of 1 of the 4 
ALN-AGT01 dosing regimens, including patients who took ALN-AGT01 during the 
6-month placebo-controlled period and patients who initially took placebo and then 
switched to ALN-AGT01 after the Month 6 visit. 
For the primary analysis for the 6-month placebo-controlled DB period, the primary population 
used to evaluate efficacy will be the FAS. Safety will be analyzed using the Safety Analysis Set. 
The PK and PD Analysis Sets will be used to conduct PK and PD analyses, respectively. 
The All ALN-AGT01 Treated Set will be used to summarize the efficacy and safety of 
ALN-AGT01 throughout the entire DB period (including DB extension period). 
To control the overall type I error, the primary and key secondary endpoints will be tested in 
hierarchical order. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
9 
Figure 1: 
Study Design 
 
Abbreviations: aHTN=antihypertensive medications; DB=double-blind; M=month; OLE=open-label extension; 
PBO=placebo; PO=per os (oral); Q3M=once every 3 months; Q6M=once every 6 months; R=randomization; 
SC=subcutaneous; WO=washout. 
Note: Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the Month 12 
predose assessments. If an individual patient reaches Month 12 prior to availability of the OLE study, they may 
continue their current blinded dosing in the DB Extension period for up to 24 additional months until the OLE study 
is open and then transition. Once the OLE study is open for enrollment, eligible patients may rollover into the OLE 
study at Months 12, 18, 24, 30, or 36 (whichever visit occurs first). 
Note: Patients who were previously taking antihypertensives at screening should undergo a washout of these 
medications for at least 2 weeks during the Screening period (4 weeks of washout is required for long-acting 
antihypertensive medications, such as long-acting diuretics or calcium channel blockers). 
 












Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
15 
Table 2: 
PK Time Points 
Study Day 
Sampling Time 
(hh:mm) 
Plasma PK Sample 
Day 1  
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Day 169±7 
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Abbreviations: hh:mm=hour:minute; PK=pharmacokinetics. 
Notes:  
• 
The hour (±range) indicates sample collection timing relative to dosing. Precise PK sample times (hour 
and minute) are recorded. Refer to Section 6.4 for additional information on PK assessments. 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
16 
TABLE OF CONTENTS 
SPONSOR PROTOCOL APPROVAL ...........................................................................................2 
INVESTIGATOR’S AGREEMENT ...............................................................................................3 
PROTOCOL SYNOPSIS ................................................................................................................4 
TABLE OF CONTENTS ...............................................................................................................16 
LIST OF TABLES .........................................................................................................................20 
LIST OF FIGURES .......................................................................................................................20 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ................................................21 
1. 
INTRODUCTION ......................................................................................................23 
1.1. 
Study Rationale ...........................................................................................................23 
1.2. 
Background .................................................................................................................23 
1.3. 
Benefit-Risk Assessment ............................................................................................24 
2. 
OBJECTIVES AND ENDPOINTS ............................................................................25 
3. 
INVESTIGATIONAL PLAN .....................................................................................27 
3.1. 
Summary of Study Design ..........................................................................................27 
3.2. 
Scientific Rationale for Study Design ........................................................................28 
3.3. 
Justification for Dose ..................................................................................................30 
3.4. 
Method of Assigning Patients to Treatment Groups ..................................................31 
3.5. 
Blinding ......................................................................................................................31 
3.5.1. 
Emergency Unblinding ...............................................................................................32 
3.6. 
Data Monitoring Committee .......................................................................................32 
3.7. 
Clinical Event Adjudication Committees ...................................................................32 
3.8. 
Definition of End of Study for an Individual Patient .................................................32 
4. 
SELECTION AND REMOVAL OF PATIENTS ......................................................33 
4.1. 
Inclusion Criteria ........................................................................................................33 
4.2. 
Exclusion Criteria .......................................................................................................33 
4.3. 
Removal from Study Drug or Assessment .................................................................36 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments ......................36 
4.3.2. 
Stopping a Patient’s Study Participation ....................................................................37 
4.3.2.1. 
Patient Stops Participation in the Study ......................................................................37 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection 
to Process Patient’s Personal Data ..............................................................................38 
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study ........................38 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
17 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation ................................38 
4.3.3. 
Lost to Follow-Up.......................................................................................................38 
4.3.4. 
Replacement of Study Patients ...................................................................................39 
5. 
TREATMENTS AND OTHER REQUIREMENTS ..................................................39 
5.1. 
Treatments Administered ............................................................................................39 
5.2. 
Study Drug ..................................................................................................................39 
5.2.1. 
Description ..................................................................................................................39 
5.2.2. 
Dose and Administration ............................................................................................39 
5.2.3. 
Dose Modifications .....................................................................................................40 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping 
Study Drug Dosing .....................................................................................................40 
5.2.5. 
Neurological Criteria for Withholding, Monitoring, and Stopping Study 
Drug Dosing ................................................................................................................41 
5.2.6. 
Preparation, Handling, and Storage ............................................................................42 
5.2.7. 
Packaging and Labeling ..............................................................................................42 
5.2.8. 
Accountability .............................................................................................................42 
5.3. 
Clinical Product Complaints .......................................................................................42 
5.3.1. 
Definition ....................................................................................................................42 
5.3.2. 
Reporting ....................................................................................................................43 
5.4. 
Monitoring for Potential Clinical Events ....................................................................43 
5.4.1. 
Monitoring and Approach for Potential Hypotension ................................................43 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure 
Elevation .....................................................................................................................44 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction .......................................45 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia ..............................................46 
5.5. 
Concomitant Medications and Procedures .................................................................47 
5.5.1. 
Oral Antihypertensive Medication .............................................................................48 
5.5.2. 
Prohibited Concomitant Medication ...........................................................................48 
5.6. 
Treatment Compliance ................................................................................................49 
5.7. 
Other Requirements ....................................................................................................49 
5.7.1. 
Contraception ..............................................................................................................49 
5.7.2. 
Alcohol Restrictions ...................................................................................................50 
5.7.3. 
Tobacco and Nicotine Restrictions .............................................................................50 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
18 
5.7.4. 
Dietary Recommendations ..........................................................................................50 
5.7.5. 
Exercise .......................................................................................................................51 
6. 
STUDY ASSESSMENTS ..........................................................................................51 
6.1. 
Screening Assessments ...............................................................................................51 
6.1.1. 
Retesting .....................................................................................................................51 
6.1.2. 
Rescreening .................................................................................................................52 
6.2. 
Efficacy Assessments .................................................................................................52 
6.2.1. 
ABPM .........................................................................................................................52 
6.2.2. 
Office Blood Pressure .................................................................................................53 
6.2.3. 
HBPM .........................................................................................................................53 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment ....................................................53 
6.3. 
Pharmacodynamic Assessments .................................................................................53 
6.4. 
Pharmacokinetic Assessments ....................................................................................54 
6.5. 
Safety Assessments .....................................................................................................54 
6.5.1. 
Vital Signs ..................................................................................................................54 
6.5.2. 
Weight, Height, and Morphometrics ..........................................................................54 
6.5.3. 
Physical Examination .................................................................................................55 
6.5.4. 
Electrocardiogram .......................................................................................................55 
6.5.5. 
Clinical Laboratory Assessments ...............................................................................56 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments ........................................................58 
6.5.5.2. 
Immunogenicity ..........................................................................................................58 
6.5.5.3. 
Pregnancy Testing ......................................................................................................58 
6.5.5.4. 
Additional Liver Function Assessments .....................................................................58 
6.5.6. 
Adverse Events ...........................................................................................................59 
6.5.6.1. 
Definitions ..................................................................................................................59 
6.5.6.2. 
Eliciting and Recording Adverse Events ....................................................................61 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee .........................62 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee ...........62 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities .................................................62 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee ........................................................................63 
6.5.6.7. 
Pregnancy Reporting ..................................................................................................63 
6.5.6.8. 
Overdose and Other Special Situations Reporting .....................................................63 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
19 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository ...................................63 
7. 
STATISTICS ..............................................................................................................64 
7.1. 
Determination of Sample Size ....................................................................................64 
7.2. 
Statistical Methodology ..............................................................................................65 
7.2.1. 
Populations to be Analyzed ........................................................................................65 
7.2.2. 
Examination of Subgroups .........................................................................................65 
7.2.3. 
Handling of Missing Data ...........................................................................................65 
7.2.4. 
Baseline Evaluations ...................................................................................................65 
7.2.5. 
Efficacy Analyses .......................................................................................................66 
7.2.6. 
Pharmacodynamic Analysis........................................................................................66 
7.2.7. 
Pharmacokinetic Analysis ..........................................................................................66 
7.2.8. 
Safety Analyses ..........................................................................................................67 
7.2.9. 
Immunogenicity Analyses ..........................................................................................67 
7.2.10. 
Interim Analysis ..........................................................................................................67 
7.2.11. 
Optional Additional Research .....................................................................................67 
8. 
STUDY ADMINISTRATION ...................................................................................67 
8.1. 
Ethical and Regulatory Considerations ......................................................................67 
8.1.1. 
Informed Consent .......................................................................................................68 
8.1.2. 
Ethical Review ............................................................................................................68 
8.1.3. 
Serious Breach of Protocol .........................................................................................69 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention .................................69 
8.1.5. 
End of Study ...............................................................................................................69 
8.1.6. 
Termination of the Clinical Study or Site Closure .....................................................69 
8.2. 
Data Quality Control and Quality Assurance .............................................................70 
8.2.1. 
Data Handling .............................................................................................................70 
8.2.2. 
Study Monitoring ........................................................................................................70 
8.2.3. 
Audits and Inspections ................................................................................................70 
8.3. 
Publication Policy .......................................................................................................71 
9. 
LIST OF REFERENCES ............................................................................................72 
10. 
APPENDICES ............................................................................................................74 
10.1. 
Measurement of Blood Pressure .................................................................................74 
10.2. 
Procedures for Optional Home Healthcare Visits ......................................................76 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
20 
LIST OF TABLES 
Table 1: 
Schedule of Assessments ............................................................................................10 
Table 2: 
PK Time Points ...........................................................................................................15 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative 
Cause Identified ..........................................................................................................41 
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation ......................................................................................................44 
Table 5: 
Recommended Interventions for Hyperkalemia .........................................................47 
Table 6: 
Clinical Laboratory Assessments ...............................................................................57 
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases .............59 
 
LIST OF FIGURES 
Figure 1: 
Study Design .................................................................................................................9 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
21 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation  
Definition 
ABPM 
Ambulatory blood pressure monitoring 
ACE 
Angiotensin converting enzyme 
ADA 
Anti-drug antibody(ies) 
AE 
Adverse event 
AGT 
Angiotensinogen 
ALT 
Alanine aminotransferase 
AngI/II 
Angiotensin I/II 
ARB 
Angiotensin II-receptor blocker 
AST 
Aspartate aminotransferase 
CCB 
Calcium channel blocker 
CPC 
Clinical product complaint 
DB 
Double-blind 
DBP 
Diastolic blood pressure 
DMC 
Data Monitoring Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eGFR 
Estimated glomerular filtration rate 
EOT 
End of treatment 
ET 
Early termination 
FAS 
Full analysis set 
GalNAc 
N-acetylgalactosamine 
GCP 
Good Clinical Practice 
HbA1c 
Hemoglobin A1c 
HBPM 
Home blood pressure monitoring 
HCV 
Hepatitis C virus 
HDL-C 
High-density lipoprotein 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use 
IEC 
Independent Ethics Committee 
INR 
International normalized ratio 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
22 
Abbreviation  
Definition 
IRB 
Institutional Review Board 
IRT 
Interactive Response Technology 
ISR 
Injection site reaction 
LFT 
Liver function test 
MAO 
Monoamine oxidase 
MMRM 
Mixed model for repeated measurements 
mRNA 
Messenger RNA 
NSAID 
Nonsteroidal anti-inflammatory drug 
OLE 
Open-label extension 
PD 
Pharmacodynamic(s) 
PK 
Pharmacokinetic(s) 
PT 
Preferred term 
q3M 
Once every 3 months 
q6M 
Once every 6 months 
RAAS 
Renin-angiotensin-aldosterone system 
RNAi 
RNA interference 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SBP 
Systolic blood pressure 
SC 
Subcutaneous(ly) 
siRNA 
Small interfering RNA 
SGLT2 
Sodium-glucose co-transporter 2 
SOC 
System Organ Class 
ULN 
Upper limit of normal 
ZS-9 
Sodium zirconium cyclosilicate 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
23 
1. 
INTRODUCTION 
Alnylam Pharmaceuticals, Inc. (the Sponsor) is developing ALN-AGT01 (zilebesiran), a 
subcutaneously (SC) administered investigational agent comprised of a synthetic small 
interfering (siRNA) covalently linked to a triantennary N-acetylgalactosamine (GalNAc) ligand, 
which is designed to suppress liver production of angiotensinogen (AGT) and thereby reduce 
blood pressure in individuals with hypertension.  
1.1. 
Study Rationale 
Study ALN-AGT01-002 (KARDIA-1) is a randomized, double-blind, placebo-controlled, dose-
ranging, multicenter Phase 2 study designed to evaluate the safety, efficacy, and 
pharmacodynamics (PD) of ALN-AGT01, administered SC, in patients with mild-to-moderate 
hypertension. Patients will be randomized to 1 of 4 ALN-AGT01 treatment regimens or placebo 
for the first 6 months of the 12-month Double-blind (DB) period. After the first 6 months of the 
DB period, patients from the placebo arm will be re-randomized to 1 of the 4 initial 
ALN-AGT01 regimens for the remaining 6 months of the DB period, while patients randomized 
to ALN-AGT01 will remain on their originally assigned regimens. After completion of the 
12-month DB period, patients may be eligible to participate in an ALN-AGT01 open-label 
extension (OLE) study. If an individual patient reaches Month 12 prior to availability of the OLE 
study, they may continue their current blinded dosing in the DB Extension period for up to 
24 additional months until the OLE study is open and then transition. 
The primary objective of the study is to evaluate the efficacy of ALN-AGT01 for the treatment 
of hypertension by evaluating the impact on systolic blood pressure (SBP) from baseline to 
Month 3, as assessed by ambulatory blood pressure monitoring (ABPM). Secondary and 
exploratory objectives of the study include evaluating the efficacy of ALN-AGT01 on other 
measures of blood pressure response and evaluating the PD effect of ALN-AGT01, including 
reduction in circulating AGT concentration. 
The full rationale for the study and design is presented in Section 3.2. 
1.2. 
Background 
Hypertension affects 30% to 45% of adults and is the strongest modifiable risk factor for 
cardiovascular disease, primarily strokes and myocardial infarction.[Olsen 2016; Williams 2018] 
The worldwide disease burden is profound, with a global prevalence of over 1 billion,[Kearney 
2005; NCD Risk Factor Collaboration 2017] and approximately 9 million deaths attributed to 
hypertension annually.[Angell 2015] 
Currently available pharmacologic therapies achieve target blood pressure in only a minority of 
patients, due in large part to physician inertia and patient nonadherence to daily oral 
medication.[Whelton 2018; Williams 2018] Low adherence to oral antihypertensives is 
associated with poor cardiovascular outcomes and is prevalent at all stages of disease.[Corrao 
2011; Peacock and Krousel-Wood 2017; Schulz 2016; van der Laan 2017] Thus, despite the 
availability of multiple efficacious agents, current rates of control are low, and the global burden 
of death and disability-adjusted life-years attributed to elevated blood pressure remains 
high.[Forouzanfar 2017; Muntner 2020] Development of new approaches to treat hypertension 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
24 
and to overcome the limitations of current therapies is a key unmet need.[Dzau and Balatbat 
2019; McClellan 2019; Services 2020] 
The Sponsor is developing ALN-AGT01, a novel synthetic RNA interference (RNAi) 
therapeutic, for SC administration for the treatment of hypertension. RNAi is a naturally 
occurring cellular mechanism for regulation of gene expression, mediated through the binding of 
siRNA to its complementary messenger RNA (mRNA) sequence, leading to mRNA cleavage 
and subsequent suppression of the synthesis and levels of the target protein. ALN-AGT01 
contains an siRNA targeting AGT mRNA, conjugated to a GalNAc-containing ligand to facilitate 
delivery to the liver. Based on the mechanism of RNAi, ALN-AGT01 is specifically designed to 
reduce the hepatic synthesis of AGT protein, the first substrate in the renin-angiotensin-
aldosterone system (RAAS) and the sole precursor of vasoactive angiotensin peptides.[Khanna 
2017; Romero 2015] Because hepatocytes are the predominant source of circulating AGT, 
ALN-AGT01 has been developed to reduce blood pressure by decreasing circulating AGT levels 
and the downstream effects of angiotensin II (AngII). 
Preliminary data from Part A of the ongoing Phase 1 Study ALN-AGT01-001 (hereafter referred 
to as Study 001) in patients with hypertension have shown that single SC doses of ALN-AGT01 
lead to dose-dependent and durable reductions in circulating AGT, accompanied by clinically 
significant reductions in SBP and diastolic blood pressure (DBP). Reductions in AGT for up to 
6 months postdose were observed in the study.  
Most adverse events (AEs) have been mild or moderate in severity, and there have been no 
severe or serious adverse events (SAEs) related to study drug. There have been no clinically 
significant elevations in serum creatinine or serum potassium, and no patient has required 
intervention for low blood pressure. No clinically significant alanine aminotransferase (ALT) 
elevations have been observed in Part A patients who received ALN-AGT01 doses as high as 
800 mg. Injection site reactions (ISRs) were reported in a minority of patients and were all mild 
and transient events that resolved without intervention. 
This Phase 2 study will further quantify the antihypertensive effects of ALN-AGT01 across a 
range of doses (150 to 600 mg) and dose intervals (once every 3 months and once every 6 
months) to identify optimal treatment. The consistent and prolonged PD effect of ALN-AGT01 
is expected to achieve the unique benefit of continuous 24-hour blood pressure lowering with 
infrequent SC dosing.  
A detailed description of the chemistry, pharmacology, efficacy, and safety of ALN-AGT01 is 
provided in the Investigator’s Brochure. 
1.3. 
Benefit-Risk Assessment 
Clinical data available from Study 001 indicate that ALN-AGT01 may offer the benefit of blood 
pressure reduction to patients with hypertension. The mean SBP reduction observed after single 
ALN-AGT01 doses of 100 mg or higher exceeds 10 mmHg, which is comparable to the effect of 
conventional antihypertensives. The blood pressure of patients will be closely monitored, and 
after Month 3, oral antihypertensives will be added as needed to control blood pressure. 
Given the mechanism of action and mode of administration of ALN-AGT01, potential 
theoretical risks include liver transaminase elevations and ISRs. Like any antihypertensive 
therapy, there is also a theoretical risk of hypotension with ALN-AGT01. Based upon the disease 








Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
28 
monitoring [HBPM] SBP <135 mmHg, or daytime mean SBP <135 mmHg by 
ABPM).[Williams 2018] Oral antihypertensives (if taking) will be temporarily held from Month 
5 to Month 6 in appropriate patients (Month 5 office SBP <155 mmHg if taking 1 oral 
antihypertensive agent or office SBP <150 mmHg if taking 2 agents) to assess the effect of 
ALN-AGT01 alone (vs placebo) at Month 6 by ABPM. During this 4-week period, blood 
pressure will be carefully monitored by HBPM and oral antihypertensive medications restarted if 
confirmed office SBP >170 mmHg (or if confirmed office SBP >160 mmHg accompanied by 
symptoms). 
Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the 
Month 12 predose assessments. If an individual patient reaches Month 12 prior to availability of 
the OLE study, they may continue their current blinded dosing in the DB Extension period for up 
to 24 additional months until the OLE study is open and then transition. Once the OLE study is 
open for enrollment, eligible patients may rollover into the OLE study at Months 12, 18, 24, 30, 
or 36 (whichever visit occurs first). 
In the DB Extension period, blood pressure will be closely monitored and individual 
modification of antihypertensive therapy will be allowed to maintain blood pressure in target 
range.  
Safety Follow-up Period 
Patients who discontinue study drug or do not enroll in the separate ALN-AGT01 OLE study 
will be asked to complete Safety Follow-up visits once every 6 months after their last dose of 
study drug until serum AGT levels return to ≥50% of their individual mean baseline level (if 
known) or until 12 months after their last dose of study drug, whichever comes earlier. During 
the Safety Follow-up period, patients should return to their pre-study medical care (usual care). 
Patients who discontinue study drug prior to the Month 6 visit will also be asked to complete the 
remainder of scheduled study visits and assessments (except for study drug administration) 
through Month 6. If a patient discontinues study drug after the Month 6 visit, end of treatment 
(EOT)/early termination (ET) assessments should be performed. 
The planned enrollment for this study is approximately 375 patients (75 patients per group). 
The duration of treatment with ALN-AGT01 is up to 36 months. The estimated total time on 
study for each patient is up to 47 months, including up to 2 months of screening, followed by up 
to 36 months of treatment, and up to 12 months in the Follow-up period. 
3.2. 
Scientific Rationale for Study Design 
This is a randomized, double-blind, placebo-controlled, dose-ranging, multicenter Phase 2 study 
designed to evaluate the safety, efficacy, and PD of ALN-AGT01, administered SC, in patients 
with mild-to-moderate hypertension. The primary objective of the study is to evaluate the 
efficacy of ALN-AGT01 by measuring the impact on SBP from baseline to Month 3, as assessed 
by ABPM.  
This study will quantify the antihypertensive effects of ALN-AGT01 across a range of doses and 
dose intervals to identify optimal treatment regimens for study in Phase 3. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
29 
Patients will discontinue prior antihypertensive medications (if taking) for 2 to 4 weeks prior to 
study drug administration. During the study, blood pressure will be monitored with both 
outpatient 24-hour ABPM and automated office blood pressure measurements 
(EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical Investigation of Medicinal Products in 
the Treatment of Hypertension, 2016). The primary endpoint will be assessed by ABPM given its 
greater precision over office blood pressure measurements. In addition, 24-hour ABPM can 
assess short-term blood pressure variability and circadian patterns (including potential restoration 
of the normal nocturnal blood pressure dipping pattern that is lost in 21% to 35% of hypertensive 
patients).[de la Sierra 2009; White 1998] More frequent measurements will be collected through 
a third method, oscillometric HBPM, to assess long-term blood pressure variability and provide 
close safety monitoring for potential hypotension (or hypertension) while not in the clinic. 
As recommended by current guidance (International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use [ICH] Principles for Clinical Evaluation of 
New Antihypertensive Drugs, 2000 and EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical 
Investigation of Medicinal Products in the Treatment of Hypertension, 2016), the first 6 months 
of the DB period is designed as a randomized, placebo-controlled, parallel-group study. To 
adhere to best ethical standards for the treatment of patients with hypertension, individual 
modification of oral antihypertensive medications per Investigator judgement to maintain blood 
pressure within target is permitted starting at Month 3 and will continue throughout the study 
(except between Month 5 and Month 6 as described in Section 3.1). Separate from these treat-to-
target modifications, any confirmed event of severe hypertension (office SBP ≥180 mmHg or 
DBP ≥120 mmHg) will be appropriately treated regardless of its timing relative to study drug 
administration. 
If a patient requires treatment with a conventional oral antihypertensive before Month 6, a CCB 
and/or thiazide/thiazide-like diuretic may be added because there is extensive experience 
combining these classes with antihypertensive drugs that impact the RAAS. Additionally, their 
blood pressure effects are expected to washout within 2 to 4 weeks.  
Rigorous assessment of the antihypertensive effects of ALN-AGT01 at Month 6 (trough for the 
once every 6 month regimens) relative to placebo is critical to evaluate the feasibility of once 
every 6 month dosing regimens for future study in Phase 3. Accordingly, oral antihypertensives 
(if taking) will be temporarily held from Month 5 to the Month 6 ABPM assessment. For each 
patient, this limited interruption in oral antihypertensives will be contingent upon the patient’s 
Month 5 office SBP being adequately controlled (see Table 4) and the Investigator’s assessment 
that interruption can be safely performed and carefully monitored by HBPM measurements. Of 
note, a withdrawal period is a standard element in studies of oral antihypertensives that is often 
used to establish assay sensitivity, to demonstrate maintenance of efficacy, and to assess possible 
withdrawal effects (ICH E12A; Principles for Clinical Evaluation of New Antihypertensive 
Drugs, 2000). Outside of research studies, antihypertensives are temporarily discontinued in 
clinical practice for diagnostic purposes, and interruptions up to 6 weeks have been shown to be 
safe.[Beeftink 2017] In this study, the period of interruption is limited to 4 weeks, and most 
patients are expected to have continued antihypertensive effect from ALN-AGT01. If a clinically 
significant blood pressure elevation (confirmed SBP >170 mmHg; or SBP >160 mmHg 
accompanied by symptoms) occurs after the interruption of oral antihypertensives, Investigators 
will instruct the patient to promptly resume dosing with their existing supply of oral medication.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
30 
After Month 6, other oral antihypertensives may be used at the discretion of the Investigator, 
following current care guidelines.[Whelton 2018; Williams 2018] Because ALN-AGT01 acts on 
the RAAS, the use of conventional RAAS inhibitors (angiotensin II-receptor blocker [ARB], 
angiotensin converting enzyme [ACE] inhibitors, or direct renin inhibitors) as rescue agents for 
high blood pressure will be avoided throughout this study. Blood pressure and pharmacokinetic 
(PK)/PD assessments will be collected through Month 12 to assess the effect of repeated dosing. 
While tissue specificity of ALN-AGT01 for the liver is hypothesized to improve tolerability 
relative to current oral antihypertensives,[Mullick 2017; Uijl 2019] the protocol’s monitoring 
plan is designed to meet the standards set by prior studies of conventional RAAS 
inhibitors,[McMurray 2016; Parving 2012] with improvements to include the use of the newer 
oral potassium binder patiromer (or with sodium zirconium cyclosilicate [ZS-9]), if available, for 
treatment of potential hyperkalemia.[Georgianos and Agarwal 2018; Weir 2015] The risk of 
renal safety events is further mitigated in this study by its eligibility criteria, which exclude 
patients who are at highest risk to have events (estimated glomerular filtration rate [eGFR] <30 
mL/min/1.73m2, baseline serum potassium >5 mEq/L, poorly controlled diabetes, or severely 
increased albuminuria) and those who may have decreased tolerance for renal safety events 
(patients with clinically significant heart failure, valvular heart disease, or recent history of 
cardiovascular event).  
3.3. 
Justification for Dose 
The doses of ALN-AGT01 in this study were selected on the basis of data from the Phase 1 
Study 001, in which single ALN-AGT01 doses up to 800 mg were found to have an acceptable 
safety profile, and clinically significant placebo-corrected reductions in mean SBP >10 mmHg 
by 24-hour ABPM were observed after doses as low as 100 mg. Dose selection was guided by 
the principle of evaluating doses that are well tolerated and predicted to result in a range of PD 
effects (ie, lowering of serum AGT) and antihypertensive responses. This is expected to enable 
development of population average dose-response relationships for PD and efficacy to guide 
identification of optimal treatment regimens (dose and dose frequency) for Phase 3.  
Preliminary PK/PD modeling based on serum AGT data from Study 001 indicates that 
ALN-AGT01 results in a dose-dependent lowering of serum AGT, with maximum reductions 
predicted to be achieved as early as 1 month postdose and significant reductions sustained for 
close to 6 months after dosing. Modeling of the relationship between serum AGT lowering and 
blood pressure suggests a log-linear relationship, with ≥92% reduction in serum AGT predicted 
to achieve median SBP reduction of ≥10 mmHg.  
Based on these, the once every 6 month doses of 150, 300, and 600 mg were selected to result in 
median serum AGT reductions of 81.9%, 89.4%, and 94.9%, respectively, at trough (Month 6), 
translating to median SBP reductions of 6.67 mmHg, 8.74 mmHg, and 11.6 mmHg, respectively. 
Thus, the selected doses will enable characterization of the dose-response relationships for serum 
AGT and blood pressure with the once every 6 month regimen. 
The selected doses also enable characterization of the dose-response relationships for serum 
AGT and blood pressure with once every 3 month regimens based on analysis of data from all 
arms at Month 3. This will provide support for development of a once every 3 month regimen, if 
desired. To this end, 300 mg once every 3 months will be evaluated to identify any cumulative 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
31 
effects. The 300 mg once every 3 months dose is predicted to result in median serum AGT 
reductions of >95% at trough (Month 3), translating to median SBP reductions of >10 mmHg.  
Thus, data from the current study will enable robust characterization of PD and efficacy of once 
every 3 month and once every 6 month regimens of ALN-AGT01 and guide further development 
of ALN-AGT01 as an antihypertensive therapeutic that results in reduction of blood pressure by 
≥10 mmHg throughout the dosing interval with infrequent administration. 
3.4. 
Method of Assigning Patients to Treatment Groups 
Using the Interactive Response Technology (IRT), patients will be randomized 1:1:1:1:1 to the 
following arms during the first 6 months of the 12-month DB period: 
• Placebo SC once every 3 months 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients initially randomized to placebo will be re-randomized 1:1:1:1 at Month 6 to 1 of the 4 
initial ALN-AGT01 regimens. 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. 
Randomization will be stratified by race (black vs all other races) and by baseline blood pressure 
(mean 24-hour SBP < or ≥145 mmHg). 
Each patient will be uniquely identified in the study by a combination of the site number and 
patient identification number. Upon signing the informed consent form (ICF), the patient will be 
assigned a patient identification number by the IRT system. The Investigator or his/her designee 
will randomize the patient in IRT after confirming that the patient fulfills all the inclusion criteria 
and none of the exclusion criteria. The Investigator or his/her designee will re-randomize the 
patient in IRT at Month 6 to assign placebo patients to 1 of the 4 initial ALN-AGT01 dose 
groups. 
3.5. 
Blinding 
The Sponsor, all site personnel (except for the site pharmacist or delegate), and patients will be 
blinded to study drug treatment through Month 6 of the 12-month DB period. During the course 
of the study, serum AGT, plasma PK, and treatment assignment using dummy IDs will be made 
available to a small, independent pharmacometrics team at the Sponsor that will not be involved 
in the conduct or oversight of the study. After the last patient completes the Month 3 visit and 
prior to the last patient’s Month 6 visit, a limited amount (ie, one-third) of SBP data will be made 
available to this small, independent pharmacometrics team for preliminary PK/PD modeling. 
After the database lock to support the analysis of Month 6 data is complete, all other Sponsor 
personnel will be unblinded to treatment assignment, but the site personnel (except for the site 
pharmacist) and patients will remain blinded to treatment assignment until after the analysis of 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
32 
Month 12 data is complete. The Sponsor and all site personnel will be blinded to serum AGT 
results until their respective unblinding. Serum AGT results will not be reported to site personnel 
until the last patient completes the assessments at the Month 12 visit. 
Blinded doses of study drug will be administered under the supervision of the Investigator (see 
Section 5.2.2). All patients will receive the same volume and number of injections regardless of 
treatment assignment (patients receiving once every 6 month ALN-AGT01 regimens will receive 
placebo SC at dosing visits at which they do not receive ALN-AGT01 to maintain the blind). 
Because ALN-AGT01 may be slightly visually distinguishable from placebo, all blinded study 
drug doses will be prepared and the syringe(s) will be masked by a site pharmacist or delegate 
prior to administration by a blinded healthcare professional. See the Pharmacy Manual for 
additional details. 
3.5.1. 
Emergency Unblinding 
If the treating physician determines that the clinical management of the patient requires 
knowledge of the study drug assignment, the Investigator may break the blind, as necessary, in 
IRT. If time permits, clinical study center personnel should contact the Medical Monitor before 
unblinding to discuss the need to unblind the patient but must do so within 1 working day after 
the unblinding event. Unblinding information should be limited to the fewest number of people 
on a need-to-know basis. A record of when the blind was broken, who was unblinded, who broke 
the blind, and why it was broken, will be maintained in the electronic trial master file. 
Refer to the IRT instructions for details on emergency unblinding. 
3.6. 
Data Monitoring Committee 
An independent DMC will oversee the safety and overall conduct of this study. The DMC will 
operate under the rules of a charter that will be reviewed and approved at the organizational 
meeting of the DMC. Details are provided in the DMC Charter. 
3.7. 
Clinical Event Adjudication Committees 
An independent Clinical Event Adjudication Committee of 2 or more nephrologists will review 
renal events blinded to treatment assignment to adjudicate whether they meet diagnostic criteria 
for acute kidney injury and, if so, their potential staging and contributing factors. Details are 
provided in the Renal Event Adjudication Committee charter. 
3.8. 
Definition of End of Study for an Individual Patient 
A patient is considered to have reached the end of the study if the patient: 
• has completed at least the Month 12 visit and enrolled in the OLE study, or 
• has completed the Safety Follow-up visits as described in Section 3.1 for patients who 
discontinue study drug or do not enroll in the OLE study. 
A definition of the end of the overall study is provided in Section 8.1.5. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
33 
4. 
SELECTION AND REMOVAL OF PATIENTS 
4.1. 
Inclusion Criteria 
Patients are eligible to be included in the study if all the following criteria apply: 
Age and Sex 
1. Age 18 to 75 years, inclusive, at time of initial informed consent 
2. Male or female 
Patient and Disease Characteristics 
3. Has untreated hypertension (not taking antihypertensive medication) or is on stable 
therapy with up to 2 antihypertensive medications. In general, stable therapy is defined as 
having no change in antihypertensive medication or dose within 30 days prior to 
screening.  
4. Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive 
medication. Patients previously taking medication for hypertension must be without 
antihypertensives for ≥2 weeks prior to this ABPM (4 weeks of washout is required for 
long-acting antihypertensive medications, such as long-acting diuretics [eg, 
chlorthalidone] or CCBs [eg, amlodipine]). 
Informed Consent 
5. Patient is able to understand and is willing and able to comply with the study 
requirements and to provide written informed consent. 
4.2. 
Exclusion Criteria 
Patients are excluded from the study if any of the following criteria apply: 
Disease-specific Conditions 
1. Secondary hypertension (including, but not limited to, renovascular hypertension, 
primary aldosteronism, pheochromocytoma, Cushing syndrome, aortic coarctation, or due 
to known history of moderate-to-severe obstructive sleep apnea not treated with 
continuous positive airway pressure therapy) 
2. Orthostatic hypotension (symptomatic or asymptomatic), defined as a fall of ≥20 mmHg 
SBP or ≥10 mmHg DBP within approximately 1 to 3 minutes of standing up from a 
seated position by office blood pressure. 
Laboratory Assessments 
3. Has any of the following laboratory parameter assessments after at least 2 to 4 weeks of 
washout:  
a. ALT or aspartate aminotransferase (AST) >2× upper limit of normal (ULN) 
b. Total bilirubin >1.5×ULN. Patients with elevated total bilirubin that is secondary to 
documented Gilbert’s syndrome are eligible if the total bilirubin is <2×ULN 
c. International normalized ratio (INR) >2.0 (patients on oral anticoagulant [eg, 
warfarin] with an INR <3.5 will be allowed) 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
34 
d. Elevated potassium >5 mEq/L  
e. eGFR of ≤30 mL/min/1.73m2 (calculation will be based on the Modification of Diet 
in Renal Disease formula)  
Prior/Concomitant Therapy 
4. Received an investigational agent within the last 30 days before randomization or are in 
follow-up of another clinical study prior to study enrollment. Any agent that has received 
health agency authorization (including for emergency use) by local or regional regulatory 
authorities is not considered investigational. Patients who are in follow-up for a 
coronavirus disease 2019 vaccine (authorized or investigational) study are allowed. 
5. Currently taking, taken within 30 days prior to randomization, or anticipated to receive 
during the study treatment period any medication or herbal supplement known to 
significantly affect blood pressure (with the exception of medications for the treatment of 
essential hypertension). Patients who require medications such as monoamine oxidase 
(MAO) inhibitors that are associated with hypertensive crisis should be 
excluded.[Whelton 2018]  
6. Currently taking beta blockers and unable to undergo a washout at least 2 weeks prior to 
randomization 
7. Changes, such as initiation or discontinuation, of sodium-glucose co-transporter 2 
(SGLT2) inhibitor therapy within 30 days prior to screening. Patients on a stable dose of 
SGLT2 therapy for at least 30 days prior to screening with no anticipated changes during 
the study treatment period are permitted. 
8. Prescription nonsteroidal anti-inflammatory drugs (NSAIDs) are not permitted. Patients 
receiving low-dose aspirin (defined as ≤100 mg per day) for at least 30 days prior to 
screening are permitted. Paracetamol/acetaminophen for analgesia will be allowed.  
9. Anticipates using organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, 
isosorbide dinitrate, pentaerythritol) during the study treatment period 
10. Currently taking, taken within 6 months prior to randomization, or anticipated to receive 
an RNAi therapeutic (approved or investigational) during the study 
Medical Conditions 
11. Current or prior history of intolerance to an ARB, ACE inhibitor (other than cough), or 
direct renin inhibitor 
12. Medical condition, other than hypertension, that requires treatment with a RAAS 
inhibitor 
13. History of multiple drug allergies or history of allergic reaction to an oligonucleotide or 
to GalNAc 
14. Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus (hemoglobin A1c 
[HbA1c] >9.0%), or laboratory evidence of diabetes during screening (HbA1c ≥7.0%) 
without known diagnosis of diabetes 
15. History of severely increased albuminuria (urine albumin:creatinine ratio >300 mg/g or 
>300 mg/day) or laboratory results consistent with this diagnosis upon screening  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
35 
16. Has known human immunodeficiency virus or known current or chronic hepatitis C virus 
(HCV) or hepatitis B virus infection 
17. History of any cardiovascular event (eg, stroke, transient ischemic attack, myocardial 
infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary 
intervention, hospitalization due to heart failure) within 6 months prior to randomization 
18. Clinically significant valvular heart disease 
19. New York Heart Association II to IV heart failure 
20. Uncontrolled serious cardiac arrhythmia, defined as recurrent and highly symptomatic 
ventricular tachycardia, atrial fibrillation with rapid ventricular response, or 
supraventricular tachycardia in the 3 months prior to randomization 
21. Has undergone liver transplantation or is anticipated to be on an active liver 
transplantation waiting list during the study treatment period 
22. History of renal transplantation or under immunosuppressive therapy 
23. Has other medical conditions or comorbidities which, in the opinion of the Investigator, 
would interfere with study compliance or data interpretation; or, in the opinion of the 
Investigator, taking part in the study would jeopardize the safety of the patient 
24. Clinically significant illness, in the opinion of the Investigator, within 7 days prior to 
randomization 
25. History of intolerance to SC injection(s) that could potentially hinder study drug 
administration or evaluation of local tolerability 
26. Has planned major surgery or general anesthesia during the study 
Contraception, Pregnancy, and Breastfeeding 
27. Is not willing to comply with the contraceptive requirements during the study period, as 
described in Section 5.7.1 
28. Female patient is pregnant, planning a pregnancy, or breast-feeding. 
Alcohol or Nicotine Use and Substance Abuse 
29. Unwilling or unable to limit alcohol consumption throughout the course of the study. 
Alcohol intake of >2 units/day is excluded during the study (unit: 1 glass of wine 
[approximately 125 mL] = 1 measure of spirits [approximately 1 fluid ounce] = ½ pint of 
beer [approximately 284 mL]). 
30. History of alcohol or substance abuse (licit or illicit drugs) within the last 12 months 
before screening, in the opinion of the Investigator 
31. Unwilling or unable to abstain from use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine 
patches, or e-cigarettes) within 30 minutes prior to office blood pressure measurements  
Other Restrictions 
32. Third shift or night shift workers 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
36 
33. Arm circumference exceeds the maximum cuff size of any of the blood pressure 
instruments provided by the Sponsor 
34. Placed in an institution on the basis of an official or court order 
4.3. 
Removal from Study Drug or Assessment 
Patients are free to discontinue study drug and/or stop protocol procedural assessments, or 
participation in the study as a whole at any time and for any reason, without penalty to their 
continuing medical care. The Investigator or the Sponsor may discontinue study drug or stop a 
patient’s participation in the study at any time if this is considered to be in the patient’s best 
interest. Any discontinuation of treatment or the stopping of the patient’s participation in the 
study must be fully documented in the electronic case report form (eCRF) and should be 
followed up by the Investigator. 
Discontinuation of study drug or declining procedural assessments is described in Section 4.3.1, 
while the stopping of a patient’s participation in the study is detailed in Section 4.3.2. 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments 
Reasons for discontinuation of study drug include any of the following: 
• Significant protocol deviation; which includes required treatment with prohibited 
medication (as defined in Section 5.5.2) per Investigator discretion 
• AE 
• Non-adherence to treatment regimen 
• Pregnancy 
• Lost to follow-up 
• Other reason (non-AE) 
• Or, study is terminated by the Sponsor 
If possible, the Investigator will confer with the Sponsor or Medical Monitor before 
discontinuing dosing in the patient. Patients who are pregnant will be discontinued from study 
drug dosing immediately (see Section 6.5.6.7 for reporting and follow-up of pregnancy). A 
positive urine pregnancy test should be confirmed by a serum pregnancy test prior to 
discontinuing the study drug. 
Patients who discontinue study drug and/or decline procedural assessments should not be 
automatically removed from study. In general, patients who discontinue study drug dosing for 
any reason will be encouraged to remain on the study to complete the remaining assessments and 
study visits so that their experience is captured in the final analyses.  
If this occurs, the Investigator is to discuss with the patient the appropriate processes for 
discontinuation from study drug and must discuss with the patient the options for continuation of 
the Schedule of Assessments (Table 1), including different options for follow-up and collection 
of data (eg, in person, by phone, by mail, through family or friends, or from options not 
involving patient contact, such as communication with other treating physicians or from review 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
37 
of medical records), including endpoints and AEs, and must document this decision in the 
patient’s medical records. 
If a patient discontinues dosing due to an AE, including SAEs, the event should be followed as 
described in Section 6.5.6. When a patient discontinues study drug dosing, the primary reason 
must be recorded in the eCRF. Patients who discontinue study drug and remain on study may 
receive treatment consistent with local standard practice for their disease per Investigator 
judgement, as applicable. 
Patients who discontinue from study drug before Month 6 will be encouraged to remain on the 
study and complete assessments (except study drug administration) through Month 6. They will 
also be asked to complete Safety Follow-up visits once every 6 months after the last dose of 
study drug per the safety follow-up schedule (see Table 1) until PD recovery or 12 months after 
the last dose of study drug (whichever is earlier); see Section 3.1. 
Patients who discontinue study drug after the Month 6 visit will be asked to return for their next 
scheduled visit to complete EOT/ET assessments and complete Safety Follow-up visits once 
every 6 months after the last dose of study drug per the safety follow-up schedule (see Table 1) 
until PD recovery or 12 months after the last dose of study drug (whichever is earlier); see 
Section 3.1. 
4.3.2. 
Stopping a Patient’s Study Participation 
4.3.2.1. 
Patient Stops Participation in the Study 
A patient may stop participation in the study at any time. A patient considering stopping 
participation in the study before Month 6 should be informed that the patient can discontinue 
study drug and/or decline procedural assessments and remain in the study to complete their study 
assessments through the Month 6 visit and complete Safety Follow-up visits as described in 
Section 4.3.1, or alternatively may complete any minimal assessments for which the patient 
consents. If a patient still chooses to discontinue study drug and stop participation in all follow-
up prior to the completion of the Month 6 visit, every effort should be made to conduct the 
Month 6 visit assessments at an earlier time (Table 1). 
A patient considering stopping participation in the study after the Month 6 visit should be 
informed that the patient can discontinue study drug and/or decline procedural assessments and 
remain in the study to complete the assessments scheduled for the EOT/ET visit and complete 
Safety Follow-up visits as described in Section 4.3.1, or alternatively may complete any minimal 
assessments for which the patient consents. 
If the patient does not wish to or is unable to continue further study participation, the Investigator 
is to discuss with the patient appropriate procedures for stopping participation in the study. Data 
collected from the patient can continue to be used. 
Note, in countries where the collection and processing of the patient’s personal data is based on 
consent, if a patient withdraws consent to collect and process his/her personal data (see 
Section 4.3.2.2), as applicable, personal data up to the withdrawal of consent will be included in 
the analysis of the study. In addition, where permitted, publicly available data (such as 
appropriate national or regional vital status registry or other relevant databases) can be included 
after withdrawal of consent, where available and allowable by local law. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
38 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection to 
Process Patient’s Personal Data 
Where allowed by local law, the patient may decide to withdraw consent to collect, store, and 
use biological samples and, as applicable, other personal data, informing the study doctor at any 
time in writing or in any other form that may be locally required. Also, where allowed by local 
law, the patient may object to the collection, storage, and use of his/her personal data, informing 
the study doctor at any time in writing or in any other form that may be locally required. In both 
cases, the Sponsor will continue to keep and use the patient’s study information (including any 
data resulting from the analysis of the patient’s biological samples until the time of 
withdrawal/objection) according to applicable law. The process for the storage and, as 
applicable, further use of remaining samples will be followed per local requirements.  
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study 
The Investigator or Sponsor may stop the participation of a patient in the study at any time if this 
is considered to be in the patient’s best interest. However, study integrity and interpretation are 
best maintained if all enrolled patients continue study assessments and follow-up even if study 
drug is discontinued. 
Termination of the clinical study and site closure are described in Section 8.1.6. 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation 
The primary reason that a patient’s study participation is stopped must be recorded in the 
appropriate section of the eCRF and all efforts will be made to complete and report the 
observations as thoroughly as possible. If a patient’s study participation is stopped due to an AE, 
including SAEs, the event should be followed as described in Section 6.5.6. 
4.3.3. 
Lost to Follow-Up 
A patient will be considered lost to follow-up if the patient repeatedly fails to return for 
scheduled visits and is unable to be contacted by the clinical study center. The following actions 
must be taken if a patient fails to return to the clinic for a required study visit: 
• The site must attempt to contact the patient and reschedule the missed visit as soon as 
possible and counsel the patient on the importance of maintaining the assigned visit 
schedule and ascertain if the patient wishes to continue in the study, and/or should 
continue in the study. 
• Before a patient is deemed lost to follow up, the Investigator or designee must make 
every effort to regain contact with the patient (where possible, 3 telephone calls and, 
if necessary, a certified letter to the patient’s last known mailing address or local 
equivalent methods). These contact attempts should be documented in the patient’s 
medical record. 
• Should the patient continue to be unreachable, the patient will be considered to have 
stopped participation in the study. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
39 
• For patients who are lost to follow-up, the Investigator can search publicly available 
records (where permitted and allowed by local law) to ascertain survival status. This 
ensures that the outcome of the study is as comprehensive as possible. 
4.3.4. 
Replacement of Study Patients 
No additional patients may be enrolled to mitigate the impact of patients who discontinue the 
study drug or stop participation in the study.  
5. 
TREATMENTS AND OTHER REQUIREMENTS 
5.1. 
Treatments Administered 
Study drug supplied for this study must not be used for any purpose other than the present study 
and must not be administered to any person not enrolled in the study. Study drug that has been 
dispensed and returned unused must not be re-dispensed. 
5.2. 
Study Drug 
Detailed information describing the preparation, administration, and storage of ALN-AGT01 SC 
and placebo SC is provided in the Pharmacy Manual. 
5.2.1. 
Description 
ALN-AGT01 will be supplied as a sterile solution for SC injection. See the Pharmacy Manual 
for further details of solution concentration and fill volume. 
The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC 
administration).  
5.2.2. 
Dose and Administration 
During the 12-month DB period, patients will be administered ALN-AGT01 or placebo, at the 
same volume and number of SC injections regardless of treatment assignment, once every 3 
months. The ALN-AGT01 and placebo groups are below: 
• Placebo SC once every 3 months, with re-randomization (1:1:1:1) at Month 6 to 1 of 
the initial 4 ALN-AGT01 regimens 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. Patients receiving once every 6 month ALN-AGT01 regimens will receive 
placebo SC at dosing visits at which they do not receive ALN-AGT01 to maintain the blind. 
Study drug injections will be administered under the supervision of the Investigator or healthcare 
professional. To maintain the blind, the doses are to be prepared by and syringes are to be 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
40 
masked by an unblinded site pharmacist or designee prior to study drug administration. A full 
description of the blinding procedure is included in the Pharmacy Manual. The injection site may 
be marked and mapped for later observation. Injections may be administered in the abdomen, 
thigh, or the side or back of the upper arms. The rotation of sites is recommended. If a local 
reaction around the injection site occurs, photographs may be obtained. Detailed instructions for 
study drug administration are found in the Pharmacy Manual. 
If a patient does not receive a dose of study drug within the specified visit window, the 
Investigator should contact the Medical Monitor. After such consultation, the dose may be 
administered up to 42 days before the next scheduled dose. Thereafter, the dose will be 
considered missed and not administered. 
Patients will be permitted to miss an occasional dose of study drug. However, if a patient misses 
2 consecutive doses, the Investigator, in consultation with the Medical Monitor, will discuss 
whether the patient will be able to continue the study (see also Section 4.3). 
Additional details can be found in the Pharmacy Manual. 
The definition of study drug overdose, follow-up procedures, and reporting requirements are 
provided Section 6.5.6.8. 
5.2.3. 
Dose Modifications 
Dose modifications are not permitted. 
If a study drug-related AE occurs in a patient that the Investigator judges as presenting a 
potential risk to the patient for further dosing, the study drug dose may be held at the discretion 
of the Investigator and the Medical Monitor should be contacted. 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping Study 
Drug Dosing  
1. Dosing decisions may be made based on the most recently available liver function test 
(LFT) results from a central laboratory (Table 6). 
2. For any ALT or AST elevation >3×ULN, central laboratory results should be used to 
guide subsequent monitoring as detailed in Table 3. 
3. For any ALT or AST elevation >3×ULN: 
a. If local laboratory results are obtained, confirm with a central laboratory as soon as 
possible, ideally within 2 to 3 days, but no later than 7 days. 
b. If an alternative cause is found, provide appropriate care. 
c. If an alternative cause is not found, perform assessments per Table 6 and Table 7. 
4. For any ALT or AST elevation >3×ULN without alternative cause that is accompanied 
by clinical symptoms consistent with liver injury (eg, nausea, right upper quadrant 
abdominal pain, jaundice) or elevated bilirubin to ≥2×ULN or INR ≥1.5, permanently 
discontinue dosing. 
5. For confirmed ALT or AST elevations >3×ULN without alternative cause and not 
accompanied by symptoms or elevated bilirubin ≥2×ULN or INR ≥1.5, see Table 3. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
41 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative Cause 
Identified 
Transaminase Level 
Action 
>3× to 5×ULN 
• 
May continue study drug dosing 
• 
Evaluate the initial elevation in LFT per the following assessments: 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6  
• 
Monitor at least every 2 weeks (LFT and coagulation per Table 6)  
• 
If elevation persists for ≥2 months, must discuss with the Medical Monitor 
before continuing dosing 
>5× to 8×ULN 
• 
Hold study drug dosing until recovery to ≤1.5×ULN or baseline; may 
resume dosing after discussion with the Medical Monitor 
• 
Evaluate the initial elevation in LFT per the following assessments 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6 
• 
Monitor at least weekly: LFT and coagulation per Table 6 until ALT and/or 
AST is declining on 2 consecutive draws, then may decrease monitoring to 
biweekly 
• 
If ALT or AST rises to >5×ULN following resumption of dosing, 
permanently discontinue dosing 
>8×ULN 
Permanently discontinue study drug dosing after confirmation of the 
transaminase value at the central laboratory. 
Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; INR=international normalized 
ratio; LFT=liver function test(s); ULN=upper limit of normal. 
Notes: In addition to these criteria, other assessments or evaluations may be performed per Investigator discretion, 
as appropriate. 
5.2.5. 
Neurological Criteria for Withholding, Monitoring, and Stopping Study Drug 
Dosing 
Clinically significant events that may be consistent with potential decreased proprioception 
(including but not limited to unusual clumsiness, gait abnormalities, and unexplained 
balance/coordination issues that are either absent at or worsening from the baseline) should be 
reported as an AE. If the treatment-emergent AE is persistent and considered related to study 
drug, specialty consultation with a neurologist should be considered. However, if such a 
treatment-emergent AE is serious or severe (regardless of the Investigator’s assessment of 
relatedness), the patient must be referred for neurologist consultation, and study drug dosing 
must be held until that consultation is complete. Resumption of dosing must be approved by the 
Medical Monitor. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
42 
5.2.6. 
Preparation, Handling, and Storage 
Staff at each clinical study center will be responsible for preparation of ALN-AGT01 or placebo 
doses according to procedures detailed in the Pharmacy Manual. No special procedures for the 
safe handling of study drug are required. 
ALN-AGT01 will be stored at approximately 2 to 30°C until dose preparation. Deviations from 
the recommended storage conditions should be reported to the Sponsor and use of ALN-AGT01 
halted until authorization for its continued use has been provided by the Sponsor or designee, as 
described in the Pharmacy Manual. 
A Sponsor representative or designee will be permitted, upon request, to audit the supplies, 
storage, dispensing procedures, and records. 
Instructions specific to unused study drug and additional storage will be provided in the 
Pharmacy Manual. 
5.2.7. 
Packaging and Labeling 
All packaging, labeling, and production of study drug will be in compliance with current Good 
Manufacturing Practice specifications, as well as applicable local regulations. Study drug labels 
and external packaging will include all appropriate information as per local labeling 
requirements. Additional details will be available in the Pharmacy Manual. 
5.2.8. 
Accountability 
The Investigator or designee will maintain accurate records of receipt and the condition of 
ALN-AGT01 supplied for this study, including dates of receipt. In addition, accurate records will 
be kept of when and how much ALN-AGT01 is dispensed and administered to each patient in 
the study. Any reasons for departure from the protocol dispensing regimen must also be 
recorded. 
At the completion of the study, there will be a final reconciliation of all ALN-AGT01. Used, 
partially used, and unused ALN-AGT01 will be returned to the Sponsor (or designee) or 
destroyed at the clinical study center according to applicable regulations. 
Further instructions about drug accountability will be detailed in the Pharmacy Manual. 
5.3. 
Clinical Product Complaints 
5.3.1. 
Definition 
A clinical product complaint (CPC) is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of the study drug and its packaging after it is released for distribution to the site at 
which study drug will be administered. 
A CPC may be detected prior to use of study drug, during use, or after use. A CPC is typically 
nonmedical in nature; however, it is possible that study drug complaints could be associated with 
an AE. Examples of a CPC include, but are not limited to: illegible clinical label, missing clinical 
label, damaged vial, empty vial, and contamination of study drug. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
43 
5.3.2. 
Reporting 
For product complaints, the Sponsor or its designee should be notified within 24 hours using the 
process outlined in the Pharmacy Manual. CPCs that may be associated with an AE must be 
evaluated and reported as indicated in Section 6.5.6. Detailed instructions on reporting CPCs will 
be provided in the Pharmacy Manual. 
5.4. 
Monitoring for Potential Clinical Events 
5.4.1. 
Monitoring and Approach for Potential Hypotension 
Hypotension is an obligate risk of antihypertensive medications. In addition to office blood 
pressure monitoring, outpatient blood pressure should be monitored weekly with HBPM to 
ensure the early detection of potential hypotension. Whenever possible, management decisions 
will be based on blood pressure measurements confirmed by office blood pressure. 
The following management recommendations for hypotension are provided: 
• Low blood pressure that is associated with symptoms should promptly be evaluated at 
the clinical study site or another hospital setting. Clinical study site evaluation for low 
blood pressure should include the assessment of orthostatic blood pressure (eg, supine 
to standing).  
• The Investigator should consider downtitration, interruption, or discontinuation of 
oral antihypertensives (if taking) if confirmed office SBP <90 mmHg or if clinical 
symptoms, such as lightheadedness or dizziness, develop coupled with a significantly 
lower SBP compared to prior visits (ie, SBP <100 mmHg). 
• Clinically significant events discovered during the course of a patient’s general 
medical care should be promptly communicated to the site and evaluated by the 
Investigator, especially if hypotension is noted. Patients will carry Independent Ethics 
Committee (IEC)-approved patient cards to facilitate this physician-to-physician 
communication.  
• If hypotension is confirmed, serum electrolytes and creatinine should be measured 
and any oral antihypertensive(s) previously started for hypertensive escape should be 
down-titrated, interrupted, or discontinued per Investigator judgement.  
• The frequency of blood pressure and biochemical monitoring (serum electrolytes and 
creatinine) should be increased during intercurrent illnesses that predispose patients to 
dehydration (eg, vomiting or diarrhea that persists for more than 24 hours) or when 
symptoms consistent with decreased effective circulating volume (eg, presyncopal 
symptoms, unexplained falls, decreased urine output) manifest, even if a patient’s 
recent blood pressure measurements have been normal. 
• Hypotension that warrants direct evaluation at the site should be communicated to the 
Medical Monitor within 24 hours. In addition, other clinical events consistent with 
potential hypotension (eg, unexplained presyncope, syncope, or falls) should be 
communicated to the Medical Monitor within 24 hours of the site being notified. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
44 
• Management of persistent hypotension may include increased salt intake or, if 
unresponsive, standard treatments for orthostatic intolerance syndromes such as 
fludrocortisone or midodrine. 
• Low blood pressure that requires medical treatment (including intravenous fluid 
support) or other clinical events consistent with potential hypotension (see above) 
should be recorded as AEs. 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure Elevation 
In addition to office blood pressure monitoring, outpatient blood pressure will be monitored 
frequently with HBPM to ensure the early detection of potential significant elevations. Whenever 
possible, management decisions will be based on blood pressure measurements confirmed by 
office blood pressure. The recommended interventions for potentially clinically significant blood 
pressure elevation are presented in Table 4.  
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation 
Study Period 
Intervention 
Throughout Study 
• 
Whenever possible, management decisions should be based on blood 
pressure measurements confirmed by office blood pressure. 
• 
Any confirmed event of severe hypertension (office SBP ≥180 mmHg 
and/or office DBP ≥120 mmHg) should be appropriately treated regardless 
of its timing relative to study drug administration.  
• 
Because ALN-AGT01 acts on the RAAS, the use of conventional RAAS 
inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors) as rescue 
agents for high blood pressure will be avoided throughout this study.  
• 
If added, oral antihypertensives must be used per their labeled instructions 
and in accordance with current care guidelines.[Whelton 2018; Williams 
2018] 
Day 1 to Month 3 
Intervene if clinically significant blood pressure elevation: 
• 
Because of the gradual onset of effects of ALN-AGT01, interventions for 
asymptomatic hypertension should be avoided in the first 6 weeks after the 
patient’s first administration of study drug.  
• 
After Week 6, patients who develop office SBP >160 mmHg and increased 
>10 mmHg from their baseline office SBP that persists for ≥24 hours on 2 
consecutive measurements or that is accompanied by hypertensive 
symptoms should be evaluated by the clinical study site. Severely 
symptomatic patients should be evaluated at the clinical study site or 
another hospital setting within 24 hours. 
• 
If persistent hypertension is confirmed (without the identification of a 
specific treatable cause) and the Investigator deems it to be a clinically 
significant change, treatment may be initiated at the medical discretion of 
the Investigator using a CCB and/or a thiazide/thiazide-like diuretic. 
Investigators should avoid long-acting agents that may not fully washout 
between Month 5 and Month 6. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
45 
Study Period 
Intervention 
Months 3 to 6 
Treat to target blood pressure using a CCB and/or thiazide/thiazide-like diuretic: 
• 
At Month 3, a CCB and/or a thiazide/thiazide-like diuretic may be added if 
the daytime mean SBP is ≥135 mmHg by ABPM. If the Investigator feels 
there is a compelling clinical reason to wait, the rationale for exception 
should be documented in the eCRF. 
• 
After Month 3, oral antihypertensive medications may also be added per 
Investigator judgement for persistent elevations in blood pressure above 
recommended target per treatment guidelines (eg, office SBP <140 mmHg, 
HBPM SBP <135 mmHg, or daytime mean SBP by ABPM <135 
mmHg).[Williams 2018] 
• 
A temporary hold of oral antihypertensives (if taking) will be performed in 
appropriate patients (below) from Month 5 to Month 6: 
- Month 5 office SBP <160 mmHg if taking no oral antihypertensive 
agents 
- Month 5 office SBP <155 mmHg if taking 1 oral antihypertensive agent 
- Month 5 office SBP <150 mmHg if taking 2 oral antihypertensive 
agents. 
• 
During this 4-week period, blood pressure will be carefully monitored by 
HBPM and oral antihypertensive medications restarted if confirmed office 
SBP >170 mmHg (or if confirmed office SBP >160 mmHg accompanied by 
symptoms) 
Month 6 to End of 
Study 
Treat to target blood pressure using Investigator’s choice of oral 
antihypertensive(s). 
• 
At Month 6, prior oral antihypertensive may be restarted per Investigator 
judgement if daytime mean SBP is ≥135 mmHg by ABPM. 
• 
Oral antihypertensive medications may also be added per Investigator 
judgement for persistent elevations in blood pressure above recommended 
target per treatment guidelines (eg, office SBP <140 mmHg; HBPM SBP 
<135 mmHg; daytime mean SBP by ABPM <135 mmHg).[Whelton 2018; 
Williams 2018] 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of eGFR 
through the anticipated onset of initial ALN-AGT01 PD. Based upon the renal dysfunction 
associated with conventional RAAS inhibitors,[McMurray 2016; Parving 2012] the following 
guidelines apply throughout the study: 
• If an individual patient experiences a decrease in eGFR by ≥30% from baseline or to 
≤30 mL/min/1.73m2, the Investigator should obtain confirmatory repeat tests, contact 
the Sponsor, and look for potentially reversible causes of renal dysfunction such as: 
− NSAIDs, antibiotics, or other treatments known to impair renal function 
− Recent exposure to intravenous contrast agents 
− Hypotension 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
46 
− Hypovolemia 
− Urinary infection 
− Urinary tract obstruction 
• If an individual patient experiences a decrease in eGFR by ≥40% from baseline or to 
≤25 mL/min/1.73m2, the Investigator should obtain confirmatory repeat tests, look for 
potentially reversible causes of renal dysfunction, and contact the Sponsor to discuss 
the potential interruption of study drug. Serum creatinine should be monitored at least 
weekly until improving.  
• If a patient is on additional oral antihypertensive agents, the Investigator should 
consider whether these agents should be interrupted, especially during intercurrent 
illness or volume depletion 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of serum 
electrolytes (at least monthly through the anticipated onset of ALN-AGT01 PD). The following 
guidelines apply for potassium elevations detected by laboratory monitoring.[McMurray 2016; 
Parving 2012] 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
47 
Table 5: 
Recommended Interventions for Hyperkalemia 
Serum K+ >5.2 and <5.5 mmol/L 
Serum K+ ≥5.5 and <6.0 mmol/L 
Serum K+ ≥6.0 mmol/L 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample. 
• 
Reinforce low-potassium diet 
and restriction of food/drinks 
with high potassium content  
• 
Review medical regimen 
(including dietary supplements 
and over-the-counter 
medications) for agents known 
to cause hyperkalemiaa. 
Consider reduction in dose or 
discontinuation of these agents. 
• 
Repeat K+ measurement within 
3 to 5 days. 
• 
If K+ remains >5.2 and <5.5 
mmol/L, regularly monitor K+ 
levels to ensure stability (at 
least weekly if in the first 6 
weeks of treatment or at least 
once monthly afterwards) 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample 
• 
Consider interruption or delay 
of study drug, according to 
Investigator medical judgment  
• 
Apply all measures outlined for 
serum K+ >5.2 and <5.5 
mmol/L 
• 
Repeat K+ measurement after 2 
to 3 days 
• 
If K+ <5.5 mmol/L, consider 
resumption of study drug (if 
interrupted) with repeat 
potassium within 5 days 
• 
If K+ persistently elevated ≥5.5 
mmol/L, consider treatment 
with patiromer (or with sodium 
zirconium cyclosilicate), if 
available 
• 
Immediately interrupt 
study drug 
• 
Confirm potassium 
concentration in a 
non-hemolyzed 
sample 
• 
Urgently evaluate 
patient and treat 
hyperkalemia as 
clinically indicated. 
After urgent 
treatment, consider 
treatment with 
patiromer (or with 
sodium zirconium 
cyclosilicate), if 
available 
• 
Apply all measures 
outlined for serum K+ 
≥5.5 and <6.0 
mmol/L 
• 
No resumption of 
study drug without 
individualized case 
discussion with and 
permission from 
Alnylam Medical 
Monitor 
Abbreviations: NSAID=nonsteroidal anti-inflammatory drug. 
a This list is not meant to be exhaustive: potassium-sparing diuretics (eg, amiloride and triamterene), potassium 
supplements (eg potassium chloride), salt substitutes, NSAIDs, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, herbal supplements (eg, Noni juice, alfalfa [Medicago sativa], 
dandelion [Taraxacum officinale], horsetail [Equisetum arvense], nettle [Urtica dioica], milkweed, lily of the 
valley, Siberian ginseng, hawthorn berries). 
The availability of patiromer or ZS-9 will be assessed at participating study sites. These 
potassium-binding drugs are indicated for the treatment of hyperkalemia and have been shown to 
safely reduce serum potassium levels and to maintain long-term normokalemia in chronic kidney 
disease patients receiving background conventional RAAS inhibitor therapy.[Georgianos and 
Agarwal 2018; Weir 2015] 
5.5. 
Concomitant Medications and Procedures 
Use of concomitant medications and procedures will be recorded on the patient’s eCRF as 
specified in the Schedule of Assessments (see Table 1). Concomitant medications include all 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
48 
prescription medications, herbal preparations, over the counter medications, vitamins, and 
minerals. Any changes in medications during the study will also be recorded on the eCRF. 
Standard vitamins and topical medications are permitted. However, topical steroids must not be 
applied anywhere near the injection site(s) unless medically indicated. For permitted concomitant 
medications administered SC, do not administer in same injection site area as the study drug for 
4 days after the last dose of study drug. 
Patients receiving low-dose aspirin (defined as ≤100 mg per day) for at least 30 days prior to 
screening and during the study treatment period are allowed. Occasional use of other over-the-
counter systemic NSAIDs is allowed. However, given their association with increased blood 
pressure, they should be avoided when possible and for at least 2 days prior to ABPM and office 
blood pressure measurements, and alternative analgesics (acetaminophen, topical NSAIDs) 
should be considered.[Whelton 2018] When used, the dosing of systemic NSAIDs should be at 
the lower end of the labeled range and for the shortest duration possible.  
Patients receiving SGLT2 inhibitors (eg, empagliflozin, canagliflozin, and dapagliflozin) should 
be on a stable dose for at least 30 days prior to screening and during the study treatment period. 
These medications should not be initiated or discontinued, if possible, during the study treatment 
period.  
Patients will be allowed to receive vaccines (eg, for SARS-CoV-2) that have received health 
agency authorization (including for emergency use) by local or regional regulatory authorities. 
Any concomitant medication that is required for the patient’s welfare may be administered by the 
Investigator, except as described in Section 5.5.2. However, it is the responsibility of the 
Investigator to ensure that details regarding the medication are recorded on the eCRF. 
Concomitant medication will be coded using an internationally recognized and accepted coding 
dictionary. 
5.5.1. 
Oral Antihypertensive Medication  
Individual initiation and modification of oral antihypertensive medications per Investigator 
judgement are permitted throughout the study if required to treat clinically significant blood 
pressure elevation (Section 5.4.2). In addition, after a patient completes the placebo-controlled 
primary endpoint at Month 3, oral antihypertensive medications may also be added per 
Investigator judgment for persistent elevations in blood pressure above recommended target per 
treatment guidelines (eg, office SBP <140 mmHg, HBPM SBP <135 mmHg, or daytime mean 
SBP by ABPM <135 mmHg).[Williams 2018] All oral antihypertensive medication that are 
dosed once daily should be taken in the morning. 
Serum electrolytes and creatinine should be measured at a central or local laboratory 
approximately 2 weeks after any antihypertensive addition or dose titration. 
5.5.2. 
Prohibited Concomitant Medication 
The following medications, treatments, and supplements are prohibited throughout the study 
treatment period (until the EOT visit): 
• Conventional RAAS inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors)  
• Prescription NSAIDs  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
49 
• Organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, isosorbide 
dinitrate, pentaerythritol) 
• An RNAi therapeutic (other than ALN-AGT01) 
• Medications, herbal supplements (including Ma Huang and St. John’s wort), or other 
substances (such as licorice) that are associated with increases in LFT abnormalities 
or with blood pressure abnormalities are prohibited. This includes certain stimulants 
(eg, amphetamine, methylphenidate dexmethylphenidate, dextroamphetamine), MAO 
inhibitors, atypical antipsychotics (eg, clozapine, olanzapine), diet pills (eg, 
phenylpropanolamine, sibutramine), and nasal decongestants (eg, phenylephrine 
hydrochloride, pseudoephedrine, naphazoline hydrochloride), unless individually 
approved by both the Investigator and the Medical Monitor. 
• Medications, herbal medicines, over-the-counter medications, or supplements known 
to cause hyperkalemia are prohibited unless individually approved by both the 
Investigator and the Medical Monitor. This includes potassium-sparing diuretics, 
potassium supplements, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, mineralocorticoid receptor 
antagonists, Noni juice, alfalfa, dandelion, horsetail, nettle, milkweed, lily of the 
valley, Siberian ginseng, and hawthorn berries. 
All concomitant medications must be reviewed and approved by the Investigator, with particular 
attention to avoiding drugs that may affect blood pressure. 
5.6. 
Treatment Compliance 
Compliance with study drug administration will be verified through observation by study staff. 
5.7. 
Other Requirements 
5.7.1. 
Contraception 
Females of child-bearing potential must be willing to use a highly effective method of 
contraception from 14 days before first dose, throughout study participation, and through safety 
follow-up (if applicable; see Section 3.1).  
Birth control methods which are considered highly effective include: 
• Placement of an intrauterine device. 
• Placement of an intrauterine hormone-releasing system. 
• Bilateral tubal occlusion. 
• Surgical sterilization of male partner (with the appropriate post-vasectomy 
documentation of the absence of sperm in the ejaculate; for female patients on the 
study, the vasectomized male partner should be the sole partner for that patient). 
• Established use of oral (except low-dose gestagens), implantable, injectable, or 
transdermal hormonal methods of contraception associated with the inhibition of 
ovulation. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
50 
• True sexual abstinence, when in line with the preferred and usual lifestyle of the 
patient. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception. Abstinent 
patients must agree to use one of the above-mentioned contraceptive methods if they 
start heterosexual relationships during the study and through safety follow-up (if 
applicable; Section 3.1). 
Investigators should advise females of childbearing potential of the most appropriate birth 
control method available within their country taking into account local medical practice. 
Females of child-bearing potential include female patients who have experienced menarche (or 
begin menarche over the course of the study), and who are not postmenopausal or permanently 
sterilized (eg, bilateral oophorectomy, hysterectomy, or bilateral salpingectomy). A 
postmenopausal state is defined as the absence of menses for 12 months without an alternative 
medical cause, confirmed by follicle stimulating hormone level within the postmenopausal 
range.  
For male patients, no contraception is required. However, use by males of contraception 
(condom) may be required in some countries, eg, France, in order to comply with local 
requirements as described in the corresponding patient ICFs.  
Compliance with contraception requirements will be assessed on a regular basis by the 
Investigator throughout the course of the study (see Section 6.5.5.3). Pregnancy testing will be 
performed before every dose for postmenarcheal females throughout the course of the study (see 
Section 6.5.5.3). 
5.7.2. 
Alcohol Restrictions 
Patients should limit alcohol consumption throughout the course of the study. Alcohol is limited 
to no more than 2 units per day (unit: 1 glass of wine [approximately 125 mL] =1 measure of 
spirits [approximately 1 fluid ounce] =½ pint of beer [approximately 284 mL]) for the duration 
of the study. Compliance with alcohol restrictions should be assessed on a regular basis by the 
Investigator throughout the course of the study. 
5.7.3. 
Tobacco and Nicotine Restrictions 
Use of nicotine or tobacco-containing products (including but not limited to snuff, chewing 
tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) must be avoided within 30 
minutes prior to blood pressure measurements. 
5.7.4. 
Dietary Recommendations  
All patients will receive educational materials on diet with recommendations to limit sodium 
consumption to approximately 2.0 g per day from screening through the end of the Treatment 
period. This direction should be provided at the start of the Screening period, and treatment-
naïve patients should follow these recommendations for at least 1 week prior to screening 
assessments of blood pressure. Of note, this is the sodium intake recommended in the 2018 
European Society of Cardiology/European Society of Hypertension Guidelines for both 
hypertensive patients and for the general population.[Williams 2018]  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
51 
On days on which samples for fasting lipid panel and glycemic assessments are collected, 
patients are required to fast for ≥10 hours before sample collection (Section 6.5.5.1). 
5.7.5. 
Exercise 
Patients should abstain from strenuous exercise for 48 hours before each blood collection for 
clinical laboratory tests and from any exercise for 30 minutes prior to office blood pressure 
measurements. 
6. 
STUDY ASSESSMENTS 
The Schedule of Assessments is provided in Table 1. Study visits should be scheduled for the 
morning. All assessments, except for postdose PK sample collection, are to be performed prior to 
dosing at dosing visits. Additional information on the collection of study assessments will be 
detailed in the study manuals. 
Where applicable country and local regulations and infrastructure for home healthcare allow, 
home healthcare may take place at a location other than the clinical study site to perform study 
assessments, which may include collection of blood and urine samples and measurement of vital 
signs (including blood pressure assessments) and weight (at the discretion of the Investigator). 
See further details in Section 10.2. 
6.1. 
Screening Assessments 
An ICF that has been approved by the appropriate Institutional Review Board (IRB)/IEC must be 
signed (in paper or electronic format per local regulations and institutional standards) by the 
patient before the screening procedures are initiated. All patients will be given a copy of the 
signed and dated ICF. 
Patients will be screened to ensure that they meet all the inclusion criteria and none of the 
exclusion criteria. Rescreening of patients is permitted with consultation of the Medical Monitor 
(see Section 6.1.2). 
Patient demographic data and medical history/disease history will be obtained. Any changes to 
medical history occurring between the screening assessment and Day 1 will be updated prior to 
study drug administration. 
6.1.1. 
Retesting  
If in the Investigator’s judgement, the screening laboratory abnormalities are likely to be 
transient, then laboratory tests may be repeated. The Investigator’s rationale should be 
documented. Laboratory values can be retested once during screening provided that the patient 
can be evaluated for eligibility after at least 2 to 4 weeks of washout (as applicable) and 
randomized within the allowed Screening period. Retesting of screening ABPM is permitted 
once if the first screening ABPM is invalid. A valid screening ABPM recording must be obtained 
within 2 weeks prior to randomization for all patients. In circumstances where it is not possible 
to randomize an eligible patient within the 2-week window following a valid screening ABPM 
result that met the inclusion criterion, a single additional ABPM assessment is permitted, with no 
option for retesting in case of an invalid reading. Eligibility is assessed by the most recent 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
52 
ABPM result obtained. If a valid ABPM reading that meets the inclusion criterion is unable to be 
obtained within 2 weeks prior to randomization, the patient is a screen failure. 
6.1.2. 
Rescreening 
A patient who does not meet all study eligibility criteria due to a transient condition observed at 
screening (eg, prohibited medications that were subsequently discontinued) will be allowed to 
return once for rescreening. A patient will be re-consented if rescreening occurs outside of the 
60-day screening window. In this case, all screening procedures must be repeated. 
6.2. 
Efficacy Assessments 
All blood pressure measurements (ABPM, office, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in 
Section 10.1.  
In patients taking oral antihypertensives, a washout of at least 2 to 4 weeks (as applicable) must 
be completed prior to measurement of the baseline ABPM (for eligibility) and baseline office 
blood pressure. The baseline ABPM and office blood pressure must be measured within 2 weeks 
before randomization. An HBPM unit will be provided during the Screening period to facilitate 
monitoring during the washout of prior oral antihypertensives (if taking) and to establish the 
HBPM baseline prior to randomization. To establish baseline, 3 recordings should be collected 
during the last week immediately prior to randomization. 
ABPM placement may be performed at home by appropriately trained individuals, as detailed in 
the ABPM Investigator Manual. If a patient is unable to report to the site for an office blood 
pressure assessment, a substitute “remote visit blood pressure measurement” may be obtained 
remotely using the methods described in Section 10.1. 
Recommendations for approach and monitoring of low blood pressure/hypotension and 
hypertensive escape are provided in Section 5.4.1 and Section 5.4.2, respectively. 
6.2.1. 
ABPM 
In patients taking oral antihypertensives (including those initiated as rescue medication), ABPM 
should be started prior to the morning dose of antihypertensive medication.  
Validity will be assessed for all ABPMs. If the ABPM recording is invalid at any point during 
the study, the patient will be provided 1 opportunity to repeat the recording.  
In circumstances where it is not possible to randomize a patient within the 2-week window 
following a valid ABPM recording that met the inclusion criterion, a single additional ABPM 
recording is permitted, with no option for retesting in case of an invalid recording. Eligibility is 
assessed by the most recent ABPM recording obtained. If a valid ABPM recording that meets the 
inclusion criterion is unable to be obtained within 2 weeks prior to randomization, the patient is a 
screen failure.  
See further details in Section 10.1 and the ABPM Investigator Manual. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
53 
6.2.2. 
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor at trough (prior to taking oral antihypertensives) and at approximately the same time 
each day; therefore, visits should be scheduled at approximately the same time of day, whenever 
possible. Office blood pressure must include orthostatic measurements (seated and standing).  
Exercise, caffeine, alcohol consumption, and use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or 
e-cigarettes) must be avoided within 30 minutes prior to blood pressure measurements. The use 
of inhaled short-acting beta agonists should be avoided within 6 hours prior to measuring blood 
pressure and/or heart rate. The use of phosphodiesterase type 5 inhibitors (eg, sildenafil, 
tadalafil, vardenafil, avanafil) should be avoided within 48 hours prior to measuring blood 
pressure. 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the HBPM and OBPM Investigator Manual.  
6.2.3. 
HBPM 
The HBPM should be measured in the morning upon waking, prior to breakfast/caffeine or 
taking morning oral medications. HBPM is not required on days when ABPM is being assessed. 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the HBPM and OBPM Investigator Manual. 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment 
Up to 100 patients at select sites will be given the option of using a wearable blood pressure 
sensor for 2 periods of 2 to 4 weeks each according to the Schedule of Assessments (Table 1). 
Wearable blood pressure assessments performed during screening should be obtained during the 
last 2 to 4 weeks before Day 1. The second period of assessment should be obtained 2 to 4 weeks 
prior to the Month 3 visit. Participation will be contingent upon individual patient consent. These 
noninvasive, cuffless devices are worn on the finger or wrist as described in the Biobeat 
Investigator Manual, using the opposite arm as that used for ABPM. 
6.3. 
Pharmacodynamic Assessments 
Blood samples for determination of AGT and RAAS biomarkers (plasma renin concentration, 
AngI, AngII, and aldosterone) will be collected according to the Schedule of Assessments 
(Table 1). Blood samples collected for AngI and AngII require special processing and will be 
assessed at sites that have appropriate resources, equipment, and reagents. Blood samples for PD 
assessments must be collected before study drug administration (on days when study drug is to 
be dosed) or at a time point corresponding to the time of study drug dosing (on other days). 
Blood AGT levels will be analyzed at a central laboratory by enzyme-linked immunosorbent 
assay for measurement of PD effect. These biomarkers may be analyzed using qualified assays. 
Details regarding the collection, processing, shipping, and storage of the samples will be 
provided in the Laboratory Manual.  
Results will not be used to adjust dosing of ALN-AGT01 or guide clinical management and will 
not be shared with sites until after the last patient completes Month 12. If clinical circumstances 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
54 
arise for which such information is required to guide patient care, local laboratory assessments 
should be drawn. 
6.4. 
Pharmacokinetic Assessments 
Blood samples will be collected for the assessment of plasma concentrations of ALN-AGT01 
and its primary metabolite AS(N-1)3′ ALN-AGT01 at the time points indicated in the Schedule 
of Assessments (Table 1). A detailed schedule of time points for the collection of blood samples 
for PK analysis is in Table 2. 
Plasma concentrations of ALN-AGT01 and AS(N-1)3′ ALN-AGT01 will be determined using a 
validated assay. Details regarding sample volumes to be collected, and the processing, shipping, 
and analysis of the samples will be provided in the Laboratory Manual. 
6.5. 
Safety Assessments 
The assessment of safety during the study will consist of the surveillance and recording of AEs, 
including SAEs, recording of concomitant medication and measurements of vital signs, weight, 
electrocardiogram (ECG) findings, and laboratory tests. Clinically significant abnormalities 
observed during the physical examination are recorded. 
6.5.1. 
Vital Signs 
Vital signs will be measured as specified in the Schedule of Assessments (Table 1) and include 
office blood pressure, heart rate, body temperature, and respiratory rate. When vital signs and 
blood sample collection occur at the same time, vital signs should be performed before blood 
samples are drawn, where possible. Vital signs should be measured predose in the seated 
position, after the patient has rested comfortably for approximately 5 minutes. Body temperature 
in degrees Celsius will be obtained via oral, tympanic, forehead, or axillary methods. Heart rate 
will be counted for a full minute and recorded in beats per minute, and respiration rate will be 
counted for a full minute and recorded in breaths per minute. Blood pressure is described in 
Section 6.2.  
Additional vital sign assessments, as medially indicated, may be added at the discretion of the 
Investigator, or as per DMC advice. 
Vital signs results will be recorded in the eCRF. 
6.5.2. 
Weight, Height, and Morphometrics 
Height and body weight measurements will be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded in the eCRF. Height will be measured at screening 
only. Height will be measured in centimeters. Body weight should be measured in kilograms to 
the first decimal point in patients wearing light clothing and without shoes.  
Waist circumference and waist-to-hip-ratio will also be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded on the eCRF. For waist circumference and waist-to-
hip ratio, patients should wear minimal clothing to ensure that the measuring tape is correctly 
positioned. Patients should stand erect with the abdomen relaxed, arms at the sides, feet together 
and with their weight equally divided over both legs. To perform the waist measurement, the 
lowest rib margin is first located and marked with a pen. The iliac crest is then palpated in the 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
55 
midaxillary line, and also marked. It is recommended to apply an elastic tape horizontally 
midway between the lowest rib margin and the iliac crest, and tie firmly so that it stays in 
position around the abdomen about the level of the umbilicus. The elastic tape thus defines the 
level of the waist circumference, which can then be measured by positioning the measuring tape 
over the elastic tape. Hip circumference measurement should be taken around the widest portion 
of the buttocks. Patients are asked to breathe normally, and to breathe out gently at the time of 
the measurement to prevent them from contracting their muscles or from holding their breath. A 
stretch-resistant tape that provides a constant 100 g of tension is recommended. Measurements 
should be obtained with the tape positioned parallel to the floor and performed using the same 
procedure throughout the study. 
The reading is taken to the nearest centimeter and entered in the source document. Each 
measurement should be repeated twice; if the measurements are within 1 cm of each other, the 
average should be calculated. If the difference between the 2 measurements exceeds 1 cm, the 2 
measurements should be repeated.  
6.5.3. 
Physical Examination 
Full and symptom-directed physical examinations will be conducted according to the Schedule 
of Assessments (Table 1); if a physical examination is scheduled for a dosing visit, it should be 
conducted prior to dosing. Full physical examinations will include the examination of the 
following: general appearance; head, eyes, ears, nose and throat; respiratory, cardiovascular, 
gastrointestinal, musculoskeletal, and dermatological systems; thyroid; lymph nodes; and 
neurological status (see the Recommended Neurological Assessments for All Physical 
Examinations document for further details on the assessments to be performed as part of the 
neurological evaluation). 
Symptom-directed physical examinations will be guided by evaluation of changes in symptoms, 
or the onset of new symptoms, since the last visit. Neurological evaluation should be performed 
during all symptom-directed physical examinations regardless of whether neurological 
symptoms have been experienced by the patient.  
Clinically significant abnormalities observed during the physical examination are recorded on 
the medical history or AE eCRF. 
6.5.4. 
Electrocardiogram 
The 12-lead ECGs reporting rhythm, ventricular rate, RR interval, PR interval, QRS duration, 
and QT interval and Fridericia-corrected QT interval will be obtained using a local machine, as 
specified in the Schedule of Assessments (Table 1). Patients should be supine for at least 10 
minutes before each ECG is obtained. The Investigator or qualified designee will review all 
single 12-lead ECGs to assess whether the results have changed since the Baseline visit and to 
determine the clinical significance of the results. These assessments will be recorded in the 
eCRF.  
When ECG and blood sample collection for RAAS biomarkers (renin, aldosterone, and Ang I/II) 
occur at the same visit, and where feasible, blood sample collection should occur first. ECGs 
should be performed at least 30 minutes after phlebotomy or other stressful assessments. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
56 
The Investigator or qualified designee will review all ECGs to assess whether the results have 
changed since the baseline visit and to determine the clinical significance of the results. These 
assessments will be recorded in the eCRF. Additional ECGs may be collected at the discretion of 
the Investigator, or as per DMC advice.  
6.5.5. 
Clinical Laboratory Assessments 
The following clinical laboratory tests will be evaluated by a central laboratory. Specific 
instructions for transaminase elevations are provided in Section 6.5.6.4. For any other 
unexplained clinically relevant abnormal laboratory test occurring after study drug 
administration, the test should be repeated and followed up at the discretion of the Investigator, 
or as per DMC advice, until it has returned to the normal range or stabilized, and/or a diagnosis 
is made to adequately explain the abnormality. Additional safety laboratories and assessments as 
indicated by the clinical situation may be requested. Clinical laboratory assessments are listed in 
Table 6 and will be assessed as specified in the Schedule of Assessments (Table 1).  
While local laboratory results may be used for urgent clinical decisions, on the day of the 
assessments all laboratory assessments specified in Table 6 which are performed at the clinic 
should also be sent in parallel to the central laboratory. In the case of discrepant local and central 
laboratory results on samples drawn on the same day, central laboratory results will be relied 
upon for clinical decisions. 
Clinical laboratory assessments may be collected at the clinical study center or at home by a 
trained healthcare professional. Blood samples collected for RAAS biomarkers should be 
collected in the morning and in the seated/upright position (after blood pressure measurements 
and before any assessments collected in the supine position). 
Spot urine collections for albumin and creatinine should be obtained in the morning.  
For any safety event or laboratory abnormality, additional laboratory assessments, imaging, and 
consultation may be performed for clinical evaluation and/or in consultation with the Medical 
Monitor; results may be collected and should be included in the clinical database. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
57 
Table 6: 
Clinical Laboratory Assessments  
Hematology 
Complete blood count with differential 
 
Serum Chemistry 
Sodium 
Potassium 
BUN 
Phosphate 
Uric acid 
Albumin 
Total protein 
Calcium 
Glucose 
Bicarbonate 
Creatinine and eGFR 
Chloride 
Liver Function Tests 
 
AST 
ALP 
ALT 
Bilirubin (total and direct) 
GGT 
 
Urinalysis 
Visual inspection for appearance and color 
Bilirubin 
pH (dipstick) 
Nitrite 
Specific gravity 
RBCs 
Ketones 
Urobilinogen 
Protein  
Leukocyte esterase 
Glucose 
Microscopy (if clinically indicated) 
Coagulation  
Prothrombin time 
International normalized ratio 
Partial thromboplastin time  
 
Fasting Lipid Panel and Glycemic Assessments (see Section 6.5.5.1) 
Lipid panel, including 
HDL-C, non-HDL-C, LDL-C, apolipoprotein A1, 
triglycerides, total cholesterol  
Insulin 
Fasting plasma glucose 
HbA1c 
Immunogenicity (see Section 6.5.5.2) 
ADA 
 
Pregnancy Testing/FSH Screening (see Section 6.5.5.3) 
β-human chorionic gonadotropin (females of 
child-bearing potential only) 
Follicle-stimulating hormone (postmenopausal 
women only) 
Abbreviations: ADA=anti-drug antibodies; ALP=alkaline phosphatase; ALT=alanine aminotransferase; 
AST=aspartate aminotransferase; BUN=blood urea nitrogen; eGFR=estimated glomerular filtration rate; 
FSH=follicle-stimulating hormone; GGT=gamma glutamyl transferase; HbA1c=hemoglobin A1c; HDL-C=high-
density lipoprotein; LDL-C=low-density lipoprotein; RBCs=red blood cells. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
58 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments 
Blood samples for fasting plasma glucose, insulin, lipid panel (including total cholesterol, high-
density lipoprotein [HDL-C], non-HDL-C, low-density lipoprotein, apolipoprotein A1, and 
triglycerides), and HbA1c will be collected at the time points listed in the Schedule of 
Assessments (Table 1). Patients are required to fast for ≥10 hours before sample collection for 
fasting plasma glucose, insulin, lipid panel, and HbA1c. Samples should be collected at 
approximately the same time of day (±2 hours). 
6.5.5.2. 
Immunogenicity 
Blood samples will be collected to evaluate anti-drug antibodies (ADA). Blood samples for ADA 
testing must be collected before study drug administration (on days when study drug is to be 
dosed) or at a time point corresponding to the time of study drug dosing (on other days) as 
specified in the Schedule of Assessments (Table 1). A blood sample to evaluate ADA will be 
collected at the ET visit, if applicable. Blood samples for ADA will be analyzed at a central 
laboratory. 
Details regarding the processing, shipping, and analysis of the samples will be provided in the 
Laboratory Manual. 
6.5.5.3. 
Pregnancy Testing 
A pregnancy test will be performed for females of child-bearing potential. A serum pregnancy 
test will be performed at screening, and urine pregnancy tests will be performed thereafter per 
the Schedule of Assessments and any time pregnancy is suspected. More frequent pregnancy 
testing may be performed where required per local requirements. The results of the pregnancy 
test must be known before study drug administration. Patients who are pregnant at screening are 
not eligible for study participation. Any woman with a positive urine pregnancy test, 
subsequently confirmed by a positive serum pregnancy test, during the study will be 
discontinued from study drug but will continue to be followed for safety. Patients determined to 
be pregnant while on study will be followed at least until the pregnancy outcome is known (see 
Section 6.5.6.7 for follow-up instructions). 
A blood sample will be drawn at screening to measure the levels of follicle stimulating hormone 
in order to confirm postmenopausal status in all women suspected to be postmenopausal (see 
Section 5.7.1 for definition of postmenopausal state). 
6.5.5.4. 
Additional Liver Function Assessments 
Additional laboratory assessments will be performed in patients who experience any LFT 
abnormalities as outlined in Section 5.2.4. Following the occurrence of elevated liver 
transaminases or other LFT abnormalities per central laboratory, all assessments in Table 7 will 
be performed 1 time, as well as hematology, serum chemistry, LFT, and coagulation assessments 
from Table 6, and other assessments or evaluations per Investigator discretion, as appropriate.  
Monitoring, including criteria for dose modification or withholding the study drug, is described 
in Section 5.2.4.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
59 
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases 
Extended Hepatic Panel 
HBsAg, HBc antibody IgM  
Parvovirus B19 DNA – quantitative 
HAV antibody IgM 
HHV-6 DNA viral load – quantitative 
HCV antibody 
Anti-nuclear antibodies 
HCV RNA PCR – quantitative 
Anti-smooth muscle antibodies 
HEV antibody IgM 
Anti-LKM1 antibody 
Herpes Simplex Virus 1 and 2 antibody IgM, IgG 
Anti-mitochondrial antibodies 
Herpes Zoster Virus IgM, IgG 
Anti-SLA 
Epstein-Barr Virus antibodies, IgM, and IgG 
Ferritin 
Cytomegalovirus antibodies, IgM, IgG 
Ceruloplasmin 
Imaging 
Abdominal ultrasound with Doppler flow (or CT or MRI) including right upper quadrant 
Focused Medical and Travel History 
Use of any potentially hepatotoxic concomitant 
medications, including over the counter medications 
and herbal remedies 
Alcohol consumption and drugs of abuse 
Other potentially hepatotoxic agents including any 
work-related exposures 
Recent travels to areas where hepatitis A or E 
is endemic 
Abbreviations: CT=computed tomography; HAV=hepatitis A virus; HBc=hepatitis B core; HBsAg=hepatitis B 
virus surface antigen; HCV=hepatitis C virus; HEV=hepatitis E virus; HHV-6=human herpesvirus 6; 
IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; LKM1=liver/kidney microsome-1 
antibody; MRI=magnetic resonance imagery; PCR=polymerase chain reaction; RNA=ribonucleic acid; 
SLA=soluble liver antigen 
Note: 
• 
All laboratory assessments will be measured in a central laboratory. The full panel of assessments should 
only be performed once; individual assessments may be repeated, as needed. 
6.5.6. 
Adverse Events 
6.5.6.1. 
Definitions 
Adverse Event 
According to the ICH E2A guideline Definitions and Standards for Expedited Reporting, and 21 
Code of Federal Regulations 312.32, Investigational New Drug Safety Reporting, an AE is any 
untoward medical occurrence in a patient or clinical investigational subject administered a 
medicinal product and which does not necessarily have a causal relationship with this treatment. 
Serious Adverse Event 
An SAE is any untoward medical occurrence that at any dose: 
• Results in death 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
60 
• Is life-threatening (an event which places the patient at immediate risk of death from 
the event as it occurred. It does not include an event that had it occurred in a more 
severe form might have caused death) 
• Requires inpatient hospitalization or prolongation of existing hospitalization 
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly or birth defect 
• Is an important medical event that may not be immediately life-threatening or result 
in death or hospitalization but may jeopardize the patient and may require 
intervention to prevent one of the other outcomes listed in the definition above (eg, 
events include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home, blood dyscrasias, convulsions, or the development of drug 
dependency or abuse). 
Adverse Events of Clinical Interest 
The following are considered to be AEs of clinical interest: 
• ALT or AST >3×ULN 
• Severe or serious ISRs; ISRs that are associated with a recall phenomenon (reaction 
at the site of a prior injection with subsequent injections), or those that lead to 
temporary dose interruption or permanent discontinuation of ALN-AGT01. 
An ISR is defined as a local reaction at or near the site of injection. “At or near” the 
injection site includes reactions at the injection site, adjacent to the injection site, or a 
reaction which may shift slightly away from the injection site due to gravity (eg, as 
may occur with swelling or hematoma). A systemic reaction which includes the 
injection site, eg, generalized urticaria, other distinct entities or conditions like 
lymphadenopathy that may be near the injection site is not considered an ISR. 
For information on recording and reporting of AEs of clinical interest, see Section 6.5.6.2 and 
Section 6.5.6.3, respectively. 
Adverse Event Severity 
Adverse events are to be graded according to the categories detailed below: 
Mild: 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
Moderate: Moderate; minimal, local, or noninvasive intervention indicated; limiting age 
appropriate instrumental activities of daily living (eg, preparing meals, shopping 
for groceries or clothes, using the telephone, managing money). 
Severe: 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting 
self-care activities of daily living (ie, bathing, dressing and undressing, feeding 
self, using the toilet, taking medications, and not bedridden); OR life-threatening 
consequences; urgent intervention indicated; OR death related to an adverse event. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
61 
Changes in severity should be documented in the medical record to allow assessment of the 
duration of the event at each level of severity. Adverse events characterized as intermittent 
require documentation of the start and stop of each incidence. When changes in the severity of an 
AE occur more frequently than once a day, the maximum severity for the experience that day 
should be noted. If the severity category changes over a number of days, then those changes 
should be recorded separately (with distinct onset dates). 
Adverse event severity and seriousness are assessed independently. ‘Severity’ characterizes the 
intensity of an AE. ‘Serious’ is a regulatory definition and serves as a guide to the Sponsor for 
defining regulatory reporting obligations (see definition for SAE). 
Relationship of the Adverse Event to Study Drug 
The relationship of each AE to study drug should be evaluated by the Investigator by a “yes” or 
“no” response to the question: “Is there a reasonable possibility that the event may have been 
caused by the study drug?” A “yes” response indicates that the event is considered as related to 
the study drug. 
6.5.6.2. 
Eliciting and Recording Adverse Events 
Eliciting Adverse Events 
The patient should be asked about medically relevant changes in the patient’s health since the 
last visit. The patient should also be asked if the patient has been hospitalized, had any accidents, 
used any new medications, or changed concomitant medication routines (both prescription and 
over-the-counter). In addition to patient observations, AEs will be documented from any 
clinically relevant laboratory findings, physical examination findings, ECG changes, or other 
findings that are relevant to patient safety. 
Recording Adverse Events 
The Investigator is responsible for recording non-serious AEs that are observed or reported by 
the patient after administration of the first dose of study drug regardless of their relationship to 
study drug through the end of study. Non-serious AEs will be followed until the end of study. 
Events occurring after signing of the ICF and before study drug administration will be captured 
as medical history (see Section 6.1), while AEs that occur after study drug administration, and 
baseline events that worsen after study drug administration, must be recorded as AEs.  
The Investigator is responsible for recording SAEs that are observed or reported by the patient 
after the time when the informed consent is signed regardless of their relationship to study drug 
through the end of study. SAEs will be followed until satisfactory resolution, until baseline level 
is reached, or until the SAE is considered by the Investigator to be chronic or the patient is 
stable, as appropriate. 
All AEs must be recorded in the source records for the clinical study center and in the eCRF for 
the patient, whether or not they are considered to be drug-related. Each AE must be described in 
detail: onset time and date, description of event, severity, relationship to study drug, action taken, 
and outcome (including time and date of resolution, if applicable). 
For SAEs, record the event(s) in the eCRF and, as applicable, the SAE form. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
62 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the supplemental AEs of 
Clinical Interest eCRF should be completed. Additional clinical and laboratory information may 
be collected. Refer to CRF completion guidelines for details on reporting events in the 
supplemental AEs of Clinical Interest eCRF. 
For all ISRs, the Investigator, or delegate, should submit an Injection Site Reaction Signs or 
Symptoms eCRF, recording additional information regarding each injection site reaction that is 
entered on the AE eCRF (eg, symptom(s), injection site location, follow-up actions taken, etc). 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the Sponsor or its designee 
should be notified within 24 hours using the appropriate eCRF. 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee 
An assessment of the seriousness of each AE will be made by the Investigator. Any AE and 
laboratory abnormality that meets the SAE criteria in Section 6.5.6.1 must be reported to the 
Sponsor or designee immediately and no later than 24 hours from the time that clinical study 
center staff first learns of the event. All SAEs must be reported regardless of the relationship to 
study drug. 
The initial report should include at least the following information: 
• Patient’s study number 
• Description and date of onset of the event 
• Criterion for serious 
• Preliminary assignment of relationship to study drug, and 
• Investigator/site information 
To report the SAE, complete the eCRF and, as applicable, the SAE form. Immediately and no 
later than 24 hours of receipt of follow-up information, the Investigator must update the eCRF 
and, as applicable, the SAE form.  
Appropriate remedial measures should be taken by the Investigator using his/her best medical 
judgment to treat the SAE. These measures and the patient’s response to these measures should 
be recorded. All SAEs, regardless of relationship to study drug, will be followed by the 
Investigator until satisfactory resolution or the Investigator deems the SAE to be chronic or 
stable. Clinical, laboratory, and diagnostic measures should be employed by the Investigator as 
needed to adequately determine the etiology of the event. 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities 
The Sponsor or its representative will report certain study events in an expedited manner to the 
Food and Drug Administration, the European Medicines Agency’s EudraVigilance electronic 
system according to Directive 2001/20/EC, and to all country Regulatory Authorities where the 
study is being conducted, according to local applicable regulations. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
63 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee 
Suspected unexpected serious adverse reactions will be reported to the IRB/IEC per their 
institutional policy by the Investigator or Sponsor (or Sponsor designee) according to country 
requirements. Copies of each report and documentation of IRB/IEC notification and 
acknowledgement of receipt will be kept in the Investigator’s study file. 
6.5.6.7. 
Pregnancy Reporting 
If a female patient becomes pregnant during the study through safety follow-up (Section 3.1), the 
Investigator must report the pregnancy to the Sponsor or designee within 24 hours of being 
notified of the pregnancy. Details of the pregnancy will be recorded on the pregnancy reporting 
form. The patient should receive any necessary counseling regarding the risks of continuing the 
pregnancy, the possible effects on the fetus, and be counseled not to breastfeed for 90 days after 
the last dose of study drug. 
The pregnancy should be followed by the Investigator until completion. At the completion of the 
pregnancy, the Investigator will document the outcome of the pregnancy. If the outcome of the 
pregnancy results in a postpartum complication, spontaneous abortion, stillbirth, neonatal death, 
or congenital anomaly, then the Investigator should follow the procedures for reporting an SAE 
as outlined in Section 6.5.6.4. 
6.5.6.8. 
Overdose and Other Special Situations Reporting 
An overdose is defined as any dose of study drug administered to the participant or taken by the 
participant that is >2× the assigned dose during a single administration and/or ≥2 doses within ½ 
the intended dosing interval. 
The Sponsor does not recommend specific treatment for an overdose.  
In an event of an overdose or other special situations (eg, medication error, abuse, misuse, CPC 
associated with an AE), the Investigator should: 
• Contact the Medical Monitor within 24 hours  
• Submit the special situations reporting form within 24 hours using the contact 
information in the Pharmacy Manual 
• Closely monitor the participant for any AE/SAE and laboratory abnormalities 
• Document the amount of study drug given  
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or 
a concomitant medication will be considered AEs/SAEs.  
Full details of overdose and other special situations reporting instructions will be outlined in the 
Pharmacy Manual. 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository 
Alnylam’s RNAi therapeutics platform permits the highly specific targeting of investigational 
therapies based on genetic sequence. It is possible that variations in the target genetic sequence 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
64 
will result in variations in drug effect. More generally, genetic variations may account for the 
well-described heterogeneous manifestations of disease in patients with hypertension, as well as 
their responses to treatment. 
Where allowed per local regulations, ethics committee (IRB/IEC) approval, and patient consent, 
samples will be collected as part of this study to permit exploratory investigations and the 
application of novel approaches to bioanalyses that may further elucidate the outcomes of this 
study, or potentially advance understanding of the safety, mechanism of action, and/or efficacy 
of ALN-AGT01. 
Biological specimens will be collected at the intervals indicated in the Schedule of Assessments 
(Table 1). These specimens will be analyzed at a central laboratory. Potential exploratory 
investigations may include DNA, RNA, or biochemical metabolite assessments as they relate to 
disease progression, efficacy, or safety. 
The biospecimen repository will also include residual material from routine samples (safety 
laboratory samples, PK samples, etc) that are obtained during the study. 
These specimens will be securely stored in a central biorepository for up to 10 years following 
the completion of this clinical study (ie, last patient last visit), or as per local regulations. After 
10 years have elapsed, samples will be destroyed. 
Details regarding the collection, processing, storage, and shipping of the samples will be 
provided in the Laboratory Manual. 
Exploratory analysis of these biospecimens will be performed by Alnylam Pharmaceuticals or its 
designees. 
When biobanking is permitted by local regulation, study participants will be advised during the 
informed consent process of these biobanking details and the potential for exploratory 
investigation of their samples. 
7. 
STATISTICS 
A Statistical Analysis Plan (SAP) will be finalized before database lock and unblinding for the 
primary analysis. The plan will detail the implementation of the statistical analyses in accordance 
with the principle features stated in the protocol. 
7.1. 
Determination of Sample Size 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline at Month 
3 in 24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 375 
patients (75 per treatment group) provides at least 84% power to detect a dose response signal in 
SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided significance level of 
0.05. In addition, this sample size provides at least 80% power to detect a 10 mmHg difference 
between an individual ALN-AGT01 dose versus placebo with a 2-sided significance level of 
0.05. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
65 
7.2. 
Statistical Methodology 
The statistical and analytical plans presented below are brief summaries of planned analyses. 
More complete plans will be detailed in the SAP. Changes to the methods described in the final 
SAP will be described and justified as needed in the clinical study report. For information on 
study endpoints, see Section 2. 
7.2.1. 
Populations to be Analyzed 
The populations (analysis sets) are defined as follows: 
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• PK Analysis Set: All patients who received at least 1 full dose of ALN-AGT01 and 
have at least 1 nonmissing postdose PK assessment. 
• PD Analysis Set: All patients who received at least 1 full dose of study drug. All by-
treatment analyses based on the PD Analysis Set will be grouped according to the 
treatment actually received. 
• All ALN-AGT01 Treated Set: All patients who received any amount of 1 of the 4 
ALN-AGT01 dosing regimens, including patients who took ALN-AGT01 during the 
6-month placebo-controlled period and patients who initially took placebo and then 
switched to ALN-AGT01 after the Month 6 visit. 
For the primary analysis for the 6-month placebo-controlled DB period, the primary population 
used to evaluate efficacy will be the FAS. Safety will be analyzed using the Safety Analysis Set. 
The PK and PD Analysis Sets will be used to conduct PK and PD analyses, respectively. 
The All ALN-AGT01 Treated Set will be used to summarize the efficacy and safety of 
ALN-AGT01 throughout the entire DB period (including DB extension period). 
7.2.2. 
Examination of Subgroups 
Subgroup analyses will be conducted for selected endpoints. Subgroup categories and detailed 
methodology will be provided in the SAP. 
7.2.3. 
Handling of Missing Data 
Handling of missing data will be described in the SAP. 
7.2.4. 
Baseline Evaluations 
Demographics and other disease-specific baseline characteristics will be summarized. 
In general, baseline will be defined as the average of all assessments, including unscheduled 
assessments, prior to the first dose of study drug. Details of the definition will be specified in the 
SAP. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
66 
7.2.5. 
Efficacy Analyses 
The primary endpoint is the change from baseline at Month 3 in 24-hour mean SBP assessed by 
ABPM. The hypothesis of the dose response signal for the primary endpoint across ALN-AGT01 
doses and placebo will be tested using Dunnett’s procedure based on mixed model for repeated 
measurements (MMRM). The MMRM model will include treatment, visit, treatment-by-visit 
interaction, and race (black; all other races) as fixed factors and baseline 24-hour mean SBP 
assessed by ABPM as a covariate. An unstructured covariance matrix will be used. 
The key secondary endpoints are: 
• Change from baseline at Month 3 in office SBP 
• Change from baseline at Month 6 in 24-hour mean SBP assessed by ABPM 
• Change from baseline at Month 6 in office SBP 
• Proportion of patients with 24-hour mean SBP assessed by ABPM <130 mmHg 
and/or reduction ≥20 mmHg without additional antihypertensive medications at 
Month 6 
To control the overall type I error, the primary and key secondary endpoints will be tested in 
hierarchical order. 
Details of the analysis method for primary, secondary, and exploratory endpoints will be 
described in the SAP. 
7.2.6. 
Pharmacodynamic Analysis 
Pharmacodynamic analyses will include the evaluation of changes in levels of serum AGT and 
other exploratory biomarkers of the RAAS pathway. Descriptive statistics for observed levels 
and the relative change from baseline for all measured biomarkers will be presented for each of 
the postdose time points. 
Statistical comparison of the biomarker levels (absolute and/or change from baseline) across 
treatment groups may be explored. Details of the analysis will be specified in the SAP.  
Population PK/PD analysis may be conducted to evaluate the dose-response relationships for PD 
lowering after ALN-AGT01 treatment. Additionally, the relationship between lowering of serum 
AGT and blood pressure may be explored within a modeling framework. If conducted, these 
analyses will be described in a pharmacometrics analysis plan and results will be presented in a 
separate report. 
7.2.7. 
Pharmacokinetic Analysis 
Plasma concentrations of ALN-AGT01 and its metabolite AS(N-1)3′ ALN-AGT01 will be 
summarized using descriptive statistics. 
Population PK analysis may be conducted on the PK data from this study. If conducted, the 
analysis methods will be described in a pharmacometrics analysis plan and results will be 
presented in a separate report. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
67 
7.2.8. 
Safety Analyses 
The primary parameter is the frequency of treatment-emergent AEs (hereafter referred to simply 
as AEs). Safety parameters also include vital signs, ECGs, clinical laboratory assessments and 
physical exams. Extent of exposure will be summarized.  
Prior and concomitant medications will be coded using the World Health Organization Drug 
Dictionary. Results will be tabulated by Anatomical Therapeutic Chemical Classification System 
and Preferred Term (PT). 
Adverse events will be classified according to the Medical Dictionary for Regulatory Activities 
(MedDRA) System Organ Class (SOC) and PT. Adverse events, SAEs, related AEs, AEs leading 
to discontinuation of study drug, and AEs leading to death will be summarized by SOC and PT 
for each treatment arm. By-patient listings will be provided for deaths, SAEs, and AEs leading to 
discontinuation of study drug.  
Descriptive statistics will be provided for clinical laboratory parameters, ECG, and vital signs 
summarizing the observed values and changes from baseline over time. Laboratory shift tables 
from baseline grade (or category) to worst post-baseline grade (or category) will be presented for 
laboratory parameters that are graded or categorized. Abnormal physical exam findings will be 
presented in listings. 
Other safety summaries will be presented as appropriate. Further details will be specified in the 
SAP. 
7.2.9. 
Immunogenicity Analyses 
The frequency and percentage of patients with confirmed positive ADA assay at any time during 
the study as well as at each scheduled visit will be summarized. The titer results for patients with 
confirmed positive ADA results will be summarized. 
7.2.10. 
Interim Analysis 
The primary analysis will be conducted after all patients complete the Month 6 visit or withdraw 
from the study prior to the Month 6 visit. No formal interim analysis is planned before the 
primary analysis.  
7.2.11. 
Optional Additional Research 
Optional additional research may be conducted in the future on the biological samples and/or 
data collected during the study in accordance with the strict terms of the ICF (see Section 4.3.2). 
8. 
STUDY ADMINISTRATION 
8.1. 
Ethical and Regulatory Considerations 
This study will be conducted in accordance with the protocol, all applicable regulatory 
requirements, and the current guidelines of Good Clinical Practice (GCP). Compliance with GCP 
provides public assurance that the rights, safety, and well-being of study patients are protected 
consistent with the principles that have their origin in the Declaration of Helsinki. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
68 
8.1.1. 
Informed Consent 
The Investigator will ensure that the patient is given full and adequate oral and written 
information about the nature, purpose, possible risk, and benefit of the study. Patients must also 
be notified that they are free to discontinue from the study at any time. The patient should be 
given the opportunity to ask questions and allowed time to consider the information provided. 
The Investigator will inform the patient if new information becomes available that may be 
relevant to the patient’s willingness to continue participation in the study. Communication of this 
information should be documented. 
The patient’s signed and dated informed consent (in paper or electronic format per local 
regulations and institutional standards) must be obtained before conducting any study tests or 
procedures that are not part of routine care. 
The Investigator must maintain the original, signed ICF. A copy of the signed ICF must be given 
to the patient. 
8.1.2. 
Ethical Review 
The study protocol, including the ICF, must be approved or given a favorable opinion in writing 
by an IRB or IEC, as appropriate. The Investigator must submit written approval before he or she 
can enroll any patient into the study. 
The Investigator is responsible for informing the IRB or IEC of any amendment to the protocol 
in accordance with local requirements. In addition, the IRB or IEC must approve all patient 
materials for the study. The protocol must be reapproved by the IRB or IEC upon receipt of 
amendments and annually, as local regulations require. 
Initial IRB or IEC approval of the protocol, and all materials approved by the IRB or IEC for this 
study including the patient consent form and recruitment materials must be maintained by the 
Investigator and made available for inspection. 
The Investigator will submit reports of SAEs as outlined in Section 6.5.6. In addition, the 
Investigator agrees to submit progress reports to the IRB or IEC per their local reporting 
requirements, or at least annually and at the conclusion of the study. The reports will be made 
available to the Sponsor or designee. 
Any communications from regulatory agencies, IRBs, or IECs in regard to inspections, other 
studies that impact this protocol or the qualifications of study personnel should be promptly 
reported to the Sponsor or its designee. 
The Investigator is also responsible for providing the IRB or IEC with reports of any reportable 
serious adverse drug reactions from any other study conducted with the study drug. The Sponsor 
or designee will provide this information to the Investigator. 
Major changes in this research activity, except those to remove an apparent immediate hazard to 
the patient, must be reviewed and approved by the Sponsor and the IRB or IEC that approved the 
study. Amendments to the protocol must be submitted in writing to the Investigator’s IRB or IEC 
and the Regulatory Authority for approval before patients are enrolled under the amended 
protocol, and patients must be re-consented to the most current version of the ICF.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
69 
8.1.3. 
Serious Breach of Protocol 
Investigators must notify the Medical Monitor within 24 hours of becoming aware of a potential 
serious breach of the protocol. A serious breach is a breach that is likely to affect to a significant 
degree the safety and rights of a study participant or the reliability and robustness of the data 
generated in the clinical study. 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention 
All documentation (including personal data) relating to the study should be retained for 2 years 
after the last approval in an ICH territory or as required by local laws and regulations, whichever 
is longer. 
If it becomes necessary for the Sponsor, the Sponsor’s designee, applicable IRB/IEC, or 
applicable regulatory authorities to review or audit any documentation relating to the study, the 
Investigator must permit direct access to all source documents/data. Records will not be 
destroyed without informing the Sponsor in writing and giving the Sponsor the opportunity to 
store the records for a longer period of time at the Sponsor’s expense. 
The Investigator must ensure that the patients’ confidentiality will be maintained. On the eCRFs 
or other documents submitted to the Sponsor or designees, patients should not be identified by 
their names, but by the assigned patient number or code. If patient names are included on copies 
of documents to be submitted to the Sponsor or designees, the names will be obliterated, and the 
assigned patient number added to the document, before sending to the Sponsor. Documents not 
for submission to the Sponsor (eg, signed ICFs) should be maintained by the Investigator in strict 
confidence. 
The Investigator must treat all of the information related to the study and the compiled data as 
confidential, whose use is for the purpose of conducting the study. The Sponsor must approve 
any transfer of information not directly involved in the study. 
To comply with local and/or regional regulations, this clinical study may be registered, and study 
results may be posted on public registries, such as ClinicalTrials.gov. 
8.1.5. 
End of Study 
The end of study is defined as the last patient last visit. 
8.1.6. 
Termination of the Clinical Study or Site Closure 
The Sponsor, or designee, reserves the right to terminate the study or a clinical study site at any 
time. Conditions that may warrant this action may include, but are not limited to: 
• The discovery of an unexpected, serious, or unacceptable risk to patients participating 
in the study 
• Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of participants by the Investigator 
• The decision on the part of the Sponsor to suspend or discontinue treatment with the 
study drug 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
70 
Should the study be terminated, and/or the site closed for whatever reason, all documentation and 
study drug pertaining to the study must be returned to the Sponsor or its representative, and the 
Investigators, IRB/IEC and Regulatory Authorities will be promptly informed of the termination 
and the reason for the decision. The Investigator should promptly inform the patients and assure 
appropriate therapy and follow-up. 
8.2. 
Data Quality Control and Quality Assurance 
8.2.1. 
Data Handling 
Study data must be recorded on CRFs (paper and/or electronic) provided by the Sponsor or 
designee on behalf of the Sponsor. Case report forms must be completed only by persons 
designated by the Investigator. If eCRFs are used, study data must be entered by trained site 
personnel with access to a valid and secure eCRF system. All data entered into the eCRF must 
also be available in the source documents. Corrections on paper CRFs must be made so as to not 
obliterate the original data and must be initialed and dated by the person who made the 
correction. 
8.2.2. 
Study Monitoring 
The Monitor, as a representative of the Sponsor, has an obligation to closely follow the study 
conduct at the site. The Monitor will visit the Investigator and clinical study center periodically 
and will maintain frequent telephone and written contact. The Monitor will maintain current 
personal knowledge of the study through observation, review of study records and source 
documentation, and discussion of the conduct of the study with the Investigator and staff. 
The Monitor will review source documents, systems and CRFs to ensure overall quality and 
completeness of the data and to confirm study procedures are complied with the requirements in 
the study protocol accurately. The Sponsor, or its designee, will be allowed to conduct site visits 
to the investigation facilities for the purpose of monitoring any aspect of the study. The 
Investigator agrees to allow the Monitor to inspect the drug storage area, study drug stocks, drug 
accountability records, patient charts and study source documents, site standard operating 
procedures and training records, and other records relative to study conduct. 
Where local regulations allow, the Monitor may request remote access to source documents and 
systems. Should this take place, it will be done in a manner that protects the confidentiality of the 
data. 
8.2.3. 
Audits and Inspections 
Periodically, the Sponsor or its authorized representatives audit clinical investigative sites as an 
independent review of core study processes and documents to determine whether these activities 
were conducted, and data were recorded, analyzed, and accurately reported according to the 
protocol, GCP guidelines of the ICH, and any applicable regulatory requirements. A regulatory 
authority, an IEC or an IRB may visit the site to perform audits or inspections, including source 
data verification. The Investigator should contact the Sponsor and designee immediately if 
contacted by a regulatory agency, an IEC, or an IRB about an inspection. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
71 
8.3. 
Publication Policy 
It is intended that after completion of the study, the data are to be submitted for publication in a 
scientific journal and/or for reporting at a scientific meeting. A copy of any proposed publication 
(eg, manuscript, abstracts, oral/slide presentations, book chapters) based on this study, must be 
provided and confirmed received at the Sponsor at least 30 days before its submission. The 
Clinical Trial Agreement will detail the procedures for publications. 
Authorship of any publications resulting from this study will be determined on the basis of the 
Uniform Requirement for Manuscripts Submitted to Biomedical Journals (International 
Committee of Medical Journal Editors). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
72 
9. 
LIST OF REFERENCES 
Angell SY, De Cock KM,Frieden TR. A public health approach to global management of 
hypertension. Lancet. 2015 Feb 28;385(9970):825-7. 
Beeftink MM, van der Sande NG, Bots ML, Doevendans PA, Blankestijn PJ, Visseren FL, et al. 
Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-
to-Control Hypertension. Hypertension. 2017 May;69(5):927-32. 
Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to 
antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011 Mar;29(3):610-8. 
de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M, et al. Prevalence and 
factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension. 
2009 Mar;53(3):466-72. 
Dzau VJ,Balatbat CA. Future of Hypertension. Hypertension. 2019 Sep;74(3):450-7. 
Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of 
Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 
2017 Jan 10;317(2):165-82. 
Georgianos PI,Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding 
drugs. Kidney Int. 2018 Feb;93(2):325-34. 
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK,He J. Global burden of 
hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23. 
Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the 
Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-30. 
McClellan M, Brown N, Califf RM,Warner JJ. Call to Action: Urgent Challenges in 
Cardiovascular Disease: A Presidential Advisory From the American Heart Association. 
Circulation. 2019 Feb 26;139(9):e44-e54. 
McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, et al. Aliskiren, 
Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016 Apr 21;374(16):1521-
32. 
Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP,Crooke RM. Blood Pressure 
Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of 
Hypertension and Kidney Injury. Hypertension. 2017 Sep;70(3):566-76. 
Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, et al. Trends in Blood 
Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020 
Sep 22;324(12):1190-200. 
NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a 
pooled analysis of 1479 population-based measurement studies with 19.1 million participants. 
Lancet. 2017 Jan 7;389(10064):37-55. 
Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and 
a lifecourse strategy to address the global burden of raised blood pressure on current and future 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
73 
generations: the Lancet Commission on hypertension. Lancet. 2016 Nov 26;388(10060):2665-
712. 
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. 
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 
6;367(23):2204-13. 
Peacock E,Krousel-Wood M. Adherence to Antihypertensive Therapy. Med Clin North Am. 
2017 Jan;101(1):229-45. 
Romero CA, Orias M,Weir MR. Novel RAAS agonists and antagonists: clinical applications and 
controversies. Nat Rev Endocrinol. 2015 Apr;11(4):242-52. 
Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE, et al. Medication 
adherence and persistence according to different antihypertensive drug classes: A retrospective 
cohort study of 255,500 patients. Int J Cardiol. 2016 Oct 1;220:668-76. 
Services UDoHaH. The Surgeon General's Call to Action to Control Hypertension. 2020 October 
2020:1-50. 
Uijl E, Mirabito Colafella KM, Sun Y, Ren L, van Veghel R, Garrelds IM, et al. Strong and 
Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen. 
Hypertension. 2019 Jun;73(6):1249-57. 
van der Laan DM, Elders PJM, Boons C, Beckeringh JJ, Nijpels G,Hugtenburg JG. Factors 
associated with antihypertensive medication non-adherence: a systematic review. J Hum 
Hypertens. 2017 Nov;31(11):687-94. 
Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients 
with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 
15;372(3):211-21. 
Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report 
of the American College of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115. 
White WB, Mansoor GA, Tendler BE,Anwar YA. Nocturnal blood pressure epidemiology, 
determinants, and effects of antihypertensive therapy. Blood Press Monit. 1998 Feb;3(1):43-51. 
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH 
Guidelines for the management of arterial hypertension: The Task Force for the management of 
arterial hypertension of the European Society of Cardiology and the European Society of 
Hypertension: The Task Force for the management of arterial hypertension of the European 
Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 
Oct;36(10):1953-2041. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
74 
10. 
APPENDICES 
10.1. 
Measurement of Blood Pressure 
All blood pressure measurements (office, ABPM, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in the 
relevant user manuals.  
The appropriately sized cuff for each modality must be used for all assessments. The arm’s 
circumference at midpoint (halfway between the acromion and olecranon) should be determined 
at screening with a metric tape measure and used to select the appropriately sized blood pressure 
cuff/bladder for each instrument as described in the ABPM Investigator Manual and the HBPM 
and OBPM Investigator Manual. Unless significant weight loss or gain occurs between visits, the 
patient should use the same cuff/bladder size throughout the study. 
At the first Screening visit only, office blood pressure will be measured in both arms to select the 
appropriate arm to use for office blood pressure and HBPM measurements. Unless a concomitant 
condition favors the use of a specific arm, the arm with the higher office SBP should be used for 
all subsequent office blood pressure and HBPM readings. The ABPM should be measured using 
the patient’s nondominant arm. If the patient is ambidextrous, the same arm used for office blood 
pressure and HBPM readings should be used. 
ABPM 
The appropriately sized cuff should be placed on the correct arm following the instructions in the 
ABPM Investigator Manual. In patients taking oral antihypertensives (including those initiated as 
rescue medication), ABPM should be started prior to the morning dose of antihypertensive 
medication. All ABPM collections must be in the outpatient/ambulatory state. During screening, 
ABPM recording must be obtained within 2 weeks prior to randomization. ABPM recordings 
that are associated with dosing visits after Day 1 must be obtained in advance of the visit (within 
7 days before the corresponding dosing visit) and the results reviewed prior to dosing. 
During the 24-hour monitoring period, patients must avoid strenuous exercise but should 
otherwise maintain their usual level of physical activity. The ABPM is programmed to take 
readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the 
night (10 pm to 5:59 am). While awake, the patient should hold their arm still by their side while 
the device is inflating for a reading. Patients must record the timing of going to sleep, waking up, 
and any oral medications taken during the ABPM, and these responses must be entered into the 
eCRF. 
After the monitoring period is complete, upload the ABPM data to receive a report with validity 
assessment. An ABPM will be considered valid if (1) the number of successful daytime readings 
is ≥33, (2) the number of successful nighttime readings is ≥11, and (3) no more than 3 hours are 
not represented (ie, 3 sections of 60 minutes where 0 valid readings were obtained). If the ABPM 
recording is invalid at any point during the study, the patient will be provided 1 opportunity to 
repeat the recording within 7 days from the end time of the invalid ABPM.  
In circumstances where it is not possible to randomize a patient within the 2-week window 
following a valid ABPM recording that met the inclusion criterion, a single additional ABPM 
recording is permitted, with no option for retesting in case of an invalid recording. Eligibility is 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
75 
assessed by the most recent ABPM recording obtained. If a valid ABPM recording that meets the 
inclusion criterion is unable to be obtained within 2 weeks prior to randomization, the patient is a 
screen failure.  
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor and the arm selected during screening. 
Office blood pressure should be measured early in the visit prior to the morning dose of 
antihypertensive medication, before phlebotomy or other potentially stressful assessments. To 
minimize confounding by circadian changes, study visits should be scheduled for a consistent 
timeframe of the day. The use of inhaled short-acting beta agonists should be avoided within 6 
hours prior to measuring blood pressure and/or heart rate. The use of phosphodiesterase type 5 
inhibitors (eg, sildenafil, tadalafil, vardenafil, avanafil) should be avoided within 48 hours prior 
to measuring blood pressure. 
Before measuring blood pressure, confirm that there has been no exercise or use of caffeine or 
nicotine- or tobacco-containing products (including but not limited to snuff, chewing tobacco, 
cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) within the last 30 minutes. If necessary, 
delay blood pressure assessment to meet these requirements. Because a full bladder can impact 
blood pressure measurements, ask the patient to use the bathroom before the assessment. 
All office blood pressure assessments will include both seated and standing measurements.  
Seated Office Blood Pressure Measurement: For seated measurements, the patient should be in a 
comfortable resting position in a chair with their back supported and their feet flat on the floor. 
• Place the appropriately sized cuff on the correct arm with no clothing between the 
patient’s arm and the cuff and with the midpoint of the bladder length positioned over 
the brachial artery (located by palpation). The arm should be supported on an armrest 
or table with mid-cuff at heart level and the palm facing the ceiling. 
• Follow the HBPM and OBPM Investigator Manual to initiate the automated blood 
pressure device’s seated measurement protocol. This program includes a 5-minute 
period of rest, followed by 4 sequential blood pressure measurements at 1-minute 
intervals. The seated blood pressure for the visit will be defined by the average of the 
last 3 individual measurements. 
• During the device’s seated measurement protocol, the staff member should leave the 
room and the patient should remain at rest without distraction (avoid mobile phones). 
The following script may be used: “The blood pressure device works best when you 
are at rest and without any distraction. If you agree, I would like to leave the room for 
the next 10 to 15 minutes while it is recording. This will include a 5-minute period of 
rest, followed by about 5 minutes of the device inflating to measure your blood 
pressure”. 
Standing Office Blood Pressure Measurement: A standing measurement should be obtained 
immediately after collection of the seated measurements. 
• Being careful to maintain the cuff’s position, ask the patient to stand with the cuffed 
arm bent slightly and the hand of the cuffed arm supported at heart level.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
76 
• Using a stopwatch or watch, measure standing blood pressure 1 minute after standing 
by using the automated blood pressure device’s single measurement protocol.  
• After the standing measurement, ask the patient if they experienced dizziness or light-
headedness when standing and enter their response in the eCRF. 
If a patient is unable to report to the site for an office blood pressure assessment, a substitute 
“remote visit blood pressure measurement” may be obtained remotely by a visiting nurse or other 
appropriately trained personnel who will bring an office blood pressure instrument to the 
patient’s location and follow the same procedure performed at the site. If a home visit is not 
possible, a “remote visit blood pressure measurement” should instead be obtained using the 
patient’s HBPM instrument under direct supervision (phone call or teleconferencing) by 
appropriately trained study staff, following the instructions detailed in the HBPM and OBPM 
Investigator Manual. Results and the remote method used should be entered into the eCRF. 
HBPM 
Patients should measure HBPM in the morning, prior to breakfast/caffeine or taking morning 
oral medications. HBPM is not required on days when ABPM is being assessed. The HBPM 
measurement should be obtained in a room without distractions, seated comfortably with the 
back supported and feet flat on the floor. The patient will initiate the automated blood pressure 
program on their HBPM device. This program includes a 5-minute period of rest, followed by 4 
sequential blood pressure measurements at 1-minute intervals. The seated blood pressure for the 
visit will be defined by the average of the last 3 individual measurements.  
To establish baseline, each patient should measure HBPM during the week (with at least 3 
successful readings) immediately prior to randomization. 
After Day 1, HBPM should be measured at least once per week. Patients may select the day of 
the week that is most convenient for their personal schedule. The frequency of HBPM may be 
increased in some patients, per Investigator discretion, if more frequent measurement is 
warranted (eg, during screening if patients are undergoing washout and during the temporary 
hold of oral antihypertensives performed from Month 5 to Month 6). 
10.2. 
Procedures for Optional Home Healthcare Visits 
Home healthcare may be allowed where applicable country and local regulations and 
infrastructure for home healthcare allow and will follow procedures that are in compliance with 
relevant local regulations and guidelines (eg, General Data Protection Regulation [EU (European 
Union) no 2016/679], ICH E6[R2], and the Declaration of Helsinki). The use of home healthcare 
is optional and will not be utilized for visits at which study drug is administered or at visits that 
are required to be performed at the site (see Table 1).  
The option for home healthcare aims to improve patient diversity, participation, engagement, and 
retention in the study by reducing patient burden and minimizing study-related travel to the site, 
allowing flexibility in the study visit schedule. 
For clinical study sites where home healthcare is utilized, the Investigator will retain 
responsibility for oversight, patient safety, and conduct of the trial, and will be responsible for 
reviewing the qualifications of and approving each home healthcare professional, delegating 
responsibilities to the home healthcare professional in the site delegation log, providing 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 5, 04 November 2022 
Alnylam Pharmaceuticals 
Confidential 
77 
instructions for home healthcare visits, communicating with the home healthcare professional at 
home visits as needed, and reviewing the source data files collected during the home healthcare 
visit. The home healthcare professional will be trained on the protocol and other relevant study 
documents and procedures and will be responsible for conducting vital sign assessments 
(including blood pressure assessments), collecting blood and urine samples, collecting weight, 
and documenting and notifying the site study team of any suspected or potential AE symptoms 
or changes to concomitant medications. The home healthcare professional will be responsible for 
providing source documentation of the visit to the study site. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
1 
 
CLINICAL STUDY PROTOCOL 
ALN-AGT01-002 
DATED 22 MARCH 2022 
 
Protocol Title:  
A Randomized, Double-blind, Placebo-Controlled, 
Dose-Ranging Multicenter Study to Evaluate the 
Efficacy and Safety of ALN-AGT01 in Patients 
with Mild-to-Moderate Hypertension 
Short Title: 
A Study to Evaluate Efficacy and Safety of 
ALN-AGT01 in Patients with Mild-to-Moderate 
Hypertension (KARDIA-1) 
Study Drug: 
ALN-AGT01 (zilebesiran) 
EudraCT Number: 
2021-001248-82 
IND Number: 
143503 
Protocol Date: 
Original protocol, 09 April 2021 
Amendment 1, 20 April 2021 
Amendment 2, 09 June 2021 
Amendment 3, 09 December 2021 
Amendment 4, 22 March 2022 
Sponsor: 
Alnylam Pharmaceuticals, Inc. 
300 Third Street 
Cambridge, MA  02142 USA 
Telephone: +1-617-551-8200 
Sponsor Contact: 
 
 
The concepts and information contained in this document or generated during the study are considered 
proprietary and may not be disclosed in whole or in part without expressed written authorization of 
Alnylam Pharmaceuticals, Inc. 
 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
2 
SPONSOR PROTOCOL APPROVAL 
 
I have read this protocol and I approve the design of this study. 
 
 
 
___________________________________________  
 
 
Alnylam Pharmaceuticals, Inc. 
 
___________________________________________  
Date 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
3 
INVESTIGATOR’S AGREEMENT 
 
I have read the ALN-AGT01-002 protocol and agree to conduct the study in accordance with the 
protocol and all applicable regulations. I agree to maintain the confidentiality of all information 
received or developed in connection with this protocol. 
 
 
 
___________________________________________  
Printed Name of Investigator 
 
 
 
___________________________________________  
Signature of Investigator 
 
 
 
___________________________________________  
Date 








Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
7 
Diagnosis and Main Eligibility Criteria 
This study will include adults (18 to 75 years, inclusive) with untreated hypertension or on stable 
therapy with up to 2 antihypertensive medications. Patients should have a daytime mean systolic 
blood pressure (SBP) ≥135 mmHg and ≤160 mmHg by ABPM after washout of background 
antihypertensive medication. Patients with secondary hypertension or orthostatic hypotension 
will be excluded. 
Study Drug, Dose, and Mode of Administration 
ALN-AGT01 is an SC administered N-acetylgalactosamine-conjugated small interfering RNA 
targeting liver-expressed messenger RNA for angiotensinogen (AGT). 
Patients randomized to receive ALN-AGT01 will be administered 150 mg ALN-AGT01 SC once 
every 6 months, 300 mg ALN-AGT01 SC once every 6 months, 300 mg ALN-AGT01 SC once 
every 3 months, or 600 mg ALN-AGT01 SC once every 6 months during the 12-month DB 
period and DB Extension period. Patients randomized to receive placebo will be randomized to 1 
of the 4 initial dose regimens of ALN-AGT01 beginning at Month 6.  
Reference Treatment, Dose, and Mode of Administration 
Placebo (sodium chloride 0.9% w/v for SC administration) will be administered once every 3 
months and at the same volume as the study drug. Patients receiving once every 6 months 
ALN-AGT01 regimens will receive placebo SC at dosing visits at which they do not receive 
ALN-AGT01 to maintain the blind. 
Duration of Treatment and Study Participation 
The duration of treatment with ALN-AGT01 is up to 24 months. The estimated total time on 
study for each patient is up to 38 months, including up to 2 months of screening, followed by up 
to 24 months of treatment, and up to 12 months in the Follow-up period. 
Statistical Methods 
The planned enrollment for this study is 375 patients. Randomization will be stratified by race 
(black vs all other races) and by baseline blood pressure (mean 24-hour SBP < or ≥145 mmHg). 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline at Month 
3 in 24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 
375 patients (75 per treatment group) provides at least 84% power to detect a dose response 
signal in SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided significance 
level of 0.05. In addition, this sample size provides at least 80% power to detect a 10 mmHg 
difference between an individual ALN-AGT01 dose versus placebo with a 2-sided significance 
level of 0.05.  
The populations (analysis sets) are defined as follows:  
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
8 
• Pharmacokinetic (PK) Analysis Set: All patients who received at least 1 full dose of 
ALN-AGT01 and have at least 1 nonmissing postdose PK assessment. 
• PD Analysis Set: All patients who received at least 1 full dose of study drug. All by-
treatment analyses based on the PD Analysis Set will be grouped according to the 
treatment actually received. 
• All ALN-AGT01 Treated Set: All patients who received any amount of 1 of the 4 
ALN-AGT01 dosing regimens, including patients who took ALN-AGT01 during the 
6-month placebo-controlled period and patients who initially took placebo and then 
switched to ALN-AGT01 after the Month 6 visit. 
For the primary analysis for the 6-month placebo-controlled DB period, the primary population 
used to evaluate efficacy will be the FAS. Safety will be analyzed using the Safety Analysis Set. 
The PK and PD Analysis Sets will be used to conduct PK and PD analyses, respectively. 
The All ALN-AGT01 Treated Set will be used to summarize the efficacy and safety of 
ALN-AGT01 throughout the entire DB period (including DB extension period). 
To control the overall type I error, the primary and key secondary endpoints will be tested in 
hierarchical order. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
9 
Figure 1: 
Study Design 
 
Abbreviations: aHTN=antihypertensive medications; DB=double-blind; M=month; OLE=open-label extension; 
PBO=placebo; PO=per os (oral); Q3M=once every 3 months; Q6M=once every 6 months; R=randomization; 
SC=subcutaneous; WO=washout. 
Note: Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the Month 12 
predose assessments. If an individual patient reaches Month 12 prior to availability of the OLE study, they may 
continue their current blinded dosing in the DB Extension period for up to 12 additional months until the OLE study 
is open and then transition. Once the OLE study is open for enrollment, eligible patients may rollover into the OLE 
study at Months 12, 18, or 24 (whichever visit occurs first). 
Note: Patients who were previously taking antihypertensives at screening should undergo a washout of these 
medications for at least 2 weeks during the Screening period (4 weeks of washout is required for long-acting 
antihypertensive medications, such as long-acting diuretics or calcium channel blockers). 
 












Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
15 
Table 2: 
PK Time Points 
Study Day 
Sampling Time 
(hh:mm) 
Plasma PK Sample 
Day 1  
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Day 169±7 
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Abbreviations: hh:mm=hour:minute; PK=pharmacokinetics. 
Notes:  
• 
The hour (±range) indicates sample collection timing relative to dosing. Precise PK sample times (hour 
and minute) are recorded. Refer to Section 6.4 for additional information on PK assessments. 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
16 
TABLE OF CONTENTS 
SPONSOR PROTOCOL APPROVAL ...........................................................................................2 
INVESTIGATOR’S AGREEMENT ...............................................................................................3 
PROTOCOL SYNOPSIS ................................................................................................................4 
TABLE OF CONTENTS ...............................................................................................................16 
LIST OF TABLES .........................................................................................................................20 
LIST OF FIGURES .......................................................................................................................20 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ................................................21 
1. 
INTRODUCTION ......................................................................................................23 
1.1. 
Study Rationale ...........................................................................................................23 
1.2. 
Background .................................................................................................................23 
1.3. 
Benefit-Risk Assessment ............................................................................................24 
2. 
OBJECTIVES AND ENDPOINTS ............................................................................25 
3. 
INVESTIGATIONAL PLAN .....................................................................................27 
3.1. 
Summary of Study Design ..........................................................................................27 
3.2. 
Scientific Rationale for Study Design ........................................................................28 
3.3. 
Justification for Dose ..................................................................................................30 
3.4. 
Method of Assigning Patients to Treatment Groups ..................................................31 
3.5. 
Blinding ......................................................................................................................31 
3.5.1. 
Emergency Unblinding ...............................................................................................32 
3.6. 
Data Monitoring Committee .......................................................................................32 
3.7. 
Clinical Event Adjudication Committees ...................................................................32 
3.8. 
Definition of End of Study for an Individual Patient .................................................32 
4. 
SELECTION AND REMOVAL OF PATIENTS ......................................................33 
4.1. 
Inclusion Criteria ........................................................................................................33 
4.2. 
Exclusion Criteria .......................................................................................................33 
4.3. 
Removal from Study Drug or Assessment .................................................................36 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments ......................36 
4.3.2. 
Stopping a Patient’s Study Participation ....................................................................37 
4.3.2.1. 
Patient or Legal Guardian Stops Participation in the Study .......................................37 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection 
to Process Patient’s Personal Data ..............................................................................38 
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study ........................38 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
17 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation ................................38 
4.3.3. 
Lost to Follow-Up.......................................................................................................38 
4.3.4. 
Replacement of Study Patients ...................................................................................39 
5. 
TREATMENTS AND OTHER REQUIREMENTS ..................................................39 
5.1. 
Treatments Administered ............................................................................................39 
5.2. 
Study Drug ..................................................................................................................39 
5.2.1. 
Description ..................................................................................................................39 
5.2.2. 
Dose and Administration ............................................................................................39 
5.2.3. 
Dose Modifications .....................................................................................................40 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping 
Study Drug Dosing .....................................................................................................40 
5.2.5. 
Neurological Criteria for Withholding, Monitoring, and Stopping Study 
Drug Dosing ................................................................................................................41 
5.2.6. 
Preparation, Handling, and Storage ............................................................................42 
5.2.7. 
Packaging and Labeling ..............................................................................................42 
5.2.8. 
Accountability .............................................................................................................42 
5.3. 
Clinical Product Complaints .......................................................................................42 
5.3.1. 
Definition ....................................................................................................................42 
5.3.2. 
Reporting ....................................................................................................................43 
5.4. 
Monitoring for Potential Clinical Events ....................................................................43 
5.4.1. 
Monitoring and Approach for Potential Hypotension ................................................43 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure 
Elevation .....................................................................................................................44 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction .......................................45 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia ..............................................46 
5.5. 
Concomitant Medications and Procedures .................................................................47 
5.5.1. 
Oral Antihypertensive Medication .............................................................................48 
5.5.2. 
Prohibited Concomitant Medication ...........................................................................48 
5.6. 
Treatment Compliance ................................................................................................49 
5.7. 
Other Requirements ....................................................................................................49 
5.7.1. 
Contraception ..............................................................................................................49 
5.7.2. 
Alcohol Restrictions ...................................................................................................50 
5.7.3. 
Tobacco and Nicotine Restrictions .............................................................................50 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
18 
5.7.4. 
Dietary Recommendations ..........................................................................................50 
5.7.5. 
Exercise .......................................................................................................................51 
6. 
STUDY ASSESSMENTS ..........................................................................................51 
6.1. 
Screening Assessments ...............................................................................................51 
6.1.1. 
Retesting .....................................................................................................................51 
6.1.2. 
Rescreening .................................................................................................................51 
6.2. 
Efficacy Assessments .................................................................................................52 
6.2.1. 
ABPM .........................................................................................................................52 
6.2.2. 
Office Blood Pressure .................................................................................................52 
6.2.3. 
HBPM .........................................................................................................................53 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment ....................................................53 
6.3. 
Pharmacodynamic Assessments .................................................................................53 
6.4. 
Pharmacokinetic Assessments ....................................................................................53 
6.5. 
Safety Assessments .....................................................................................................54 
6.5.1. 
Vital Signs ..................................................................................................................54 
6.5.2. 
Weight, Height, and Morphometrics ..........................................................................54 
6.5.3. 
Physical Examination .................................................................................................55 
6.5.4. 
Electrocardiogram .......................................................................................................55 
6.5.5. 
Clinical Laboratory Assessments ...............................................................................55 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments ........................................................57 
6.5.5.2. 
Immunogenicity ..........................................................................................................57 
6.5.5.3. 
Pregnancy Testing ......................................................................................................57 
6.5.5.4. 
Additional Liver Function Assessments .....................................................................58 
6.5.6. 
Adverse Events ...........................................................................................................59 
6.5.6.1. 
Definitions ..................................................................................................................59 
6.5.6.2. 
Eliciting and Recording Adverse Events ....................................................................61 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee .........................62 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee ...........62 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities .................................................62 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee ........................................................................63 
6.5.6.7. 
Pregnancy Reporting ..................................................................................................63 
6.5.6.8. 
Overdose and Other Special Situations Reporting .....................................................63 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
19 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository ...................................63 
7. 
STATISTICS ..............................................................................................................64 
7.1. 
Determination of Sample Size ....................................................................................64 
7.2. 
Statistical Methodology ..............................................................................................65 
7.2.1. 
Populations to be Analyzed ........................................................................................65 
7.2.2. 
Examination of Subgroups .........................................................................................65 
7.2.3. 
Handling of Missing Data ...........................................................................................65 
7.2.4. 
Baseline Evaluations ...................................................................................................65 
7.2.5. 
Efficacy Analyses .......................................................................................................66 
7.2.6. 
Pharmacodynamic Analysis........................................................................................66 
7.2.7. 
Pharmacokinetic Analysis ..........................................................................................66 
7.2.8. 
Safety Analyses ..........................................................................................................67 
7.2.9. 
Immunogenicity Analyses ..........................................................................................67 
7.2.10. 
Interim Analysis ..........................................................................................................67 
7.2.11. 
Optional Additional Research .....................................................................................67 
8. 
STUDY ADMINISTRATION ...................................................................................67 
8.1. 
Ethical and Regulatory Considerations ......................................................................67 
8.1.1. 
Informed Consent .......................................................................................................68 
8.1.2. 
Ethical Review ............................................................................................................68 
8.1.3. 
Serious Breach of Protocol .........................................................................................69 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention .................................69 
8.1.5. 
End of Study ...............................................................................................................69 
8.1.6. 
Termination of the Clinical Study or Site Closure .....................................................69 
8.2. 
Data Quality Control and Quality Assurance .............................................................70 
8.2.1. 
Data Handling .............................................................................................................70 
8.2.2. 
Study Monitoring ........................................................................................................70 
8.2.3. 
Audits and Inspections ................................................................................................70 
8.3. 
Publication Policy .......................................................................................................71 
9. 
LIST OF REFERENCES ............................................................................................72 
10. 
APPENDICES ............................................................................................................74 
10.1. 
Measurement of Blood Pressure .................................................................................74 
 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
20 
LIST OF TABLES 
Table 1: 
Schedule of Assessments ............................................................................................10 
Table 2: 
PK Time Points ...........................................................................................................15 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative 
Cause Identified ..........................................................................................................41 
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation ......................................................................................................44 
Table 5: 
Recommended Interventions for Hyperkalemia .........................................................47 
Table 6: 
Clinical Laboratory Assessments ...............................................................................56 
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases .............59 
 
LIST OF FIGURES 
Figure 1: 
Study Design .................................................................................................................9 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
21 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation  
Definition 
ABPM 
Ambulatory blood pressure monitoring 
ACE 
Angiotensin converting enzyme 
ADA 
Anti-drug antibody(ies) 
AE 
Adverse event 
AGT 
Angiotensinogen 
ALT 
Alanine aminotransferase 
AngI/II 
Angiotensin I/II 
ARB 
Angiotensin II-receptor blocker 
AST 
Aspartate aminotransferase 
CCB 
Calcium channel blocker 
CPC 
Clinical product complaint 
DB 
Double-blind 
DBP 
Diastolic blood pressure 
DMC 
Data Monitoring Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eGFR 
Estimated glomerular filtration rate 
EOT 
End of treatment 
ET 
Early termination 
FAS 
Full analysis set 
GalNAc 
N-acetylgalactosamine 
GCP 
Good Clinical Practice 
HbA1c 
Hemoglobin A1c 
HBPM 
Home blood pressure monitoring 
HCV 
Hepatitis C virus 
HDL-C 
High-density lipoprotein 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use 
IEC 
Independent Ethics Committee 
INR 
International normalized ratio 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
22 
Abbreviation  
Definition 
IRB 
Institutional Review Board 
IRT 
Interactive Response Technology 
ISR 
Injection site reaction 
LFT 
Liver function test 
MAO 
Monoamine oxidase 
MMRM 
Mixed model for repeated measurements 
mRNA 
Messenger RNA 
NSAID 
Nonsteroidal anti-inflammatory drug 
OLE 
Open-label extension 
PD 
Pharmacodynamic(s) 
PK 
Pharmacokinetic(s) 
PT 
Preferred term 
q3M 
Once every 3 months 
q6M 
Once every 6 months 
RAAS 
Renin-angiotensin-aldosterone system 
RNAi 
RNA interference 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SBP 
Systolic blood pressure 
SC 
Subcutaneous(ly) 
siRNA 
Small interfering RNA 
SGLT2 
Sodium-glucose co-transporter 2 
SOC 
System Organ Class 
ULN 
Upper limit of normal 
ZS-9 
Sodium zirconium cyclosilicate 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
23 
1. 
INTRODUCTION 
Alnylam Pharmaceuticals, Inc. (the Sponsor) is developing ALN-AGT01 (zilebesiran), a 
subcutaneously (SC) administered investigational agent comprised of a synthetic small 
interfering (siRNA) covalently linked to a triantennary N-acetylgalactosamine (GalNAc) ligand, 
which is designed to suppress liver production of angiotensinogen (AGT) and thereby reduce 
blood pressure in individuals with hypertension.  
1.1. 
Study Rationale 
Study ALN-AGT01-002 (KARDIA-1) is a randomized, double-blind, placebo-controlled, dose-
ranging, multicenter Phase 2 study designed to evaluate the safety, efficacy, and 
pharmacodynamics (PD) of ALN-AGT01, administered SC, in patients with mild-to-moderate 
hypertension. Patients will be randomized to 1 of 4 ALN-AGT01 treatment regimens or placebo 
for the first 6 months of the 12-month Double-blind (DB) period. After the first 6 months of the 
DB period, patients from the placebo arm will be re-randomized to 1 of the 4 initial 
ALN-AGT01 regimens for the remaining 6 months of the DB period, while patients randomized 
to ALN-AGT01 will remain on their originally assigned regimens. After completion of the 
12-month DB period, patients may be eligible to participate in an ALN-AGT01 open-label 
extension (OLE) study. If an individual patient reaches Month 12 prior to availability of the OLE 
study, they may continue their current blinded dosing in the DB Extension period for up to 12 
additional months until the OLE study is open and then transition. 
The primary objective of the study is to evaluate the efficacy of ALN-AGT01 for the treatment 
of hypertension by evaluating the impact on systolic blood pressure (SBP) from baseline to 
Month 3, as assessed by ambulatory blood pressure monitoring (ABPM). Secondary and 
exploratory objectives of the study include evaluating the efficacy of ALN-AGT01 on other 
measures of blood pressure response and evaluating the PD effect of ALN-AGT01, including 
reduction in circulating AGT concentration. 
The full rationale for the study and design is presented in Section 3.2. 
1.2. 
Background 
Hypertension affects 30% to 45% of adults and is the strongest modifiable risk factor for 
cardiovascular disease, primarily strokes and myocardial infarction.[Olsen 2016; Williams 2018] 
The worldwide disease burden is profound, with a global prevalence of over 1 billion,[Kearney 
2005; NCD Risk Factor Collaboration 2017] and approximately 9 million deaths attributed to 
hypertension annually.[Angell 2015] 
Currently available pharmacologic therapies achieve target blood pressure in only a minority of 
patients, due in large part to physician inertia and patient nonadherence to daily oral 
medication.[Whelton 2018; Williams 2018] Low adherence to oral antihypertensives is 
associated with poor cardiovascular outcomes and is prevalent at all stages of disease.[Corrao 
2011; Peacock and Krousel-Wood 2017; Schulz 2016; van der Laan 2017] Thus, despite the 
availability of multiple efficacious agents, current rates of control are low, and the global burden 
of death and disability-adjusted life-years attributed to elevated blood pressure remains 
high.[Forouzanfar 2017; Muntner 2020] Development of new approaches to treat hypertension 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
24 
and to overcome the limitations of current therapies is a key unmet need.[Dzau and Balatbat 
2019; McClellan 2019; Services 2020] 
The Sponsor is developing ALN-AGT01, a novel synthetic RNA interference (RNAi) 
therapeutic, for SC administration for the treatment of hypertension. RNAi is a naturally 
occurring cellular mechanism for regulation of gene expression, mediated through the binding of 
siRNA to its complementary messenger RNA (mRNA) sequence, leading to mRNA cleavage 
and subsequent suppression of the synthesis and levels of the target protein. ALN-AGT01 
contains an siRNA targeting AGT mRNA, conjugated to a GalNAc-containing ligand to facilitate 
delivery to the liver. Based on the mechanism of RNAi, ALN-AGT01 is specifically designed to 
reduce the hepatic synthesis of AGT protein, the first substrate in the renin-angiotensin-
aldosterone system (RAAS) and the sole precursor of vasoactive angiotensin peptides.[Khanna 
2017; Romero 2015] Because hepatocytes are the predominant source of circulating AGT, 
ALN-AGT01 has been developed to reduce blood pressure by decreasing circulating AGT levels 
and the downstream effects of angiotensin II (AngII). 
Preliminary data from Part A of the ongoing Phase 1 Study ALN-AGT01-001 (hereafter referred 
to as Study 001) in patients with hypertension have shown that single SC doses of ALN-AGT01 
lead to dose-dependent and durable reductions in circulating AGT, accompanied by clinically 
significant reductions in SBP and diastolic blood pressure (DBP). Reductions in AGT for up to 
6 months postdose were observed in the study.  
Most adverse events (AEs) have been mild or moderate in severity, and there have been no 
severe or serious adverse events (SAEs) related to study drug. There have been no clinically 
significant elevations in serum creatinine or serum potassium, and no patient has required 
intervention for low blood pressure. No clinically significant alanine aminotransferase (ALT) 
elevations have been observed in Part A patients who received ALN-AGT01 doses as high as 
800 mg. Injection site reactions (ISRs) were reported in a minority of patients and were all mild 
and transient events that resolved without intervention. 
This Phase 2 study will further quantify the antihypertensive effects of ALN-AGT01 across a 
range of doses (150 to 600 mg) and dose intervals (once every 3 months and once every 6 
months) to identify optimal treatment. The consistent and prolonged PD effect of ALN-AGT01 
is expected to achieve the unique benefit of continuous 24-hour blood pressure lowering with 
infrequent SC dosing.  
A detailed description of the chemistry, pharmacology, efficacy, and safety of ALN-AGT01 is 
provided in the Investigator’s Brochure. 
1.3. 
Benefit-Risk Assessment 
Clinical data available from Study 001 indicate that ALN-AGT01 may offer the benefit of blood 
pressure reduction to patients with hypertension. The mean SBP reduction observed after single 
ALN-AGT01 doses of 100 mg or higher exceeds 10 mmHg, which is comparable to the effect of 
conventional antihypertensives. The blood pressure of patients will be closely monitored, and 
after Month 3, oral antihypertensives will be added as needed to control blood pressure. 
Given the mechanism of action and mode of administration of ALN-AGT01, potential 
theoretical risks include liver transaminase elevations and ISRs. Like any antihypertensive 
therapy, there is also a theoretical risk of hypotension with ALN-AGT01. Based upon the disease 








Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
28 
may also be added per Investigator judgement for persistent elevations in blood pressure above 
recommended target per treatment guidelines (eg, office SBP <140 mmHg, home blood pressure 
monitoring [HBPM] SBP <135 mmHg, or daytime mean SBP <135 mmHg by 
ABPM).[Williams 2018] Oral antihypertensives (if taking) will be temporarily held from Month 
5 to Month 6 in appropriate patients (Month 5 office SBP <155 mmHg if taking 1 oral 
antihypertensive agent or office SBP <150 mmHg if taking 2 agents) to assess the effect of 
ALN-AGT01 alone (vs placebo) at Month 6 by ABPM. During this 4-week period, blood 
pressure will be carefully monitored by HBPM and oral antihypertensive medications restarted if 
confirmed office SBP >170 mmHg (or if confirmed office SBP >160 mmHg accompanied by 
symptoms). 
Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the 
Month 12 predose assessments. If an individual patient reaches Month 12 prior to availability of 
the OLE study, they may continue their current blinded dosing in the DB Extension period for up 
to 12 additional months until the OLE study is open and then transition. Once the OLE study is 
open for enrollment, eligible patients may rollover into the OLE study at Months 12, 18, or 24 
(whichever visit occurs first). 
In the DB Extension period, blood pressure will be closely monitored and individual 
modification of antihypertensive therapy will be allowed to maintain blood pressure in target 
range.  
Safety Follow-up Period 
Patients who discontinue study drug or do not enroll in the separate ALN-AGT01 OLE study 
will be asked to complete Safety Follow-up visits once every 6 months after their last dose of 
study drug until serum AGT levels return to ≥50% of their individual mean baseline level (if 
known) or until 12 months after their last dose of study drug, whichever comes earlier. 
Patients who discontinue study drug prior to the Month 6 visit will also be asked to complete the 
remainder of scheduled study visits and assessments (except for study drug administration) 
through Month 6. If a patient discontinues study drug after the Month 6 visit, end of treatment 
(EOT)/early termination (ET) assessments should be performed. 
The planned enrollment for this study is approximately 375 patients (75 patients per group). 
The duration of treatment with ALN-AGT01 is up to 24 months. The estimated total time on 
study for each patient is up to 38 months, including up to 2 months of screening, followed by up 
to 24 months of treatment, and up to 12 months in the Follow-up period. 
3.2. 
Scientific Rationale for Study Design 
This is a randomized, double-blind, placebo-controlled, dose-ranging, multicenter Phase 2 study 
designed to evaluate the safety, efficacy, and PD of ALN-AGT01, administered SC, in patients 
with mild-to-moderate hypertension. The primary objective of the study is to evaluate the 
efficacy of ALN-AGT01 by measuring the impact on SBP from baseline to Month 3, as assessed 
by ABPM.  
This study will quantify the antihypertensive effects of ALN-AGT01 across a range of doses and 
dose intervals to identify optimal treatment regimens for study in Phase 3. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
29 
Patients will discontinue prior antihypertensive medications (if taking) for 2 to 4 weeks prior to 
study drug administration. During the study, blood pressure will be monitored with both 
outpatient 24-hour ABPM and automated office blood pressure measurements 
(EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical Investigation of Medicinal Products in 
the Treatment of Hypertension, 2016). The primary endpoint will be assessed by ABPM given its 
greater precision over office blood pressure measurements. In addition, 24-hour ABPM can 
assess short-term blood pressure variability and circadian patterns (including potential restoration 
of the normal nocturnal blood pressure dipping pattern that is lost in 21% to 35% of hypertensive 
patients).[de la Sierra 2009; White 1998] More frequent measurements will be collected through 
a third method, oscillometric HBPM, to assess long-term blood pressure variability and provide 
close safety monitoring for potential hypotension (or hypertension) while not in the clinic. 
As recommended by current guidance (International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use [ICH] Principles for Clinical Evaluation of 
New Antihypertensive Drugs, 2000 and EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical 
Investigation of Medicinal Products in the Treatment of Hypertension, 2016), the first 6 months 
of the DB period is designed as a randomized, placebo-controlled, parallel-group study. To 
adhere to best ethical standards for the treatment of patients with hypertension, individual 
modification of oral antihypertensive medications per Investigator judgement to maintain blood 
pressure within target is permitted starting at Month 3 and will continue throughout the study 
(except between Month 5 and Month 6 as described in Section 3.1). Separate from these treat-to-
target modifications, any confirmed event of severe hypertension (office SBP ≥180 mmHg or 
DBP ≥120 mmHg) will be appropriately treated regardless of its timing relative to study drug 
administration. 
If a patient requires treatment with a conventional oral antihypertensive before Month 6, a CCB 
and/or thiazide/thiazide-like diuretic may be added because there is extensive experience 
combining these classes with antihypertensive drugs that impact the RAAS. Additionally, their 
blood pressure effects are expected to washout within 2 to 4 weeks.  
Rigorous assessment of the antihypertensive effects of ALN-AGT01 at Month 6 (trough for the 
once every 6 month regimens) relative to placebo is critical to evaluate the feasibility of once 
every 6 month dosing regimens for future study in Phase 3. Accordingly, oral antihypertensives 
(if taking) will be temporarily held from Month 5 to the Month 6 ABPM assessment. For each 
patient, this limited interruption in oral antihypertensives will be contingent upon the patient’s 
Month 5 office SBP being adequately controlled (see Table 4) and the Investigator’s assessment 
that interruption can be safely performed and carefully monitored by HBPM measurements. Of 
note, a withdrawal period is a standard element in studies of oral antihypertensives that is often 
used to establish assay sensitivity, to demonstrate maintenance of efficacy, and to assess possible 
withdrawal effects (ICH E12A; Principles for Clinical Evaluation of New Antihypertensive 
Drugs, 2000). Outside of research studies, antihypertensives are temporarily discontinued in 
clinical practice for diagnostic purposes, and interruptions up to 6 weeks have been shown to be 
safe.[Beeftink 2017] In this study, the period of interruption is limited to 4 weeks, and most 
patients are expected to have continued antihypertensive effect from ALN-AGT01. If a clinically 
significant blood pressure elevation (confirmed SBP >170 mmHg; or SBP >160 mmHg 
accompanied by symptoms) occurs after the interruption of oral antihypertensives, Investigators 
will instruct the patient to promptly resume dosing with their existing supply of oral medication.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
30 
After Month 6, other oral antihypertensives may be used at the discretion of the Investigator, 
following current care guidelines.[Whelton 2018; Williams 2018] Because ALN-AGT01 acts on 
the RAAS, the use of conventional RAAS inhibitors (angiotensin II-receptor blocker [ARB], 
angiotensin converting enzyme [ACE] inhibitors, or direct renin inhibitors) as rescue agents for 
high blood pressure will be avoided throughout this study. Blood pressure and pharmacokinetic 
(PK)/PD assessments will be collected through Month 12 to assess the effect of repeated dosing. 
While tissue specificity of ALN-AGT01 for the liver is hypothesized to improve tolerability 
relative to current oral antihypertensives,[Mullick 2017; Uijl 2019] the protocol’s monitoring 
plan is designed to meet the standards set by prior studies of conventional RAAS 
inhibitors,[McMurray 2016; Parving 2012] with improvements to include the use of the newer 
oral potassium binder patiromer (or with sodium zirconium cyclosilicate [ZS-9]), if available, for 
treatment of potential hyperkalemia.[Georgianos and Agarwal 2018; Weir 2015] The risk of 
renal safety events is further mitigated in this study by its eligibility criteria, which exclude 
patients who are at highest risk to have events (estimated glomerular filtration rate [eGFR] <30 
mL/min/1.73m2, baseline serum potassium >5 mEq/L, poorly controlled diabetes, or severely 
increased albuminuria) and those who may have decreased tolerance for renal safety events 
(patients with clinically significant heart failure, valvular heart disease, or recent history of 
cardiovascular event).  
3.3. 
Justification for Dose 
The doses of ALN-AGT01 in this study were selected on the basis of data from the Phase 1 
Study 001, in which single ALN-AGT01 doses up to 800 mg were found to have an acceptable 
safety profile, and clinically significant placebo-corrected reductions in mean SBP >10 mmHg 
by 24-hour ABPM were observed after doses as low as 100 mg. Dose selection was guided by 
the principle of evaluating doses that are well tolerated and predicted to result in a range of PD 
effects (ie, lowering of serum AGT) and antihypertensive responses. This is expected to enable 
development of population average dose-response relationships for PD and efficacy to guide 
identification of optimal treatment regimens (dose and dose frequency) for Phase 3.  
Preliminary PK/PD modeling based on serum AGT data from Study 001 indicates that 
ALN-AGT01 results in a dose-dependent lowering of serum AGT, with maximum reductions 
predicted to be achieved as early as 1 month postdose and significant reductions sustained for 
close to 6 months after dosing. Modeling of the relationship between serum AGT lowering and 
blood pressure suggests a log-linear relationship, with ≥92% reduction in serum AGT predicted 
to achieve median SBP reduction of ≥10 mmHg.  
Based on these, the once every 6 month doses of 150, 300, and 600 mg were selected to result in 
median serum AGT reductions of 81.9%, 89.4%, and 94.9%, respectively, at trough (Month 6), 
translating to median SBP reductions of 6.67 mmHg, 8.74 mmHg, and 11.6 mmHg, respectively. 
Thus, the selected doses will enable characterization of the dose-response relationships for serum 
AGT and blood pressure with the once every 6 month regimen. 
The selected doses also enable characterization of the dose-response relationships for serum 
AGT and blood pressure with once every 3 month regimens based on analysis of data from all 
arms at Month 3. This will provide support for development of a once every 3 month regimen, if 
desired. To this end, 300 mg once every 3 months will be evaluated to identify any cumulative 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
31 
effects. The 300 mg once every 3 months dose is predicted to result in median serum AGT 
reductions of >95% at trough (Month 3), translating to median SBP reductions of >10 mmHg.  
Thus, data from the current study will enable robust characterization of PD and efficacy of once 
every 3 month and once every 6 month regimens of ALN-AGT01 and guide further development 
of ALN-AGT01 as an antihypertensive therapeutic that results in reduction of blood pressure by 
≥10 mmHg throughout the dosing interval with infrequent administration. 
3.4. 
Method of Assigning Patients to Treatment Groups 
Using the Interactive Response Technology (IRT), patients will be randomized 1:1:1:1:1 to the 
following arms during the first 6 months of the 12-month DB period: 
• Placebo SC once every 3 months 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients initially randomized to placebo will be re-randomized 1:1:1:1 at Month 6 to 1 of the 4 
initial ALN-AGT01 regimens. 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. 
Randomization will be stratified by race (black vs all other races) and by baseline blood pressure 
(mean 24-hour SBP < or ≥145 mmHg). 
Each patient will be uniquely identified in the study by a combination of the site number and 
patient identification number. Upon signing the informed consent form (ICF), the patient will be 
assigned a patient identification number by the IRT system. The Investigator or his/her designee 
will randomize the patient in IRT after confirming that the patient fulfills all the inclusion criteria 
and none of the exclusion criteria. The Investigator or his/her designee will re-randomize the 
patient in IRT at Month 6 to assign placebo patients to 1 of the 4 initial ALN-AGT01 dose 
groups. 
3.5. 
Blinding 
The Sponsor, all site personnel (except for the site pharmacist or delegate), and patients will be 
blinded to study drug treatment through Month 6 of the 12-month DB period. During the course 
of the study, serum AGT, plasma PK, and treatment assignment using dummy IDs will be made 
available to a small, independent pharmacometrics team at the Sponsor that will not be involved 
in the conduct or oversight of the study. After the last patient completes the Month 3 visit and 
prior to the last patient’s Month 6 visit, a limited amount (ie, one-third) of SBP data will be made 
available to this small, independent pharmacometrics team for preliminary PK/PD modeling. 
After the database lock to support the analysis of Month 6 data is complete, all other Sponsor 
personnel will be unblinded to treatment assignment, but the site personnel (except for the site 
pharmacist) and patients will remain blinded to treatment assignment until after the analysis of 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
32 
Month 12 data is complete. The Sponsor and all site personnel will be blinded to serum AGT 
results until their respective unblinding. Serum AGT results will not be reported to site personnel 
until the last patient completes the assessments at the Month 12 visit. 
Blinded doses of study drug will be administered under the supervision of the Investigator (see 
Section 5.2.2). All patients will receive the same volume and number of injections regardless of 
treatment assignment (patients receiving once every 6 month ALN-AGT01 regimens will receive 
placebo SC at dosing visits at which they do not receive ALN-AGT01 to maintain the blind). 
Because ALN-AGT01 may be slightly visually distinguishable from placebo, all blinded study 
drug doses will be prepared and the syringe(s) will be masked by a site pharmacist or delegate 
prior to administration by a blinded healthcare professional. See the Pharmacy Manual for 
additional details. 
3.5.1. 
Emergency Unblinding 
If the treating physician determines that the clinical management of the patient requires 
knowledge of the study drug assignment, the Investigator may break the blind, as necessary, in 
IRT. If time permits, clinical study center personnel should contact the Medical Monitor before 
unblinding to discuss the need to unblind the patient but must do so within 1 working day after 
the unblinding event. Unblinding information should be limited to the fewest number of people 
on a need-to-know basis. A record of when the blind was broken, who was unblinded, who broke 
the blind, and why it was broken, will be maintained in the electronic trial master file. 
Refer to the IRT instructions for details on emergency unblinding. 
3.6. 
Data Monitoring Committee 
An independent DMC will oversee the safety and overall conduct of this study. The DMC will 
operate under the rules of a charter that will be reviewed and approved at the organizational 
meeting of the DMC. Details are provided in the DMC Charter. 
3.7. 
Clinical Event Adjudication Committees 
An independent Clinical Event Adjudication Committee of 2 or more nephrologists will review 
renal events blinded to treatment assignment to adjudicate whether they meet diagnostic criteria 
for acute kidney injury and, if so, their potential staging and contributing factors. Details are 
provided in the Renal Event Adjudication Committee charter. 
3.8. 
Definition of End of Study for an Individual Patient 
A patient is considered to have reached the end of the study if the patient: 
• has completed at least the Month 12 visit and enrolled in the OLE study, or 
• has completed the Safety Follow-up visits as described in Section 3.1 for patients who 
discontinue study drug or do not enroll in the OLE study. 
A definition of the end of the overall study is provided in Section 8.1.5. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
33 
4. 
SELECTION AND REMOVAL OF PATIENTS 
4.1. 
Inclusion Criteria 
Patients are eligible to be included in the study if all the following criteria apply: 
Age and Sex 
1. Age 18 to 75 years, inclusive 
2. Male or female 
Patient and Disease Characteristics 
3. Has untreated hypertension (not taking antihypertensive medication) or is on stable 
therapy with up to 2 antihypertensive medications. In general, stable therapy is defined as 
having no change in antihypertensive medication or dose within 30 days prior to 
screening.  
4. Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive 
medication. Patients previously taking medication for hypertension must be without 
antihypertensives for ≥2 weeks prior to this ABPM (4 weeks of washout is required for 
long-acting antihypertensive medications, such as long-acting diuretics [eg, 
chlorthalidone] or CCBs [eg, amlodipine]). 
Informed Consent 
5. Patient is able to understand and is willing and able to comply with the study 
requirements and to provide written informed consent. 
4.2. 
Exclusion Criteria 
Patients are excluded from the study if any of the following criteria apply: 
Disease-specific Conditions 
1. Secondary hypertension (including, but not limited to, renovascular hypertension, 
primary aldosteronism, pheochromocytoma, Cushing syndrome, aortic coarctation, or due 
to known history of moderate-to-severe obstructive sleep apnea not treated with 
continuous positive airway pressure therapy) 
2. Orthostatic hypotension (symptomatic or asymptomatic), defined as a fall of ≥20 mmHg 
SBP or ≥10 mmHg DBP within approximately 1 to 3 minutes of standing up from a 
seated position by office blood pressure. 
Laboratory Assessments 
3. Has any of the following laboratory parameter assessments after at least 2 to 4 weeks of 
washout:  
a. ALT or aspartate aminotransferase (AST) >2× upper limit of normal (ULN) 
b. Total bilirubin >1.5×ULN. Patients with elevated total bilirubin that is secondary to 
documented Gilbert’s syndrome are eligible if the total bilirubin is <2×ULN 
c. International normalized ratio (INR) >2.0 (patients on oral anticoagulant [eg, 
warfarin] with an INR <3.5 will be allowed) 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
34 
d. Elevated potassium >5 mEq/L  
e. eGFR of ≤30 mL/min/1.73m2 (calculation will be based on the Modification of Diet 
in Renal Disease formula)  
Prior/Concomitant Therapy 
4. Received an investigational agent within the last 30 days before randomization or are in 
follow-up of another clinical study prior to study enrollment. Any agent that has received 
health agency authorization (including for emergency use) by local or regional regulatory 
authorities is not considered investigational. Patients who are in follow-up for a 
coronavirus disease 2019 vaccine (authorized or investigational) study are allowed. 
5. Currently taking, taken within 30 days prior to randomization, or anticipated to receive 
during the study treatment period any medication or herbal supplement known to 
significantly affect blood pressure (with the exception of medications for the treatment of 
essential hypertension). Patients who require medications such as monoamine oxidase 
(MAO) inhibitors that are associated with hypertensive crisis should be 
excluded.[Whelton 2018]  
6. Currently taking beta blockers and unable to undergo a washout at least 2 weeks prior to 
randomization 
7. Changes, such as initiation or discontinuation, of sodium-glucose co-transporter 2 
(SGLT2) inhibitor therapy within 30 days prior to screening. Patients on a stable dose of 
SGLT2 therapy for at least 30 days prior to screening with no anticipated changes during 
the study treatment period are permitted. 
8. Prescription nonsteroidal anti-inflammatory drugs (NSAIDs) are not permitted. Patients 
receiving low-dose aspirin (defined as ≤100 mg per day) for at least 30 days prior to 
screening are permitted. Paracetamol/acetaminophen for analgesia will be allowed.  
9. Anticipates using organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, 
isosorbide dinitrate, pentaerythritol) during the study treatment period 
10. Currently taking, taken within 6 months prior to randomization, or anticipated to receive 
an RNAi therapeutic (approved or investigational) during the study 
Medical Conditions 
11. Current or prior history of intolerance to an ARB, ACE inhibitor (other than cough), or 
direct renin inhibitor 
12. Medical condition, other than hypertension, that requires treatment with a RAAS 
inhibitor 
13. History of multiple drug allergies or history of allergic reaction to an oligonucleotide or 
to GalNAc 
14. Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus (hemoglobin A1c 
[HbA1c] >9.0%), or laboratory evidence of diabetes during screening (HbA1c ≥7.0%) 
without known diagnosis of diabetes 
15. History of severely increased albuminuria (urine albumin:creatinine ratio >300 mg/g or 
>300 mg/day) or laboratory results consistent with this diagnosis upon screening  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
35 
16. Has known human immunodeficiency virus or known current or chronic hepatitis C virus 
(HCV) or hepatitis B virus infection 
17. History of any cardiovascular event (eg, stroke, transient ischemic attack, myocardial 
infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary 
intervention, hospitalization due to heart failure) within 6 months prior to randomization 
18. Clinically significant valvular heart disease 
19. New York Heart Association II to IV heart failure 
20. Uncontrolled serious cardiac arrhythmia, defined as recurrent and highly symptomatic 
ventricular tachycardia, atrial fibrillation with rapid ventricular response, or 
supraventricular tachycardia in the 3 months prior to randomization 
21. Has undergone liver transplantation or is anticipated to be on an active liver 
transplantation waiting list during the study treatment period 
22. History of renal transplantation or under immunosuppressive therapy 
23. Has other medical conditions or comorbidities which, in the opinion of the Investigator, 
would interfere with study compliance or data interpretation; or, in the opinion of the 
Investigator, taking part in the study would jeopardize the safety of the patient 
24. Clinically significant illness, in the opinion of the Investigator, within 7 days prior to 
randomization 
25. History of intolerance to SC injection(s) that could potentially hinder study drug 
administration or evaluation of local tolerability 
26. Has planned major surgery or general anesthesia during the study 
Contraception, Pregnancy, and Breastfeeding 
27. Is not willing to comply with the contraceptive requirements during the study period, as 
described in Section 5.7.1 
28. Female patient is pregnant, planning a pregnancy, or breast-feeding. 
Alcohol or Nicotine Use and Substance Abuse 
29. Unwilling or unable to limit alcohol consumption throughout the course of the study. 
Alcohol intake of >2 units/day is excluded during the study (unit: 1 glass of wine 
[approximately 125 mL] = 1 measure of spirits [approximately 1 fluid ounce] = ½ pint of 
beer [approximately 284 mL]). 
30. History of alcohol or substance abuse (licit or illicit drugs) within the last 12 months 
before screening, in the opinion of the Investigator 
31. Unwilling or unable to abstain from use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine 
patches, or e-cigarettes) within 30 minutes prior to office blood pressure measurements  
Other Restrictions 
32. Third shift or night shift workers 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
36 
33. Arm circumference exceeds the maximum cuff size of any of the blood pressure 
instruments provided by the Sponsor 
4.3. 
Removal from Study Drug or Assessment 
Patients or their legal guardians are free to discontinue study drug and/or stop protocol 
procedural assessments, or participation in the study as a whole at any time and for any reason, 
without penalty to their continuing medical care. The Investigator or the Sponsor may 
discontinue study drug or stop a patient’s participation in the study at any time if this is 
considered to be in the patient’s best interest. Any discontinuation of treatment or the stopping of 
the patient’s participation in the study must be fully documented in the electronic case report 
form (eCRF) and should be followed up by the Investigator. 
Discontinuation of study drug or declining procedural assessments is described in Section 4.3.1, 
while the stopping of a patient’s participation in the study is detailed in Section 4.3.2. 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments 
Reasons for discontinuation of study drug include any of the following: 
• Significant protocol deviation; which includes required treatment with prohibited 
medication (as defined in Section 5.5.2) per Investigator discretion 
• AE 
• Non-adherence to treatment regimen 
• Pregnancy 
• Lost to follow-up 
• Other reason (non-AE) 
• Or, study is terminated by the Sponsor 
If possible, the Investigator will confer with the Sponsor or Medical Monitor before 
discontinuing dosing in the patient. Patients who are pregnant will be discontinued from study 
drug dosing immediately (see Section 6.5.6.7 for reporting and follow-up of pregnancy). A 
positive urine pregnancy test should be confirmed by a serum pregnancy test prior to 
discontinuing the study drug. 
Patients who discontinue study drug and/or decline procedural assessments should not be 
automatically removed from study. In general, patients who discontinue study drug dosing for 
any reason will be encouraged to remain on the study to complete the remaining assessments and 
study visits so that their experience is captured in the final analyses.  
If this occurs, the Investigator is to discuss with the patient the appropriate processes for 
discontinuation from study drug and must discuss with the patient the options for continuation of 
the Schedule of Assessments (Table 1), including different options for follow-up and collection 
of data (eg, in person, by phone, by mail, through family or friends, or from options not 
involving patient contact, such as communication with other treating physicians or from review 
of medical records), including endpoints and AEs, and must document this decision in the 
patient’s medical records. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
37 
If a patient discontinues dosing due to an AE, including SAEs, the event should be followed as 
described in Section 6.5.6. When a patient discontinues study drug dosing, the primary reason 
must be recorded in the eCRF. Patients who discontinue study drug and remain on study may 
receive treatment consistent with local standard practice for their disease per Investigator 
judgement, as applicable. 
Patients who discontinue from study drug before Month 6 will be encouraged to remain on the 
study and complete assessments (except study drug administration) through Month 6. They will 
also be asked to complete Safety Follow-up visits once every 6 months after the last dose of 
study drug per the safety follow-up schedule (see Table 1) until PD recovery or 12 months 
(whichever is earlier); see Section 3.1. 
Patients who discontinue study drug after the Month 6 visit will be asked to return for their next 
scheduled visit to complete EOT/ET assessments and complete Safety Follow-up visits once 
every 6 months after the last dose of study drug per the safety follow-up schedule (see Table 1) 
until PD recovery or 12 months (whichever is earlier); see Section 3.1. 
4.3.2. 
Stopping a Patient’s Study Participation 
4.3.2.1. 
Patient or Legal Guardian Stops Participation in the Study 
A patient or their legal guardian may stop participation in the study at any time. A patient or 
legal guardian considering stopping participation in the study before Month 6 should be 
informed that the patient can discontinue study drug and/or decline procedural assessments and 
remain in the study to complete their study assessments through the Month 6 visit and complete 
Safety Follow-up visits as described in Section 4.3.1, or alternatively may complete any minimal 
assessments for which the patient or legal guardian consents. If a patient or legal guardian still 
chooses to discontinue study drug and stop participation in all follow-up prior to the completion 
of the Month 6 visit, every effort should be made to conduct the Month 6 visit assessments at an 
earlier time (Table 1). 
A patient considering stopping participation in the study after the Month 6 visit should be 
informed that the patient can discontinue study drug and/or decline procedural assessments and 
remain in the study to complete the assessments scheduled for the EOT/ET visit and complete 
Safety Follow-up visits as described in Section 4.3.1, or alternatively may complete any minimal 
assessments for which the patient consents. 
If the patient does not wish to or is unable to continue further study participation, the Investigator 
is to discuss with the patient appropriate procedures for stopping participation in the study. Data 
collected from the patient can continue to be used. 
Note, in countries where the collection and processing of the patient’s personal data is based on 
consent, if a patient withdraws consent to collect and process his/her personal data (see 
Section 4.3.2.2), as applicable, personal data up to the withdrawal of consent will be included in 
the analysis of the study. In addition, where permitted, publicly available data (such as 
appropriate national or regional vital status registry or other relevant databases) can be included 
after withdrawal of consent, where available and allowable by local law. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
38 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection to 
Process Patient’s Personal Data 
Where allowed by local law, the patient may decide to withdraw consent to collect, store, and 
use biological samples and, as applicable, other personal data, informing the study doctor at any 
time in writing or in any other form that may be locally required. Also, where allowed by local 
law, the patient may object to the collection, storage, and use of his/her personal data, informing 
the study doctor at any time in writing or in any other form that may be locally required. In both 
cases, the Sponsor will continue to keep and use the patient’s study information (including any 
data resulting from the analysis of the patient’s biological samples until the time of 
withdrawal/objection) according to applicable law. The process for the storage and, as 
applicable, further use of remaining samples will be followed per local requirements.  
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study 
The Investigator or Sponsor may stop the participation of a patient in the study at any time if this 
is considered to be in the patient’s best interest. However, study integrity and interpretation are 
best maintained if all enrolled patients continue study assessments and follow-up even if study 
drug is discontinued. 
Termination of the clinical study and site closure are described in Section 8.1.6. 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation 
The primary reason that a patient’s study participation is stopped must be recorded in the 
appropriate section of the eCRF and all efforts will be made to complete and report the 
observations as thoroughly as possible. If a patient’s study participation is stopped due to an AE, 
including SAEs, the event should be followed as described in Section 6.5.6. 
4.3.3. 
Lost to Follow-Up 
A patient will be considered lost to follow-up if the patient repeatedly fails to return for 
scheduled visits and is unable to be contacted by the clinical study center. The following actions 
must be taken if a patient fails to return to the clinic for a required study visit: 
• The site must attempt to contact the patient or legal guardian and reschedule the 
missed visit as soon as possible and counsel the patient or legal guardian on the 
importance of maintaining the assigned visit schedule and ascertain if the patient or 
legal guardian wishes [for the patient] to continue in the study, and/or should continue 
in the study. 
• Before a patient is deemed lost to follow up, the Investigator or designee must make 
every effort to regain contact with the patient or legal guardian (where possible, 3 
telephone calls and, if necessary, a certified letter to the patient’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the patient’s medical record. 
• Should the patient or legal guardian continue to be unreachable, the patient will be 
considered to have stopped participation in the study. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
39 
• For patients who are lost to follow-up, the Investigator can search publicly available 
records (where permitted and allowed by local law) to ascertain survival status. This 
ensures that the outcome of the study is as comprehensive as possible. 
4.3.4. 
Replacement of Study Patients 
No additional patients may be enrolled to mitigate the impact of patients who discontinue the 
study drug or stop participation in the study.  
5. 
TREATMENTS AND OTHER REQUIREMENTS 
5.1. 
Treatments Administered 
Study drug supplied for this study must not be used for any purpose other than the present study 
and must not be administered to any person not enrolled in the study. Study drug that has been 
dispensed and returned unused must not be re-dispensed. 
5.2. 
Study Drug 
Detailed information describing the preparation, administration, and storage of ALN-AGT01 SC 
and placebo SC is provided in the Pharmacy Manual. 
5.2.1. 
Description 
ALN-AGT01 will be supplied as a sterile solution for SC injection. See the Pharmacy Manual 
for further details of solution concentration and fill volume. 
The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC 
administration).  
5.2.2. 
Dose and Administration 
During the 12-month DB period, patients will be administered ALN-AGT01 or placebo, at the 
same volume and number of SC injections regardless of treatment assignment, once every 3 
months. The ALN-AGT01 and placebo groups are below: 
• Placebo SC once every 3 months, with re-randomization (1:1:1:1) at Month 6 to 1 of 
the initial 4 ALN-AGT01 regimens 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. Patients receiving once every 6 month ALN-AGT01 regimens will receive 
placebo SC at dosing visits at which they do not receive ALN-AGT01 to maintain the blind. 
Study drug injections will be administered under the supervision of the Investigator or healthcare 
professional. To maintain the blind, the doses are to be prepared by and syringes are to be 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
40 
masked by an unblinded site pharmacist or designee prior to study drug administration. A full 
description of the blinding procedure is included in the Pharmacy Manual. The injection site may 
be marked and mapped for later observation. Injections may be administered in the abdomen, 
thigh, or the side or back of the upper arms. The rotation of sites is recommended. If a local 
reaction around the injection site occurs, photographs may be obtained. Detailed instructions for 
study drug administration are found in the Pharmacy Manual. 
If a patient does not receive a dose of study drug within the specified visit window, the 
Investigator should contact the Medical Monitor. After such consultation, the dose may be 
administered up to 42 days before the next scheduled dose. Thereafter, the dose will be 
considered missed and not administered. 
Patients will be permitted to miss an occasional dose of study drug. However, if a patient misses 
2 consecutive doses, the Investigator, in consultation with the Medical Monitor, will discuss 
whether the patient will be able to continue the study (see also Section 4.3). 
Additional details can be found in the Pharmacy Manual. 
The definition of study drug overdose, follow-up procedures, and reporting requirements are 
provided Section 6.5.6.8. 
5.2.3. 
Dose Modifications 
Dose modifications are not permitted. 
If a study drug-related AE occurs in a patient that the Investigator judges as presenting a 
potential risk to the patient for further dosing, the study drug dose may be held at the discretion 
of the Investigator and the Medical Monitor should be contacted. 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping Study 
Drug Dosing  
1. Dosing decisions may be made based on the most recently available liver function test 
(LFT) results from a central laboratory (Table 6). 
2. For any ALT or AST elevation >3×ULN, central laboratory results should be used to 
guide subsequent monitoring as detailed in Table 3. 
3. For any ALT or AST elevation >3×ULN: 
a. If local laboratory results are obtained, confirm with a central laboratory as soon as 
possible, ideally within 2 to 3 days, but no later than 7 days. 
b. If an alternative cause is found, provide appropriate care. 
c. If an alternative cause is not found, perform assessments per Table 6 and Table 7. 
4. For any ALT or AST elevation >3×ULN without alternative cause that is accompanied 
by clinical symptoms consistent with liver injury (eg, nausea, right upper quadrant 
abdominal pain, jaundice) or elevated bilirubin to ≥2×ULN or INR ≥1.5, permanently 
discontinue dosing. 
5. For confirmed ALT or AST elevations >3×ULN without alternative cause and not 
accompanied by symptoms or elevated bilirubin ≥2×ULN or INR ≥1.5, see Table 3. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
41 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative Cause 
Identified 
Transaminase Level 
Action 
>3× to 5×ULN 
• 
May continue study drug dosing 
• 
Evaluate the initial elevation in LFT per the following assessments: 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6  
• 
Monitor at least every 2 weeks (LFT and coagulation per Table 6)  
• 
If elevation persists for ≥2 months, must discuss with the Medical Monitor 
before continuing dosing 
>5× to 8×ULN 
• 
Hold study drug dosing until recovery to ≤1.5×ULN or baseline; may 
resume dosing after discussion with the Medical Monitor 
• 
Evaluate the initial elevation in LFT per the following assessments 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6 
• 
Monitor at least weekly: LFT and coagulation per Table 6 until ALT and/or 
AST is declining on 2 consecutive draws, then may decrease monitoring to 
biweekly 
• 
If ALT or AST rises to >5×ULN following resumption of dosing, 
permanently discontinue dosing 
>8×ULN 
Permanently discontinue study drug dosing after confirmation of the 
transaminase value at the central laboratory. 
Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; INR=international normalized 
ratio; LFT=liver function test(s); ULN=upper limit of normal. 
Notes: In addition to these criteria, other assessments or evaluations may be performed per Investigator discretion, 
as appropriate. 
5.2.5. 
Neurological Criteria for Withholding, Monitoring, and Stopping Study Drug 
Dosing 
Clinically significant events that may be consistent with potential decreased proprioception 
(including but not limited to unusual clumsiness, gait abnormalities, and unexplained 
balance/coordination issues that are either absent at or worsening from the baseline) should be 
reported as an AE. If the treatment-emergent AE is persistent and considered related to study 
drug, specialty consultation with a neurologist should be considered. However, if such a 
treatment-emergent AE is serious or severe (regardless of the Investigator’s assessment of 
relatedness), the patient must be referred for neurologist consultation, and study drug dosing 
must be held until that consultation is complete. Resumption of dosing must be approved by the 
Medical Monitor. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
42 
5.2.6. 
Preparation, Handling, and Storage 
Staff at each clinical study center will be responsible for preparation of ALN-AGT01 or placebo 
doses according to procedures detailed in the Pharmacy Manual. No special procedures for the 
safe handling of study drug are required. 
ALN-AGT01 will be stored and refrigerated at approximately 2 to 30°C until dose preparation. 
Deviations from the recommended storage conditions should be reported to the Sponsor and use 
of ALN-AGT01 halted until authorization for its continued use has been provided by the Sponsor 
or designee, as described in the Pharmacy Manual. 
A Sponsor representative or designee will be permitted, upon request, to audit the supplies, 
storage, dispensing procedures, and records. 
Instructions specific to unused study drug and additional storage will be provided in the 
Pharmacy Manual. 
5.2.7. 
Packaging and Labeling 
All packaging, labeling, and production of study drug will be in compliance with current Good 
Manufacturing Practice specifications, as well as applicable local regulations. Study drug labels 
and external packaging will include all appropriate information as per local labeling 
requirements. Additional details will be available in the Pharmacy Manual. 
5.2.8. 
Accountability 
The Investigator or designee will maintain accurate records of receipt and the condition of 
ALN-AGT01 supplied for this study, including dates of receipt. In addition, accurate records will 
be kept of when and how much ALN-AGT01 is dispensed and administered to each patient in 
the study. Any reasons for departure from the protocol dispensing regimen must also be 
recorded. 
At the completion of the study, there will be a final reconciliation of all ALN-AGT01. Used, 
partially used, and unused ALN-AGT01 will be returned to the Sponsor (or designee) or 
destroyed at the clinical study center according to applicable regulations. 
Further instructions about drug accountability will be detailed in the Pharmacy Manual. 
5.3. 
Clinical Product Complaints 
5.3.1. 
Definition 
A clinical product complaint (CPC) is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of the study drug and its packaging after it is released for distribution to the site at 
which study drug will be administered. 
A CPC may be detected prior to use of study drug, during use, or after use. A CPC is typically 
nonmedical in nature; however, it is possible that study drug complaints could be associated with 
an AE. Examples of a CPC include, but are not limited to: illegible clinical label, missing clinical 
label, damaged vial, empty vial, and contamination of study drug. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
43 
5.3.2. 
Reporting 
For product complaints, the Sponsor or its designee should be notified within 24 hours using the 
process outlined in the Pharmacy Manual. CPCs that may be associated with an AE must be 
evaluated and reported as indicated in Section 6.5.6. Detailed instructions on reporting CPCs will 
be provided in the Pharmacy Manual. 
5.4. 
Monitoring for Potential Clinical Events 
5.4.1. 
Monitoring and Approach for Potential Hypotension 
Hypotension is an obligate risk of antihypertensive medications. In addition to office blood 
pressure monitoring, outpatient blood pressure should be monitored weekly with HBPM to 
ensure the early detection of potential hypotension. Whenever possible, management decisions 
will be based on blood pressure measurements confirmed by office blood pressure. 
The following management recommendations for hypotension are provided: 
• Low blood pressure that is associated with symptoms should promptly be evaluated at 
the clinical study site or another hospital setting. Clinical study site evaluation for low 
blood pressure should include the assessment of orthostatic blood pressure (eg, supine 
to standing).  
• The Investigator should consider downtitration, interruption, or discontinuation of 
oral antihypertensives (if taking) if confirmed office SBP <90 mmHg or if clinical 
symptoms, such as lightheadedness or dizziness, develop coupled with a significantly 
lower SBP compared to prior visits (ie, SBP <100 mmHg). 
• Clinically significant events discovered during the course of a patient’s general 
medical care should be promptly communicated to the site and evaluated by the 
Investigator, especially if hypotension is noted. Patients will carry Independent Ethics 
Committee (IEC)-approved patient cards to facilitate this physician-to-physician 
communication.  
• If hypotension is confirmed, serum electrolytes and creatinine should be measured 
and any oral antihypertensive(s) previously started for hypertensive escape should be 
down-titrated, interrupted, or discontinued per Investigator judgement.  
• The frequency of blood pressure and biochemical monitoring (serum electrolytes and 
creatinine) should be increased during intercurrent illnesses that predispose patients to 
dehydration (eg, vomiting or diarrhea that persists for more than 24 hours) or when 
symptoms consistent with decreased effective circulating volume (eg, presyncopal 
symptoms, unexplained falls, decreased urine output) manifest, even if a patient’s 
recent blood pressure measurements have been normal. 
• Hypotension that warrants direct evaluation at the site should be communicated to the 
Medical Monitor within 24 hours. In addition, other clinical events consistent with 
potential hypotension (eg, unexplained presyncope, syncope, or falls) should be 
communicated to the Medical Monitor within 24 hours of the site being notified. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
44 
• Management of persistent hypotension may include increased salt intake or, if 
unresponsive, standard treatments for orthostatic intolerance syndromes such as 
fludrocortisone or midodrine. 
• Low blood pressure that requires medical treatment (including intravenous fluid 
support) or other clinical events consistent with potential hypotension (see above) 
should be recorded as AEs. 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure Elevation 
In addition to office blood pressure monitoring, outpatient blood pressure will be monitored 
frequently with HBPM to ensure the early detection of potential significant elevations. Whenever 
possible, management decisions will be based on blood pressure measurements confirmed by 
office blood pressure. The recommended interventions for potentially clinically significant blood 
pressure elevation are presented in Table 4.  
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation 
Study Period 
Intervention 
Throughout Study 
• 
Whenever possible, management decisions should be based on blood 
pressure measurements confirmed by office blood pressure. 
• 
Any confirmed event of severe hypertension (office SBP ≥180 mmHg 
and/or office DBP ≥120 mmHg) should be appropriately treated regardless 
of its timing relative to study drug administration.  
• 
Because ALN-AGT01 acts on the RAAS, the use of conventional RAAS 
inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors) as rescue 
agents for high blood pressure will be avoided throughout this study.  
• 
If added, oral antihypertensives must be used per their labeled instructions 
and in accordance with current care guidelines.[Whelton 2018; Williams 
2018] 
Day 1 to Month 3 
Intervene if clinically significant blood pressure elevation: 
• 
Because of the gradual onset of effects of ALN-AGT01, interventions for 
asymptomatic hypertension should be avoided in the first 6 weeks after the 
patient’s first administration of study drug.  
• 
After Week 6, patients who develop office SBP >160 mmHg and increased 
>10 mmHg from their baseline office SBP that persists for ≥24 hours on 2 
consecutive measurements or that is accompanied by hypertensive 
symptoms should be evaluated by the clinical study site. Severely 
symptomatic patients should be evaluated at the clinical study site or 
another hospital setting within 24 hours. 
• 
If persistent hypertension is confirmed (without the identification of a 
specific treatable cause) and the Investigator deems it to be a clinically 
significant change, treatment may be initiated at the medical discretion of 
the Investigator using a CCB and/or a thiazide/thiazide-like diuretic. 
Investigators should avoid long-acting agents that may not fully washout 
between Month 5 and Month 6. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
45 
Study Period 
Intervention 
Months 3 to 6 
Treat to target blood pressure using a CCB and/or thiazide/thiazide-like diuretic: 
• 
At Month 3, a CCB and/or a thiazide/thiazide-like diuretic may be added if 
the daytime mean SBP is ≥135 mmHg by ABPM. If the Investigator feels 
there is a compelling clinical reason to wait, the rationale for exception 
should be documented in the eCRF. 
• 
After Month 3, oral antihypertensive medications may also be added per 
Investigator judgement for persistent elevations in blood pressure above 
recommended target per treatment guidelines (eg, office SBP <140 mmHg, 
HBPM SBP <135 mmHg, or daytime mean SBP by ABPM <135 
mmHg).[Williams 2018] 
• 
A temporary hold of oral antihypertensives (if taking) will be performed in 
appropriate patients (below) from Month 5 to Month 6: 
- Month 5 office SBP <160 mmHg if taking no oral antihypertensive 
agents 
- Month 5 office SBP <155 mmHg if taking 1 oral antihypertensive agent 
- Month 5 office SBP <150 mmHg if taking 2 oral antihypertensive 
agents. 
• 
During this 4-week period, blood pressure will be carefully monitored by 
HBPM and oral antihypertensive medications restarted if confirmed office 
SBP >170 mmHg (or if confirmed office SBP >160 mmHg accompanied by 
symptoms) 
Month 6 to End of 
Study 
Treat to target blood pressure using Investigator’s choice of oral 
antihypertensive(s). 
• 
At Month 6, prior oral antihypertensive may be restarted per Investigator 
judgement if daytime mean SBP is ≥135 mmHg by ABPM. 
• 
Oral antihypertensive medications may also be added per Investigator 
judgement for persistent elevations in blood pressure above recommended 
target per treatment guidelines (eg, office SBP <140 mmHg; HBPM SBP 
<135 mmHg; daytime mean SBP by ABPM <135 mmHg).[Whelton 2018; 
Williams 2018] 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of eGFR 
through the anticipated onset of initial ALN-AGT01 PD. Based upon the renal dysfunction 
associated with conventional RAAS inhibitors,[McMurray 2016; Parving 2012] the following 
guidelines apply throughout the study: 
• If an individual patient experiences a decrease in eGFR by ≥30% from baseline or to 
≤30 mL/min/1.73m2, the Investigator should obtain confirmatory repeat tests, contact 
the Sponsor, and look for potentially reversible causes of renal dysfunction such as: 
− NSAIDs, antibiotics, or other treatments known to impair renal function 
− Recent exposure to intravenous contrast agents 
− Hypotension 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
46 
− Hypovolemia 
− Urinary infection 
− Urinary tract obstruction 
• If an individual patient experiences a decrease in eGFR by ≥40% from baseline or to 
≤25 mL/min/1.73m2, the Investigator should obtain confirmatory repeat tests, look for 
potentially reversible causes of renal dysfunction, and contact the Sponsor to discuss 
the potential interruption of study drug. Serum creatinine should be monitored at least 
weekly until improving.  
• If a patient is on additional oral antihypertensive agents, the Investigator should 
consider whether these agents should be interrupted, especially during intercurrent 
illness or volume depletion 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of serum 
electrolytes (at least monthly through the anticipated onset of ALN-AGT01 PD). The following 
guidelines apply for potassium elevations detected by laboratory monitoring.[McMurray 2016; 
Parving 2012] 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
47 
Table 5: 
Recommended Interventions for Hyperkalemia 
Serum K+ ≥5.2 and <5.5 mmol/L 
Serum K+ ≥5.5 and <6.0 mmol/L 
Serum K+ ≥6.0 mmol/L 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample. 
• 
Reinforce low-potassium diet 
and restriction of food/drinks 
with high potassium content  
• 
Review medical regimen 
(including dietary supplements 
and over-the-counter 
medications) for agents known 
to cause hyperkalemia.a 
Consider reduction in dose or 
discontinuation of these agents. 
• 
Repeat K+ measurement within 
3 to 5 days. 
• 
If K+ remains ≥5.2 and <5.5 
mmol/L, regularly monitor K+ 
levels to ensure stability (at 
least weekly if in the first 6 
weeks of treatment or at least 
once monthly afterwards) 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample 
• 
Consider interruption or delay 
of study drug, according to 
Investigator medical judgment  
• 
Apply all measures outlined for 
serum K+ ≥5.2 and <5.5 
mmol/L 
• 
Repeat K+ measurement after 2 
to 3 days 
• 
If K+ <5.5 mmol/L, consider 
resumption of study drug (if 
interrupted) with repeat 
potassium within 5 days 
• 
If K+ persistently elevated ≥5.5 
mmol/L, consider treatment 
with patiromer (or with sodium 
zirconium cyclosilicate), if 
available 
• 
Immediately interrupt 
study drug 
• 
Confirm potassium 
concentration in a 
non-hemolyzed 
sample 
• 
Urgently evaluate 
patient and treat 
hyperkalemia as 
clinically indicated. 
After urgent 
treatment, consider 
treatment with 
patiromer (or with 
sodium zirconium 
cyclosilicate), if 
available 
• 
Apply all measures 
outlined for serum K+ 
≥5.5 and <6.0 
mmol/L 
• 
No resumption of 
study drug without 
individualized case 
discussion with and 
permission from 
Alnylam Medical 
Monitor 
Abbreviations: NSAID=nonsteroidal anti-inflammatory drug. 
a This list is not meant to be exhaustive: potassium-sparing diuretics (eg, amiloride and triamterene), potassium 
supplements (eg potassium chloride), salt substitutes, NSAIDs, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, herbal supplements (eg, Noni juice, alfalfa [Medicago sativa], 
dandelion [Taraxacum officinale], horsetail [Equisetum arvense], nettle [Urtica dioica], milkweed, lily of the 
valley, Siberian ginseng, hawthorn berries). 
The availability of patiromer or ZS-9 will be assessed at participating study sites. These 
potassium-binding drugs are indicated for the treatment of hyperkalemia and have been shown to 
safely reduce serum potassium levels and to maintain long-term normokalemia in chronic kidney 
disease patients receiving background conventional RAAS inhibitor therapy.[Georgianos and 
Agarwal 2018; Weir 2015] 
5.5. 
Concomitant Medications and Procedures 
Use of concomitant medications and procedures will be recorded on the patient’s eCRF as 
specified in the Schedule of Assessments (see Table 1). Concomitant medications include all 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
48 
prescription medications, herbal preparations, over the counter medications, vitamins, and 
minerals. Any changes in medications during the study will also be recorded on the eCRF. 
Standard vitamins and topical medications are permitted. However, topical steroids must not be 
applied anywhere near the injection site(s) unless medically indicated. For permitted concomitant 
medications administered SC, do not administer in same injection site area as the study drug for 
4 days after the last dose of study drug. 
Patients receiving low-dose aspirin (defined as ≤100 mg per day) for at least 30 days prior to 
screening and during the study treatment period are allowed. Occasional use of other over-the-
counter systemic NSAIDs is allowed. However, given their association with increased blood 
pressure, they should be avoided when possible and for at least 2 days prior to ABPM and office 
blood pressure measurements, and alternative analgesics (acetaminophen, topical NSAIDs) 
should be considered.[Whelton 2018] When used, the dosing of systemic NSAIDs should be at 
the lower end of the labeled range and for the shortest duration possible.  
Patients receiving SGLT2 inhibitors (eg, empagliflozin, canagliflozin, and dapagliflozin) should 
be on a stable dose for at least 30 days prior to screening and during the study treatment period. 
These medications should not be initiated or discontinued, if possible, during the study treatment 
period. 
Patients will be allowed to receive vaccines (eg, for SARS-CoV-2) that have received health 
agency authorization (including for emergency use) by local or regional regulatory authorities. 
Any concomitant medication that is required for the patient’s welfare may be administered by the 
Investigator, except as described in Section 5.5.2. However, it is the responsibility of the 
Investigator to ensure that details regarding the medication are recorded on the eCRF. 
Concomitant medication will be coded using an internationally recognized and accepted coding 
dictionary. 
5.5.1. 
Oral Antihypertensive Medication  
Individual initiation and modification of oral antihypertensive medications per Investigator 
judgement are permitted throughout the study if required to treat clinically significant blood 
pressure elevation (Section 5.4.2). In addition, after a patient completes the placebo-controlled 
primary endpoint at Month 3, oral antihypertensive medications may also be added per 
Investigator judgment for persistent elevations in blood pressure above recommended target per 
treatment guidelines (eg, office SBP <140 mmHg, HBPM SBP <135 mmHg, or daytime mean 
SBP by ABPM <135 mmHg).[Williams 2018] All oral antihypertensive medication that are 
dosed once daily should be taken in the morning. 
Serum electrolytes and creatinine should be measured at a central or local laboratory 
approximately 2 weeks after any antihypertensive addition or dose titration. 
5.5.2. 
Prohibited Concomitant Medication 
The following medications, treatments, and supplements are prohibited throughout the study 
treatment period (until the EOT visit): 
• Conventional RAAS inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors)  
• Prescription NSAIDs  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
49 
• Organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, isosorbide 
dinitrate, pentaerythritol) 
• An RNAi therapeutic (other than ALN-AGT01) 
• Medications, herbal supplements (including Ma Huang and St. John’s wort), or other 
substances (such as licorice) that are associated with increases in LFT abnormalities 
or with blood pressure abnormalities are prohibited. This includes certain stimulants 
(eg, amphetamine, methylphenidate dexmethylphenidate, dextroamphetamine), MAO 
inhibitors, atypical antipsychotics (eg, clozapine, olanzapine), diet pills (eg, 
phenylpropanolamine, sibutramine), and nasal decongestants (eg, phenylephrine 
hydrochloride, pseudoephedrine, naphazoline hydrochloride). 
• Medications, herbal medicines, over-the-counter medications, or supplements known 
to cause hyperkalemia are prohibited unless individually approved by both the 
Investigator and the Medical Monitor. This includes potassium-sparing diuretics, 
potassium supplements, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, mineralocorticoid receptor 
antagonists, Noni juice, alfalfa, dandelion, horsetail, nettle, milkweed, lily of the 
valley, Siberian ginseng, and hawthorn berries. 
All concomitant medications must be reviewed and approved by the Investigator, with particular 
attention to avoiding drugs that may affect blood pressure. 
5.6. 
Treatment Compliance 
Compliance with study drug administration will be verified through observation by study staff. 
5.7. 
Other Requirements 
5.7.1. 
Contraception 
Females of child-bearing potential must be willing to use a highly effective method of 
contraception from 14 days before first dose, throughout study participation, and through safety 
follow-up (if applicable; see Section 3.1).  
Birth control methods which are considered highly effective include: 
• Placement of an intrauterine device. 
• Placement of an intrauterine hormone-releasing system. 
• Bilateral tubal occlusion. 
• Surgical sterilization of male partner (with the appropriate post-vasectomy 
documentation of the absence of sperm in the ejaculate; for female patients on the 
study, the vasectomized male partner should be the sole partner for that patient). 
• Established use of oral (except low-dose gestagens), implantable, injectable, or 
transdermal hormonal methods of contraception associated with the inhibition of 
ovulation. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
50 
• True sexual abstinence, when in line with the preferred and usual lifestyle of the 
patient. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception. Abstinent 
patients must agree to use one of the above-mentioned contraceptive methods if they 
start heterosexual relationships during the study and through safety follow-up (if 
applicable; Section 3.1). 
Investigators should advise females of childbearing potential of the most appropriate birth 
control method available within their country taking into account local medical practice. 
Females of child-bearing potential include female patients who have experienced menarche (or 
begin menarche over the course of the study), and who are not postmenopausal or permanently 
sterilized (eg, bilateral oophorectomy, hysterectomy, or bilateral salpingectomy). A 
postmenopausal state is defined as the absence of menses for 12 months without an alternative 
medical cause, confirmed by follicle stimulating hormone level within the postmenopausal 
range.  
For male patients, no contraception is required. However, use by males of contraception 
(condom) may be required in some countries, eg, France, in order to comply with local 
requirements as described in the corresponding patient ICFs.  
Compliance with contraception requirements will be assessed on a regular basis by the 
Investigator throughout the course of the study (see Section 6.5.5.3). Pregnancy testing will be 
performed before every dose for postmenarcheal females throughout the course of the study (see 
Section 6.5.5.3). 
5.7.2. 
Alcohol Restrictions 
Patients should limit alcohol consumption throughout the course of the study. Alcohol is limited 
to no more than 2 units per day (unit: 1 glass of wine [approximately 125 mL] =1 measure of 
spirits [approximately 1 fluid ounce] =½ pint of beer [approximately 284 mL]) for the duration 
of the study. Compliance with alcohol restrictions should be assessed on a regular basis by the 
Investigator throughout the course of the study. 
5.7.3. 
Tobacco and Nicotine Restrictions 
Use of nicotine or tobacco-containing products (including but not limited to snuff, chewing 
tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) must be avoided within 30 
minutes prior to blood pressure measurements. 
5.7.4. 
Dietary Recommendations  
All patients will receive educational materials on diet with recommendations to limit sodium 
consumption to approximately 2.0 g per day from screening through the end of the Treatment 
period. This direction should be provided at the start of the Screening period, and treatment-
naïve patients should follow these recommendations for at least 1 week prior to screening 
assessments of blood pressure. Of note, this is the sodium intake recommended in the 2018 
European Society of Cardiology/European Society of Hypertension Guidelines for both 
hypertensive patients and for the general population.[Williams 2018]  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
51 
On days on which samples for fasting lipid panel and glycemic assessments are collected, 
patients are required to fast for ≥10 hours before sample collection (Section 6.5.5.1). 
5.7.5. 
Exercise 
Patients should abstain from strenuous exercise for 48 hours before each blood collection for 
clinical laboratory tests and from any exercise for 30 minutes prior to office blood pressure 
measurements. 
6. 
STUDY ASSESSMENTS 
The Schedule of Assessments is provided in Table 1. Study visits should be scheduled for the 
morning. All assessments, except for postdose PK sample collection, are to be performed prior to 
dosing at dosing visits. Additional information on the collection of study assessments will be 
detailed in the Study Manuals. 
Where applicable country and local regulations and infrastructure for home healthcare allow, 
home healthcare may take place at a location other than the clinical study site to perform study 
assessments, which may include collection of blood and urine samples and measurement of vital 
signs and weight (at the discretion of the Investigator). 
6.1. 
Screening Assessments 
An ICF that has been approved by the appropriate Institutional Review Board (IRB)/IEC must be 
signed (in paper or electronic format per local regulations and institutional standards) by the 
patient or legal guardian before the screening procedures are initiated. All patients or their legal 
guardians will be given a copy of the signed and dated ICF. 
Patients will be screened to ensure that they meet all the inclusion criteria and none of the 
exclusion criteria. Rescreening of patients is permitted with consultation of the Medical Monitor 
(see Section 6.1.2). 
Patient demographic data and medical history/disease history will be obtained. Any changes to 
medical history occurring between the screening assessment and Day 1 will be updated prior to 
study drug administration. 
6.1.1. 
Retesting  
If in the Investigator’s judgement, the screening laboratory abnormalities are likely to be 
transient, then laboratory tests may be repeated. The Investigator’s rationale should be 
documented. Laboratory values can be retested once during screening provided that the patient 
can be evaluated for eligibility after at least 2 to 4 weeks of washout (as applicable) and 
randomized within the allowed Screening period. Retesting of screening ABPM is permitted 
once, with eligibility assessed by the second ABPM result. 
6.1.2. 
Rescreening 
A patient who does not meet all study eligibility criteria due to a transient condition observed at 
screening (eg, prohibited medications that were subsequently discontinued) will be allowed to 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
52 
return once for rescreening. A patient will be re-consented if rescreening occurs outside of the 
60-day screening window. In this case, all screening procedures must be repeated. 
6.2. 
Efficacy Assessments 
All blood pressure measurements (ABPM, office, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in 
Section 10.1.  
In patients taking oral antihypertensives, a washout of at least 2 to 4 weeks (as applicable) must 
be completed prior to measurement of the baseline ABPM (for eligibility) and baseline office 
blood pressure. The baseline ABPM and office blood pressure must be measured within 2 weeks 
before randomization. An HBPM unit will be provided during the Screening period to facilitate 
monitoring during the washout of prior oral antihypertensives (if taking) and to establish the 
HBPM baseline prior to randomization. To establish baseline, 3 recordings should be collected 
during the last week immediately prior to randomization. 
ABPM placement may be performed at home by appropriately trained individuals, as detailed in 
the Study Manual. If a patient is unable to report to the site for an office blood pressure 
assessment, a substitute “remote visit blood pressure measurement” may be obtained remotely 
using the methods described in Section 10.1. 
Recommendations for approach and monitoring of low blood pressure/hypotension and 
hypertensive escape are provided in Section 5.4.1 and Section 5.4.2, respectively. 
6.2.1. 
ABPM 
In patients taking oral antihypertensives (including those initiated as rescue medication), ABPM 
should be started prior to the morning dose of antihypertensive medication.  
Validity will be assessed for all ABPMs. If the ABPM recording is invalid at any point during 
the study, the patient will be provided 1 opportunity to repeat the recording. If the second ABPM 
recording is also invalid during screening, the patient is a screen failure.  
See further details in Section 10.1 and the Study Manual. 
6.2.2. 
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor at trough (prior to taking oral antihypertensives) and at approximately the same time 
each day; therefore, visits should be scheduled at approximately the same time of day, whenever 
possible. Office blood pressure must include orthostatic measurements (seated and standing).  
Exercise, caffeine, alcohol consumption, and use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or 
e-cigarettes) must be avoided within 30 minutes prior to blood pressure measurements. The use 
of inhaled short-acting beta agonists should be avoided within 6 hours prior to measuring blood 
pressure and/or heart rate. The use of phosphodiesterase type 5 inhibitors (eg, sildenafil, 
tadalafil, vardenafil, avanafil) should be avoided within 48 hours prior to measuring blood 
pressure. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
53 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the Study Manual.  
6.2.3. 
HBPM 
The HBPM should be measured in the morning upon waking, prior to breakfast/caffeine or 
taking morning oral medications. HBPM is not required at times when ABPM is being assessed. 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the Study Manual. 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment 
Up to 100 patients at select sites will be given the option of using a wearable blood pressure 
sensor for 2 periods of 2 to 4 weeks each according to the Schedule of Assessments (Table 1). 
Wearable blood pressure assessments performed during screening should be obtained during the 
last 2 to 4 weeks before Day 1. Participation will be contingent upon individual patient consent. 
These noninvasive, cuffless devices are worn on the finger or wrist as described in the Study 
Manual, using the opposite arm as that used for ABPM. 
6.3. 
Pharmacodynamic Assessments 
Blood samples for determination of AGT and RAAS biomarkers (plasma renin concentration, 
AngI, AngII, and aldosterone) will be collected according to the Schedule of Assessments 
(Table 1). Blood samples collected for AngI and AngII require special processing and will be 
assessed at sites that have appropriate resources, equipment, and reagents. Blood samples for PD 
assessments must be collected before study drug administration (on days when study drug is to 
be dosed) or at a time point corresponding to the time of study drug dosing (on other days). 
Blood AGT levels will be analyzed at a central laboratory by enzyme-linked immunosorbent 
assay for measurement of PD effect. These biomarkers may be analyzed using qualified assays. 
Details regarding the collection, processing, shipping, and storage of the samples will be 
provided in the Laboratory Manual.  
Results will not be used to adjust dosing of ALN-AGT01 or guide clinical management and will 
not be shared with sites until after the last patient completes Month 12. If clinical circumstances 
arise for which such information is required to guide patient care, local laboratory assessments 
should be drawn. 
6.4. 
Pharmacokinetic Assessments 
Blood samples will be collected for the assessment of plasma concentrations of ALN-AGT01 
and its primary metabolite AS(N-1)3′ ALN-AGT01 at the time points indicated in the Schedule 
of Assessments (Table 1). A detailed schedule of time points for the collection of blood samples 
for PK analysis is in Table 2. 
Plasma concentrations of ALN-AGT01 and AS(N-1)3′ ALN-AGT01 will be determined using a 
validated assay. Details regarding sample volumes to be collected, and the processing, shipping, 
and analysis of the samples will be provided in the Laboratory Manual. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
54 
6.5. 
Safety Assessments 
The assessment of safety during the study will consist of the surveillance and recording of AEs, 
including SAEs, recording of concomitant medication and measurements of vital signs, weight, 
electrocardiogram (ECG) findings, and laboratory tests. Clinically significant abnormalities 
observed during the physical examination are recorded. 
6.5.1. 
Vital Signs 
Vital signs will be measured as specified in the Schedule of Assessments (Table 1) and include 
blood pressure, heart rate, body temperature, and respiratory rate. When vital signs and blood 
sample collection occur at the same time, vital signs should be performed before blood samples 
are drawn, where possible. Vital signs should be measured predose in the seated position, after 
the patient has rested comfortably for approximately 10 minutes. Body temperature in degrees 
Celsius will be obtained via oral, tympanic, or axillary methods. Heart rate will be counted for a 
full minute and recorded in beats per minute, and respiration rate will be counted for a full 
minute and recorded in breaths per minute. Blood pressure is described in Section 6.2.  
Additional vital sign assessments, as medially indicated, may be added at the discretion of the 
Investigator, or as per DMC advice. 
Vital signs results will be recorded in the eCRF. 
6.5.2. 
Weight, Height, and Morphometrics 
Height and body weight measurements will be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded in the eCRF. Height will be measured at screening 
only. Height will be measured in centimeters. Body weight should be measured in kilograms to 
the first decimal point in patients wearing light clothing and without shoes.  
Waist circumference and waist-to-hip-ratio will also be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded on the eCRF. For waist circumference and waist-to-
hip ratio, patients should wear minimal clothing to ensure that the measuring tape is correctly 
positioned. Patients should stand erect with the abdomen relaxed, arms at the sides, feet together 
and with their weight equally divided over both legs. To perform the waist measurement, the 
lowest rib margin is first located and marked with a pen. The iliac crest is then palpated in the 
midaxillary line, and also marked. It is recommended to apply an elastic tape horizontally 
midway between the lowest rib margin and the iliac crest, and tie firmly so that it stays in 
position around the abdomen about the level of the umbilicus. The elastic tape thus defines the 
level of the waist circumference, which can then be measured by positioning the measuring tape 
over the elastic tape. Hip circumference measurement should be taken around the widest portion 
of the buttocks. Patients are asked to breathe normally, and to breathe out gently at the time of 
the measurement to prevent them from contracting their muscles or from holding their breath. A 
stretch-resistant tape that provides a constant 100 g of tension is recommended. Measurements 
should be obtained with the tape positioned parallel to the floor and performed using the same 
procedure throughout the study. 
The reading is taken to the nearest centimeter and entered in the source document. Each 
measurement should be repeated twice; if the measurements are within 1 cm of each other, the 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
55 
average should be calculated. If the difference between the 2 measurements exceeds 1 cm, the 2 
measurements should be repeated.  
6.5.3. 
Physical Examination 
Full and symptom-directed physical examinations will be conducted according to the Schedule 
of Assessments (Table 1); if a physical examination is scheduled for a dosing visit, it should be 
conducted prior to dosing. Full physical examinations will include the examination of the 
following: general appearance; head, eyes, ears, nose and throat; respiratory, cardiovascular, 
gastrointestinal, musculoskeletal, and dermatological systems; thyroid; lymph nodes; and 
neurological status (see the Study Manual for further details on the assessments to be performed 
as part of the neurological evaluation). 
Symptom-directed physical examinations will be guided by evaluation of changes in symptoms, 
or the onset of new symptoms, since the last visit. Neurological evaluation should be performed 
according to the Study Manual during all symptom-directed physical examinations regardless of 
whether neurological symptoms have been experienced by the patient.  
Clinically significant abnormalities observed during the physical examination are recorded on 
the medical history or AE eCRF. 
6.5.4. 
Electrocardiogram 
The 12-lead ECGs reporting rhythm, ventricular rate, RR interval, PR interval, QRS duration, 
and QT interval and Fridericia-corrected QT interval will be obtained using a local machine, as 
specified in the Schedule of Assessments (Table 1). Patients should be supine for at least 10 
minutes before each ECG is obtained. The Investigator or qualified designee will review all 
single 12-lead ECGs to assess whether the results have changed since the Baseline visit and to 
determine the clinical significance of the results. These assessments will be recorded in the 
eCRF.  
When ECG and blood sample collection occur at the same visit, blood sample collection should 
occur first. ECGs should be performed at least 30 minutes after phlebotomy or other stressful 
assessments. 
The Investigator or qualified designee will review all ECGs to assess whether the results have 
changed since the baseline visit and to determine the clinical significance of the results. These 
assessments will be recorded in the eCRF. Additional ECGs may be collected at the discretion of 
the Investigator, or as per DMC advice. Recordings will be archived according to the Study 
Manual. 
6.5.5. 
Clinical Laboratory Assessments 
The following clinical laboratory tests will be evaluated by a central laboratory. Specific 
instructions for transaminase elevations are provided in Section 6.5.6.4. For any other 
unexplained clinically relevant abnormal laboratory test occurring after study drug 
administration, the test should be repeated and followed up at the discretion of the Investigator, 
or as per DMC advice, until it has returned to the normal range or stabilized, and/or a diagnosis 
is made to adequately explain the abnormality. Additional safety laboratories and assessments as 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
56 
indicated by the clinical situation may be requested. Clinical laboratory assessments are listed in 
Table 6 and will be assessed as specified in the Schedule of Assessments (Table 1).  
While local laboratory results may be used for urgent clinical decisions, on the day of the 
assessments all laboratory assessments specified in Table 6 which are performed at the clinic 
should also be sent in parallel to the central laboratory. In the case of discrepant local and central 
laboratory results on samples drawn on the same day, central laboratory results will be relied 
upon for clinical decisions. 
Clinical laboratory assessments may be collected at the clinical study center or at home by a 
trained healthcare professional. Blood samples collected for RAAS biomarkers should be 
collected in the morning and in the seated/upright position (after blood pressure measurements 
and before any assessments collected in the supine position). 
Spot urine collections for albumin and creatinine should be obtained in the morning.  
For any safety event or laboratory abnormality, additional laboratory assessments, imaging, and 
consultation may be performed for clinical evaluation and/or in consultation with the Medical 
Monitor; results may be collected and should be included in the clinical database. 
Table 6: 
Clinical Laboratory Assessments  
Hematology 
Complete blood count with differential 
 
Serum Chemistry 
Sodium 
Potassium 
BUN 
Phosphate 
Uric acid 
Albumin 
Total protein 
Calcium 
Glucose 
Bicarbonate 
Creatinine and eGFR 
Chloride 
Liver Function Tests 
 
AST 
ALP 
ALT 
Bilirubin (total and direct) 
GGT 
 
Urinalysis 
Visual inspection for appearance and color 
Bilirubin 
pH (dipstick) 
Nitrite 
Specific gravity 
RBCs 
Ketones 
Urobilinogen 
Protein  
Leukocyte esterase 
Glucose 
Microscopy (if clinically indicated) 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
57 
Coagulation  
Prothrombin time 
International normalized ratio 
Partial thromboplastin time  
 
Fasting Lipid Panel and Glycemic Assessments (see Section 6.5.5.1) 
Lipid panel, including 
HDL-C, non-HDL-C, LDL-C, apolipoprotein A1, 
triglycerides, total cholesterol  
Insulin 
Fasting plasma glucose 
HbA1c 
Immunogenicity (see Section 6.5.5.2) 
ADA 
 
Pregnancy Testing/FSH Screening (see Section 6.5.5.3) 
β-human chorionic gonadotropin (females of 
child-bearing potential only) 
Follicle-stimulating hormone (postmenopausal 
women only) 
Abbreviations: ADA=anti-drug antibodies; ALP=alkaline phosphatase; ALT=alanine aminotransferase; 
AST=aspartate aminotransferase; BUN=blood urea nitrogen; eGFR=estimated glomerular filtration rate; 
FSH=follicle-stimulating hormone; GGT=gamma glutamyl transferase; HbA1c=hemoglobin A1c; HDL-C=high-
density lipoprotein; LDL-C=low-density lipoprotein; RBCs=red blood cells. 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments 
Blood samples for fasting plasma glucose, insulin, lipid panel (including total cholesterol, high-
density lipoprotein [HDL-C], non-HDL-C, low-density lipoprotein, apolipoprotein A1, and 
triglycerides), and HbA1c will be collected at the time points listed in the Schedule of 
Assessments (Table 1). Patients are required to fast for ≥10 hours before sample collection for 
fasting plasma glucose, insulin, lipid panel, and HbA1c. Samples should be collected at 
approximately the same time of day (±2 hours). 
6.5.5.2. 
Immunogenicity 
Blood samples will be collected to evaluate anti-drug antibodies (ADA). Blood samples for ADA 
testing must be collected before study drug administration (on days when study drug is to be 
dosed) or at a time point corresponding to the time of study drug dosing (on other days) as 
specified in the Schedule of Assessments (Table 1). A blood sample to evaluate ADA will be 
collected at the ET visit, if applicable. Blood samples for ADA will be analyzed at a central 
laboratory. 
Details regarding the processing, shipping, and analysis of the samples will be provided in the 
Laboratory Manual. 
6.5.5.3. 
Pregnancy Testing 
A pregnancy test will be performed for females of child-bearing potential. A serum pregnancy 
test will be performed at screening, and urine pregnancy tests will be performed thereafter per 
the Schedule of Assessments and any time pregnancy is suspected. More frequent pregnancy 
testing may be performed where required per local requirements. The results of the pregnancy 
test must be known before study drug administration. Patients who are pregnant at screening are 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
58 
not eligible for study participation. Any woman with a positive urine pregnancy test, 
subsequently confirmed by a positive serum pregnancy test, during the study will be 
discontinued from study drug but will continue to be followed for safety. Patients determined to 
be pregnant while on study will be followed at least until the pregnancy outcome is known (see 
Section 6.5.6.7 for follow-up instructions). 
A blood sample will be drawn at screening to measure the levels of follicle stimulating hormone 
in order to confirm postmenopausal status in all women suspected to be postmenopausal (see 
Section 5.7.1 for definition of postmenopausal state). 
6.5.5.4. 
Additional Liver Function Assessments 
Additional laboratory assessments will be performed in patients who experience any LFT 
abnormalities as outlined in Section 5.2.4. Following the occurrence of elevated liver 
transaminases or other LFT abnormalities per central laboratory, all assessments in Table 7 will 
be performed 1 time, as well as hematology, serum chemistry, LFT, and coagulation assessments 
from Table 6, and other assessments or evaluations per Investigator discretion, as appropriate.  
Monitoring, including criteria for dose modification or withholding the study drug, is described 
in Section 5.2.4.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
59 
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases 
Extended Hepatic Panel 
HBsAg, HBc antibody IgM  
Parvovirus B19 DNA – quantitative 
HAV antibody IgM 
HHV-6 DNA viral load – quantitative 
HCV antibody 
Anti-nuclear antibodies 
HCV RNA PCR – quantitative 
Anti-smooth muscle antibodies 
HEV antibody IgM 
Anti-LKM1 antibody 
Herpes Simplex Virus 1 and 2 antibody IgM, IgG 
Anti-mitochondrial antibodies 
Herpes Zoster Virus IgM, IgG 
Anti-SLA 
Epstein-Barr Virus antibodies, IgM, and IgG 
Ferritin 
Cytomegalovirus antibodies, IgM, IgG 
Ceruloplasmin 
Imaging 
Abdominal ultrasound with Doppler flow (or CT or MRI) including right upper quadrant 
Focused Medical and Travel History 
Use of any potentially hepatotoxic concomitant 
medications, including over the counter medications 
and herbal remedies 
Alcohol consumption and drugs of abuse 
Other potentially hepatotoxic agents including any 
work-related exposures 
Recent travels to areas where hepatitis A or E 
is endemic 
Abbreviations: CT=computed tomography; HAV=hepatitis A virus; HBc=hepatitis B core; HBsAg=hepatitis B 
virus surface antigen; HCV=hepatitis C virus; HEV=hepatitis E virus; HHV-6=human herpesvirus 6; 
IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; LKM1=liver/kidney microsome-1 
antibody; MRI=magnetic resonance imagery; PCR=polymerase chain reaction; RNA=ribonucleic acid; 
SLA=soluble liver antigen 
Note: 
• 
All laboratory assessments will be measured in a central laboratory. The full panel of assessments should 
only be performed once; individual assessments may be repeated, as needed. 
6.5.6. 
Adverse Events 
6.5.6.1. 
Definitions 
Adverse Event 
According to the ICH E2A guideline Definitions and Standards for Expedited Reporting, and 21 
Code of Federal Regulations 312.32, Investigational New Drug Safety Reporting, an AE is any 
untoward medical occurrence in a patient or clinical investigational subject administered a 
medicinal product and which does not necessarily have a causal relationship with this treatment. 
Serious Adverse Event 
An SAE is any untoward medical occurrence that at any dose: 
• Results in death 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
60 
• Is life-threatening (an event which places the patient at immediate risk of death from 
the event as it occurred. It does not include an event that had it occurred in a more 
severe form might have caused death) 
• Requires inpatient hospitalization or prolongation of existing hospitalization 
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly or birth defect 
• Is an important medical event that may not be immediately life-threatening or result 
in death or hospitalization but may jeopardize the patient and may require 
intervention to prevent one of the other outcomes listed in the definition above (eg, 
events include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home, blood dyscrasias, convulsions, or the development of drug 
dependency or abuse). 
Adverse Events of Clinical Interest 
The following are considered to be AEs of clinical interest: 
• ALT or AST >3×ULN 
• Severe or serious ISRs; ISRs that are associated with a recall phenomenon (reaction 
at the site of a prior injection with subsequent injections), or those that lead to 
temporary dose interruption or permanent discontinuation of ALN-AGT01. 
An ISR is defined as a local reaction at or near the site of injection. “At or near” the 
injection site includes reactions at the injection site, adjacent to the injection site, or a 
reaction which may shift slightly away from the injection site due to gravity (eg, as 
may occur with swelling or hematoma). A systemic reaction which includes the 
injection site, eg, generalized urticaria, other distinct entities or conditions like 
lymphadenopathy that may be near the injection site is not considered an ISR. 
For information on recording and reporting of AEs of clinical interest, see Section 6.5.6.2 and 
Section 6.5.6.3, respectively. 
Adverse Event Severity 
Adverse events are to be graded according to the categories detailed below: 
Mild: 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
Moderate: Moderate; minimal, local, or noninvasive intervention indicated; limiting age 
appropriate instrumental activities of daily living (eg, preparing meals, shopping 
for groceries or clothes, using the telephone, managing money). 
Severe: 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting 
self-care activities of daily living (ie, bathing, dressing and undressing, feeding 
self, using the toilet, taking medications, and not bedridden); OR life-threatening 
consequences; urgent intervention indicated; OR death related to an adverse event. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
61 
Changes in severity should be documented in the medical record to allow assessment of the 
duration of the event at each level of severity. Adverse events characterized as intermittent 
require documentation of the start and stop of each incidence. When changes in the severity of an 
AE occur more frequently than once a day, the maximum severity for the experience that day 
should be noted. If the severity category changes over a number of days, then those changes 
should be recorded separately (with distinct onset dates). 
Adverse event severity and seriousness are assessed independently. ‘Severity’ characterizes the 
intensity of an AE. ‘Serious’ is a regulatory definition and serves as a guide to the Sponsor for 
defining regulatory reporting obligations (see definition for SAE). 
Relationship of the Adverse Event to Study Drug 
The relationship of each AE to study drug should be evaluated by the Investigator by a “yes” or 
“no” response to the question: “Is there a reasonable possibility that the event may have been 
caused by the study drug?” A “yes” response indicates that the event is considered as related to 
the study drug. 
6.5.6.2. 
Eliciting and Recording Adverse Events 
Eliciting Adverse Events 
The patient and legal guardian, if applicable, should be asked about medically relevant changes 
in the patient’s health since the last visit. The patient and legal guardian, if applicable, should 
also be asked if the patient has been hospitalized, had any accidents, used any new medications, 
or changed concomitant medication routines (both prescription and over-the-counter). In addition 
to patient observations, AEs will be documented from any clinically relevant laboratory findings, 
physical examination findings, ECG changes, or other findings that are relevant to patient safety. 
Recording Adverse Events 
The Investigator is responsible for recording non-serious AEs that are observed or reported by 
the patient after administration of the first dose of study drug regardless of their relationship to 
study drug through the end of study. Non-serious AEs will be followed until the end of study. 
Events occurring after signing of the ICF and before study drug administration will be captured 
as medical history (see Section 6.1), while AEs that occur after study drug administration, and 
baseline events that worsen after study drug administration, must be recorded as AEs.  
The Investigator is responsible for recording SAEs that are observed or reported by the patient 
after the time when the informed consent is signed regardless of their relationship to study drug 
through the end of study. SAEs will be followed until satisfactory resolution, until baseline level 
is reached, or until the SAE is considered by the Investigator to be chronic or the patient is 
stable, as appropriate. 
All AEs must be recorded in the source records for the clinical study center and in the eCRF for 
the patient, whether or not they are considered to be drug-related. Each AE must be described in 
detail: onset time and date, description of event, severity, relationship to study drug, action taken, 
and outcome (including time and date of resolution, if applicable). 
For SAEs, record the event(s) in the eCRF and, as applicable, the SAE form. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
62 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the supplemental AEs of 
Clinical Interest eCRF should be completed. Additional clinical and laboratory information may 
be collected. Refer to CRF completion guidelines for details on reporting events in the 
supplemental AEs of Clinical Interest eCRF. 
For all ISRs, the Investigator, or delegate, should submit an Injection Site Reaction Signs or 
Symptoms eCRF, recording additional information regarding each injection site reaction that is 
entered on the AE eCRF (eg, symptom(s), injection site location, follow-up actions taken, etc). 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the Sponsor or its designee 
should be notified within 24 hours using the appropriate eCRF. 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee 
An assessment of the seriousness of each AE will be made by the Investigator. Any AE and 
laboratory abnormality that meets the SAE criteria in Section 6.5.6.1 must be reported to the 
Sponsor or designee within 24 hours from the time that clinical study center staff first learns of 
the event. All SAEs must be reported regardless of the relationship to study drug. 
The initial report should include at least the following information: 
• Patient’s study number 
• Description and date of onset of the event 
• Criterion for serious 
• Preliminary assignment of relationship to study drug, and 
• Investigator/site information 
To report the SAE, complete the eCRF and, as applicable, the SAE form. Within 24 hours of 
receipt of follow-up information, the Investigator must update the eCRF and, as applicable, the 
SAE form. Serious adverse events must be reported using the contact information provided in the 
Study Manual. 
Appropriate remedial measures should be taken by the Investigator using his/her best medical 
judgment to treat the SAE. These measures and the patient’s response to these measures should 
be recorded. All SAEs, regardless of relationship to study drug, will be followed by the 
Investigator until satisfactory resolution or the Investigator deems the SAE to be chronic or 
stable. Clinical, laboratory, and diagnostic measures should be employed by the Investigator as 
needed to adequately determine the etiology of the event. 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities 
The Sponsor or its representative will report certain study events in an expedited manner to the 
Food and Drug Administration, the European Medicines Agency’s EudraVigilance electronic 
system according to Directive 2001/20/EC, and to all country Regulatory Authorities where the 
study is being conducted, according to local applicable regulations. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
63 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee 
Suspected unexpected serious adverse reactions will be reported to the IRB/IEC per their 
institutional policy by the Investigator or Sponsor (or Sponsor designee) according to country 
requirements. Copies of each report and documentation of IRB/IEC notification and 
acknowledgement of receipt will be kept in the Investigator’s study file. 
6.5.6.7. 
Pregnancy Reporting 
If a female patient becomes pregnant during the study through safety follow-up (Section 3.1), the 
Investigator must report the pregnancy to the Sponsor or designee within 24 hours of being 
notified of the pregnancy. Details of the pregnancy will be recorded on the pregnancy reporting 
form. The patient should receive any necessary counseling regarding the risks of continuing the 
pregnancy, the possible effects on the fetus, and be counseled not to breastfeed for 90 days after 
the last dose of study drug. 
The pregnancy should be followed by the Investigator until completion. At the completion of the 
pregnancy, the Investigator will document the outcome of the pregnancy. If the outcome of the 
pregnancy results in a postpartum complication, spontaneous abortion, stillbirth, neonatal death, 
or congenital anomaly, then the Investigator should follow the procedures for reporting an SAE 
as outlined in Section 6.5.6.4. 
6.5.6.8. 
Overdose and Other Special Situations Reporting 
An overdose is defined as any dose of study drug administered to the participant or taken by the 
participant that is >2× the assigned dose during a single administration and/or ≥2 doses within ½ 
the intended dosing interval. 
The Sponsor does not recommend specific treatment for an overdose.  
In an event of an overdose or other special situations (eg, medication error, abuse, misuse, CPC 
associated with an AE), the Investigator should: 
• Contact the Medical Monitor within 24 hours  
• Submit the special situations reporting form within 24 hours using the contact 
information in the Pharmacy Manual 
• Closely monitor the participant for any AE/SAE and laboratory abnormalities 
• Document the amount of study drug given  
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or 
a concomitant medication will be considered AEs/SAEs.  
Full details of overdose and other special situations reporting instructions will be outlined in the 
Pharmacy Manual. 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository 
Alnylam’s RNAi therapeutics platform permits the highly specific targeting of investigational 
therapies based on genetic sequence. It is possible that variations in the target genetic sequence 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
64 
will result in variations in drug effect. More generally, genetic variations may account for the 
well-described heterogeneous manifestations of disease in patients with hypertension, as well as 
their responses to treatment. 
Where allowed per local regulations, ethics committee (IRB/IEC) approval, and patient consent, 
samples will be collected as part of this study to permit exploratory investigations and the 
application of novel approaches to bioanalyses that may further elucidate the outcomes of this 
study, or potentially advance understanding of the safety, mechanism of action, and/or efficacy 
of ALN-AGT01. 
Biological specimens will be collected at the intervals indicated in the Schedule of Assessments 
(Table 1). These specimens will be analyzed at a central laboratory. Potential exploratory 
investigations may include DNA, RNA, or biochemical metabolite assessments as they relate to 
disease progression, efficacy, or safety. 
The biospecimen repository will also include residual material from routine samples (safety 
laboratory samples, PK samples, etc) that are obtained during the study. 
These specimens will be securely stored in a central biorepository for up to 10 years following 
the completion of this clinical study (ie, last patient last visit), or as per local regulations. After 
10 years have elapsed, samples will be destroyed. 
Details regarding the collection, processing, storage, and shipping of the samples will be 
provided in the Laboratory Manual. 
Exploratory analysis of these biospecimens will be performed by Alnylam Pharmaceuticals or its 
designees. 
When biobanking is permitted by local regulation, study participants will be advised during the 
informed consent process of these biobanking details and the potential for exploratory 
investigation of their samples. 
7. 
STATISTICS 
A Statistical Analysis Plan (SAP) will be finalized before database lock and unblinding for the 
primary analysis. The plan will detail the implementation of the statistical analyses in accordance 
with the principle features stated in the protocol. 
7.1. 
Determination of Sample Size 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline at Month 
3 in 24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 375 
patients (75 per treatment group) provides at least 84% power to detect a dose response signal in 
SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided significance level of 
0.05. In addition, this sample size provides at least 80% power to detect a 10 mmHg difference 
between an individual ALN-AGT01 dose versus placebo with a 2-sided significance level of 
0.05. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
65 
7.2. 
Statistical Methodology 
The statistical and analytical plans presented below are brief summaries of planned analyses. 
More complete plans will be detailed in the SAP. Changes to the methods described in the final 
SAP will be described and justified as needed in the clinical study report. For information on 
study endpoints, see Section 2. 
7.2.1. 
Populations to be Analyzed 
The populations (analysis sets) are defined as follows: 
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• PK Analysis Set: All patients who received at least 1 full dose of ALN-AGT01 and 
have at least 1 nonmissing postdose PK assessment. 
• PD Analysis Set: All patients who received at least 1 full dose of study drug. All by-
treatment analyses based on the PD Analysis Set will be grouped according to the 
treatment actually received. 
• All ALN-AGT01 Treated Set: All patients who received any amount of 1 of the 4 
ALN-AGT01 dosing regimens, including patients who took ALN-AGT01 during the 
6-month placebo-controlled period and patients who initially took placebo and then 
switched to ALN-AGT01 after the Month 6 visit. 
For the primary analysis for the 6-month placebo-controlled DB period, the primary population 
used to evaluate efficacy will be the FAS. Safety will be analyzed using the Safety Analysis Set. 
The PK and PD Analysis Sets will be used to conduct PK and PD analyses, respectively. 
The All ALN-AGT01 Treated Set will be used to summarize the efficacy and safety of 
ALN-AGT01 throughout the entire DB period (including DB extension period). 
7.2.2. 
Examination of Subgroups 
Subgroup analyses will be conducted for selected endpoints. Subgroup categories and detailed 
methodology will be provided in the SAP. 
7.2.3. 
Handling of Missing Data 
Handling of missing data will be described in the SAP. 
7.2.4. 
Baseline Evaluations 
Demographics and other disease-specific baseline characteristics will be summarized. 
In general, baseline will be defined as the average of all assessments, including unscheduled 
assessments, prior to the first dose of study drug. Details of the definition will be specified in the 
SAP. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
66 
7.2.5. 
Efficacy Analyses 
The primary endpoint is the change from baseline at Month 3 in 24-hour mean SBP assessed by 
ABPM. The hypothesis of the dose response signal for the primary endpoint across ALN-AGT01 
doses and placebo will be tested using Dunnett’s procedure based on mixed model for repeated 
measurements (MMRM). The MMRM model will include treatment, visit, treatment-by-visit 
interaction, and race (black; all other races) as fixed factors and baseline 24-hour mean SBP 
assessed by ABPM as a covariate. An unstructured covariance matrix will be used. 
The key secondary endpoints are: 
• Change from baseline at Month 3 in office SBP 
• Change from baseline at Month 6 in 24-hour mean SBP assessed by ABPM 
• Change from baseline at Month 6 in office SBP 
• Proportion of patients with 24-hour mean SBP assessed by ABPM <130 mmHg 
and/or reduction ≥20 mmHg without additional antihypertensive medications at 
Month 6 
To control the overall type I error, the primary and key secondary endpoints will be tested in 
hierarchical order. 
Details of the analysis method for primary, secondary, and exploratory endpoints will be 
described in the SAP. 
7.2.6. 
Pharmacodynamic Analysis 
Pharmacodynamic analyses will include the evaluation of changes in levels of serum AGT and 
other exploratory biomarkers of the RAAS pathway. Descriptive statistics for observed levels 
and the relative change from baseline for all measured biomarkers will be presented for each of 
the postdose time points. 
Statistical comparison of the biomarker levels (absolute and/or change from baseline) across 
treatment groups may be explored. Details of the analysis will be specified in the SAP.  
Population PK/PD analysis may be conducted to evaluate the dose-response relationships for PD 
lowering after ALN-AGT01 treatment. Additionally, the relationship between lowering of serum 
AGT and blood pressure may be explored within a modeling framework. If conducted, these 
analyses will be described in a pharmacometrics analysis plan and results will be presented in a 
separate report. 
7.2.7. 
Pharmacokinetic Analysis 
Plasma concentrations of ALN-AGT01 and its metabolite AS(N-1)3′ ALN-AGT01 will be 
summarized using descriptive statistics. 
Population PK analysis may be conducted on the PK data from this study. If conducted, the 
analysis methods will be described in a pharmacometrics analysis plan and results will be 
presented in a separate report. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
67 
7.2.8. 
Safety Analyses 
The primary parameter is the frequency of treatment-emergent AEs (hereafter referred to simply 
as AEs). Safety parameters also include vital signs, ECGs, clinical laboratory assessments and 
physical exams. Extent of exposure will be summarized.  
Prior and concomitant medications will be coded using the World Health Organization Drug 
Dictionary. Results will be tabulated by Anatomical Therapeutic Chemical Classification System 
and Preferred Term (PT). 
Adverse events will be classified according to the Medical Dictionary for Regulatory Activities 
(MedDRA) System Organ Class (SOC) and PT. Adverse events, SAEs, related AEs, AEs leading 
to discontinuation of study drug, and AEs leading to death will be summarized by SOC and PT 
for each treatment arm. By-patient listings will be provided for deaths, SAEs, and AEs leading to 
discontinuation of study drug.  
Descriptive statistics will be provided for clinical laboratory parameters, ECG, and vital signs 
summarizing the observed values and changes from baseline over time. Laboratory shift tables 
from baseline grade (or category) to worst post-baseline grade (or category) will be presented for 
laboratory parameters that are graded or categorized. Abnormal physical exam findings will be 
presented in listings. 
Other safety summaries will be presented as appropriate. Further details will be specified in the 
SAP. 
7.2.9. 
Immunogenicity Analyses 
The frequency and percentage of patients with confirmed positive ADA assay at any time during 
the study as well as at each scheduled visit will be summarized. The titer results for patients with 
confirmed positive ADA results will be summarized. 
7.2.10. 
Interim Analysis 
The primary analysis will be conducted after all patients complete the Month 6 visit or withdraw 
from the study prior to the Month 6 visit. No formal interim analysis is planned before the 
primary analysis.  
7.2.11. 
Optional Additional Research 
Optional additional research may be conducted in the future on the biological samples and/or 
data collected during the study in accordance with the strict terms of the ICF (see Section 4.3.2). 
8. 
STUDY ADMINISTRATION 
8.1. 
Ethical and Regulatory Considerations 
This study will be conducted in accordance with the protocol, all applicable regulatory 
requirements, and the current guidelines of Good Clinical Practice (GCP). Compliance with GCP 
provides public assurance that the rights, safety, and well-being of study patients are protected 
consistent with the principles that have their origin in the Declaration of Helsinki. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
68 
8.1.1. 
Informed Consent 
The Investigator will ensure that the patient is given full and adequate oral and written 
information about the nature, purpose, possible risk, and benefit of the study. Patients must also 
be notified that they are free to discontinue from the study at any time. The patient should be 
given the opportunity to ask questions and allowed time to consider the information provided. 
The Investigator will inform the patient/legal guardian if new information becomes available that 
may be relevant to the patient’s/legal guardian’s willingness to continue participation in the 
study. Communication of this information should be documented. 
The patient’s signed and dated informed consent (in paper or electronic format per local 
regulations and institutional standards) must be obtained before conducting any study tests or 
procedures that are not part of routine care. 
The Investigator must maintain the original, signed ICF. A copy of the signed ICF must be given 
to the patient or legal guardian. 
8.1.2. 
Ethical Review 
The study protocol, including the ICF, must be approved or given a favorable opinion in writing 
by an IRB or IEC, as appropriate. The Investigator must submit written approval before he or she 
can enroll any patient into the study. 
The Investigator is responsible for informing the IRB or IEC of any amendment to the protocol 
in accordance with local requirements. In addition, the IRB or IEC must approve all patient 
materials for the study. The protocol must be reapproved by the IRB or IEC upon receipt of 
amendments and annually, as local regulations require. 
Initial IRB or IEC approval of the protocol, and all materials approved by the IRB or IEC for this 
study including the patient consent form and recruitment materials must be maintained by the 
Investigator and made available for inspection. 
The Investigator will submit reports of SAEs as outlined in Section 6.5.6. In addition, the 
Investigator agrees to submit progress reports to the IRB or IEC per their local reporting 
requirements, or at least annually and at the conclusion of the study. The reports will be made 
available to the Sponsor or designee. 
Any communications from regulatory agencies, IRBs, or IECs in regard to inspections, other 
studies that impact this protocol or the qualifications of study personnel should be promptly 
reported to the Sponsor or its designee. 
The Investigator is also responsible for providing the IRB or IEC with reports of any reportable 
serious adverse drug reactions from any other study conducted with the study drug. The Sponsor 
or designee will provide this information to the Investigator. 
Major changes in this research activity, except those to remove an apparent immediate hazard to 
the patient, must be reviewed and approved by the Sponsor and the IRB or IEC that approved the 
study. Amendments to the protocol must be submitted in writing to the Investigator’s IRB or IEC 
and the Regulatory Authority for approval before patients are enrolled under the amended 
protocol, and patients or their legal guardians must be re-consented to the most current version of 
the ICF.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
69 
8.1.3. 
Serious Breach of Protocol 
Investigators must notify the Medical Monitor within 24 hours of becoming aware of a potential 
serious breach of the protocol. A serious breach is a breach that is likely to affect to a significant 
degree the safety and rights of a study participant or the reliability and robustness of the data 
generated in the clinical study. 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention 
All documentation (including personal data) relating to the study should be retained for 2 years 
after the last approval in an ICH territory or as required by local laws and regulations, whichever 
is longer. 
If it becomes necessary for the Sponsor, the Sponsor’s designee, applicable IRB/IEC, or 
applicable regulatory authorities to review or audit any documentation relating to the study, the 
Investigator must permit direct access to all source documents/data. Records will not be 
destroyed without informing the Sponsor in writing and giving the Sponsor the opportunity to 
store the records for a longer period of time at the Sponsor’s expense. 
The Investigator must ensure that the patients’ confidentiality will be maintained. On the eCRFs 
or other documents submitted to the Sponsor or designees, patients should not be identified by 
their names, but by the assigned patient number or code. If patient names are included on copies 
of documents to be submitted to the Sponsor or designees, the names will be obliterated, and the 
assigned patient number added to the document, before sending to the Sponsor. Documents not 
for submission to the Sponsor (eg, signed ICFs) should be maintained by the Investigator in strict 
confidence. 
The Investigator must treat all of the information related to the study and the compiled data as 
confidential, whose use is for the purpose of conducting the study. The Sponsor must approve 
any transfer of information not directly involved in the study. 
To comply with local and/or regional regulations, this clinical study may be registered, and study 
results may be posted on public registries, such as ClinicalTrials.gov. 
8.1.5. 
End of Study 
The end of study is defined as the last patient last visit. 
8.1.6. 
Termination of the Clinical Study or Site Closure 
The Sponsor, or designee, reserves the right to terminate the study or a clinical study site at any 
time. Conditions that may warrant this action may include, but are not limited to: 
• The discovery of an unexpected, serious, or unacceptable risk to patients participating 
in the study 
• Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of participants by the Investigator 
• The decision on the part of the Sponsor to suspend or discontinue treatment with the 
study drug 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
70 
Should the study be terminated, and/or the site closed for whatever reason, all documentation and 
study drug pertaining to the study must be returned to the Sponsor or its representative, and the 
Investigators, IRB/IEC and Regulatory Authorities will be promptly informed of the termination 
and the reason for the decision. The Investigator should promptly inform the patients and assure 
appropriate therapy and follow-up. 
8.2. 
Data Quality Control and Quality Assurance 
8.2.1. 
Data Handling 
Study data must be recorded on CRFs (paper and/or electronic) provided by the Sponsor or 
designee on behalf of the Sponsor. Case report forms must be completed only by persons 
designated by the Investigator. If eCRFs are used, study data must be entered by trained site 
personnel with access to a valid and secure eCRF system. All data entered into the eCRF must 
also be available in the source documents. Corrections on paper CRFs must be made so as to not 
obliterate the original data and must be initialed and dated by the person who made the 
correction. 
8.2.2. 
Study Monitoring 
The Monitor, as a representative of the Sponsor, has an obligation to closely follow the study 
conduct at the site. The Monitor will visit the Investigator and clinical study center periodically 
and will maintain frequent telephone and written contact. The Monitor will maintain current 
personal knowledge of the study through observation, review of study records and source 
documentation, and discussion of the conduct of the study with the Investigator and staff. 
The Monitor will review source documents, systems and CRFs to ensure overall quality and 
completeness of the data and to confirm study procedures are complied with the requirements in 
the study protocol accurately. The Sponsor, or its designee, will be allowed to conduct site visits 
to the investigation facilities for the purpose of monitoring any aspect of the study. The 
Investigator agrees to allow the Monitor to inspect the drug storage area, study drug stocks, drug 
accountability records, patient charts and study source documents, site standard operating 
procedures and training records, and other records relative to study conduct. 
Where local regulations allow, the Monitor may request remote access to source documents and 
systems. Should this take place, it will be done in a manner that protects the confidentiality of the 
data. 
8.2.3. 
Audits and Inspections 
Periodically, the Sponsor or its authorized representatives audit clinical investigative sites as an 
independent review of core study processes and documents to determine whether these activities 
were conducted, and data were recorded, analyzed, and accurately reported according to the 
protocol, GCP guidelines of the ICH, and any applicable regulatory requirements. A regulatory 
authority, an IEC or an IRB may visit the site to perform audits or inspections, including source 
data verification. The Investigator should contact the Sponsor and designee immediately if 
contacted by a regulatory agency, an IEC, or an IRB about an inspection. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
71 
8.3. 
Publication Policy 
It is intended that after completion of the study, the data are to be submitted for publication in a 
scientific journal and/or for reporting at a scientific meeting. A copy of any proposed publication 
(eg, manuscript, abstracts, oral/slide presentations, book chapters) based on this study, must be 
provided and confirmed received at the Sponsor at least 30 days before its submission. The 
Clinical Trial Agreement will detail the procedures for publications. 
Authorship of any publications resulting from this study will be determined on the basis of the 
Uniform Requirement for Manuscripts Submitted to Biomedical Journals (International 
Committee of Medical Journal Editors). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
72 
9. 
LIST OF REFERENCES 
Angell SY, De Cock KM,Frieden TR. A public health approach to global management of 
hypertension. Lancet. 2015 Feb 28;385(9970):825-7. 
Beeftink MM, van der Sande NG, Bots ML, Doevendans PA, Blankestijn PJ, Visseren FL, et al. 
Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-
to-Control Hypertension. Hypertension. 2017 May;69(5):927-32. 
Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to 
antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011 Mar;29(3):610-8. 
de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M, et al. Prevalence and 
factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension. 
2009 Mar;53(3):466-72. 
Dzau VJ,Balatbat CA. Future of Hypertension. Hypertension. 2019 Sep;74(3):450-7. 
Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of 
Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 
2017 Jan 10;317(2):165-82. 
Georgianos PI,Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding 
drugs. Kidney Int. 2018 Feb;93(2):325-34. 
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK,He J. Global burden of 
hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23. 
Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the 
Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-30. 
McClellan M, Brown N, Califf RM,Warner JJ. Call to Action: Urgent Challenges in 
Cardiovascular Disease: A Presidential Advisory From the American Heart Association. 
Circulation. 2019 Feb 26;139(9):e44-e54. 
McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, et al. Aliskiren, 
Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016 Apr 21;374(16):1521-
32. 
Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP,Crooke RM. Blood Pressure 
Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of 
Hypertension and Kidney Injury. Hypertension. 2017 Sep;70(3):566-76. 
Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, et al. Trends in Blood 
Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020 
Sep 22;324(12):1190-200. 
NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a 
pooled analysis of 1479 population-based measurement studies with 19.1 million participants. 
Lancet. 2017 Jan 7;389(10064):37-55. 
Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and 
a lifecourse strategy to address the global burden of raised blood pressure on current and future 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
73 
generations: the Lancet Commission on hypertension. Lancet. 2016 Nov 26;388(10060):2665-
712. 
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. 
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 
6;367(23):2204-13. 
Peacock E,Krousel-Wood M. Adherence to Antihypertensive Therapy. Med Clin North Am. 
2017 Jan;101(1):229-45. 
Romero CA, Orias M,Weir MR. Novel RAAS agonists and antagonists: clinical applications and 
controversies. Nat Rev Endocrinol. 2015 Apr;11(4):242-52. 
Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE, et al. Medication 
adherence and persistence according to different antihypertensive drug classes: A retrospective 
cohort study of 255,500 patients. Int J Cardiol. 2016 Oct 1;220:668-76. 
Services UDoHaH. The Surgeon General's Call to Action to Control Hypertension. 2020 October 
2020:1-50. 
Uijl E, Mirabito Colafella KM, Sun Y, Ren L, van Veghel R, Garrelds IM, et al. Strong and 
Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen. 
Hypertension. 2019 Jun;73(6):1249-57. 
van der Laan DM, Elders PJM, Boons C, Beckeringh JJ, Nijpels G,Hugtenburg JG. Factors 
associated with antihypertensive medication non-adherence: a systematic review. J Hum 
Hypertens. 2017 Nov;31(11):687-94. 
Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients 
with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 
15;372(3):211-21. 
Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report 
of the American College of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115. 
White WB, Mansoor GA, Tendler BE,Anwar YA. Nocturnal blood pressure epidemiology, 
determinants, and effects of antihypertensive therapy. Blood Press Monit. 1998 Feb;3(1):43-51. 
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH 
Guidelines for the management of arterial hypertension: The Task Force for the management of 
arterial hypertension of the European Society of Cardiology and the European Society of 
Hypertension: The Task Force for the management of arterial hypertension of the European 
Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 
Oct;36(10):1953-2041. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
74 
10. 
APPENDICES 
10.1. 
Measurement of Blood Pressure 
All blood pressure measurements (office, ABPM, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in the 
relevant user manuals.  
The appropriately sized cuff for each modality must be used for all assessments. The arm’s 
circumference at midpoint (halfway between the acromion and olecranon) should be determined 
at screening with a metric tape measure and used to select the appropriately sized blood pressure 
cuff/bladder for each instrument as described in the Study Manual. Unless significant weight loss 
or gain occurs between visits, the patient should use the same cuff/bladder size throughout the 
study. 
At the first Screening visit only, office blood pressure will be measured in both arms to select the 
appropriate arm to use for office blood pressure and HBPM measurements. Unless a concomitant 
condition favors the use of a specific arm, the arm with the higher office SBP should be used for 
all subsequent office blood pressure and HBPM readings. The ABPM should be measured using 
the patient’s nondominant arm. If the patient is ambidextrous, the same arm used for office blood 
pressure and HBPM readings should be used. 
ABPM 
The appropriately sized cuff should be placed on the correct arm following the instructions in the 
Study Manual. In patients taking oral antihypertensives (including those initiated as rescue 
medication), ABPM should be started prior to the morning dose of antihypertensive medication. 
All ABPM collections must be in the outpatient/ambulatory state. During screening, ABPM 
recording should be obtained within 2 weeks prior to randomization. ABPM recordings that are 
associated with dosing visits after Day 1 must be obtained in advance of the visit (within 7 days 
before the corresponding dosing visit) and the results reviewed prior to dosing. 
During the 24-hour monitoring period, patients must avoid strenuous exercise but should 
otherwise maintain their usual level of physical activity. The ABPM is programmed to take 
readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the 
night (10 pm to 5:59 am). While awake, the patient should hold their arm still by their side while 
the device is inflating for a reading. Patients must record the timing of going to sleep, waking up, 
and any oral medications taken during the ABPM, and these responses must be entered into the 
eCRF. 
After the monitoring period is complete, upload the ABPM data to receive a report with validity 
assessment. An ABPM will be considered valid if (1) the number of successful daytime readings 
is ≥33, (2) the number of successful nighttime readings is ≥11, and (3) no more than 3 hours are 
not represented (ie, 3 sections of 60 minutes where 0 valid readings were obtained). If the ABPM 
recording is invalid at any point during the study, the patient will be provided 1 opportunity to 
repeat the recording within 4 days. If the second ABPM recording is also invalid during 
screening, the patient is a screen failure. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
75 
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor and the arm selected during screening. 
Office blood pressure should be measured early in the visit prior to the morning dose of 
antihypertensive medication, before phlebotomy or other potentially stressful assessments. To 
minimize confounding by circadian changes, study visits should be scheduled for a consistent 
timeframe of the day. The use of inhaled short-acting beta agonists should be avoided within 6 
hours prior to measuring blood pressure and/or heart rate. The use of phosphodiesterase type 5 
inhibitors (eg, sildenafil, tadalafil, vardenafil, avanafil) should be avoided within 48 hours prior 
to measuring blood pressure. 
Before measuring blood pressure, confirm that there has been no exercise or use of caffeine or 
nicotine- or tobacco-containing products (including but not limited to snuff, chewing tobacco, 
cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) within the last 30 minutes. If necessary, 
delay blood pressure assessment to meet these requirements. Because a full bladder can impact 
blood pressure measurements, ask the patient to use the bathroom before the assessment. 
All office blood pressure assessments will include both seated and standing measurements.  
Seated Office Blood Pressure Measurement: For seated measurements, the patient should be in a 
comfortable resting position in a chair with their back supported and their feet flat on the floor. 
• Place the appropriately sized cuff on the correct arm with no clothing between the 
patient’s arm and the cuff and with the midpoint of the bladder length positioned over 
the brachial artery (located by palpation). The arm should be supported on an armrest 
or table with mid-cuff at heart level and the palm facing the ceiling. 
• Follow the Study Manual to initiate the automated blood pressure device’s seated 
measurement protocol. This program includes a 5-minute period of rest, followed by 
4 sequential blood pressure measurements at 1-minute intervals. The seated blood 
pressure for the visit will be defined by the average of the last 3 individual 
measurements. 
• During the device’s seated measurement protocol, the staff member should leave the 
room and the patient should remain at rest without distraction (avoid mobile phones). 
The following script may be used: “The blood pressure device works best when you 
are at rest and without any distraction. If you agree, I would like to leave the room for 
the next 10 to 15 minutes while it is recording. This will include a 5-minute period of 
rest, followed by about 5 minutes of the device inflating to measure your blood 
pressure”. 
Standing Office Blood Pressure Measurement: A standing measurement should be obtained 
immediately after collection of the seated measurements. 
• Being careful to maintain the cuff’s position, ask the patient to stand with the cuffed 
arm bent slightly and the hand of the cuffed arm supported at heart level.  
• Using a stopwatch or watch, measure standing blood pressure 1 minute after standing 
by using the automated blood pressure device’s single measurement protocol.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 4, 22 March 2022 
Alnylam Pharmaceuticals 
Confidential 
76 
• After the standing measurement, ask the patient if they experienced dizziness or light-
headedness when standing and enter their response in the eCRF. 
If a patient is unable to report to the site for an office blood pressure assessment, a substitute 
“remote visit blood pressure measurement” may be obtained remotely by a visiting nurse or other 
appropriately trained personnel who will bring an office blood pressure instrument to the 
patient’s location and follow the same procedure performed at the site. If a home visit is not 
possible, a “remote visit blood pressure measurement” should instead be obtained using the 
patient’s HBPM instrument under direct supervision (phone call or teleconferencing) by 
appropriately trained study staff, following the instructions detailed in the Study Manual. Results 
and the remote method used should be entered into the eCRF. 
HBPM 
Patients should measure HBPM in the morning, prior to breakfast/caffeine or taking morning 
oral medications. HBPM is not required at times when ABPM is being assessed. The HBPM 
measurement should be obtained in a room without distractions, seated comfortably with the 
back supported and feet flat on the floor. The patient will initiate the automated blood pressure 
program on their HBPM device. This program includes a 5-minute period of rest, followed by 4 
sequential blood pressure measurements at 1-minute intervals. The seated blood pressure for the 
visit will be defined by the average of the last 3 individual measurements.  
To establish baseline, each patient should measure HBPM during the week (with at least 3 
successful readings) immediately prior to randomization. 
After Day 1, HBPM should be measured at least once per week. Patients may select the day of 
the week that is most convenient for their personal schedule. The frequency of HBPM may be 
increased in some patients, per Investigator discretion, if more frequent measurement is 
warranted (eg, during screening if patients are undergoing washout and during the temporary 
hold of oral antihypertensives performed from Month 5 to Month 6). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
1 
 
CLINICAL STUDY PROTOCOL 
ALN-AGT01-002 
DATED 09 DECEMBER 2021 
 
Protocol Title:  
A Randomized, Double-blind, Placebo-Controlled, 
Dose-Ranging Multicenter Study to Evaluate the 
Efficacy and Safety of ALN-AGT01 in Patients 
with Mild-to-Moderate Hypertension 
Short Title: 
A Study to Evaluate Efficacy and Safety of 
ALN-AGT01 in Patients with Mild-to-Moderate 
Hypertension (KARDIA-1) 
Study Drug: 
ALN-AGT01 (zilebesiran) 
EudraCT Number: 
2021-001248-82 
IND Number: 
143503 
Protocol Date: 
Original protocol, 09 April 2021 
Amendment 1, 20 April 2021 
Amendment 2, 09 June 2021 
Amendment 3, 09 December 2021 
Sponsor: 
Alnylam Pharmaceuticals, Inc. 
300 Third Street 
Cambridge, MA  02142 USA 
Telephone: +1-617-551-8200 
Sponsor Contact: 
 
 
The concepts and information contained in this document or generated during the study are considered 
proprietary and may not be disclosed in whole or in part without expressed written authorization of 
Alnylam Pharmaceuticals, Inc. 
 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
2 
SPONSOR PROTOCOL APPROVAL 
 
I have read this protocol and I approve the design of this study. 
 
 
 
___________________________________________  
 
 
Alnylam Pharmaceuticals, Inc. 
 
___________________________________________  
Date 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
3 
INVESTIGATOR’S AGREEMENT 
 
I have read the ALN-AGT01-002 protocol and agree to conduct the study in accordance with the 
protocol and all applicable regulations. I agree to maintain the confidentiality of all information 
received or developed in connection with this protocol. 
 
 
 
___________________________________________  
Printed Name of Investigator 
 
 
 
___________________________________________  
Signature of Investigator 
 
 
 
___________________________________________  
Date 






Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
6 
of the study design is provided in Figure 1. Before randomization, patients will discontinue prior 
antihypertensive medications (if taking) for a Washout period of at least 2 weeks (4 weeks of 
washout is required for long-acting antihypertensive medications, such as long-acting diuretics or 
calcium channel blockers). Patients who complete the Screening period and meet all 
inclusion/exclusion criteria for enrollment will receive ALN-AGT01 or placebo for the first 
6 months of the 12-month Double-blind (DB) treatment period.  
Starting at Month 3, conventional oral antihypertensives may be added per Investigator 
judgement for elevated blood pressure. Oral antihypertensives (if taking) will be temporarily 
held from Month 5 to Month 6 to assess the effect of ALN-AGT01 alone (vs placebo) at Month 6 
by ambulatory blood pressure monitoring (ABPM). During this 4-week period, blood pressure 
will be carefully monitored by daily home blood pressure monitoring and medications restarted 
if indicated. Patients may resume conventional oral antihypertensives at Month 6 per Investigator 
judgement. 
Patients randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial 
ALN-AGT01 regimens until the end of the DB period. Patients randomized to ALN-AGT01 
regimens will remain on their originally assigned regimens through Month 12. 
After the 12-month DB treatment period, patients may be eligible to participate in an 
ALN-AGT01 open-label extension (OLE) study. If an individual patient reaches Month 12 prior 
to availability of the OLE study, they may continue their current blinded dosing in the DB 
Extension period for up to 12 additional months until the OLE study is open and then transition. 
Number of Planned Patients 
Approximately 375 patients will be enrolled in this study. 
Diagnosis and Main Eligibility Criteria 
This study will include adults (18 to 75 years, inclusive) with untreated hypertension or on stable 
therapy with 1 or more antihypertensive medications. Patients should have a daytime mean 
systolic blood pressure (SBP) ≥135 mmHg and ≤160 mmHg by ABPM after washout of 
background antihypertensive medication. Patients with secondary hypertension or orthostatic 
hypotension will be excluded. 
Study Drug, Dose, and Mode of Administration 
ALN-AGT01 is an SC administered N-acetylgalactosamine-conjugated small interfering RNA 
targeting liver-expressed messenger RNA for angiotensinogen (AGT). 
Patients randomized to receive ALN-AGT01 will be administered 150 mg ALN-AGT01 SC once 
every 6 months, 300 mg ALN-AGT01 SC once every 6 months, 300 mg ALN-AGT01 SC once 
every 3 months, or 600 mg ALN-AGT01 SC once every 6 months during the 12-month DB 
period and DB Extension period. Patients randomized to receive placebo will be randomized to 1 
of the 4 initial dose regimens of ALN-AGT01 beginning at Month 6.  
Reference Treatment, Dose, and Mode of Administration 
Placebo (sodium chloride 0.9% w/v for SC administration) will be administered once every 3 
months and at the same volume as the study drug. Patients receiving once every 6 months 
ALN-AGT01 regimens will receive placebo SC at dosing visits at which they do not receive 
ALN-AGT01 to maintain the blind. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
7 
Duration of Treatment and Study Participation 
The duration of treatment with ALN-AGT01 is up to 24 months. The estimated total time on 
study for each patient is up to 38 months, including up to 2 months of screening, followed by up 
to 24 months of treatment, and up to 12 months in the Follow-up period. 
Statistical Methods 
The planned enrollment for this study is 375 patients. Randomization will be stratified by race 
(black vs all other races) and by baseline blood pressure (mean 24-hour SBP < or ≥145 mmHg). 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline in 
24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 
375 patients (75 per treatment group) provides at least 84% power to detect a dose response 
relationship in SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided 
significance level of 0.05. In addition, this sample size provides at least 80% power to detect a 
10 mmHg difference between an individual ALN-AGT01 dose versus placebo with a 2-sided 
significance level of 0.05.  
The populations (analysis sets) are defined as follows:  
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• Pharmacokinetic (PK) Analysis Set: All patients who received at least 1 full dose of 
ALN-AGT01 and have at least 1 nonmissing postdose PK assessment. 
• PD Analysis Set: All patients who received at least 1 full dose of study drug. All by-
treatment analyses based on the PD Analysis Set will be grouped according to the 
treatment actually received. 
• All ALN-AGT01 Treated Set: All patients who received any amount of 1 of the 4 
ALN-AGT01 dosing regimens, including patients who took ALN-AGT01 during the 
6-month placebo-controlled period and patients who initially took placebo and then 
switched to ALN-AGT01 after the Month 6 visit. 
The primary population used to evaluate efficacy will be the FAS. For the efficacy endpoints of 
change from baseline to Month 3, ALN-AGT01 300 mg once every 3 months and once every 6 
months will be pooled together and analyzed. For all other efficacy endpoints, analysis will be 
performed according to the randomized treatment arm. 
Safety will be analyzed using the Safety Analysis Set. The PK and PD Analysis Sets will be used 
to conduct PK and PD analyses, respectively. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
8 
Figure 1: 
Study Design 
 
Abbreviations: aHTN=antihypertensive medications; DB=double-blind; M=month; OLE=open-label extension; 
PBO=placebo; PO=per os (oral); Q3M=once every 3 months; Q6M=once every 6 months; R=randomization; 
SC=subcutaneous; WO=washout. 
Note: Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the Month 12 
predose assessments. If an individual patient reaches Month 12 prior to availability of the OLE study, they may 
continue their current blinded dosing in the DB Extension period for up to 12 additional months until the OLE study 
is open and then transition. Once the OLE study is open for enrollment, eligible patients may rollover into the OLE 
study at Months 12, 18, or 24 (whichever visit occurs first). 
Note: Patients who were previously taking antihypertensives at screening should undergo a washout of these 
medications for at least 2 weeks during the Screening period (4 weeks of washout is required for long-acting 
antihypertensive medications, such as long-acting diuretics or calcium channel blockers). 












Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
14 
Table 2: 
PK Time Points 
Study Day 
Sampling Time 
(hh:mm) 
Plasma PK Sample 
Day 1  
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Day 169±7 
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Abbreviations: hh:mm=hour:minute; PK=pharmacokinetics. 
Notes:  
• 
The hour (±range) indicates sample collection timing relative to dosing. Precise PK sample times (hour 
and minute) are recorded. Refer to Section 6.4 for additional information on PK assessments. 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
15 
TABLE OF CONTENTS 
SPONSOR PROTOCOL APPROVAL ...........................................................................................2 
INVESTIGATOR’S AGREEMENT ...............................................................................................3 
PROTOCOL SYNOPSIS ................................................................................................................4 
TABLE OF CONTENTS ...............................................................................................................15 
LIST OF TABLES .........................................................................................................................19 
LIST OF FIGURES .......................................................................................................................19 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ................................................20 
1. 
INTRODUCTION ......................................................................................................22 
1.1. 
Study Rationale ...........................................................................................................22 
1.2. 
Background .................................................................................................................22 
1.3. 
Benefit-Risk Assessment ............................................................................................23 
2. 
OBJECTIVES AND ENDPOINTS ............................................................................24 
3. 
INVESTIGATIONAL PLAN .....................................................................................26 
3.1. 
Summary of Study Design ..........................................................................................26 
3.2. 
Scientific Rationale for Study Design ........................................................................27 
3.3. 
Justification for Dose ..................................................................................................29 
3.4. 
Method of Assigning Patients to Treatment Groups ..................................................29 
3.5. 
Blinding ......................................................................................................................30 
3.5.1. 
Emergency Unblinding ...............................................................................................30 
3.6. 
Data Monitoring Committee .......................................................................................31 
3.7. 
Clinical Event Adjudication Committees ...................................................................31 
3.8. 
Definition of End of Study for an Individual Patient .................................................31 
4. 
SELECTION AND REMOVAL OF PATIENTS ......................................................31 
4.1. 
Inclusion Criteria ........................................................................................................31 
4.2. 
Exclusion Criteria .......................................................................................................32 
4.3. 
Removal from Study Drug or Assessment .................................................................34 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments ......................34 
4.3.2. 
Stopping a Patient’s Study Participation ....................................................................36 
4.3.2.1. 
Patient or Legal Guardian Stops Participation in the Study .......................................36 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection 
to Process Patient’s Personal Data ..............................................................................36 
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study ........................36 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
16 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation ................................37 
4.3.3. 
Lost to Follow-Up.......................................................................................................37 
4.3.4. 
Replacement of Study Patients ...................................................................................37 
5. 
TREATMENTS AND OTHER REQUIREMENTS ..................................................37 
5.1. 
Treatments Administered ............................................................................................37 
5.2. 
Study Drug ..................................................................................................................38 
5.2.1. 
Description ..................................................................................................................38 
5.2.2. 
Dose and Administration ............................................................................................38 
5.2.3. 
Dose Modifications .....................................................................................................39 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping 
Study Drug Dosing .....................................................................................................39 
5.2.5. 
Neurological Criteria for Withholding, Monitoring, and Stopping Study 
Drug Dosing ................................................................................................................40 
5.2.6. 
Preparation, Handling, and Storage ............................................................................40 
5.2.7. 
Packaging and Labeling ..............................................................................................41 
5.2.8. 
Accountability .............................................................................................................41 
5.3. 
Clinical Product Complaints .......................................................................................41 
5.3.1. 
Definition ....................................................................................................................41 
5.3.2. 
Reporting ....................................................................................................................41 
5.4. 
Monitoring for Potential Clinical Events ....................................................................41 
5.4.1. 
Monitoring and Approach for Potential Hypotension ................................................41 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure 
Elevation .....................................................................................................................42 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction .......................................44 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia ..............................................45 
5.5. 
Concomitant Medications and Procedures .................................................................46 
5.5.1. 
Oral Antihypertensive Medication .............................................................................46 
5.5.2. 
Prohibited Concomitant Medication ...........................................................................46 
5.6. 
Treatment Compliance ................................................................................................47 
5.7. 
Other Requirements ....................................................................................................47 
5.7.1. 
Contraception ..............................................................................................................47 
5.7.2. 
Alcohol Restrictions ...................................................................................................48 
5.7.3. 
Tobacco and Nicotine Restrictions .............................................................................48 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
17 
5.7.4. 
Dietary Recommendations ..........................................................................................48 
5.7.5. 
Exercise .......................................................................................................................49 
6. 
STUDY ASSESSMENTS ..........................................................................................49 
6.1. 
Screening Assessments ...............................................................................................49 
6.1.1. 
Retesting .....................................................................................................................49 
6.1.2. 
Rescreening .................................................................................................................49 
6.2. 
Efficacy Assessments .................................................................................................50 
6.2.1. 
ABPM .........................................................................................................................50 
6.2.2. 
Office Blood Pressure .................................................................................................50 
6.2.3. 
HBPM .........................................................................................................................51 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment ....................................................51 
6.3. 
Pharmacodynamic Assessments .................................................................................51 
6.4. 
Pharmacokinetic Assessments ....................................................................................51 
6.5. 
Safety Assessments .....................................................................................................52 
6.5.1. 
Vital Signs ..................................................................................................................52 
6.5.2. 
Weight, Height, and Morphometrics ..........................................................................52 
6.5.3. 
Physical Examination .................................................................................................53 
6.5.4. 
Electrocardiogram .......................................................................................................53 
6.5.5. 
Clinical Laboratory Assessments ...............................................................................53 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments ........................................................55 
6.5.5.2. 
Immunogenicity ..........................................................................................................55 
6.5.5.3. 
Pregnancy Testing ......................................................................................................55 
6.5.5.4. 
Additional Liver Function Assessments .....................................................................56 
6.5.6. 
Adverse Events ...........................................................................................................57 
6.5.6.1. 
Definitions ..................................................................................................................57 
6.5.6.2. 
Eliciting and Recording Adverse Events ....................................................................58 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee .........................59 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee ...........59 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities .................................................60 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee ........................................................................60 
6.5.6.7. 
Pregnancy Reporting ..................................................................................................60 
6.5.6.8. 
Overdose and Other Special Situations Reporting .....................................................61 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
18 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository ...................................61 
7. 
STATISTICS ..............................................................................................................62 
7.1. 
Determination of Sample Size ....................................................................................62 
7.2. 
Statistical Methodology ..............................................................................................62 
7.2.1. 
Populations to be Analyzed ........................................................................................62 
7.2.2. 
Examination of Subgroups .........................................................................................63 
7.2.3. 
Handling of Missing Data ...........................................................................................63 
7.2.4. 
Baseline Evaluations ...................................................................................................63 
7.2.5. 
Efficacy Analyses .......................................................................................................63 
7.2.6. 
Pharmacodynamic Analysis........................................................................................64 
7.2.7. 
Pharmacokinetic Analysis ..........................................................................................64 
7.2.8. 
Safety Analyses ..........................................................................................................64 
7.2.9. 
Immunogenicity Analyses ..........................................................................................65 
7.2.10. 
Interim Analysis ..........................................................................................................65 
7.2.11. 
Optional Additional Research .....................................................................................65 
8. 
STUDY ADMINISTRATION ...................................................................................65 
8.1. 
Ethical and Regulatory Considerations ......................................................................65 
8.1.1. 
Informed Consent .......................................................................................................65 
8.1.2. 
Ethical Review ............................................................................................................66 
8.1.3. 
Serious Breach of Protocol .........................................................................................66 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention .................................67 
8.1.5. 
End of Study ...............................................................................................................67 
8.1.6. 
Termination of the Clinical Study or Site Closure .....................................................67 
8.2. 
Data Quality Control and Quality Assurance .............................................................68 
8.2.1. 
Data Handling .............................................................................................................68 
8.2.2. 
Study Monitoring ........................................................................................................68 
8.2.3. 
Audits and Inspections ................................................................................................68 
8.3. 
Publication Policy .......................................................................................................68 
9. 
LIST OF REFERENCES ............................................................................................70 
10. 
APPENDICES ............................................................................................................72 
10.1. 
Measurement of Blood Pressure .................................................................................72 
 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
19 
LIST OF TABLES 
Table 1: 
Schedule of Assessments ..............................................................................................9 
Table 2: 
PK Time Points ...........................................................................................................14 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative 
Cause Identified ..........................................................................................................39 
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation ......................................................................................................43 
Table 5: 
Recommended Interventions for Hyperkalemia .........................................................45 
Table 6: 
Clinical Laboratory Assessments ...............................................................................54 
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases .............56 
Table 8: 
Statistical Power to Detect 10 mmHg Difference Between ALN-AGT01 and 
Placebo With Various Standard Deviation Assumptions ...........................................62 
 
LIST OF FIGURES 
Figure 1: 
Study Design .................................................................................................................8 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
20 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation  
Definition 
ABPM 
Ambulatory blood pressure monitoring 
ACE 
Angiotensin converting enzyme 
ADA 
Anti-drug antibody(ies) 
AE 
Adverse event 
AGT 
Angiotensinogen 
ALT 
Alanine aminotransferase 
AngI/II 
Angiotensin I/II 
ARB 
Angiotensin II-receptor blocker 
AST 
Aspartate aminotransferase 
CCB 
Calcium channel blocker 
CPC 
Clinical product complaint 
DB 
Double-blind 
DBP 
Diastolic blood pressure 
DMC 
Data Monitoring Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eGFR 
Estimated glomerular filtration rate 
EOT 
End of treatment 
ET 
Early termination 
FAS 
Full analysis set 
GalNAc 
N-acetylgalactosamine 
GCP 
Good Clinical Practice 
HbA1c 
Hemoglobin A1c 
HBPM 
Home blood pressure monitoring 
HCV 
Hepatitis C virus 
HDL-C 
High-density lipoprotein 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use 
IEC 
Independent Ethics Committee 
INR 
International normalized ratio 
IRB 
Institutional Review Board 
IRT 
Interactive Response Technology 
ISR 
Injection site reaction 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
21 
Abbreviation  
Definition 
LFT 
Liver function test 
MAO 
Monoamine oxidase 
MCP-Mod 
Multiple comparison-modeling 
mRNA 
Messenger RNA 
NSAID 
Nonsteroidal anti-inflammatory drug 
OLE 
Open-label extension 
PD 
Pharmacodynamic(s) 
PK 
Pharmacokinetic(s) 
PT 
Preferred term 
q3M 
Once every 3 months 
q6M 
Once every 6 months 
RAAS 
Renin-angiotensin-aldosterone system 
RNAi 
RNA interference 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SBP 
Systolic blood pressure 
SC 
Subcutaneous(ly) 
siRNA 
Small interfering RNA 
SGLT2 
Sodium-glucose co-transporter 2 
SOC 
System Organ Class 
ULN 
Upper limit of normal 
ZS-9 
Sodium zirconium cyclosilicate 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
22 
1. 
INTRODUCTION 
Alnylam Pharmaceuticals, Inc. (the Sponsor) is developing ALN-AGT01 (zilebesiran), a 
subcutaneously (SC) administered investigational agent comprised of a synthetic small 
interfering (siRNA) covalently linked to a triantennary N-acetylgalactosamine (GalNAc) ligand, 
which is designed to suppress liver production of angiotensinogen (AGT) and thereby reduce 
blood pressure in individuals with hypertension.  
1.1. 
Study Rationale 
Study ALN-AGT01-002 (KARDIA-1) is a randomized, double-blind, placebo-controlled, dose-
ranging, multicenter Phase 2 study designed to evaluate the safety, efficacy, and 
pharmacodynamics (PD) of ALN-AGT01, administered SC, in patients with mild-to-moderate 
hypertension. Patients will be randomized to 1 of 4 ALN-AGT01 treatment regimens or placebo 
for the first 6 months of the 12-month Double-blind (DB) period. After the first 6 months of the 
DB period, patients from the placebo arm will be re-randomized to 1 of the 4 initial 
ALN-AGT01 regimens for the remaining 6 months of the DB period, while patients randomized 
to ALN-AGT01 will remain on their originally assigned regimens. After completion of the 
12-month DB period, patients may be eligible to participate in an ALN-AGT01 open-label 
extension (OLE) study. If an individual patient reaches Month 12 prior to availability of the OLE 
study, they may continue their current blinded dosing in the DB Extension period for up to 12 
additional months until the OLE study is open and then transition. 
The primary objective of the study is to evaluate the efficacy of ALN-AGT01 for the treatment 
of hypertension by evaluating the impact on systolic blood pressure (SBP) from baseline to 
Month 3, as assessed by ambulatory blood pressure monitoring (ABPM). Secondary and 
exploratory objectives of the study include evaluating the efficacy of ALN-AGT01 on other 
measures of blood pressure response and evaluating the PD effect of ALN-AGT01, including 
reduction in circulating AGT concentration. 
The full rationale for the study and design is presented in Section 3.2. 
1.2. 
Background 
Hypertension affects 30% to 45% of adults and is the strongest modifiable risk factor for 
cardiovascular disease, primarily strokes and myocardial infarction.[Olsen 2016; Williams 2018] 
The worldwide disease burden is profound, with a global prevalence of over 1 billion,[Kearney 
2005; NCD Risk Factor Collaboration 2017] and approximately 9 million deaths attributed to 
hypertension annually.[Angell 2015] 
Currently available pharmacologic therapies achieve target blood pressure in only a minority of 
patients, due in large part to physician inertia and patient nonadherence to daily oral 
medication.[Whelton 2018; Williams 2018] Low adherence to oral antihypertensives is 
associated with poor cardiovascular outcomes and is prevalent at all stages of disease.[Corrao 
2011; Peacock and Krousel-Wood 2017; Schulz 2016; van der Laan 2017] Thus, despite the 
availability of multiple efficacious agents, current rates of control are low, and the global burden 
of death and disability-adjusted life-years attributed to elevated blood pressure remains 
high.[Forouzanfar 2017; Muntner 2020] Development of new approaches to treat hypertension 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
23 
and to overcome the limitations of current therapies is a key unmet need.[Dzau and Balatbat 
2019; McClellan 2019; Services 2020] 
The Sponsor is developing ALN-AGT01, a novel synthetic RNA interference (RNAi) 
therapeutic, for SC administration for the treatment of hypertension. RNAi is a naturally 
occurring cellular mechanism for regulation of gene expression, mediated through the binding of 
siRNA to its complementary messenger RNA (mRNA) sequence, leading to mRNA cleavage 
and subsequent suppression of the synthesis and levels of the target protein. ALN-AGT01 
contains an siRNA targeting AGT mRNA, conjugated to a GalNAc-containing ligand to facilitate 
delivery to the liver. Based on the mechanism of RNAi, ALN-AGT01 is specifically designed to 
reduce the hepatic synthesis of AGT protein, the first substrate in the renin-angiotensin-
aldosterone system (RAAS) and the sole precursor of vasoactive angiotensin peptides.[Khanna 
2017; Romero 2015] Because hepatocytes are the predominant source of circulating AGT, 
ALN-AGT01 has been developed to reduce blood pressure by decreasing circulating AGT levels 
and the downstream effects of angiotensin II (AngII). 
Preliminary data from Part A of the ongoing Phase 1 Study ALN-AGT01-001 (hereafter referred 
to as Study 001) in patients with hypertension have shown that single SC doses of ALN-AGT01 
lead to dose-dependent and durable reductions in circulating AGT, accompanied by clinically 
significant reductions in SBP and diastolic blood pressure (DBP). Reductions in AGT for up to 
6 months postdose were observed in the study.  
Most adverse events (AEs) have been mild or moderate in severity, and there have been no 
severe or serious adverse events (SAEs) related to study drug. There have been no clinically 
significant elevations in serum creatinine or serum potassium, and no patient has required 
intervention for low blood pressure. No clinically significant alanine aminotransferase (ALT) 
elevations have been observed in Part A patients who received ALN-AGT01 doses as high as 
800 mg. Injection site reactions (ISRs) were reported in a minority of patients and were all mild 
and transient events that resolved without intervention. 
This Phase 2 study will further quantify the antihypertensive effects of ALN-AGT01 across a 
range of doses (150 to 600 mg) and dose intervals (once every 3 months and once every 6 
months) to identify optimal treatment. The consistent and prolonged PD effect of ALN-AGT01 
is expected to achieve the unique benefit of continuous 24-hour blood pressure lowering with 
infrequent SC dosing.  
A detailed description of the chemistry, pharmacology, efficacy, and safety of ALN-AGT01 is 
provided in the Investigator’s Brochure. 
1.3. 
Benefit-Risk Assessment 
Clinical data available from Study 001 indicate that ALN-AGT01 may offer the benefit of blood 
pressure reduction to patients with hypertension. The mean SBP reduction observed after single 
ALN-AGT01 doses of 100 mg or higher exceeds 10 mmHg, which is comparable to the effect of 
conventional antihypertensives. The blood pressure of patients will be closely monitored, and 
after Month 3, oral antihypertensives will be added as needed to control blood pressure. 
Given the mechanism of action and mode of administration of ALN-AGT01, potential 
theoretical risks include liver transaminase elevations and ISRs. Like any antihypertensive 
therapy, there is also a theoretical risk of hypotension with ALN-AGT01. Based upon the disease 






Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
26 
3. 
INVESTIGATIONAL PLAN 
3.1. 
Summary of Study Design 
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study 
designed to evaluate the safety, efficacy, and PD of ALN-AGT01, administered SC, in patients 
with mild-to-moderate hypertension. A schematic of the study design is provided in Figure 1. 
Before randomization, patients will discontinue prior antihypertensive medications (if taking) for 
a Washout period of at least 2 weeks (4 weeks of washout is required for long-acting 
antihypertensive medications, such as long-acting diuretics or calcium channel blockers [CCBs]).  
DB and DB Extension Periods 
Patients who complete the Screening period and meet all inclusion/exclusion criteria for 
enrollment will be randomized 1:1:1:1:1 to receive 1 of the following regimens over a 12-month 
DB treatment period. Randomization will be stratified by race (black vs all other races) and by 
baseline blood pressure (mean 24-hour SBP < or ≥145 mmHg).  
• Placebo SC once every 3 months, with re-randomization (1:1:1:1) at Month 6 to 1 of 
the initial 4 ALN-AGT01 regimens 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients receiving once every 6 month ALN-AGT01 regimens will receive placebo SC at dosing 
visits at which they do not receive ALN-AGT01 to maintain the blind. 
At Month 3, conventional oral antihypertensives may be added per Investigator judgement for 
daytime mean SBP ≥135 mmHg by ABPM. After Month 3, oral antihypertensive medications 
may also be added per Investigator judgement for persistent elevations in blood pressure above 
target (target defined as office SBP <140 mmHg, home blood pressure monitoring [HBPM] SBP 
<135 mmHg, or daytime mean SBP <135 mmHg by ABPM). Oral antihypertensives (if taking) 
will be temporarily held from Month 5 to Month 6 in appropriate patients (Month 5 office SBP 
<155 mmHg if taking 1 oral antihypertensive agent or office SBP <150 mmHg if taking 2 
agents) to assess the effect of ALN-AGT01 alone (vs placebo) at Month 6 by ABPM. During this 
4-week period, blood pressure will be carefully monitored by daily HBPM and oral 
antihypertensive medications restarted if confirmed office SBP >170 mmHg (or if confirmed 
office SBP >160 mmHg accompanied by symptoms). 
Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the 
Month 12 predose assessments. If an individual patient reaches Month 12 prior to availability of 
the OLE study, they may continue their current blinded dosing in the DB Extension period for up 
to 12 additional months until the OLE study is open and then transition. Once the OLE study is 
open for enrollment, eligible patients may rollover into the OLE study at Months 12, 18, or 24 
(whichever visit occurs first). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
27 
In the DB Extension period, blood pressure will be closely monitored and individual 
modification of antihypertensive therapy will be allowed to maintain blood pressure in target 
range.  
Safety Follow-up Period 
Patients who discontinue study drug or do not enroll in the separate ALN-AGT01 OLE study 
will be asked to complete Safety Follow-up visits once every 6 months after their last dose of 
study drug until serum AGT levels return to ≥50% of their individual mean baseline level (if 
known) or until 12 months after their last dose of study drug, whichever comes earlier. 
Patients who discontinue study drug prior to the Month 6 visit will also be asked to complete the 
remainder of scheduled study visits and assessments (except for study drug administration) 
through Month 6. If a patient discontinues study drug after the Month 6 visit, end of treatment 
(EOT)/early termination (ET) assessments should be performed. 
The planned enrollment for this study is approximately 375 patients (75 patients per group). 
The duration of treatment with ALN-AGT01 is up to 24 months. The estimated total time on 
study for each patient is up to 38 months, including up to 2 months of screening, followed by up 
to 24 months of treatment, and up to 12 months in the Follow-up period. 
3.2. 
Scientific Rationale for Study Design 
This is a randomized, double-blind, placebo-controlled, dose-ranging, multicenter Phase 2 study 
designed to evaluate the safety, efficacy, and PD of ALN-AGT01, administered SC, in patients 
with mild-to-moderate hypertension. The primary objective of the study is to evaluate the 
efficacy of ALN-AGT01 by measuring the impact on SBP from baseline to Month 3, as assessed 
by ABPM.  
This study will quantify the antihypertensive effects of ALN-AGT01 across a range of doses and 
dose intervals to identify optimal treatment regimens for study in Phase 3. 
Patients will discontinue prior antihypertensive medications (if taking) for 2 to 4 weeks prior to 
study drug administration. During the study, blood pressure will be monitored with both 
outpatient 24-hour ABPM and automated office blood pressure measurements 
(EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical Investigation of Medicinal Products in 
the Treatment of Hypertension, 2016). The primary endpoint will be assessed by ABPM given its 
greater precision over office blood pressure measurements. In addition, 24-hour ABPM can 
assess short-term blood pressure variability and circadian patterns (including potential restoration 
of the normal nocturnal blood pressure dipping pattern that is lost in 21% to 35% of hypertensive 
patients).[de la Sierra 2009; White 1998] More frequent measurements will be collected through 
a third method, oscillometric HBPM, to assess long-term blood pressure variability and provide 
close safety monitoring for potential hypotension (or hypertension) while not in the clinic. 
As recommended by current guidance (International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use [ICH] Principles for Clinical Evaluation of 
New Antihypertensive Drugs, 2000 and EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical 
Investigation of Medicinal Products in the Treatment of Hypertension, 2016), the first 6 months 
of the DB period is designed as a randomized, placebo-controlled, parallel-group study. To 
adhere to best ethical standards for the treatment of patients with hypertension, individual 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
28 
modification of oral antihypertensive medications per Investigator judgement to maintain blood 
pressure within target is permitted starting at Month 3 and will continue throughout the study 
(except between Month 5 and Month 6 as described in Section 3.1). Separate from these treat-to-
target modifications, any confirmed event of severe hypertension (office SBP ≥180 mmHg or 
DBP ≥120 mmHg) will be appropriately treated regardless of its timing relative to study drug 
administration. 
If a patient requires treatment with a conventional oral antihypertensive before Month 6, a CCB 
and/or thiazide/thiazide-like diuretic will be added because there is extensive experience 
combining these classes with antihypertensive drugs that impact the RAAS. Additionally, their 
blood pressure effects are expected to washout within 2 to 4 weeks.  
Rigorous assessment of the antihypertensive effects of ALN-AGT01 at Month 6 (trough for the 
once every 6 month regimens) relative to placebo is critical to evaluate the feasibility of once 
every 6 month dosing regimens for future study in Phase 3. Accordingly, oral antihypertensives 
(if taking) will be temporarily held from Month 5 to the Month 6 ABPM assessment. For each 
patient, this limited interruption in oral antihypertensives will be contingent upon the patient’s 
Month 5 office SBP being adequately controlled (see Table 4) and the Investigator’s assessment 
that interruption can be safely performed and carefully monitored by daily HBPM 
measurements. Of note, a withdrawal period is a standard element in studies of oral 
antihypertensives that is often used to establish assay sensitivity, to demonstrate maintenance of 
efficacy, and to assess possible withdrawal effects (ICH E12A; Principles for Clinical Evaluation 
of New Antihypertensive Drugs, 2000). Outside of research studies, antihypertensives are 
temporarily discontinued in clinical practice for diagnostic purposes, and interruptions up to 6 
weeks have been shown to be safe.[Beeftink 2017] In this study, the period of interruption is 
limited to 4 weeks, and most patients are expected to have continued antihypertensive effect 
from ALN-AGT01. If a clinically significant blood pressure elevation (confirmed SBP >170 
mmHg; or SBP >160 mmHg accompanied by symptoms) occurs after the interruption of oral 
antihypertensives, Investigators will instruct the patient to promptly resume dosing with their 
existing supply of oral medication.  
After Month 6, other oral antihypertensives may be used at the discretion of the Investigator, 
following current care guidelines.[Whelton 2018; Williams 2018] Because ALN-AGT01 acts on 
the RAAS, the use of conventional RAAS inhibitors (angiotensin II-receptor blocker [ARB], 
angiotensin converting enzyme [ACE] inhibitors, or direct renin inhibitors) as rescue agents for 
high blood pressure will be avoided throughout this study. Blood pressure and pharmacokinetic 
(PK)/PD assessments will be collected through Month 12 to assess the effect of repeated dosing. 
While tissue specificity of ALN-AGT01 for the liver is hypothesized to improve tolerability 
relative to current oral antihypertensives,[Mullick 2017; Uijl 2019] the protocol’s monitoring 
plan is designed to meet the standards set by prior studies of conventional RAAS 
inhibitors,[McMurray 2016; Parving 2012] with improvements to include the use of the newer 
oral potassium binder patiromer (or with sodium zirconium cyclosilicate [ZS-9]), if available, for 
treatment of potential hyperkalemia.[Georgianos and Agarwal 2018; Weir 2015] The risk of 
renal safety events is further mitigated in this study by its eligibility criteria, which exclude 
patients who are at highest risk to have events (estimated glomerular filtration rate [eGFR] <30 
mL/min/1.73m2, baseline serum potassium >5 mEq/L, poorly controlled diabetes, or severely 
increased albuminuria) and those who may have decreased tolerance for renal safety events 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
29 
(patients with clinically significant heart failure, valvular heart disease, or recent history of 
cardiovascular event).  
3.3. 
Justification for Dose 
The doses of ALN-AGT01 in this study were selected on the basis of data from the Phase 1 
Study 001, in which single ALN-AGT01 doses up to 800 mg were found to have an acceptable 
safety profile, and clinically significant placebo-corrected reductions in mean SBP >10 mmHg 
by 24-hour ABPM were observed after doses as low as 100 mg. Dose selection was guided by 
the principle of evaluating doses that are well tolerated and predicted to result in a range of PD 
effects (ie, lowering of serum AGT) and antihypertensive responses. This is expected to enable 
development of population average dose-response relationships for PD and efficacy to guide 
identification of optimal treatment regimens (dose and dose frequency) for Phase 3.  
Preliminary PK/PD modeling based on serum AGT data from Study 001 indicates that 
ALN-AGT01 results in a dose-dependent lowering of serum AGT, with maximum reductions 
predicted to be achieved as early as 1 month postdose and significant reductions sustained for 
close to 6 months after dosing. Modeling of the relationship between serum AGT lowering and 
blood pressure suggests a log-linear relationship, with ≥92% reduction in serum AGT predicted 
to achieve median SBP reduction of ≥10 mmHg.  
Based on these, the once every 6 month doses of 150, 300, and 600 mg were selected to result in 
median serum AGT reductions of 81.9%, 89.4%, and 94.9%, respectively, at trough (Month 6), 
translating to median SBP reductions of 6.67 mmHg, 8.74 mmHg, and 11.6 mmHg, respectively. 
Thus, the selected doses will enable characterization of the dose-response relationships for serum 
AGT and blood pressure with the once every 6 month regimen. 
The selected doses also enable characterization of the dose-response relationships for serum 
AGT and blood pressure with once every 3 month regimens based on analysis of data from all 
arms at Month 3. This will provide support for development of a once every 3 month regimen, if 
desired. To this end, 300 mg once every 3 months will be evaluated to identify any cumulative 
effects. The 300 mg once every 3 months dose is predicted to result in median serum AGT 
reductions of >95% at trough (Month 3), translating to median SBP reductions of >10 mmHg.  
Thus, data from the current study will enable robust characterization of PD and efficacy of once 
every 3 month and once every 6 month regimens of ALN-AGT01 and guide further development 
of ALN-AGT01 as an antihypertensive therapeutic that results in reduction of blood pressure by 
≥10 mmHg throughout the dosing interval with infrequent administration. 
3.4. 
Method of Assigning Patients to Treatment Groups 
Using the Interactive Response Technology (IRT), patients will be randomized 1:1:1:1:1 to the 
following arms during the first 6 months of the 12-month DB period: 
• Placebo SC once every 3 months 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
30 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients initially randomized to placebo will be re-randomized 1:1:1:1 at Month 6 to 1 of the 4 
initial ALN-AGT01 regimens. 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. 
Randomization will be stratified by race (black vs all other races) and by baseline blood pressure 
(mean 24-hour SBP < or ≥145 mmHg). 
Each patient will be uniquely identified in the study by a combination of the site number and 
patient identification number. Upon signing the informed consent form (ICF), the patient will be 
assigned a patient identification number by the IRT system. The Investigator or his/her designee 
will randomize the patient in IRT after confirming that the patient fulfills all the inclusion criteria 
and none of the exclusion criteria. The Investigator or his/her designee will re-randomize the 
patient in IRT at Month 6 to assign placebo patients to 1 of the 4 initial ALN-AGT01 dose 
groups. 
3.5. 
Blinding 
The Sponsor, all site personnel (except for the site pharmacist or delegate), and patients will be 
blinded to study drug treatment through Month 6 of the 12-month DB period. After the last 
patient completes the Month 3 visit and prior to the last patient’s Month 6 visit, serum AGT, PK, 
and a limited amount (ie, one-third) of SBP data and treatment assignment using dummy IDs will 
be made available to a small, independent pharmacometrics team at the Sponsor that will not be 
involved in the conduct or oversight of the study. After the database lock to support the analysis 
of Month 6 data is complete, all other Sponsor personnel will be unblinded to treatment 
assignment, but the site personnel (except for the site pharmacist) and patients will remain 
blinded to treatment assignment until after the analysis of Month 12 data is complete. The 
Sponsor and all site personnel will be blinded to serum AGT results until their respective 
unblinding. Serum AGT results will not be reported to site personnel until the last patient 
completes the assessments at the Month 12 visit. 
Blinded doses of study drug will be administered under the supervision of the Investigator (see 
Section 5.2.2). All patients will receive the same volume and number of injections regardless of 
treatment assignment (patients receiving once every 6 month ALN-AGT01 regimens will receive 
placebo SC at dosing visits at which they do not receive ALN-AGT01 to maintain the blind). 
Because ALN-AGT01 may be slightly visually distinguishable from placebo, all blinded study 
drug doses will be prepared and the syringe(s) will be masked by a site pharmacist or delegate 
prior to administration by a blinded healthcare professional. See the Pharmacy Manual for 
additional details. 
3.5.1. 
Emergency Unblinding 
If the treating physician determines that the clinical management of the patient requires 
knowledge of the study drug assignment, the Investigator may break the blind, as necessary, in 
IRT. If time permits, clinical study center personnel should contact the Medical Monitor before 
unblinding to discuss the need to unblind the patient but must do so within 1 working day after 
the unblinding event. Unblinding information should be limited to the fewest number of people 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
31 
on a need-to-know basis. A record of when the blind was broken, who was unblinded, who broke 
the blind, and why it was broken, will be maintained in the electronic trial master file. 
Refer to the IRT instructions for details on emergency unblinding. 
3.6. 
Data Monitoring Committee 
An independent DMC will oversee the safety and overall conduct of this study. The DMC will 
operate under the rules of a charter that will be reviewed and approved at the organizational 
meeting of the DMC. Details are provided in the DMC Charter. 
3.7. 
Clinical Event Adjudication Committees 
An independent Clinical Event Adjudication Committee of 2 or more nephrologists will review 
renal events blinded to treatment assignment to adjudicate whether they meet diagnostic criteria 
for acute kidney injury and, if so, their potential staging and contributing factors. Details are 
provided in the Renal Event Adjudication Committee charter. 
3.8. 
Definition of End of Study for an Individual Patient 
A patient is considered to have reached the end of the study if the patient: 
• has completed at least the Month 12 visit and enrolled in the OLE study, or 
• has completed the Safety Follow-up visits as described in Section 3.1 for patients who 
discontinue study drug or do not enroll in the OLE study. 
A definition of the end of the overall study is provided in Section 8.1.5. 
4. 
SELECTION AND REMOVAL OF PATIENTS 
4.1. 
Inclusion Criteria 
Patients are eligible to be included in the study if all the following criteria apply: 
Age and Sex 
1. Age 18 to 75 years, inclusive 
2. Male or female 
Patient and Disease Characteristics 
3. Has untreated hypertension (not taking antihypertensive medication) or is on stable 
therapy with 1 or more antihypertensive medications. In general, stable therapy is defined 
as having no change in antihypertensive medication or dose within 30 days prior to 
screening.  
4. Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive 
medication. Patients previously taking medication for hypertension must be without 
antihypertensives for ≥2 weeks prior to this ABPM (4 weeks of washout is required for 
long-acting antihypertensive medications, such as long-acting diuretics [eg, 
chlorthalidone] or CCBs [eg, amlodipine]). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
32 
Informed Consent 
5. Patient is able to understand and is willing and able to comply with the study 
requirements and to provide written informed consent. 
4.2. 
Exclusion Criteria 
Patients are excluded from the study if any of the following criteria apply: 
Disease-specific Conditions 
1. Secondary hypertension 
2. Orthostatic hypotension (symptomatic or asymptomatic), defined as a fall of ≥20 mmHg 
SBP or ≥10 mmHg DBP within approximately 1 to 3 minutes of standing up from a 
seated position by office blood pressure. 
Laboratory Assessments 
3. Has any of the following laboratory parameter assessments after at least 2 to 4 weeks of 
washout:  
a. ALT or aspartate aminotransferase (AST) >2× upper limit of normal (ULN) 
b. Total bilirubin >1.5×ULN. Patients with elevated total bilirubin that is secondary to 
documented Gilbert’s syndrome are eligible if the total bilirubin is <2×ULN 
c. International normalized ratio (INR) >2.0 (patients on oral anticoagulant [eg, 
warfarin] with an INR <3.5 will be allowed) 
d. Elevated potassium >5 mEq/L  
e. eGFR of ≤30 mL/min/1.73m2 (calculation will be based on the Modification of Diet 
in Renal Disease formula)  
Prior/Concomitant Therapy 
4. Received an investigational agent within the last 30 days before randomization or are in 
follow-up of another clinical study prior to study enrollment. Any agent that has received 
health agency authorization (including for emergency use) by local or regional regulatory 
authorities is not considered investigational. 
5. Currently taking, taken within 30 days prior to randomization, or anticipated to receive 
during the study treatment period any medication or herbal supplement known to 
significantly affect blood pressure (with the exception of medications for the treatment of 
essential hypertension). Patients who require medications such as monoamine oxidase 
(MAO) inhibitors that are associated with hypertensive crisis should be 
excluded.[Whelton 2018]  
6. Currently taking beta blockers and unable to undergo a washout at least 2 weeks prior to 
randomization 
7. Changes, such as initiation or discontinuation, of sodium-glucose co-transporter 2 
(SGLT2) inhibitor therapy within 30 days prior to screening. Patients on a stable dose of 
SGLT2 therapy for at least 30 days prior to screening with no anticipated changes during 
the study treatment period are permitted. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
33 
8. Prescription nonsteroidal anti-inflammatory drugs (NSAIDs) are not permitted. Patients 
receiving low-dose aspirin (defined as ≤100 mg per day) for at least 30 days prior to 
screening are permitted. Paracetamol/acetaminophen for analgesia will be allowed.  
9. Anticipates using organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, 
isosorbide dinitrate, pentaerythritol) during the study treatment period 
10. Currently taking, taken within 6 months prior to randomization, or anticipated to receive 
an RNAi therapeutic (approved or investigational) during the study 
Medical Conditions 
11. Current or prior history of intolerance to an ARB, ACE inhibitor (other than cough), or 
direct renin inhibitor 
12. Medical condition, other than hypertension, that requires treatment with a RAAS 
inhibitor 
13. History of multiple drug allergies or history of allergic reaction to an oligonucleotide or 
to GalNAc 
14. Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus (hemoglobin A1c 
[HbA1c] >8.0%), newly diagnosed Type 2 diabetes mellitus (within 6 months prior to 
randomization), or laboratory evidence of diabetes during screening (fasting plasma 
glucose ≥126 mg/dL [7.0 mmol/L], random plasma glucose ≥200 mg/dL [11.1 mmol/L], 
or HbA1c ≥6.5%) without known diagnosis of diabetes 
15. History of severely increased albuminuria (urine albumin:creatinine ratio >300 mg/g or 
>300 mg/day) or laboratory results consistent with this diagnosis upon screening  
16. Has known human immunodeficiency virus or known current or chronic hepatitis C virus 
(HCV) or hepatitis B virus infection 
17. History of any cardiovascular event (eg, stroke, transient ischemic attack, myocardial 
infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary 
intervention, hospitalization due to heart failure) within 6 months prior to randomization 
18. Clinically significant valvular heart disease 
19. New York Heart Association II to IV heart failure 
20. Uncontrolled serious cardiac arrhythmia, defined as recurrent and highly symptomatic 
ventricular tachycardia, atrial fibrillation with rapid ventricular response, or 
supraventricular tachycardia in the 3 months prior to randomization 
21. Has undergone liver transplantation or is anticipated to be on an active liver 
transplantation waiting list during the study treatment period 
22. History of renal transplantation or under immunosuppressive therapy 
23. Has other medical conditions or comorbidities which, in the opinion of the Investigator, 
would interfere with study compliance or data interpretation; or, in the opinion of the 
Investigator, taking part in the study would jeopardize the safety of the patient 
24. Clinically significant illness, in the opinion of the Investigator, within 7 days prior to 
randomization 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
34 
25. Known change in body weight >10% in last 6 months prior to screening 
26. History of intolerance to SC injection(s) that could potentially hinder study drug 
administration or evaluation of local tolerability 
27. Has planned major surgery or general anesthesia during the study 
Contraception, Pregnancy, and Breastfeeding 
28. Is not willing to comply with the contraceptive requirements during the study period, as 
described in Section 5.7.1 
29. Female patient is pregnant, planning a pregnancy, or breast-feeding. 
Alcohol or Nicotine Use and Substance Abuse 
30. Unwilling or unable to limit alcohol consumption throughout the course of the study. 
Alcohol intake of >2 units/day is excluded during the study (unit: 1 glass of wine 
[approximately 125 mL] = 1 measure of spirits [approximately 1 fluid ounce] = ½ pint of 
beer [approximately 284 mL]). 
31. History of alcohol or substance abuse (licit or illicit drugs) within the last 12 months 
before screening, in the opinion of the Investigator 
32. Unwilling or unable to abstain from use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine 
patches, or e-cigarettes) within 30 minutes prior to office blood pressure measurements  
Other Restrictions 
33. Third shift or night shift workers 
34. Arm circumference exceeds the maximum cuff size of any of the blood pressure 
instruments provided by the Sponsor 
35. Unable or unwilling to perform HBPM as specified 
4.3. 
Removal from Study Drug or Assessment 
Patients or their legal guardians are free to discontinue study drug and/or stop protocol 
procedural assessments, or participation in the study as a whole at any time and for any reason, 
without penalty to their continuing medical care. The Investigator or the Sponsor may 
discontinue study drug or stop a patient’s participation in the study at any time if this is 
considered to be in the patient’s best interest. Any discontinuation of treatment or the stopping of 
the patient’s participation in the study must be fully documented in the electronic case report 
form (eCRF) and should be followed up by the Investigator. 
Discontinuation of study drug or declining procedural assessments is described in Section 4.3.1, 
while the stopping of a patient’s participation in the study is detailed in Section 4.3.2. 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments 
Reasons for discontinuation of study drug include any of the following: 
• Significant protocol deviation; which includes required treatment with prohibited 
medication (as defined in Section 5.5.2) per Investigator discretion 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
35 
• AE 
• Non-adherence to treatment regimen 
• Pregnancy 
• Lost to follow-up 
• Other reason (non-AE) 
• Or, study is terminated by the Sponsor 
If possible, the Investigator will confer with the Sponsor or Medical Monitor before 
discontinuing dosing in the patient. Patients who are pregnant will be discontinued from study 
drug dosing immediately (see Section 6.5.6.7 for reporting and follow-up of pregnancy). A 
positive urine pregnancy test should be confirmed by a serum pregnancy test prior to 
discontinuing the study drug. 
Patients who discontinue study drug and/or decline procedural assessments should not be 
automatically removed from study. In general, patients who discontinue study drug dosing for 
any reason will be encouraged to remain on the study to complete the remaining assessments and 
study visits so that their experience is captured in the final analyses.  
If this occurs, the Investigator is to discuss with the patient the appropriate processes for 
discontinuation from study drug and must discuss with the patient the options for continuation of 
the Schedule of Assessments (Table 1), including different options for follow-up and collection 
of data (eg, in person, by phone, by mail, through family or friends, or from options not 
involving patient contact, such as communication with other treating physicians or from review 
of medical records), including endpoints and AEs, and must document this decision in the 
patient’s medical records. 
If a patient discontinues dosing due to an AE, including SAEs, the event should be followed as 
described in Section 6.5.6. When a patient discontinues study drug dosing, the primary reason 
must be recorded in the eCRF. Patients who discontinue study drug and remain on study may 
receive treatment consistent with local standard practice for their disease per Investigator 
judgement, as applicable. 
Patients who discontinue from study drug before Month 6 will be encouraged to remain on the 
study and complete assessments (except study drug administration) through Month 6. They will 
also be asked to complete Safety Follow-up visits once every 6 months after the last dose of 
study drug per the safety follow-up schedule (see Table 1) until PD recovery or 12 months 
(whichever is earlier); see Section 3.1. 
Patients who discontinue study drug after the Month 6 visit will be asked to return for their next 
scheduled visit to complete EOT/ET assessments and complete Safety Follow-up visits once 
every 6 months after the last dose of study drug per the safety follow-up schedule (see Table 1) 
until PD recovery or 12 months (whichever is earlier); see Section 3.1. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
36 
4.3.2. 
Stopping a Patient’s Study Participation 
4.3.2.1. 
Patient or Legal Guardian Stops Participation in the Study 
A patient or their legal guardian may stop participation in the study at any time. A patient or 
legal guardian considering stopping participation in the study before Month 6 should be 
informed that the patient can discontinue study drug and/or decline procedural assessments and 
remain in the study to complete their study assessments through the Month 6 visit and complete 
Safety Follow-up visits as described in Section 4.3.1, or alternatively may complete any minimal 
assessments for which the patient or legal guardian consents. If a patient or legal guardian still 
chooses to discontinue study drug and stop participation in all follow-up prior to the completion 
of the Month 6 visit, every effort should be made to conduct the Month 6 visit assessments at an 
earlier time (Table 1). 
A patient considering stopping participation in the study after the Month 6 visit should be 
informed that the patient can discontinue study drug and/or decline procedural assessments and 
remain in the study to complete the assessments scheduled for the EOT/ET visit and complete 
Safety Follow-up visits as described in Section 4.3.1, or alternatively may complete any minimal 
assessments for which the patient consents. 
If the patient does not wish to or is unable to continue further study participation, the Investigator 
is to discuss with the patient appropriate procedures for stopping participation in the study. Data 
collected from the patient can continue to be used. 
Note, in countries where the collection and processing of the patient’s personal data is based on 
consent, if a patient withdraws consent to collect and process his/her personal data (see 
Section 4.3.2.2), as applicable, personal data up to the withdrawal of consent will be included in 
the analysis of the study. In addition, where permitted, publicly available data (such as 
appropriate national or regional vital status registry or other relevant databases) can be included 
after withdrawal of consent, where available and allowable by local law. 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection to 
Process Patient’s Personal Data 
Where allowed by local law, the patient may decide to withdraw consent to collect, store, and 
use biological samples and, as applicable, other personal data, informing the study doctor at any 
time in writing or in any other form that may be locally required. Also, where allowed by local 
law, the patient may object to the collection, storage, and use of his/her personal data, informing 
the study doctor at any time in writing or in any other form that may be locally required. In both 
cases, the Sponsor will continue to keep and use the patient’s study information (including any 
data resulting from the analysis of the patient’s biological samples until the time of 
withdrawal/objection) according to applicable law. The process for the storage and, as 
applicable, further use of remaining samples will be followed per local requirements.  
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study 
The Investigator or Sponsor may stop the participation of a patient in the study at any time if this 
is considered to be in the patient’s best interest. However, study integrity and interpretation are 
best maintained if all enrolled patients continue study assessments and follow-up even if study 
drug is discontinued. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
37 
Termination of the clinical study and site closure are described in Section 8.1.6. 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation 
The primary reason that a patient’s study participation is stopped must be recorded in the 
appropriate section of the eCRF and all efforts will be made to complete and report the 
observations as thoroughly as possible. If a patient’s study participation is stopped due to an AE, 
including SAEs, the event should be followed as described in Section 6.5.6. 
4.3.3. 
Lost to Follow-Up 
A patient will be considered lost to follow-up if the patient repeatedly fails to return for 
scheduled visits and is unable to be contacted by the clinical study center. The following actions 
must be taken if a patient fails to return to the clinic for a required study visit: 
• The site must attempt to contact the patient or legal guardian and reschedule the 
missed visit as soon as possible and counsel the patient or legal guardian on the 
importance of maintaining the assigned visit schedule and ascertain if the patient or 
legal guardian wishes [for the patient] to continue in the study, and/or should continue 
in the study. 
• Before a patient is deemed lost to follow up, the Investigator or designee must make 
every effort to regain contact with the patient or legal guardian (where possible, 3 
telephone calls and, if necessary, a certified letter to the patient’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the patient’s medical record. 
• Should the patient or legal guardian continue to be unreachable, the patient will be 
considered to have stopped participation in the study. 
• For patients who are lost to follow-up, the Investigator can search publicly available 
records (where permitted and allowed by local law) to ascertain survival status. This 
ensures that the outcome of the study is as comprehensive as possible. 
4.3.4. 
Replacement of Study Patients 
No additional patients may be enrolled to mitigate the impact of patients who discontinue the 
study drug or stop participation in the study.  
5. 
TREATMENTS AND OTHER REQUIREMENTS 
5.1. 
Treatments Administered 
Study drug supplied for this study must not be used for any purpose other than the present study 
and must not be administered to any person not enrolled in the study. Study drug that has been 
dispensed and returned unused must not be re-dispensed. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
38 
5.2. 
Study Drug 
Detailed information describing the preparation, administration, and storage of ALN-AGT01 SC 
and placebo SC is provided in the Pharmacy Manual. 
5.2.1. 
Description 
ALN-AGT01 will be supplied as a sterile solution for SC injection. See the Pharmacy Manual 
for further details of solution concentration and fill volume. 
The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC 
administration).  
5.2.2. 
Dose and Administration 
During the 12-month DB period, patients will be administered ALN-AGT01 or placebo, at the 
same volume and number of SC injections regardless of treatment assignment, once every 3 
months. The ALN-AGT01 and placebo groups are below: 
• Placebo SC once every 3 months, with re-randomization (1:1:1:1) at Month 6 to 1 of 
the initial 4 ALN-AGT01 regimens 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. Patients receiving once every 6 month ALN-AGT01 regimens will receive 
placebo SC at dosing visits at which they do not receive ALN-AGT01 to maintain the blind. 
Study drug injections will be administered under the supervision of the Investigator or healthcare 
professional. To maintain the blind, the doses are to be prepared by and syringes are to be 
masked by an unblinded site pharmacist or designee prior to study drug administration. A full 
description of the blinding procedure is included in the Pharmacy Manual. The injection site may 
be marked and mapped for later observation. Injections may be administered in the abdomen, 
thigh, or the side or back of the upper arms. The rotation of sites is recommended. If a local 
reaction around the injection site occurs, photographs may be obtained. Detailed instructions for 
study drug administration are found in the Pharmacy Manual. 
If a patient does not receive a dose of study drug within the specified visit window, the 
Investigator should contact the Medical Monitor. After such consultation, the dose may be 
administered up to 42 days before the next scheduled dose. Thereafter, the dose will be 
considered missed and not administered. 
Patients will be permitted to miss an occasional dose of study drug. However, if a patient misses 
2 consecutive doses, the Investigator, in consultation with the Medical Monitor, will discuss 
whether the patient will be able to continue the study (see also Section 4.3). 
Additional details can be found in the Pharmacy Manual. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
39 
The definition of study drug overdose, follow-up procedures, and reporting requirements are 
provided Section 6.5.6.8. 
5.2.3. 
Dose Modifications 
Dose modifications are not permitted. 
If a study drug-related AE occurs in a patient that the Investigator judges as presenting a 
potential risk to the patient for further dosing, the study drug dose may be held at the discretion 
of the Investigator and the Medical Monitor should be contacted. 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping Study 
Drug Dosing  
1. Dosing decisions may be made based on the most recently available liver function test 
(LFT) results from a central laboratory (Table 6). 
2. For any ALT or AST elevation >3×ULN, central laboratory results should be used to 
guide subsequent monitoring as detailed in Table 3. 
3. For any ALT or AST elevation >3×ULN: 
a. If local laboratory results are obtained, confirm with a central laboratory as soon as 
possible, ideally within 2 to 3 days, but no later than 7 days. 
b. If an alternative cause is found, provide appropriate care. 
c. If an alternative cause is not found, perform assessments per Table 6 and Table 7. 
4. For any ALT or AST elevation >3×ULN without alternative cause that is accompanied 
by clinical symptoms consistent with liver injury (eg, nausea, right upper quadrant 
abdominal pain, jaundice) or elevated bilirubin to ≥2×ULN or INR ≥1.5, permanently 
discontinue dosing. 
5. For confirmed ALT or AST elevations >3×ULN without alternative cause and not 
accompanied by symptoms or elevated bilirubin ≥2×ULN or INR ≥1.5, see Table 3. 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative Cause 
Identified 
Transaminase Level 
Action 
>3× to 5×ULN 
• 
May continue study drug dosing 
• 
Evaluate the initial elevation in LFT per the following assessments: 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6  
• 
Monitor at least every 2 weeks (LFT and coagulation per Table 6)  
• 
If elevation persists for ≥2 months, must discuss with the Medical Monitor 
before continuing dosing 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
40 
Transaminase Level 
Action 
>5× to 8×ULN 
• 
Hold study drug dosing until recovery to ≤1.5×ULN or baseline; may 
resume dosing after discussion with the Medical Monitor 
• 
Evaluate the initial elevation in LFT per the following assessments 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6 
• 
Monitor at least weekly: LFT and coagulation per Table 6 until ALT and/or 
AST is declining on 2 consecutive draws, then may decrease monitoring to 
biweekly 
• 
If ALT or AST rises to >5×ULN following resumption of dosing, 
permanently discontinue dosing 
>8×ULN 
Permanently discontinue study drug dosing after confirmation of the 
transaminase value at the central laboratory. 
Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; INR=international normalized 
ratio; LFT=liver function test(s); ULN=upper limit of normal. 
Notes: In addition to these criteria, other assessments or evaluations may be performed per Investigator discretion, 
as appropriate. 
5.2.5. 
Neurological Criteria for Withholding, Monitoring, and Stopping Study Drug 
Dosing 
Clinically significant events that may be consistent with potential decreased proprioception 
(including but not limited to unusual clumsiness, gait abnormalities, and unexplained 
balance/coordination issues that are either absent at or worsening from the baseline) should be 
reported as an AE. If the treatment-emergent AE is persistent and considered related to study 
drug, specialty consultation with a neurologist should be considered. However, if such a 
treatment-emergent AE is serious or severe (regardless of the Investigator’s assessment of 
relatedness), the patient must be referred for neurologist consultation, and study drug dosing 
must be held until that consultation is complete. Resumption of dosing must be approved by the 
Medical Monitor. 
5.2.6. 
Preparation, Handling, and Storage 
Staff at each clinical study center will be responsible for preparation of ALN-AGT01 or placebo 
doses according to procedures detailed in the Pharmacy Manual. No special procedures for the 
safe handling of study drug are required. 
ALN-AGT01 will be stored and refrigerated at approximately 2 to 30°C until dose preparation. 
Deviations from the recommended storage conditions should be reported to the Sponsor and use 
of ALN-AGT01 halted until authorization for its continued use has been provided by the Sponsor 
or designee, as described in the Pharmacy Manual. 
A Sponsor representative or designee will be permitted, upon request, to audit the supplies, 
storage, dispensing procedures, and records. 
Instructions specific to unused study drug and additional storage will be provided in the 
Pharmacy Manual. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
41 
5.2.7. 
Packaging and Labeling 
All packaging, labeling, and production of study drug will be in compliance with current Good 
Manufacturing Practice specifications, as well as applicable local regulations. Study drug labels 
and external packaging will include all appropriate information as per local labeling 
requirements. Additional details will be available in the Pharmacy Manual. 
5.2.8. 
Accountability 
The Investigator or designee will maintain accurate records of receipt and the condition of 
ALN-AGT01 supplied for this study, including dates of receipt. In addition, accurate records will 
be kept of when and how much ALN-AGT01 is dispensed and administered to each patient in 
the study. Any reasons for departure from the protocol dispensing regimen must also be 
recorded. 
At the completion of the study, there will be a final reconciliation of all ALN-AGT01. Used, 
partially used, and unused ALN-AGT01 will be returned to the Sponsor (or designee) or 
destroyed at the clinical study center according to applicable regulations. 
Further instructions about drug accountability will be detailed in the Pharmacy Manual. 
5.3. 
Clinical Product Complaints 
5.3.1. 
Definition 
A clinical product complaint (CPC) is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of the study drug and its packaging after it is released for distribution to the site at 
which study drug will be administered. 
A CPC may be detected prior to use of study drug, during use, or after use. A CPC is typically 
nonmedical in nature; however, it is possible that study drug complaints could be associated with 
an AE. Examples of a CPC include, but are not limited to: illegible clinical label, missing clinical 
label, damaged vial, empty vial, and contamination of study drug. 
5.3.2. 
Reporting 
For product complaints, the Sponsor or its designee should be notified within 24 hours using the 
process outlined in the Pharmacy Manual. CPCs that may be associated with an AE must be 
evaluated and reported as indicated in Section 6.5.6. Detailed instructions on reporting CPCs will 
be provided in the Pharmacy Manual. 
5.4. 
Monitoring for Potential Clinical Events 
5.4.1. 
Monitoring and Approach for Potential Hypotension 
Hypotension is an obligate risk of antihypertensive medications. In addition to office blood 
pressure monitoring, outpatient blood pressure will be monitored weekly with HBPM to ensure 
the early detection of potential hypotension. Whenever possible, management decisions will be 
based on blood pressure measurements confirmed by office blood pressure. 
The following management recommendations for hypotension are provided: 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
42 
• Low blood pressure that is associated with symptoms should promptly be evaluated at 
the clinical study site or another hospital setting. Clinical study site evaluation for low 
blood pressure should include the assessment of orthostatic blood pressure (eg, supine 
to standing).  
• The Investigator should consider downtitration, interruption, or discontinuation of 
oral antihypertensives (if taking) if confirmed office SBP <90 mmHg or if clinical 
symptoms, such as lightheadedness or dizziness, develop coupled with a significantly 
lower SBP compared to prior visits (ie, SBP <100 mmHg). 
• Clinically significant events discovered during the course of a patient’s general 
medical care should be promptly communicated to the site and evaluated by the 
Investigator, especially if hypotension is noted. Patients will carry Independent Ethics 
Committee (IEC)-approved patient cards to facilitate this physician-to-physician 
communication.  
• If hypotension is confirmed, serum electrolytes and creatinine should be measured 
and any oral antihypertensive(s) previously started for hypertensive escape should be 
down-titrated, interrupted, or discontinued per Investigator judgement.  
• The frequency of blood pressure and biochemical monitoring (serum electrolytes and 
creatinine) should be increased during intercurrent illnesses that predispose patients to 
dehydration (eg, vomiting or diarrhea that persists for more than 24 hours) or when 
symptoms consistent with decreased effective circulating volume (eg, presyncopal 
symptoms, unexplained falls, decreased urine output) manifest, even if a patient’s 
recent blood pressure measurements have been normal. 
• Hypotension that warrants direct evaluation at the site should be communicated to the 
Medical Monitor within 24 hours. In addition, other clinical events consistent with 
potential hypotension (eg, unexplained presyncope, syncope, or falls) should be 
communicated to the Medical Monitor within 24 hours of the site being notified. 
• Management of persistent hypotension may include increased salt intake or, if 
unresponsive, standard treatments for orthostatic intolerance syndromes such as 
fludrocortisone or midodrine. 
• Low blood pressure that requires medical treatment (including intravenous fluid 
support) or other clinical events consistent with potential hypotension (see above) 
should be recorded as AEs. 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure Elevation 
In addition to office blood pressure monitoring, outpatient blood pressure will be monitored 
frequently with HBPM to ensure the early detection of potential significant elevations. Whenever 
possible, management decisions will be based on blood pressure measurements confirmed by 
office blood pressure. The recommended interventions for potentially clinically significant blood 
pressure elevation are presented in Table 4.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
43 
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation 
Study Period 
Intervention 
Throughout Study 
• 
Whenever possible, management decisions should be based on blood 
pressure measurements confirmed by office blood pressure. 
• 
Any confirmed event of severe hypertension (office SBP ≥180 mmHg 
and/or office DBP ≥120 mmHg) should be appropriately treated regardless 
of its timing relative to study drug administration.  
• 
Because ALN-AGT01 acts on the RAAS, the use of conventional RAAS 
inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors) as rescue 
agents for high blood pressure will be avoided throughout this study.  
• 
If added, oral antihypertensives must be used per their labeled instructions 
and in accordance with current care guidelines.[Whelton 2018; Williams 
2018] 
Day 1 to Month 3 
Intervene if clinically significant blood pressure elevation: 
• 
Because of the gradual onset of effects of ALN-AGT01, interventions for 
asymptomatic hypertension should be avoided in the first 6 weeks after the 
patient’s first administration of study drug.  
• 
After Week 6, patients who develop office SBP >160 mmHg and increased 
>10 mmHg from their baseline office SBP that persists for ≥24 hours on 2 
consecutive measurements or that is accompanied by hypertensive 
symptoms should be evaluated by the clinical study site. Severely 
symptomatic patients should be evaluated at the clinical study site or 
another hospital setting within 24 hours. 
• 
If persistent hypertension is confirmed (without the identification of a 
specific treatable cause) and the Investigator deems it to be a clinically 
significant change, treatment may be initiated at the medical discretion of 
the Investigator using a CCB and/or a thiazide/thiazide-like diuretic. 
Investigators should avoid long-acting agents that may not fully washout 
between Month 5 and Month 6. 
Months 3 to 6 
Treat to target blood pressure using a CCB and/or thiazide/thiazide-like diuretic: 
• 
At Month 3, a CCB and/or a thiazide/thiazide-like diuretic should be added 
if the daytime mean SBP is ≥135 mmHg by ABPM. If the Investigator feels 
there is a compelling clinical reason to wait, the rationale for exception 
should be documented in the eCRF. 
• 
After Month 3, oral antihypertensive medications may also be added per 
Investigator judgement for persistent elevations in blood pressure above 
target (target defined as office SBP <140 mmHg, HBPM SBP <135 mmHg, 
or daytime mean SBP by ABPM <135 mmHg).[Williams 2018] 
• 
A temporary hold of oral antihypertensives (if taking) will be performed in 
appropriate patients (below) from Month 5 to Month 6: 
- Month 5 office SBP <160 mmHg if taking no oral antihypertensive 
agents 
- Month 5 office SBP <155 mmHg if taking 1 oral antihypertensive agent 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
44 
Study Period 
Intervention 
- Month 5 office SBP <150 mmHg if taking 2 oral antihypertensive 
agents. 
• 
During this 4-week period, blood pressure will be carefully monitored by 
daily HBPM and oral antihypertensive medications restarted if confirmed 
office SBP >170 mmHg (or if confirmed office SBP >160 mmHg 
accompanied by symptoms) 
Month 6 to End of 
Study 
Treat to target blood pressure using Investigator’s choice of oral 
antihypertensive(s). 
• 
At Month 6, prior oral antihypertensive should be restarted per Investigator 
judgement if daytime mean SBP is ≥135 mmHg by ABPM. 
• 
Oral antihypertensive medications may also be added per Investigator 
judgement for persistent elevations in blood pressure above target (target 
defined as office SBP <140 mmHg; HBPM SBP <135 mmHg; daytime 
mean SBP by ABPM <135 mmHg).[Whelton 2018; Williams 2018] 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of eGFR 
through the anticipated onset of initial ALN-AGT01 PD. Based upon the renal dysfunction 
associated with conventional RAAS inhibitors,[McMurray 2016; Parving 2012] the following 
guidelines apply throughout the study: 
• If an individual patient experiences a decrease in eGFR by ≥30% from baseline or to 
≤30 mL/min/1.73m2, the Investigator should obtain confirmatory repeat tests, contact 
the Sponsor, and look for potentially reversible causes of renal dysfunction such as: 
− NSAIDs, antibiotics, or other treatments known to impair renal function 
− Recent exposure to intravenous contrast agents 
− Hypotension 
− Hypovolemia 
− Urinary infection 
− Urinary tract obstruction 
• If an individual patient experiences a decrease in eGFR by ≥40% from baseline or to 
≤25 mL/min/1.73m2, the Investigator should obtain confirmatory repeat tests, look for 
potentially reversible causes of renal dysfunction, and contact the Sponsor to discuss 
the potential interruption of study drug. Serum creatinine should be monitored at least 
weekly until improving.  
• If a patient is on additional oral antihypertensive agents, the Investigator should 
consider whether these agents should be interrupted, especially during intercurrent 
illness or volume depletion 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
45 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of serum 
electrolytes (at least monthly through the anticipated onset of ALN-AGT01 PD). The following 
guidelines apply for potassium elevations detected by laboratory monitoring.[McMurray 2016; 
Parving 2012] 
Table 5: 
Recommended Interventions for Hyperkalemia 
Serum K+ ≥5.2 and <5.5 mmol/L 
Serum K+ ≥5.5 and <6.0 mmol/L 
Serum K+ ≥6.0 mmol/L 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample. 
• 
Reinforce low-potassium diet 
and restriction of food/drinks 
with high potassium content  
• 
Review medical regimen 
(including dietary supplements 
and over-the-counter 
medications) for agents known 
to cause hyperkalemia.a 
Consider reduction in dose or 
discontinuation of these agents. 
• 
Repeat K+ measurement within 
3 to 5 days. 
• 
If K+ remains ≥5.2 and <5.5 
mmol/L, regularly monitor K+ 
levels to ensure stability (at 
least weekly if in the first 6 
weeks of treatment or at least 
once monthly afterwards) 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample 
• 
Consider interruption or delay 
of study drug, according to 
Investigator medical judgment  
• 
Apply all measures outlined for 
serum K+ ≥5.2 and <5.5 
mmol/L 
• 
Repeat K+ measurement after 2 
to 3 days 
• 
If K+ <5.5 mmol/L, consider 
resumption of study drug (if 
interrupted) with repeat 
potassium within 5 days 
• 
If K+ persistently elevated ≥5.5 
mmol/L, consider treatment 
with patiromer (or with sodium 
zirconium cyclosilicate), if 
available 
• 
Immediately interrupt 
study drug 
• 
Confirm potassium 
concentration in a 
non-hemolyzed 
sample 
• 
Urgently evaluate 
patient and treat 
hyperkalemia as 
clinically indicated. 
After urgent 
treatment, consider 
treatment with 
patiromer (or with 
sodium zirconium 
cyclosilicate), if 
available 
• 
Apply all measures 
outlined for serum K+ 
≥5.5 and <6.0 
mmol/L 
• 
No resumption of 
study drug without 
individualized case 
discussion with and 
permission from 
Alnylam Medical 
Monitor 
Abbreviations: NSAID=nonsteroidal anti-inflammatory drug. 
a This list is not meant to be exhaustive: potassium-sparing diuretics (eg, amiloride and triamterene), potassium 
supplements (eg potassium chloride), salt substitutes, NSAIDs, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, herbal supplements (eg, Noni juice, alfalfa [Medicago sativa], 
dandelion [Taraxacum officinale], horsetail [Equisetum arvense], nettle [Urtica dioica], milkweed, lily of the 
valley, Siberian ginseng, hawthorn berries). 
The availability of patiromer or ZS-9 will be assessed at participating study sites. These 
potassium-binding drugs are indicated for the treatment of hyperkalemia and have been shown to 
safely reduce serum potassium levels and to maintain long-term normokalemia in chronic kidney 
disease patients receiving background conventional RAAS inhibitor therapy.[Georgianos and 
Agarwal 2018; Weir 2015] 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
46 
5.5. 
Concomitant Medications and Procedures 
Use of concomitant medications and procedures will be recorded on the patient’s eCRF as 
specified in the Schedule of Assessments (see Table 1). Concomitant medications include all 
prescription medications, herbal preparations, over the counter medications, vitamins, and 
minerals. Any changes in medications during the study will also be recorded on the eCRF. 
Standard vitamins and topical medications are permitted. However, topical steroids must not be 
applied anywhere near the injection site(s) unless medically indicated. For permitted concomitant 
medications administered SC, do not administer in same injection site area as the study drug for 
4 days after the last dose of study drug. 
Patients receiving low-dose aspirin (defined as ≤100 mg per day) for at least 30 days prior to 
screening and during the study treatment period are allowed. Occasional use of other over-the-
counter systemic NSAIDs is allowed. However, given their association with increased blood 
pressure, they should be avoided when possible and for at least 7 days prior to ABPM and office 
blood pressure measurements, and alternative analgesics (acetaminophen, topical NSAIDs) 
should be considered.[Whelton 2018] When used, the dosing of systemic NSAIDs should be at 
the lower end of the labeled range and for the shortest duration possible.  
Patients receiving SGLT2 inhibitors (eg, empagliflozin, canagliflozin, and dapagliflozin) should 
be on a stable dose for at least 30 days prior to screening and during the study treatment period. 
These medications should not be initiated or discontinued, if possible, during the study treatment 
period. 
Patients will be allowed to receive vaccines (eg, for SARS-CoV-2) that have received health 
agency authorization (including for emergency use) by local or regional regulatory authorities. 
Any concomitant medication that is required for the patient’s welfare may be administered by the 
Investigator, except as described in Section 5.5.2. However, it is the responsibility of the 
Investigator to ensure that details regarding the medication are recorded on the eCRF. 
Concomitant medication will be coded using an internationally recognized and accepted coding 
dictionary. 
5.5.1. 
Oral Antihypertensive Medication  
Individual initiation and modification of oral antihypertensive medications per Investigator 
judgement are permitted throughout the study if required to treat clinically significant blood 
pressure elevation (Section 5.4.2). In addition, after a patient completes the placebo-controlled 
primary endpoint at Month 3, Investigators will titrate therapy with oral antihypertensives to a 
target blood pressure range (office SBP <140 mmHg, HBPM SBP <135 mmHg, or daytime 
mean SBP by ABPM <135 mmHg). All oral antihypertensive medication that are dosed once 
daily should be taken in the morning. 
Serum electrolytes and creatinine should be measured at a central or local laboratory 
approximately 2 weeks after any antihypertensive addition or dose titration. 
5.5.2. 
Prohibited Concomitant Medication 
The following medications, treatments, and supplements are prohibited throughout the study 
treatment period (until the EOT visit): 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
47 
• Conventional RAAS inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors)  
• Prescription NSAIDs  
• Organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, isosorbide 
dinitrate, pentaerythritol) 
• An RNAi therapeutic (other than ALN-AGT01) 
• Medications, herbal supplements (including Ma Huang and St. John’s wort), or other 
substances (such as licorice) that are associated with increases in LFT abnormalities 
or with blood pressure abnormalities are prohibited. This includes certain stimulants 
(eg, amphetamine, methylphenidate dexmethylphenidate, dextroamphetamine), MAO 
inhibitors, atypical antipsychotics (eg, clozapine, olanzapine), diet pills (eg, 
phenylpropanolamine, sibutramine), and nasal decongestants (eg, phenylephrine 
hydrochloride, pseudoephedrine, naphazoline hydrochloride). 
• Medications, herbal medicines, over-the-counter medications, or supplements known 
to cause hyperkalemia are prohibited unless individually approved by both the 
Investigator and the Medical Monitor. This includes potassium-sparing diuretics, 
potassium supplements, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, mineralocorticoid receptor 
antagonists, Noni juice, alfalfa, dandelion, horsetail, nettle, milkweed, lily of the 
valley, Siberian ginseng, and hawthorn berries. 
All concomitant medications must be reviewed and approved by the Investigator, with particular 
attention to avoiding drugs that may affect blood pressure. 
5.6. 
Treatment Compliance 
Compliance with study drug administration will be verified through observation by study staff. 
5.7. 
Other Requirements 
5.7.1. 
Contraception 
Females of child-bearing potential must be willing to use a highly effective method of 
contraception from 14 days before first dose, throughout study participation, and through safety 
follow-up (if applicable; see Section 3.1).  
Birth control methods which are considered highly effective include: 
• Placement of an intrauterine device. 
• Placement of an intrauterine hormone-releasing system. 
• Bilateral tubal occlusion. 
• Surgical sterilization of male partner (with the appropriate post-vasectomy 
documentation of the absence of sperm in the ejaculate; for female patients on the 
study, the vasectomized male partner should be the sole partner for that patient). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
48 
• Established use of oral (except low-dose gestagens), implantable, injectable, or 
transdermal hormonal methods of contraception associated with the inhibition of 
ovulation. 
• True sexual abstinence, when in line with the preferred and usual lifestyle of the 
patient. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception. Abstinent 
patients must agree to use one of the above-mentioned contraceptive methods if they 
start heterosexual relationships during the study and through safety follow-up (if 
applicable; Section 3.1). 
Investigators should advise females of childbearing potential of the most appropriate birth 
control method available within their country taking into account local medical practice. 
Females of child-bearing potential include female patients who have experienced menarche (or 
begin menarche over the course of the study), and who are not postmenopausal or permanently 
sterilized (eg, bilateral tubal occlusion, hysterectomy, or bilateral salpingectomy). A 
postmenopausal state is defined as the absence of menses for 12 months without an alternative 
medical cause, confirmed by follicle stimulating hormone level within the postmenopausal 
range.  
For male patients, no contraception is required. However, use by males of contraception 
(condom) may be required in some countries, eg, France, in order to comply with local 
requirements as described in the corresponding patient ICFs.  
Compliance with contraception requirements will be assessed on a regular basis by the 
Investigator throughout the course of the study (see Section 6.5.5.3). Pregnancy testing will be 
performed before every dose for postmenarcheal females throughout the course of the study (see 
Section 6.5.5.3). 
5.7.2. 
Alcohol Restrictions 
Patients should limit alcohol consumption throughout the course of the study. Alcohol is limited 
to no more than 2 units per day (unit: 1 glass of wine [approximately 125 mL] =1 measure of 
spirits [approximately 1 fluid ounce] =½ pint of beer [approximately 284 mL]) for the duration 
of the study. Compliance with alcohol restrictions should be assessed on a regular basis by the 
Investigator throughout the course of the study. 
5.7.3. 
Tobacco and Nicotine Restrictions 
Use of nicotine or tobacco-containing products (including but not limited to snuff, chewing 
tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) must be avoided within 30 
minutes prior to blood pressure measurements. 
5.7.4. 
Dietary Recommendations  
All patients will receive educational materials on diet with recommendations to limit sodium 
consumption to approximately 2.0 g per day from screening through the end of the Treatment 
period. This direction should be provided at the start of the Screening period, and treatment-
naïve patients should follow these recommendations for at least 1 week prior to screening 
assessments of blood pressure. Of note, this is the sodium intake recommended in the 2018 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
49 
European Society of Cardiology/European Society of Hypertension Guidelines for both 
hypertensive patients and for the general population.[Williams 2018]  
On days on which samples for fasting lipid panel and glycemic assessments are collected, 
patients are required to fast for ≥10 hours before sample collection (Section 6.5.5.1). 
5.7.5. 
Exercise 
Patients should abstain from strenuous exercise for 48 hours before each blood collection for 
clinical laboratory tests. 
6. 
STUDY ASSESSMENTS 
The Schedule of Assessments is provided in Table 1. Study visits should be scheduled for the 
morning. All assessments, except for postdose PK sample collection, are to be performed prior to 
dosing at dosing visits. Additional information on the collection of study assessments will be 
detailed in the Study Manual. 
Where applicable country and local regulations and infrastructure for home healthcare allow, 
home healthcare may take place at a location other than the clinical study site to perform study 
assessments, which may include collection of blood and urine samples and measurement of vital 
signs and weight (at the discretion of the Investigator). 
6.1. 
Screening Assessments 
An ICF that has been approved by the appropriate Institutional Review Board (IRB)/IEC must be 
signed (in paper or electronic format per local regulations and institutional standards) by the 
patient or legal guardian before the screening procedures are initiated. All patients or their legal 
guardians will be given a copy of the signed and dated ICF. 
Patients will be screened to ensure that they meet all the inclusion criteria and none of the 
exclusion criteria. Rescreening of patients is permitted with consultation of the Medical Monitor 
(see Section 6.1.2). 
Patient demographic data and medical history/disease history will be obtained. Any changes to 
medical history occurring between the screening assessment and Day 1 will be updated prior to 
study drug administration. 
6.1.1. 
Retesting  
If in the Investigator’s judgement, the screening laboratory abnormalities are likely to be 
transient, then laboratory tests may be repeated. The Investigator’s rationale should be 
documented. Laboratory values can be retested once during screening provided that the patient 
can be evaluated for eligibility after at least 2 to 4 weeks of washout (as applicable) and 
randomized within the allowed Screening period. Retesting of screening ABPM is permitted 
once as described in Section 6.2.1, with eligibility assessed by the second ABPM result. 
6.1.2. 
Rescreening 
A patient who does not meet all study eligibility criteria due to a transient condition observed at 
screening (eg, prohibited medications that were subsequently discontinued) will be allowed to 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
50 
return once for rescreening. A patient will be re-consented if rescreening occurs outside of the 
60-day screening window. In this case, all screening procedures must be repeated. 
6.2. 
Efficacy Assessments 
All blood pressure measurements (ABPM, office, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in 
Section 10.1.  
In patients taking oral antihypertensives, a washout of at least 2 to 4 weeks (as applicable) must 
be completed prior to measurement of the baseline ABPM (for eligibility) and baseline office 
blood pressure. The baseline ABPM and office blood pressure must be measured within 2 weeks 
before randomization. An HBPM unit will be provided during the Screening period to facilitate 
monitoring during the washout of prior oral antihypertensives (if taking) and to establish the 
HBPM baseline prior to randomization. HBPM must be collected after at least 2 to 4 weeks of 
washout (as applicable) for at least 2 consecutive weeks (at least 3 recordings per week) prior to 
randomization to establish baseline. 
ABPM placement may be performed at home by appropriately trained individuals, as detailed in 
the Study Manual. If a patient is unable to report to the site for an office blood pressure 
assessment, a substitute “remote visit blood pressure measurement” may be obtained remotely 
using the methods described in Section 10.1. 
Recommendations for approach and monitoring of low blood pressure/hypotension and 
hypertensive escape are provided in Section 5.4.1 and Section 5.4.2, respectively. 
6.2.1. 
ABPM 
In patients taking oral antihypertensives (including those initiated as rescue medication), ABPM 
should be started prior to the morning dose of antihypertensive medication.  
Adequacy will be assessed for all ABPMs. If the ABPM recording is inadequate, the patient will 
be provided 1 opportunity to repeat the study. If the second ABPM recording is also inadequate 
during screening, the patient is a screen failure.  
See further details in Section 10.1 and the Study Manual. 
6.2.2. 
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor at trough (prior to taking oral antihypertensives) and at approximately the same time 
each day; therefore, visits should be scheduled at approximately the same time of day, whenever 
possible. Office blood pressure must include orthostatic measurements (seated and standing).  
Exercise, caffeine, alcohol consumption, and use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or 
e-cigarettes) must be avoided within 30 minutes prior to blood pressure measurements. The use 
of inhaled short-acting beta agonists should be avoided within 6 hours prior to measuring blood 
pressure and/or heart rate. The use of phosphodiesterase type 5 inhibitors (eg, sildenafil, 
tadalafil, vardenafil, avanafil) should be avoided within 48 hours prior to measuring blood 
pressure. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
51 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the Study Manual.  
6.2.3. 
HBPM 
The HBPM should be measured in the morning upon waking, prior to breakfast/caffeine or 
taking morning oral medications. HBPM is not required at times when ABPM is being assessed. 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the Study Manual. 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment 
Approximately 100 patients at select sites will be given the option of using a wearable blood 
pressure sensor for 2 periods of 2 to 4 weeks each according to the Schedule of Assessments 
(Table 1). Wearable blood pressure assessments performed during screening should be obtained 
after at least 2 to 4 weeks of washout (as applicable). Participation will be contingent upon 
individual patient consent. These noninvasive, cuffless devices are worn on the finger or wrist as 
described in the Study Manual, using the opposite arm as that used for ABPM. 
6.3. 
Pharmacodynamic Assessments 
Blood samples for determination of AGT and RAAS biomarkers (plasma renin concentration, 
AngI, AngII, and aldosterone) will be collected according to the Schedule of Assessments 
(Table 1). Blood samples collected for AngI and AngII require special processing and will be 
assessed at sites that have appropriate resources, equipment, and reagents. Blood samples for PD 
assessments must be collected before study drug administration (on days when study drug is to 
be dosed) or at a time point corresponding to the time of study drug dosing (on other days). 
Levels of aldosterone will also be analyzed in urine collections at the time points listed in the 
Schedule of Assessments (Table 1). Blood AGT levels will be analyzed at a central laboratory by 
enzyme-linked immunosorbent assay for measurement of PD effect. These biomarkers may be 
analyzed using qualified assays. Details regarding the collection, processing, shipping, and 
storage of the samples will be provided in the Laboratory Manual.  
Results will not be used to adjust dosing of ALN-AGT01 or guide clinical management and will 
not be shared with sites until after the last patient completes Month 12. If clinical circumstances 
arise for which such information is required to guide patient care, local laboratory assessments 
should be drawn. 
6.4. 
Pharmacokinetic Assessments 
Blood samples will be collected for the assessment of plasma concentrations of ALN-AGT01 
and its primary metabolite AS(N-1)3′ ALN-AGT01 at the time points indicated in the Schedule 
of Assessments (Table 1). A detailed schedule of time points for the collection of blood samples 
for PK analysis is in Table 2. 
Plasma concentrations of ALN-AGT01 and AS(N-1)3′ ALN-AGT01 will be determined using a 
validated assay. Details regarding sample volumes to be collected, and the processing, shipping, 
and analysis of the samples will be provided in the Laboratory Manual. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
52 
6.5. 
Safety Assessments 
The assessment of safety during the study will consist of the surveillance and recording of AEs, 
including SAEs, recording of concomitant medication and measurements of vital signs, weight, 
electrocardiogram (ECG) findings, and laboratory tests. Clinically significant abnormalities 
observed during the physical examination are recorded. 
6.5.1. 
Vital Signs 
Vital signs will be measured as specified in the Schedule of Assessments (Table 1) and include 
blood pressure, heart rate, body temperature, and respiratory rate. When vital signs and blood 
sample collection occur at the same time, vital signs should be performed before blood samples 
are drawn, where possible. Vital signs should be measured predose in the seated position, after 
the patient has rested comfortably for approximately 10 minutes. Body temperature in degrees 
Celsius will be obtained via oral, tympanic, or axillary methods. Heart rate will be counted for a 
full minute and recorded in beats per minute, and respiration rate will be counted for a full 
minute and recorded in breaths per minute. Blood pressure is described in Section 6.2.  
Additional vital sign assessments, as medially indicated, may be added at the discretion of the 
Investigator, or as per DMC advice. 
Vital signs results will be recorded in the eCRF. 
6.5.2. 
Weight, Height, and Morphometrics 
Height and body weight measurements will be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded in the eCRF. Height will be measured at screening 
only. Height will be measured in centimeters. Body weight should be measured in kilograms to 
the first decimal point in patients wearing light clothing and without shoes.  
Waist circumference and waist-to-hip-ratio will also be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded on the eCRF. For waist circumference and waist-to-
hip ratio, patients should wear minimal clothing to ensure that the measuring tape is correctly 
positioned. Patients should stand erect with the abdomen relaxed, arms at the sides, feet together 
and with their weight equally divided over both legs. To perform the waist measurement, the 
lowest rib margin is first located and marked with a pen. The iliac crest is then palpated in the 
midaxillary line, and also marked. It is recommended to apply an elastic tape horizontally 
midway between the lowest rib margin and the iliac crest, and tie firmly so that it stays in 
position around the abdomen about the level of the umbilicus. The elastic tape thus defines the 
level of the waist circumference, which can then be measured by positioning the measuring tape 
over the elastic tape. Hip circumference measurement should be taken around the widest portion 
of the buttocks. Patients are asked to breathe normally, and to breathe out gently at the time of 
the measurement to prevent them from contracting their muscles or from holding their breath. A 
stretch-resistant tape that provides a constant 100 g of tension is recommended. Measurements 
should be obtained with the tape positioned parallel to the floor and performed using the same 
procedure throughout the study. 
The reading is taken to the nearest centimeter and entered in the source document. Each 
measurement should be repeated twice; if the measurements are within 1 cm of each other, the 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
53 
average should be calculated. If the difference between the 2 measurements exceeds 1 cm, the 2 
measurements should be repeated.  
6.5.3. 
Physical Examination 
Full and symptom-directed physical examinations will be conducted according to the Schedule 
of Assessments (Table 1); if a physical examination is scheduled for a dosing visit, it should be 
conducted prior to dosing. Full physical examinations will include the examination of the 
following: general appearance; head, eyes, ears, nose and throat; respiratory, cardiovascular, 
gastrointestinal, musculoskeletal, and dermatological systems; thyroid; lymph nodes; and 
neurological status (see the Study Manual for further details on the assessments to be performed 
as part of the neurological evaluation). 
Symptom-directed physical examinations will be guided by evaluation of changes in symptoms, 
or the onset of new symptoms, since the last visit. Neurological evaluation should be performed 
according to the Study Manual during all symptom-directed physical examinations regardless of 
whether neurological symptoms have been experienced by the patient.  
Clinically significant abnormalities observed during the physical examination are recorded on 
the medical history or AE eCRF. 
6.5.4. 
Electrocardiogram 
The 12-lead ECGs reporting rhythm, ventricular rate, RR interval, PR interval, QRS duration, 
and QT interval and Fridericia-corrected QT interval will be obtained using a local machine, as 
specified in the Schedule of Assessments (Table 1). Patients should be supine for at least 10 
minutes before each ECG is obtained. The Investigator or qualified designee will review all 
single 12-lead ECGs to assess whether the results have changed since the Baseline visit and to 
determine the clinical significance of the results. These assessments will be recorded in the 
eCRF.  
When ECG and blood sample collection occur at the same visit, blood sample collection should 
occur first. ECGs should be performed at least 30 minutes after phlebotomy or other stressful 
assessments. 
The Investigator or qualified designee will review all ECGs to assess whether the results have 
changed since the baseline visit and to determine the clinical significance of the results. These 
assessments will be recorded in the eCRF. Additional ECGs may be collected at the discretion of 
the Investigator, or as per DMC advice. Recordings will be archived according to the Study 
Manual. 
6.5.5. 
Clinical Laboratory Assessments 
The following clinical laboratory tests will be evaluated by a central laboratory. Specific 
instructions for transaminase elevations are provided in Section 6.5.6.4. For any other 
unexplained clinically relevant abnormal laboratory test occurring after study drug 
administration, the test should be repeated and followed up at the discretion of the Investigator, 
or as per DMC advice, until it has returned to the normal range or stabilized, and/or a diagnosis 
is made to adequately explain the abnormality. Additional safety laboratories and assessments as 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
54 
indicated by the clinical situation may be requested. Clinical laboratory assessments are listed in 
Table 6 and will be assessed as specified in the Schedule of Assessments (Table 1).  
While local laboratory results may be used for urgent clinical decisions, on the day of the 
assessments all laboratory assessments specified in Table 6 which are performed at the clinic 
should also be sent in parallel to the central laboratory. In the case of discrepant local and central 
laboratory results on samples drawn on the same day, central laboratory results will be relied 
upon for clinical decisions. 
Clinical laboratory assessments may be collected at the clinical study center or at home by a 
trained healthcare professional. Blood samples collected for RAAS biomarkers should be 
collected in the morning and in the seated/upright position (after blood pressure measurements 
and before any assessments collected in the supine position). 
Spot urine collections for albumin and creatinine should be obtained in the morning. A 24-hour 
urine collection for aldosterone, sodium, and creatinine will be performed at time points listed in 
the Schedule of Assessments (Table 1). These 24-hour collections should be obtained within 2 
days before the ABPM associated with the same visit. 
For any safety event or laboratory abnormality, additional laboratory assessments, imaging, and 
consultation may be performed for clinical evaluation and/or in consultation with the Medical 
Monitor; results may be collected and should be included in the clinical database. 
Table 6: 
Clinical Laboratory Assessments  
Hematology 
Complete blood count with differential 
 
Serum Chemistry 
Sodium 
Potassium 
BUN 
Phosphate 
Uric acid 
Albumin 
Total protein 
Calcium 
Glucose 
Bicarbonate 
Creatinine and eGFR 
Chloride 
Liver Function Tests 
 
AST 
ALP 
ALT 
Bilirubin (total and direct) 
GGT 
 
Urinalysis 
Visual inspection for appearance and color 
Bilirubin 
pH (dipstick) 
Nitrite 
Specific gravity 
RBCs 
Ketones 
Urobilinogen 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
55 
Protein  
Leukocyte esterase 
Glucose 
Microscopy (if clinically indicated) 
Coagulation  
Prothrombin time 
International normalized ratio 
Partial thromboplastin time  
 
Fasting Lipid Panel and Glycemic Assessments (see Section 6.5.5.1) 
Lipid panel, including 
HDL-C, non-HDL-C, LDL-C, apolipoprotein A1, 
triglycerides, total cholesterol  
Insulin 
Fasting plasma glucose 
HbA1c 
Immunogenicity (see Section 6.5.5.2) 
ADA 
 
Pregnancy Testing/FSH Screening (see Section 6.5.5.3) 
β-human chorionic gonadotropin (females of 
child-bearing potential only) 
Follicle-stimulating hormone (postmenopausal 
women only) 
Abbreviations: ADA=anti-drug antibodies; ALP=alkaline phosphatase; ALT=alanine aminotransferase; 
AST=aspartate aminotransferase; BUN=blood urea nitrogen; eGFR=estimated glomerular filtration rate; 
FSH=follicle-stimulating hormone; GGT=gamma glutamyl transferase; HbA1c=hemoglobin A1c; HDL-C=high-
density lipoprotein; LDL-C=low-density lipoprotein; RBCs=red blood cells. 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments 
Blood samples for fasting plasma glucose, insulin, lipid panel (including total cholesterol, high-
density lipoprotein [HDL-C], non-HDL-C, low-density lipoprotein, apolipoprotein A1, and 
triglycerides), and HbA1c will be collected at the time points listed in the Schedule of 
Assessments (Table 1). Patients are required to fast for ≥10 hours before sample collection for 
fasting plasma glucose, insulin, lipid panel, and HbA1c. Samples should be collected at 
approximately the same time of day (±2 hours). 
6.5.5.2. 
Immunogenicity 
Blood samples will be collected to evaluate anti-drug antibodies (ADA). Blood samples for ADA 
testing must be collected before study drug administration (on days when study drug is to be 
dosed) or at a time point corresponding to the time of study drug dosing (on other days) as 
specified in the Schedule of Assessments (Table 1). A blood sample to evaluate ADA will be 
collected at the ET visit, if applicable. Blood samples for ADA will be analyzed at a central 
laboratory. 
Details regarding the processing, shipping, and analysis of the samples will be provided in the 
Laboratory Manual. 
6.5.5.3. 
Pregnancy Testing 
A pregnancy test will be performed for females of child-bearing potential. A serum pregnancy 
test will be performed at screening, and urine pregnancy tests will be performed thereafter per 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
56 
the Schedule of Assessments and any time pregnancy is suspected. More frequent pregnancy 
testing may be performed where required per local requirements. The results of the pregnancy 
test must be known before study drug administration. Patients who are pregnant at screening are 
not eligible for study participation. Any woman with a positive urine pregnancy test, 
subsequently confirmed by a positive serum pregnancy test, during the study will be 
discontinued from study drug but will continue to be followed for safety. Patients determined to 
be pregnant while on study will be followed at least until the pregnancy outcome is known (see 
Section 6.5.6.7 for follow-up instructions). 
A blood sample will be drawn at screening to measure the levels of follicle stimulating hormone 
in order to confirm postmenopausal status in all women suspected to be postmenopausal (see 
Section 5.7.1 for definition of postmenopausal state). 
6.5.5.4. 
Additional Liver Function Assessments 
Additional laboratory assessments will be performed in patients who experience any LFT 
abnormalities as outlined in Section 5.2.4. Following the occurrence of elevated liver 
transaminases or other LFT abnormalities per central laboratory, all assessments in Table 7 will 
be performed 1 time, as well as hematology, serum chemistry, LFT, and coagulation assessments 
from Table 6, and other assessments or evaluations per Investigator discretion, as appropriate.  
Monitoring, including criteria for dose modification or withholding the study drug, is described 
in Section 5.2.4.  
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases 
Extended Hepatic Panel 
HBsAg, HBc antibody IgM and IgG 
Parvovirus B19 DNA – quantitative 
HAV antibody IgM 
HHV-6 DNA viral load – quantitative 
HCV antibody 
Anti-nuclear antibodies 
HCV RNA PCR – qualitative and quantitative 
Anti-smooth muscle antibodies 
HEV antibody IgM 
Anti-LKM1 antibody 
Herpes Simplex Virus 1 and 2 antibody IgM, IgG 
Anti-mitochondrial antibodies 
Herpes Zoster Virus IgM, IgG 
Anti-SLA 
Epstein-Barr Virus antibodies, IgM, and IgG 
Ferritin 
Cytomegalovirus antibodies, IgM, IgG 
Ceruloplasmin 
Imaging 
Abdominal ultrasound with Doppler flow (or CT or MRI) including right upper quadrant 
Focused Medical and Travel History 
Use of any potentially hepatotoxic concomitant 
medications, including over the counter medications 
and herbal remedies 
Alcohol consumption and drugs of abuse 
Other potentially hepatotoxic agents including any 
work-related exposures 
Recent travels to areas where hepatitis A or E 
is endemic 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
57 
Abbreviations: CT=computed tomography; HAV=hepatitis A virus; HBc=hepatitis B core; HBsAg=hepatitis B 
virus surface antigen; HCV=hepatitis C virus; HEV=hepatitis E virus; HHV-6=human herpesvirus 6; 
IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; LKM1=liver/kidney microsome-1 
antibody; MRI=magnetic resonance imagery; PCR=polymerase chain reaction; RNA=ribonucleic acid; 
SLA=soluble liver antigen 
Note: 
• 
All laboratory assessments will be measured in a central laboratory. The full panel of assessments should 
only be performed once; individual assessments may be repeated, as needed. 
6.5.6. 
Adverse Events 
6.5.6.1. 
Definitions 
Adverse Event 
According to the ICH E2A guideline Definitions and Standards for Expedited Reporting, and 21 
Code of Federal Regulations 312.32, Investigational New Drug Safety Reporting, an AE is any 
untoward medical occurrence in a patient or clinical investigational subject administered a 
medicinal product and which does not necessarily have a causal relationship with this treatment. 
Serious Adverse Event 
An SAE is any untoward medical occurrence that at any dose: 
• Results in death 
• Is life-threatening (an event which places the patient at immediate risk of death from 
the event as it occurred. It does not include an event that had it occurred in a more 
severe form might have caused death) 
• Requires inpatient hospitalization or prolongation of existing hospitalization 
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly or birth defect 
• Is an important medical event that may not be immediately life-threatening or result 
in death or hospitalization but may jeopardize the patient and may require 
intervention to prevent one of the other outcomes listed in the definition above (eg, 
events include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home, blood dyscrasias, convulsions, or the development of drug 
dependency or abuse). 
Adverse Events of Clinical Interest 
The following are considered to be AEs of clinical interest: 
• ALT or AST >3×ULN 
• Severe or serious ISRs; ISRs that are associated with a recall phenomenon (reaction 
at the site of a prior injection with subsequent injections), or those that lead to 
temporary dose interruption or permanent discontinuation of ALN-AGT01. 
An ISR is defined as a local reaction at or near the site of injection. “At or near” the 
injection site includes reactions at the injection site, adjacent to the injection site, or a 
reaction which may shift slightly away from the injection site due to gravity (eg, as 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
58 
may occur with swelling or hematoma). A systemic reaction which includes the 
injection site, eg, generalized urticaria, other distinct entities or conditions like 
lymphadenopathy that may be near the injection site is not considered an ISR. 
For information on recording and reporting of AEs of clinical interest, see Section 6.5.6.2 and 
Section 6.5.6.3, respectively. 
Adverse Event Severity 
Adverse events are to be graded according to the categories detailed below: 
Mild: 
Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated. 
Moderate: 
Moderate; minimal, local, or noninvasive intervention indicated; 
limiting age appropriate instrumental activities of daily living (eg, 
preparing meals, shopping for groceries or clothes, using the telephone, 
managing money). 
Severe: 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self-care activities of daily living (ie, bathing, dressing and 
undressing, feeding self, using the toilet, taking medications, and not 
bedridden); OR life-threatening consequences; urgent intervention 
indicated; OR death related to an adverse event. 
Changes in severity should be documented in the medical record to allow assessment of the 
duration of the event at each level of severity. Adverse events characterized as intermittent 
require documentation of the start and stop of each incidence. When changes in the severity of an 
AE occur more frequently than once a day, the maximum severity for the experience that day 
should be noted. If the severity category changes over a number of days, then those changes 
should be recorded separately (with distinct onset dates). 
Adverse event severity and seriousness are assessed independently. ‘Severity’ characterizes the 
intensity of an AE. ‘Serious’ is a regulatory definition and serves as a guide to the Sponsor for 
defining regulatory reporting obligations (see definition for SAE). 
Relationship of the Adverse Event to Study Drug 
The relationship of each AE to study drug should be evaluated by the Investigator by a “yes” or 
“no” response to the question: “Is there a reasonable possibility that the event may have been 
caused by the study drug?” A “yes” response indicates that the event is considered as related to 
the study drug. 
6.5.6.2. 
Eliciting and Recording Adverse Events 
Eliciting Adverse Events 
The patient and legal guardian, if applicable, should be asked about medically relevant changes 
in the patient’s health since the last visit. The patient and legal guardian, if applicable, should 
also be asked if the patient has been hospitalized, had any accidents, used any new medications, 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
59 
or changed concomitant medication routines (both prescription and over-the-counter). In addition 
to patient observations, AEs will be documented from any clinically relevant laboratory findings, 
physical examination findings, ECG changes, or other findings that are relevant to patient safety. 
Recording Adverse Events 
The Investigator is responsible for recording non-serious AEs that are observed or reported by 
the patient after administration of the first dose of study drug regardless of their relationship to 
study drug through the end of study. Non-serious AEs will be followed until the end of study. 
Events occurring after signing of the ICF and before study drug administration will be captured 
as medical history (see Section 6.1), while AEs that occur after study drug administration, and 
baseline events that worsen after study drug administration, must be recorded as AEs.  
The Investigator is responsible for recording SAEs that are observed or reported by the patient 
after the time when the informed consent is signed regardless of their relationship to study drug 
through the end of study. SAEs will be followed until satisfactory resolution, until baseline level 
is reached, or until the SAE is considered by the Investigator to be chronic or the patient is 
stable, as appropriate. 
All AEs must be recorded in the source records for the clinical study center and in the eCRF for 
the patient, whether or not they are considered to be drug-related. Each AE must be described in 
detail: onset time and date, description of event, severity, relationship to study drug, action taken, 
and outcome (including time and date of resolution, if applicable). 
For SAEs, record the event(s) in the eCRF and, as applicable, the SAE form. 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the supplemental AEs of 
Clinical Interest eCRF should be completed. Additional clinical and laboratory information may 
be collected. Refer to CRF completion guidelines for details on reporting events in the 
supplemental AEs of Clinical Interest eCRF. 
For all ISRs, the Investigator, or delegate, should submit an Injection Site Reaction Signs or 
Symptoms eCRF, recording additional information regarding each injection site reaction that is 
entered on the AE eCRF (eg, symptom(s), injection site location, follow-up actions taken, etc). 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the Sponsor or its designee 
should be notified within 24 hours using the appropriate eCRF. 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee 
An assessment of the seriousness of each AE will be made by the Investigator. Any AE and 
laboratory abnormality that meets the SAE criteria in Section 6.5.6.1 must be reported to the 
Sponsor or designee within 24 hours from the time that clinical study center staff first learns of 
the event. All SAEs must be reported regardless of the relationship to study drug. 
The initial report should include at least the following information: 
• Patient’s study number 
• Description and date of onset of the event 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
60 
• Criterion for serious 
• Preliminary assignment of relationship to study drug, and 
• Investigator/site information 
To report the SAE, complete the eCRF and, as applicable, the SAE form. Within 24 hours of 
receipt of follow-up information, the Investigator must update the eCRF and, as applicable, the 
SAE form. Serious adverse events must be reported using the contact information provided in the 
Study Manual. 
Appropriate remedial measures should be taken by the Investigator using his/her best medical 
judgment to treat the SAE. These measures and the patient’s response to these measures should 
be recorded. All SAEs, regardless of relationship to study drug, will be followed by the 
Investigator until satisfactory resolution or the Investigator deems the SAE to be chronic or 
stable. Clinical, laboratory, and diagnostic measures should be employed by the Investigator as 
needed to adequately determine the etiology of the event. 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities 
The Sponsor or its representative will report certain study events in an expedited manner to the 
Food and Drug Administration, the European Medicines Agency’s EudraVigilance electronic 
system according to Directive 2001/20/EC, and to all country Regulatory Authorities where the 
study is being conducted, according to local applicable regulations. 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee 
Suspected unexpected serious adverse reactions will be reported to the IRB/IEC per their 
institutional policy by the Investigator or Sponsor (or Sponsor designee) according to country 
requirements. Copies of each report and documentation of IRB/IEC notification and 
acknowledgement of receipt will be kept in the Investigator’s study file. 
6.5.6.7. 
Pregnancy Reporting 
If a female patient becomes pregnant during the study through safety follow-up (Section 3.1), the 
Investigator must report the pregnancy to the Sponsor or designee within 24 hours of being 
notified of the pregnancy. Details of the pregnancy will be recorded on the pregnancy reporting 
form. The patient should receive any necessary counseling regarding the risks of continuing the 
pregnancy, the possible effects on the fetus, and be counseled not to breastfeed for 90 days after 
the last dose of study drug. 
The pregnancy should be followed by the Investigator until completion. At the completion of the 
pregnancy, the Investigator will document the outcome of the pregnancy. If the outcome of the 
pregnancy results in a postpartum complication, spontaneous abortion, stillbirth, neonatal death, 
or congenital anomaly, then the Investigator should follow the procedures for reporting an SAE 
as outlined in Section 6.5.6.4. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
61 
6.5.6.8. 
Overdose and Other Special Situations Reporting 
An overdose is defined as any dose of study drug administered to the participant or taken by the 
participant that is >2× the assigned dose during a single administration and/or ≥2 doses within ½ 
the intended dosing interval. 
The Sponsor does not recommend specific treatment for an overdose.  
In an event of an overdose or other special situations (eg, medication error, abuse, misuse, CPC 
associated with an AE), the Investigator should: 
• Contact the Medical Monitor within 24 hours  
• Submit the special situations reporting form within 24 hours using the contact 
information in the Pharmacy Manual 
• Closely monitor the participant for any AE/SAE and laboratory abnormalities 
• Document the amount of study drug given  
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or 
a concomitant medication will be considered AEs/SAEs.  
Full details of overdose and other special situations reporting instructions will be outlined in the 
Pharmacy Manual. 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository 
Alnylam’s RNAi therapeutics platform permits the highly specific targeting of investigational 
therapies based on genetic sequence. It is possible that variations in the target genetic sequence 
will result in variations in drug effect. More generally, genetic variations may account for the 
well-described heterogeneous manifestations of disease in patients with hypertension, as well as 
their responses to treatment. 
Where allowed per local regulations, ethics committee (IRB/IEC) approval, and patient consent, 
samples will be collected as part of this study to permit exploratory investigations and the 
application of novel approaches to bioanalyses that may further elucidate the outcomes of this 
study, or potentially advance understanding of the safety, mechanism of action, and/or efficacy 
of ALN-AGT01. 
Biological specimens will be collected at the intervals indicated in the Schedule of Assessments 
(Table 1). In addition to the dedicated collections for optional exploratory biomarkers (urine, 
plasma, serum), aliquots from each 24-hour urine collection will be archived for potential 
exploratory investigations. These specimens will be analyzed at a central laboratory. Potential 
exploratory investigations may include DNA, RNA, or biochemical metabolite assessments as 
they relate to disease progression, efficacy, or safety. 
The biospecimen repository will also include residual material from routine samples (safety 
laboratory samples, PK samples, etc) that are obtained during the study. 
These specimens will be securely stored in a central biorepository for up to 10 years following 
the completion of this clinical study (ie, last patient last visit), or as per local regulations. After 
10 years have elapsed, samples will be destroyed. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
62 
Details regarding the collection, processing, storage, and shipping of the samples will be 
provided in the Laboratory Manual. 
Exploratory analysis of these biospecimens will be performed by Alnylam Pharmaceuticals or its 
designees. 
When biobanking is permitted by local regulation, study participants will be advised during the 
informed consent process of these biobanking details and the potential for exploratory 
investigation of their samples. 
7. 
STATISTICS 
A Statistical Analysis Plan (SAP) will be finalized before database lock and unblinding for the 
primary analysis. The plan will detail the implementation of the statistical analyses in accordance 
with the principle features stated in the protocol. 
7.1. 
Determination of Sample Size 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline in 
24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 375 
patients (75 per treatment group) provides at least 84% power to detect a dose response 
relationship in SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided 
significance level of 0.05. In addition, this sample size provides at least 80% power to detect a 
10 mmHg difference between an individual ALN-AGT01 dose versus placebo with a 2-sided 
significance level of 0.05. Table 8 shows the statistical power with various standard deviation 
assumptions. 
Table 8: 
Statistical Power to Detect 10 mmHg Difference Between ALN-AGT01 and 
Placebo With Various Standard Deviation Assumptions 
Assumption of Standard 
Deviation (mmHg) 
Statistical Power to Detect 
Dose Response Trend (%) 
Statistical Power to Detect Difference 
Between an Individual ALN-AGT01 
Dose Versus Placebo (%) 
15 
97 
96 
18 
90 
88 
20 
84 
80 
7.2. 
Statistical Methodology 
The statistical and analytical plans presented below are brief summaries of planned analyses. 
More complete plans will be detailed in the SAP. Changes to the methods described in the final 
SAP will be described and justified as needed in the clinical study report. For information on 
study endpoints, see Section 2. 
7.2.1. 
Populations to be Analyzed 
The populations (analysis sets) are defined as follows: 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
63 
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• PK Analysis Set: All patients who received at least 1 full dose of ALN-AGT01 and 
have at least 1 nonmissing postdose PK assessment. 
• PD Analysis Set: All patients who received at least 1 full dose of study drug. All by-
treatment analyses based on the PD Analysis Set will be grouped according to the 
treatment actually received. 
• All ALN-AGT01 Treated Set: All patients who received any amount of 1 of the 4 
ALN-AGT01 dosing regimens, including patients who took ALN-AGT01 during the 
6-month placebo-controlled period and patients who initially took placebo and then 
switched to ALN-AGT01 after the Month 6 visit. 
The primary population used to evaluate efficacy will be the FAS. For the efficacy endpoints of 
change from baseline to Month 3, ALN-AGT01 300 mg once every 3 months and once every 6 
months will be pooled together and analyzed. For all other efficacy endpoints, analysis will be 
performed according to the randomized treatment arm. 
Safety will be analyzed using the Safety Analysis Set. The PK and PD Analysis Sets will be used 
to conduct PK and PD analyses, respectively. 
7.2.2. 
Examination of Subgroups 
Subgroup analyses will be conducted for selected endpoints. Subgroup categories and detailed 
methodology will be provided in the SAP. 
7.2.3. 
Handling of Missing Data 
Handling of missing data will be described in the SAP. 
7.2.4. 
Baseline Evaluations 
Demographics and other disease-specific baseline characteristics will be summarized. 
In general, baseline will be defined as the average of all assessments, including unscheduled 
assessments, prior to the first dose of study drug. Details of the definition will be specified in the 
SAP. 
7.2.5. 
Efficacy Analyses 
The primary endpoint is the change in SBP from baseline at Month 3 assessed by ABPM. The 
primary hypothesis of the dose response relationship for the primary endpoint across 
ALN-AGT01 doses and placebo will be tested using a multiple comparison– modeling (MCP 
Mod) approach.[Bretz 2005] The presence of a dose-response trend will be initially tested 
against a set of prespecified dose-response models at a 2-sided significance level of 0.05, 
adjusted for multiplicity (the MCP step). Several candidate models will be prespecified in the 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
64 
SAP. Then, the dose-response curves will be further estimated (the modeling step) based on the 
‘best’ fitted dose response model. Furthermore, each ALN-AGT01 dose group will be compared 
against placebo using Dunnett’s Test.  
For the secondary endpoints of change in DBP assessed by ABPM at Month 3 and change in 
SBP and DBP assessed by ABPM at Month 6, each ALN-AGT01 dose group will be compared 
with placebo. For change in office SBP and DBP, each ALN-AGT01 dose group will be 
compared with placebo at Month 3 and Month 6 and also using the time-adjusted average from 
Month 1 to Month 3 and from Month 1 to Month 6. 
No multiplicity adjustment is applied across primary and secondary endpoints.  
Details of the analysis method for primary, secondary, and exploratory endpoints will be 
described in the SAP. 
7.2.6. 
Pharmacodynamic Analysis 
Pharmacodynamic analyses will include the evaluation of changes in levels of serum AGT and 
other exploratory biomarkers of the RAAS pathway. Descriptive statistics for observed levels 
and the relative change from baseline for all measured biomarkers will be presented for each of 
the postdose time points. 
Statistical comparison of the biomarker levels (absolute and/or change from baseline) across 
treatment groups may be explored. Details of the analysis will be specified in the SAP.  
Population PK/PD analysis may be conducted to evaluate the dose-response relationships for PD 
lowering after ALN-AGT01 treatment. Additionally, the relationship between lowering of serum 
AGT and blood pressure may be explored within a modeling framework. If conducted, these 
analyses will be described in a pharmacometrics analysis plan and results will be presented in a 
separate report. 
7.2.7. 
Pharmacokinetic Analysis 
Plasma concentrations of ALN-AGT01 and its metabolite AS(N-1)3′ ALN-AGT01 will be 
summarized using descriptive statistics. 
Population PK analysis may be conducted on the PK data from this study. If conducted, the 
analysis methods will be described in a pharmacometrics analysis plan and results will be 
presented in a separate report. 
7.2.8. 
Safety Analyses 
The primary parameter is the frequency of treatment-emergent AEs (hereafter referred to simply 
as AEs). Safety parameters also include vital signs, ECGs, clinical laboratory assessments and 
physical exams. Extent of exposure will be summarized.  
Prior and concomitant medications will be coded using the World Health Organization Drug 
Dictionary. Results will be tabulated by Anatomical Therapeutic Chemical Classification System 
and Preferred Term (PT). 
Adverse events will be classified according to the Medical Dictionary for Regulatory Activities 
(MedDRA) System Organ Class (SOC) and PT. Adverse events, SAEs, related AEs, AEs leading 
to discontinuation of study drug, and AEs leading to death will be summarized by SOC and PT 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
65 
for each treatment arm. By-patient listings will be provided for deaths, SAEs, and AEs leading to 
discontinuation of study drug.  
Descriptive statistics will be provided for clinical laboratory parameters, ECG, and vital signs 
summarizing the observed values and changes from baseline over time. Laboratory shift tables 
from baseline grade (or category) to worst post-baseline grade (or category) will be presented for 
laboratory parameters that are graded or categorized. Abnormal physical exam findings will be 
presented in listings. 
Other safety summaries will be presented as appropriate. Further details will be specified in the 
SAP. 
7.2.9. 
Immunogenicity Analyses 
The frequency and percentage of patients with confirmed positive ADA assay at any time during 
the study as well as at each scheduled visit will be summarized. The titer results for patients with 
confirmed positive ADA results will be summarized. 
7.2.10. 
Interim Analysis 
The primary analysis will be conducted after all patients complete the Month 6 visit or withdraw 
from the study prior to the Month 6 visit. No formal interim analysis is planned before the 
primary analysis.  
7.2.11. 
Optional Additional Research 
Optional additional research may be conducted in the future on the biological samples and/or 
data collected during the study in accordance with the strict terms of the ICF (see Section 4.3.2). 
8. 
STUDY ADMINISTRATION 
8.1. 
Ethical and Regulatory Considerations 
This study will be conducted in accordance with the protocol, all applicable regulatory 
requirements, and the current guidelines of Good Clinical Practice (GCP). Compliance with GCP 
provides public assurance that the rights, safety, and well-being of study patients are protected 
consistent with the principles that have their origin in the Declaration of Helsinki. 
8.1.1. 
Informed Consent 
The Investigator will ensure that the patient is given full and adequate oral and written 
information about the nature, purpose, possible risk, and benefit of the study. Patients must also 
be notified that they are free to discontinue from the study at any time. The patient should be 
given the opportunity to ask questions and allowed time to consider the information provided. 
The Investigator will inform the patient/legal guardian if new information becomes available that 
may be relevant to the patient’s/legal guardian’s willingness to continue participation in the 
study. Communication of this information should be documented. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
66 
The patient’s signed and dated informed consent (in paper or electronic format per local 
regulations and institutional standards) must be obtained before conducting any study tests or 
procedures that are not part of routine care. 
The Investigator must maintain the original, signed ICF. A copy of the signed ICF must be given 
to the patient or legal guardian. 
8.1.2. 
Ethical Review 
The study protocol, including the ICF, must be approved or given a favorable opinion in writing 
by an IRB or IEC, as appropriate. The Investigator must submit written approval before he or she 
can enroll any patient into the study. 
The Investigator is responsible for informing the IRB or IEC of any amendment to the protocol 
in accordance with local requirements. In addition, the IRB or IEC must approve all patient 
materials for the study. The protocol must be reapproved by the IRB or IEC upon receipt of 
amendments and annually, as local regulations require. 
Initial IRB or IEC approval of the protocol, and all materials approved by the IRB or IEC for this 
study including the patient consent form and recruitment materials must be maintained by the 
Investigator and made available for inspection. 
The Investigator will submit reports of SAEs as outlined in Section 6.5.6. In addition, the 
Investigator agrees to submit progress reports to the IRB or IEC per their local reporting 
requirements, or at least annually and at the conclusion of the study. The reports will be made 
available to the Sponsor or designee. 
Any communications from regulatory agencies, IRBs, or IECs in regard to inspections, other 
studies that impact this protocol or the qualifications of study personnel should be promptly 
reported to the Sponsor or its designee. 
The Investigator is also responsible for providing the IRB or IEC with reports of any reportable 
serious adverse drug reactions from any other study conducted with the study drug. The Sponsor 
or designee will provide this information to the Investigator. 
Major changes in this research activity, except those to remove an apparent immediate hazard to 
the patient, must be reviewed and approved by the Sponsor and the IRB or IEC that approved the 
study. Amendments to the protocol must be submitted in writing to the Investigator’s IRB or IEC 
and the Regulatory Authority for approval before patients are enrolled under the amended 
protocol, and patients or their legal guardians must be re-consented to the most current version of 
the ICF.  
8.1.3. 
Serious Breach of Protocol 
Investigators must notify the Medical Monitor within 24 hours of becoming aware of a potential 
serious breach of the protocol. A serious breach is a breach that is likely to affect to a significant 
degree the safety and rights of a study participant or the reliability and robustness of the data 
generated in the clinical study. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
67 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention 
All documentation (including personal data) relating to the study should be retained for 2 years 
after the last approval in an ICH territory or as required by local laws and regulations, whichever 
is longer. 
If it becomes necessary for the Sponsor, the Sponsor’s designee, applicable IRB/IEC, or 
applicable regulatory authorities to review or audit any documentation relating to the study, the 
Investigator must permit direct access to all source documents/data. Records will not be 
destroyed without informing the Sponsor in writing and giving the Sponsor the opportunity to 
store the records for a longer period of time at the Sponsor’s expense. 
The Investigator must ensure that the patients’ confidentiality will be maintained. On the eCRFs 
or other documents submitted to the Sponsor or designees, patients should not be identified by 
their names, but by the assigned patient number or code. If patient names are included on copies 
of documents to be submitted to the Sponsor or designees, the names will be obliterated, and the 
assigned patient number added to the document, before sending to the Sponsor. Documents not 
for submission to the Sponsor (eg, signed ICFs) should be maintained by the Investigator in strict 
confidence. 
The Investigator must treat all of the information related to the study and the compiled data as 
confidential, whose use is for the purpose of conducting the study. The Sponsor must approve 
any transfer of information not directly involved in the study. 
To comply with local and/or regional regulations, this clinical study may be registered, and study 
results may be posted on public registries, such as ClinicalTrials.gov. 
8.1.5. 
End of Study 
The end of study is defined as the last patient last visit. 
8.1.6. 
Termination of the Clinical Study or Site Closure 
The Sponsor, or designee, reserves the right to terminate the study or a clinical study site at any 
time. Conditions that may warrant this action may include, but are not limited to: 
• The discovery of an unexpected, serious, or unacceptable risk to patients participating 
in the study 
• Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of participants by the Investigator 
• The decision on the part of the Sponsor to suspend or discontinue treatment with the 
study drug 
Should the study be terminated, and/or the site closed for whatever reason, all documentation and 
study drug pertaining to the study must be returned to the Sponsor or its representative, and the 
Investigators, IRB/IEC and Regulatory Authorities will be promptly informed of the termination 
and the reason for the decision. The Investigator should promptly inform the patients and assure 
appropriate therapy and follow-up. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
68 
8.2. 
Data Quality Control and Quality Assurance 
8.2.1. 
Data Handling 
Study data must be recorded on CRFs (paper and/or electronic) provided by the Sponsor or 
designee on behalf of the Sponsor. Case report forms must be completed only by persons 
designated by the Investigator. If eCRFs are used, study data must be entered by trained site 
personnel with access to a valid and secure eCRF system. All data entered into the eCRF must 
also be available in the source documents. Corrections on paper CRFs must be made so as to not 
obliterate the original data and must be initialed and dated by the person who made the 
correction. 
8.2.2. 
Study Monitoring 
The Monitor, as a representative of the Sponsor, has an obligation to closely follow the study 
conduct at the site. The Monitor will visit the Investigator and clinical study center periodically 
and will maintain frequent telephone and written contact. The Monitor will maintain current 
personal knowledge of the study through observation, review of study records and source 
documentation, and discussion of the conduct of the study with the Investigator and staff. 
The Monitor will review source documents, systems and CRFs to ensure overall quality and 
completeness of the data and to confirm study procedures are complied with the requirements in 
the study protocol accurately. The Sponsor, or its designee, will be allowed to conduct site visits 
to the investigation facilities for the purpose of monitoring any aspect of the study. The 
Investigator agrees to allow the Monitor to inspect the drug storage area, study drug stocks, drug 
accountability records, patient charts and study source documents, site standard operating 
procedures and training records, and other records relative to study conduct. 
Where local regulations allow, the Monitor may request remote access to source documents and 
systems. Should this take place, it will be done in a manner that protects the confidentiality of the 
data. 
8.2.3. 
Audits and Inspections 
Periodically, the Sponsor or its authorized representatives audit clinical investigative sites as an 
independent review of core study processes and documents to determine whether these activities 
were conducted, and data were recorded, analyzed, and accurately reported according to the 
protocol, GCP guidelines of the ICH, and any applicable regulatory requirements. A regulatory 
authority, an IEC or an IRB may visit the site to perform audits or inspections, including source 
data verification. The Investigator should contact the Sponsor and designee immediately if 
contacted by a regulatory agency, an IEC, or an IRB about an inspection. 
8.3. 
Publication Policy 
It is intended that after completion of the study, the data are to be submitted for publication in a 
scientific journal and/or for reporting at a scientific meeting. A copy of any proposed publication 
(eg, manuscript, abstracts, oral/slide presentations, book chapters) based on this study, must be 
provided and confirmed received at the Sponsor at least 30 days before its submission. The 
Clinical Trial Agreement will detail the procedures for publications. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
69 
Authorship of any publications resulting from this study will be determined on the basis of the 
Uniform Requirement for Manuscripts Submitted to Biomedical Journals (International 
Committee of Medical Journal Editors). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
70 
9. 
LIST OF REFERENCES 
Angell SY, De Cock KM,Frieden TR. A public health approach to global management of 
hypertension. Lancet. 2015 Feb 28;385(9970):825-7. 
Beeftink MM, van der Sande NG, Bots ML, Doevendans PA, Blankestijn PJ, Visseren FL, et al. 
Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-
to-Control Hypertension. Hypertension. 2017 May;69(5):927-32. 
Bretz F, Pinheiro JC,Branson M. Combining multiple comparisons and modeling techniques in 
dose-response studies. Biometrics. 2005 Sep;61(3):738-48. 
Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to 
antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011 Mar;29(3):610-8. 
de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M, et al. Prevalence and 
factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension. 
2009 Mar;53(3):466-72. 
Dzau VJ,Balatbat CA. Future of Hypertension. Hypertension. 2019 Sep;74(3):450-7. 
Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of 
Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 
2017 Jan 10;317(2):165-82. 
Georgianos PI,Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding 
drugs. Kidney Int. 2018 Feb;93(2):325-34. 
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK,He J. Global burden of 
hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23. 
Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the 
Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-30. 
McClellan M, Brown N, Califf RM,Warner JJ. Call to Action: Urgent Challenges in 
Cardiovascular Disease: A Presidential Advisory From the American Heart Association. 
Circulation. 2019 Feb 26;139(9):e44-e54. 
McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, et al. Aliskiren, 
Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016 Apr 21;374(16):1521-
32. 
Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP,Crooke RM. Blood Pressure 
Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of 
Hypertension and Kidney Injury. Hypertension. 2017 Sep;70(3):566-76. 
Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, et al. Trends in Blood 
Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020 
Sep 22;324(12):1190-200. 
NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a 
pooled analysis of 1479 population-based measurement studies with 19.1 million participants. 
Lancet. 2017 Jan 7;389(10064):37-55. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
71 
Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and 
a lifecourse strategy to address the global burden of raised blood pressure on current and future 
generations: the Lancet Commission on hypertension. Lancet. 2016 Nov 26;388(10060):2665-
712. 
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. 
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 
6;367(23):2204-13. 
Peacock E,Krousel-Wood M. Adherence to Antihypertensive Therapy. Med Clin North Am. 
2017 Jan;101(1):229-45. 
Romero CA, Orias M,Weir MR. Novel RAAS agonists and antagonists: clinical applications and 
controversies. Nat Rev Endocrinol. 2015 Apr;11(4):242-52. 
Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE, et al. Medication 
adherence and persistence according to different antihypertensive drug classes: A retrospective 
cohort study of 255,500 patients. Int J Cardiol. 2016 Oct 1;220:668-76. 
Services UDoHaH. The Surgeon General's Call to Action to Control Hypertension. 2020 October 
2020:1-50. 
Uijl E, Mirabito Colafella KM, Sun Y, Ren L, van Veghel R, Garrelds IM, et al. Strong and 
Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen. 
Hypertension. 2019 Jun;73(6):1249-57. 
van der Laan DM, Elders PJM, Boons C, Beckeringh JJ, Nijpels G,Hugtenburg JG. Factors 
associated with antihypertensive medication non-adherence: a systematic review. J Hum 
Hypertens. 2017 Nov;31(11):687-94. 
Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients 
with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 
15;372(3):211-21. 
Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report 
of the American College of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115. 
White WB, Mansoor GA, Tendler BE,Anwar YA. Nocturnal blood pressure epidemiology, 
determinants, and effects of antihypertensive therapy. Blood Press Monit. 1998 Feb;3(1):43-51. 
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH 
Guidelines for the management of arterial hypertension: The Task Force for the management of 
arterial hypertension of the European Society of Cardiology and the European Society of 
Hypertension: The Task Force for the management of arterial hypertension of the European 
Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 
Oct;36(10):1953-2041. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
72 
10. 
APPENDICES 
10.1. 
Measurement of Blood Pressure 
All blood pressure measurements (office, ABPM, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in the 
relevant user manuals.  
The appropriately sized cuff for each modality must be used for all assessments. The arm’s 
circumference at midpoint (halfway between the acromion and olecranon) should be determined 
at screening with a metric tape measure and used to select the appropriately sized blood pressure 
cuff/bladder for each instrument as described in the Study Manual. Unless significant weight loss 
or gain occurs between visits, the patient should use the same cuff/bladder size throughout the 
study. 
At the first Screening visit only, office blood pressure will be measured in both arms to select the 
appropriate arm to use for office blood pressure and HBPM measurements. Unless a concomitant 
condition favors the use of a specific arm, the arm with the higher office SBP should be used for 
all subsequent office blood pressure and HBPM readings. The ABPM should be measured using 
the patient’s nondominant arm. If the patient is ambidextrous, the same arm used for office blood 
pressure and HBPM readings should be used. 
ABPM 
The appropriately sized cuff should be placed on the correct arm following the instructions in the 
Study Manual. In patients taking oral antihypertensives (including those initiated as rescue 
medication), ABPM should be started prior to the morning dose of antihypertensive medication. 
All ABPM collections must be in the outpatient/ambulatory state. ABPM recordings that are 
associated with dosing visits must be obtained in advance of the visit (within 7 days before the 
corresponding dosing visit) and the results reviewed prior to dosing. 
During the 24-hour monitoring period, patients must avoid strenuous exercise but should 
otherwise maintain their usual level of physical activity. The ABPM is programmed to take 
readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the 
night (10 pm to 5:59 am). While awake, the patient should hold their arm still by their side while 
the device is inflating for a reading. Patients must record the timing of going to sleep, waking up, 
and any oral medications taken during the ABPM, and these responses must be entered into the 
eCRF. 
After the monitoring period is complete, upload the ABPM data to receive a report with 
adequacy assessment. An ABPM will be considered adequate if (1) the number of successful 
daytime readings is ≥33, (2) the number of successful nighttime readings is ≥11, and (3) no more 
than 3 hours are not represented (ie, 3 sections of 60 minutes where 0 valid readings were 
obtained). If the ABPM recording is inadequate, the patient will be provided 1 opportunity to 
repeat the study within 4 days. If the second ABPM recording is also inadequate during 
screening, the patient is a screen failure. 
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor and the arm selected during screening. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
73 
Office blood pressure should be measured early in the visit prior to the morning dose of 
antihypertensive medication, before phlebotomy or other potentially stressful assessments. To 
minimize confounding by circadian changes, study visits should be scheduled for a consistent 
timeframe of the day. The use of inhaled short-acting beta agonists should be avoided within 6 
hours prior to measuring blood pressure and/or heart rate. The use of phosphodiesterase type 5 
inhibitors (eg, sildenafil, tadalafil, vardenafil, avanafil) should be avoided within 48 hours prior 
to measuring blood pressure. 
Before measuring blood pressure, confirm that there has been no exercise or use of caffeine or 
nicotine- or tobacco-containing products (including but not limited to snuff, chewing tobacco, 
cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) within the last 30 minutes. If necessary, 
delay blood pressure assessment to meet these requirements. Because a full bladder can impact 
blood pressure measurements, ask the patient to use the bathroom before the assessment. 
All office blood pressure assessments will include both seated and standing measurements.  
Seated Office Blood Pressure Measurement: For seated measurements, the patient should be in a 
comfortable resting position in a chair with their back supported and their feet flat on the floor. 
• Place the appropriately sized cuff on the correct arm with no clothing between the 
patient’s arm and the cuff and with the midpoint of the bladder length positioned over 
the brachial artery (located by palpation). The arm should be supported on an armrest 
or table with mid-cuff at heart level and the palm facing the ceiling. 
• Follow the Study Manual to initiate the automated blood pressure device’s seated 
measurement protocol. This program includes a 5-minute period of rest, followed by 
4 sequential blood pressure measurements at 1-minute intervals. The seated blood 
pressure for the visit will be defined by the average of the last 3 individual 
measurements. 
• During the device’s seated measurement protocol, the staff member should leave the 
room and the patient should remain at rest without distraction (avoid mobile phones). 
The following script may be used: “The blood pressure device works best when you 
are at rest and without any distraction. If you agree, I would like to leave the room for 
the next 10 to 15 minutes while it is recording. This will include a 5-minute period of 
rest, followed by about 5 minutes of the device inflating to measure your blood 
pressure”. 
Standing Office Blood Pressure Measurement: A standing measurement should be obtained 
immediately after collection of the seated measurements. 
• Being careful to maintain the cuff’s position, ask the patient to stand with the cuffed 
arm bent slightly and the hand of the cuffed arm supported at heart level.  
• Using a stopwatch or watch, measure standing blood pressure 1 minute after standing 
by using the automated blood pressure device’s single measurement protocol.  
• After the standing measurement, ask the patient if they experienced dizziness or light-
headedness when standing and enter their response in the eCRF. 
If a patient is unable to report to the site for an office blood pressure assessment, a substitute 
“remote visit blood pressure measurement” may be obtained remotely by a visiting nurse or other 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 (zilebesiran) 
Amendment 3, 09 December 2021 
Alnylam Pharmaceuticals 
Confidential 
74 
appropriately trained personnel who will bring an office blood pressure instrument to the 
patient’s location and follow the same procedure performed at the site. If a home visit is not 
possible, a “remote visit blood pressure measurement” should instead be obtained using the 
patient’s HBPM instrument under direct supervision (phone call or teleconferencing) by 
appropriately trained study staff, following the instructions detailed in the Study Manual. Results 
and the remote method used should be entered into the eCRF. 
HBPM 
Patients should measure HBPM every morning, prior to breakfast/caffeine or taking morning 
oral medications. HBPM is not required at times when ABPM is being assessed. The HBPM 
measurement should be obtained in a room without distractions, seated comfortably with the 
back supported and feet flat on the floor. The patient will initiate the automated blood pressure 
program on their HBPM device. This program includes a 5-minute period of rest, followed by 4 
sequential blood pressure measurements at 1-minute intervals. The seated blood pressure for the 
visit will be defined by the average of the last 3 individual measurements.  
To establish baseline, each patient must measure HBPM for at least 2 consecutive weeks (and 
with at least 3 successful readings per week) prior to randomization. Patients previously taking 
medication for hypertension must be without antihypertensives for ≥2 weeks prior to collecting 
these baseline HBPM measurements (4 weeks of washout is required for long-acting 
antihypertensive medications, such as long-acting diuretics or CCBs). If adequate baseline 
HBPM data (at least 3 successful readings per week for at least 2 consecutive weeks) are not 
collected within the Screening period, the patient is a screen failure. 
After Day 1, HBPM should be measured at least 3 times per week. Patients may select the 3 days 
of the week that are most convenient for their personal schedule. The frequency of HBPM 
monitoring should be increased to daily during the temporary hold of oral antihypertensives 
performed in some patients from Month 5 to Month 6. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
1 
 
CLINICAL STUDY PROTOCOL 
ALN-AGT01-002 
DATED 09 JUNE 2021 
 
Protocol Title:  
A Randomized, Double-blind, Placebo-Controlled, 
Dose-Ranging Multicenter Study to Evaluate the 
Efficacy and Safety of ALN-AGT01 in Patients 
with Mild-to-Moderate Hypertension 
Short Title: 
A Study to Evaluate Efficacy and Safety of 
ALN-AGT01 in Patients with Mild-to-Moderate 
Hypertension (KARDIA-1) 
Study Drug: 
ALN-AGT01 
EudraCT Number: 
2021-001248-82 
IND Number: 
143503 
Protocol Date: 
Original protocol, 09 April 2021 
Amendment 1, 20 April 2021 
Amendment 2, 09 June 2021 
Sponsor: 
Alnylam Pharmaceuticals, Inc. 
300 Third Street 
Cambridge, MA  02142 USA 
Telephone: +1-617-551-8200 
Sponsor Contact: 
 
 
The concepts and information contained in this document or generated during the study are considered 
proprietary and may not be disclosed in whole or in part without expressed written authorization of 
Alnylam Pharmaceuticals, Inc. 
 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
2 
SPONSOR PROTOCOL APPROVAL 
 
I have read this protocol and I approve the design of this study. 
 
 
 
___________________________________________  
 
 
Alnylam Pharmaceuticals, Inc. 
 
___________________________________________  
Date 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
3 
INVESTIGATOR’S AGREEMENT 
 
I have read the ALN-AGT01-002 protocol and agree to conduct the study in accordance with the 
protocol and all applicable regulations. I agree to maintain the confidentiality of all information 
received or developed in connection with this protocol. 
 
 
 
___________________________________________  
Printed Name of Investigator 
 
 
 
___________________________________________  
Signature of Investigator 
 
 
 
___________________________________________  
Date 






Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
6 
of the study design is provided in Figure 1. Before randomization, patients will discontinue prior 
antihypertensive medications (if taking) for a Washout period of at least 4 weeks. Patients who 
complete the Screening period and meet all inclusion/exclusion criteria for enrollment will 
receive ALN-AGT01 or placebo for the first 6 months of the 12-month Double-blind (DB) 
treatment period.  
Starting at Month 3, conventional oral antihypertensives may be added per Investigator 
judgement for elevated blood pressure. Oral antihypertensives (if taking) will be temporarily 
held from Month 5 to Month 6 to assess the effect of ALN-AGT01 alone (vs placebo) at Month 6 
by ambulatory blood pressure monitoring (ABPM). During this 4-week period, blood pressure 
will be carefully monitored by daily home blood pressure monitoring and medications restarted 
if indicated. Patients may resume conventional oral antihypertensives at Month 6 per Investigator 
judgement. 
Patients randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial 
ALN-AGT01 regimens until the end of the DB period. Patients randomized to ALN-AGT01 
regimens will remain on their originally assigned regimens through Month 12. 
After the 12-month DB treatment period, patients may be eligible to participate in an 
ALN-AGT01 open-label extension (OLE) study. If an individual patient reaches Month 12 prior 
to availability of the OLE study, they may continue their current blinded dosing in the DB 
Extension period for up to 12 additional months until the OLE study is open and then transition. 
Number of Planned Patients 
Approximately 375 patients will be enrolled in this study. 
Diagnosis and Main Eligibility Criteria 
This study will include adults (18 to 75 years, inclusive) with untreated hypertension or on stable 
therapy with 1 or more antihypertensive medications of the following classes: an angiotensin 
converting enzyme inhibitor, angiotensin II-receptor blocker, renin inhibitor, calcium channel 
blocker, thiazide diuretic, and/or thiazide-like diuretic. Patients should have a daytime mean 
systolic blood pressure (SBP) ≥135 mmHg and ≤160 mmHg by ABPM at least 4 weeks after 
washout of background antihypertensive medication. Patients with secondary hypertension or 
orthostatic hypotension will be excluded. 
Study Drug, Dose, and Mode of Administration 
ALN-AGT01 is an SC administered N-acetylgalactosamine-conjugated small interfering RNA 
targeting liver-expressed messenger RNA for angiotensinogen (AGT). 
Patients randomized to receive ALN-AGT01 will be administered 150 mg ALN-AGT01 SC once 
every 6 months, 300 mg ALN-AGT01 SC once every 6 months, 300 mg ALN-AGT01 SC once 
every 3 months, or 600 mg ALN-AGT01 SC once every 6 months during the 12-month DB 
period and DB Extension period. Patients randomized to receive placebo will be randomized to 1 
of the 4 initial dose regimens of ALN-AGT01 beginning at Month 6.  
Reference Treatment, Dose, and Mode of Administration 
Placebo (sodium chloride 0.9% w/v for SC administration) will be administered once every 3 
months and at the same volume as the study drug. Patients receiving once every 6 months 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
7 
ALN-AGT01 regimens will receive placebo SC at dosing visits at which they do not receive 
ALN-AGT01 to maintain the blind. 
Duration of Treatment and Study Participation 
The duration of treatment with ALN-AGT01 is up to 24 months. The estimated total time on 
study for each patient is up to 44 months, including up to 2 months of screening, followed by up 
to 24 months of treatment, and up to 18 months in the Follow-up period. 
Statistical Methods 
The planned enrollment for this study is 375 patients. Randomization will be stratified by race 
(black vs all other races) and by baseline blood pressure (mean 24-hour SBP < or ≥145 mmHg). 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline in 
24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 375 
patients (75 per treatment group) provides at least 84% power to detect a dose response 
relationship in SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided 
significance level of 0.05. In addition, this sample size provides at least 80% power to detect a 10 
mmHg difference between an individual ALN-AGT01 dose versus placebo with a 2-sided 
significance level of 0.05.  
The populations (analysis sets) are defined as follows:  
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• Pharmacokinetic (PK) Analysis Set: All patients who received at least 1 full dose of 
study drug and have at least 1 evaluable postdose blood sample for the determination 
of plasma ALN-AGT01 concentrations. 
• PD Analysis Set: All patients who received any amount of study drug and who have 
baseline and at least 1 postdose blood sample for the determination of serum AGT 
will be included in the PD analyses. 
The primary population used to evaluate efficacy will be the FAS. For the efficacy endpoints of 
change from baseline to Month 3, ALN-AGT01 300 mg once every 3 months and once every 6 
months will be pooled together and analyzed. For all other efficacy endpoints, analysis will be 
performed according to the randomized treatment arm. 
Safety will be analyzed using the Safety Analysis Set. The PK and PD Analysis Sets will be used 
to conduct PK and PD analyses, respectively. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
8 
Figure 1: 
Study Design 
 
Abbreviations: aHTN=antihypertensive medications; DB=double-blind; M=month; OLE=open-label extension; 
PBO=placebo; PO=per os (oral); Q3M=once every 3 months; Q6M=once every 6 months; R=randomization; 
SC=subcutaneous; WO=washout. 
Note: Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the Month 12 
predose assessments. If an individual patient reaches Month 12 prior to availability of the OLE study, they may 
continue their current blinded dosing in the DB Extension period for up to 12 additional months until the OLE study 
is open and then transition. Once the OLE study is open for enrollment, eligible patients may rollover into the OLE 
study at Months 12, 18, or 24 (whichever visit occurs first). 












Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
14 
Table 2: 
PK Time Points 
Study Day 
Sampling Time 
(hh:mm) 
Plasma PK Sample 
Day 1  
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Day 169±7 
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Abbreviations: hh:mm=hour:minute; PK=pharmacokinetics. 
Notes:  
• 
The hour (±range) indicates sample collection timing relative to dosing. Precise PK sample times (hour 
and minute) are recorded. Refer to Section 6.4 for additional information on PK assessments. 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
15 
TABLE OF CONTENTS 
SPONSOR PROTOCOL APPROVAL ...........................................................................................2 
INVESTIGATOR’S AGREEMENT ...............................................................................................3 
PROTOCOL SYNOPSIS ................................................................................................................4 
TABLE OF CONTENTS ...............................................................................................................15 
LIST OF TABLES .........................................................................................................................19 
LIST OF FIGURES .......................................................................................................................19 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ................................................20 
1. 
INTRODUCTION ......................................................................................................22 
1.1. 
Study Rationale ...........................................................................................................22 
1.2. 
Background .................................................................................................................22 
1.3. 
Benefit-Risk Assessment ............................................................................................23 
2. 
OBJECTIVES AND ENDPOINTS ............................................................................24 
3. 
INVESTIGATIONAL PLAN .....................................................................................26 
3.1. 
Summary of Study Design ..........................................................................................26 
3.2. 
Scientific Rationale for Study Design ........................................................................27 
3.3. 
Justification for Dose ..................................................................................................29 
3.4. 
Method of Assigning Patients to Treatment Groups ..................................................29 
3.5. 
Blinding ......................................................................................................................30 
3.5.1. 
Emergency Unblinding ...............................................................................................30 
3.6. 
Data Monitoring Committee .......................................................................................31 
3.7. 
Clinical Event Adjudication Committees ...................................................................31 
3.8. 
Definition of End of Study for an Individual Patient .................................................31 
4. 
SELECTION AND REMOVAL OF PATIENTS ......................................................31 
4.1. 
Inclusion Criteria ........................................................................................................31 
4.2. 
Exclusion Criteria .......................................................................................................32 
4.3. 
Removal from Study Drug or Assessment .................................................................34 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments ......................34 
4.3.2. 
Stopping a Patient’s Study Participation ....................................................................35 
4.3.2.1. 
Patient or Legal Guardian Stops Participation in the Study .......................................35 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection 
to Process Patient’s Personal Data ..............................................................................36 
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study ........................36 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
16 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation ................................37 
4.3.3. 
Lost to Follow-Up.......................................................................................................37 
4.3.4. 
Replacement of Study Patients ...................................................................................37 
5. 
TREATMENTS AND OTHER REQUIREMENTS ..................................................37 
5.1. 
Treatments Administered ............................................................................................37 
5.2. 
Study Drug ..................................................................................................................37 
5.2.1. 
Description ..................................................................................................................38 
5.2.2. 
Dose and Administration ............................................................................................38 
5.2.3. 
Dose Modifications .....................................................................................................39 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping 
Study Drug Dosing .....................................................................................................39 
5.2.5. 
Neurological Criteria for Withholding, Monitoring, and Stopping Study 
Drug Dosing ................................................................................................................40 
5.2.6. 
Preparation, Handling, and Storage ............................................................................40 
5.2.7. 
Packaging and Labeling ..............................................................................................41 
5.2.8. 
Accountability .............................................................................................................41 
5.3. 
Clinical Product Complaints .......................................................................................41 
5.3.1. 
Definition ....................................................................................................................41 
5.3.2. 
Reporting ....................................................................................................................41 
5.4. 
Monitoring for Potential Clinical Events ....................................................................41 
5.4.1. 
Monitoring and Approach for Potential Hypotension ................................................41 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure 
Elevation .....................................................................................................................42 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction .......................................44 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia ..............................................44 
5.5. 
Concomitant Medications and Procedures .................................................................45 
5.5.1. 
Oral Antihypertensive Medication .............................................................................46 
5.5.2. 
Prohibited Concomitant Medication ...........................................................................46 
5.6. 
Treatment Compliance ................................................................................................47 
5.7. 
Other Requirements ....................................................................................................47 
5.7.1. 
Contraception ..............................................................................................................47 
5.7.2. 
Alcohol Restrictions ...................................................................................................48 
5.7.3. 
Tobacco and Nicotine Restrictions .............................................................................48 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
17 
5.7.4. 
Dietary Recommendations ..........................................................................................48 
5.7.5. 
Exercise .......................................................................................................................48 
6. 
STUDY ASSESSMENTS ..........................................................................................48 
6.1. 
Screening Assessments ...............................................................................................49 
6.1.1. 
Retesting .....................................................................................................................49 
6.1.2. 
Rescreening .................................................................................................................49 
6.2. 
Efficacy Assessments .................................................................................................49 
6.2.1. 
ABPM .........................................................................................................................50 
6.2.2. 
Office Blood Pressure .................................................................................................50 
6.2.3. 
HBPM .........................................................................................................................50 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment ....................................................50 
6.3. 
Pharmacodynamic Assessments .................................................................................51 
6.4. 
Pharmacokinetic Assessments ....................................................................................51 
6.5. 
Safety Assessments .....................................................................................................51 
6.5.1. 
Vital Signs ..................................................................................................................51 
6.5.2. 
Weight, Height, and Morphometrics ..........................................................................52 
6.5.3. 
Physical Examination .................................................................................................52 
6.5.4. 
Electrocardiogram .......................................................................................................53 
6.5.5. 
Clinical Laboratory Assessments ...............................................................................53 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments ........................................................55 
6.5.5.2. 
Immunogenicity ..........................................................................................................55 
6.5.5.3. 
Pregnancy Testing ......................................................................................................55 
6.5.5.4. 
Additional Liver Function Assessments .....................................................................56 
6.5.6. 
Adverse Events ...........................................................................................................57 
6.5.6.1. 
Definitions ..................................................................................................................57 
6.5.6.2. 
Eliciting and Recording Adverse Events ....................................................................58 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee .........................59 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee ...........59 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities .................................................60 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee ........................................................................60 
6.5.6.7. 
Pregnancy Reporting ..................................................................................................60 
6.5.6.8. 
Overdose and Other Special Situations Reporting .....................................................61 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
18 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository ...................................61 
7. 
STATISTICS ..............................................................................................................62 
7.1. 
Determination of Sample Size ....................................................................................62 
7.2. 
Statistical Methodology ..............................................................................................62 
7.2.1. 
Populations to be Analyzed ........................................................................................62 
7.2.2. 
Examination of Subgroups .........................................................................................63 
7.2.3. 
Handling of Missing Data ...........................................................................................63 
7.2.4. 
Baseline Evaluations ...................................................................................................63 
7.2.5. 
Efficacy Analyses .......................................................................................................63 
7.2.6. 
Pharmacodynamic Analysis........................................................................................64 
7.2.7. 
Pharmacokinetic Analysis ..........................................................................................64 
7.2.8. 
Safety Analyses ..........................................................................................................64 
7.2.9. 
Immunogenicity Analyses ..........................................................................................65 
7.2.10. 
Interim Analysis ..........................................................................................................65 
7.2.11. 
Optional Additional Research .....................................................................................65 
8. 
STUDY ADMINISTRATION ...................................................................................65 
8.1. 
Ethical and Regulatory Considerations ......................................................................65 
8.1.1. 
Informed Consent .......................................................................................................65 
8.1.2. 
Ethical Review ............................................................................................................66 
8.1.3. 
Serious Breach of Protocol .........................................................................................66 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention .................................66 
8.1.5. 
End of Study ...............................................................................................................67 
8.1.6. 
Termination of the Clinical Study or Site Closure .....................................................67 
8.2. 
Data Quality Control and Quality Assurance .............................................................67 
8.2.1. 
Data Handling .............................................................................................................67 
8.2.2. 
Study Monitoring ........................................................................................................68 
8.2.3. 
Audits and Inspections ................................................................................................68 
8.3. 
Publication Policy .......................................................................................................68 
9. 
LIST OF REFERENCES ............................................................................................69 
10. 
APPENDICES ............................................................................................................71 
10.1. 
Measurement of Blood Pressure .................................................................................71 
 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
19 
LIST OF TABLES 
Table 1: 
Schedule of Assessments ..............................................................................................9 
Table 2: 
PK Time Points ...........................................................................................................14 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative 
Cause Identified ..........................................................................................................39 
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation ......................................................................................................43 
Table 5: 
Recommended Interventions for Hyperkalemia .........................................................45 
Table 6: 
Clinical Laboratory Assessments ...............................................................................54 
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases .............56 
Table 8: 
Statistical Power to Detect 10 mmHg Difference Between ALN-AGT01 and 
Placebo With Various Standard Deviation Assumptions ...........................................62 
 
LIST OF FIGURES 
Figure 1: 
Study Design .................................................................................................................8 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
20 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation  
Definition 
ABPM 
Ambulatory blood pressure monitoring 
ACE 
Angiotensin converting enzyme 
ADA 
Anti-drug antibody(ies) 
AE 
Adverse event 
AGT 
Angiotensinogen 
ALT 
Alanine aminotransferase 
AngI/II 
Angiotensin I/II 
ARB 
Angiotensin II-receptor blocker 
AST 
Aspartate aminotransferase 
CCB 
Calcium channel blocker 
CPC 
Clinical product complaint 
DB 
Double-blind 
DBP 
Diastolic blood pressure 
DMC 
Data Monitoring Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eGFR 
Estimated glomerular filtration rate 
EOT 
End of treatment 
ET 
Early termination 
FAS 
Full analysis set 
GalNAc 
N-acetylgalactosamine 
GCP 
Good Clinical Practice 
HbA1c 
Hemoglobin A1c 
HBPM 
Home blood pressure monitoring 
HBV 
Hepatitis B virus 
HCV 
Hepatitis C virus 
HDL-C 
High-density lipoprotein 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use 
IEC 
Independent Ethics Committee 
INR 
International normalized ratio 
IRB 
Institutional Review Board 
IRT 
Interactive Response Technology 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
21 
Abbreviation  
Definition 
ISR 
Injection site reaction 
LFT 
Liver function test 
MAO 
Monoamine oxidase 
MCP-Mod 
Multiple comparison-modeling 
mRNA 
Messenger RNA 
NSAID 
Nonsteroidal anti-inflammatory drug 
OLE 
Open-label extension 
PD 
Pharmacodynamic(s) 
PK 
Pharmacokinetic(s) 
PT 
Preferred term 
q3M 
Once every 3 months 
q6M 
Once every 6 months 
RAAS 
Renin-angiotensin-aldosterone system 
RNAi 
RNA interference 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SBP 
Systolic blood pressure 
SC 
Subcutaneous(ly) 
siRNA 
Small interfering RNA 
SGLT2 
Sodium-glucose co-transporter 2 
SOC 
System Organ Class 
ULN 
Upper limit of normal 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
22 
1. 
INTRODUCTION 
Alnylam Pharmaceuticals, Inc. (the Sponsor) is developing ALN-AGT01, a subcutaneously (SC) 
administered investigational agent comprised of a synthetic small interfering (siRNA) covalently 
linked to a triantennary N-acetylgalactosamine (GalNAc) ligand, which is designed to suppress 
liver production of angiotensinogen (AGT) and thereby reduce blood pressure in individuals with 
hypertension.  
1.1. 
Study Rationale 
Study ALN-AGT01-002 (KARDIA-1) is a randomized, double-blind, placebo-controlled, dose-
ranging, multicenter Phase 2 study designed to evaluate the safety, efficacy, and 
pharmacodynamics (PD) of ALN-AGT01, administered SC, in patients with mild-to-moderate 
hypertension. Patients will be randomized to 1 of 4 ALN-AGT01 treatment regimens or placebo 
for the first 6 months of the 12-month Double-blind (DB) period. After the first 6 months of the 
DB period, patients from the placebo arm will be re-randomized to 1 of the 4 initial 
ALN-AGT01 regimens for the remaining 6 months of the DB period, while patients randomized 
to ALN-AGT01 will remain on their originally assigned regimens. After completion of the 
12-month DB period, patients may be eligible to participate in an ALN-AGT01 open-label 
extension (OLE) study. If an individual patient reaches Month 12 prior to availability of the OLE 
study, they may continue their current blinded dosing in the DB Extension period for up to 12 
additional months until the OLE study is open and then transition. 
The primary objective of the study is to evaluate the efficacy of ALN-AGT01 for the treatment 
of hypertension by evaluating the impact on systolic blood pressure (SBP) from baseline to 
Month 3, as assessed by ambulatory blood pressure monitoring (ABPM). Secondary and 
exploratory objectives of the study include evaluating the efficacy of ALN-AGT01 on other 
measures of blood pressure response and evaluating the PD effect of ALN-AGT01, including 
reduction in circulating AGT concentration. 
The full rationale for the study and design is presented in Section 3.2. 
1.2. 
Background 
Hypertension affects 30% to 45% of adults and is the strongest modifiable risk factor for 
cardiovascular disease, primarily strokes and myocardial infarction.[Olsen 2016; Williams 2018] 
The worldwide disease burden is profound, with a global prevalence of over 1 billion,[Kearney 
2005; NCD Risk Factor Collaboration 2017] and approximately 9 million deaths attributed to 
hypertension annually.[Angell 2015] 
Currently available pharmacologic therapies achieve target blood pressure in only a minority of 
patients, due in large part to physician inertia and patient nonadherence to daily oral 
medication.[Whelton 2018; Williams 2018] Low adherence to oral antihypertensives is 
associated with poor cardiovascular outcomes and is prevalent at all stages of disease.[Corrao 
2011; Peacock and Krousel-Wood 2017; Schulz 2016; van der Laan 2017] Thus, despite the 
availability of multiple efficacious agents, current rates of control are low, and the global burden 
of death and disability-adjusted life-years attributed to elevated blood pressure remains 
high.[Forouzanfar 2017; Muntner 2020] Development of new approaches to treat hypertension 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
23 
and to overcome the limitations of current therapies is a key unmet need.[Dzau and Balatbat 
2019; McClellan 2019; Services 2020] 
The Sponsor is developing ALN-AGT01, a novel synthetic RNA interference (RNAi) 
therapeutic, for SC administration for the treatment of hypertension. RNAi is a naturally 
occurring cellular mechanism for regulation of gene expression, mediated through the binding of 
siRNA to its complementary messenger RNA (mRNA) sequence, leading to mRNA cleavage 
and subsequent suppression of the synthesis and levels of the target protein. ALN-AGT01 
contains an siRNA targeting AGT mRNA, conjugated to a GalNAc-containing ligand to facilitate 
delivery to the liver. Based on the mechanism of RNAi, ALN-AGT01 is specifically designed to 
reduce the hepatic synthesis of AGT protein, the first substrate in the renin-angiotensin-
aldosterone system (RAAS) and the sole precursor of vasoactive angiotensin peptides.[Khanna 
2017; Romero 2015] Because hepatocytes are the predominant source of circulating AGT, 
ALN-AGT01 has been developed to reduce blood pressure by decreasing circulating AGT levels 
and the downstream effects of angiotensin II (AngII). 
Preliminary data from Part A of the ongoing Phase 1 Study ALN-AGT01-001 (hereafter referred 
to as Study 001) in patients with hypertension have shown that single SC doses of ALN-AGT01 
lead to dose-dependent and durable reductions in circulating AGT, accompanied by clinically 
significant reductions in SBP and diastolic blood pressure (DBP). Reductions in AGT for up to 
6 months postdose were observed in the study.  
Most adverse events (AEs) have been mild or moderate in severity, and there have been no 
severe or serious adverse events (SAEs) related to study drug. There have been no clinically 
significant elevations in serum creatinine or serum potassium, and no patient has required 
intervention for low blood pressure. No clinically significant alanine aminotransferase (ALT) 
elevations have been observed in Part A patients who received ALN-AGT01 doses as high as 
800 mg. Injection site reactions (ISRs) were reported in a minority of patients and were all mild 
and transient events that resolved without intervention. 
This Phase 2 study will further quantify the antihypertensive effects of ALN-AGT01 across a 
range of doses (150 to 600 mg) and dose intervals (once every 3 months and once every 6 
months) to identify optimal treatment. The consistent and prolonged PD effect of ALN-AGT01 
is expected to achieve the unique benefit of continuous 24-hour blood pressure lowering with 
infrequent SC dosing.  
A detailed description of the chemistry, pharmacology, efficacy, and safety of ALN-AGT01 is 
provided in the Investigator’s Brochure. 
1.3. 
Benefit-Risk Assessment 
Clinical data available from Study 001 indicate that ALN-AGT01 may offer the benefit of blood 
pressure reduction to patients with hypertension. The mean SBP reduction observed after single 
ALN-AGT01 doses of 100 mg or higher exceeds 10 mmHg, which is comparable to the effect of 
conventional antihypertensives. The blood pressure of patients will be closely monitored, and 
after Month 3, oral antihypertensives will be added as needed to control blood pressure. 
Given the mechanism of action and mode of administration of ALN-AGT01, potential 
theoretical risks include liver transaminase elevations and ISRs. Like any antihypertensive 
therapy, there is also a theoretical risk of hypotension with ALN-AGT01. Based upon the disease 






Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
26 
3. 
INVESTIGATIONAL PLAN 
3.1. 
Summary of Study Design 
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study 
designed to evaluate the safety, efficacy, and PD of ALN-AGT01, administered SC, in patients 
with mild-to-moderate hypertension. A schematic of the study design is provided in Figure 1. 
Before randomization, patients will discontinue prior antihypertensive medications (if taking) for 
a Washout period of at least 4 weeks.  
DB and DB Extension Periods 
Patients who complete the Screening period and meet all inclusion/exclusion criteria for 
enrollment will be randomized 1:1:1:1:1 to receive 1 of the following regimens over a 12-month 
DB treatment period. Randomization will be stratified by race (black vs all other races) and by 
baseline blood pressure (mean 24-hour SBP < or ≥145 mmHg).  
• Placebo SC once every 3 months, with re-randomization (1:1:1:1) at Month 6 to 1 of 
the initial 4 ALN-AGT01 regimens 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients receiving once every 6 month ALN-AGT01 regimens will receive placebo SC at dosing 
visits at which they do not receive ALN-AGT01 to maintain the blind. 
At Month 3, conventional oral antihypertensives may be added per Investigator judgement for 
daytime mean SBP ≥135 mmHg by ABPM. After Month 3, oral antihypertensive medications 
may also be added per Investigator judgement for persistent elevations in blood pressure above 
target (target defined as office SBP <140 mmHg, home blood pressure monitoring [HBPM] SBP 
<135 mmHg, or daytime mean SBP <135 mmHg by ABPM). Oral antihypertensives (if taking) 
will be temporarily held from Month 5 to Month 6 in appropriate patients (Month 5 office SBP 
<155 mmHg if taking 1 oral antihypertensive agent or office SBP <150 mmHg if taking 2 
agents) to assess the effect of ALN-AGT01 alone (vs placebo) at Month 6 by ABPM. During this 
4-week period, blood pressure will be carefully monitored by daily HBPM and oral 
antihypertensive medications restarted if confirmed office SBP >170 mmHg (or if confirmed 
office SBP >160 mmHg accompanied by symptoms). 
Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the 
Month 12 predose assessments. If an individual patient reaches Month 12 prior to availability of 
the OLE study, they may continue their current blinded dosing in the DB Extension period for up 
to 12 additional months until the OLE study is open and then transition. Once the OLE study is 
open for enrollment, eligible patients may rollover into the OLE study at Months 12, 18, or 24 
(whichever visit occurs first). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
27 
In the DB Extension period, blood pressure will be closely monitored and individual 
modification of antihypertensive therapy will be allowed to maintain blood pressure in target 
range.  
Safety Follow-up Period 
Patients who discontinue study drug or do not enroll in the ALN-AGT01 OLE study will be 
asked to complete Safety Follow-up visits after their last dose of study drug: 
• Patients who discontinue study drug before Month 6: Safety Follow-up visits will occur 
once every 6 months after the last dose of study drug until the last patient’s Month 6 visit 
or until serum AGT levels return to ≥50% of their individual mean baseline level, 
whichever comes later. 
• Patients who discontinue study drug after the Month 6 visit: Safety Follow-up visits will 
occur once every 6 months after the last dose of study drug until serum AGT levels return 
to ≥50% of their individual mean baseline level. 
Patients who discontinue study drug prior to the Month 6 visit will be asked to complete the 
remainder of scheduled study visits and assessments (except for study drug administration) 
through Month 6. If a patient discontinues study drug after the Month 6 visit, early termination 
(ET) assessments should be performed. 
The planned enrollment for this study is approximately 375 patients (75 patients per group). 
The duration of treatment with ALN-AGT01 is up to 24 months. The estimated total time on 
study for each patient is up to 44 months, including up to 2 months of screening, followed by up 
to 24 months of treatment, and up to 18 months in the Follow-up period. 
3.2. 
Scientific Rationale for Study Design 
This is a randomized, double-blind, placebo-controlled, dose-ranging, multicenter Phase 2 study 
designed to evaluate the safety, efficacy, and PD of ALN-AGT01, administered SC, in patients 
with mild-to-moderate hypertension. The primary objective of the study is to evaluate the 
efficacy of ALN-AGT01 by measuring the impact on SBP from baseline to Month 3, as assessed 
by ABPM.  
This study will quantify the antihypertensive effects of ALN-AGT01 across a range of doses and 
dose intervals to identify optimal treatment regimens for study in Phase 3. 
Patients will discontinue prior antihypertensive medications (if taking) for at least 4 weeks prior 
to study drug administration. During the study, blood pressure will be monitored with both 
outpatient 24-hour ABPM and automated office blood pressure measurements 
(EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical Investigation of Medicinal Products in 
the Treatment of Hypertension, 2016). The primary endpoint will be assessed by ABPM given its 
greater precision over office blood pressure measurements. In addition, 24-hour ABPM can 
assess short-term blood pressure variability and circadian patterns (including potential restoration 
of the normal nocturnal blood pressure dipping pattern that is lost in 21% to 35% of hypertensive 
patients).[de la Sierra 2009; White 1998] More frequent measurements will be collected through 
a third method, oscillometric HBPM, to assess long-term blood pressure variability and provide 
close safety monitoring for potential hypotension (or hypertension) while not in the clinic. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
28 
As recommended by current guidance (International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use [ICH] Principles for Clinical Evaluation of 
New Antihypertensive Drugs, 2000 and EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical 
Investigation of Medicinal Products in the Treatment of Hypertension, 2016), the first 6 months 
of the DB period is designed as a randomized, placebo-controlled, parallel-group study. To 
adhere to best ethical standards for the treatment of patients with hypertension, individual 
modification of oral antihypertensive medications per Investigator judgement to maintain blood 
pressure within target is permitted starting at Month 3 and will continue throughout the study 
(except between Month 5 and Month 6 as described in Section 3.1). Separate from these treat-to-
target modifications, any confirmed event of severe systolic hypertension (SBP ≥180 mmHg) 
will be appropriately treated regardless of its timing relative to study drug administration. 
If a patient requires treatment with a conventional oral antihypertensive before Month 6, a 
calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic will be added because there 
is extensive experience combining these classes with antihypertensive drugs that impact the 
RAAS. Additionally, their blood pressure effects are expected to washout within 4 weeks.  
Rigorous assessment of the antihypertensive effects of ALN-AGT01 at Month 6 (trough for the 
once every 6 month regimens) relative to placebo is critical to evaluate the feasibility of once 
every 6 month dosing regimens for future study in Phase 3. Accordingly, oral antihypertensives 
(if taking) will be temporarily held from Month 5 to the Month 6 ABPM assessment. For each 
patient, this limited interruption in oral antihypertensives will be contingent upon the patient’s 
Month 5 office SBP being adequately controlled (see Table 4) and the Investigator’s assessment 
that interruption can be safely performed and carefully monitored by daily HBPM 
measurements. Of note, a withdrawal period is a standard element in studies of oral 
antihypertensives that is often used to establish assay sensitivity, to demonstrate maintenance of 
efficacy, and to assess possible withdrawal effects (ICH E12A; Principles for Clinical Evaluation 
of New Antihypertensive Drugs, 2000). Outside of research studies, antihypertensives are 
temporarily discontinued in clinical practice for diagnostic purposes, and interruptions up to 6 
weeks have been shown to be safe.[Beeftink 2017] In this study, the period of interruption is 
limited to 4 weeks, and most patients are expected to have continued antihypertensive effect 
from ALN-AGT01. If a clinically significant blood pressure elevation (confirmed SBP >170 
mmHg; or SBP >160 mmHg accompanied by symptoms) occurs after the interruption of oral 
antihypertensives, Investigators will instruct the patient to promptly resume dosing with their 
existing supply of oral medication.  
After Month 6, other oral antihypertensives may be used at the discretion of the Investigator, 
following current care guidelines.[Whelton 2018; Williams 2018] Because ALN-AGT01 acts on 
the RAAS, the use of conventional RAAS inhibitors (angiotensin II-receptor blocker [ARB], 
angiotensin converting enzyme [ACE] inhibitors, or direct renin inhibitors) as rescue agents for 
high blood pressure will be avoided throughout this study. Blood pressure and pharmacokinetic 
(PK)/PD assessments will be collected through Month 12 to assess the effect of repeated dosing. 
While tissue specificity of ALN-AGT01 for the liver is hypothesized to improve tolerability 
relative to current oral antihypertensives,[Mullick 2017; Uijl 2019] the protocol’s monitoring 
plan is designed to meet the standards set by prior studies of conventional RAAS 
inhibitors,[McMurray 2016; Parving 2012] with improvements to include the use of the newer 
oral potassium binder patiromer for treatment of potential hyperkalemia.[Georgianos and 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
29 
Agarwal 2018; Weir 2015] The risk of renal safety events is further mitigated in this study by its 
eligibility criteria, which exclude patients who are at highest risk to have events (estimated 
glomerular filtration rate [eGFR] <30 mL/min/1.73m2, baseline serum potassium >5 mEq/L, 
poorly controlled diabetes, or severely increased albuminuria) and those who may have 
decreased tolerance for renal safety events (patients with clinically significant heart failure, 
valvular heart disease, or recent history of cardiovascular event).  
3.3. 
Justification for Dose 
The doses of ALN-AGT01 in this study were selected on the basis of data from the Phase 1 
Study 001, in which single ALN-AGT01 doses up to 800 mg were found to have an acceptable 
safety profile, and clinically significant placebo-corrected reductions in mean SBP >10 mmHg 
by 24-hour ABPM were observed after doses as low as 100 mg. Dose selection was guided by 
the principle of evaluating doses that are well tolerated and predicted to result in a range of PD 
effects (ie, lowering of serum AGT) and antihypertensive responses. This is expected to enable 
development of population average dose-response relationships for PD and efficacy to guide 
identification of optimal treatment regimens (dose and dose frequency) for Phase 3.  
Preliminary PK/PD modeling based on serum AGT data from Study 001 indicates that 
ALN-AGT01 results in a dose-dependent lowering of serum AGT, with maximum reductions 
predicted to be achieved as early as 1 month postdose and significant reductions sustained for 
close to 6 months after dosing. Modeling of the relationship between serum AGT lowering and 
blood pressure suggests a log-linear relationship, with ≥92% reduction in serum AGT predicted 
to achieve median SBP reduction of ≥10 mmHg.  
Based on these, the once every 6 month doses of 150, 300, and 600 mg were selected to result in 
median serum AGT reductions of 81.9%, 89.4%, and 94.9%, respectively, at trough (Month 6), 
translating to median SBP reductions of 6.67 mmHg, 8.74 mmHg, and 11.6 mmHg, respectively. 
Thus, the selected doses will enable characterization of the dose-response relationships for serum 
AGT and blood pressure with the once every 6 month regimen. 
The selected doses also enable characterization of the dose-response relationships for serum 
AGT and blood pressure with once every 3 month regimens based on analysis of data from all 
arms at Month 3. This will provide support for development of a once every 3 month regimen, if 
desired. To this end, 300 mg once every 3 months will be evaluated to identify any cumulative 
effects. The 300 mg once every 3 months dose is predicted to result in median serum AGT 
reductions of >95% at trough (Month 3), translating to median SBP reductions of >10 mmHg.  
Thus, data from the current study will enable robust characterization of PD and efficacy of once 
every 3 month and once every 6 month regimens of ALN-AGT01 and guide further development 
of ALN-AGT01 as an antihypertensive therapeutic that results in reduction of blood pressure by 
≥10 mmHg throughout the dosing interval with infrequent administration. 
3.4. 
Method of Assigning Patients to Treatment Groups 
Using the Interactive Response Technology (IRT), patients will be randomized 1:1:1:1:1 to the 
following arms during the first 6 months of the 12-month DB period: 
• Placebo SC once every 3 months 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
30 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients initially randomized to placebo will be re-randomized 1:1:1:1 at Month 6 to 1 of the 4 
initial ALN-AGT01 regimens. 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. 
Randomization will be stratified by race (black vs all other races) and by baseline blood pressure 
(mean 24-hour SBP < or ≥145 mmHg). 
Each patient will be uniquely identified in the study by a combination of the site number and 
patient identification number. Upon signing the informed consent form (ICF), the patient will be 
assigned a patient identification number by the IRT system. The Investigator or his/her designee 
will randomize the patient in IRT after confirming that the patient fulfills all the inclusion criteria 
and none of the exclusion criteria. The Investigator or his/her designee will re-randomize the 
patient in IRT at Month 6 to assign placebo patients to 1 of the 4 initial ALN-AGT01 dose 
groups. 
3.5. 
Blinding 
The Sponsor, all site personnel (except for the site pharmacist or delegate), and patients will be 
blinded to study drug treatment through Month 6 of the 12-month DB period. After the database 
lock to support the analysis of Month 6 data is complete, the Sponsor will be unblinded to 
treatment assignment, but the site personnel (except for the site pharmacist) and patients will 
remain blinded to treatment assignment until after the analysis of Month 12 data is complete.  
Blinded doses of study drug will be administered under the supervision of the Investigator (see 
Section 5.2.2). All patients will receive the same volume and number of injections regardless of 
treatment assignment (patients receiving once every 6 month ALN-AGT01 regimens will receive 
placebo SC at dosing visits at which they do not receive ALN-AGT01 to maintain the blind). 
Because ALN-AGT01 may be slightly visually distinguishable from placebo, all blinded study 
drug doses will be prepared and the syringe(s) will be masked by a site pharmacist or delegate 
prior to administration by a blinded healthcare professional. See the Pharmacy Manual for 
additional details. 
3.5.1. 
Emergency Unblinding 
If the treating physician determines that the clinical management of the patient requires 
knowledge of the study drug assignment, the Investigator may break the blind, as necessary, in 
IRT. If time permits, clinical study center personnel should contact the Medical Monitor before 
unblinding to discuss the need to unblind the patient but must do so within 1 working day after 
the unblinding event. Unblinding information should be limited to the fewest number of people 
on a need-to-know basis. A record of when the blind was broken, who was unblinded, who broke 
the blind, and why it was broken, will be maintained in the electronic trial master file. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
31 
Refer to the IRT instructions for details on emergency unblinding. 
3.6. 
Data Monitoring Committee 
An independent DMC will oversee the safety and overall conduct of this study. The DMC will 
operate under the rules of a charter that will be reviewed and approved at the organizational 
meeting of the DMC. Details are provided in the DMC Charter. 
3.7. 
Clinical Event Adjudication Committees 
An independent Clinical Event Adjudication Committee of 2 or more nephrologists will review 
renal events blinded to treatment assignment to adjudicate whether they meet diagnostic criteria 
for acute kidney injury and, if so, their potential staging and contributing factors. Details are 
provided in the Renal Event Adjudication Committee charter. 
3.8. 
Definition of End of Study for an Individual Patient 
A patient is considered to have reached the end of the study if the patient: 
• has completed at least the Month 12 visit and enrolled in the OLE study, or 
• has completed the Safety Follow-up visits as described in Section 3.1 for patients who 
discontinue study drug or do not enroll in the OLE study. 
A definition of the end of the overall study is provided in Section 8.1.5. 
4. 
SELECTION AND REMOVAL OF PATIENTS 
4.1. 
Inclusion Criteria 
Patients are eligible to be included in the study if all the following criteria apply: 
Age and Sex 
1. Age 18 to 75 years, inclusive 
2. Male or female 
Patient and Disease Characteristics 
3. Has untreated hypertension (not taking antihypertensive medication) or is on stable 
therapy with 1 or more antihypertensive medications of the following classes: an ACE 
inhibitor, ARB, renin inhibitor, CCB, thiazide diuretic, and/or thiazide-like diuretic. In 
general, stable therapy is defined as having no change in antihypertensive medication or 
dose within 30 days prior to screening.  
4. Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive 
medication. Patients previously taking medication for hypertension must be without 
antihypertensives for ≥4 weeks prior to this ABPM. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
32 
Informed Consent 
5. Patient is able to understand and is willing and able to comply with the study 
requirements and to provide written informed consent. 
4.2. 
Exclusion Criteria 
Patients are excluded from the study if any of the following criteria apply: 
Disease-specific Conditions 
1. Secondary hypertension 
2. Orthostatic hypotension (symptomatic or asymptomatic), defined as a fall of ≥20 mmHg 
SBP or ≥10 mmHg DBP within approximately 1 to 3 minutes of standing up from a 
seated position by office blood pressure. 
Laboratory Assessments 
3. Has any of the following laboratory parameter assessments after at least 4 weeks of 
washout:  
a. ALT or aspartate aminotransferase (AST) >2× upper limit of normal (ULN) 
b. Total bilirubin >1.5×ULN. Patients with elevated total bilirubin that is secondary to 
documented Gilbert’s syndrome are eligible if the total bilirubin is <2×ULN 
c. International normalized ratio (INR) >2.0 (patients on oral anticoagulant [eg, 
warfarin] with an INR <3.5 will be allowed) 
d. Elevated potassium >5 mEq/L  
e. eGFR of ≤30 mL/min/1.73m2 (calculation will be based on the Modification of Diet 
in Renal Disease formula)  
Prior/Concomitant Therapy 
4. Received an investigational agent within the last 30 days before randomization or are in 
follow-up of another clinical study prior to study enrollment. Any agent that has received 
health agency authorization (including for emergency use) by local or regional regulatory 
authorities is not considered investigational. 
5. Currently taking, taken within 30 days prior to randomization, or anticipated to receive 
during the course of the study any medication or herbal supplement known to 
significantly affect blood pressure (with the exception of medications for the treatment of 
essential hypertension). Patients who require medications such as monoamine oxidase 
(MAO) inhibitors that are associated with hypertensive crisis should be 
excluded.[Whelton 2018]  
6. Currently taking, or taken within 30 days prior to randomization, beta blockers 
7. Currently taking, taken within 30 days prior to randomization, or anticipated to receive 
during the course of the study sodium-glucose co-transporter 2 (SGLT2) inhibitors 
8. Prescription nonsteroidal anti-inflammatory drugs (NSAIDs) are not permitted. In 
addition, chronic/standing use of over-the-counter NSAIDs is not permitted. 
Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
33 
9. Anticipates using organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, 
isosorbide dinitrate, pentaerythritol) during the course of the study 
10. Received an RNAi therapeutic (approved or investigational) within 6 months prior to 
randomization 
Medical Conditions 
11. Current or prior history of intolerance to an ARB, ACE inhibitor (other than cough), or 
direct renin inhibitor 
12. Medical condition, other than hypertension, that requires treatment with a RAAS 
inhibitor 
13. History of multiple drug allergies or history of allergic reaction to an oligonucleotide or 
to GalNAc 
14. Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus (hemoglobin A1c 
[HbA1c] >8.0%), newly diagnosed Type 2 diabetes mellitus (within 6 months prior to 
randomization), or laboratory evidence of diabetes during screening (fasting plasma 
glucose ≥126 mg/dL [7.0 mmol/L], random plasma glucose ≥200 mg/dL [11.1 mmol/L], 
or HbA1c ≥6.5%) without known diagnosis of diabetes 
15. History of severely increased albuminuria (urine albumin:creatinine ratio >300 mg/g or 
>300 mg/day) or laboratory results consistent with this diagnosis upon screening  
16. Has known human immunodeficiency virus or evidence of current or chronic hepatitis C 
virus (HCV) or hepatitis B virus (HBV) infection 
17. History of any cardiovascular event (eg, stroke, transient ischemic attack, myocardial 
infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary 
intervention, hospitalization due to heart failure) within 6 months prior to randomization 
18. Clinically significant valvular heart disease 
19. New York Heart Association II to IV heart failure 
20. Uncontrolled serious cardiac arrhythmia, defined as recurrent and highly symptomatic 
ventricular tachycardia, atrial fibrillation with rapid ventricular response, or 
supraventricular tachycardia in the 3 months prior to randomization 
21. Has undergone liver transplantation or is anticipated to be on an active liver 
transplantation waiting list during the study treatment period 
22. History of renal transplantation or under immunosuppressive therapy 
23. Has other medical conditions or comorbidities which, in the opinion of the Investigator, 
would interfere with study compliance or data interpretation; or, in the opinion of the 
Investigator, taking part in the study would jeopardize the safety of the patient 
24. Clinically significant illness, in the opinion of the Investigator, within 7 days prior to 
randomization 
25. Known change in body weight >10% in last 6 months prior to screening 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
34 
26. History of intolerance to SC injection(s) that could potentially hinder study drug 
administration or evaluation of local tolerability 
27. Has planned major surgery or general anesthesia during the study 
Contraception, Pregnancy, and Breastfeeding 
28. Is not willing to comply with the contraceptive requirements during the study period, as 
described in Section 5.7.1 
29. Female patient is pregnant, planning a pregnancy, or breast-feeding. 
Alcohol or Nicotine Use and Substance Abuse 
30. Unwilling or unable to limit alcohol consumption throughout the course of the study. 
Alcohol intake of >2 units/day is excluded during the study (unit: 1 glass of wine 
[approximately 125 mL] = 1 measure of spirits [approximately 1 fluid ounce] = ½ pint of 
beer [approximately 284 mL]). 
31. History of alcohol or substance abuse (licit or illicit drugs) within the last 12 months 
before screening, in the opinion of the Investigator 
32. Unwilling or unable to abstain from use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine 
patches, or e-cigarettes) within 30 minutes prior to office blood pressure measurements  
Other Restrictions 
33. Third shift or night shift workers 
34. Arm circumference exceeds the maximum cuff size of any of the blood pressure 
instruments provided by the Sponsor 
35. Unable or unwilling to perform HBPM as specified 
4.3. 
Removal from Study Drug or Assessment 
Patients or their legal guardians are free to discontinue study drug and/or stop protocol 
procedural assessments, or participation in the study as a whole at any time and for any reason, 
without penalty to their continuing medical care. The Investigator or the Sponsor may 
discontinue study drug or stop a patient’s participation in the study at any time if this is 
considered to be in the patient’s best interest. Any discontinuation of treatment or the stopping of 
the patient’s participation in the study must be fully documented in the electronic case report 
form (eCRF) and should be followed up by the Investigator. 
Discontinuation of study drug or declining procedural assessments is described in Section 4.3.1, 
while the stopping of a patient’s participation in the study is detailed in Section 4.3.2. 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments 
Reasons for discontinuation of study drug include any of the following: 
• Significant protocol deviation; which includes required treatment with prohibited 
medication (as defined in Section 5.5.2) per Investigator discretion 
• AE 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
35 
• Non-adherence to treatment regimen 
• Pregnancy 
• Lost to follow-up 
• Other reason (non-AE) 
• Or, study is terminated by the Sponsor 
If possible, the Investigator will confer with the Sponsor or Medical Monitor before 
discontinuing dosing in the patient. Patients who are pregnant will be discontinued from study 
drug dosing immediately (see Section 6.5.6.7 for reporting and follow-up of pregnancy). A 
positive urine pregnancy test should be confirmed by a serum pregnancy test prior to 
discontinuing the study drug. 
Patients who discontinue study drug and/or decline procedural assessments should not be 
automatically removed from study. In general, patients who discontinue study drug dosing for 
any reason will be encouraged to remain on the study to complete the remaining assessments and 
study visits so that their experience is captured in the final analyses.  
If this occurs, the Investigator is to discuss with the patient the appropriate processes for 
discontinuation from study drug and must discuss with the patient the options for continuation of 
the Schedule of Assessments (Table 1), including different options for follow-up and collection 
of data (eg, in person, by phone, by mail, through family or friends, or from options not 
involving patient contact, such as communication with other treating physicians or from review 
of medical records), including endpoints and AEs, and must document this decision in the 
patient’s medical records. 
If a patient discontinues dosing due to an AE, including SAEs, the event should be followed as 
described in Section 6.5.6. When a patient discontinues study drug dosing, the primary reason 
must be recorded in the eCRF. Patients who discontinue study drug and remain on study may 
receive treatment consistent with local standard practice for their disease per Investigator 
judgement, as applicable. 
Patients who discontinue from study drug before Month 6 will be encouraged to remain on the 
study and complete assessments (excluding PK assessments) through Month 6. They will also be 
asked to complete Safety Follow-up visits once every 6 months after the last dose of study drug 
per the safety follow-up schedule (see Table 1) until the last patient’s Month 6 visit or until PD 
recovery (whichever is later); see Section 3.1. 
Patients who discontinue study drug after the Month 6 visit will be asked to return for their next 
scheduled visit to complete end of treatment (EOT)/ET assessments and complete Safety Follow-
up visits once every 6 months after the last dose of study drug per the safety follow-up schedule 
(see Table 1) until PD recovery; see Section 3.1. 
4.3.2. 
Stopping a Patient’s Study Participation 
4.3.2.1. 
Patient or Legal Guardian Stops Participation in the Study 
A patient or their legal guardian may stop participation in the study at any time. A patient or 
legal guardian considering stopping participation in the study before Month 6 should be 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
36 
informed that the patient can discontinue study drug and/or decline procedural assessments and 
remain in the study to complete their study assessments through the Month 6 visit and complete 
Safety Follow-up visits as described in Section 4.3.1, or alternatively may complete any minimal 
assessments for which the patient or legal guardian consents. If a patient or legal guardian still 
chooses to discontinue study drug and stop participation in all follow-up prior to the completion 
of the Month 6 visit, every effort should be made to conduct the Month 6 visit assessments at an 
earlier time (Table 1). 
A patient considering stopping participation in the study after the Month 6 visit should be 
informed that the patient can discontinue study drug and/or decline procedural assessments and 
remain in the study to complete the assessments scheduled for the EOT/ET visit and complete 
Safety Follow-up visits as described in Section 4.3.1, or alternatively may complete any minimal 
assessments for which the patient consents. 
If the patient does not wish to or is unable to continue further study participation, the Investigator 
is to discuss with the patient appropriate procedures for stopping participation in the study. Data 
collected from the patient can continue to be used. 
Note, in countries where the collection and processing of the patient’s personal data is based on 
consent, if a patient withdraws consent to collect and process his/her personal data (see 
Section 4.3.2.2), as applicable, personal data up to the withdrawal of consent will be included in 
the analysis of the study. In addition, where permitted, publicly available data (such as 
appropriate national or regional vital status registry or other relevant databases) can be included 
after withdrawal of consent, where available and allowable by local law. 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection to 
Process Patient’s Personal Data 
Where allowed by local law, the patient may decide to withdraw consent to collect, store, and 
use biological samples and, as applicable, other personal data, informing the study doctor at any 
time in writing or in any other form that may be locally required. Also, where allowed by local 
law, the patient may object to the collection, storage, and use of his/her personal data, informing 
the study doctor at any time in writing or in any other form that may be locally required. In both 
cases, the Sponsor will continue to keep and use the patient’s study information (including any 
data resulting from the analysis of the patient’s biological samples until the time of 
withdrawal/objection) according to applicable law. The process for the storage and, as 
applicable, further use of remaining samples will be followed per local requirements.  
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study 
The Investigator or Sponsor may stop the participation of a patient in the study at any time if this 
is considered to be in the patient’s best interest. However, study integrity and interpretation are 
best maintained if all enrolled patients continue study assessments and follow-up even if study 
drug is discontinued. 
Termination of the clinical study and site closure are described in Section 8.1.6. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
37 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation 
The primary reason that a patient’s study participation is stopped must be recorded in the 
appropriate section of the eCRF and all efforts will be made to complete and report the 
observations as thoroughly as possible. If a patient’s study participation is stopped due to an AE, 
including SAEs, the event should be followed as described in Section 6.5.6. 
4.3.3. 
Lost to Follow-Up 
A patient will be considered lost to follow-up if the patient repeatedly fails to return for 
scheduled visits and is unable to be contacted by the clinical study center. The following actions 
must be taken if a patient fails to return to the clinic for a required study visit: 
• The site must attempt to contact the patient or legal guardian and reschedule the 
missed visit as soon as possible and counsel the patient or legal guardian on the 
importance of maintaining the assigned visit schedule and ascertain if the patient or 
legal guardian wishes [for the patient] to continue in the study, and/or should continue 
in the study. 
• Before a patient is deemed lost to follow up, the Investigator or designee must make 
every effort to regain contact with the patient or legal guardian (where possible, 3 
telephone calls and, if necessary, a certified letter to the patient’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the patient’s medical record. 
• Should the patient or legal guardian continue to be unreachable, the patient will be 
considered to have stopped participation in the study. 
• For patients who are lost to follow-up, the Investigator can search publicly available 
records (where permitted and allowed by local law) to ascertain survival status. This 
ensures that the outcome of the study is as comprehensive as possible. 
4.3.4. 
Replacement of Study Patients 
No additional patients may be enrolled to mitigate the impact of patients who discontinue the 
study drug or stop participation in the study.  
5. 
TREATMENTS AND OTHER REQUIREMENTS 
5.1. 
Treatments Administered 
Study drug supplied for this study must not be used for any purpose other than the present study 
and must not be administered to any person not enrolled in the study. Study drug that has been 
dispensed and returned unused must not be re-dispensed. 
5.2. 
Study Drug 
Detailed information describing the preparation, administration, and storage of ALN-AGT01 SC 
and placebo SC is provided in the Pharmacy Manual. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
38 
5.2.1. 
Description 
ALN-AGT01 will be supplied as a sterile solution for SC injection. See the Pharmacy Manual 
for further details of solution concentration and fill volume. 
The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC 
administration).  
5.2.2. 
Dose and Administration 
During the 12-month DB period, patients will be administered ALN-AGT01 or placebo, at the 
same volume and number of SC injections regardless of treatment assignment, once every 3 
months. The ALN-AGT01 and placebo groups are below: 
• Placebo SC once every 3 months, with re-randomization (1:1:1:1) at Month 6 to 1 of 
the initial 4 ALN-AGT01 regimens 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. Patients receiving once every 6 month ALN-AGT01 regimens will receive 
placebo SC at dosing visits at which they do not receive ALN-AGT01 to maintain the blind. 
Study drug injections will be administered under the supervision of the Investigator or healthcare 
professional. To maintain the blind, the doses are to be prepared by and syringes are to be 
masked by an unblinded site pharmacist or designee prior to study drug administration. A full 
description of the blinding procedure is included in the Pharmacy Manual. The injection site may 
be marked and mapped for later observation. Injections may be administered in the abdomen, 
thigh, or the side or back of the upper arms. The rotation of sites is recommended. If a local 
reaction around the injection site occurs, photographs may be obtained. Detailed instructions for 
study drug administration are found in the Pharmacy Manual. 
If a patient does not receive a dose of study drug within the specified visit window, the 
Investigator should contact the Medical Monitor. After such consultation, the dose may be 
administered up to 42 days before the next scheduled dose. Thereafter, the dose will be 
considered missed and not administered. 
Patients will be permitted to miss an occasional dose of study drug. However, if a patient misses 
2 consecutive doses, the Investigator, in consultation with the Medical Monitor, will discuss 
whether the patient will be able to continue the study (see also Section 4.3). 
Additional details can be found in the Pharmacy Manual. 
The definition of study drug overdose, follow-up procedures, and reporting requirements are 
provided Section 6.5.6.8. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
39 
5.2.3. 
Dose Modifications 
Dose modifications are not permitted. 
If a study drug-related AE occurs in a patient that the Investigator judges as presenting a 
potential risk to the patient for further dosing, the study drug dose may be held at the discretion 
of the Investigator and the Medical Monitor should be contacted. 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping Study 
Drug Dosing  
1. Dosing decisions may be made based on the most recently available liver function test 
(LFT) results from a central laboratory (Table 6). 
2. For any ALT or AST elevation >3×ULN, central laboratory results should be used to 
guide subsequent monitoring as detailed in Table 3. 
3. For any ALT or AST elevation >3×ULN: 
a. If local laboratory results are obtained, confirm with a central laboratory as soon as 
possible, ideally within 2 to 3 days, but no later than 7 days. 
b. If an alternative cause is found, provide appropriate care. 
c. If an alternative cause is not found, perform assessments per Table 6 and Table 7. 
4. For any ALT or AST elevation >3×ULN without alternative cause that is accompanied 
by clinical symptoms consistent with liver injury (eg, nausea, right upper quadrant 
abdominal pain, jaundice) or elevated bilirubin to ≥2×ULN or INR ≥1.5, permanently 
discontinue dosing. 
5. For confirmed ALT or AST elevations >3×ULN without alternative cause and not 
accompanied by symptoms or elevated bilirubin ≥2×ULN or INR ≥1.5, see Table 3. 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative Cause 
Identified 
Transaminase Level 
Action 
>3× to 5×ULN 
• 
May continue study drug dosing 
• 
Evaluate the initial elevation in LFT per the following assessments: 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6  
• 
Monitor at least every 2 weeks (LFT and coagulation per Table 6)  
• 
If elevation persists for ≥2 months, must discuss with the Medical Monitor 
before continuing dosing 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
40 
Transaminase Level 
Action 
>5× to 8×ULN 
• 
Hold study drug dosing until recovery to ≤1.5×ULN or baseline; may 
resume dosing after discussion with the Medical Monitor 
• 
Evaluate the initial elevation in LFT per the following assessments 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6 
• 
Monitor at least weekly: LFT and coagulation per Table 6 until ALT and/or 
AST is declining on 2 consecutive draws, then may decrease monitoring to 
biweekly 
• 
If ALT or AST rises to >5×ULN following resumption of dosing, 
permanently discontinue dosing 
>8×ULN 
Permanently discontinue study drug dosing after confirmation of the 
transaminase value at the central laboratory. 
Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; INR=international normalized 
ratio; LFT=liver function test(s); ULN=upper limit of normal. 
Notes: In addition to these criteria, other assessments or evaluations may be performed per Investigator discretion, 
as appropriate. 
5.2.5. 
Neurological Criteria for Withholding, Monitoring, and Stopping Study Drug 
Dosing 
Clinically significant events that may be consistent with potential decreased proprioception 
(including but not limited to unusual clumsiness, gait abnormalities, and unexplained 
balance/coordination issues that are either absent at or worsening from the baseline) should be 
reported as an AE. If the treatment-emergent AE is persistent and considered related to study 
drug, specialty consultation with a neurologist should be considered. However, if such a 
treatment-emergent AE is serious or severe (regardless of the Investigator’s assessment of 
relatedness), the patient must be referred for neurologist consultation, and study drug dosing 
must be held until that consultation is complete. Resumption of dosing must be approved by the 
Medical Monitor. 
5.2.6. 
Preparation, Handling, and Storage 
Staff at each clinical study center will be responsible for preparation of ALN-AGT01 or placebo 
doses according to procedures detailed in the Pharmacy Manual. No special procedures for the 
safe handling of study drug are required. 
ALN-AGT01 will be stored upright and refrigerated at approximately 2 to 30°C until dose 
preparation. Deviations from the recommended storage conditions should be reported to the 
Sponsor and use of ALN-AGT01 halted until authorization for its continued use has been 
provided by the Sponsor or designee, as described in the Pharmacy Manual. 
A Sponsor representative or designee will be permitted, upon request, to audit the supplies, 
storage, dispensing procedures, and records. 
Instructions specific to unused study drug and additional storage will be provided in the 
Pharmacy Manual. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
41 
5.2.7. 
Packaging and Labeling 
All packaging, labeling, and production of study drug will be in compliance with current Good 
Manufacturing Practice specifications, as well as applicable local regulations. Study drug labels 
and external packaging will include all appropriate information as per local labeling 
requirements. Additional details will be available in the Pharmacy Manual. 
5.2.8. 
Accountability 
The Investigator or designee will maintain accurate records of receipt and the condition of 
ALN-AGT01 supplied for this study, including dates of receipt. In addition, accurate records will 
be kept of when and how much ALN-AGT01 is dispensed and administered to each patient in 
the study. Any reasons for departure from the protocol dispensing regimen must also be 
recorded. 
At the completion of the study, there will be a final reconciliation of all ALN-AGT01. Used, 
partially used, and unused ALN-AGT01 will be returned to the Sponsor (or designee) or 
destroyed at the clinical study center according to applicable regulations. 
Further instructions about drug accountability will be detailed in the Pharmacy Manual. 
5.3. 
Clinical Product Complaints 
5.3.1. 
Definition 
A clinical product complaint (CPC) is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of the investigational product and its packaging after it is released for distribution at 
clinical site. 
A CPC may be detected prior to use of study drug, during use, or after use. A CPC is typically 
nonmedical in nature; however, it is possible that investigational product complaints could be 
associated with an AE. Examples of a CPC include, but are not limited to: illegible clinical label, 
missing clinical label, damaged vial, empty vial, contamination of investigational product, and 
malfunction of syringe needle safety device. 
5.3.2. 
Reporting 
For product complaints, the Sponsor or its designee should be notified within 24 hours using the 
appropriate eCRF. CPCs that may be associated with an AE must be evaluated and reported as 
indicated in Section 6.5.6 instructions on reporting CPCs will also be detailed in the Pharmacy 
Manual. 
5.4. 
Monitoring for Potential Clinical Events 
5.4.1. 
Monitoring and Approach for Potential Hypotension 
Hypotension is an obligate risk of antihypertensive medications. In addition to office blood 
pressure monitoring, outpatient blood pressure will be monitored weekly with HBPM to ensure 
the early detection of potential hypotension. Whenever possible, management decisions will be 
based on blood pressure measurements confirmed by office blood pressure. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
42 
The following management recommendations for hypotension are provided: 
• Low blood pressure that is associated with symptoms should be evaluated at the 
clinical study site or another hospital setting within 24 hours. Clinical study site 
evaluation for low blood pressure should include the assessment of orthostatic blood 
pressure.  
• The Investigator should consider downtitration or discontinuation of oral 
antihypertensives (if taking) if confirmed office SBP <100 mmHg or if clinical 
symptoms, such as lightheadedness or dizziness, develop coupled with a significantly 
lower SBP compared to prior visits (ie, SBP <110 mmHg). 
• Clinically significant events discovered during the course of a patient’s general 
medical care should be promptly communicated to the site and evaluated by the 
Investigator, especially if hypotension is noted. Patients will carry Independent Ethics 
Committee (IEC)-approved patient cards to facilitate this physician-to-physician 
communication.  
• If hypotension is confirmed, serum electrolytes and creatinine should be measured 
and any oral antihypertensive(s) previously started for hypertensive escape should be 
down-titrated or discontinued.  
• The frequency of blood pressure and biochemical monitoring (serum electrolytes and 
creatinine) should be increased during intercurrent illnesses that predispose patients to 
dehydration (eg, vomiting or diarrhea that persists for more than 24 hours) or when 
symptoms consistent with decreased effective circulating volume (eg, presyncopal 
symptoms, unexplained falls, decreased urine output) manifest, even if a patient’s 
recent blood pressure measurements have been normal. 
• Hypotension that warrants direct evaluation at the site should be communicated to the 
Medical Monitor within 24 hours. In addition, other clinical events consistent with 
potential hypotension (eg, unexplained presyncope, syncope, or falls) should be 
communicated to the Medical Monitor within 24 hours of the site being notified. 
• Management of persistent hypotension may include increased salt intake or, if 
unresponsive, standard treatments for orthostatic intolerance syndromes such as 
fludrocortisone or midodrine. 
• Low blood pressure that requires medical treatment (including intravenous fluid 
support) or other clinical events consistent with potential hypotension (see above) 
should be recorded as AEs. 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure Elevation 
In addition to office blood pressure monitoring, outpatient blood pressure will be monitored 
frequently with HBPM to ensure the early detection of potential significant elevations. Whenever 
possible, management decisions will be based on blood pressure measurements confirmed by 
office blood pressure. The recommended interventions for potentially clinically significant blood 
pressure elevation are presented in Table 4.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
43 
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation 
Study Period 
Intervention 
Throughout Study 
• 
Whenever possible, management decisions should be based on blood 
pressure measurements confirmed by office blood pressure. 
• 
Any confirmed event of severe systolic hypertension (office SBP 
≥180 mmHg) should be appropriately treated regardless of its timing 
relative to study drug administration.  
• 
Because ALN-AGT01 acts on the RAAS, the use of conventional RAAS 
inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors) as rescue 
agents for high blood pressure will be avoided throughout this study.  
• 
If added, oral antihypertensives must be used per their labeled instructions 
and in accordance with current care guidelines.[Whelton 2018; Williams 
2018] 
Day 1 to Month 3 
Intervene if clinically significant blood pressure elevation: 
• 
Because of the gradual onset of effects of ALN-AGT01, interventions for 
asymptomatic hypertension should be avoided in the first 6 weeks after the 
patient’s first administration of study drug.  
• 
After Week 6, patients who develop office SBP >160 mmHg and increased 
>10 mmHg from their baseline office SBP that persists for ≥24 hours on 2 
consecutive measurements or that is accompanied by hypertensive 
symptoms should be evaluated by the clinical study site. Severely 
symptomatic patients should be evaluated at the clinical study site or 
another hospital setting within 24 hours. 
• 
If persistent hypertension is confirmed (without the identification of a 
specific treatable cause) and the Investigator deems it to be a clinically 
significant change, treatment may be initiated at the medical discretion of 
the Investigator using a CCB and/or a thiazide/thiazide-like diuretic. 
Investigators should avoid long-acting agents that may not fully washout 
between Month 5 and Month 6. 
Months 3 to 6 
Treat to target blood pressure using a CCB and/or thiazide/thiazide-like diuretic: 
• 
At Month 3, a CCB and/or a thiazide/thiazide-like diuretic should be added 
if the daytime mean SBP is ≥135 mmHg by ABPM. If the Investigator feels 
there is a compelling clinical reason to wait, the rationale for exception 
should be documented in the eCRF. 
• 
After Month 3, oral antihypertensive medications may also be added per 
Investigator judgement for persistent elevations in blood pressure above 
target (target defined as office SBP <140 mmHg, HBPM SBP <135 mmHg, 
or daytime mean SBP by ABPM <135 mmHg).[Williams 2018] 
• 
A temporary hold of oral antihypertensives (if taking) will be performed in 
appropriate patients (below) from Month 5 to Month 6: 
- Month 5 office SBP <160 mmHg if taking no oral antihypertensive 
agents 
- Month 5 office SBP <155 mmHg if taking 1 oral antihypertensive agent 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
44 
Study Period 
Intervention 
- Month 5 office SBP <150 mmHg if taking 2 oral antihypertensive 
agents. 
• 
During this 4-week period, blood pressure will be carefully monitored by 
daily HBPM and oral antihypertensive medications restarted if confirmed 
office SBP >170 mmHg (or if confirmed office SBP >160 mmHg 
accompanied by symptoms) 
Month 6 to End of 
Study 
Treat to target blood pressure using Investigator’s choice of oral 
antihypertensive(s). 
• 
At Month 6, prior oral antihypertensive should be restarted per Investigator 
judgement if daytime mean SBP is ≥135 mmHg by ABPM. 
• 
Oral antihypertensive medications may also be added per Investigator 
judgement for persistent elevations in blood pressure above target (target 
defined as office SBP <140 mmHg; HBPM SBP <135 mmHg; daytime 
mean SBP by ABPM <135 mmHg).[Whelton 2018; Williams 2018] 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of eGFR 
through the anticipated onset of initial ALN-AGT01 PD. Based upon the renal dysfunction 
associated with conventional RAAS inhibitors,[McMurray 2016; Parving 2012] the following 
guidelines apply throughout the study: 
• Study drug (and additional oral antihypertensive agents, if applicable) should be 
prophylactically held during intercurrent illness or volume depletion 
• If an individual patient experiences a decrease in eGFR by ≥30% from baseline or to 
≤30 mL/min/1.73m2, the Investigator should obtain confirmatory repeat tests, contact 
the Sponsor, and look for potentially reversible causes of renal dysfunction such as: 
− NSAIDs, antibiotics, or other treatments known to impair renal function 
− Recent exposure to intravenous contrast agents 
− Hypovolemia 
− Urinary infection 
− Urinary tract obstruction 
• If an individual patient experiences a decrease in eGFR by ≥40% from baseline or to 
≤25 mL/min/1.73m2, the Investigator should look for potentially reversible causes of 
renal dysfunction and contact the Sponsor to discuss the potential interruption of 
study drug. Serum creatinine should be monitored at least weekly until improving. 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of serum 
electrolytes (at least monthly through the anticipated onset of ALN-AGT01 PD). The following 
guidelines apply for potassium elevations detected by laboratory monitoring.[McMurray 2016; 
Parving 2012] 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
45 
Table 5: 
Recommended Interventions for Hyperkalemia 
Serum K+ ≥5.2 and <5.5 mmol/L 
Serum K+ ≥5.5 and <6.0 mmol/L 
Serum K+ ≥6.0 mmol/L 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample. 
• 
Reinforce low-potassium diet 
and restriction of food/drinks 
with high potassium content  
• 
Review medical regimen 
(including dietary supplements 
and over-the-counter 
medications) for agents known 
to cause hyperkalemia.a 
Consider reduction in dose or 
discontinuation of these agents. 
• 
Repeat K+ measurement within 
3 to 5 days. 
• 
If K+ remains ≥5.2 and <5.5 
mmol/L, regularly monitor K+ 
levels to ensure stability (at 
least weekly if in the first 6 
weeks of treatment or at least 
once monthly afterwards) 
• 
Consider interruption of 
ALN-AGT01, according to 
Investigator medical judgment. 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample 
• 
Consider interruption of ALN-
AGT01, according to 
Investigator medical judgment  
• 
Apply all measures outlined for 
serum K+ ≥5.2 and <5.5 
mmol/L 
• 
Repeat K+ measurement after 2 
to 3 days 
• 
If K+ <5.5 mmol/L, consider 
resumption of study drug (if 
interrupted) with repeat 
potassium within 5 days 
• 
If K+ persistently elevated ≥5.5 
mmol/L, consider treatment 
with patiromer 
• 
Immediately interrupt 
ALN-AGT01 
• 
Confirm potassium 
concentration in a 
non-hemolyzed 
sample 
• 
Urgently evaluate 
patient and treat 
hyperkalemia as 
clinically indicated. 
After urgent 
treatment, consider 
treatment with 
patiromer 
• 
Apply all measures 
outlined for serum K+ 
≥5.5 and < 6.0 
mmol/L 
• 
No resumption of 
study drug without 
individualized case 
discussion with and 
permission from 
Alnylam Medical 
Monitor 
Abbreviations: NSAID=nonsteroidal anti-inflammatory drug. 
a This list is not meant to be exhaustive: potassium-sparing diuretics (eg, amiloride and triamterene), potassium 
supplements (eg potassium chloride), salt substitutes, NSAIDs, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, herbal supplements (eg, Noni juice, alfalfa [Medicago sativa], 
dandelion [Taraxacum officinale], horsetail [Equisetum arvense], nettle [Urtica dioica], milkweed, lily of the 
valley, Siberian ginseng, hawthorn berries). 
The availability of patiromer will be assessed at participating study sites. This potassium-binding 
drug is approved for the treatment of hyperkalemia and has been shown to safely reduce serum 
potassium levels and to maintain long-term normokalemia in chronic kidney disease patients 
receiving background conventional RAAS inhibitor therapy.[Georgianos and Agarwal 2018; 
Weir 2015] 
5.5. 
Concomitant Medications and Procedures 
Use of concomitant medications and procedures will be recorded on the patient’s eCRF as 
specified in the Schedule of Assessments (see Table 1). Concomitant medications include all 
prescription medications, herbal preparations, over the counter medications, vitamins, and 
minerals. Any changes in medications during the study will also be recorded on the eCRF. 
Standard vitamins and topical medications are permitted. However, topical steroids must not be 
applied anywhere near the injection site(s) unless medically indicated. For permitted concomitant 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
46 
medications administered SC, do not administer in same injection site area as the study drug for 
4 days after the last dose of study drug. 
Occasional use of systemic NSAIDs is allowed. However, given their association with increased 
blood pressure, they should be avoided when possible and alternative analgesics (acetaminophen, 
topical NSAIDs) should be considered.[Whelton 2018] When used, the dosing of systemic 
NSAIDs should be at the lower end of the labeled range and for the shortest duration possible.  
Patients will be allowed to receive vaccines (eg, for SARS-CoV-2) that have received health 
agency authorization (including for emergency use) by local or regional regulatory authorities. 
Any concomitant medication that is required for the patient’s welfare may be administered by the 
Investigator, except as described in Section 5.5.2. However, it is the responsibility of the 
Investigator to ensure that details regarding the medication are recorded on the eCRF. 
Concomitant medication will be coded using an internationally recognized and accepted coding 
dictionary. 
5.5.1. 
Oral Antihypertensive Medication  
Individual initiation and modification of oral antihypertensive medications per Investigator 
judgement are permitted throughout the study if required to treat clinically significant blood 
pressure elevation (Section 5.4.2). In addition, after a patient completes the placebo-controlled 
primary endpoint at Month 3, Investigators will titrate therapy with oral antihypertensives to a 
target blood pressure range (office SBP <140 mmHg, HBPM SBP <135 mmHg, or daytime 
mean SBP by ABPM <135 mmHg). All oral antihypertensive medication that are dosed once 
daily should be taken in the morning. 
Serum electrolytes and creatinine should be measured at a central or local laboratory 
approximately 2 weeks after any antihypertensive addition or dose titration. 
5.5.2. 
Prohibited Concomitant Medication 
The following medications, treatments, and supplements are prohibited throughout the study 
(until the EOT visit): 
• Conventional RAAS inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors)  
• SGLT2 inhibitors (eg, empagliflozin, canagliflozin, and dapagliflozin) 
• Prescription NSAIDs  
• Chronic/standing use of nonprescription NSAIDs 
• Organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, isosorbide 
dinitrate, pentaerythritol) 
• Medications, herbal supplements (including Ma Huang and St. John’s wort), or other 
substances (such as licorice) that are associated with increases in LFT abnormalities 
or with blood pressure abnormalities are prohibited. This includes certain stimulants 
(eg, amphetamine, methylphenidate dexmethylphenidate, dextroamphetamine), MAO 
inhibitors, atypical antipsychotics (eg, clozapine, olanzapine), diet pills (eg, 
phenylpropanolamine, sibutramine), and nasal decongestants (eg, phenylephrine 
hydrochloride, pseudoephedrine, naphazoline hydrochloride). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
47 
• Medications, herbal medicines, over-the-counter medications, or supplements known 
to cause hyperkalemia are prohibited unless individually approved by both the 
Investigator and the Medical Monitor. This includes potassium-sparing diuretics, 
potassium supplements, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, mineralocorticoid receptor 
antagonists, Noni juice, alfalfa, dandelion, horsetail, nettle, milkweed, lily of the 
valley, Siberian ginseng, and hawthorn berries. 
All concomitant medications must be reviewed and approved by the Investigator, with particular 
attention to avoiding drugs that may affect blood pressure. 
5.6. 
Treatment Compliance 
Compliance with study drug administration will be verified through observation by study staff or 
trained home healthcare professionals. 
5.7. 
Other Requirements 
5.7.1. 
Contraception 
Females of child-bearing potential must be willing to use a highly effective method of 
contraception from 14 days before first dose, throughout study participation, and through safety 
follow-up (if applicable; see Section 3.1).  
Birth control methods which are considered highly effective include: 
• Placement of an intrauterine device. 
• Placement of an intrauterine hormone-releasing system. 
• Bilateral tubal occlusion. 
• Surgical sterilization of male partner (with the appropriate post-vasectomy 
documentation of the absence of sperm in the ejaculate; for female patients on the 
study, the vasectomized male partner should be the sole partner for that patient). 
• Established use of oral (except low-dose gestagens), implantable, injectable, or 
transdermal hormonal methods of contraception associated with the inhibition of 
ovulation. 
• True sexual abstinence, when in line with the preferred and usual lifestyle of the 
patient. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception. Abstinent 
patients must agree to use one of the above-mentioned contraceptive methods if they 
start heterosexual relationships during the study and through safety follow-up (if 
applicable; Section 3.1). 
Investigators should advise females of childbearing potential of the most appropriate birth 
control method available within their country taking into account local medical practice. 
Females of child-bearing potential include female patients who have experienced menarche (or 
begin menarche over the course of the study), and who are not postmenopausal or permanently 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
48 
sterilized (eg, bilateral tubal occlusion, hysterectomy, or bilateral salpingectomy). A 
postmenopausal state is defined as the absence of menses for 12 months without an alternative 
medical cause, confirmed by follicle stimulating hormone level within the postmenopausal 
range.  
For male patients, no contraception is required. However, use by males of contraception 
(condom) may be required in some countries, eg, France, in order to comply with local 
requirements as described in the corresponding patient ICFs.  
Compliance with contraception requirements will be assessed on a regular basis by the 
Investigator throughout the course of the study (see Section 6.5.5.3). Pregnancy testing will be 
performed before every dose for postmenarcheal females throughout the course of the study (see 
Section 6.5.5.3). 
5.7.2. 
Alcohol Restrictions 
Patients should limit alcohol consumption throughout the course of the study. Alcohol is limited 
to no more than 2 units per day (unit: 1 glass of wine [approximately 125 mL] =1 measure of 
spirits [approximately 1 fluid ounce] =½ pint of beer [approximately 284 mL]) for the duration 
of the study. Compliance with alcohol restrictions should be assessed on a regular basis by the 
Investigator throughout the course of the study. 
5.7.3. 
Tobacco and Nicotine Restrictions 
Use of nicotine or tobacco-containing products (including but not limited to snuff, chewing 
tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) must be avoided within 30 
minutes prior to blood pressure measurements. 
5.7.4. 
Dietary Recommendations  
All patients will receive educational materials on diet with recommendations to limit sodium 
consumption to approximately 2.0 g per day from screening through the end of the Treatment 
period. This direction should be provided at the start of the Screening period, and treatment-
naïve patients should follow these recommendations for at least 1 week prior to screening 
assessments of blood pressure. Of note, this is the sodium intake recommended in the 2018 
European Society of Cardiology/European Society of Hypertension Guidelines for both 
hypertensive patients and for the general population.[Williams 2018]  
On days on which samples for fasting lipid panel and glycemic assessments are collected, 
patients are required to fast for ≥10 hours before sample collection (Section 6.5.5.1). 
5.7.5. 
Exercise 
Patients should abstain from strenuous exercise for 48 hours before each blood collection for 
clinical laboratory tests. 
6. 
STUDY ASSESSMENTS 
The Schedule of Assessments is provided in Table 1. Study visits should be scheduled for the 
morning. All assessments, except for postdose PK sample collection, are to be performed prior to 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
49 
dosing at dosing visits. Additional information on the collection of study assessments will be 
detailed in the Study Manual. 
Where applicable country and local regulations and infrastructure for home healthcare allow, 
home healthcare may take place at a location other than the clinical study site to perform study 
assessments, which may include collection of blood and urine samples and measurement of vital 
signs and weight (at the discretion of the Investigator). 
6.1. 
Screening Assessments 
An ICF that has been approved by the appropriate Institutional Review Board (IRB)/IEC must be 
signed by the patient or legal guardian before the screening procedures are initiated. All patients 
or their legal guardians will be given a copy of the signed and dated ICF. 
Patients will be screened to ensure that they meet all the inclusion criteria and none of the 
exclusion criteria. Rescreening of patients is permitted with consultation of the Medical Monitor 
(see Section 6.1.2). 
Patient demographic data and medical history/disease history will be obtained. Any changes to 
medical history occurring between the screening assessment and Day 1 will be updated prior to 
study drug administration. 
6.1.1. 
Retesting  
If in the Investigator’s judgement, the screening laboratory abnormalities are likely to be 
transient, then laboratory tests may be repeated. The Investigator’s rationale should be 
documented. Laboratory values can be retested once during screening provided that the patient 
can be evaluated for eligibility after at least 4 weeks of washout and randomized within the 
allowed Screening period. Retesting of screening ABPM is permitted once as described in 
Section 6.2.1, with eligibility assessed by the second ABPM result. 
6.1.2. 
Rescreening 
A patient who does not meet all study eligibility criteria due to a transient condition observed at 
screening (eg, prohibited medications that were subsequently discontinued) will be allowed to 
return once for rescreening. A patient will be re-consented if rescreening occurs outside of the 
60-day screening window. In this case, all screening procedures must be repeated. 
6.2. 
Efficacy Assessments 
All blood pressure measurements (ABPM, office, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in 
Section 10.1.  
In patients taking oral antihypertensives, a washout of at least 4 weeks must be completed prior 
to measurement of the baseline ABPM (for eligibility) and baseline office blood pressure. The 
baseline ABPM and office blood pressure must be measured within 2 weeks before 
randomization. An HBPM unit will be provided during the Screening period to facilitate 
monitoring during the washout of prior oral antihypertensives (if taking) and to establish the 
HBPM baseline prior to randomization. HBPM must be collected after at least 4 weeks of 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
50 
washout for at least 2 consecutive weeks (at least 3 recordings per week) prior to randomization 
to establish baseline. 
ABPM placement may be performed at home by appropriately trained individuals, as detailed in 
the Study Manual. If a patient is unable to report to the site for an office blood pressure 
assessment, a substitute “remote visit blood pressure measurement” may be obtained remotely 
using the methods described in Section 10.1. 
Recommendations for approach and monitoring of low blood pressure/hypotension and 
hypertensive escape are provided in Section 5.4.1 and Section 5.4.2, respectively. 
6.2.1. 
ABPM 
In patients taking oral antihypertensives (including those initiated as rescue medication), ABPM 
must be started prior to the morning dose of antihypertensive medication.  
Adequacy will be assessed for all ABPMs. If the ABPM recording is inadequate, the patient will 
be provided 1 opportunity to repeat the study. If the second ABPM recording is also inadequate 
during screening, the patient is a screen failure.  
See further details in Section 10.1 and the Study Manual. 
6.2.2. 
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor at trough (prior to taking oral antihypertensives) and at approximately the same time 
each day; therefore, visits should be scheduled at approximately the same time of day, whenever 
possible. Office blood pressure must include orthostatic measurements (seated and standing).  
Exercise, caffeine, alcohol consumption, and use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or 
e-cigarettes) must be avoided within 30 minutes prior to blood pressure measurements. The use 
of inhaled short-acting beta agonists should be avoided within 6 hours prior to measuring blood 
pressure and/or heart rate. The use of phosphodiesterase type 5 inhibitors (eg, sildenafil, 
tadalafil, vardenafil, avanafil) should be avoided within 48 hours prior to measuring blood 
pressure. 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the Study Manual.  
6.2.3. 
HBPM 
The HBPM should be measured in the morning upon waking, prior to breakfast/caffeine or 
taking morning oral medications. HBPM is not required at times when ABPM is being assessed. 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the Study Manual. 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment 
Approximately 100 patients at select sites will be given the option of using a wearable blood 
pressure sensor for 2 periods of 2 to 4 weeks each according to the Schedule of Assessments 
(Table 1). Wearable blood pressure assessments performed during screening should be obtained 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
51 
after at least 4 weeks of washout. Participation will be contingent upon individual patient 
consent. These noninvasive, cuffless devices are worn on the finger or wrist as described in the 
Study Manual, using the opposite arm as that used for ABPM. 
6.3. 
Pharmacodynamic Assessments 
Blood samples for determination of AGT and RAAS biomarkers (plasma renin concentration, 
AngI, AngII, and aldosterone) will be collected according to the Schedule of Assessments 
(Table 1). Blood samples collected for AngI and AngII require special processing and will be 
assessed at sites that have appropriate resources, equipment, and reagents. Blood samples for PD 
assessments must be collected before study drug administration (on days when study drug is to 
be dosed) or at a time point corresponding to the time of study drug dosing (on other days). 
Levels of aldosterone will also be analyzed in urine collections at the time points listed in the 
Schedule of Assessments (Table 1). Blood AGT levels will be analyzed at a central laboratory by 
enzyme-linked immunosorbent assay for measurement of PD effect. These biomarkers may be 
analyzed using qualified assays. Details regarding the collection, processing, shipping, and 
storage of the samples will be provided in the Laboratory Manual.  
Results will not be used to adjust dosing of ALN-AGT01 or guide other elements of study 
conduct or clinical management and will not be shared with sites until after study completion. If 
clinical circumstances arise for which such information is required to guide patient care, local 
laboratory assessments should be drawn. 
6.4. 
Pharmacokinetic Assessments 
Blood samples will be collected for the assessment of plasma concentrations of ALN-AGT01 
and its primary metabolite AS(N-1)3′ ALN-AGT01 at the time points indicated in the Schedule 
of Assessments (Table 1). A detailed schedule of time points for the collection of blood samples 
for PK analysis is in Table 2. 
Plasma concentrations of ALN-AGT01 and AS(N-1)3′ ALN-AGT01 will be determined using a 
validated assay. Details regarding sample volumes to be collected, and the processing, shipping, 
and analysis of the samples will be provided in the Laboratory Manual. 
6.5. 
Safety Assessments 
The assessment of safety during the study will consist of the surveillance and recording of AEs, 
including SAEs, recording of concomitant medication and measurements of vital signs, weight, 
electrocardiogram (ECG) findings, and laboratory tests. Clinically significant abnormalities 
observed during the physical examination are recorded. 
6.5.1. 
Vital Signs 
Vital signs will be measured as specified in the Schedule of Assessments (Table 1) and include 
blood pressure, heart rate, body temperature, and respiratory rate. When vital signs and blood 
sample collection occur at the same time, vital signs should be performed before blood samples 
are drawn, where possible. Vital signs should be measured predose in the seated position, after 
the patient has rested comfortably for 10 minutes. Body temperature in degrees Celsius will be 
obtained via oral, tympanic, or axillary methods. Heart rate will be counted for a full minute and 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
52 
recorded in beats per minute, and respiration rate will be counted for a full minute and recorded 
in breaths per minute. Blood pressure is described in Section 6.2.  
Additional vital sign assessments, as medially indicated, may be added at the discretion of the 
Investigator, or as per DMC advice. 
Vital signs results will be recorded in the eCRF. 
6.5.2. 
Weight, Height, and Morphometrics 
Height and body weight measurements will be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded in the eCRF. Height will be measured at screening 
only. Height will be measured in centimeters. Body weight should be measured in kilograms to 
the first decimal point in patients wearing light clothing and without shoes.  
Waist circumference and waist-to-hip-ratio will also be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded on the eCRF. For waist circumference and waist-to-
hip ratio, patients should wear minimal clothing to ensure that the measuring tape is correctly 
positioned. Patients should stand erect with the abdomen relaxed, arms at the sides, feet together 
and with their weight equally divided over both legs. To perform the waist measurement, the 
lowest rib margin is first located and marked with a pen. The iliac crest is then palpated in the 
midaxillary line, and also marked. It is recommended to apply an elastic tape horizontally 
midway between the lowest rib margin and the iliac crest, and tie firmly so that it stays in 
position around the abdomen about the level of the umbilicus. The elastic tape thus defines the 
level of the waist circumference, which can then be measured by positioning the measuring tape 
over the elastic tape. Hip circumference measurement should be taken around the widest portion 
of the buttocks. Patients are asked to breathe normally, and to breathe out gently at the time of 
the measurement to prevent them from contracting their muscles or from holding their breath. A 
stretch-resistant tape that provides a constant 100 g of tension is recommended. Measurements 
should be obtained with the tape positioned parallel to the floor and performed using the same 
procedure throughout the study. 
The reading is taken to the nearest centimeter and entered in the source document. Each 
measurement should be repeated twice; if the measurements are within 1 cm of each other, the 
average should be calculated. If the difference between the 2 measurements exceeds 1 cm, the 2 
measurements should be repeated.  
6.5.3. 
Physical Examination 
Full and symptom-directed physical examinations will be conducted according to the Schedule 
of Assessments (Table 1); if a physical examination is scheduled for a dosing visit, it should be 
conducted prior to dosing. Full physical examinations will include the examination of the 
following: general appearance; head, eyes, ears, nose and throat; respiratory, cardiovascular, 
gastrointestinal, musculoskeletal, and dermatological systems; thyroid; lymph nodes; and 
neurological status (see the Study Manual for further details on the assessments to be performed 
as part of the neurological evaluation). 
Symptom-directed physical examinations will be guided by evaluation of changes in symptoms, 
or the onset of new symptoms, since the last visit. Neurological evaluation should be performed 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
53 
according to the Study Manual during all symptom-directed physical examinations regardless of 
whether neurological symptoms have been experienced by the patient.  
Clinically significant abnormalities observed during the physical examination are recorded on 
the medical history or AE eCRF. 
6.5.4. 
Electrocardiogram 
The 12-lead ECGs reporting rhythm, ventricular rate, RR interval, PR interval, QRS duration, 
and QT interval and Fridericia-corrected QT interval will be obtained using a local machine, as 
specified in the Schedule of Assessments (Table 1). Patients should be supine for at least 10 
minutes before each ECG is obtained. The Investigator or qualified designee will review all 
single 12-lead ECGs to assess whether the results have changed since the Baseline visit and to 
determine the clinical significance of the results. These assessments will be recorded in the 
eCRF.  
When ECG and blood sample collection occur at the same visit, blood sample collection should 
occur first. ECGs should be performed at least 30 minutes after phlebotomy or other stressful 
assessments. 
The Investigator or qualified designee will review all ECGs to assess whether the results have 
changed since the baseline visit and to determine the clinical significance of the results. These 
assessments will be recorded in the eCRF. Additional ECGs may be collected at the discretion of 
the Investigator, or as per DMC advice. Recordings will be archived according to the Study 
Manual. 
6.5.5. 
Clinical Laboratory Assessments 
The following clinical laboratory tests will be evaluated by a central laboratory. Specific 
instructions for transaminase elevations are provided in Section 6.5.6.4. For any other 
unexplained clinically relevant abnormal laboratory test occurring after study drug 
administration, the test should be repeated and followed up at the discretion of the Investigator, 
or as per DMC advice, until it has returned to the normal range or stabilized, and/or a diagnosis 
is made to adequately explain the abnormality. Additional safety laboratories and assessments as 
indicated by the clinical situation may be requested. Clinical laboratory assessments are listed in 
Table 6 and will be assessed as specified in the Schedule of Assessments (Table 1).  
While local laboratory results may be used for urgent clinical decisions, on the day of the 
assessments all laboratory assessments specified in Table 6 which are performed at the clinic 
should also be sent in parallel to the central laboratory. In the case of discrepant local and central 
laboratory results on samples drawn on the same day, central laboratory results will be relied 
upon for clinical decisions. 
Clinical laboratory assessments may be collected at the clinical study center or at home by a 
trained healthcare professional. Blood samples collected for RAAS biomarkers should be 
collected in the morning and in the seated/upright position (after blood pressure measurements 
and before any assessments collected in the supine position). 
Spot urine collections for albumin and creatinine should be obtained in the morning. A 24-hour 
urine collection for aldosterone, sodium, and creatinine will be performed at time points listed in 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
54 
the Schedule of Assessments (Table 1). These 24-hour collections should be obtained within 2 
days before the ABPM associated with the same visit. 
For any safety event or laboratory abnormality, additional laboratory assessments, imaging, and 
consultation may be performed for clinical evaluation and/or in consultation with the Medical 
Monitor; results may be collected and should be included in the clinical database. 
Table 6: 
Clinical Laboratory Assessments  
Hematology 
Complete blood count with differential 
 
Serum Chemistry 
Sodium 
Potassium 
BUN 
Phosphate 
Uric acid 
Albumin 
Total protein 
Calcium 
Glucose 
Bicarbonate 
Creatinine 
Chloride 
Liver Function Tests 
 
AST 
ALP 
ALT 
Bilirubin (total and direct) 
GGT 
 
Urinalysis 
Visual inspection for appearance and color 
Bilirubin 
pH (dipstick) 
Nitrite 
Specific gravity 
RBCs 
Ketones 
Urobilinogen 
Albumin 
Leukocytes 
Glucose 
Microscopy (if clinically indicated) 
Protein 
 
Coagulation  
Prothrombin time 
International normalized ratio 
Partial thromboplastin time  
 
Hepatitis Tests  
Hepatitis A, including: 
HAV antibody IgM and IgG 
Hepatitis B, including:  
HBsAg, HBc antibody IgM and IgG 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
55 
Hepatitis C, including:  
HCV antibody 
HCV RNA PCR – qualitative and quantitative 
assays 
Hepatitis E, including: 
HEV antibody IgM and IgG 
Fasting Lipid Panel and Glycemic Assessments (see Section 6.5.5.1) 
Lipid panel, including 
HDL-C, non-HDL-C, LDL-C, apolipoprotein A1, 
triglycerides, total cholesterol  
Insulin 
Fasting glucose 
HbA1c 
Immunogenicity (see Section 6.5.5.2) 
ADA 
 
Pregnancy Testing/FSH Screening (see Section 6.5.5.3) 
β-human chorionic gonadotropin (females of 
child-bearing potential only) 
Follicle-stimulating hormone (postmenopausal 
women only) 
Abbreviations: ADA=anti-drug antibodies; ALP=alkaline phosphatase; ALT=alanine aminotransferase; 
AST=aspartate aminotransferase; BUN=blood urea nitrogen; FSH=follicle-stimulating hormone; GGT=gamma 
glutamyl transferase; HAV=hepatitis A virus; HbA1c=hemoglobin A1c; HBc=hepatitis B virus core; 
HBsAg=hepatitis B virus surface antigen; HCV=hepatitis C virus; HDL-C=high-density lipoprotein; 
HEV=hepatitis E virus; IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; LDL-C=low-
density lipoprotein; PCR=polymerase chain reaction; RBCs=red blood cells; RNA=ribonucleic acid. 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments 
Blood samples for fasting glucose, insulin, lipid panel (including total cholesterol, high-density 
lipoprotein [HDL-C], non-HDL-C, low-density lipoprotein, apolipoprotein A1, and 
triglycerides), and HbA1c will be collected at the time points listed in the Schedule of 
Assessments (Table 1). Patients are required to fast for ≥10 hours before sample collection for 
fasting glucose, insulin, lipid panel, and HbA1c. Samples should be collected at approximately 
the same time of day (±2 hours). 
6.5.5.2. 
Immunogenicity 
Blood samples will be collected to evaluate anti-drug antibodies (ADA). Blood samples for ADA 
testing must be collected before study drug administration (on days when study drug is to be 
dosed) or at a time point corresponding to the time of study drug dosing (on other days) as 
specified in the Schedule of Assessments (Table 1). A blood sample to evaluate ADA will be 
collected at the ET visit, if applicable. Blood samples for ADA will be analyzed at a central 
laboratory. 
Details regarding the processing, shipping, and analysis of the samples will be provided in the 
Laboratory Manual. 
6.5.5.3. 
Pregnancy Testing 
A pregnancy test will be performed for females of child-bearing potential. A serum pregnancy 
test will be performed at screening, and urine pregnancy tests will be performed thereafter per 
the Schedule of Assessments and any time pregnancy is suspected. More frequent pregnancy 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
56 
testing may be performed where required per local requirements. The results of the pregnancy 
test must be known before study drug administration. Patients who are pregnant at screening are 
not eligible for study participation. Any woman with a positive urine pregnancy test, 
subsequently confirmed by a positive serum pregnancy test, during the study will be 
discontinued from study drug but will continue to be followed for safety. Patients determined to 
be pregnant while on study will be followed at least until the pregnancy outcome is known (see 
Section 6.5.6.7 for follow-up instructions). 
A blood sample will be drawn at screening to measure the levels of follicle stimulating hormone 
in order to confirm postmenopausal status in all women suspected to be postmenopausal (see 
Section 5.7.1 for definition of postmenopausal state). 
6.5.5.4. 
Additional Liver Function Assessments 
Additional laboratory assessments will be performed in patients who experience any LFT 
abnormalities as outlined in Section 5.2.4. Following the occurrence of elevated liver 
transaminases or other LFT abnormalities per central laboratory, all assessments in Table 7 will 
be performed 1 time, as well as hematology, serum chemistry, LFT, and coagulation assessments 
from Table 6, and other assessments or evaluations per Investigator discretion, as appropriate.  
Monitoring, including criteria for dose modification or withholding the study drug, is described 
in Section 5.2.4.  
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases 
Extended Hepatic Panel 
HBsAg, HBc antibody IgM and IgG 
Parvovirus B19 
HAV antibody IgM 
HHV-6 
HCV antibody 
Anti-nuclear antibodies 
HCV RNA PCR – qualitative and quantitative 
Anti-smooth muscle antibodies 
HEV antibody IgM 
Anti-LKM1 antibody 
Herpes Simplex Virus 1 and 2 antibody IgM, IgG 
Anti-mitochondrial antibodies 
Herpes Zoster Virus IgM, IgG 
Anti-SLA 
Epstein-Barr Virus antibodies, IgM, and IgG 
Ferritin 
Cytomegalovirus antibodies, IgM, IgG 
Ceruloplasmin 
Imaging 
Abdominal ultrasound with Doppler flow (or CT or MRI) including right upper quadrant 
Focused Medical and Travel History 
Use of any potentially hepatotoxic concomitant 
medications, including over the counter medications 
and herbal remedies 
Alcohol consumption and drugs of abuse 
Other potentially hepatotoxic agents including any 
work-related exposures 
Recent travels to areas where hepatitis A or E 
is endemic 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
57 
Abbreviations: CT=computed tomography; HAV=hepatitis A virus; HBc=hepatitis B core; HBsAg=hepatitis B 
virus surface antigen; HCV=hepatitis C virus; HEV=hepatitis E virus; HHV-6=human herpesvirus 6; 
IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; LKM1=liver/kidney microsome-1 
antibody; MRI=magnetic resonance imagery; PCR=polymerase chain reaction; RNA=ribonucleic acid; 
SLA=soluble liver antigen 
Note: 
• 
All assessments will be measured in central laboratory. The full panel of assessments should only be 
performed once; individual assessments may be repeated, as needed. 
6.5.6. 
Adverse Events 
6.5.6.1. 
Definitions 
Adverse Event 
According to the ICH E2A guideline Definitions and Standards for Expedited Reporting, and 21 
Code of Federal Regulations 312.32, Investigational New Drug Safety Reporting, an AE is any 
untoward medical occurrence in a patient or clinical investigational subject administered a 
medicinal product and which does not necessarily have a causal relationship with this treatment. 
Serious Adverse Event 
An SAE is any untoward medical occurrence that at any dose: 
• Results in death 
• Is life-threatening (an event which places the patient at immediate risk of death from 
the event as it occurred. It does not include an event that had it occurred in a more 
severe form might have caused death) 
• Requires inpatient hospitalization or prolongation of existing hospitalization 
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly or birth defect 
• Is an important medical event that may not be immediately life-threatening or result 
in death or hospitalization but may jeopardize the patient and may require 
intervention to prevent one of the other outcomes listed in the definition above (eg, 
events include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home, blood dyscrasias, convulsions, or the development of drug 
dependency or abuse). 
Adverse Events of Clinical Interest 
The following are considered to be AEs of clinical interest: 
• ALT or AST >3×ULN 
• Severe or serious ISRs; ISRs that are associated with a recall phenomenon (reaction 
at the site of a prior injection with subsequent injections), or those that lead to 
temporary dose interruption or permanent discontinuation of ALN-AGT01. 
An ISR is defined as a local reaction at or near the site of injection. “At or near” the injection site 
includes reactions at the injection site, adjacent to the injection site, or a reaction which may shift 
slightly away from the injection site due to gravity (eg, as may occur with swelling or 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
58 
hematoma). A systemic reaction which includes the injection site, eg, generalized urticaria, other 
distinct entities or conditions like lymphadenopathy that may be near the injection site is not 
considered an ISR. 
For information on recording and reporting of AEs of clinical interest, see Section 6.5.6.2 and 
Section 6.5.6.3, respectively. 
Adverse Event Severity 
Adverse events are to be graded according to the categories detailed below: 
Mild: 
Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated. 
Moderate: 
Moderate; minimal, local, or noninvasive intervention indicated; 
limiting age appropriate instrumental activities of daily living (eg, 
preparing meals, shopping for groceries or clothes, using the telephone, 
managing money). 
Severe: 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self-care activities of daily living (ie, bathing, dressing and 
undressing, feeding self, using the toilet, taking medications, and not 
bedridden); OR life-threatening consequences; urgent intervention 
indicated; OR death related to an adverse event. 
Changes in severity should be documented in the medical record to allow assessment of the 
duration of the event at each level of severity. Adverse events characterized as intermittent 
require documentation of the start and stop of each incidence. When changes in the severity of an 
AE occur more frequently than once a day, the maximum severity for the experience that day 
should be noted. If the severity category changes over a number of days, then those changes 
should be recorded separately (with distinct onset dates). 
Adverse event severity and seriousness are assessed independently. ‘Severity’ characterizes the 
intensity of an AE. ‘Serious’ is a regulatory definition and serves as a guide to the Sponsor for 
defining regulatory reporting obligations (see definition for SAE). 
Relationship of the Adverse Event to Study Drug 
The relationship of each AE to study drug should be evaluated by the Investigator by a “yes” or 
“no” response to the question: “Is there a reasonable possibility that the event may have been 
caused by the study drug?” A “yes” response indicates that the event is considered as related to 
the study drug. 
6.5.6.2. 
Eliciting and Recording Adverse Events 
Eliciting Adverse Events 
The patient and legal guardian, if applicable, should be asked about medically relevant changes 
in the patient’s health since the last visit. The patient and legal guardian, if applicable, should 
also be asked if the patient has been hospitalized, had any accidents, used any new medications, 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
59 
or changed concomitant medication routines (both prescription and over-the-counter). In addition 
to patient observations, AEs will be documented from any clinically relevant laboratory findings, 
physical examination findings, ECG changes, or other findings that are relevant to patient safety. 
Recording Adverse Events 
The Investigator is responsible for recording non-serious AEs that are observed or reported by 
the patient after administration of the first dose of study drug regardless of their relationship to 
study drug through the end of study. Non-serious AEs will be followed until the end of study. 
Events occurring after signing of the ICF and before study drug administration will be captured 
as medical history (see Section 6.1), while AEs that occur after study drug administration, and 
baseline events that worsen after study drug administration, must be recorded as AEs.  
The Investigator is responsible for recording SAEs that are observed or reported by the patient 
after the time when the informed consent is signed regardless of their relationship to study drug 
through the end of study. SAEs will be followed until satisfactory resolution, until baseline level 
is reached, or until the SAE is considered by the Investigator to be chronic or the patient is 
stable, as appropriate. 
All AEs must be recorded in the source records for the clinical study center and in the eCRF for 
the patient, whether or not they are considered to be drug-related. Each AE must be described in 
detail: onset time and date, description of event, severity, relationship to study drug, action taken, 
and outcome (including time and date of resolution, if applicable). 
For SAEs, record the event(s) in the eCRF and, as applicable, the SAE form. 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the supplemental AEs of 
Clinical Interest eCRF should be completed. Additional clinical and laboratory information may 
be collected. Refer to CRF completion guidelines for details on reporting events in the 
supplemental AEs of Clinical Interest eCRF. 
For all ISRs, the Investigator, or delegate, should submit an Injection Site Reaction Signs or 
Symptoms eCRF, recording additional information regarding each injection site reaction that is 
entered on the AE eCRF (eg, symptom(s), injection site location, follow-up actions taken, etc). 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the Sponsor or its designee 
should be notified within 24 hours using the appropriate eCRF. 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee 
An assessment of the seriousness of each AE will be made by the Investigator. Any AE and 
laboratory abnormality that meets the SAE criteria in Section 6.5.6.1 must be reported to the 
Sponsor or designee within 24 hours from the time that clinical study center staff first learns of 
the event. All SAEs must be reported regardless of the relationship to study drug. 
The initial report should include at least the following information: 
• Patient’s study number 
• Description and date of onset of the event 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
60 
• Criterion for serious 
• Preliminary assignment of relationship to study drug, and 
• Investigator/site information 
To report the SAE, complete the eCRF and, as applicable, the SAE form. Within 24 hours of 
receipt of follow-up information, the Investigator must update the eCRF and, as applicable, the 
SAE form. Serious adverse events must be reported using the contact information provided in the 
Study Manual. 
Appropriate remedial measures should be taken by the Investigator using his/her best medical 
judgment to treat the SAE. These measures and the patient’s response to these measures should 
be recorded. All SAEs, regardless of relationship to study drug, will be followed by the 
Investigator until satisfactory resolution or the Investigator deems the SAE to be chronic or 
stable. Clinical, laboratory, and diagnostic measures should be employed by the Investigator as 
needed to adequately determine the etiology of the event. 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities 
The Sponsor or its representative will report certain study events in an expedited manner to the 
Food and Drug Administration, the European Medicines Agency’s EudraVigilance electronic 
system according to Directive 2001/20/EC, and to all country Regulatory Authorities where the 
study is being conducted, according to local applicable regulations. 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee 
Suspected unexpected serious adverse reactions will be reported to the IRB/IEC per their 
institutional policy by the Investigator or Sponsor (or Sponsor designee) according to country 
requirements. Copies of each report and documentation of IRB/IEC notification and 
acknowledgement of receipt will be kept in the Investigator’s study file. 
6.5.6.7. 
Pregnancy Reporting 
If a female patient becomes pregnant during the study through safety follow-up (Section 3.1), the 
Investigator must report the pregnancy to the Sponsor or designee within 24 hours of being 
notified of the pregnancy. Details of the pregnancy will be recorded on the pregnancy reporting 
form. The patient should receive any necessary counseling regarding the risks of continuing the 
pregnancy, the possible effects on the fetus, and be counseled not to breastfeed for 90 days after 
the last dose of study drug. 
The pregnancy should be followed by the Investigator until completion. At the completion of the 
pregnancy, the Investigator will document the outcome of the pregnancy. If the outcome of the 
pregnancy results in a postpartum complication, spontaneous abortion, stillbirth, neonatal death, 
or congenital anomaly, then the Investigator should follow the procedures for reporting an SAE 
as outlined in Section 6.5.6.4. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
61 
6.5.6.8. 
Overdose and Other Special Situations Reporting 
An overdose is defined as any dose of study drug administered to the participant or taken by the 
participant that is >2× the assigned dose during a single administration and/or ≥2 doses within ½ 
the intended dosing interval. 
The Sponsor does not recommend specific treatment for an overdose.  
In an event of an overdose or other special situations (eg, medication error, abuse, misuse, CPC 
associated with an AE), the Investigator should: 
• Contact the Medical Monitor within 24 hours  
• Submit the special situations reporting form within 24 hours using the contact 
information in the Pharmacy Manual 
• Closely monitor the participant for any AE/SAE and laboratory abnormalities 
• Document the amount of study drug given  
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or 
a concomitant medication will be considered AEs/SAEs.  
Full details of overdose and other special situations reporting instructions will be outlined in the 
Pharmacy Manual. 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository 
Alnylam’s RNAi therapeutics platform permits the highly specific targeting of investigational 
therapies based on genetic sequence. It is possible that variations in the target genetic sequence 
will result in variations in drug effect. More generally, genetic variations may account for the 
well-described heterogeneous manifestations of disease in patients with hypertension, as well as 
their responses to treatment. 
Where allowed per local regulations, ethics committee (IRB/IEC) approval, and patient consent, 
samples will be collected as part of this study to permit exploratory investigations and the 
application of novel approaches to bioanalyses that may further elucidate the outcomes of this 
study, or potentially advance understanding of the safety, mechanism of action, and/or efficacy 
of ALN-AGT01. 
Biological specimens will be collected at the intervals indicated in the Schedule of Assessments 
(Table 1). In addition to the dedicated collections for optional exploratory biomarkers (urine, 
plasma, serum), aliquots from each 24-hour urine collection will be archived for potential 
exploratory investigations. These specimens will be analyzed at a central laboratory. Potential 
exploratory investigations may include DNA, RNA, or biochemical metabolite assessments as 
they relate to disease progression, efficacy, or safety. 
The biospecimen repository will also include residual material from routine samples (safety 
laboratory samples, PK samples, etc) that are obtained during the study. 
These specimens will be securely stored in a central biorepository for up to 10 years following 
the completion of this clinical study (ie, last patient last visit), or as per local regulations. After 
10 years have elapsed, samples will be destroyed. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
62 
Details regarding the collection, processing, storage, and shipping of the samples will be 
provided in the Laboratory Manual. 
Exploratory analysis of these biospecimens will be performed by Alnylam Pharmaceuticals or its 
designees. 
When biobanking is permitted by local regulation, study participants will be advised during the 
informed consent process of these biobanking details and the potential for exploratory 
investigation of their samples. 
7. 
STATISTICS 
A Statistical Analysis Plan (SAP) will be finalized before database lock and unblinding for the 
primary analysis. The plan will detail the implementation of the statistical analyses in accordance 
with the principle features stated in the protocol. 
7.1. 
Determination of Sample Size 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline in 
24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 375 
patients (75 per treatment group) provides at least 84% power to detect a dose response 
relationship in SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided 
significance level of 0.05. In addition, this sample size provides at least 80% power to detect a 
10 mmHg difference between an individual ALN-AGT01 dose versus placebo with a 2-sided 
significance level of 0.05. Table 8 shows the statistical power with various standard deviation 
assumptions. 
Table 8: 
Statistical Power to Detect 10 mmHg Difference Between ALN-AGT01 and 
Placebo With Various Standard Deviation Assumptions 
Assumption of Standard 
Deviation (mmHg) 
Statistical Power to Detect 
Dose Response Trend (%) 
Statistical Power to Detect Difference 
Between an Individual ALN-AGT01 
Dose Versus Placebo (%) 
15 
97 
96 
18 
90 
88 
20 
84 
80 
7.2. 
Statistical Methodology 
The statistical and analytical plans presented below are brief summaries of planned analyses. 
More complete plans will be detailed in the SAP. Changes to the methods described in the final 
SAP will be described and justified as needed in the clinical study report. For information on 
study endpoints, see Section 2. 
7.2.1. 
Populations to be Analyzed 
The populations (analysis sets) are defined as follows: 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
63 
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• PK Analysis Set: All patients who received at least 1 full dose of study drug and 
have at least 1 evaluable postdose blood sample for the determination of plasma 
ALN-AGT01 concentrations. 
• PD Analysis Set: All patients who received any amount of study drug and who have 
baseline and at least 1 postdose blood sample for the determination of serum AGT 
will be included in the PD analyses. 
The primary population used to evaluate efficacy will be the FAS. For the efficacy endpoints of 
change from baseline to Month 3, ALN-AGT01 300 mg once every 3 months and once every 6 
months will be pooled together and analyzed. For all other efficacy endpoints, analysis will be 
performed according to the randomized treatment arm. 
Safety will be analyzed using the Safety Analysis Set. The PK and PD Analysis Sets will be used 
to conduct PK and PD analyses, respectively. 
7.2.2. 
Examination of Subgroups 
Subgroup analyses will be conducted for selected endpoints. Subgroup categories and detailed 
methodology will be provided in the SAP. 
7.2.3. 
Handling of Missing Data 
Handling of missing data will be described in the SAP. 
7.2.4. 
Baseline Evaluations 
Demographics and other disease-specific baseline characteristics will be summarized. 
In general, baseline will be defined as the average of all assessments, including unscheduled 
assessments, prior to the first dose of study drug. Details of the definition will be specified in the 
SAP. 
7.2.5. 
Efficacy Analyses 
The primary endpoint is the change in SBP from baseline at Month 3 assessed by ABPM. The 
primary hypothesis of the dose response relationship for the primary endpoint across 
ALN-AGT01 doses and placebo will be tested using a multiple comparison– modeling (MCP 
Mod) approach.[Bretz 2005] The presence of a dose-response trend will be initially tested 
against a set of prespecified dose-response models at a 2-sided significance level of 0.05, 
adjusted for multiplicity (the MCP step). Several candidate models will be prespecified in the 
SAP. Then, the dose-response curves will be further estimated (the modeling step) based on the 
‘best’ fitted dose response model. Furthermore, each ALN-AGT01 dose group will be compared 
against placebo using Dunnett’s Test.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
64 
For the secondary endpoints of change in DBP assessed by ABPM at Month 3 and change in 
SBP and DBP assessed by ABPM at Month 6, each ALN-AGT01 dose group will be compared 
with placebo. For change in office SBP and DBP, each ALN-AGT01 dose group will be 
compared with placebo at Month 3 and Month 6 and also using the time-adjusted average from 
Month 1 to Month 3 and from Month 1 to Month 6. 
No multiplicity adjustment is applied across primary and secondary endpoints.  
Details of the analysis method for primary, secondary, and exploratory endpoints will be 
described in the SAP. 
7.2.6. 
Pharmacodynamic Analysis 
Pharmacodynamic analyses will include the evaluation of changes in levels of serum AGT and 
other exploratory biomarkers of the RAAS pathway. Descriptive statistics for observed levels 
and the relative change from baseline for all measured biomarkers will be presented for each of 
the postdose time points. 
Statistical comparison of the biomarker levels (absolute and/or change from baseline) across 
treatment groups may be explored. Details of the analysis will be specified in the SAP.  
Population PK/PD analysis may be conducted to evaluate the dose-response relationships for PD 
lowering after ALN-AGT01 treatment. Additionally, the relationship between lowering of serum 
AGT and blood pressure may be explored within a modeling framework. If conducted, these 
analyses will be described in a pharmacometrics analysis plan and results will be presented in a 
separate report. 
7.2.7. 
Pharmacokinetic Analysis 
Plasma concentrations of ALN-AGT01 and its metabolite AS(N-1)3′ ALN-AGT01 will be 
summarized using descriptive statistics. 
Population PK analysis may be conducted on the PK data from this study. If conducted, the 
analysis methods will be described in a pharmacometrics analysis plan and results will be 
presented in a separate report. 
7.2.8. 
Safety Analyses 
The primary parameter is the frequency of treatment-emergent AEs (hereafter referred to simply 
as AEs). Safety parameters also include vital signs, ECGs, clinical laboratory assessments and 
physical exams. Extent of exposure will be summarized.  
Prior and concomitant medications will be coded using the World Health Organization Drug 
Dictionary. Results will be tabulated by Anatomical Therapeutic Chemical Classification System 
and Preferred Term (PT). 
Adverse events will be classified according to the Medical Dictionary for Regulatory Activities 
(MedDRA) System Organ Class (SOC) and PT. Adverse events, SAEs, related AEs, AEs leading 
to discontinuation of study drug, and AEs leading to death will be summarized by SOC and PT 
for each treatment arm. By-patient listings will be provided for deaths, SAEs, and AEs leading to 
discontinuation of study drug.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
65 
Descriptive statistics will be provided for clinical laboratory parameters, ECG, and vital signs 
summarizing the observed values and changes from baseline over time. Laboratory shift tables 
from baseline grade (or category) to worst post-baseline grade (or category) will be presented for 
laboratory parameters that are graded or categorized. Abnormal physical exam findings will be 
presented in listings. 
Other safety summaries will be presented as appropriate. Further details will be specified in the 
SAP. 
7.2.9. 
Immunogenicity Analyses 
The frequency and percentage of patients with confirmed positive ADA assay at any time during 
the study as well as at each scheduled visit will be summarized. The titer results for patients with 
confirmed positive ADA results will be summarized. 
7.2.10. 
Interim Analysis 
The primary analysis will be conducted after all patients complete the Month 6 visit or withdraw 
from the study prior to the Month 6 visit. No formal interim analysis is planned before the 
primary analysis.  
7.2.11. 
Optional Additional Research 
Optional additional research may be conducted in the future on the biological samples and/or 
data collected during the study in accordance with the strict terms of the ICF (see Section 4.3.2). 
8. 
STUDY ADMINISTRATION 
8.1. 
Ethical and Regulatory Considerations 
This study will be conducted in accordance with the protocol, all applicable regulatory 
requirements, and the current guidelines of Good Clinical Practice (GCP). Compliance with GCP 
provides public assurance that the rights, safety, and well-being of study patients are protected 
consistent with the principles that have their origin in the Declaration of Helsinki. 
8.1.1. 
Informed Consent 
The Investigator will ensure that the patient is given full and adequate oral and written 
information about the nature, purpose, possible risk, and benefit of the study. Patients must also 
be notified that they are free to discontinue from the study at any time. The patient should be 
given the opportunity to ask questions and allowed time to consider the information provided. 
The Investigator will inform the patient/legal guardian if new information becomes available that 
may be relevant to the patient’s/legal guardian’s willingness to continue participation in the 
study. Communication of this information should be documented. 
The patient’s signed and dated informed consent must be obtained before conducting any study 
tests or procedures that are not part of routine care. 
The Investigator must maintain the original, signed ICF. A copy of the signed ICF must be given 
to the patient or legal guardian. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
66 
8.1.2. 
Ethical Review 
The study protocol, including the ICF, must be approved or given a favorable opinion in writing 
by an IRB or IEC, as appropriate. The Investigator must submit written approval before he or she 
can enroll any patient into the study. 
The Investigator is responsible for informing the IRB or IEC of any amendment to the protocol 
in accordance with local requirements. In addition, the IRB or IEC must approve all patient 
materials for the study. The protocol must be reapproved by the IRB or IEC upon receipt of 
amendments and annually, as local regulations require. 
Initial IRB or IEC approval of the protocol, and all materials approved by the IRB or IEC for this 
study including the patient consent form and recruitment materials must be maintained by the 
Investigator and made available for inspection. 
The Investigator will submit reports of SAEs as outlined in Section 6.5.6. In addition, the 
Investigator agrees to submit progress reports to the IRB or IEC per their local reporting 
requirements, or at least annually and at the conclusion of the study. The reports will be made 
available to the Sponsor or designee. 
Any communications from regulatory agencies, IRBs, or IECs in regard to inspections, other 
studies that impact this protocol or the qualifications of study personnel should be promptly 
reported to the Sponsor or its designee. 
The Investigator is also responsible for providing the IRB or IEC with reports of any reportable 
serious adverse drug reactions from any other study conducted with the study drug. The Sponsor 
or designee will provide this information to the Investigator. 
Major changes in this research activity, except those to remove an apparent immediate hazard to 
the patient, must be reviewed and approved by the Sponsor and the IRB or IEC that approved the 
study. Amendments to the protocol must be submitted in writing to the Investigator’s IRB or IEC 
and the Regulatory Authority for approval before patients are enrolled under the amended 
protocol, and patients or their legal guardians must be re-consented to the most current version of 
the ICF.  
8.1.3. 
Serious Breach of Protocol 
Investigators must notify the Medical Monitor within 24 hours of becoming aware of a potential 
serious breach of the protocol. A serious breach is a breach that is likely to affect to a significant 
degree the safety and rights of a study participant or the reliability and robustness of the data 
generated in the clinical study. 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention 
All documentation (including personal data) relating to the study should be retained for 2 years 
after the last approval in an ICH territory or as required by local laws and regulations, whichever 
is longer. 
If it becomes necessary for the Sponsor, the Sponsor’s designee, applicable IRB/IEC, or 
applicable regulatory authorities to review or audit any documentation relating to the study, the 
Investigator must permit direct access to all source documents/data. Records will not be 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
67 
destroyed without informing the Sponsor in writing and giving the Sponsor the opportunity to 
store the records for a longer period of time at the Sponsor’s expense. 
The Investigator must ensure that the patients’ confidentiality will be maintained. On the eCRFs 
or other documents submitted to the Sponsor or designees, patients should not be identified by 
their names, but by the assigned patient number or code. If patient names are included on copies 
of documents to be submitted to the Sponsor or designees, the names will be obliterated, and the 
assigned patient number added to the document, before sending to the Sponsor. Documents not 
for submission to the Sponsor (eg, signed ICFs) should be maintained by the Investigator in strict 
confidence. 
The Investigator must treat all of the information related to the study and the compiled data as 
confidential, whose use is for the purpose of conducting the study. The Sponsor must approve 
any transfer of information not directly involved in the study. 
To comply with local and/or regional regulations, this clinical study may be registered, and study 
results may be posted on public registries, such as ClinicalTrials.gov. 
8.1.5. 
End of Study 
The end of study is defined as the last patient last visit. 
8.1.6. 
Termination of the Clinical Study or Site Closure 
The Sponsor, or designee, reserves the right to terminate the study or a clinical study site at any 
time. Conditions that may warrant this action may include, but are not limited to: 
• The discovery of an unexpected, serious, or unacceptable risk to patients participating 
in the study 
• Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of participants by the Investigator 
• The decision on the part of the Sponsor to suspend or discontinue treatment with the 
study drug 
Should the study be terminated, and/or the site closed for whatever reason, all documentation and 
study drug pertaining to the study must be returned to the Sponsor or its representative, and the 
Investigators, IRB/IEC and Regulatory Authorities will be promptly informed of the termination 
and the reason for the decision. The Investigator should promptly inform the patients and assure 
appropriate therapy and follow-up. 
8.2. 
Data Quality Control and Quality Assurance 
8.2.1. 
Data Handling 
Study data must be recorded on CRFs (paper and/or electronic) provided by the Sponsor or 
designee on behalf of the Sponsor. Case report forms must be completed only by persons 
designated by the Investigator. If eCRFs are used, study data must be entered by trained site 
personnel with access to a valid and secure eCRF system. All data entered into the eCRF must 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
68 
also be available in the source documents. Corrections on paper CRFs must be made so as to not 
obliterate the original data and must be initialed and dated by the person who made the 
correction. 
8.2.2. 
Study Monitoring 
The Monitor, as a representative of the Sponsor, has an obligation to closely follow the study 
conduct at the site. The Monitor will visit the Investigator and clinical study center periodically 
and will maintain frequent telephone and written contact. The Monitor will maintain current 
personal knowledge of the study through observation, review of study records and source 
documentation, and discussion of the conduct of the study with the Investigator and staff. 
The Monitor will review source documents, systems and CRFs to ensure overall quality and 
completeness of the data and to confirm study procedures are complied with the requirements in 
the study protocol accurately. The Sponsor, or its designee, will be allowed to conduct site visits 
to the investigation facilities for the purpose of monitoring any aspect of the study. The 
Investigator agrees to allow the Monitor to inspect the drug storage area, study drug stocks, drug 
accountability records, patient charts and study source documents, site standard operating 
procedures and training records, and other records relative to study conduct. 
8.2.3. 
Audits and Inspections 
Periodically, the Sponsor or its authorized representatives audit clinical investigative sites as an 
independent review of core study processes and documents to determine whether these activities 
were conducted, and data were recorded, analyzed, and accurately reported according to the 
protocol, GCP guidelines of the ICH, and any applicable regulatory requirements. A regulatory 
authority, an IEC or an IRB may visit the site to perform audits or inspections, including source 
data verification. The Investigator should contact the Sponsor and designee immediately if 
contacted by a regulatory agency, an IEC, or an IRB about an inspection. 
8.3. 
Publication Policy 
It is intended that after completion of the study, the data are to be submitted for publication in a 
scientific journal and/or for reporting at a scientific meeting. A copy of any proposed publication 
(eg, manuscript, abstracts, oral/slide presentations, book chapters) based on this study, must be 
provided and confirmed received at the Sponsor at least 30 days before its submission. The 
Clinical Trial Agreement will detail the procedures for publications. 
Authorship of any publications resulting from this study will be determined on the basis of the 
Uniform Requirement for Manuscripts Submitted to Biomedical Journals (International 
Committee of Medical Journal Editors). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
69 
9. 
LIST OF REFERENCES 
Angell SY, De Cock KM,Frieden TR. A public health approach to global management of 
hypertension. Lancet. 2015 Feb 28;385(9970):825-7. 
Beeftink MM, van der Sande NG, Bots ML, Doevendans PA, Blankestijn PJ, Visseren FL, et al. 
Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-
to-Control Hypertension. Hypertension. 2017 May;69(5):927-32. 
Bretz F, Pinheiro JC,Branson M. Combining multiple comparisons and modeling techniques in 
dose-response studies. Biometrics. 2005 Sep;61(3):738-48. 
Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to 
antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011 Mar;29(3):610-8. 
de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M, et al. Prevalence and 
factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension. 
2009 Mar;53(3):466-72. 
Dzau VJ,Balatbat CA. Future of Hypertension. Hypertension. 2019 Sep;74(3):450-7. 
Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of 
Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 
2017 Jan 10;317(2):165-82. 
Georgianos PI,Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding 
drugs. Kidney Int. 2018 Feb;93(2):325-34. 
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK,He J. Global burden of 
hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23. 
Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the 
Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-30. 
McClellan M, Brown N, Califf RM,Warner JJ. Call to Action: Urgent Challenges in 
Cardiovascular Disease: A Presidential Advisory From the American Heart Association. 
Circulation. 2019 Feb 26;139(9):e44-e54. 
McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, et al. Aliskiren, 
Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016 Apr 21;374(16):1521-
32. 
Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP,Crooke RM. Blood Pressure 
Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of 
Hypertension and Kidney Injury. Hypertension. 2017 Sep;70(3):566-76. 
Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, et al. Trends in Blood 
Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020 
Sep 22;324(12):1190-200. 
NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a 
pooled analysis of 1479 population-based measurement studies with 19.1 million participants. 
Lancet. 2017 Jan 7;389(10064):37-55. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
70 
Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and 
a lifecourse strategy to address the global burden of raised blood pressure on current and future 
generations: the Lancet Commission on hypertension. Lancet. 2016 Nov 26;388(10060):2665-
712. 
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. 
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 
6;367(23):2204-13. 
Peacock E,Krousel-Wood M. Adherence to Antihypertensive Therapy. Med Clin North Am. 
2017 Jan;101(1):229-45. 
Romero CA, Orias M,Weir MR. Novel RAAS agonists and antagonists: clinical applications and 
controversies. Nat Rev Endocrinol. 2015 Apr;11(4):242-52. 
Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE, et al. Medication 
adherence and persistence according to different antihypertensive drug classes: A retrospective 
cohort study of 255,500 patients. Int J Cardiol. 2016 Oct 1;220:668-76. 
Services UDoHaH. The Surgeon General's Call to Action to Control Hypertension. 2020 October 
2020:1-50. 
Uijl E, Mirabito Colafella KM, Sun Y, Ren L, van Veghel R, Garrelds IM, et al. Strong and 
Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen. 
Hypertension. 2019 Jun;73(6):1249-57. 
van der Laan DM, Elders PJM, Boons C, Beckeringh JJ, Nijpels G,Hugtenburg JG. Factors 
associated with antihypertensive medication non-adherence: a systematic review. J Hum 
Hypertens. 2017 Nov;31(11):687-94. 
Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients 
with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 
15;372(3):211-21. 
Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report 
of the American College of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115. 
White WB, Mansoor GA, Tendler BE,Anwar YA. Nocturnal blood pressure epidemiology, 
determinants, and effects of antihypertensive therapy. Blood Press Monit. 1998 Feb;3(1):43-51. 
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH 
Guidelines for the management of arterial hypertension: The Task Force for the management of 
arterial hypertension of the European Society of Cardiology and the European Society of 
Hypertension: The Task Force for the management of arterial hypertension of the European 
Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 
Oct;36(10):1953-2041. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
71 
10. 
APPENDICES 
10.1. 
Measurement of Blood Pressure 
All blood pressure measurements (office, ABPM, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in the 
relevant user manuals.  
The appropriately sized cuff for each modality must be used for all assessments. The arm’s 
circumference at midpoint (halfway between the acromion and olecranon) should be determined 
at screening with a metric tape measure and used to select the appropriately sized blood pressure 
cuff/bladder for each instrument as described in the Study Manual. Unless significant weight loss 
or gain occurs between visits, the patient should use the same cuff/bladder size throughout the 
study. 
At the first Screening visit only, office blood pressure will be measured in both arms to select the 
appropriate arm to use for office blood pressure and HBPM measurements. Unless a concomitant 
condition favors the use of a specific arm, the arm with the higher office SBP should be used for 
all subsequent office blood pressure and HBPM readings. The ABPM should be measured using 
the patient’s nondominant arm. If the patient is ambidextrous, the same arm used for office blood 
pressure and HBPM readings should be used. 
ABPM 
The appropriately sized cuff should be placed on the correct arm following the instructions in the 
Study Manual. In patients taking oral antihypertensives (including those initiated as rescue 
medication), ABPM should be started prior to the morning dose of antihypertensive medication. 
All ABPM collections must be in the outpatient/ambulatory state. ABPM recordings that are 
associated with dosing visits must be obtained in advance of the visit (within 7 days before the 
corresponding dosing visit) and the results reviewed prior to dosing. 
During the 24-hour monitoring period, patients must avoid strenuous exercise but should 
otherwise maintain their usual level of physical activity. The ABPM is programmed to take 
readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the 
night (10 pm to 5:59 am). While awake, the patient should hold their arm still by their side while 
the device is inflating for a reading. Patients must record the timing of going to sleep, waking up, 
and any oral medications taken during the ABPM, and these responses must be entered into the 
eCRF. 
After the monitoring period is complete, upload the ABPM data to receive a report with 
adequacy assessment. An ABPM will be considered adequate if (1) the number of successful 
daytime readings is ≥33, (2) the number of successful nighttime readings is ≥11, and (3) no more 
than 3 hours are not represented (ie, 3 sections of 60 minutes where 0 valid readings were 
obtained). If the ABPM recording is inadequate, the patient will be provided 1 opportunity to 
repeat the study within 2 days. If the second ABPM recording is also inadequate during 
screening, the patient is a screen failure. 
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor and the arm selected during screening. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
72 
Office blood pressure should be measured early in the visit, before phlebotomy or other 
potentially stressful assessments. To minimize confounding by circadian changes, study visits 
should be scheduled for a consistent timeframe of the day. The use of inhaled short-acting beta 
agonists should be avoided within 6 hours prior to measuring blood pressure and/or heart rate. 
The use of phosphodiesterase type 5 inhibitors (eg, sildenafil, tadalafil, vardenafil, avanafil) 
should be avoided within 48 hours prior to measuring blood pressure. 
Before measuring blood pressure, confirm that there has been no exercise or use of caffeine or 
nicotine- or tobacco-containing products (including but not limited to snuff, chewing tobacco, 
cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) within the last 30 minutes. If necessary, 
delay blood pressure assessment to meet these requirements. Because a full bladder can impact 
blood pressure measurements, ask the patient to use the bathroom before the assessment. 
All office blood pressure assessments will include both seated and standing measurements.  
Seated Office Blood Pressure Measurement: For seated measurements, the patient should be in a 
comfortable resting position in a chair with their back supported and their feet flat on the floor. 
• Place the appropriately sized cuff on the correct arm with no clothing between the 
patient’s arm and the cuff and with the midpoint of the bladder length positioned over 
the brachial artery (located by palpation). The arm should be supported on an armrest 
or table with mid-cuff at heart level and the palm facing the ceiling. 
• Follow the Study Manual to initiate the automated blood pressure device’s seated 
measurement protocol. This program includes a 5-minute period of rest, followed by 
4 sequential blood pressure measurements at 1-minute intervals. The seated blood 
pressure for the visit will be defined by the average of the last 3 individual 
measurements. 
• During the device’s seated measurement protocol, the staff member should leave the 
room and the patient should remain at rest without distraction (avoid mobile phones). 
The following script may be used: “The blood pressure device works best when you 
are at rest and without any distraction. If you agree, I would like to leave the room for 
the next 10 to 15 minutes while it is recording. This will include a 5-minute period of 
rest, followed by about 5 minutes of the device inflating to measure your blood 
pressure”. 
Standing Office Blood Pressure Measurement: A standing measurement should be obtained 
immediately after collection of the seated measurements. 
• Being careful to maintain the cuff’s position, ask the patient to stand with the cuffed 
arm bent slightly and the hand of the cuffed arm supported at heart level.  
• Using a stopwatch or watch, measure standing blood pressure 1 minute after standing 
by using the automated blood pressure device’s single measurement protocol.  
• After the standing measurement, ask the patient if they experienced dizziness or light-
headedness when standing and enter their response in the eCRF. 
If a patient is unable to report to the site for an office blood pressure assessment, a substitute 
“remote visit blood pressure measurement” may be obtained remotely by a visiting nurse or other 
appropriately trained personnel who will bring an office blood pressure instrument to the 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 2, 09 June 2021 
Alnylam Pharmaceuticals 
Confidential 
73 
patient’s location and follow the same procedure performed at the site. If a home visit is not 
possible, a “remote visit blood pressure measurement” should instead be obtained using the 
patient’s HBPM instrument under direct supervision (phone call or teleconferencing) by 
appropriately trained study staff, following the instructions detailed in the Study Manual. Results 
and the remote method used should be entered into the eCRF. 
HBPM 
Patients should measure HBPM every morning, prior to breakfast/caffeine or taking morning 
oral medications. HBPM is not required at times when ABPM is being assessed. The HBPM 
measurement should be obtained in a room without distractions, seated comfortably with the 
back supported and feet flat on the floor. The patient will initiate the automated blood pressure 
program on their HBPM device. This program includes a 5-minute period of rest, followed by 4 
sequential blood pressure measurements at 1-minute intervals. The seated blood pressure for the 
visit will be defined by the average of the last 3 individual measurements.  
To establish baseline, each patient must measure HBPM for at least 2 consecutive weeks (and 
with at least 3 successful readings per week) prior to randomization. Patients previously taking 
medication for hypertension must be without antihypertensives for ≥4 weeks prior to collecting 
these baseline HBPM measurements. If adequate baseline HBPM data (at least 3 successful 
readings per week for at least 2 consecutive weeks) are not collected within the Screening period, 
the patient is a screen failure. 
After Day 1, HBPM should be measured at least 3 times per week. Patients may select the 3 days 
of the week that are most convenient for their personal schedule. The frequency of HBPM 
monitoring should be increased to daily during the temporary hold of oral antihypertensives 
performed in some patients from Month 5 to Month 6. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
1 
 
CLINICAL STUDY PROTOCOL 
ALN-AGT01-002 
DATED 20 APRIL 2021 
 
Protocol Title:  
A Randomized, Double-blind, Placebo-Controlled, 
Dose-Ranging Multicenter Study to Evaluate the 
Efficacy and Safety of ALN-AGT01 in Patients 
with Mild-to-Moderate Hypertension 
Short Title: 
A Study to Evaluate Efficacy and Safety of 
ALN-AGT01 in Patients with Mild-to-Moderate 
Hypertension (KARDIA-1) 
Study Drug: 
ALN-AGT01 
EudraCT Number: 
2021-001248-82 
IND Number: 
143503 
Protocol Date: 
Original protocol, 09 April 2021 
Amendment 1, 20 April 2021 
Sponsor: 
Alnylam Pharmaceuticals, Inc. 
300 Third Street 
Cambridge, MA  02142 USA 
Telephone: +1-617-551-8200 
Sponsor Contact: 
 
 
The concepts and information contained in this document or generated during the study are considered 
proprietary and may not be disclosed in whole or in part without expressed written authorization of 
Alnylam Pharmaceuticals, Inc. 
 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
2 
SPONSOR PROTOCOL APPROVAL 
 
I have read this protocol and I approve the design of this study. 
 
 
 
___________________________________________  
 
 
Alnylam Pharmaceuticals, Inc. 
 
___________________________________________  
Date 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
3 
INVESTIGATOR’S AGREEMENT 
 
I have read the ALN-AGT01-002 protocol and agree to conduct the study in accordance with the 
protocol and all applicable regulations. I agree to maintain the confidentiality of all information 
received or developed in connection with this protocol. 
 
 
 
___________________________________________  
Printed Name of Investigator 
 
 
 
___________________________________________  
Signature of Investigator 
 
 
 
___________________________________________  
Date 






Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
6 
of the study design is provided in Figure 1. Before randomization, patients will discontinue prior 
antihypertensive medications (if taking) for a Washout period of at least 4 weeks. Patients who 
complete the Screening period and meet all inclusion/exclusion criteria for enrollment will 
receive ALN-AGT01 or placebo for the first 6 months of the 12-month Double-blind (DB) 
treatment period.  
Starting at Month 3, conventional oral antihypertensives may be added per Investigator 
judgement for elevated blood pressure. Oral antihypertensives (if taking) will be temporarily 
held from Month 5 to Month 6 to assess the effect of ALN-AGT01 alone (vs placebo) at Month 6 
by ambulatory blood pressure monitoring (ABPM). During this 4-week period, blood pressure 
will be carefully monitored by daily home blood pressure monitoring and medications restarted 
if indicated. Patients may resume conventional oral antihypertensives at Month 6 per Investigator 
judgement. 
Patients randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial 
ALN-AGT01 regimens until the end of the DB period. Patients randomized to ALN-AGT01 
regimens will remain on their originally assigned regimens through Month 12. 
After the 12-month DB treatment period, patients may be eligible to participate in an 
ALN-AGT01 open-label extension (OLE) study. If an individual patient reaches Month 12 prior 
to availability of the OLE study, they may continue their current blinded dosing in the DB 
Extension period for up to 12 additional months until the OLE study is open and then transition. 
Number of Planned Patients 
Approximately 375 patients will be enrolled in this study. 
Diagnosis and Main Eligibility Criteria 
This study will include adults (18 to 75 years, inclusive) with untreated hypertension or on stable 
therapy with 1 or more antihypertensive medications of the following classes: an angiotensin 
converting enzyme inhibitor, angiotensin II-receptor blocker, renin inhibitor, calcium channel 
blocker, thiazide diuretic, and/or thiazide-like diuretic. Patients should have a daytime mean 
systolic blood pressure (SBP) ≥135 mmHg and ≤160 mmHg by ABPM at least 4 weeks after 
washout of background antihypertensive medication. Patients with secondary hypertension or 
orthostatic hypotension will be excluded. 
Study Drug, Dose, and Mode of Administration 
ALN-AGT01 is an SC administered N-acetylgalactosamine-conjugated small interfering RNA 
targeting liver-expressed messenger RNA for angiotensinogen (AGT). 
Patients randomized to receive ALN-AGT01 will be administered 150 mg ALN-AGT01 SC once 
every 6 months, 300 mg ALN-AGT01 SC once every 6 months, 300 mg ALN-AGT01 SC once 
every 3 months, or 600 mg ALN-AGT01 SC once every 6 months during the 12-month DB 
period and DB Extension period. Patients randomized to receive placebo will be randomized to 1 
of the 4 initial dose regimens of ALN-AGT01 beginning at Month 6.  
Reference Treatment, Dose, and Mode of Administration 
Placebo (sodium chloride 0.9% w/v for SC administration) will be administered once every 3 
months and at the same volume as the study drug. Patients receiving once every 6 months 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
7 
ALN-AGT01 regimens will receive placebo SC at dosing visits at which they do not receive 
ALN-AGT01 to maintain the blind. 
Duration of Treatment and Study Participation 
The duration of treatment with ALN-AGT01 is up to 24 months. The estimated total time on 
study for each patient is up to 44 months, including up to 2 months of screening, followed by up 
to 24 months of treatment, and up to 18 months in the Follow-up period. 
Statistical Methods 
The planned enrollment for this study is 375 patients. Randomization will be stratified by race 
(black vs all other races) and by baseline blood pressure (mean 24-hour SBP < or ≥145 mmHg). 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline in 
24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 375 
patients (75 per treatment group) provides at least 84% power to detect a dose response 
relationship in SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided 
significance level of 0.05. In addition, this sample size provides at least 80% power to detect a 10 
mmHg difference between an individual ALN-AGT01 dose versus placebo with a 2-sided 
significance level of 0.05.  
The populations (analysis sets) are defined as follows:  
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• Pharmacokinetic (PK) Analysis Set: All patients who received at least 1 full dose of 
study drug and have at least 1 evaluable postdose blood sample for the determination 
of plasma ALN-AGT01 concentrations. 
• PD Analysis Set: All patients who received any amount of study drug and who have 
baseline and at least 1 postdose blood sample for the determination of serum AGT 
will be included in the PD analyses. 
The primary population used to evaluate efficacy will be the FAS. For the efficacy endpoints of 
change from baseline to Month 3, ALN-AGT01 300 mg once every 3 months and once every 6 
months will be pooled together and analyzed. For all other efficacy endpoints, analysis will be 
performed according to the randomized treatment arm. 
Safety will be analyzed using the Safety Analysis Set. The PK and PD Analysis Sets will be used 
to conduct PK and PD analyses, respectively. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
8 
Figure 1: 
Study Design 
 
Abbreviations: aHTN=antihypertensive medications; DB=double-blind; M=month; OLE=open-label extension; 
PBO=placebo; PO=per os (oral); Q3M=once every 3 months; Q6M=once every 6 months; R=randomization; 
SC=subcutaneous; WO=washout. 
Note: Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the Month 12 
predose assessments. If an individual patient reaches Month 12 prior to availability of the OLE study, they may 
continue their current blinded dosing in the DB Extension period for up to 12 additional months until the OLE study 
is open and then transition. Once the OLE study is open for enrollment, eligible patients may rollover into the OLE 
study at Months 12, 18, or 24 (whichever visit occurs first). 










Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
13 
Table 2: 
PK Time Points 
Study Day 
Sampling Time 
(hh:mm) 
Plasma PK Sample 
Day 1  
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Day 169±7 
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Abbreviations: hh:mm=hour:minute; PK=pharmacokinetics. 
Notes:  
• 
The hour (±range) indicates sample collection timing relative to dosing. Precise PK sample times (hour 
and minute) are recorded. Refer to Section 6.4 for additional information on PK assessments. 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
14 
TABLE OF CONTENTS 
SPONSOR PROTOCOL APPROVAL ...........................................................................................2 
INVESTIGATOR’S AGREEMENT ...............................................................................................3 
PROTOCOL SYNOPSIS ................................................................................................................4 
TABLE OF CONTENTS ...............................................................................................................14 
LIST OF TABLES .........................................................................................................................18 
LIST OF FIGURES .......................................................................................................................18 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ................................................19 
1. 
INTRODUCTION ......................................................................................................21 
1.1. 
Study Rationale ...........................................................................................................21 
1.2. 
Background .................................................................................................................21 
1.3. 
Benefit-Risk Assessment ............................................................................................22 
2. 
OBJECTIVES AND ENDPOINTS ............................................................................23 
3. 
INVESTIGATIONAL PLAN .....................................................................................25 
3.1. 
Summary of Study Design ..........................................................................................25 
3.2. 
Scientific Rationale for Study Design ........................................................................26 
3.3. 
Justification for Dose ..................................................................................................28 
3.4. 
Method of Assigning Patients to Treatment Groups ..................................................28 
3.5. 
Blinding ......................................................................................................................29 
3.5.1. 
Emergency Unblinding ...............................................................................................29 
3.6. 
Data Monitoring Committee .......................................................................................30 
3.7. 
Clinical Event Adjudication Committees ...................................................................30 
3.8. 
Definition of End of Study for an Individual Patient .................................................30 
4. 
SELECTION AND REMOVAL OF PATIENTS ......................................................30 
4.1. 
Inclusion Criteria ........................................................................................................30 
4.2. 
Exclusion Criteria .......................................................................................................31 
4.3. 
Removal from Study Drug or Assessment .................................................................33 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments ......................33 
4.3.2. 
Stopping a Patient’s Study Participation ....................................................................34 
4.3.2.1. 
Patient or Legal Guardian Stops Participation in the Study .......................................34 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection 
to Process Patient’s Personal Data ..............................................................................35 
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study ........................35 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
15 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation ................................36 
4.3.3. 
Lost to Follow-Up.......................................................................................................36 
4.3.4. 
Replacement of Study Patients ...................................................................................36 
5. 
TREATMENTS AND OTHER REQUIREMENTS ..................................................36 
5.1. 
Treatments Administered ............................................................................................36 
5.2. 
Study Drug ..................................................................................................................36 
5.2.1. 
Description ..................................................................................................................37 
5.2.2. 
Dose and Administration ............................................................................................37 
5.2.3. 
Dose Modifications .....................................................................................................38 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping 
Study Drug Dosing .....................................................................................................38 
5.2.5. 
Preparation, Handling, and Storage ............................................................................39 
5.2.6. 
Packaging and Labeling ..............................................................................................39 
5.2.7. 
Accountability .............................................................................................................39 
5.3. 
Clinical Product Complaints .......................................................................................40 
5.3.1. 
Definition ....................................................................................................................40 
5.3.2. 
Reporting ....................................................................................................................40 
5.4. 
Monitoring for Potential Clinical Events ....................................................................40 
5.4.1. 
Monitoring and Approach for Potential Hypotension ................................................40 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure 
Elevation .....................................................................................................................41 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction .......................................43 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia ..............................................43 
5.5. 
Concomitant Medications and Procedures .................................................................44 
5.5.1. 
Oral Antihypertensive Medication .............................................................................45 
5.5.2. 
Prohibited Concomitant Medication ...........................................................................45 
5.6. 
Treatment Compliance ................................................................................................46 
5.7. 
Other Requirements ....................................................................................................46 
5.7.1. 
Contraception ..............................................................................................................46 
5.7.2. 
Alcohol Restrictions ...................................................................................................47 
5.7.3. 
Tobacco and Nicotine Restrictions .............................................................................47 
5.7.4. 
Dietary Recommendations ..........................................................................................47 
5.7.5. 
Exercise .......................................................................................................................47 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
16 
6. 
STUDY ASSESSMENTS ..........................................................................................47 
6.1. 
Screening Assessments ...............................................................................................48 
6.1.1. 
Retesting .....................................................................................................................48 
6.1.2. 
Rescreening .................................................................................................................48 
6.2. 
Efficacy Assessments .................................................................................................48 
6.2.1. 
ABPM .........................................................................................................................49 
6.2.2. 
Office Blood Pressure .................................................................................................49 
6.2.3. 
HBPM .........................................................................................................................49 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment ....................................................49 
6.3. 
Pharmacodynamic Assessments .................................................................................50 
6.4. 
Pharmacokinetic Assessments ....................................................................................50 
6.5. 
Safety Assessments .....................................................................................................50 
6.5.1. 
Vital Signs ..................................................................................................................50 
6.5.2. 
Weight, Height, and Morphometrics ..........................................................................51 
6.5.3. 
Physical Examination .................................................................................................51 
6.5.4. 
Electrocardiogram .......................................................................................................52 
6.5.5. 
Clinical Laboratory Assessments ...............................................................................52 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments ........................................................54 
6.5.5.2. 
Immunogenicity ..........................................................................................................54 
6.5.5.3. 
Pregnancy Testing ......................................................................................................54 
6.5.5.4. 
Additional Liver Function Assessments .....................................................................55 
6.5.6. 
Adverse Events ...........................................................................................................56 
6.5.6.1. 
Definitions ..................................................................................................................56 
6.5.6.2. 
Eliciting and Recording Adverse Events ....................................................................57 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee .........................58 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee ...........58 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities .................................................59 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee ........................................................................59 
6.5.6.7. 
Pregnancy Reporting ..................................................................................................59 
6.5.6.8. 
Overdose and Other Special Situations Reporting .....................................................59 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository ...................................60 
7. 
STATISTICS ..............................................................................................................61 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
17 
7.1. 
Determination of Sample Size ....................................................................................61 
7.2. 
Statistical Methodology ..............................................................................................61 
7.2.1. 
Populations to be Analyzed ........................................................................................61 
7.2.2. 
Examination of Subgroups .........................................................................................62 
7.2.3. 
Handling of Missing Data ...........................................................................................62 
7.2.4. 
Baseline Evaluations ...................................................................................................62 
7.2.5. 
Efficacy Analyses .......................................................................................................62 
7.2.6. 
Pharmacodynamic Analysis........................................................................................63 
7.2.7. 
Pharmacokinetic Analysis ..........................................................................................63 
7.2.8. 
Safety Analyses ..........................................................................................................63 
7.2.9. 
Immunogenicity Analyses ..........................................................................................64 
7.2.10. 
Interim Analysis ..........................................................................................................64 
7.2.11. 
Optional Additional Research .....................................................................................64 
8. 
STUDY ADMINISTRATION ...................................................................................64 
8.1. 
Ethical and Regulatory Considerations ......................................................................64 
8.1.1. 
Informed Consent .......................................................................................................64 
8.1.2. 
Ethical Review ............................................................................................................65 
8.1.3. 
Serious Breach of Protocol .........................................................................................65 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention .................................65 
8.1.5. 
End of Study ...............................................................................................................66 
8.1.6. 
Termination of the Clinical Study or Site Closure .....................................................66 
8.2. 
Data Quality Control and Quality Assurance .............................................................66 
8.2.1. 
Data Handling .............................................................................................................66 
8.2.2. 
Study Monitoring ........................................................................................................67 
8.2.3. 
Audits and Inspections ................................................................................................67 
8.3. 
Publication Policy .......................................................................................................67 
9. 
LIST OF REFERENCES ............................................................................................68 
10. 
APPENDICES ............................................................................................................70 
10.1. 
Measurement of Blood Pressure .................................................................................70 
 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
18 
LIST OF TABLES 
Table 1: 
Schedule of Assessments ..............................................................................................9 
Table 2: 
PK Time Points ...........................................................................................................13 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative 
Cause Identified ..........................................................................................................38 
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation ......................................................................................................41 
Table 5: 
Recommended Interventions for Hyperkalemia .........................................................44 
Table 6: 
Clinical Laboratory Assessments ...............................................................................53 
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases .............55 
Table 8: 
Statistical Power to Detect 10 mmHg Difference Between ALN-AGT01 and 
Placebo With Various Standard Deviation Assumptions ...........................................61 
 
LIST OF FIGURES 
Figure 1: 
Study Design .................................................................................................................8 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
19 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation  
Definition 
ABPM 
Ambulatory blood pressure monitoring 
ACE 
Angiotensin converting enzyme 
ADA 
Anti-drug antibody(ies) 
AE 
Adverse event 
AGT 
Angiotensinogen 
ALT 
Alanine aminotransferase 
AngI/II 
Angiotensin I/II 
ARB 
Angiotensin II-receptor blocker 
AST 
Aspartate aminotransferase 
CCB 
Calcium channel blocker 
CPC 
Clinical product complaint 
DB 
Double-blind 
DBP 
Diastolic blood pressure 
DMC 
Data Monitoring Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eGFR 
Estimated glomerular filtration rate 
EOT 
End of treatment 
ET 
Early termination 
FAS 
Full analysis set 
GalNAc 
N-acetylgalactosamine 
GCP 
Good Clinical Practice 
HbA1c 
Hemoglobin A1c 
HBPM 
Home blood pressure monitoring 
HBV 
Hepatitis B virus 
HCV 
Hepatitis C virus 
HDL-C 
High-density lipoprotein 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use 
IEC 
Independent Ethics Committee 
INR 
International normalized ratio 
IRB 
Institutional Review Board 
IRT 
Interactive Response Technology 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
20 
Abbreviation  
Definition 
ISR 
Injection site reaction 
LFT 
Liver function test 
MAO 
Monoamine oxidase 
MCP-Mod 
Multiple comparison-modeling 
mRNA 
Messenger RNA 
NSAID 
Nonsteroidal anti-inflammatory drug 
OLE 
Open-label extension 
PD 
Pharmacodynamic(s) 
PK 
Pharmacokinetic(s) 
PT 
Preferred term 
q3M 
Once every 3 months 
q6M 
Once every 6 months 
RAAS 
Renin-angiotensin-aldosterone system 
RNAi 
RNA interference 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SBP 
Systolic blood pressure 
SC 
Subcutaneous(ly) 
siRNA 
Small interfering RNA 
SGLT2 
Sodium-glucose co-transporter 2 
SOC 
System Organ Class 
ULN 
Upper limit of normal 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
21 
1. 
INTRODUCTION 
Alnylam Pharmaceuticals, Inc. (the Sponsor) is developing ALN-AGT01, a subcutaneously (SC) 
administered investigational agent comprised of a synthetic small interfering (siRNA) covalently 
linked to a triantennary N-acetylgalactosamine (GalNAc) ligand, which is designed to suppress 
liver production of angiotensinogen (AGT) and thereby reduce blood pressure in individuals with 
hypertension.  
1.1. 
Study Rationale 
Study ALN-AGT01-002 (KARDIA-1) is a randomized, double-blind, placebo-controlled, dose-
ranging, multicenter Phase 2 study designed to evaluate the safety, efficacy, and 
pharmacodynamics (PD) of ALN-AGT01, administered SC, in patients with mild-to-moderate 
hypertension. Patients will be randomized to 1 of 4 ALN-AGT01 treatment regimens or placebo 
for the first 6 months of the 12-month Double-blind (DB) period. After the first 6 months of the 
DB period, patients from the placebo arm will be re-randomized to 1 of the 4 initial 
ALN-AGT01 regimens for the remaining 6 months of the DB period, while patients randomized 
to ALN-AGT01 will remain on their originally assigned regimens. After completion of the 
12-month DB period, patients may be eligible to participate in an ALN-AGT01 open-label 
extension (OLE) study. If an individual patient reaches Month 12 prior to availability of the OLE 
study, they may continue their current blinded dosing in the DB Extension period for up to 12 
additional months until the OLE study is open and then transition. 
The primary objective of the study is to evaluate the efficacy of ALN-AGT01 for the treatment 
of hypertension by evaluating the impact on systolic blood pressure (SBP) from baseline to 
Month 3, as assessed by ambulatory blood pressure monitoring (ABPM). Secondary and 
exploratory objectives of the study include evaluating the efficacy of ALN-AGT01 on other 
measures of blood pressure response and evaluating the PD effect of ALN-AGT01, including 
reduction in circulating AGT concentration. 
The full rationale for the study and design is presented in Section 3.2. 
1.2. 
Background 
Hypertension affects 30% to 45% of adults and is the strongest modifiable risk factor for 
cardiovascular disease, primarily strokes and myocardial infarction.[Olsen 2016; Williams 2018] 
The worldwide disease burden is profound, with a global prevalence of over 1 billion,[Kearney 
2005; NCD Risk Factor Collaboration 2017] and approximately 9 million deaths attributed to 
hypertension annually.[Angell 2015] 
Currently available pharmacologic therapies achieve target blood pressure in only a minority of 
patients, due in large part to physician inertia and patient nonadherence to daily oral 
medication.[Whelton 2018; Williams 2018] Low adherence to oral antihypertensives is 
associated with poor cardiovascular outcomes and is prevalent at all stages of disease.[Corrao 
2011; Peacock and Krousel-Wood 2017; Schulz 2016; van der Laan 2017] Thus, despite the 
availability of multiple efficacious agents, current rates of control are low, and the global burden 
of death and disability-adjusted life-years attributed to elevated blood pressure remains 
high.[Forouzanfar 2017; Muntner 2020] Development of new approaches to treat hypertension 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
22 
and to overcome the limitations of current therapies is a key unmet need.[Dzau and Balatbat 
2019; McClellan 2019; Services 2020] 
The Sponsor is developing ALN-AGT01, a novel synthetic RNA interference (RNAi) 
therapeutic, for SC administration for the treatment of hypertension. RNAi is a naturally 
occurring cellular mechanism for regulation of gene expression, mediated through the binding of 
siRNA to its complementary messenger RNA (mRNA) sequence, leading to mRNA cleavage 
and subsequent suppression of the synthesis and levels of the target protein. ALN-AGT01 
contains an siRNA targeting AGT mRNA, conjugated to a GalNAc-containing ligand to facilitate 
delivery to the liver. Based on the mechanism of RNAi, ALN-AGT01 is specifically designed to 
reduce the hepatic synthesis of AGT protein, the first substrate in the renin-angiotensin-
aldosterone system (RAAS) and the sole precursor of vasoactive angiotensin peptides.[Khanna 
2017; Romero 2015] Because hepatocytes are the predominant source of circulating AGT, 
ALN-AGT01 has been developed to reduce blood pressure by decreasing circulating AGT levels 
and the downstream effects of angiotensin II (AngII). 
Preliminary data from Part A of the ongoing Phase 1 Study ALN-AGT01-001 (hereafter referred 
to as Study 001) in patients with hypertension have shown that single SC doses of ALN-AGT01 
lead to dose-dependent and durable reductions in circulating AGT, accompanied by clinically 
significant reductions in SBP and diastolic blood pressure (DBP). Reductions in AGT for up to 
6 months postdose were observed in the study.  
Most adverse events (AEs) have been mild or moderate in severity, and there have been no 
severe or serious adverse events (SAEs) related to study drug. There have been no clinically 
significant elevations in serum creatinine or serum potassium, and no patient has required 
intervention for low blood pressure. No clinically significant alanine aminotransferase (ALT) 
elevations have been observed in Part A patients who received ALN-AGT01 doses as high as 
800 mg. Injection site reactions (ISRs) were reported in a minority of patients and were all mild 
and transient events that resolved without intervention. 
This Phase 2 study will further quantify the antihypertensive effects of ALN-AGT01 across a 
range of doses (150 to 600 mg) and dose intervals (once every 3 months and once every 6 
months) to identify optimal treatment. The consistent and prolonged PD effect of ALN-AGT01 
is expected to achieve the unique benefit of continuous 24-hour blood pressure lowering with 
infrequent SC dosing.  
A detailed description of the chemistry, pharmacology, efficacy, and safety of ALN-AGT01 is 
provided in the Investigator’s Brochure. 
1.3. 
Benefit-Risk Assessment 
Clinical data available from Study 001 indicate that ALN-AGT01 may offer the benefit of blood 
pressure reduction to patients with hypertension. The mean SBP reduction observed after single 
ALN-AGT01 doses of 100 mg or higher exceeds 10 mmHg, which is comparable to the effect of 
conventional antihypertensives. The blood pressure of patients will be closely monitored, and 
after Month 3, oral antihypertensives will be added as needed to control blood pressure. 
Given the mechanism of action and mode of administration of ALN-AGT01, potential 
theoretical risks include liver transaminase elevations and ISRs. Like any antihypertensive 
therapy, there is also a theoretical risk of hypotension with ALN-AGT01. Based upon the disease 






Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
25 
3. 
INVESTIGATIONAL PLAN 
3.1. 
Summary of Study Design 
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study 
designed to evaluate the safety, efficacy, and PD of ALN-AGT01, administered SC, in patients 
with mild-to-moderate hypertension. A schematic of the study design is provided in Figure 1. 
Before randomization, patients will discontinue prior antihypertensive medications (if taking) for 
a Washout period of at least 4 weeks.  
DB and DB Extension Periods 
Patients who complete the Screening period and meet all inclusion/exclusion criteria for 
enrollment will be randomized 1:1:1:1:1 to receive 1 of the following regimens over a 12-month 
DB treatment period. Randomization will be stratified by race (black vs all other races) and by 
baseline blood pressure (mean 24-hour SBP < or ≥145 mmHg).  
• Placebo SC once every 3 months, with re-randomization (1:1:1:1) at Month 6 to 1 of 
the initial 4 ALN-AGT01 regimens 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients receiving once every 6 month ALN-AGT01 regimens will receive placebo SC at dosing 
visits at which they do not receive ALN-AGT01 to maintain the blind. 
At Month 3, conventional oral antihypertensives may be added per Investigator judgement for 
daytime mean SBP ≥135 mmHg by ABPM. After Month 3, oral antihypertensive medications 
may also be added per Investigator judgement for persistent elevations in blood pressure above 
target (target defined as office SBP <140 mmHg, home blood pressure monitoring [HBPM] SBP 
<135 mmHg, or daytime mean SBP <135 mmHg by ABPM). Oral antihypertensives (if taking) 
will be temporarily held from Month 5 to Month 6 in appropriate patients (Month 5 office SBP 
<155 mmHg if taking 1 oral antihypertensive agent or office SBP <150 mmHg if taking 2 
agents) to assess the effect of ALN-AGT01 alone (vs placebo) at Month 6 by ABPM. During this 
4-week period, blood pressure will be carefully monitored by daily HBPM and oral 
antihypertensive medications restarted if confirmed office SBP >170 mmHg (or if confirmed 
office SBP >160 mmHg accompanied by symptoms). 
Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the 
Month 12 predose assessments. If an individual patient reaches Month 12 prior to availability of 
the OLE study, they may continue their current blinded dosing in the DB Extension period for up 
to 12 additional months until the OLE study is open and then transition. Once the OLE study is 
open for enrollment, eligible patients may rollover into the OLE study at Months 12, 18, or 24 
(whichever visit occurs first). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
26 
In the DB Extension period, blood pressure will be closely monitored and individual 
modification of antihypertensive therapy will be allowed to maintain blood pressure in target 
range.  
Safety Follow-up Period 
Patients who discontinue study drug or do not enroll in the ALN-AGT01 OLE study will be 
asked to complete Safety Follow-up visits after their last dose of study drug: 
• Patients who discontinue study drug before Month 6: Safety Follow-up visits will occur 
once every 6 months after the last dose of study drug until the last patient’s Month 6 visit 
or until serum AGT levels return to ≥50% of their individual mean baseline level, 
whichever comes later. 
• Patients who discontinue study drug after the Month 6 visit: Safety Follow-up visits will 
occur once every 6 months after the last dose of study drug until serum AGT levels return 
to ≥50% of their individual mean baseline level. 
Patients who discontinue study drug prior to the Month 6 visit will be asked to complete the 
remainder of scheduled study visits and assessments (except for study drug administration) 
through Month 6. If a patient discontinues study drug after the Month 6 visit, early termination 
(ET) assessments should be performed. 
The planned enrollment for this study is approximately 375 patients (75 patients per group). 
The duration of treatment with ALN-AGT01 is up to 24 months. The estimated total time on 
study for each patient is up to 44 months, including up to 2 months of screening, followed by up 
to 24 months of treatment, and up to 18 months in the Follow-up period. 
3.2. 
Scientific Rationale for Study Design 
This is a randomized, double-blind, placebo-controlled, dose-ranging, multicenter Phase 2 study 
designed to evaluate the safety, efficacy, and PD of ALN-AGT01, administered SC, in patients 
with mild-to-moderate hypertension. The primary objective of the study is to evaluate the 
efficacy of ALN-AGT01 by measuring the impact on SBP from baseline to Month 3, as assessed 
by ABPM.  
This study will quantify the antihypertensive effects of ALN-AGT01 across a range of doses and 
dose intervals to identify optimal treatment regimens for study in Phase 3. 
Patients will discontinue prior antihypertensive medications (if taking) for at least 4 weeks prior 
to study drug administration. During the study, blood pressure will be monitored with both 
outpatient 24-hour ABPM and automated office blood pressure measurements 
(EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical Investigation of Medicinal Products in 
the Treatment of Hypertension, 2016). The primary endpoint will be assessed by ABPM given its 
greater precision over office blood pressure measurements. In addition, 24-hour ABPM can 
assess short-term blood pressure variability and circadian patterns (including potential restoration 
of the normal nocturnal blood pressure dipping pattern that is lost in 21% to 35% of hypertensive 
patients).[de la Sierra 2009; White 1998] More frequent measurements will be collected through 
a third method, oscillometric HBPM, to assess long-term blood pressure variability and provide 
close safety monitoring for potential hypotension (or hypertension) while not in the clinic. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
27 
As recommended by current guidance (International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use [ICH] Principles for Clinical Evaluation of 
New Antihypertensive Drugs, 2000 and EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical 
Investigation of Medicinal Products in the Treatment of Hypertension, 2016), the first 6 months 
of the DB period is designed as a randomized, placebo-controlled, parallel-group study. To 
adhere to best ethical standards for the treatment of patients with hypertension, individual 
modification of oral antihypertensive medications per Investigator judgement to maintain blood 
pressure within target is permitted starting at Month 3 and will continue throughout the study 
(except between Month 5 and Month 6 as described in Section 3.1). Separate from these treat-to-
target modifications, any confirmed event of severe systolic hypertension (SBP ≥180 mmHg) 
will be appropriately treated regardless of its timing relative to study drug administration. 
If a patient requires treatment with a conventional oral antihypertensive before Month 6, a 
calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic will be added because there 
is extensive experience combining these classes with antihypertensive drugs that impact the 
RAAS. Additionally, their blood pressure effects are expected to washout within 4 weeks.  
Rigorous assessment of the antihypertensive effects of ALN-AGT01 at Month 6 (trough for the 
once every 6 month regimens) relative to placebo is critical to evaluate the feasibility of once 
every 6 month dosing regimens for future study in Phase 3. Accordingly, oral antihypertensives 
(if taking) will be temporarily held from Month 5 to the Month 6 ABPM assessment. For each 
patient, this limited interruption in oral antihypertensives will be contingent upon the patient’s 
Month 5 office SBP being adequately controlled (see Table 4) and the Investigator’s assessment 
that interruption can be safely performed and carefully monitored by daily HBPM 
measurements. Of note, a withdrawal period is a standard element in studies of oral 
antihypertensives that is often used to establish assay sensitivity, to demonstrate maintenance of 
efficacy, and to assess possible withdrawal effects (ICH E12A; Principles for Clinical Evaluation 
of New Antihypertensive Drugs, 2000). Outside of research studies, antihypertensives are 
temporarily discontinued in clinical practice for diagnostic purposes, and interruptions up to 6 
weeks have been shown to be safe.[Beeftink 2017] In this study, the period of interruption is 
limited to 4 weeks, and most patients are expected to have continued antihypertensive effect 
from ALN-AGT01. If a clinically significant blood pressure elevation (confirmed SBP >170 
mmHg; or SBP >160 mmHg accompanied by symptoms) occurs after the interruption of oral 
antihypertensives, Investigators will instruct the patient to promptly resume dosing with their 
existing supply of oral medication.  
After Month 6, other oral antihypertensives may be used at the discretion of the Investigator, 
following current care guidelines.[Whelton 2018; Williams 2018] Because ALN-AGT01 acts on 
the RAAS, the use of conventional RAAS inhibitors (angiotensin II-receptor blocker [ARB], 
angiotensin converting enzyme [ACE] inhibitors, or direct renin inhibitors) as rescue agents for 
high blood pressure will be avoided throughout this study. Blood pressure and pharmacokinetic 
(PK)/PD assessments will be collected through Month 12 to assess the effect of repeated dosing. 
While tissue specificity of ALN-AGT01 for the liver is hypothesized to improve tolerability 
relative to current oral antihypertensives,[Mullick 2017; Uijl 2019] the protocol’s monitoring 
plan is designed to meet the standards set by prior studies of conventional RAAS 
inhibitors,[McMurray 2016; Parving 2012] with improvements to include the use of the newer 
oral potassium binder patiromer for treatment of potential hyperkalemia.[Georgianos and 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
28 
Agarwal 2018; Weir 2015] The risk of renal safety events is further mitigated in this study by its 
eligibility criteria, which exclude patients who are at highest risk to have events (estimated 
glomerular filtration rate [eGFR] <30 mL/min/1.73m2, baseline serum potassium >5 mEq/L, 
poorly controlled diabetes, or severely increased albuminuria) and those who may have 
decreased tolerance for renal safety events (patients with clinically significant heart failure, 
valvular heart disease, or recent history of cardiovascular event).  
3.3. 
Justification for Dose 
The doses of ALN-AGT01 in this study were selected on the basis of data from the Phase 1 
Study 001, in which single ALN-AGT01 doses up to 800 mg were found to have an acceptable 
safety profile, and clinically significant placebo-corrected reductions in mean SBP >10 mmHg 
by 24-hour ABPM were observed after doses as low as 100 mg. Dose selection was guided by 
the principle of evaluating doses that are well tolerated and predicted to result in a range of PD 
effects (ie, lowering of serum AGT) and antihypertensive responses. This is expected to enable 
development of population average dose-response relationships for PD and efficacy to guide 
identification of optimal treatment regimens (dose and dose frequency) for Phase 3.  
Preliminary PK/PD modeling based on serum AGT data from Study 001 indicates that 
ALN-AGT01 results in a dose-dependent lowering of serum AGT, with maximum reductions 
predicted to be achieved as early as 1 month postdose and significant reductions sustained for 
close to 6 months after dosing. Modeling of the relationship between serum AGT lowering and 
blood pressure suggests a log-linear relationship, with ≥92% reduction in serum AGT predicted 
to achieve median SBP reduction of ≥10 mmHg.  
Based on these, the once every 6 month doses of 150, 300, and 600 mg were selected to result in 
median serum AGT reductions of 81.9%, 89.4%, and 94.9%, respectively, at trough (Month 6), 
translating to median SBP reductions of 6.67 mmHg, 8.74 mmHg, and 11.6 mmHg, respectively. 
Thus, the selected doses will enable characterization of the dose-response relationships for serum 
AGT and blood pressure with the once every 6 month regimen. 
The selected doses also enable characterization of the dose-response relationships for serum 
AGT and blood pressure with once every 3 month regimens based on analysis of data from all 
arms at Month 3. This will provide support for development of a once every 3 month regimen, if 
desired. To this end, 300 mg once every 3 months will be evaluated to identify any cumulative 
effects. The 300 mg once every 3 months dose is predicted to result in median serum AGT 
reductions of >95% at trough (Month 3), translating to median SBP reductions of >10 mmHg.  
Thus, data from the current study will enable robust characterization of PD and efficacy of once 
every 3 month and once every 6 month regimens of ALN-AGT01 and guide further development 
of ALN-AGT01 as an antihypertensive therapeutic that results in reduction of blood pressure by 
≥10 mmHg throughout the dosing interval with infrequent administration. 
3.4. 
Method of Assigning Patients to Treatment Groups 
Using the Interactive Response Technology (IRT), patients will be randomized 1:1:1:1:1 to the 
following arms during the first 6 months of the 12-month DB period: 
• Placebo SC once every 3 months 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
29 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients initially randomized to placebo will be re-randomized 1:1:1:1 at Month 6 to 1 of the 4 
initial ALN-AGT01 regimens. 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. 
Randomization will be stratified by race (black vs all other races) and by baseline blood pressure 
(mean 24-hour SBP < or ≥145 mmHg). 
Each patient will be uniquely identified in the study by a combination of the site number and 
patient identification number. Upon signing the informed consent form (ICF), the patient will be 
assigned a patient identification number by the IRT system. The Investigator or his/her designee 
will randomize the patient in IRT after confirming that the patient fulfills all the inclusion criteria 
and none of the exclusion criteria. The Investigator or his/her designee will re-randomize the 
patient in IRT at Month 6 to assign placebo patients to 1 of the 4 initial ALN-AGT01 dose 
groups. 
3.5. 
Blinding 
The Sponsor, all site personnel (except for the site pharmacist or delegate), and patients will be 
blinded to study drug treatment through Month 6 of the 12-month DB period. After the database 
lock to support the analysis of Month 6 data is complete, the Sponsor will be unblinded to 
treatment assignment, but the site personnel (except for the site pharmacist) and patients will 
remain blinded to treatment assignment until after the analysis of Month 12 data is complete.  
Blinded doses of study drug will be administered under the supervision of the Investigator (see 
Section 5.2.2). All patients will receive the same volume and number of injections regardless of 
treatment assignment (patients receiving once every 6 month ALN-AGT01 regimens will receive 
placebo SC at dosing visits at which they do not receive ALN-AGT01 to maintain the blind). 
Because ALN-AGT01 may be slightly visually distinguishable from placebo, all blinded study 
drug doses will be prepared and the syringe(s) will be masked by a site pharmacist or delegate 
prior to administration by a blinded healthcare professional. See the Pharmacy Manual for 
additional details. 
3.5.1. 
Emergency Unblinding 
If the treating physician determines that the clinical management of the patient requires 
knowledge of the study drug assignment, the Investigator may break the blind, as necessary, in 
IRT. If time permits, clinical study center personnel should contact the Medical Monitor before 
unblinding to discuss the need to unblind the patient but must do so within 1 working day after 
the unblinding event. Unblinding information should be limited to the fewest number of people 
on a need-to-know basis. A record of when the blind was broken, who was unblinded, who broke 
the blind, and why it was broken, will be maintained in the electronic trial master file. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
30 
Refer to the IRT instructions for details on emergency unblinding. 
3.6. 
Data Monitoring Committee 
An independent DMC will oversee the safety and overall conduct of this study. The DMC will 
operate under the rules of a charter that will be reviewed and approved at the organizational 
meeting of the DMC. Details are provided in the DMC Charter. 
3.7. 
Clinical Event Adjudication Committees 
An independent Clinical Event Adjudication Committee of 2 or more nephrologists will review 
renal events blinded to treatment assignment to adjudicate whether they meet diagnostic criteria 
for acute kidney injury and, if so, their potential staging and contributing factors. Details are 
provided in the Renal Event Adjudication Committee charter. 
3.8. 
Definition of End of Study for an Individual Patient 
A patient is considered to have reached the end of the study if the patient: 
• has completed at least the Month 12 visit and enrolled in the OLE study, or 
• has completed the Safety Follow-up visits as described in Section 3.1 for patients who 
discontinue study drug or do not enroll in the OLE study. 
A definition of the end of the overall study is provided in Section 8.1.5. 
4. 
SELECTION AND REMOVAL OF PATIENTS 
4.1. 
Inclusion Criteria 
Patients are eligible to be included in the study if all the following criteria apply: 
Age and Sex 
1. Age 18 to 75 years, inclusive 
2. Male or female 
Patient and Disease Characteristics 
3. Has untreated hypertension (not taking antihypertensive medication) or is on stable 
therapy with 1 or more antihypertensive medications of the following classes: an ACE 
inhibitor, ARB, renin inhibitor, CCB, thiazide diuretic, and/or thiazide-like diuretic. In 
general, stable therapy is defined as having no change in antihypertensive medication or 
dose within 30 days prior to screening.  
4. Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive 
medication. Patients previously taking medication for hypertension must be without 
antihypertensives for ≥4 weeks prior to this ABPM. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
31 
Informed Consent 
5. Patient is able to understand and is willing and able to comply with the study 
requirements and to provide written informed consent. 
4.2. 
Exclusion Criteria 
Patients are excluded from the study if any of the following criteria apply: 
Disease-specific Conditions 
1. Secondary hypertension 
2. Orthostatic hypotension (symptomatic or asymptomatic), defined as a fall of ≥20 mmHg 
SBP or ≥10 mmHg DBP within approximately 1 to 3 minutes of standing up from a 
seated position by office blood pressure. 
Laboratory Assessments 
3. Has any of the following laboratory parameter assessments after at least 4 weeks of 
washout:  
a. ALT or aspartate aminotransferase (AST) >2× upper limit of normal (ULN) 
b. Total bilirubin >1.5×ULN. Patients with elevated total bilirubin that is secondary to 
documented Gilbert’s syndrome are eligible if the total bilirubin is <2×ULN 
c. International normalized ratio (INR) >2.0 (patients on oral anticoagulant [eg, 
warfarin] with an INR <3.5 will be allowed) 
d. Elevated potassium >5 mEq/L  
e. eGFR of ≤30 mL/min/1.73m2 (calculation will be based on the Modification of Diet 
in Renal Disease formula)  
Prior/Concomitant Therapy 
4. Received an investigational agent within the last 30 days before randomization or are in 
follow-up of another clinical study prior to study enrollment. Any agent that has received 
health agency authorization (including for emergency use) by local or regional regulatory 
authorities is not considered investigational. 
5. Currently taking, taken within 30 days prior to randomization, or anticipated to receive 
during the course of the study any medication or herbal supplement known to 
significantly affect blood pressure (with the exception of medications for the treatment of 
essential hypertension). Patients who require medications such as monoamine oxidase 
(MAO) inhibitors that are associated with hypertensive crisis should be 
excluded.[Whelton 2018]  
6. Currently taking, or taken within 30 days prior to randomization, beta blockers 
7. Currently taking, taken within 30 days prior to randomization, or anticipated to receive 
during the course of the study sodium-glucose co-transporter 2 (SGLT2) inhibitors 
8. Prescription nonsteroidal anti-inflammatory drugs (NSAIDs) are not permitted. In 
addition, chronic/standing use of over-the-counter NSAIDs is not permitted. 
Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
32 
9. Anticipates using organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, 
isosorbide dinitrate, pentaerythritol) during the course of the study 
10. Received an RNAi therapeutic (approved or investigational) within 6 months prior to 
randomization 
Medical Conditions 
11. Current or prior history of intolerance to an ARB, ACE inhibitor (other than cough), or 
direct renin inhibitor 
12. Medical condition, other than hypertension, that requires treatment with a RAAS 
inhibitor 
13. History of multiple drug allergies or history of allergic reaction to an oligonucleotide or 
to GalNAc 
14. Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus (hemoglobin A1c 
[HbA1c] >8.0%), newly diagnosed Type 2 diabetes mellitus (within 6 months prior to 
randomization), or laboratory evidence of diabetes during screening (fasting plasma 
glucose ≥126 mg/dL [7.0 mmol/L], random plasma glucose ≥200 mg/dL [11.1 mmol/L], 
or HbA1c ≥6.5%) without known diagnosis of diabetes 
15. History of severely increased albuminuria (urine albumin:creatinine ratio >300 mg/g or 
>300 mg/day) or laboratory results consistent with this diagnosis upon screening  
16. Has known human immunodeficiency virus or evidence of current or chronic hepatitis C 
virus (HCV) or hepatitis B virus (HBV) infection 
17. History of any cardiovascular event (eg, stroke, transient ischemic attack, myocardial 
infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary 
intervention, hospitalization due to heart failure) within 6 months prior to randomization 
18. Clinically significant valvular heart disease 
19. New York Heart Association II to IV heart failure 
20. Uncontrolled serious cardiac arrhythmia, defined as recurrent and highly symptomatic 
ventricular tachycardia, atrial fibrillation with rapid ventricular response, or 
supraventricular tachycardia in the 3 months prior to randomization 
21. Has undergone liver transplantation or is anticipated to be on an active liver 
transplantation waiting list during the study treatment period 
22. History of renal transplantation or under immunosuppressive therapy 
23. Has other medical conditions or comorbidities which, in the opinion of the Investigator, 
would interfere with study compliance or data interpretation; or, in the opinion of the 
Investigator, taking part in the study would jeopardize the safety of the patient 
24. Clinically significant illness, in the opinion of the Investigator, within 7 days prior to 
randomization 
25. Known change in body weight >10% in last 6 months prior to screening 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
33 
26. History of intolerance to SC injection(s) that could potentially hinder study drug 
administration or evaluation of local tolerability 
27. Has planned major surgery or general anesthesia during the study 
Contraception, Pregnancy, and Breastfeeding 
28. Is not willing to comply with the contraceptive requirements during the study period, as 
described in Section 5.7.1 
29. Female patient is pregnant, planning a pregnancy, or breast-feeding. 
Alcohol or Nicotine Use and Substance Abuse 
30. Unwilling or unable to limit alcohol consumption throughout the course of the study. 
Alcohol intake of >2 units/day is excluded during the study (unit: 1 glass of wine 
[approximately 125 mL] = 1 measure of spirits [approximately 1 fluid ounce] = ½ pint of 
beer [approximately 284 mL]). 
31. History of alcohol or substance abuse (licit or illicit drugs) within the last 12 months 
before screening, in the opinion of the Investigator 
32. Unwilling or unable to abstain from use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine 
patches, or e-cigarettes) within 30 minutes prior to office blood pressure measurements  
Other Restrictions 
33. Third shift or night shift workers 
34. Arm circumference exceeds the maximum cuff size of any of the blood pressure 
instruments provided by the Sponsor 
35. Unable or unwilling to perform HBPM as specified 
4.3. 
Removal from Study Drug or Assessment 
Patients or their legal guardians are free to discontinue study drug and/or stop protocol 
procedural assessments, or participation in the study as a whole at any time and for any reason, 
without penalty to their continuing medical care. The Investigator or the Sponsor may 
discontinue study drug or stop a patient’s participation in the study at any time if this is 
considered to be in the patient’s best interest. Any discontinuation of treatment or the stopping of 
the patient’s participation in the study must be fully documented in the electronic case report 
form (eCRF) and should be followed up by the Investigator. 
Discontinuation of study drug or declining procedural assessments is described in Section 4.3.1, 
while the stopping of a patient’s participation in the study is detailed in Section 4.3.2. 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments 
Reasons for discontinuation of study drug include any of the following: 
• Significant protocol deviation; which includes required treatment with prohibited 
medication (as defined in Section 5.5.2) per Investigator discretion 
• AE 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
34 
• Non-adherence to treatment regimen 
• Pregnancy 
• Lost to follow-up 
• Other reason (non-AE) 
• Or, study is terminated by the Sponsor 
If possible, the Investigator will confer with the Sponsor or Medical Monitor before 
discontinuing dosing in the patient. Patients who are pregnant will be discontinued from study 
drug dosing immediately (see Section 6.5.6.7 for reporting and follow-up of pregnancy). A 
positive urine pregnancy test should be confirmed by a serum pregnancy test prior to 
discontinuing the study drug. 
Patients who discontinue study drug and/or decline procedural assessments should not be 
automatically removed from study. In general, patients who discontinue study drug dosing for 
any reason will be encouraged to remain on the study to complete the remaining assessments and 
study visits so that their experience is captured in the final analyses.  
If this occurs, the Investigator is to discuss with the patient the appropriate processes for 
discontinuation from study drug and must discuss with the patient the options for continuation of 
the Schedule of Assessments (Table 1), including different options for follow-up and collection 
of data (eg, in person, by phone, by mail, through family or friends, or from options not 
involving patient contact, such as communication with other treating physicians or from review 
of medical records), including endpoints and AEs, and must document this decision in the 
patient’s medical records. 
If a patient discontinues dosing due to an AE, including SAEs, the event should be followed as 
described in Section 6.5.6. When a patient discontinues study drug dosing, the primary reason 
must be recorded in the eCRF. Patients who discontinue study drug and remain on study may 
receive treatment consistent with local standard practice for their disease per Investigator 
judgement, as applicable. 
Patients who discontinue from study drug before Month 6 will be encouraged to remain on the 
study and complete assessments (excluding PK assessments) through Month 6. They will also be 
asked to complete Safety Follow-up visits once every 6 months after the last dose of study drug 
per the safety follow-up schedule (see Table 1) until the last patient’s Month 6 visit or until PD 
recovery (whichever is later); see Section 3.1. 
Patients who discontinue study drug after the Month 6 visit will be asked to return for their next 
scheduled visit to complete end of treatment (EOT)/ET assessments and complete Safety Follow-
up visits once every 6 months after the last dose of study drug per the safety follow-up schedule 
(see Table 1) until PD recovery; see Section 3.1. 
4.3.2. 
Stopping a Patient’s Study Participation 
4.3.2.1. 
Patient or Legal Guardian Stops Participation in the Study 
A patient or their legal guardian may stop participation in the study at any time. A patient or 
legal guardian considering stopping participation in the study before Month 6 should be 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
35 
informed that the patient can discontinue study drug and/or decline procedural assessments and 
remain in the study to complete their study assessments through the Month 6 visit and complete 
Safety Follow-up visits as described in Section 4.3.1, or alternatively may complete any minimal 
assessments for which the patient or legal guardian consents. If a patient or legal guardian still 
chooses to discontinue study drug and stop participation in all follow-up prior to the completion 
of the Month 6 visit, every effort should be made to conduct the Month 6 visit assessments at an 
earlier time (Table 1). 
A patient considering stopping participation in the study after the Month 6 visit should be 
informed that the patient can discontinue study drug and/or decline procedural assessments and 
remain in the study to complete the assessments scheduled for the EOT/ET visit and complete 
Safety Follow-up visits as described in Section 4.3.1, or alternatively may complete any minimal 
assessments for which the patient consents. 
If the patient does not wish to or is unable to continue further study participation, the Investigator 
is to discuss with the patient appropriate procedures for stopping participation in the study. Data 
collected from the patient can continue to be used. 
Note, in countries where the collection and processing of the patient’s personal data is based on 
consent, if a patient withdraws consent to collect and process his/her personal data (see 
Section 4.3.2.2), as applicable, personal data up to the withdrawal of consent will be included in 
the analysis of the study. In addition, where permitted, publicly available data (such as 
appropriate national or regional vital status registry or other relevant databases) can be included 
after withdrawal of consent, where available and allowable by local law. 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection to 
Process Patient’s Personal Data 
Where allowed by local law, the patient may decide to withdraw consent to collect, store, and 
use biological samples and, as applicable, other personal data, informing the study doctor at any 
time in writing or in any other form that may be locally required. Also, where allowed by local 
law, the patient may object to the collection, storage, and use of his/her personal data, informing 
the study doctor at any time in writing or in any other form that may be locally required. In both 
cases, the Sponsor will continue to keep and use the patient’s study information (including any 
data resulting from the analysis of the patient’s biological samples until the time of 
withdrawal/objection) according to applicable law. The process for the storage and, as 
applicable, further use of remaining samples will be followed per local requirements.  
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study 
The Investigator or Sponsor may stop the participation of a patient in the study at any time if this 
is considered to be in the patient’s best interest. However, study integrity and interpretation are 
best maintained if all enrolled patients continue study assessments and follow-up even if study 
drug is discontinued. 
Termination of the clinical study and site closure are described in Section 8.1.6. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
36 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation 
The primary reason that a patient’s study participation is stopped must be recorded in the 
appropriate section of the eCRF and all efforts will be made to complete and report the 
observations as thoroughly as possible. If a patient’s study participation is stopped due to an AE, 
including SAEs, the event should be followed as described in Section 6.5.6. 
4.3.3. 
Lost to Follow-Up 
A patient will be considered lost to follow-up if the patient repeatedly fails to return for 
scheduled visits and is unable to be contacted by the clinical study center. The following actions 
must be taken if a patient fails to return to the clinic for a required study visit: 
• The site must attempt to contact the patient or legal guardian and reschedule the 
missed visit as soon as possible and counsel the patient or legal guardian on the 
importance of maintaining the assigned visit schedule and ascertain if the patient or 
legal guardian wishes [for the patient] to continue in the study, and/or should continue 
in the study. 
• Before a patient is deemed lost to follow up, the Investigator or designee must make 
every effort to regain contact with the patient or legal guardian (where possible, 3 
telephone calls and, if necessary, a certified letter to the patient’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the patient’s medical record. 
• Should the patient or legal guardian continue to be unreachable, the patient will be 
considered to have stopped participation in the study. 
• For patients who are lost to follow-up, the Investigator can search publicly available 
records (where permitted and allowed by local law) to ascertain survival status. This 
ensures that the outcome of the study is as comprehensive as possible. 
4.3.4. 
Replacement of Study Patients 
No additional patients may be enrolled to mitigate the impact of patients who discontinue the 
study drug or stop participation in the study.  
5. 
TREATMENTS AND OTHER REQUIREMENTS 
5.1. 
Treatments Administered 
Study drug supplied for this study must not be used for any purpose other than the present study 
and must not be administered to any person not enrolled in the study. Study drug that has been 
dispensed and returned unused must not be re-dispensed. 
5.2. 
Study Drug 
Detailed information describing the preparation, administration, and storage of ALN-AGT01 SC 
and placebo SC is provided in the Pharmacy Manual. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
37 
5.2.1. 
Description 
ALN-AGT01 will be supplied as a sterile solution for SC injection. See the Pharmacy Manual 
for further details of solution concentration and fill volume. 
The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC 
administration).  
5.2.2. 
Dose and Administration 
During the 12-month DB period, patients will be administered ALN-AGT01 or placebo, at the 
same volume and number of SC injections regardless of treatment assignment, once every 3 
months. The ALN-AGT01 and placebo groups are below: 
• Placebo SC once every 3 months, with re-randomization (1:1:1:1) at Month 6 to 1 of 
the initial 4 ALN-AGT01 regimens 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. Patients receiving once every 6 month ALN-AGT01 regimens will receive 
placebo SC at dosing visits at which they do not receive ALN-AGT01 to maintain the blind. 
Study drug injections will be administered under the supervision of the Investigator or healthcare 
professional. To maintain the blind, the doses are to be prepared by and syringes are to be 
masked by an unblinded site pharmacist or designee prior to study drug administration. A full 
description of the blinding procedure is included in the Pharmacy Manual. The injection site may 
be marked and mapped for later observation. Injections may be administered in the abdomen, 
thigh, or the side or back of the upper arms. The rotation of sites is recommended. If a local 
reaction around the injection site occurs, photographs may be obtained. Detailed instructions for 
study drug administration are found in the Pharmacy Manual. 
If a patient does not receive a dose of study drug within the specified visit window, the 
Investigator should contact the Medical Monitor. After such consultation, the dose may be 
administered up to 42 days before the next scheduled dose. Thereafter, the dose will be 
considered missed and not administered. 
Patients will be permitted to miss an occasional dose of study drug. However, if a patient misses 
2 consecutive doses, the Investigator, in consultation with the Medical Monitor, will discuss 
whether the patient will be able to continue the study (see also Section 4.3). 
Additional details can be found in the Pharmacy Manual. 
The definition of study drug overdose, follow-up procedures, and reporting requirements are 
provided Section 6.5.6.8. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
38 
5.2.3. 
Dose Modifications 
Dose modifications are not permitted. 
If a study drug-related AE occurs in a patient that the Investigator judges as presenting a 
potential risk to the patient for further dosing, the study drug dose may be held at the discretion 
of the Investigator and the Medical Monitor should be contacted. 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping Study 
Drug Dosing  
1. Dosing decisions may be made based on the most recently available liver function test 
(LFT) results from a central laboratory (Table 6). 
2. For any ALT or AST elevation >3×ULN, central laboratory results should be used to 
guide subsequent monitoring as detailed in Table 3. 
3. For any ALT or AST elevation >3×ULN: 
a. If local laboratory results are obtained, confirm with a central laboratory as soon as 
possible, ideally within 2 to 3 days, but no later than 7 days. 
b. If an alternative cause is found, provide appropriate care. 
c. If an alternative cause is not found, perform assessments per Table 6 and Table 7. 
4. For any ALT or AST elevation >3×ULN without alternative cause that is accompanied 
by clinical symptoms consistent with liver injury (eg, nausea, right upper quadrant 
abdominal pain, jaundice) or elevated bilirubin to ≥2×ULN or INR ≥1.5, permanently 
discontinue dosing. 
5. For confirmed ALT or AST elevations >3×ULN without alternative cause and not 
accompanied by symptoms or elevated bilirubin ≥2×ULN or INR ≥1.5, see Table 3. 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative Cause 
Identified 
Transaminase Level 
Action 
>3× to 5×ULN 
• 
May continue study drug dosing 
• 
Evaluate the initial elevation in LFT per the following assessments: 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6  
• 
Monitor at least every 2 weeks (LFT and coagulation per Table 6)  
• 
If elevation persists for ≥2 months, must discuss with the Medical Monitor 
before continuing dosing 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
39 
Transaminase Level 
Action 
>5× to 8×ULN 
• 
Hold study drug dosing until recovery to ≤1.5×ULN or baseline; may 
resume dosing after discussion with the Medical Monitor 
• 
Evaluate the initial elevation in LFT per the following assessments 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6 
• 
Monitor at least weekly: LFT and coagulation per Table 6 until ALT and/or 
AST is declining on 2 consecutive draws, then may decrease monitoring to 
biweekly 
• 
If ALT or AST rises to >5×ULN following resumption of dosing, 
permanently discontinue dosing 
>8×ULN 
Permanently discontinue study drug dosing after confirmation of the 
transaminase value at the central laboratory. 
Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; INR=international normalized 
ratio; LFT=liver function test(s); ULN=upper limit of normal. 
Notes: In addition to these criteria, other assessments or evaluations may be performed per Investigator discretion, 
as appropriate. 
5.2.5. 
Preparation, Handling, and Storage 
Staff at each clinical study center will be responsible for preparation of ALN-AGT01 or placebo 
doses according to procedures detailed in the Pharmacy Manual. No special procedures for the 
safe handling of study drug are required. 
ALN-AGT01 will be stored upright and refrigerated at approximately 2 to 30°C until dose 
preparation. Deviations from the recommended storage conditions should be reported to the 
Sponsor and use of ALN-AGT01 halted until authorization for its continued use has been 
provided by the Sponsor or designee, as described in the Pharmacy Manual. 
A Sponsor representative or designee will be permitted, upon request, to audit the supplies, 
storage, dispensing procedures, and records. 
Instructions specific to unused study drug and additional storage will be provided in the 
Pharmacy Manual. 
5.2.6. 
Packaging and Labeling 
All packaging, labeling, and production of study drug will be in compliance with current Good 
Manufacturing Practice specifications, as well as applicable local regulations. Study drug labels 
and external packaging will include all appropriate information as per local labeling 
requirements. Additional details will be available in the Pharmacy Manual. 
5.2.7. 
Accountability 
The Investigator or designee will maintain accurate records of receipt and the condition of 
ALN-AGT01 supplied for this study, including dates of receipt. In addition, accurate records will 
be kept of when and how much ALN-AGT01 is dispensed and administered to each patient in 
the study. Any reasons for departure from the protocol dispensing regimen must also be 
recorded. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
40 
At the completion of the study, there will be a final reconciliation of all ALN-AGT01. Used, 
partially used, and unused ALN-AGT01 will be returned to the Sponsor (or designee) or 
destroyed at the clinical study center according to applicable regulations. 
Further instructions about drug accountability will be detailed in the Pharmacy Manual. 
5.3. 
Clinical Product Complaints 
5.3.1. 
Definition 
A clinical product complaint (CPC) is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of the investigational product and its packaging after it is released for distribution at 
clinical site. 
A CPC may be detected prior to use of study drug, during use, or after use. A CPC is typically 
nonmedical in nature; however, it is possible that investigational product complaints could be 
associated with an AE. Examples of a CPC include, but are not limited to: illegible clinical label, 
missing clinical label, damaged vial, empty vial, contamination of investigational product, and 
malfunction of syringe needle safety device. 
5.3.2. 
Reporting 
For product complaints, the Sponsor or its designee should be notified within 24 hours using the 
appropriate eCRF. CPCs that may be associated with an AE must be evaluated and reported as 
indicated in Section 6.5.6 instructions on reporting CPCs will also be detailed in the Pharmacy 
Manual. 
5.4. 
Monitoring for Potential Clinical Events 
5.4.1. 
Monitoring and Approach for Potential Hypotension 
Hypotension is an obligate risk of antihypertensive medications. In addition to office blood 
pressure monitoring, outpatient blood pressure will be monitored weekly with HBPM to ensure 
the early detection of potential hypotension. Whenever possible, management decisions will be 
based on blood pressure measurements confirmed by office blood pressure. 
The following management recommendations for hypotension are provided: 
• Low blood pressure that is associated with symptoms should be evaluated at the 
clinical study site or another hospital setting within 24 hours. Clinical study site 
evaluation for low blood pressure should include the assessment of orthostatic blood 
pressure.  
• The Investigator should consider downtitration or discontinuation of oral 
antihypertensives (if taking) if confirmed office SBP <100 mmHg or if clinical 
symptoms, such as lightheadedness or dizziness, develop coupled with a significantly 
lower SBP compared to prior visits (ie, SBP <110 mmHg). 
• Clinically significant events discovered during the course of a patient’s general 
medical care should be promptly communicated to the site and evaluated by the 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
41 
Investigator, especially if hypotension is noted. Patients will carry Independent Ethics 
Committee (IEC)-approved patient cards to facilitate this physician-to-physician 
communication.  
• If hypotension is confirmed, serum electrolytes and creatinine should be measured 
and any oral antihypertensive(s) previously started for hypertensive escape should be 
down-titrated or discontinued.  
• The frequency of blood pressure and biochemical monitoring (serum electrolytes and 
creatinine) should be increased during intercurrent illnesses that predispose patients to 
dehydration (eg, vomiting or diarrhea that persists for more than 24 hours) or when 
symptoms consistent with decreased effective circulating volume (eg, presyncopal 
symptoms, unexplained falls, decreased urine output) manifest, even if a patient’s 
recent blood pressure measurements have been normal. 
• Hypotension that warrants direct evaluation at the site should be communicated to the 
Medical Monitor within 24 hours. In addition, other clinical events consistent with 
potential hypotension (eg, unexplained presyncope, syncope, or falls) should be 
communicated to the Medical Monitor within 24 hours of the site being notified. 
• Management of persistent hypotension may include increased salt intake or, if 
unresponsive, standard treatments for orthostatic intolerance syndromes such as 
fludrocortisone or midodrine. 
• Low blood pressure that requires medical treatment (including intravenous fluid 
support) or other clinical events consistent with potential hypotension (see above) 
should be recorded as AEs. 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure Elevation 
In addition to office blood pressure monitoring, outpatient blood pressure will be monitored 
frequently with HBPM to ensure the early detection of potential significant elevations. Whenever 
possible, management decisions will be based on blood pressure measurements confirmed by 
office blood pressure. The recommended interventions for potentially clinically significant blood 
pressure elevation are presented in Table 4.  
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation 
Study Period 
Intervention 
Throughout Study 
• 
Whenever possible, management decisions should be based on blood 
pressure measurements confirmed by office blood pressure. 
• 
Any confirmed event of severe systolic hypertension (office SBP 
≥180 mmHg) should be appropriately treated regardless of its timing 
relative to study drug administration.  
• 
Because ALN-AGT01 acts on the RAAS, the use of conventional RAAS 
inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors) as rescue 
agents for high blood pressure will be avoided throughout this study.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
42 
Study Period 
Intervention 
• 
If added, oral antihypertensives must be used per their labeled instructions 
and in accordance with current care guidelines.[Whelton 2018; Williams 
2018] 
Day 1 to Month 3 
Intervene if clinically significant blood pressure elevation: 
• 
Because of the gradual onset of effects of ALN-AGT01, interventions for 
asymptomatic hypertension should be avoided in the first 6 weeks after the 
patient’s first administration of study drug.  
• 
After Week 6, patients who develop office SBP >160 mmHg and increased 
>10 mmHg from their baseline office SBP that persists for ≥24 hours on 2 
consecutive measurements or that is accompanied by hypertensive 
symptoms should be evaluated by the clinical study site. Severely 
symptomatic patients should be evaluated at the clinical study site or 
another hospital setting within 24 hours. 
• 
If persistent hypertension is confirmed (without the identification of a 
specific treatable cause) and the Investigator deems it to be a clinically 
significant change, treatment may be initiated at the medical discretion of 
the Investigator using a CCB and/or a thiazide/thiazide-like diuretic. 
Investigators should avoid long-acting agents that may not fully washout 
between Month 5 and Month 6. 
Months 3 to 6 
Treat to target blood pressure using a CCB and/or thiazide/thiazide-like diuretic: 
• 
At Month 3, a CCB and/or a thiazide/thiazide-like diuretic should be added 
if the daytime mean SBP is ≥135 mmHg by ABPM. If the Investigator feels 
there is a compelling clinical reason to wait, the rationale for exception 
should be documented in the eCRF. 
• 
After Month 3, oral antihypertensive medications may also be added per 
Investigator judgement for persistent elevations in blood pressure above 
target (target defined as office SBP <140 mmHg, HBPM SBP <135 mmHg, 
or daytime mean SBP by ABPM <135 mmHg).[Williams 2018] 
• 
A temporary hold of oral antihypertensives (if taking) will be performed in 
appropriate patients (below) from Month 5 to Month 6: 
- Month 5 office SBP <160 mmHg if taking no oral antihypertensive 
agents 
- Month 5 office SBP <155 mmHg if taking 1 oral antihypertensive agent 
- Month 5 office SBP <150 mmHg if taking 2 oral antihypertensive 
agents. 
• 
During this 4-week period, blood pressure will be carefully monitored by 
daily HBPM and oral antihypertensive medications restarted if confirmed 
office SBP >170 mmHg (or if confirmed office SBP >160 mmHg 
accompanied by symptoms) 
Month 6 to End of 
Study 
Treat to target blood pressure using Investigator’s choice of oral 
antihypertensive(s). 
• 
At Month 6, prior oral antihypertensive should be restarted per Investigator 
judgement if daytime mean SBP is ≥135 mmHg by ABPM. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
43 
Study Period 
Intervention 
• 
Oral antihypertensive medications may also be added per Investigator 
judgement for persistent elevations in blood pressure above target (target 
defined as office SBP <140 mmHg; HBPM SBP <135 mmHg; daytime 
mean SBP by ABPM <135 mmHg).[Whelton 2018; Williams 2018] 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of eGFR 
through the anticipated onset of initial ALN-AGT01 PD. Based upon the renal dysfunction 
associated with conventional RAAS inhibitors,[McMurray 2016; Parving 2012] the following 
guidelines apply throughout the study: 
• Study drug (and additional oral antihypertensive agents, if applicable) should be 
prophylactically held during intercurrent illness or volume depletion 
• If an individual patient experiences a decrease in eGFR by ≥30% from baseline or to 
≤30 mL/min/1.73m2, the Investigator should obtain confirmatory repeat tests, contact 
the Sponsor, and look for potentially reversible causes of renal dysfunction such as: 
− NSAIDs, antibiotics, or other treatments known to impair renal function 
− Recent exposure to intravenous contrast agents 
− Hypovolemia 
− Urinary infection 
− Urinary tract obstruction 
• If an individual patient experiences a decrease in eGFR by ≥40% from baseline or to 
≤25 mL/min/1.73m2, the Investigator should look for potentially reversible causes of 
renal dysfunction and contact the Sponsor to discuss the potential interruption of 
study drug. Serum creatinine should be monitored at least weekly until improving. 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of serum 
electrolytes (at least monthly through the anticipated onset of ALN-AGT01 PD). The following 
guidelines apply for potassium elevations detected by laboratory monitoring.[McMurray 2016; 
Parving 2012] 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
44 
Table 5: 
Recommended Interventions for Hyperkalemia 
Serum K+ ≥5.2 and <5.5 mmol/L 
Serum K+ ≥5.5 and <6.0 mmol/L 
Serum K+ ≥6.0 mmol/L 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample. 
• 
Reinforce low-potassium diet 
and restriction of food/drinks 
with high potassium content  
• 
Review medical regimen 
(including dietary supplements 
and over-the-counter 
medications) for agents known 
to cause hyperkalemia.a 
Consider reduction in dose or 
discontinuation of these agents. 
• 
Repeat K+ measurement within 
3 to 5 days. 
• 
If K+ remains ≥5.2 and <5.5 
mmol/L, regularly monitor K+ 
levels to ensure stability (at 
least weekly if in the first 6 
weeks of treatment or at least 
once monthly afterwards) 
• 
Consider interruption of 
ALN-AGT01, according to 
Investigator medical judgment. 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample 
• 
Consider interruption of ALN-
AGT01, according to 
Investigator medical judgment  
• 
Apply all measures outlined for 
serum K+ ≥5.2 and <5.5 
mmol/L 
• 
Repeat K+ measurement after 2 
to 3 days 
• 
If K+ <5.5 mmol/L, consider 
resumption of study drug (if 
interrupted) with repeat 
potassium within 5 days 
• 
If K+ persistently elevated ≥5.5 
mmol/L, consider treatment 
with patiromer 
• 
Immediately interrupt 
ALN-AGT01 
• 
Confirm potassium 
concentration in a 
non-hemolyzed 
sample 
• 
Urgently evaluate 
patient and treat 
hyperkalemia as 
clinically indicated. 
After urgent 
treatment, consider 
treatment with 
patiromer 
• 
Apply all measures 
outlined for serum K+ 
≥5.5 and < 6.0 
mmol/L 
• 
No resumption of 
study drug without 
individualized case 
discussion with and 
permission from 
Alnylam Medical 
Monitor 
Abbreviations: NSAID=nonsteroidal anti-inflammatory drug. 
a This list is not meant to be exhaustive: potassium-sparing diuretics (eg, amiloride and triamterene), potassium 
supplements (eg potassium chloride), salt substitutes, NSAIDs, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, herbal supplements (eg, Noni juice, alfalfa [Medicago sativa], 
dandelion [Taraxacum officinale], horsetail [Equisetum arvense], nettle [Urtica dioica], milkweed, lily of the 
valley, Siberian ginseng, hawthorn berries). 
The availability of patiromer will be assessed at participating study sites. This potassium-binding 
drug is approved for the treatment of hyperkalemia and has been shown to safely reduce serum 
potassium levels and to maintain long-term normokalemia in chronic kidney disease patients 
receiving background conventional RAAS inhibitor therapy.[Georgianos and Agarwal 2018; 
Weir 2015] 
5.5. 
Concomitant Medications and Procedures 
Use of concomitant medications and procedures will be recorded on the patient’s eCRF as 
specified in the Schedule of Assessments (see Table 1). Concomitant medications include all 
prescription medications, herbal preparations, over the counter medications, vitamins, and 
minerals. Any changes in medications during the study will also be recorded on the eCRF. 
Standard vitamins and topical medications are permitted. However, topical steroids must not be 
applied anywhere near the injection site(s) unless medically indicated. For permitted concomitant 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
45 
medications administered SC, do not administer in same injection site area as the study drug for 
4 days after the last dose of study drug. 
Occasional use of systemic NSAIDs is allowed. However, given their association with increased 
blood pressure, they should be avoided when possible and alternative analgesics (acetaminophen, 
topical NSAIDs) should be considered.[Whelton 2018] When used, the dosing of systemic 
NSAIDs should be at the lower end of the labeled range and for the shortest duration possible.  
Patients will be allowed to receive vaccines (eg, for SARS-CoV-2) that have received health 
agency authorization (including for emergency use) by local or regional regulatory authorities. 
Any concomitant medication that is required for the patient’s welfare may be administered by the 
Investigator, except as described in Section 5.5.2. However, it is the responsibility of the 
Investigator to ensure that details regarding the medication are recorded on the eCRF. 
Concomitant medication will be coded using an internationally recognized and accepted coding 
dictionary. 
5.5.1. 
Oral Antihypertensive Medication  
Individual initiation and modification of oral antihypertensive medications per Investigator 
judgement are permitted throughout the study if required to treat clinically significant blood 
pressure elevation (Section 5.4.2). In addition, after a patient completes the placebo-controlled 
primary endpoint at Month 3, Investigators will titrate therapy with oral antihypertensives to a 
target blood pressure range (office SBP <140 mmHg, HBPM SBP <135 mmHg, or daytime 
mean SBP by ABPM <135 mmHg). All oral antihypertensive medication that are dosed once 
daily should be taken in the morning. 
Serum electrolytes and creatinine should be measured at a central or local laboratory 
approximately 2 weeks after any antihypertensive addition or dose titration. 
5.5.2. 
Prohibited Concomitant Medication 
The following medications, treatments, and supplements are prohibited throughout the study 
(until the EOT visit): 
• Conventional RAAS inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors)  
• SGLT2 inhibitors (eg, empagliflozin, canagliflozin, and dapagliflozin) 
• Prescription NSAIDs  
• Chronic/standing use of nonprescription NSAIDs 
• Organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, isosorbide 
dinitrate, pentaerythritol) 
• Medications, herbal supplements (including Ma Huang and St. John’s wort), or other 
substances (such as licorice) that are associated with increases in LFT abnormalities 
or with blood pressure abnormalities are prohibited. This includes certain stimulants 
(eg, amphetamine, methylphenidate dexmethylphenidate, dextroamphetamine), MAO 
inhibitors, atypical antipsychotics (eg, clozapine, olanzapine), diet pills (eg, 
phenylpropanolamine, sibutramine), and nasal decongestants (eg, phenylephrine 
hydrochloride, pseudoephedrine, naphazoline hydrochloride). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
46 
• Medications, herbal medicines, over-the-counter medications, or supplements known 
to cause hyperkalemia are prohibited unless individually approved by both the 
Investigator and the Medical Monitor. This includes potassium-sparing diuretics, 
potassium supplements, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, mineralocorticoid receptor 
antagonists, Noni juice, alfalfa, dandelion, horsetail, nettle, milkweed, lily of the 
valley, Siberian ginseng, and hawthorn berries. 
All concomitant medications must be reviewed and approved by the Investigator, with particular 
attention to avoiding drugs that may affect blood pressure. 
5.6. 
Treatment Compliance 
Compliance with study drug administration will be verified through observation by study staff or 
trained home healthcare professionals. 
5.7. 
Other Requirements 
5.7.1. 
Contraception 
Females of child-bearing potential must be willing to use a highly effective method of 
contraception from 14 days before first dose, throughout study participation, and through safety 
follow-up (if applicable; see Section 3.1).  
Birth control methods which are considered highly effective include: 
• Placement of an intrauterine device. 
• Placement of an intrauterine hormone-releasing system. 
• Bilateral tubal occlusion. 
• Surgical sterilization of male partner (with the appropriate post-vasectomy 
documentation of the absence of sperm in the ejaculate; for female patients on the 
study, the vasectomized male partner should be the sole partner for that patient). 
• Established use of oral (except low-dose gestagens), implantable, injectable, or 
transdermal hormonal methods of contraception associated with the inhibition of 
ovulation. 
• True sexual abstinence, when in line with the preferred and usual lifestyle of the 
patient. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception. Abstinent 
patients must agree to use one of the above-mentioned contraceptive methods if they 
start heterosexual relationships during the study and through safety follow-up (if 
applicable; Section 3.1). 
Investigators should advise females of childbearing potential of the most appropriate birth 
control method available within their country taking into account local medical practice. 
Females of child-bearing potential include female patients who have experienced menarche (or 
begin menarche over the course of the study), and who are not postmenopausal or permanently 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
47 
sterilized (eg, bilateral tubal occlusion, hysterectomy, or bilateral salpingectomy). A 
postmenopausal state is defined as the absence of menses for 12 months without an alternative 
medical cause, confirmed by follicle stimulating hormone level within the postmenopausal 
range.  
For male patients, no contraception is required. However, use by males of contraception 
(condom) may be required in some countries, eg, France, in order to comply with local 
requirements as described in the corresponding patient ICFs.  
Compliance with contraception requirements will be assessed on a regular basis by the 
Investigator throughout the course of the study (see Section 6.5.5.3). Pregnancy testing will be 
performed before every dose for postmenarcheal females throughout the course of the study (see 
Section 6.5.5.3). 
5.7.2. 
Alcohol Restrictions 
Patients should limit alcohol consumption throughout the course of the study. Alcohol is limited 
to no more than 2 units per day (unit: 1 glass of wine [approximately 125 mL] =1 measure of 
spirits [approximately 1 fluid ounce] =½ pint of beer [approximately 284 mL]) for the duration 
of the study. Compliance with alcohol restrictions should be assessed on a regular basis by the 
Investigator throughout the course of the study. 
5.7.3. 
Tobacco and Nicotine Restrictions 
Use of nicotine or tobacco-containing products (including but not limited to snuff, chewing 
tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) must be avoided within 30 
minutes prior to blood pressure measurements. 
5.7.4. 
Dietary Recommendations  
All patients will receive educational materials on diet with recommendations to limit sodium 
consumption to approximately 2.0 g per day from screening through the end of the Treatment 
period. This direction should be provided at the start of the Screening period, and treatment-
naïve patients should follow these recommendations for at least 1 week prior to screening 
assessments of blood pressure. Of note, this is the sodium intake recommended in the 2018 
European Society of Cardiology/European Society of Hypertension Guidelines for both 
hypertensive patients and for the general population.[Williams 2018]  
On days on which samples for fasting lipid panel and glycemic assessments are collected, 
patients are required to fast for ≥10 hours before sample collection (Section 6.5.5.1). 
5.7.5. 
Exercise 
Patients should abstain from strenuous exercise for 48 hours before each blood collection for 
clinical laboratory tests. 
6. 
STUDY ASSESSMENTS 
The Schedule of Assessments is provided in Table 1. Study visits should be scheduled for the 
morning. All assessments, except for postdose PK sample collection, are to be performed prior to 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
48 
dosing at dosing visits. Additional information on the collection of study assessments will be 
detailed in the Study Manual. 
Where applicable country and local regulations and infrastructure for home healthcare allow, 
home healthcare may take place at a location other than the clinical study site to perform study 
assessments, which may include collection of blood and urine samples and measurement of vital 
signs and weight (at the discretion of the Investigator). 
6.1. 
Screening Assessments 
An ICF that has been approved by the appropriate Institutional Review Board (IRB)/IEC must be 
signed by the patient or legal guardian before the screening procedures are initiated. All patients 
or their legal guardians will be given a copy of the signed and dated ICF. 
Patients will be screened to ensure that they meet all the inclusion criteria and none of the 
exclusion criteria. Rescreening of patients is permitted with consultation of the Medical Monitor 
(see Section 6.1.2). 
Patient demographic data and medical history/disease history will be obtained. Any changes to 
medical history occurring between the screening assessment and Day 1 will be updated prior to 
study drug administration. 
6.1.1. 
Retesting  
If in the Investigator’s judgement, the screening laboratory abnormalities are likely to be 
transient, then laboratory tests may be repeated. The Investigator’s rationale should be 
documented. Laboratory values can be retested once during screening provided that the patient 
can be evaluated for eligibility after at least 4 weeks of washout and randomized within the 
allowed Screening period. Retesting of screening ABPM is permitted once as described in 
Section 6.2.1, with eligibility assessed by the second ABPM result. 
6.1.2. 
Rescreening 
A patient who does not meet all study eligibility criteria due to a transient condition observed at 
screening (eg, prohibited medications that were subsequently discontinued) will be allowed to 
return once for rescreening. A patient will be re-consented if rescreening occurs outside of the 
60-day screening window. In this case, all screening procedures must be repeated. 
6.2. 
Efficacy Assessments 
All blood pressure measurements (ABPM, office, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in 
Section 10.1.  
In patients taking oral antihypertensives, a washout of at least 4 weeks must be completed prior 
to measurement of the baseline ABPM (for eligibility) and baseline office blood pressure. The 
baseline ABPM and office blood pressure must be measured within 2 weeks before 
randomization. An HBPM unit will be provided during the Screening period to facilitate 
monitoring during the washout of prior oral antihypertensives (if taking) and to establish the 
HBPM baseline prior to randomization. HBPM must be collected after at least 4 weeks of 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
49 
washout for at least 2 consecutive weeks (at least 3 recordings per week) prior to randomization 
to establish baseline. 
ABPM placement may be performed at home by appropriately trained individuals, as detailed in 
the Study Manual. If a patient is unable to report to the site for an office blood pressure 
assessment, a substitute “remote visit blood pressure measurement” may be obtained remotely 
using the methods described in Section 10.1. 
Recommendations for approach and monitoring of low blood pressure/hypotension and 
hypertensive escape are provided in Section 5.4.1 and Section 5.4.2, respectively. 
6.2.1. 
ABPM 
In patients taking oral antihypertensives (including those initiated as rescue medication), ABPM 
must be started prior to the morning dose of antihypertensive medication.  
Adequacy will be assessed for all ABPMs. If the ABPM recording is inadequate, the patient will 
be provided 1 opportunity to repeat the study. If the second ABPM recording is also inadequate 
during screening, the patient is a screen failure.  
See further details in Section 10.1 and the Study Manual. 
6.2.2. 
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor at trough (prior to taking oral antihypertensives) and at approximately the same time 
each day; therefore, visits should be scheduled at approximately the same time of day, whenever 
possible. Office blood pressure must include orthostatic measurements (seated and standing).  
Exercise, caffeine, alcohol consumption, and use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or 
e-cigarettes) must be avoided within 30 minutes prior to blood pressure measurements. The use 
of inhaled short-acting beta agonists should be avoided within 6 hours prior to measuring blood 
pressure and/or heart rate. The use of phosphodiesterase type 5 inhibitors (eg, sildenafil, 
tadalafil, vardenafil, avanafil) should be avoided within 48 hours prior to measuring blood 
pressure. 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the Study Manual.  
6.2.3. 
HBPM 
The HBPM should be measured in the morning upon waking, prior to breakfast/caffeine or 
taking morning oral medications. HBPM is not required at times when ABPM is being assessed. 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the Study Manual. 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment 
Approximately 100 patients at select sites will be given the option of using a wearable blood 
pressure sensor for 2 periods of 2 to 4 weeks each according to the Schedule of Assessments 
(Table 1). Wearable blood pressure assessments performed during screening should be obtained 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
50 
after at least 4 weeks of washout. Participation will be contingent upon individual patient 
consent. These noninvasive, cuffless devices are worn on the finger or wrist as described in the 
Study Manual, using the opposite arm as that used for ABPM. 
6.3. 
Pharmacodynamic Assessments 
Blood samples for determination of AGT and RAAS biomarkers (plasma renin concentration, 
AngI, AngII, and aldosterone) will be collected according to the Schedule of Assessments 
(Table 1). Blood samples collected for AngI and AngII require special processing and will be 
assessed at sites that have appropriate resources, equipment, and reagents. Blood samples for PD 
assessments must be collected before study drug administration (on days when study drug is to 
be dosed) or at a time point corresponding to the time of study drug dosing (on other days). 
Levels of aldosterone will also be analyzed in urine collections at the time points listed in the 
Schedule of Assessments (Table 1). Blood AGT levels will be analyzed at a central laboratory by 
enzyme-linked immunosorbent assay for measurement of PD effect. These biomarkers may be 
analyzed using qualified assays. Details regarding the collection, processing, shipping, and 
storage of the samples will be provided in the Laboratory Manual.  
Results will not be used to adjust dosing of ALN-AGT01 or guide other elements of study 
conduct or clinical management and will not be shared with sites until after study completion. If 
clinical circumstances arise for which such information is required to guide patient care, local 
laboratory assessments should be drawn. 
6.4. 
Pharmacokinetic Assessments 
Blood samples will be collected for the assessment of plasma concentrations of ALN-AGT01 
and its primary metabolite AS(N-1)3′ ALN-AGT01 at the time points indicated in the Schedule 
of Assessments (Table 1). A detailed schedule of time points for the collection of blood samples 
for PK analysis is in Table 2. 
Plasma concentrations of ALN-AGT01 and AS(N-1)3′ ALN-AGT01 will be determined using a 
validated assay. Details regarding sample volumes to be collected, and the processing, shipping, 
and analysis of the samples will be provided in the Laboratory Manual. 
6.5. 
Safety Assessments 
The assessment of safety during the study will consist of the surveillance and recording of AEs, 
including SAEs, recording of concomitant medication and measurements of vital signs, weight, 
electrocardiogram (ECG) findings, and laboratory tests. Clinically significant abnormalities 
observed during the physical examination are recorded. 
6.5.1. 
Vital Signs 
Vital signs will be measured as specified in the Schedule of Assessments (Table 1) and include 
blood pressure, heart rate, body temperature, and respiratory rate. When vital signs and blood 
sample collection occur at the same time, vital signs should be performed before blood samples 
are drawn, where possible. Vital signs should be measured predose in the seated position, after 
the patient has rested comfortably for 10 minutes. Body temperature in degrees Celsius will be 
obtained via oral, tympanic, or axillary methods. Heart rate will be counted for a full minute and 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
51 
recorded in beats per minute, and respiration rate will be counted for a full minute and recorded 
in breaths per minute. Blood pressure is described in Section 6.2.  
Additional vital sign assessments, as medially indicated, may be added at the discretion of the 
Investigator, or as per DMC advice. 
Vital signs results will be recorded in the eCRF. 
6.5.2. 
Weight, Height, and Morphometrics 
Height and body weight measurements will be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded in the eCRF. Height will be measured at screening 
only. Height will be measured in centimeters. Body weight should be measured in kilograms to 
the first decimal point in patients wearing light clothing and without shoes.  
Waist circumference and waist-to-hip-ratio will also be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded on the eCRF. For waist circumference and waist-to-
hip ratio, patients should wear minimal clothing to ensure that the measuring tape is correctly 
positioned. Patients should stand erect with the abdomen relaxed, arms at the sides, feet together 
and with their weight equally divided over both legs. To perform the waist measurement, the 
lowest rib margin is first located and marked with a pen. The iliac crest is then palpated in the 
midaxillary line, and also marked. It is recommended to apply an elastic tape horizontally 
midway between the lowest rib margin and the iliac crest, and tie firmly so that it stays in 
position around the abdomen about the level of the umbilicus. The elastic tape thus defines the 
level of the waist circumference, which can then be measured by positioning the measuring tape 
over the elastic tape. Hip circumference measurement should be taken around the widest portion 
of the buttocks. Patients are asked to breathe normally, and to breathe out gently at the time of 
the measurement to prevent them from contracting their muscles or from holding their breath. A 
stretch-resistant tape that provides a constant 100 g of tension is recommended. Measurements 
should be obtained with the tape positioned parallel to the floor and performed using the same 
procedure throughout the study. 
The reading is taken to the nearest centimeter and entered in the source document. Each 
measurement should be repeated twice; if the measurements are within 1 cm of each other, the 
average should be calculated. If the difference between the 2 measurements exceeds 1 cm, the 2 
measurements should be repeated.  
6.5.3. 
Physical Examination 
Full and symptom-directed physical examinations will be conducted according to the Schedule 
of Assessments (Table 1); if a physical examination is scheduled for a dosing visit, it should be 
conducted prior to dosing. Full physical examinations will include the examination of the 
following: general appearance; head, eyes, ears, nose and throat; respiratory, cardiovascular, 
gastrointestinal, musculoskeletal, and dermatological systems; thyroid; lymph nodes; and 
neurological status. 
Symptom-directed physical examinations will be guided by evaluation of changes in symptoms, 
or the onset of new symptoms, since the last visit. 
Clinically significant abnormalities observed during the physical examination are recorded on 
the medical history or AE eCRF. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
52 
6.5.4. 
Electrocardiogram 
The 12-lead ECGs reporting rhythm, ventricular rate, RR interval, PR interval, QRS duration, 
and QT interval and Fridericia-corrected QT interval will be obtained using a local machine, as 
specified in the Schedule of Assessments (Table 1). Patients should be supine for at least 10 
minutes before each ECG is obtained. The Investigator or qualified designee will review all 
single 12-lead ECGs to assess whether the results have changed since the Baseline visit and to 
determine the clinical significance of the results. These assessments will be recorded in the 
eCRF.  
When ECG and blood sample collection occur at the same visit, blood sample collection should 
occur first. ECGs should be performed at least 30 minutes after phlebotomy or other stressful 
assessments. 
The Investigator or qualified designee will review all ECGs to assess whether the results have 
changed since the baseline visit and to determine the clinical significance of the results. These 
assessments will be recorded in the eCRF. Additional ECGs may be collected at the discretion of 
the Investigator, or as per DMC advice. Recordings will be archived according to the Study 
Manual. 
6.5.5. 
Clinical Laboratory Assessments 
The following clinical laboratory tests will be evaluated by a central laboratory. Specific 
instructions for transaminase elevations are provided in Section 6.5.6.4. For any other 
unexplained clinically relevant abnormal laboratory test occurring after study drug 
administration, the test should be repeated and followed up at the discretion of the Investigator, 
or as per DMC advice, until it has returned to the normal range or stabilized, and/or a diagnosis 
is made to adequately explain the abnormality. Additional safety laboratories and assessments as 
indicated by the clinical situation may be requested. Clinical laboratory assessments are listed in 
Table 6 and will be assessed as specified in the Schedule of Assessments (Table 1).  
While local laboratory results may be used for urgent clinical decisions, on the day of the 
assessments all laboratory assessments specified in Table 6 which are performed at the clinic 
should also be sent in parallel to the central laboratory. In the case of discrepant local and central 
laboratory results on samples drawn on the same day, central laboratory results will be relied 
upon for clinical decisions. 
Clinical laboratory assessments may be collected at the clinical study center or at home by a 
trained healthcare professional. Blood samples collected for RAAS biomarkers should be 
collected in the morning and in the seated/upright position (after blood pressure measurements 
and before any assessments collected in the supine position). 
Spot urine collections for albumin and creatinine should be obtained in the morning. A 24-hour 
urine collection for aldosterone, sodium, and creatinine will be performed at time points listed in 
the Schedule of Assessments (Table 1). These 24-hour collections should be obtained within 2 
days before the ABPM associated with the same visit. 
For any safety event or laboratory abnormality, additional laboratory assessments, imaging, and 
consultation may be performed for clinical evaluation and/or in consultation with the Medical 
Monitor; results may be collected and should be included in the clinical database. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
53 
Table 6: 
Clinical Laboratory Assessments  
Hematology 
Complete blood count with differential 
 
Serum Chemistry 
Sodium 
Potassium 
BUN 
Phosphate 
Uric acid 
Albumin 
Total protein 
Calcium 
Glucose 
Bicarbonate 
Creatinine 
Chloride 
Liver Function Tests 
 
AST 
ALP 
ALT 
Bilirubin (total and direct) 
GGT 
 
Urinalysis 
Visual inspection for appearance and color 
Bilirubin 
pH (dipstick) 
Nitrite 
Specific gravity 
RBCs 
Ketones 
Urobilinogen 
Albumin 
Leukocytes 
Glucose 
Microscopy (if clinically indicated) 
Protein 
 
Coagulation  
Prothrombin time 
International normalized ratio 
Partial thromboplastin time  
 
Hepatitis Tests  
Hepatitis A, including: 
HAV antibody IgM and IgG 
Hepatitis B, including:  
HBsAg, HBc antibody IgM and IgG 
Hepatitis C, including:  
HCV antibody 
HCV RNA PCR – qualitative and quantitative 
assays 
Hepatitis E, including: 
HEV antibody IgM and IgG 
Fasting Lipid Panel and Glycemic Assessments (see Section 6.5.5.1) 
Lipid panel, including 
HDL-C, non-HDL-C, LDL-C, apolipoprotein A1, 
triglycerides, total cholesterol  
Insulin 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
54 
Fasting glucose 
HbA1c 
Immunogenicity (see Section 6.5.5.2) 
ADA 
 
Pregnancy Testing/FSH Screening (see Section 6.5.5.3) 
β-human chorionic gonadotropin (females of 
child-bearing potential only) 
Follicle-stimulating hormone (postmenopausal 
women only) 
Abbreviations: ADA=anti-drug antibodies; ALP=alkaline phosphatase; ALT=alanine aminotransferase; 
AST=aspartate aminotransferase; BUN=blood urea nitrogen; FSH=follicle-stimulating hormone; GGT=gamma 
glutamyl transferase; HAV=hepatitis A virus; HbA1c=hemoglobin A1c; HBc=hepatitis B virus core; 
HBsAg=hepatitis B virus surface antigen; HCV=hepatitis C virus; HDL-C=high-density lipoprotein; 
HEV=hepatitis E virus; IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; LDL-C=low-
density lipoprotein; PCR=polymerase chain reaction; RBCs=red blood cells; RNA=ribonucleic acid. 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments 
Blood samples for fasting glucose, insulin, lipid panel (including total cholesterol, high-density 
lipoprotein [HDL-C], non-HDL-C, low-density lipoprotein, apolipoprotein A1, and 
triglycerides), and HbA1c will be collected at the time points listed in the Schedule of 
Assessments (Table 1). Patients are required to fast for ≥10 hours before sample collection for 
fasting glucose, insulin, lipid panel, and HbA1c. Samples should be collected at approximately 
the same time of day (±2 hours). 
6.5.5.2. 
Immunogenicity 
Blood samples will be collected to evaluate anti-drug antibodies (ADA). Blood samples for ADA 
testing must be collected before study drug administration (on days when study drug is to be 
dosed) or at a time point corresponding to the time of study drug dosing (on other days) as 
specified in the Schedule of Assessments (Table 1). A blood sample to evaluate ADA will be 
collected at the ET visit, if applicable. Blood samples for ADA will be analyzed at a central 
laboratory. 
Details regarding the processing, shipping, and analysis of the samples will be provided in the 
Laboratory Manual. 
6.5.5.3. 
Pregnancy Testing 
A pregnancy test will be performed for females of child-bearing potential. A serum pregnancy 
test will be performed at screening, and urine pregnancy tests will be performed thereafter per 
the Schedule of Assessments and any time pregnancy is suspected. More frequent pregnancy 
testing may be performed where required per local requirements. The results of the pregnancy 
test must be known before study drug administration. Patients who are pregnant at screening are 
not eligible for study participation. Any woman with a positive urine pregnancy test, 
subsequently confirmed by a positive serum pregnancy test, during the study will be 
discontinued from study drug but will continue to be followed for safety. Patients determined to 
be pregnant while on study will be followed at least until the pregnancy outcome is known (see 
Section 6.5.6.7 for follow-up instructions). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
55 
A blood sample will be drawn at screening to measure the levels of follicle stimulating hormone 
in order to confirm postmenopausal status in all women suspected to be postmenopausal (see 
Section 5.7.1 for definition of postmenopausal state). 
6.5.5.4. 
Additional Liver Function Assessments 
Additional laboratory assessments will be performed in patients who experience any LFT 
abnormalities as outlined in Section 5.2.4. Following the occurrence of elevated liver 
transaminases or other LFT abnormalities per central laboratory, all assessments in Table 7 will 
be performed 1 time, as well as hematology, serum chemistry, LFT, and coagulation assessments 
from Table 6, and other assessments or evaluations per Investigator discretion, as appropriate.  
Monitoring, including criteria for dose modification or withholding the study drug, is described 
in Section 5.2.4.  
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases 
Extended Hepatic Panel 
HBsAg, HBc antibody IgM and IgG 
Parvovirus B19 
HAV antibody IgM 
HHV-6 
HCV antibody 
Anti-nuclear antibodies 
HCV RNA PCR – qualitative and quantitative 
Anti-smooth muscle antibodies 
HEV antibody IgM 
Anti-LKM1 antibody 
Herpes Simplex Virus 1 and 2 antibody IgM, IgG 
Anti-mitochondrial antibodies 
Herpes Zoster Virus IgM, IgG 
Anti-SLA 
Epstein-Barr Virus antibodies, IgM, and IgG 
Ferritin 
Cytomegalovirus antibodies, IgM, IgG 
Ceruloplasmin 
Imaging 
Abdominal ultrasound with Doppler flow (or CT or MRI) including right upper quadrant 
Focused Medical and Travel History 
Use of any potentially hepatotoxic concomitant 
medications, including over the counter medications 
and herbal remedies 
Alcohol consumption and drugs of abuse 
Other potentially hepatotoxic agents including any 
work-related exposures 
Recent travels to areas where hepatitis A or E 
is endemic 
Abbreviations: CT=computed tomography; HAV=hepatitis A virus; HBc=hepatitis B core; HBsAg=hepatitis B 
virus surface antigen; HCV=hepatitis C virus; HEV=hepatitis E virus; HHV-6=human herpesvirus 6; 
IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; LKM1=liver/kidney microsome-1 
antibody; MRI=magnetic resonance imagery; PCR=polymerase chain reaction; RNA=ribonucleic acid; 
SLA=soluble liver antigen 
Note: 
• 
All assessments will be measured in central laboratory. The full panel of assessments should only be 
performed once; individual assessments may be repeated, as needed. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
56 
6.5.6. 
Adverse Events 
6.5.6.1. 
Definitions 
Adverse Event 
According to the ICH E2A guideline Definitions and Standards for Expedited Reporting, and 21 
Code of Federal Regulations 312.32, Investigational New Drug Safety Reporting, an AE is any 
untoward medical occurrence in a patient or clinical investigational subject administered a 
medicinal product and which does not necessarily have a causal relationship with this treatment. 
Serious Adverse Event 
An SAE is any untoward medical occurrence that at any dose: 
• Results in death 
• Is life-threatening (an event which places the patient at immediate risk of death from 
the event as it occurred. It does not include an event that had it occurred in a more 
severe form might have caused death) 
• Requires inpatient hospitalization or prolongation of existing hospitalization 
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly or birth defect 
• Is an important medical event that may not be immediately life-threatening or result 
in death or hospitalization but may jeopardize the patient and may require 
intervention to prevent one of the other outcomes listed in the definition above (eg, 
events include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home, blood dyscrasias, convulsions, or the development of drug 
dependency or abuse). 
Adverse Events of Clinical Interest 
The following are considered to be AEs of clinical interest: 
• ALT or AST >3×ULN 
• Severe or serious ISRs; ISRs that are associated with a recall phenomenon (reaction 
at the site of a prior injection with subsequent injections), or those that lead to 
temporary dose interruption or permanent discontinuation of ALN-AGT01. 
An ISR is defined as a local reaction at or near the site of injection. “At or near” the injection site 
includes reactions at the injection site, adjacent to the injection site, or a reaction which may shift 
slightly away from the injection site due to gravity (eg, as may occur with swelling or 
hematoma). A systemic reaction which includes the injection site, eg, generalized urticaria, other 
distinct entities or conditions like lymphadenopathy that may be near the injection site is not 
considered an ISR. 
For information on recording and reporting of AEs of clinical interest, see Section 6.5.6.2 and 
Section 6.5.6.3, respectively. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
57 
Adverse Event Severity 
Adverse events are to be graded according to the categories detailed below: 
Mild: 
Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated. 
Moderate: 
Moderate; minimal, local, or noninvasive intervention indicated; 
limiting age appropriate instrumental activities of daily living (eg, 
preparing meals, shopping for groceries or clothes, using the telephone, 
managing money). 
Severe: 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self-care activities of daily living (ie, bathing, dressing and 
undressing, feeding self, using the toilet, taking medications, and not 
bedridden); OR life-threatening consequences; urgent intervention 
indicated; OR death related to an adverse event. 
Changes in severity should be documented in the medical record to allow assessment of the 
duration of the event at each level of severity. Adverse events characterized as intermittent 
require documentation of the start and stop of each incidence. When changes in the severity of an 
AE occur more frequently than once a day, the maximum severity for the experience that day 
should be noted. If the severity category changes over a number of days, then those changes 
should be recorded separately (with distinct onset dates). 
Adverse event severity and seriousness are assessed independently. ‘Severity’ characterizes the 
intensity of an AE. ‘Serious’ is a regulatory definition and serves as a guide to the Sponsor for 
defining regulatory reporting obligations (see definition for SAE). 
Relationship of the Adverse Event to Study Drug 
The relationship of each AE to study drug should be evaluated by the Investigator by a “yes” or 
“no” response to the question: “Is there a reasonable possibility that the event may have been 
caused by the study drug?” A “yes” response indicates that the event is considered as related to 
the study drug. 
6.5.6.2. 
Eliciting and Recording Adverse Events 
Eliciting Adverse Events 
The patient and legal guardian, if applicable, should be asked about medically relevant changes 
in the patient’s health since the last visit. The patient and legal guardian, if applicable, should 
also be asked if the patient has been hospitalized, had any accidents, used any new medications, 
or changed concomitant medication routines (both prescription and over-the-counter). In addition 
to patient observations, AEs will be documented from any clinically relevant laboratory findings, 
physical examination findings, ECG changes, or other findings that are relevant to patient safety. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
58 
Recording Adverse Events 
The Investigator is responsible for recording non-serious AEs that are observed or reported by 
the patient after administration of the first dose of study drug regardless of their relationship to 
study drug through the end of study. Non-serious AEs will be followed until the end of study. 
Events occurring after signing of the ICF and before study drug administration will be captured 
as medical history (see Section 6.1), while AEs that occur after study drug administration, and 
baseline events that worsen after study drug administration, must be recorded as AEs.  
The Investigator is responsible for recording SAEs that are observed or reported by the patient 
after the time when the informed consent is signed regardless of their relationship to study drug 
through the end of study. SAEs will be followed until satisfactory resolution, until baseline level 
is reached, or until the SAE is considered by the Investigator to be chronic or the patient is 
stable, as appropriate. 
All AEs must be recorded in the source records for the clinical study center and in the eCRF for 
the patient, whether or not they are considered to be drug-related. Each AE must be described in 
detail: onset time and date, description of event, severity, relationship to study drug, action taken, 
and outcome (including time and date of resolution, if applicable). 
For SAEs, record the event(s) in the eCRF and, as applicable, the SAE form. 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the supplemental AEs of 
Clinical Interest eCRF should be completed. Additional clinical and laboratory information may 
be collected. Refer to CRF completion guidelines for details on reporting events in the 
supplemental AEs of Clinical Interest eCRF. 
For all ISRs, the Investigator, or delegate, should submit an Injection Site Reaction Signs or 
Symptoms eCRF, recording additional information regarding each injection site reaction that is 
entered on the AE eCRF (eg, symptom(s), injection site location, follow-up actions taken, etc). 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the Sponsor or its designee 
should be notified within 24 hours using the appropriate eCRF. 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee 
An assessment of the seriousness of each AE will be made by the Investigator. Any AE and 
laboratory abnormality that meets the SAE criteria in Section 6.5.6.1 must be reported to the 
Sponsor or designee within 24 hours from the time that clinical study center staff first learns of 
the event. All SAEs must be reported regardless of the relationship to study drug. 
The initial report should include at least the following information: 
• Patient’s study number 
• Description and date of onset of the event 
• Criterion for serious 
• Preliminary assignment of relationship to study drug, and 
• Investigator/site information 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
59 
To report the SAE, complete the eCRF and, as applicable, the SAE form. Within 24 hours of 
receipt of follow-up information, the Investigator must update the eCRF and, as applicable, the 
SAE form. Serious adverse events must be reported using the contact information provided in the 
Study Manual. 
Appropriate remedial measures should be taken by the Investigator using his/her best medical 
judgment to treat the SAE. These measures and the patient’s response to these measures should 
be recorded. All SAEs, regardless of relationship to study drug, will be followed by the 
Investigator until satisfactory resolution or the Investigator deems the SAE to be chronic or 
stable. Clinical, laboratory, and diagnostic measures should be employed by the Investigator as 
needed to adequately determine the etiology of the event. 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities 
The Sponsor or its representative will report certain study events in an expedited manner to the 
Food and Drug Administration, the European Medicines Agency’s EudraVigilance electronic 
system according to Directive 2001/20/EC, and to all country Regulatory Authorities where the 
study is being conducted, according to local applicable regulations. 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee 
Suspected unexpected serious adverse reactions will be reported to the IRB/IEC per their 
institutional policy by the Investigator or Sponsor (or Sponsor designee) according to country 
requirements. Copies of each report and documentation of IRB/IEC notification and 
acknowledgement of receipt will be kept in the Investigator’s study file. 
6.5.6.7. 
Pregnancy Reporting 
If a female patient becomes pregnant during the study through safety follow-up (Section 3.1), the 
Investigator must report the pregnancy to the Sponsor or designee within 24 hours of being 
notified of the pregnancy. Details of the pregnancy will be recorded on the pregnancy reporting 
form. The patient should receive any necessary counseling regarding the risks of continuing the 
pregnancy, the possible effects on the fetus, and be counseled not to breastfeed for 90 days after 
the last dose of study drug. 
The pregnancy should be followed by the Investigator until completion. At the completion of the 
pregnancy, the Investigator will document the outcome of the pregnancy. If the outcome of the 
pregnancy results in a postpartum complication, spontaneous abortion, stillbirth, neonatal death, 
or congenital anomaly, then the Investigator should follow the procedures for reporting an SAE 
as outlined in Section 6.5.6.4. 
6.5.6.8. 
Overdose and Other Special Situations Reporting 
An overdose is defined as any dose of study drug administered to the participant or taken by the 
participant that is >2× the assigned dose during a single administration and/or ≥2 doses within ½ 
the intended dosing interval. 
The Sponsor does not recommend specific treatment for an overdose.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
60 
In an event of an overdose or other special situations (eg, medication error, abuse, misuse, CPC 
associated with an AE), the Investigator should: 
• Contact the Medical Monitor within 24 hours  
• Submit the special situations reporting form within 24 hours using the contact 
information in the Pharmacy Manual 
• Closely monitor the participant for any AE/SAE and laboratory abnormalities 
• Document the amount of study drug given  
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or 
a concomitant medication will be considered AEs/SAEs.  
Full details of overdose and other special situations reporting instructions will be outlined in the 
Pharmacy Manual. 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository 
Alnylam’s RNAi therapeutics platform permits the highly specific targeting of investigational 
therapies based on genetic sequence. It is possible that variations in the target genetic sequence 
will result in variations in drug effect. More generally, genetic variations may account for the 
well-described heterogeneous manifestations of disease in patients with hypertension, as well as 
their responses to treatment. 
Where allowed per local regulations, ethics committee (IRB/IEC) approval, and patient consent, 
samples will be collected as part of this study to permit exploratory investigations and the 
application of novel approaches to bioanalyses that may further elucidate the outcomes of this 
study, or potentially advance understanding of the safety, mechanism of action, and/or efficacy 
of ALN-AGT01. 
Biological specimens will be collected at the intervals indicated in the Schedule of Assessments 
(Table 1). In addition to the dedicated collections for optional exploratory biomarkers (urine, 
plasma, serum), aliquots from each 24-hour urine collection will be archived for potential 
exploratory investigations. These specimens will be analyzed at a central laboratory. Potential 
exploratory investigations may include DNA, RNA, or biochemical metabolite assessments as 
they relate to disease progression, efficacy, or safety. 
The biospecimen repository will also include residual material from routine samples (safety 
laboratory samples, PK samples, etc) that are obtained during the study. 
These specimens will be securely stored in a central biorepository for up to 10 years following 
the completion of this clinical study (ie, last patient last visit), or as per local regulations. After 
10 years have elapsed, samples will be destroyed. 
Details regarding the collection, processing, storage, and shipping of the samples will be 
provided in the Laboratory Manual. 
Exploratory analysis of these biospecimens will be performed by Alnylam Pharmaceuticals or its 
designees. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
61 
When biobanking is permitted by local regulation, study participants will be advised during the 
informed consent process of these biobanking details and the potential for exploratory 
investigation of their samples. 
7. 
STATISTICS 
A Statistical Analysis Plan (SAP) will be finalized before database lock and unblinding for the 
primary analysis. The plan will detail the implementation of the statistical analyses in accordance 
with the principle features stated in the protocol. 
7.1. 
Determination of Sample Size 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline in 
24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 375 
patients (75 per treatment group) provides at least 84% power to detect a dose response 
relationship in SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided 
significance level of 0.05. In addition, this sample size provides at least 80% power to detect a 
10 mmHg difference between an individual ALN-AGT01 dose versus placebo with a 2-sided 
significance level of 0.05. Table 8 shows the statistical power with various standard deviation 
assumptions. 
Table 8: 
Statistical Power to Detect 10 mmHg Difference Between ALN-AGT01 and 
Placebo With Various Standard Deviation Assumptions 
Assumption of Standard 
Deviation (mmHg) 
Statistical Power to Detect 
Dose Response Trend (%) 
Statistical Power to Detect Difference 
Between an Individual ALN-AGT01 
Dose Versus Placebo (%) 
15 
97 
96 
18 
90 
88 
20 
84 
80 
7.2. 
Statistical Methodology 
The statistical and analytical plans presented below are brief summaries of planned analyses. 
More complete plans will be detailed in the SAP. Changes to the methods described in the final 
SAP will be described and justified as needed in the clinical study report. For information on 
study endpoints, see Section 2. 
7.2.1. 
Populations to be Analyzed 
The populations (analysis sets) are defined as follows: 
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
62 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• PK Analysis Set: All patients who received at least 1 full dose of study drug and 
have at least 1 evaluable postdose blood sample for the determination of plasma 
ALN-AGT01 concentrations. 
• PD Analysis Set: All patients who received any amount of study drug and who have 
baseline and at least 1 postdose blood sample for the determination of serum AGT 
will be included in the PD analyses. 
The primary population used to evaluate efficacy will be the FAS. For the efficacy endpoints of 
change from baseline to Month 3, ALN-AGT01 300 mg once every 3 months and once every 6 
months will be pooled together and analyzed. For all other efficacy endpoints, analysis will be 
performed according to the randomized treatment arm. 
Safety will be analyzed using the Safety Analysis Set. The PK and PD Analysis Sets will be used 
to conduct PK and PD analyses, respectively. 
7.2.2. 
Examination of Subgroups 
Subgroup analyses will be conducted for selected endpoints. Subgroup categories and detailed 
methodology will be provided in the SAP. 
7.2.3. 
Handling of Missing Data 
Handling of missing data will be described in the SAP. 
7.2.4. 
Baseline Evaluations 
Demographics and other disease-specific baseline characteristics will be summarized. 
In general, baseline will be defined as the average of all assessments, including unscheduled 
assessments, prior to the first dose of study drug. Details of the definition will be specified in the 
SAP. 
7.2.5. 
Efficacy Analyses 
The primary endpoint is the change in SBP from baseline at Month 3 assessed by ABPM. The 
primary hypothesis of the dose response relationship for the primary endpoint across 
ALN-AGT01 doses and placebo will be tested using a multiple comparison– modeling (MCP 
Mod) approach.[Bretz 2005] The presence of a dose-response trend will be initially tested 
against a set of prespecified dose-response models at a 2-sided significance level of 0.05, 
adjusted for multiplicity (the MCP step). Several candidate models will be prespecified in the 
SAP. Then, the dose-response curves will be further estimated (the modeling step) based on the 
‘best’ fitted dose response model. Furthermore, each ALN-AGT01 dose group will be compared 
against placebo using Dunnett’s Test.  
For the secondary endpoints of change in DBP assessed by ABPM at Month 3 and change in 
SBP and DBP assessed by ABPM at Month 6, each ALN-AGT01 dose group will be compared 
with placebo. For change in office SBP and DBP, each ALN-AGT01 dose group will be 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
63 
compared with placebo at Month 3 and Month 6 and also using the time-adjusted average from 
Month 1 to Month 3 and from Month 1 to Month 6. 
No multiplicity adjustment is applied across primary and secondary endpoints.  
Details of the analysis method for primary, secondary, and exploratory endpoints will be 
described in the SAP. 
7.2.6. 
Pharmacodynamic Analysis 
Pharmacodynamic analyses will include the evaluation of changes in levels of serum AGT and 
other exploratory biomarkers of the RAAS pathway. Descriptive statistics for observed levels 
and the relative change from baseline for all measured biomarkers will be presented for each of 
the postdose time points. 
Statistical comparison of the biomarker levels (absolute and/or change from baseline) across 
treatment groups may be explored. Details of the analysis will be specified in the SAP.  
Population PK/PD analysis may be conducted to evaluate the dose-response relationships for PD 
lowering after ALN-AGT01 treatment. Additionally, the relationship between lowering of serum 
AGT and blood pressure may be explored within a modeling framework. If conducted, these 
analyses will be described in a pharmacometrics analysis plan and results will be presented in a 
separate report. 
7.2.7. 
Pharmacokinetic Analysis 
Plasma concentrations of ALN-AGT01 and its metabolite AS(N-1)3′ ALN-AGT01 will be 
summarized using descriptive statistics. 
Population PK analysis may be conducted on the PK data from this study. If conducted, the 
analysis methods will be described in a pharmacometrics analysis plan and results will be 
presented in a separate report. 
7.2.8. 
Safety Analyses 
The primary parameter is the frequency of treatment-emergent AEs (hereafter referred to simply 
as AEs). Safety parameters also include vital signs, ECGs, clinical laboratory assessments and 
physical exams. Extent of exposure will be summarized.  
Prior and concomitant medications will be coded using the World Health Organization Drug 
Dictionary. Results will be tabulated by Anatomical Therapeutic Chemical Classification System 
and Preferred Term (PT). 
Adverse events will be classified according to the Medical Dictionary for Regulatory Activities 
(MedDRA) System Organ Class (SOC) and PT. Adverse events, SAEs, related AEs, AEs leading 
to discontinuation of study drug, and AEs leading to death will be summarized by SOC and PT 
for each treatment arm. By-patient listings will be provided for deaths, SAEs, and AEs leading to 
discontinuation of study drug.  
Descriptive statistics will be provided for clinical laboratory parameters, ECG, and vital signs 
summarizing the observed values and changes from baseline over time. Laboratory shift tables 
from baseline grade (or category) to worst post-baseline grade (or category) will be presented for 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
64 
laboratory parameters that are graded or categorized. Abnormal physical exam findings will be 
presented in listings. 
Other safety summaries will be presented as appropriate. Further details will be specified in the 
SAP. 
7.2.9. 
Immunogenicity Analyses 
The frequency and percentage of patients with confirmed positive ADA assay at any time during 
the study as well as at each scheduled visit will be summarized. The titer results for patients with 
confirmed positive ADA results will be summarized. 
7.2.10. 
Interim Analysis 
The primary analysis will be conducted after all patients complete the Month 6 visit or withdraw 
from the study prior to the Month 6 visit. No formal interim analysis is planned before the 
primary analysis.  
7.2.11. 
Optional Additional Research 
Optional additional research may be conducted in the future on the biological samples and/or 
data collected during the study in accordance with the strict terms of the ICF (see Section 4.3.2). 
8. 
STUDY ADMINISTRATION 
8.1. 
Ethical and Regulatory Considerations 
This study will be conducted in accordance with the protocol, all applicable regulatory 
requirements, and the current guidelines of Good Clinical Practice (GCP). Compliance with GCP 
provides public assurance that the rights, safety, and well-being of study patients are protected 
consistent with the principles that have their origin in the Declaration of Helsinki. 
8.1.1. 
Informed Consent 
The Investigator will ensure that the patient is given full and adequate oral and written 
information about the nature, purpose, possible risk, and benefit of the study. Patients must also 
be notified that they are free to discontinue from the study at any time. The patient should be 
given the opportunity to ask questions and allowed time to consider the information provided. 
The Investigator will inform the patient/legal guardian if new information becomes available that 
may be relevant to the patient’s/legal guardian’s willingness to continue participation in the 
study. Communication of this information should be documented. 
The patient’s signed and dated informed consent must be obtained before conducting any study 
tests or procedures that are not part of routine care. 
The Investigator must maintain the original, signed ICF. A copy of the signed ICF must be given 
to the patient or legal guardian. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
65 
8.1.2. 
Ethical Review 
The study protocol, including the ICF, must be approved or given a favorable opinion in writing 
by an IRB or IEC, as appropriate. The Investigator must submit written approval before he or she 
can enroll any patient into the study. 
The Investigator is responsible for informing the IRB or IEC of any amendment to the protocol 
in accordance with local requirements. In addition, the IRB or IEC must approve all patient 
materials for the study. The protocol must be reapproved by the IRB or IEC upon receipt of 
amendments and annually, as local regulations require. 
Initial IRB or IEC approval of the protocol, and all materials approved by the IRB or IEC for this 
study including the patient consent form and recruitment materials must be maintained by the 
Investigator and made available for inspection. 
The Investigator will submit reports of SAEs as outlined in Section 6.5.6. In addition, the 
Investigator agrees to submit progress reports to the IRB or IEC per their local reporting 
requirements, or at least annually and at the conclusion of the study. The reports will be made 
available to the Sponsor or designee. 
Any communications from regulatory agencies, IRBs, or IECs in regard to inspections, other 
studies that impact this protocol or the qualifications of study personnel should be promptly 
reported to the Sponsor or its designee. 
The Investigator is also responsible for providing the IRB or IEC with reports of any reportable 
serious adverse drug reactions from any other study conducted with the study drug. The Sponsor 
or designee will provide this information to the Investigator. 
Major changes in this research activity, except those to remove an apparent immediate hazard to 
the patient, must be reviewed and approved by the Sponsor and the IRB or IEC that approved the 
study. Amendments to the protocol must be submitted in writing to the Investigator’s IRB or IEC 
and the Regulatory Authority for approval before patients are enrolled under the amended 
protocol, and patients or their legal guardians must be re-consented to the most current version of 
the ICF.  
8.1.3. 
Serious Breach of Protocol 
Investigators must notify the Medical Monitor within 24 hours of becoming aware of a potential 
serious breach of the protocol. A serious breach is a breach that is likely to affect to a significant 
degree the safety and rights of a study participant or the reliability and robustness of the data 
generated in the clinical study. 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention 
All documentation (including personal data) relating to the study should be retained for 2 years 
after the last approval in an ICH territory or as required by local laws and regulations, whichever 
is longer. 
If it becomes necessary for the Sponsor, the Sponsor’s designee, applicable IRB/IEC, or 
applicable regulatory authorities to review or audit any documentation relating to the study, the 
Investigator must permit direct access to all source documents/data. Records will not be 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
66 
destroyed without informing the Sponsor in writing and giving the Sponsor the opportunity to 
store the records for a longer period of time at the Sponsor’s expense. 
The Investigator must ensure that the patients’ confidentiality will be maintained. On the eCRFs 
or other documents submitted to the Sponsor or designees, patients should not be identified by 
their names, but by the assigned patient number or code. If patient names are included on copies 
of documents to be submitted to the Sponsor or designees, the names will be obliterated, and the 
assigned patient number added to the document, before sending to the Sponsor. Documents not 
for submission to the Sponsor (eg, signed ICFs) should be maintained by the Investigator in strict 
confidence. 
The Investigator must treat all of the information related to the study and the compiled data as 
confidential, whose use is for the purpose of conducting the study. The Sponsor must approve 
any transfer of information not directly involved in the study. 
To comply with local and/or regional regulations, this clinical study may be registered, and study 
results may be posted on public registries, such as ClinicalTrials.gov. 
8.1.5. 
End of Study 
The end of study is defined as the last patient last visit. 
8.1.6. 
Termination of the Clinical Study or Site Closure 
The Sponsor, or designee, reserves the right to terminate the study or a clinical study site at any 
time. Conditions that may warrant this action may include, but are not limited to: 
• The discovery of an unexpected, serious, or unacceptable risk to patients participating 
in the study 
• Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of participants by the Investigator 
• The decision on the part of the Sponsor to suspend or discontinue treatment with the 
study drug 
Should the study be terminated, and/or the site closed for whatever reason, all documentation and 
study drug pertaining to the study must be returned to the Sponsor or its representative, and the 
Investigators, IRB/IEC and Regulatory Authorities will be promptly informed of the termination 
and the reason for the decision. The Investigator should promptly inform the patients and assure 
appropriate therapy and follow-up. 
8.2. 
Data Quality Control and Quality Assurance 
8.2.1. 
Data Handling 
Study data must be recorded on CRFs (paper and/or electronic) provided by the Sponsor or 
designee on behalf of the Sponsor. Case report forms must be completed only by persons 
designated by the Investigator. If eCRFs are used, study data must be entered by trained site 
personnel with access to a valid and secure eCRF system. All data entered into the eCRF must 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
67 
also be available in the source documents. Corrections on paper CRFs must be made so as to not 
obliterate the original data and must be initialed and dated by the person who made the 
correction. 
8.2.2. 
Study Monitoring 
The Monitor, as a representative of the Sponsor, has an obligation to closely follow the study 
conduct at the site. The Monitor will visit the Investigator and clinical study center periodically 
and will maintain frequent telephone and written contact. The Monitor will maintain current 
personal knowledge of the study through observation, review of study records and source 
documentation, and discussion of the conduct of the study with the Investigator and staff. 
The Monitor will review source documents, systems and CRFs to ensure overall quality and 
completeness of the data and to confirm study procedures are complied with the requirements in 
the study protocol accurately. The Sponsor, or its designee, will be allowed to conduct site visits 
to the investigation facilities for the purpose of monitoring any aspect of the study. The 
Investigator agrees to allow the Monitor to inspect the drug storage area, study drug stocks, drug 
accountability records, patient charts and study source documents, site standard operating 
procedures and training records, and other records relative to study conduct. 
8.2.3. 
Audits and Inspections 
Periodically, the Sponsor or its authorized representatives audit clinical investigative sites as an 
independent review of core study processes and documents to determine whether these activities 
were conducted, and data were recorded, analyzed, and accurately reported according to the 
protocol, GCP guidelines of the ICH, and any applicable regulatory requirements. A regulatory 
authority, an IEC or an IRB may visit the site to perform audits or inspections, including source 
data verification. The Investigator should contact the Sponsor and designee immediately if 
contacted by a regulatory agency, an IEC, or an IRB about an inspection. 
8.3. 
Publication Policy 
It is intended that after completion of the study, the data are to be submitted for publication in a 
scientific journal and/or for reporting at a scientific meeting. A copy of any proposed publication 
(eg, manuscript, abstracts, oral/slide presentations, book chapters) based on this study, must be 
provided and confirmed received at the Sponsor at least 30 days before its submission. The 
Clinical Trial Agreement will detail the procedures for publications. 
Authorship of any publications resulting from this study will be determined on the basis of the 
Uniform Requirement for Manuscripts Submitted to Biomedical Journals (International 
Committee of Medical Journal Editors). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
68 
9. 
LIST OF REFERENCES 
Angell SY, De Cock KM,Frieden TR. A public health approach to global management of 
hypertension. Lancet. 2015 Feb 28;385(9970):825-7. 
Beeftink MM, van der Sande NG, Bots ML, Doevendans PA, Blankestijn PJ, Visseren FL, et al. 
Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-
to-Control Hypertension. Hypertension. 2017 May;69(5):927-32. 
Bretz F, Pinheiro JC,Branson M. Combining multiple comparisons and modeling techniques in 
dose-response studies. Biometrics. 2005 Sep;61(3):738-48. 
Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to 
antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011 Mar;29(3):610-8. 
de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M, et al. Prevalence and 
factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension. 
2009 Mar;53(3):466-72. 
Dzau VJ,Balatbat CA. Future of Hypertension. Hypertension. 2019 Sep;74(3):450-7. 
Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of 
Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 
2017 Jan 10;317(2):165-82. 
Georgianos PI,Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding 
drugs. Kidney Int. 2018 Feb;93(2):325-34. 
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK,He J. Global burden of 
hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23. 
Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the 
Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-30. 
McClellan M, Brown N, Califf RM,Warner JJ. Call to Action: Urgent Challenges in 
Cardiovascular Disease: A Presidential Advisory From the American Heart Association. 
Circulation. 2019 Feb 26;139(9):e44-e54. 
McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, et al. Aliskiren, 
Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016 Apr 21;374(16):1521-
32. 
Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP,Crooke RM. Blood Pressure 
Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of 
Hypertension and Kidney Injury. Hypertension. 2017 Sep;70(3):566-76. 
Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, et al. Trends in Blood 
Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020 
Sep 22;324(12):1190-200. 
NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a 
pooled analysis of 1479 population-based measurement studies with 19.1 million participants. 
Lancet. 2017 Jan 7;389(10064):37-55. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
69 
Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and 
a lifecourse strategy to address the global burden of raised blood pressure on current and future 
generations: the Lancet Commission on hypertension. Lancet. 2016 Nov 26;388(10060):2665-
712. 
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. 
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 
6;367(23):2204-13. 
Peacock E,Krousel-Wood M. Adherence to Antihypertensive Therapy. Med Clin North Am. 
2017 Jan;101(1):229-45. 
Romero CA, Orias M,Weir MR. Novel RAAS agonists and antagonists: clinical applications and 
controversies. Nat Rev Endocrinol. 2015 Apr;11(4):242-52. 
Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE, et al. Medication 
adherence and persistence according to different antihypertensive drug classes: A retrospective 
cohort study of 255,500 patients. Int J Cardiol. 2016 Oct 1;220:668-76. 
Services UDoHaH. The Surgeon General's Call to Action to Control Hypertension. 2020 October 
2020:1-50. 
Uijl E, Mirabito Colafella KM, Sun Y, Ren L, van Veghel R, Garrelds IM, et al. Strong and 
Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen. 
Hypertension. 2019 Jun;73(6):1249-57. 
van der Laan DM, Elders PJM, Boons C, Beckeringh JJ, Nijpels G,Hugtenburg JG. Factors 
associated with antihypertensive medication non-adherence: a systematic review. J Hum 
Hypertens. 2017 Nov;31(11):687-94. 
Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients 
with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 
15;372(3):211-21. 
Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report 
of the American College of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115. 
White WB, Mansoor GA, Tendler BE,Anwar YA. Nocturnal blood pressure epidemiology, 
determinants, and effects of antihypertensive therapy. Blood Press Monit. 1998 Feb;3(1):43-51. 
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH 
Guidelines for the management of arterial hypertension: The Task Force for the management of 
arterial hypertension of the European Society of Cardiology and the European Society of 
Hypertension: The Task Force for the management of arterial hypertension of the European 
Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 
Oct;36(10):1953-2041. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
70 
10. 
APPENDICES 
10.1. 
Measurement of Blood Pressure 
All blood pressure measurements (office, ABPM, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in the 
relevant user manuals.  
The appropriately sized cuff for each modality must be used for all assessments. The arm’s 
circumference at midpoint (halfway between the acromion and olecranon) should be determined 
at screening with a metric tape measure and used to select the appropriately sized blood pressure 
cuff/bladder for each instrument as described in the Study Manual. Unless significant weight loss 
or gain occurs between visits, the patient should use the same cuff/bladder size throughout the 
study. 
At the first Screening visit only, office blood pressure will be measured in both arms to select the 
appropriate arm to use for office blood pressure and HBPM measurements. Unless a concomitant 
condition favors the use of a specific arm, the arm with the higher office SBP should be used for 
all subsequent office blood pressure and HBPM readings. The ABPM should be measured using 
the patient’s nondominant arm. If the patient is ambidextrous, the same arm used for office blood 
pressure and HBPM readings should be used. 
ABPM 
The appropriately sized cuff should be placed on the correct arm following the instructions in the 
Study Manual. In patients taking oral antihypertensives (including those initiated as rescue 
medication), ABPM should be started prior to the morning dose of antihypertensive medication. 
All ABPM collections must be in the outpatient/ambulatory state. ABPM recordings that are 
associated with dosing visits must be obtained in advance of the visit (within 7 days before the 
corresponding dosing visit) and the results reviewed prior to dosing. 
During the 24-hour monitoring period, patients must avoid strenuous exercise but should 
otherwise maintain their usual level of physical activity. The ABPM is programmed to take 
readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the 
night (10 pm to 5:59 am). While awake, the patient should hold their arm still by their side while 
the device is inflating for a reading. Patients must record the timing of going to sleep, waking up, 
and any oral medications taken during the ABPM, and these responses must be entered into the 
eCRF. 
After the monitoring period is complete, upload the ABPM data to receive a report with 
adequacy assessment. An ABPM will be considered adequate if (1) the number of successful 
daytime readings is ≥33, (2) the number of successful nighttime readings is ≥11, and (3) no more 
than 3 hours are not represented (ie, 3 sections of 60 minutes where 0 valid readings were 
obtained). If the ABPM recording is inadequate, the patient will be provided 1 opportunity to 
repeat the study within 2 days. If the second ABPM recording is also inadequate during 
screening, the patient is a screen failure. 
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor and the arm selected during screening. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
71 
Office blood pressure should be measured early in the visit, before phlebotomy or other 
potentially stressful assessments. To minimize confounding by circadian changes, study visits 
should be scheduled for a consistent timeframe of the day. The use of inhaled short-acting beta 
agonists should be avoided within 6 hours prior to measuring blood pressure and/or heart rate. 
The use of phosphodiesterase type 5 inhibitors (eg, sildenafil, tadalafil, vardenafil, avanafil) 
should be avoided within 48 hours prior to measuring blood pressure. 
Before measuring blood pressure, confirm that there has been no exercise or use of caffeine or 
nicotine- or tobacco-containing products (including but not limited to snuff, chewing tobacco, 
cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) within the last 30 minutes. If necessary, 
delay blood pressure assessment to meet these requirements. Because a full bladder can impact 
blood pressure measurements, ask the patient to use the bathroom before the assessment. 
All office blood pressure assessments will include both seated and standing measurements.  
Seated Office Blood Pressure Measurement: For seated measurements, the patient should be in a 
comfortable resting position in a chair with their back supported and their feet flat on the floor. 
• Place the appropriately sized cuff on the correct arm with no clothing between the 
patient’s arm and the cuff and with the midpoint of the bladder length positioned over 
the brachial artery (located by palpation). The arm should be supported on an armrest 
or table with mid-cuff at heart level and the palm facing the ceiling. 
• Follow the Study Manual to initiate the automated blood pressure device’s seated 
measurement protocol. This program includes a 5-minute period of rest, followed by 
4 sequential blood pressure measurements at 1-minute intervals. The seated blood 
pressure for the visit will be defined by the average of the last 3 individual 
measurements. 
• During the device’s seated measurement protocol, the staff member should leave the 
room and the patient should remain at rest without distraction (avoid mobile phones). 
The following script may be used: “The blood pressure device works best when you 
are at rest and without any distraction. If you agree, I would like to leave the room for 
the next 10 to 15 minutes while it is recording. This will include a 5-minute period of 
rest, followed by about 5 minutes of the device inflating to measure your blood 
pressure”. 
Standing Office Blood Pressure Measurement: A standing measurement should be obtained 
immediately after collection of the seated measurements. 
• Being careful to maintain the cuff’s position, ask the patient to stand with the cuffed 
arm bent slightly and the hand of the cuffed arm supported at heart level.  
• Using a stopwatch or watch, measure standing blood pressure 1 minute after standing 
by using the automated blood pressure device’s single measurement protocol.  
• After the standing measurement, ask the patient if they experienced dizziness or light-
headedness when standing and enter their response in the eCRF. 
If a patient is unable to report to the site for an office blood pressure assessment, a substitute 
“remote visit blood pressure measurement” may be obtained remotely by a visiting nurse or other 
appropriately trained personnel who will bring an office blood pressure instrument to the 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Amendment 1, 20 April 2021 
Alnylam Pharmaceuticals 
Confidential 
72 
patient’s location and follow the same procedure performed at the site. If a home visit is not 
possible, a “remote visit blood pressure measurement” should instead be obtained using the 
patient’s HBPM instrument under direct supervision (phone call or teleconferencing) by 
appropriately trained study staff, following the instructions detailed in the Study Manual. Results 
and the remote method used should be entered into the eCRF. 
HBPM 
Patients should measure HBPM every morning, prior to breakfast/caffeine or taking morning 
oral medications. HBPM is not required at times when ABPM is being assessed. The HBPM 
measurement should be obtained in a room without distractions, seated comfortably with the 
back supported and feet flat on the floor. The patient will initiate the automated blood pressure 
program on their HBPM device. This program includes a 5-minute period of rest, followed by 4 
sequential blood pressure measurements at 1-minute intervals. The seated blood pressure for the 
visit will be defined by the average of the last 3 individual measurements.  
To establish baseline, each patient must measure HBPM for at least 2 consecutive weeks (and 
with at least 3 successful readings per week) prior to randomization. Patients previously taking 
medication for hypertension must be without antihypertensives for ≥4 weeks prior to collecting 
these baseline HBPM measurements. If adequate baseline HBPM data (at least 3 successful 
readings per week for at least 2 consecutive weeks) are not collected within the Screening period, 
the patient is a screen failure. 
After Day 1, HBPM should be measured at least 3 times per week. Patients may select the 3 days 
of the week that are most convenient for their personal schedule. The frequency of HBPM 
monitoring should be increased to daily during the temporary hold of oral antihypertensives 
performed in some patients from Month 5 to Month 6. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
1 
 
CLINICAL STUDY PROTOCOL 
ALN-AGT01-002 
DATED 09 APRIL 2021 
 
Protocol Title:  
A Randomized, Double-blind, Placebo-Controlled, 
Dose-Ranging Multicenter Study to Evaluate the 
Efficacy and Safety of ALN-AGT01 in Patients 
with Mild-to-Moderate Hypertension 
Short Title: 
A Study to Evaluate Efficacy and Safety of 
ALN-AGT01 in Patients with Mild-to-Moderate 
Hypertension (KARDIA-1) 
Study Drug: 
ALN-AGT01 
EudraCT Number: 
2021-001248-82 
IND Number: 
143503 
Protocol Date: 
Original protocol, 09 April 2021 
Sponsor: 
Alnylam Pharmaceuticals, Inc. 
300 Third Street 
Cambridge, MA  02142 USA 
Telephone: +1-617-551-8200 
Sponsor Contact: 
 
 
The concepts and information contained in this document or generated during the study are considered 
proprietary and may not be disclosed in whole or in part without expressed written authorization of 
Alnylam Pharmaceuticals, Inc. 
 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
2 
SPONSOR PROTOCOL APPROVAL 
 
I have read this protocol and I approve the design of this study. 
 
 
 
___________________________________________  
 
 
Alnylam Pharmaceuticals, Inc. 
 
___________________________________________  
Date 
PPD
PPD


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
3 
INVESTIGATOR’S AGREEMENT 
 
I have read the ALN-AGT01-002 protocol and agree to conduct the study in accordance with the 
protocol and all applicable regulations. I agree to maintain the confidentiality of all information 
received or developed in connection with this protocol. 
 
 
 
___________________________________________  
Printed Name of Investigator 
 
 
 
___________________________________________  
Signature of Investigator 
 
 
 
___________________________________________  
Date 






Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
6 
of the study design is provided in Figure 1. Before randomization, patients will discontinue prior 
antihypertensive medications (if taking) for a Washout period of at least 4 weeks. Patients who 
complete the Screening period and meet all inclusion/exclusion criteria for enrollment will 
receive ALN-AGT01 or placebo for the first 6 months of the 12-month Double-blind (DB) 
treatment period.  
Starting at Month 3, conventional oral antihypertensives may be added per Investigator 
judgement for elevated blood pressure. Oral antihypertensives (if taking) will be temporarily 
held from Month 5 to Month 6 to assess the effect of ALN-AGT01 alone (vs placebo) at Month 6 
by ambulatory blood pressure monitoring (ABPM). During this 4-week period, blood pressure 
will be carefully monitored by daily home blood pressure monitoring and medications restarted 
if indicated. Patients may resume conventional oral antihypertensives at Month 6 per Investigator 
judgement. 
Patients randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial 
ALN-AGT01 regimens until the end of the DB period. Patients randomized to ALN-AGT01 
regimens will remain on their originally assigned regimens through Month 12. 
After the 12-month DB treatment period, patients may be eligible to participate in an 
ALN-AGT01 open-label extension (OLE) study. If an individual patient reaches Month 12 prior 
to availability of the OLE study, they may continue their current blinded dosing in the DB 
Extension period for up to 12 additional months until the OLE study is open and then transition. 
Number of Planned Patients 
Approximately 375 patients will be enrolled in this study. 
Diagnosis and Main Eligibility Criteria 
This study will include adults (18 to 75 years, inclusive) with untreated hypertension or on stable 
therapy with 1 or more antihypertensive medications of the following classes: an angiotensin 
converting enzyme inhibitor, angiotensin II-receptor blocker, renin inhibitor, calcium channel 
blocker, thiazide diuretic, and/or thiazide-like diuretic. Patients should have a mean 24-hour 
systolic blood pressure (SBP) ≥135 mmHg and ≤160 mmHg by ABPM at least 4 weeks after 
washout of background antihypertensive medication. Patients with secondary hypertension or 
orthostatic hypotension will be excluded. 
Study Drug, Dose, and Mode of Administration 
ALN-AGT01 is an SC administered N-acetylgalactosamine-conjugated small interfering RNA 
targeting liver-expressed messenger RNA for angiotensinogen (AGT). 
Patients randomized to receive ALN-AGT01 will be administered 150 mg ALN-AGT01 SC once 
every 6 months, 300 mg ALN-AGT01 SC once every 6 months, 300 mg ALN-AGT01 SC once 
every 3 months, or 600 mg ALN-AGT01 SC once every 6 months during the 12-month DB 
period and DB Extension period. Patients randomized to receive placebo will be randomized to 1 
of the 4 initial dose regimens of ALN-AGT01 beginning at Month 6.  
Reference Treatment, Dose, and Mode of Administration 
Placebo (sodium chloride 0.9% w/v for SC administration) will be administered once every 3 
months and at the same volume as the study drug. Patients receiving once every 6 months 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
7 
ALN-AGT01 regimens will receive placebo SC at dosing visits at which they do not receive 
ALN-AGT01 to maintain the blind. 
Duration of Treatment and Study Participation 
The duration of treatment with ALN-AGT01 is up to 24 months. The estimated total time on 
study for each patient is up to 44 months, including up to 2 months of screening, followed by up 
to 24 months of treatment, and up to 18 months in the Follow-up period. 
Statistical Methods 
The planned enrollment for this study is 375 patients. Randomization will be stratified by race 
(black vs all other races) and by baseline blood pressure (mean 24 hour SBP < or ≥145 mmHg). 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline in 
24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 375 
patients (75 per treatment group) provides at least 84% power to detect a dose response 
relationship in SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided 
significance level of 0.05. In addition, this sample size provides at least 80% power to detect a 10 
mmHg difference between an individual ALN-AGT01 dose versus placebo with a 2-sided 
significance level of 0.05.  
The populations (analysis sets) are defined as follows:  
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• Pharmacokinetic (PK) Analysis Set: All patients who received at least 1 full dose of 
study drug and have at least 1 evaluable postdose blood sample for the determination 
of plasma ALN-AGT01 concentrations. 
• PD Analysis Set: All patients who received any amount of study drug and who have 
baseline and at least 1 postdose blood sample for the determination of serum AGT 
will be included in the PD analyses. 
The primary population used to evaluate efficacy will be the FAS. For the efficacy endpoints of 
change from baseline to Month 3, ALN-AGT01 300 mg once every 3 months and once every 6 
months will be pooled together and analyzed. For all other efficacy endpoints, analysis will be 
performed according to the randomized treatment arm. 
Safety will be analyzed using the Safety Analysis Set. The PK and PD Analysis Sets will be used 
to conduct PK and PD analyses, respectively. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
8 
Figure 1: 
Study Design 
 
Abbreviations: aHTN=antihypertensive medications; DB=double-blind; M=month; OLE=open-label extension; 
PBO=placebo; PO=per os (oral); Q3M=once every 3 months; Q6M=once every 6 months; R=randomization; 
SC=subcutaneous; WO=washout. 
Note: Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the Month 12 
predose assessments. If an individual patient reaches Month 12 prior to availability of the OLE study, they may 
continue their current blinded dosing in the DB Extension period for up to 12 additional months until the OLE study 
is open and then transition. Once the OLE study is open for enrollment, eligible patients may rollover into the OLE 
study at Months 12, 18, or 24 (whichever visit occurs first). 










Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
13 
Table 2: 
PK Time Points 
Study Day 
Sampling Time 
(hh:mm) 
Plasma PK Sample 
Day 1  
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Day 169±7 
Predose (any time before dosing) 
X 
04:00 (±1 h) 
X 
Abbreviations: hh:mm=hour:minute; PK=pharmacokinetics. 
Notes:  
• 
The hour (±range) indicates sample collection timing relative to dosing. Precise PK sample times (hour 
and minute) are recorded. Refer to Section 6.4 for additional information on PK assessments. 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
14 
TABLE OF CONTENTS 
SPONSOR PROTOCOL APPROVAL ...........................................................................................2 
INVESTIGATOR’S AGREEMENT ...............................................................................................3 
PROTOCOL SYNOPSIS ................................................................................................................4 
TABLE OF CONTENTS ...............................................................................................................14 
LIST OF TABLES .........................................................................................................................18 
LIST OF FIGURES .......................................................................................................................18 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ................................................19 
1. 
INTRODUCTION ......................................................................................................21 
1.1. 
Study Rationale ...........................................................................................................21 
1.2. 
Background .................................................................................................................21 
1.3. 
Benefit-Risk Assessment ............................................................................................22 
2. 
OBJECTIVES AND ENDPOINTS ............................................................................23 
3. 
INVESTIGATIONAL PLAN .....................................................................................25 
3.1. 
Summary of Study Design ..........................................................................................25 
3.2. 
Scientific Rationale for Study Design ........................................................................26 
3.3. 
Justification for Dose ..................................................................................................28 
3.4. 
Method of Assigning Patients to Treatment Groups ..................................................28 
3.5. 
Blinding ......................................................................................................................29 
3.5.1. 
Emergency Unblinding ...............................................................................................29 
3.6. 
Data Monitoring Committee .......................................................................................30 
3.7. 
Clinical Event Adjudication Committees ...................................................................30 
3.8. 
Definition of End of Study for an Individual Patient .................................................30 
4. 
SELECTION AND REMOVAL OF PATIENTS ......................................................30 
4.1. 
Inclusion Criteria ........................................................................................................30 
4.2. 
Exclusion Criteria .......................................................................................................31 
4.3. 
Removal from Study Drug or Assessment .................................................................33 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments ......................33 
4.3.2. 
Stopping a Patient’s Study Participation ....................................................................34 
4.3.2.1. 
Patient or Legal Guardian Stops Participation in the Study .......................................34 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection 
to Process Patient’s Personal Data ..............................................................................35 
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study ........................35 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
15 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation ................................36 
4.3.3. 
Lost to Follow-Up.......................................................................................................36 
4.3.4. 
Replacement of Study Patients ...................................................................................36 
5. 
TREATMENTS AND OTHER REQUIREMENTS ..................................................36 
5.1. 
Treatments Administered ............................................................................................36 
5.2. 
Study Drug ..................................................................................................................36 
5.2.1. 
Description ..................................................................................................................37 
5.2.2. 
Dose and Administration ............................................................................................37 
5.2.3. 
Dose Modifications .....................................................................................................38 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping 
Study Drug Dosing .....................................................................................................38 
5.2.5. 
Preparation, Handling, and Storage ............................................................................39 
5.2.6. 
Packaging and Labeling ..............................................................................................39 
5.2.7. 
Accountability .............................................................................................................39 
5.3. 
Clinical Product Complaints .......................................................................................40 
5.3.1. 
Definition ....................................................................................................................40 
5.3.2. 
Reporting ....................................................................................................................40 
5.4. 
Monitoring for Potential Clinical Events ....................................................................40 
5.4.1. 
Monitoring and Approach for Potential Hypotension ................................................40 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure 
Elevation .....................................................................................................................41 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction .......................................43 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia ..............................................43 
5.5. 
Concomitant Medications and Procedures .................................................................44 
5.5.1. 
Oral Antihypertensive Medication .............................................................................45 
5.5.2. 
Prohibited Concomitant Medication ...........................................................................45 
5.6. 
Treatment Compliance ................................................................................................46 
5.7. 
Other Requirements ....................................................................................................46 
5.7.1. 
Contraception ..............................................................................................................46 
5.7.2. 
Alcohol Restrictions ...................................................................................................47 
5.7.3. 
Tobacco and Nicotine Restrictions .............................................................................47 
5.7.4. 
Dietary Recommendations ..........................................................................................47 
5.7.5. 
Exercise .......................................................................................................................47 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
16 
6. 
STUDY ASSESSMENTS ..........................................................................................47 
6.1. 
Screening Assessments ...............................................................................................48 
6.1.1. 
Retesting .....................................................................................................................48 
6.1.2. 
Rescreening .................................................................................................................48 
6.2. 
Efficacy Assessments .................................................................................................48 
6.2.1. 
ABPM .........................................................................................................................49 
6.2.2. 
Office Blood Pressure .................................................................................................49 
6.2.3. 
HBPM .........................................................................................................................49 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment ....................................................49 
6.3. 
Pharmacodynamic Assessments .................................................................................50 
6.4. 
Pharmacokinetic Assessments ....................................................................................50 
6.5. 
Safety Assessments .....................................................................................................50 
6.5.1. 
Vital Signs ..................................................................................................................50 
6.5.2. 
Weight, Height, and Morphometrics ..........................................................................51 
6.5.3. 
Physical Examination .................................................................................................51 
6.5.4. 
Electrocardiogram .......................................................................................................52 
6.5.5. 
Clinical Laboratory Assessments ...............................................................................52 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments ........................................................54 
6.5.5.2. 
Immunogenicity ..........................................................................................................54 
6.5.5.3. 
Pregnancy Testing ......................................................................................................54 
6.5.5.4. 
Additional Liver Function Assessments .....................................................................55 
6.5.6. 
Adverse Events ...........................................................................................................56 
6.5.6.1. 
Definitions ..................................................................................................................56 
6.5.6.2. 
Eliciting and Recording Adverse Events ....................................................................57 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee .........................58 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee ...........58 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities .................................................59 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee ........................................................................59 
6.5.6.7. 
Pregnancy Reporting ..................................................................................................59 
6.5.6.8. 
Overdose and Other Special Situations Reporting .....................................................59 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository ...................................60 
7. 
STATISTICS ..............................................................................................................61 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
17 
7.1. 
Determination of Sample Size ....................................................................................61 
7.2. 
Statistical Methodology ..............................................................................................61 
7.2.1. 
Populations to be Analyzed ........................................................................................61 
7.2.2. 
Examination of Subgroups .........................................................................................62 
7.2.3. 
Handling of Missing Data ...........................................................................................62 
7.2.4. 
Baseline Evaluations ...................................................................................................62 
7.2.5. 
Efficacy Analyses .......................................................................................................62 
7.2.6. 
Pharmacodynamic Analysis........................................................................................63 
7.2.7. 
Pharmacokinetic Analysis ..........................................................................................63 
7.2.8. 
Safety Analyses ..........................................................................................................63 
7.2.9. 
Immunogenicity Analyses ..........................................................................................64 
7.2.10. 
Interim Analysis ..........................................................................................................64 
7.2.11. 
Optional Additional Research .....................................................................................64 
8. 
STUDY ADMINISTRATION ...................................................................................64 
8.1. 
Ethical and Regulatory Considerations ......................................................................64 
8.1.1. 
Informed Consent .......................................................................................................64 
8.1.2. 
Ethical Review ............................................................................................................65 
8.1.3. 
Serious Breach of Protocol .........................................................................................65 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention .................................65 
8.1.5. 
End of Study ...............................................................................................................66 
8.1.6. 
Termination of the Clinical Study or Site Closure .....................................................66 
8.2. 
Data Quality Control and Quality Assurance .............................................................66 
8.2.1. 
Data Handling .............................................................................................................66 
8.2.2. 
Study Monitoring ........................................................................................................67 
8.2.3. 
Audits and Inspections ................................................................................................67 
8.3. 
Publication Policy .......................................................................................................67 
9. 
LIST OF REFERENCES ............................................................................................68 
10. 
APPENDICES ............................................................................................................70 
10.1. 
Measurement of Blood Pressure .................................................................................70 
 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
18 
LIST OF TABLES 
Table 1: 
Schedule of Assessments ..............................................................................................9 
Table 2: 
PK Time Points ...........................................................................................................13 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative 
Cause Identified ..........................................................................................................38 
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation ......................................................................................................41 
Table 5: 
Recommended Interventions for Hyperkalemia .........................................................44 
Table 6: 
Clinical Laboratory Assessments ...............................................................................53 
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases .............55 
Table 8: 
Statistical Power to Detect 10 mmHg Difference Between ALN-AGT01 and 
Placebo With Various Standard Deviation Assumptions ...........................................61 
 
LIST OF FIGURES 
Figure 1: 
Study Design .................................................................................................................8 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
19 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation  
Definition 
ABPM 
Ambulatory blood pressure monitoring 
ACE 
Angiotensin converting enzyme 
ADA 
Anti-drug antibody(ies) 
AE 
Adverse event 
AGT 
Angiotensinogen 
ALT 
Alanine aminotransferase 
AngI/II 
Angiotensin I/II 
ARB 
Angiotensin II-receptor blocker 
AST 
Aspartate aminotransferase 
CCB 
Calcium channel blocker 
CPC 
Clinical product complaint 
DB 
Double-blind 
DBP 
Diastolic blood pressure 
DMC 
Data Monitoring Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eGFR 
Estimated glomerular filtration rate 
EOT 
End of treatment 
ET 
Early termination 
FAS 
Full analysis set 
GalNAc 
N-acetylgalactosamine 
GCP 
Good Clinical Practice 
HbA1c 
Hemoglobin A1c 
HBPM 
Home blood pressure monitoring 
HBV 
Hepatitis B virus 
HCV 
Hepatitis C virus 
HDL-C 
High-density lipoprotein 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use 
IEC 
Independent Ethics Committee 
INR 
International normalized ratio 
IRB 
Institutional Review Board 
IRT 
Interactive Response Technology 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
20 
Abbreviation  
Definition 
ISR 
Injection site reaction 
LFT 
Liver function test 
MAO 
Monoamine oxidase 
MCP-Mod 
Multiple comparison-modeling 
mRNA 
Messenger RNA 
NSAID 
Nonsteroidal anti-inflammatory drug 
OLE 
Open-label extension 
PD 
Pharmacodynamic(s) 
PK 
Pharmacokinetic(s) 
PT 
Preferred term 
q3M 
Once every 3 months 
q6M 
Once every 6 months 
RAAS 
Renin-angiotensin-aldosterone system 
RNAi 
RNA interference 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SBP 
Systolic blood pressure 
SC 
Subcutaneous(ly) 
siRNA 
Small interfering RNA 
SGLT2 
Sodium-glucose co-transporter 2 
SOC 
System Organ Class 
ULN 
Upper limit of normal 
 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
21 
1. 
INTRODUCTION 
Alnylam Pharmaceuticals, Inc. (the Sponsor) is developing ALN-AGT01, a subcutaneously (SC) 
administered investigational agent comprised of a synthetic small interfering (siRNA) covalently 
linked to a triantennary N-acetylgalactosamine (GalNAc) ligand, which is designed to suppress 
liver production of angiotensinogen (AGT) and thereby reduce blood pressure in individuals with 
hypertension.  
1.1. 
Study Rationale 
Study ALN-AGT01-002 (KARDIA-1) is a randomized, double-blind, placebo-controlled, dose-
ranging, multicenter Phase 2 study designed to evaluate the safety, efficacy, and 
pharmacodynamics (PD) of ALN-AGT01, administered SC, in patients with mild-to-moderate 
hypertension. Patients will be randomized to 1 of 4 ALN-AGT01 treatment regimens or placebo 
for the first 6 months of the 12-month Double-blind (DB) period. After the first 6 months of the 
DB period, patients from the placebo arm will be re-randomized to 1 of the 4 initial 
ALN-AGT01 regimens for the remaining 6 months of the DB period, while patients randomized 
to ALN-AGT01 will remain on their originally assigned regimens. After completion of the 
12-month DB period, patients may be eligible to participate in an ALN-AGT01 open-label 
extension (OLE) study. If an individual patient reaches Month 12 prior to availability of the OLE 
study, they may continue their current blinded dosing in the DB Extension period for up to 12 
additional months until the OLE study is open and then transition. 
The primary objective of the study is to evaluate the efficacy of ALN-AGT01 for the treatment 
of hypertension by evaluating the impact on systolic blood pressure (SBP) from baseline to 
Month 3, as assessed by ambulatory blood pressure monitoring (ABPM). Secondary and 
exploratory objectives of the study include evaluating the efficacy of ALN-AGT01 on other 
measures of blood pressure response and evaluating the PD effect of ALN-AGT01, including 
reduction in circulating AGT concentration. 
The full rationale for the study and design is presented in Section 3.2. 
1.2. 
Background 
Hypertension affects 30% to 45% of adults and is the strongest modifiable risk factor for 
cardiovascular disease, primarily strokes and myocardial infarction.[Olsen 2016; Williams 2018] 
The worldwide disease burden is profound, with a global prevalence of over 1 billion,[Kearney 
2005; NCD Risk Factor Collaboration 2017] and approximately 9 million deaths attributed to 
hypertension annually.[Angell 2015] 
Currently available pharmacologic therapies achieve target blood pressure in only a minority of 
patients, due in large part to physician inertia and patient nonadherence to daily oral 
medication.[Whelton 2018; Williams 2018] Low adherence to oral antihypertensives is 
associated with poor cardiovascular outcomes and is prevalent at all stages of disease.[Corrao 
2011; Peacock and Krousel-Wood 2017; Schulz 2016; van der Laan 2017] Thus, despite the 
availability of multiple efficacious agents, current rates of control are low, and the global burden 
of death and disability-adjusted life-years attributed to elevated blood pressure remains 
high.[Forouzanfar 2017; Muntner 2020] Development of new approaches to treat hypertension 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
22 
and to overcome the limitations of current therapies is a key unmet need.[Dzau and Balatbat 
2019; McClellan 2019; Services 2020] 
The Sponsor is developing ALN-AGT01, a novel synthetic RNA interference (RNAi) 
therapeutic, for SC administration for the treatment of hypertension. RNAi is a naturally 
occurring cellular mechanism for regulation of gene expression, mediated through the binding of 
siRNA to its complementary messenger RNA (mRNA) sequence, leading to mRNA cleavage 
and subsequent suppression of the synthesis and levels of the target protein. ALN-AGT01 
contains an siRNA targeting AGT mRNA, conjugated to a GalNAc-containing ligand to facilitate 
delivery to the liver. Based on the mechanism of RNAi, ALN-AGT01 is specifically designed to 
reduce the hepatic synthesis of AGT protein, the first substrate in the renin-angiotensin-
aldosterone system (RAAS) and the sole precursor of vasoactive angiotensin peptides.[Khanna 
2017; Romero 2015] Because hepatocytes are the predominant source of circulating AGT, 
ALN-AGT01 has been developed to reduce blood pressure by decreasing circulating AGT levels 
and the downstream effects of angiotensin II (AngII). 
Preliminary data from Part A of the ongoing Phase 1 Study ALN-AGT01-001 (hereafter referred 
to as Study 001) in patients with hypertension have shown that single SC doses of ALN-AGT01 
lead to dose-dependent and durable reductions in circulating AGT, accompanied by clinically 
significant reductions in SBP and diastolic blood pressure (DBP). Reductions in AGT for up to 
6 months postdose were observed in the study.  
Most adverse events (AEs) have been mild or moderate in severity, and there have been no 
severe or serious adverse events (SAEs) related to study drug. There have been no clinically 
significant elevations in serum creatinine or serum potassium, and no patient has required 
intervention for low blood pressure. No clinically significant alanine aminotransferase (ALT) 
elevations have been observed in Part A patients who received ALN-AGT01 doses as high as 
800 mg. Injection site reactions (ISRs) were reported in a minority of patients and were all mild 
and transient events that resolved without intervention. 
This Phase 2 study will further quantify the antihypertensive effects of ALN-AGT01 across a 
range of doses (150 to 600 mg) and dose intervals (once every 3 months and once every 6 
months) to identify optimal treatment. The consistent and prolonged PD effect of ALN-AGT01 
is expected to achieve the unique benefit of continuous 24-hour blood pressure lowering with 
infrequent SC dosing.  
A detailed description of the chemistry, pharmacology, efficacy, and safety of ALN-AGT01 is 
provided in the Investigator’s Brochure. 
1.3. 
Benefit-Risk Assessment 
Clinical data available from Study 001 indicate that ALN-AGT01 may offer the benefit of blood 
pressure reduction to patients with hypertension. The mean SBP reduction observed after single 
ALN-AGT01 doses of 100 mg or higher exceeds 10 mmHg, which is comparable to the effect of 
conventional antihypertensives. The blood pressure of patients will be closely monitored, and 
after Month 3, oral antihypertensives will be added as needed to control blood pressure. 
Given the mechanism of action and mode of administration of ALN-AGT01, potential 
theoretical risks include liver transaminase elevations and ISRs. Like any antihypertensive 
therapy, there is also a theoretical risk of hypotension with ALN-AGT01. Based upon the disease 






Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
25 
3. 
INVESTIGATIONAL PLAN 
3.1. 
Summary of Study Design 
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study 
designed to evaluate the safety, efficacy, and PD of ALN-AGT01, administered SC, in patients 
with mild-to-moderate hypertension. A schematic of the study design is provided in Figure 1. 
Before randomization, patients will discontinue prior antihypertensive medications (if taking) for 
a Washout period of at least 4 weeks.  
DB and DB Extension Periods 
Patients who complete the Screening period and meet all inclusion/exclusion criteria for 
enrollment will be randomized 1:1:1:1:1 to receive 1 of the following regimens over a 12-month 
DB treatment period. Randomization will be stratified by race (black vs all other races) and by 
baseline blood pressure (mean 24 hour SBP < or ≥145 mmHg).  
• Placebo SC once every 3 months, with re-randomization (1:1:1:1) at Month 6 to 1 of 
the initial 4 ALN-AGT01 regimens 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients receiving once every 6 month ALN-AGT01 regimens will receive placebo SC at dosing 
visits at which they do not receive ALN-AGT01 to maintain the blind. 
At Month 3, conventional oral antihypertensives may be added per Investigator judgement for 
daytime mean SBP ≥135 mmHg by ABPM. After Month 3, oral antihypertensive medications 
may also be added per Investigator judgement for persistent elevations in blood pressure above 
target (target defined as office SBP <140 mmHg, home blood pressure monitoring [HBPM] SBP 
<135 mmHg, or daytime mean SBP <135 mmHg by ABPM). Oral antihypertensives (if taking) 
will be temporarily held from Month 5 to Month 6 in appropriate patients (Month 5 office SBP 
<155 mmHg if taking 1 oral antihypertensive agent or office SBP <150 mmHg if taking 2 
agents) to assess the effect of ALN-AGT01 alone (vs placebo) at Month 6 by ABPM. During this 
4-week period, blood pressure will be carefully monitored by daily HBPM and oral 
antihypertensive medications restarted if confirmed office SBP >170 mmHg (or if confirmed 
office SBP >160 mmHg accompanied by symptoms). 
Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the 
Month 12 predose assessments. If an individual patient reaches Month 12 prior to availability of 
the OLE study, they may continue their current blinded dosing in the DB Extension period for up 
to 12 additional months until the OLE study is open and then transition. Once the OLE study is 
open for enrollment, eligible patients may rollover into the OLE study at Months 12, 18, or 24 
(whichever visit occurs first). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
26 
In the DB Extension period, blood pressure will be closely monitored and individual 
modification of antihypertensive therapy will be allowed to maintain blood pressure in target 
range.  
Safety Follow-up Period 
Patients who discontinue study drug or do not enroll in the ALN-AGT01 OLE study will be 
asked to complete Safety Follow-up visits after their last dose of study drug: 
• Patients who discontinue study drug before Month 6: Safety Follow-up visits will occur 
once every 6 months after the last dose of study drug until the last patient’s Month 6 visit 
or until serum AGT levels return to ≥50% of their individual mean baseline level, 
whichever comes later. 
• Patients who discontinue study drug after the Month 6 visit: Safety Follow-up visits will 
occur once every 6 months after the last dose of study drug until serum AGT levels return 
to ≥50% of their individual mean baseline level. 
Patients who discontinue study drug prior to the Month 6 visit will be asked to complete the 
remainder of scheduled study visits and assessments (except for study drug administration) 
through Month 6. If a patient discontinues study drug after the Month 6 visit, early termination 
(ET) assessments should be performed. 
The planned enrollment for this study is approximately 375 patients (75 patients per group). 
The duration of treatment with ALN-AGT01 is up to 24 months. The estimated total time on 
study for each patient is up to 44 months, including up to 2 months of screening, followed by up 
to 24 months of treatment, and up to 18 months in the Follow-up period. 
3.2. 
Scientific Rationale for Study Design 
This is a randomized, double-blind, placebo-controlled, dose-ranging, multicenter Phase 2 study 
designed to evaluate the safety, efficacy, and PD of ALN-AGT01, administered SC, in patients 
with mild-to-moderate hypertension. The primary objective of the study is to evaluate the 
efficacy of ALN-AGT01 by measuring the impact on SBP from baseline to Month 3, as assessed 
by ABPM.  
This study will quantify the antihypertensive effects of ALN-AGT01 across a range of doses and 
dose intervals to identify optimal treatment regimens for study in Phase 3. 
Patients will discontinue prior antihypertensive medications (if taking) for at least 4 weeks prior 
to study drug administration. During the study, blood pressure will be monitored with both 
outpatient 24-hour ABPM and automated office blood pressure measurements 
(EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical Investigation of Medicinal Products in 
the Treatment of Hypertension, 2016). The primary endpoint will be assessed by ABPM given its 
greater precision over office blood pressure measurements. In addition, 24-hour ABPM can 
assess short-term blood pressure variability and circadian patterns (including potential restoration 
of the normal nocturnal blood pressure dipping pattern that is lost in 21% to 35% of hypertensive 
patients).[de la Sierra 2009; White 1998] More frequent measurements will be collected through 
a third method, oscillometric HBPM, to assess long-term blood pressure variability and provide 
close safety monitoring for potential hypotension (or hypertension) while not in the clinic. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
27 
As recommended by current guidance (International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use [ICH] Principles for Clinical Evaluation of 
New Antihypertensive Drugs, 2000 and EMA/CHMP/29947/2013/Rev. 4; Guideline on Clinical 
Investigation of Medicinal Products in the Treatment of Hypertension, 2016), the first 6 months 
of the DB period is designed as a randomized, placebo-controlled, parallel-group study. To 
adhere to best ethical standards for the treatment of patients with hypertension, individual 
modification of oral antihypertensive medications per Investigator judgement to maintain blood 
pressure within target is permitted starting at Month 3 and will continue throughout the study 
(except between Month 5 and Month 6 as described in Section 3.1). Separate from these treat-to-
target modifications, any confirmed event of severe systolic hypertension (SBP ≥180 mmHg) 
will be appropriately treated regardless of its timing relative to study drug administration. 
If a patient requires treatment with a conventional oral antihypertensive before Month 6, a 
calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic will be added because there 
is extensive experience combining these classes with antihypertensive drugs that impact the 
RAAS. Additionally, their blood pressure effects are expected to washout within 4 weeks.  
Rigorous assessment of the antihypertensive effects of ALN-AGT01 at Month 6 (trough for the 
once every 6 month regimens) relative to placebo is critical to evaluate the feasibility of once 
every 6 month dosing regimens for future study in Phase 3. Accordingly, oral antihypertensives 
(if taking) will be temporarily held from Month 5 to the Month 6 ABPM assessment. For each 
patient, this limited interruption in oral antihypertensives will be contingent upon the patient’s 
Month 5 office SBP being adequately controlled (see Table 4) and the Investigator’s assessment 
that interruption can be safely performed and carefully monitored by daily HBPM 
measurements. Of note, a withdrawal period is a standard element in studies of oral 
antihypertensives that is often used to establish assay sensitivity, to demonstrate maintenance of 
efficacy, and to assess possible withdrawal effects (ICH E12A; Principles for Clinical Evaluation 
of New Antihypertensive Drugs, 2000). Outside of research studies, antihypertensives are 
temporarily discontinued in clinical practice for diagnostic purposes, and interruptions up to 6 
weeks have been shown to be safe.[Beeftink 2017] In this study, the period of interruption is 
limited to 4 weeks, and most patients are expected to have continued antihypertensive effect 
from ALN-AGT01. If a clinically significant blood pressure elevation (confirmed SBP >170 
mmHg; or SBP >160 mmHg accompanied by symptoms) occurs after the interruption of oral 
antihypertensives, Investigators will instruct the patient to promptly resume dosing with their 
existing supply of oral medication.  
After Month 6, other oral antihypertensives may be used at the discretion of the Investigator, 
following current care guidelines.[Whelton 2018; Williams 2018] Because ALN-AGT01 acts on 
the RAAS, the use of conventional RAAS inhibitors (angiotensin II-receptor blocker [ARB], 
angiotensin converting enzyme [ACE] inhibitors, or direct renin inhibitors) as rescue agents for 
high blood pressure will be avoided throughout this study. Blood pressure and pharmacokinetic 
(PK)/PD assessments will be collected through Month 12 to assess the effect of repeated dosing. 
While tissue specificity of ALN-AGT01 for the liver is hypothesized to improve tolerability 
relative to current oral antihypertensives,[Mullick 2017; Uijl 2019] the protocol’s monitoring 
plan is designed to meet the standards set by prior studies of conventional RAAS 
inhibitors,[McMurray 2016; Parving 2012] with improvements to include the use of the newer 
oral potassium binder patiromer for treatment of potential hyperkalemia.[Georgianos and 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
28 
Agarwal 2018; Weir 2015] The risk of renal safety events is further mitigated in this study by its 
eligibility criteria, which exclude patients who are at highest risk to have events (estimated 
glomerular filtration rate [eGFR] <30 mL/min/1.73m2, baseline serum potassium >5 mEq/L, 
poorly controlled diabetes, or severely increased albuminuria) and those who may have 
decreased tolerance for renal safety events (patients with clinically significant heart failure, 
valvular heart disease, or recent history of cardiovascular event).  
3.3. 
Justification for Dose 
The doses of ALN-AGT01 in this study were selected on the basis of data from the Phase 1 
Study 001, in which single ALN-AGT01 doses up to 800 mg were found to have an acceptable 
safety profile, and clinically significant placebo-corrected reductions in mean SBP >10 mmHg 
by 24-hour ABPM were observed after doses as low as 100 mg. Dose selection was guided by 
the principle of evaluating doses that are well tolerated and predicted to result in a range of PD 
effects (ie, lowering of serum AGT) and antihypertensive responses. This is expected to enable 
development of population average dose-response relationships for PD and efficacy to guide 
identification of optimal treatment regimens (dose and dose frequency) for Phase 3.  
Preliminary PK/PD modeling based on serum AGT data from Study 001 indicates that 
ALN-AGT01 results in a dose-dependent lowering of serum AGT, with maximum reductions 
predicted to be achieved as early as 1 month postdose and significant reductions sustained for 
close to 6 months after dosing. Modeling of the relationship between serum AGT lowering and 
blood pressure suggests a log-linear relationship, with ≥92% reduction in serum AGT predicted 
to achieve median SBP reduction of ≥10 mmHg.  
Based on these, the once every 6 month doses of 150, 300, and 600 mg were selected to result in 
median serum AGT reductions of 81.9%, 89.4%, and 94.9%, respectively, at trough (Month 6), 
translating to median SBP reductions of 6.67 mmHg, 8.74 mmHg, and 11.6 mmHg, respectively. 
Thus, the selected doses will enable characterization of the dose-response relationships for serum 
AGT and blood pressure with the once every 6 month regimen. 
The selected doses also enable characterization of the dose-response relationships for serum 
AGT and blood pressure with once every 3 month regimens based on analysis of data from all 
arms at Month 3. This will provide support for development of a once every 3 month regimen, if 
desired. To this end, 300 mg once every 3 months will be evaluated to identify any cumulative 
effects. The 300 mg once every 3 months dose is predicted to result in median serum AGT 
reductions of >95% at trough (Month 3), translating to median SBP reductions of >10 mmHg.  
Thus, data from the current study will enable robust characterization of PD and efficacy of once 
every 3 month and once every 6 month regimens of ALN-AGT01 and guide further development 
of ALN-AGT01 as an antihypertensive therapeutic that results in reduction of blood pressure by 
≥10 mmHg throughout the dosing interval with infrequent administration. 
3.4. 
Method of Assigning Patients to Treatment Groups 
Using the Interactive Response Technology (IRT), patients will be randomized 1:1:1:1:1 to the 
following arms during the first 6 months of the 12-month DB period: 
• Placebo SC once every 3 months 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
29 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients initially randomized to placebo will be re-randomized 1:1:1:1 at Month 6 to 1 of the 4 
initial ALN-AGT01 regimens. 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. 
Randomization will be stratified by race (black vs all other races) and by baseline blood pressure 
(mean 24 hour SBP < or ≥145 mmHg). 
Each patient will be uniquely identified in the study by a combination of the site number and 
patient identification number. Upon signing the informed consent form (ICF), the patient will be 
assigned a patient identification number by the IRT system. The Investigator or his/her designee 
will randomize the patient in IRT after confirming that the patient fulfills all the inclusion criteria 
and none of the exclusion criteria. The Investigator or his/her designee will re-randomize the 
patient in IRT at Month 6 to assign placebo patients to 1 of the 4 initial ALN-AGT01 dose 
groups. 
3.5. 
Blinding 
The Sponsor, all site personnel (except for the site pharmacist or delegate), and patients will be 
blinded to study drug treatment through Month 6 of the 12-month DB period. After the database 
lock to support the analysis of Month 6 data is complete, the Sponsor will be unblinded to 
treatment assignment, but the site personnel (except for the site pharmacist) and patients will 
remain blinded to treatment assignment until after the analysis of Month 12 data is complete.  
Blinded doses of study drug will be administered under the supervision of the Investigator (see 
Section 5.2.2). All patients will receive the same volume and number of injections regardless of 
treatment assignment (patients receiving once every 6 month ALN-AGT01 regimens will receive 
placebo SC at dosing visits at which they do not receive ALN-AGT01 to maintain the blind). 
Because ALN-AGT01 may be slightly visually distinguishable from placebo, all blinded study 
drug doses will be prepared and the syringe(s) will be masked by a site pharmacist or delegate 
prior to administration by a blinded healthcare professional. See the Pharmacy Manual for 
additional details. 
3.5.1. 
Emergency Unblinding 
If the treating physician determines that the clinical management of the patient requires 
knowledge of the study drug assignment, the Investigator may break the blind, as necessary, in 
IRT. If time permits, clinical study center personnel should contact the Medical Monitor before 
unblinding to discuss the need to unblind the patient but must do so within 1 working day after 
the unblinding event. Unblinding information should be limited to the fewest number of people 
on a need-to-know basis. A record of when the blind was broken, who was unblinded, who broke 
the blind, and why it was broken, will be maintained in the electronic trial master file. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
30 
Refer to the IRT instructions for details on emergency unblinding. 
3.6. 
Data Monitoring Committee 
An independent DMC will oversee the safety and overall conduct of this study. The DMC will 
operate under the rules of a charter that will be reviewed and approved at the organizational 
meeting of the DMC. Details are provided in the DMC Charter. 
3.7. 
Clinical Event Adjudication Committees 
An independent Clinical Event Adjudication Committee of 2 or more nephrologists will review 
renal events blinded to treatment assignment to adjudicate whether they meet diagnostic criteria 
for acute kidney injury and, if so, their potential staging and contributing factors. Details are 
provided in the Renal Event Adjudication Committee charter. 
3.8. 
Definition of End of Study for an Individual Patient 
A patient is considered to have reached the end of the study if the patient: 
• has completed at least the Month 12 visit and enrolled in the OLE study, or 
• has completed the Safety Follow-up visits as described in Section 3.1 for patients who 
discontinue study drug or do not enroll in the OLE study. 
A definition of the end of the overall study is provided in Section 8.1.5. 
4. 
SELECTION AND REMOVAL OF PATIENTS 
4.1. 
Inclusion Criteria 
Patients are eligible to be included in the study if all the following criteria apply: 
Age and Sex 
1. Age 18 to 75 years, inclusive 
2. Male or female 
Patient and Disease Characteristics 
3. Has untreated hypertension (not taking antihypertensive medication) or is on stable 
therapy with 1 or more antihypertensive medications of the following classes: an ACE 
inhibitor, ARB, renin inhibitor, CCB, thiazide diuretic, and/or thiazide-like diuretic. In 
general, stable therapy is defined as having no change in antihypertensive medication or 
dose within 30 days prior to screening.  
4. Mean 24-hour SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive 
medication. Patients previously taking medication for hypertension must be without 
antihypertensives for ≥4 weeks prior to this ABPM. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
31 
Informed Consent 
5. Patient is able to understand and is willing and able to comply with the study 
requirements and to provide written informed consent. 
4.2. 
Exclusion Criteria 
Patients are excluded from the study if any of the following criteria apply: 
Disease-specific Conditions 
1. Secondary hypertension 
2. Orthostatic hypotension (symptomatic or asymptomatic), defined as a fall of ≥20 mmHg 
SBP or ≥10 mmHg DBP within approximately 1 to 3 minutes of standing up from a 
seated position by office blood pressure. 
Laboratory Assessments 
3. Has any of the following laboratory parameter assessments after at least 4 weeks of 
washout:  
a. ALT or aspartate aminotransferase (AST) >2× upper limit of normal (ULN) 
b. Total bilirubin >1.5×ULN. Patients with elevated total bilirubin that is secondary to 
documented Gilbert’s syndrome are eligible if the total bilirubin is <2×ULN 
c. International normalized ratio (INR) >2.0 (patients on oral anticoagulant [eg, 
warfarin] with an INR <3.5 will be allowed) 
d. Elevated potassium >5 mEq/L  
e. eGFR of ≤30 mL/min/1.73m2 (calculation will be based on the Modification of Diet 
in Renal Disease formula)  
Prior/Concomitant Therapy 
4. Received an investigational agent within the last 30 days before randomization or are in 
follow-up of another clinical study prior to study enrollment. Any agent that has received 
health agency authorization (including for emergency use) by local or regional regulatory 
authorities is not considered investigational. 
5. Currently taking, taken within 30 days prior to randomization, or anticipated to receive 
during the course of the study any medication or herbal supplement known to 
significantly affect blood pressure (with the exception of medications for the treatment of 
essential hypertension). Patients who require medications such as monoamine oxidase 
(MAO) inhibitors that are associated with hypertensive crisis should be 
excluded.[Whelton 2018]  
6. Currently taking, or taken within 30 days prior to randomization, beta blockers 
7. Currently taking, taken within 30 days prior to randomization, or anticipated to receive 
during the course of the study sodium-glucose co-transporter 2 (SGLT2) inhibitors 
8. Prescription nonsteroidal anti-inflammatory drugs (NSAIDs) are not permitted. In 
addition, chronic/standing use of over-the-counter NSAIDs is not permitted. 
Paracetamol/acetaminophen (up to 2 g per day) for analgesia will be allowed.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
32 
9. Anticipates using organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, 
isosorbide dinitrate, pentaerythritol) during the course of the study 
10. Received an RNAi therapeutic (approved or investigational) within 6 months prior to 
randomization 
Medical Conditions 
11. Current or prior history of intolerance to an ARB, ACE inhibitor (other than cough), or 
direct renin inhibitor 
12. Medical condition, other than hypertension, that requires treatment with a RAAS 
inhibitor 
13. History of multiple drug allergies or history of allergic reaction to an oligonucleotide or 
to GalNAc 
14. Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus (hemoglobin A1c 
[HbA1c] >8.0%), newly diagnosed Type 2 diabetes mellitus (within 6 months prior to 
randomization), or laboratory evidence of diabetes during screening (fasting plasma 
glucose ≥126 mg/dL [7.0 mmol/L], random plasma glucose ≥200 mg/dL [11.1 mmol/L], 
or HbA1c ≥6.5%) without known diagnosis of diabetes 
15. History of severely increased albuminuria (urine albumin:creatinine ratio >300 mg/g or 
>300 mg/day) or laboratory results consistent with this diagnosis upon screening  
16. Has known human immunodeficiency virus or evidence of current or chronic hepatitis C 
virus (HCV) or hepatitis B virus (HBV) infection 
17. History of any cardiovascular event (eg, stroke, transient ischemic attack, myocardial 
infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary 
intervention, hospitalization due to heart failure) within 6 months prior to randomization 
18. Clinically significant valvular heart disease 
19. New York Heart Association II to IV heart failure 
20. Uncontrolled serious cardiac arrhythmia, defined as recurrent and highly symptomatic 
ventricular tachycardia, atrial fibrillation with rapid ventricular response, or 
supraventricular tachycardia in the 3 months prior to randomization 
21. Has undergone liver transplantation or is anticipated to be on an active liver 
transplantation waiting list during the study treatment period 
22. History of renal transplantation or under immunosuppressive therapy 
23. Has other medical conditions or comorbidities which, in the opinion of the Investigator, 
would interfere with study compliance or data interpretation; or, in the opinion of the 
Investigator, taking part in the study would jeopardize the safety of the patient 
24. Clinically significant illness, in the opinion of the Investigator, within 7 days prior to 
randomization 
25. Known change in body weight >10% in last 6 months prior to screening 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
33 
26. History of intolerance to SC injection(s) that could potentially hinder study drug 
administration or evaluation of local tolerability 
27. Has planned major surgery or general anesthesia during the study 
Contraception, Pregnancy, and Breastfeeding 
28. Is not willing to comply with the contraceptive requirements during the study period, as 
described in Section 5.7.1 
29. Female patient is pregnant, planning a pregnancy, or breast-feeding. 
Alcohol or Nicotine Use and Substance Abuse 
30. Unwilling or unable to limit alcohol consumption throughout the course of the study. 
Alcohol intake of >2 units/day is excluded during the study (unit: 1 glass of wine 
[approximately 125 mL] = 1 measure of spirits [approximately 1 fluid ounce] = ½ pint of 
beer [approximately 284 mL]). 
31. History of alcohol or substance abuse (licit or illicit drugs) within the last 12 months 
before screening, in the opinion of the Investigator 
32. Unwilling or unable to abstain from use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine 
patches, or e-cigarettes) within 30 minutes prior to office blood pressure measurements  
Other Restrictions 
33. Third shift or night shift workers 
34. Arm circumference exceeds the maximum cuff size of any of the blood pressure 
instruments provided by the Sponsor 
35. Unable or unwilling to perform HBPM as specified 
4.3. 
Removal from Study Drug or Assessment 
Patients or their legal guardians are free to discontinue study drug and/or stop protocol 
procedural assessments, or participation in the study as a whole at any time and for any reason, 
without penalty to their continuing medical care. The Investigator or the Sponsor may 
discontinue study drug or stop a patient’s participation in the study at any time if this is 
considered to be in the patient’s best interest. Any discontinuation of treatment or the stopping of 
the patient’s participation in the study must be fully documented in the electronic case report 
form (eCRF) and should be followed up by the Investigator. 
Discontinuation of study drug or declining procedural assessments is described in Section 4.3.1, 
while the stopping of a patient’s participation in the study is detailed in Section 4.3.2. 
4.3.1. 
Discontinuation of Study Drug or Declining Procedural Assessments 
Reasons for discontinuation of study drug include any of the following: 
• Significant protocol deviation; which includes required treatment with prohibited 
medication (as defined in Section 5.5.2) per Investigator discretion 
• AE 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
34 
• Non-adherence to treatment regimen 
• Pregnancy 
• Lost to follow-up 
• Other reason (non-AE) 
• Or, study is terminated by the Sponsor 
If possible, the Investigator will confer with the Sponsor or Medical Monitor before 
discontinuing dosing in the patient. Patients who are pregnant will be discontinued from study 
drug dosing immediately (see Section 6.5.6.7 for reporting and follow-up of pregnancy). A 
positive urine pregnancy test should be confirmed by a serum pregnancy test prior to 
discontinuing the study drug. 
Patients who discontinue study drug and/or decline procedural assessments should not be 
automatically removed from study. In general, patients who discontinue study drug dosing for 
any reason will be encouraged to remain on the study to complete the remaining assessments and 
study visits so that their experience is captured in the final analyses.  
If this occurs, the Investigator is to discuss with the patient the appropriate processes for 
discontinuation from study drug and must discuss with the patient the options for continuation of 
the Schedule of Assessments (Table 1), including different options for follow-up and collection 
of data (eg, in person, by phone, by mail, through family or friends, or from options not 
involving patient contact, such as communication with other treating physicians or from review 
of medical records), including endpoints and AEs, and must document this decision in the 
patient’s medical records. 
If a patient discontinues dosing due to an AE, including SAEs, the event should be followed as 
described in Section 6.5.6. When a patient discontinues study drug dosing, the primary reason 
must be recorded in the eCRF. Patients who discontinue study drug and remain on study may 
receive treatment consistent with local standard practice for their disease per Investigator 
judgement, as applicable. 
Patients who discontinue from study drug before Month 6 will be encouraged to remain on the 
study and complete assessments (excluding PK assessments) through Month 6. They will also be 
asked to complete Safety Follow-up visits once every 6 months after the last dose of study drug 
per the safety follow-up schedule (see Table 1) until the last patient’s Month 6 visit or until PD 
recovery (whichever is later); see Section 3.1. 
Patients who discontinue study drug after the Month 6 visit will be asked to return for their next 
scheduled visit to complete end of treatment (EOT)/ET assessments and complete Safety Follow-
up visits once every 6 months after the last dose of study drug per the safety follow-up schedule 
(see Table 1) until PD recovery; see Section 3.1. 
4.3.2. 
Stopping a Patient’s Study Participation 
4.3.2.1. 
Patient or Legal Guardian Stops Participation in the Study 
A patient or their legal guardian may stop participation in the study at any time. A patient or 
legal guardian considering stopping participation in the study before Month 6 should be 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
35 
informed that the patient can discontinue study drug and/or decline procedural assessments and 
remain in the study to complete their study assessments through the Month 6 visit and complete 
Safety Follow-up visits as described in Section 4.3.1, or alternatively may complete any minimal 
assessments for which the patient or legal guardian consents. If a patient or legal guardian still 
chooses to discontinue study drug and stop participation in all follow-up prior to the completion 
of the Month 6 visit, every effort should be made to conduct the Month 6 visit assessments at an 
earlier time (Table 1). 
A patient considering stopping participation in the study after the Month 6 visit should be 
informed that the patient can discontinue study drug and/or decline procedural assessments and 
remain in the study to complete the assessments scheduled for the EOT/ET visit and complete 
Safety Follow-up visits as described in Section 4.3.1, or alternatively may complete any minimal 
assessments for which the patient consents. 
If the patient does not wish to or is unable to continue further study participation, the Investigator 
is to discuss with the patient appropriate procedures for stopping participation in the study. Data 
collected from the patient can continue to be used. 
Note, in countries where the collection and processing of the patient’s personal data is based on 
consent, if a patient withdraws consent to collect and process his/her personal data (see 
Section 4.3.2.2), as applicable, personal data up to the withdrawal of consent will be included in 
the analysis of the study. In addition, where permitted, publicly available data (such as 
appropriate national or regional vital status registry or other relevant databases) can be included 
after withdrawal of consent, where available and allowable by local law. 
4.3.2.2. 
Withdrawal of Consent to Process the Patient’s Personal Data or Objection to 
Process Patient’s Personal Data 
Where allowed by local law, the patient may decide to withdraw consent to collect, store, and 
use biological samples and, as applicable, other personal data, informing the study doctor at any 
time in writing or in any other form that may be locally required. Also, where allowed by local 
law, the patient may object to the collection, storage, and use of his/her personal data, informing 
the study doctor at any time in writing or in any other form that may be locally required. In both 
cases, the Sponsor will continue to keep and use the patient’s study information (including any 
data resulting from the analysis of the patient’s biological samples until the time of 
withdrawal/objection) according to applicable law. The process for the storage and, as 
applicable, further use of remaining samples will be followed per local requirements.  
4.3.2.3. 
Investigator or Sponsor Stops Participation of a Patient in the Study 
The Investigator or Sponsor may stop the participation of a patient in the study at any time if this 
is considered to be in the patient’s best interest. However, study integrity and interpretation are 
best maintained if all enrolled patients continue study assessments and follow-up even if study 
drug is discontinued. 
Termination of the clinical study and site closure are described in Section 8.1.6. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
36 
4.3.2.4. 
Recording Reason for Stopping a Patient’s Study Participation 
The primary reason that a patient’s study participation is stopped must be recorded in the 
appropriate section of the eCRF and all efforts will be made to complete and report the 
observations as thoroughly as possible. If a patient’s study participation is stopped due to an AE, 
including SAEs, the event should be followed as described in Section 6.5.6. 
4.3.3. 
Lost to Follow-Up 
A patient will be considered lost to follow-up if the patient repeatedly fails to return for 
scheduled visits and is unable to be contacted by the clinical study center. The following actions 
must be taken if a patient fails to return to the clinic for a required study visit: 
• The site must attempt to contact the patient or legal guardian and reschedule the 
missed visit as soon as possible and counsel the patient or legal guardian on the 
importance of maintaining the assigned visit schedule and ascertain if the patient or 
legal guardian wishes [for the patient] to continue in the study, and/or should continue 
in the study. 
• Before a patient is deemed lost to follow up, the Investigator or designee must make 
every effort to regain contact with the patient or legal guardian (where possible, 3 
telephone calls and, if necessary, a certified letter to the patient’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the patient’s medical record. 
• Should the patient or legal guardian continue to be unreachable, the patient will be 
considered to have stopped participation in the study. 
• For patients who are lost to follow-up, the Investigator can search publicly available 
records (where permitted and allowed by local law) to ascertain survival status. This 
ensures that the outcome of the study is as comprehensive as possible. 
4.3.4. 
Replacement of Study Patients 
No additional patients may be enrolled to mitigate the impact of patients who discontinue the 
study drug or stop participation in the study.  
5. 
TREATMENTS AND OTHER REQUIREMENTS 
5.1. 
Treatments Administered 
Study drug supplied for this study must not be used for any purpose other than the present study 
and must not be administered to any person not enrolled in the study. Study drug that has been 
dispensed and returned unused must not be re-dispensed. 
5.2. 
Study Drug 
Detailed information describing the preparation, administration, and storage of ALN-AGT01 SC 
and placebo SC is provided in the Pharmacy Manual. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
37 
5.2.1. 
Description 
ALN-AGT01 will be supplied as a sterile solution for SC injection. See the Pharmacy Manual 
for further details of solution concentration and fill volume. 
The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC 
administration).  
5.2.2. 
Dose and Administration 
During the 12-month DB period, patients will be administered ALN-AGT01 or placebo, at the 
same volume and number of SC injections regardless of treatment assignment, once every 3 
months. The ALN-AGT01 and placebo groups are below: 
• Placebo SC once every 3 months, with re-randomization (1:1:1:1) at Month 6 to 1 of 
the initial 4 ALN-AGT01 regimens 
• 150 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 6 months 
• 300 mg ALN-AGT01 SC once every 3 months 
• 600 mg ALN-AGT01 SC once every 6 months 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. Patients receiving once every 6 month ALN-AGT01 regimens will receive 
placebo SC at dosing visits at which they do not receive ALN-AGT01 to maintain the blind. 
Study drug injections will be administered under the supervision of the Investigator or healthcare 
professional. To maintain the blind, the doses are to be prepared by and syringes are to be 
masked by an unblinded site pharmacist or designee prior to study drug administration. A full 
description of the blinding procedure is included in the Pharmacy Manual. The injection site may 
be marked and mapped for later observation. Injections may be administered in the abdomen, 
thigh, or the side or back of the upper arms. The rotation of sites is recommended. If a local 
reaction around the injection site occurs, photographs may be obtained. Detailed instructions for 
study drug administration are found in the Pharmacy Manual. 
If a patient does not receive a dose of study drug within the specified visit window, the 
Investigator should contact the Medical Monitor. After such consultation, the dose may be 
administered up to 42 days before the next scheduled dose. Thereafter, the dose will be 
considered missed and not administered. 
Patients will be permitted to miss an occasional dose of study drug. However, if a patient misses 
2 consecutive doses, the Investigator, in consultation with the Medical Monitor, will discuss 
whether the patient will be able to continue the study (see also Section 4.3). 
Additional details can be found in the Pharmacy Manual. 
The definition of study drug overdose, follow-up procedures, and reporting requirements are 
provided Section 6.5.6.8. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
38 
5.2.3. 
Dose Modifications 
Dose modifications are not permitted. 
If a study drug-related AE occurs in a patient that the Investigator judges as presenting a 
potential risk to the patient for further dosing, the study drug dose may be held at the discretion 
of the Investigator and the Medical Monitor should be contacted. 
5.2.4. 
Liver Function Test Criteria for Withholding, Monitoring and Stopping Study 
Drug Dosing  
1. Dosing decisions may be made based on the most recently available liver function test 
(LFT) results from a central laboratory (Table 6). 
2. For any ALT or AST elevation >3×ULN, central laboratory results should be used to 
guide subsequent monitoring as detailed in Table 3. 
3. For any ALT or AST elevation >3×ULN: 
a. If local laboratory results are obtained, confirm with a central laboratory as soon as 
possible, ideally within 2 to 3 days, but no later than 7 days. 
b. If an alternative cause is found, provide appropriate care. 
c. If an alternative cause is not found, perform assessments per Table 6 and Table 7. 
4. For any ALT or AST elevation >3×ULN without alternative cause that is accompanied 
by clinical symptoms consistent with liver injury (eg, nausea, right upper quadrant 
abdominal pain, jaundice) or elevated bilirubin to ≥2×ULN or INR ≥1.5, permanently 
discontinue dosing. 
5. For confirmed ALT or AST elevations >3×ULN without alternative cause and not 
accompanied by symptoms or elevated bilirubin ≥2×ULN or INR ≥1.5, see Table 3. 
Table 3: 
Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3×ULN, With No Alternative Cause 
Identified 
Transaminase Level 
Action 
>3× to 5×ULN 
• 
May continue study drug dosing 
• 
Evaluate the initial elevation in LFT per the following assessments: 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6  
• 
Monitor at least every 2 weeks (LFT and coagulation per Table 6)  
• 
If elevation persists for ≥2 months, must discuss with the Medical Monitor 
before continuing dosing 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
39 
Transaminase Level 
Action 
>5× to 8×ULN 
• 
Hold study drug dosing until recovery to ≤1.5×ULN or baseline; may 
resume dosing after discussion with the Medical Monitor 
• 
Evaluate the initial elevation in LFT per the following assessments 
­ Table 7 (all assessments to be performed once) 
­ Hematology, serum chemistry, LFT, and coagulation per Table 6 
• 
Monitor at least weekly: LFT and coagulation per Table 6 until ALT and/or 
AST is declining on 2 consecutive draws, then may decrease monitoring to 
biweekly 
• 
If ALT or AST rises to >5×ULN following resumption of dosing, 
permanently discontinue dosing 
>8×ULN 
Permanently discontinue study drug dosing after confirmation of the 
transaminase value at the central laboratory. 
Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; INR=international normalized 
ratio; LFT=liver function test(s); ULN=upper limit of normal. 
Notes: In addition to these criteria, other assessments or evaluations may be performed per Investigator discretion, 
as appropriate. 
5.2.5. 
Preparation, Handling, and Storage 
Staff at each clinical study center will be responsible for preparation of ALN-AGT01 or placebo 
doses according to procedures detailed in the Pharmacy Manual. No special procedures for the 
safe handling of study drug are required. 
ALN-AGT01 will be stored upright and refrigerated at approximately 2 to 30°C until dose 
preparation. Deviations from the recommended storage conditions should be reported to the 
Sponsor and use of ALN-AGT01 halted until authorization for its continued use has been 
provided by the Sponsor or designee, as described in the Pharmacy Manual. 
A Sponsor representative or designee will be permitted, upon request, to audit the supplies, 
storage, dispensing procedures, and records. 
Instructions specific to unused study drug and additional storage will be provided in the 
Pharmacy Manual. 
5.2.6. 
Packaging and Labeling 
All packaging, labeling, and production of study drug will be in compliance with current Good 
Manufacturing Practice specifications, as well as applicable local regulations. Study drug labels 
and external packaging will include all appropriate information as per local labeling 
requirements. Additional details will be available in the Pharmacy Manual. 
5.2.7. 
Accountability 
The Investigator or designee will maintain accurate records of receipt and the condition of 
ALN-AGT01 supplied for this study, including dates of receipt. In addition, accurate records will 
be kept of when and how much ALN-AGT01 is dispensed and administered to each patient in 
the study. Any reasons for departure from the protocol dispensing regimen must also be 
recorded. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
40 
At the completion of the study, there will be a final reconciliation of all ALN-AGT01. Used, 
partially used, and unused ALN-AGT01 will be returned to the Sponsor (or designee) or 
destroyed at the clinical study center according to applicable regulations. 
Further instructions about drug accountability will be detailed in the Pharmacy Manual. 
5.3. 
Clinical Product Complaints 
5.3.1. 
Definition 
A clinical product complaint (CPC) is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of the investigational product and its packaging after it is released for distribution at 
clinical site. 
A CPC may be detected prior to use of study drug, during use, or after use. A CPC is typically 
nonmedical in nature; however, it is possible that investigational product complaints could be 
associated with an AE. Examples of a CPC include, but are not limited to: illegible clinical label, 
missing clinical label, damaged vial, empty vial, contamination of investigational product, and 
malfunction of syringe needle safety device. 
5.3.2. 
Reporting 
For product complaints, the Sponsor or its designee should be notified within 24 hours using the 
appropriate eCRF. CPCs that may be associated with an AE must be evaluated and reported as 
indicated in Section 6.5.6 instructions on reporting CPCs will also be detailed in the Pharmacy 
Manual. 
5.4. 
Monitoring for Potential Clinical Events 
5.4.1. 
Monitoring and Approach for Potential Hypotension 
Hypotension is an obligate risk of antihypertensive medications. In addition to office blood 
pressure monitoring, outpatient blood pressure will be monitored weekly with HBPM to ensure 
the early detection of potential hypotension. Whenever possible, management decisions will be 
based on blood pressure measurements confirmed by office blood pressure. 
The following management recommendations for hypotension are provided: 
• Low blood pressure that is associated with symptoms should be evaluated at the 
clinical study site or another hospital setting within 24 hours. Clinical study site 
evaluation for low blood pressure should include the assessment of orthostatic blood 
pressure.  
• The Investigator should consider downtitration or discontinuation of oral 
antihypertensives (if taking) if confirmed office SBP <100 mmHg or if clinical 
symptoms, such as lightheadedness or dizziness, develop coupled with a significantly 
lower SBP compared to prior visits (ie, SBP <110 mmHg). 
• Clinically significant events discovered during the course of a patient’s general 
medical care should be promptly communicated to the site and evaluated by the 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
41 
Investigator, especially if hypotension is noted. Patients will carry Independent Ethics 
Committee (IEC)-approved patient cards to facilitate this physician-to-physician 
communication.  
• If hypotension is confirmed, serum electrolytes and creatinine should be measured 
and any oral antihypertensive(s) previously started for hypertensive escape should be 
down-titrated or discontinued.  
• The frequency of blood pressure and biochemical monitoring (serum electrolytes and 
creatinine) should be increased during intercurrent illnesses that predispose patients to 
dehydration (eg, vomiting or diarrhea that persists for more than 24 hours) or when 
symptoms consistent with decreased effective circulating volume (eg, presyncopal 
symptoms, unexplained falls, decreased urine output) manifest, even if a patient’s 
recent blood pressure measurements have been normal. 
• Hypotension that warrants direct evaluation at the site should be communicated to the 
Medical Monitor within 24 hours. In addition, other clinical events consistent with 
potential hypotension (eg, unexplained presyncope, syncope, or falls) should be 
communicated to the Medical Monitor within 24 hours of the site being notified. 
• Management of persistent hypotension may include increased salt intake or, if 
unresponsive, standard treatments for orthostatic intolerance syndromes such as 
fludrocortisone or midodrine. 
• Low blood pressure that requires medical treatment (including intravenous fluid 
support) or other clinical events consistent with potential hypotension (see above) 
should be recorded as AEs. 
5.4.2. 
Monitoring and Approach for Clinically Significant Blood Pressure Elevation 
In addition to office blood pressure monitoring, outpatient blood pressure will be monitored 
frequently with HBPM to ensure the early detection of potential significant elevations. Whenever 
possible, management decisions will be based on blood pressure measurements confirmed by 
office blood pressure. The recommended interventions for potentially clinically significant blood 
pressure elevation are presented in Table 4.  
Table 4: 
Recommended Interventions for Potentially Clinically Significant Blood 
Pressure Elevation 
Study Period 
Intervention 
Throughout Study 
• 
Whenever possible, management decisions should be based on blood 
pressure measurements confirmed by office blood pressure. 
• 
Any confirmed event of severe systolic hypertension (office SBP 
≥180 mmHg) should be appropriately treated regardless of its timing 
relative to study drug administration.  
• 
Because ALN-AGT01 acts on the RAAS, the use of conventional RAAS 
inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors) as rescue 
agents for high blood pressure will be avoided throughout this study.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
42 
Study Period 
Intervention 
• 
If added, oral antihypertensives must be used per their labeled instructions 
and in accordance with current care guidelines.[Whelton 2018; Williams 
2018] 
• 
The Investigator should consider downtitration or discontinuation of oral 
antihypertensives (if taking) if confirmed office SBP <100 mmHg (or 
<115 mmHg with clinical symptoms such as lightheadedness or dizziness). 
Day 1 to Month 3 
Intervene if clinically significant blood pressure elevation: 
• 
Because of the gradual onset of effects of ALN-AGT01, interventions for 
asymptomatic hypertension should be avoided in the first 6 weeks after the 
patient’s first administration of study drug.  
• 
After Week 6, patients who develop office SBP >160 mmHg and increased 
>10 mmHg from their baseline office SBP that persists for ≥24 hours on 2 
consecutive measurements or that is accompanied by hypertensive 
symptoms should be evaluated by the clinical study site. Severely 
symptomatic patients should be evaluated at the clinical study site or 
another hospital setting within 24 hours. 
• 
If persistent hypertension is confirmed (without the identification of a 
specific treatable cause) and the Investigator deems it to be a clinically 
significant change, treatment may be initiated at the medical discretion of 
the Investigator using a CCB and/or a thiazide/thiazide-like diuretic. 
Investigators should avoid long-acting agents that may not fully washout 
between Month 5 and Month 6. 
Months 3 to 6 
Treat to target blood pressure using a CCB and/or thiazide/thiazide-like diuretic: 
• 
At Month 3, a CCB and/or a thiazide/thiazide-like diuretic should be added 
if the daytime mean SBP is ≥135 mmHg by ABPM. If the Investigator feels 
there is a compelling clinical reason to wait, the rationale for exception 
should be documented in the eCRF. 
• 
After Month 3, oral antihypertensive medications may also be added per 
Investigator judgement for persistent elevations in blood pressure above 
target (target defined as office SBP <140 mmHg, HBPM SBP <135 mmHg, 
or daytime mean SBP by ABPM <135 mmHg).[Williams 2018] 
• 
A temporary hold of oral antihypertensives (if taking) will be performed in 
appropriate patients (below) from Month 5 to Month 6: 
- Month 5 office SBP <160 mmHg if taking no oral antihypertensive 
agents 
- Month 5 office SBP <155 mmHg if taking 1 oral antihypertensive agent 
- Month 5 office SBP <150 mmHg if taking 2 oral antihypertensive 
agents. 
• 
During this 4-week period, blood pressure will be carefully monitored by 
daily HBPM and oral antihypertensive medications restarted if confirmed 
office SBP >170 mmHg (or if confirmed office SBP >160 mmHg 
accompanied by symptoms) 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
43 
Study Period 
Intervention 
Month 6 to End of 
Study 
Treat to target blood pressure using Investigator’s choice of oral 
antihypertensive(s). 
• 
At Month 6, prior oral antihypertensive should be restarted per Investigator 
judgement if daytime mean SBP is ≥135 mmHg by ABPM. 
• 
Oral antihypertensive medications may also be added per Investigator 
judgement for persistent elevations in blood pressure above target (target 
defined as office SBP <140 mmHg; HBPM SBP <135 mmHg; daytime 
mean SBP by ABPM <135 mmHg).[Whelton 2018; Williams 2018] 
5.4.3. 
Monitoring and Approach for Potential Renal Dysfunction 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of eGFR 
through the anticipated onset of initial ALN-AGT01 PD. Based upon the renal dysfunction 
associated with conventional RAAS inhibitors,[McMurray 2016; Parving 2012] the following 
guidelines apply throughout the study: 
• Study drug (and additional oral antihypertensive agents, if applicable) should be 
prophylactically held during intercurrent illness or volume depletion 
• If an individual patient experiences a decrease in eGFR by ≥30% from baseline or to 
≤30 mL/min/1.73m2, the Investigator should obtain confirmatory repeat tests, contact 
the Sponsor, and look for potentially reversible causes of renal dysfunction such as: 
− NSAIDs, antibiotics, or other treatments known to impair renal function 
− Recent exposure to intravenous contrast agents 
− Hypovolemia 
− Urinary infection 
− Urinary tract obstruction 
• If an individual patient experiences a decrease in eGFR by ≥40% from baseline or to 
≤25 mL/min/1.73m2, the Investigator should look for potentially reversible causes of 
renal dysfunction and contact the Sponsor to discuss the potential interruption of 
study drug. Serum creatinine should be monitored at least weekly until improving. 
5.4.4. 
Monitoring and Approach for Potential Hyperkalemia 
The Schedule of Assessments (Table 1) includes frequent laboratory monitoring of serum 
electrolytes (at least monthly through the anticipated onset of ALN-AGT01 PD). The following 
guidelines apply for potassium elevations detected by laboratory monitoring.[McMurray 2016; 
Parving 2012] 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
44 
Table 5: 
Recommended Interventions for Hyperkalemia 
Serum K+ ≥5.2 and <5.5 mmol/L 
Serum K+ ≥5.5 and <6.0 mmol/L 
Serum K+ ≥6.0 mmol/L 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample. 
• 
Reinforce low-potassium diet 
and restriction of food/drinks 
with high potassium content  
• 
Review medical regimen 
(including dietary supplements 
and over-the-counter 
medications) for agents known 
to cause hyperkalemia.a 
Consider reduction in dose or 
discontinuation of these agents. 
• 
Repeat K+ measurement within 
3 to 5 days. 
• 
If K+ remains ≥5.2 and <5.5 
mmol/L, regularly monitor K+ 
levels to ensure stability (at 
least weekly if in the first 6 
weeks of treatment or at least 
once monthly afterwards) 
• 
Consider interruption of 
ALN-AGT01, according to 
Investigator medical judgment. 
• 
Confirm potassium 
concentration in a non-
hemolyzed sample 
• 
Consider interruption of ALN-
AGT01, according to 
Investigator medical judgment  
• 
Apply all measures outlined for 
serum K+ ≥5.2 and <5.5 
mmol/L 
• 
Repeat K+ measurement after 2 
to 3 days 
• 
If K+ <5.5 mmol/L, consider 
resumption of study drug (if 
interrupted) with repeat 
potassium within 5 days 
• 
If K+ persistently elevated ≥5.5 
mmol/L, consider treatment 
with patiromer 
• 
Immediately interrupt 
ALN-AGT01 
• 
Confirm potassium 
concentration in a 
non-hemolyzed 
sample 
• 
Urgently evaluate 
patient and treat 
hyperkalemia as 
clinically indicated. 
After urgent 
treatment, consider 
treatment with 
patiromer 
• 
Apply all measures 
outlined for serum K+ 
≥5.5 and < 6.0 
mmol/L 
• 
No resumption of 
study drug without 
individualized case 
discussion with and 
permission from 
Alnylam Medical 
Monitor 
Abbreviations: NSAID=nonsteroidal anti-inflammatory drug. 
a This list is not meant to be exhaustive: potassium-sparing diuretics (eg, amiloride and triamterene), potassium 
supplements (eg potassium chloride), salt substitutes, NSAIDs, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, herbal supplements (eg, Noni juice, alfalfa [Medicago sativa], 
dandelion [Taraxacum officinale], horsetail [Equisetum arvense], nettle [Urtica dioica], milkweed, lily of the 
valley, Siberian ginseng, hawthorn berries). 
The availability of patiromer will be assessed at participating study sites. This potassium-binding 
drug is approved for the treatment of hyperkalemia and has been shown to safely reduce serum 
potassium levels and to maintain long-term normokalemia in chronic kidney disease patients 
receiving background conventional RAAS inhibitor therapy.[Georgianos and Agarwal 2018; 
Weir 2015] 
5.5. 
Concomitant Medications and Procedures 
Use of concomitant medications and procedures will be recorded on the patient’s eCRF as 
specified in the Schedule of Assessments (see Table 1). Concomitant medications include all 
prescription medications, herbal preparations, over the counter medications, vitamins, and 
minerals. Any changes in medications during the study will also be recorded on the eCRF. 
Standard vitamins and topical medications are permitted. However, topical steroids must not be 
applied anywhere near the injection site(s) unless medically indicated. For permitted concomitant 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
45 
medications administered SC, do not administer in same injection site area as the study drug for 
4 days after the last dose of study drug. 
Occasional use of systemic NSAIDs is allowed. However, given their association with increased 
blood pressure, they should be avoided when possible and alternative analgesics (acetaminophen, 
topical NSAIDs) should be considered.[Whelton 2018] When used, the dosing of systemic 
NSAIDs should be at the lower end of the labeled range and for the shortest duration possible.  
Patients will be allowed to receive vaccines (eg, for SARS-CoV-2) that have received health 
agency authorization (including for emergency use) by local or regional regulatory authorities. 
Any concomitant medication that is required for the patient’s welfare may be administered by the 
Investigator, except as described in Section 5.5.2. However, it is the responsibility of the 
Investigator to ensure that details regarding the medication are recorded on the eCRF. 
Concomitant medication will be coded using an internationally recognized and accepted coding 
dictionary. 
5.5.1. 
Oral Antihypertensive Medication  
Individual initiation and modification of oral antihypertensive medications per Investigator 
judgement are permitted throughout the study if required to treat clinically significant blood 
pressure elevation (Section 5.4.2). In addition, after a patient completes the placebo-controlled 
primary endpoint at Month 3, Investigators will titrate therapy with oral antihypertensives to a 
target blood pressure range (office SBP <140 mmHg, HBPM SBP <135 mmHg, or daytime 
mean SBP by ABPM <135 mmHg). All oral antihypertensive medication that are dosed once 
daily should be taken in the morning. 
Serum electrolytes and creatinine should be measured at a central or local laboratory 
approximately 2 weeks after any antihypertensive addition or dose titration. 
5.5.2. 
Prohibited Concomitant Medication 
The following medications, treatments, and supplements are prohibited throughout the study 
(until the EOT visit): 
• Conventional RAAS inhibitors (ARBs, ACE inhibitors, or direct renin inhibitors)  
• SGLT2 inhibitors (eg, empagliflozin, canagliflozin, and dapagliflozin) 
• Prescription NSAIDs  
• Chronic/standing use of nonprescription NSAIDs 
• Organic nitrate preparations (eg, nitroglycerin, isosorbide mononitrate, isosorbide 
dinitrate, pentaerythritol) 
• Medications, herbal supplements (including Ma Huang and St. John’s wort), or other 
substances (such as licorice) that are associated with increases in LFT abnormalities 
or with blood pressure abnormalities are prohibited. This includes certain stimulants 
(eg, amphetamine, methylphenidate dexmethylphenidate, dextroamphetamine), MAO 
inhibitors, atypical antipsychotics (eg, clozapine, olanzapine), diet pills (eg, 
phenylpropanolamine, sibutramine), and nasal decongestants (eg, phenylephrine 
hydrochloride, pseudoephedrine, naphazoline hydrochloride). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
46 
• Medications, herbal medicines, over-the-counter medications, or supplements known 
to cause hyperkalemia are prohibited unless individually approved by both the 
Investigator and the Medical Monitor. This includes potassium-sparing diuretics, 
potassium supplements, cyclo-oxygenase-2 inhibitors, trimethoprim and 
trimethoprim-containing combination products, mineralocorticoid receptor 
antagonists, Noni juice, alfalfa, dandelion, horsetail, nettle, milkweed, lily of the 
valley, Siberian ginseng, and hawthorn berries. 
All concomitant medications must be reviewed and approved by the Investigator, with particular 
attention to avoiding drugs that may affect blood pressure. 
5.6. 
Treatment Compliance 
Compliance with study drug administration will be verified through observation by study staff or 
trained home healthcare professionals. 
5.7. 
Other Requirements 
5.7.1. 
Contraception 
Females of child-bearing potential must be willing to use a highly effective method of 
contraception from 14 days before first dose, throughout study participation, and through safety 
follow-up (if applicable; see Section 3.1).  
Birth control methods which are considered highly effective include: 
• Placement of an intrauterine device. 
• Placement of an intrauterine hormone-releasing system. 
• Bilateral tubal occlusion. 
• Surgical sterilization of male partner (with the appropriate post-vasectomy 
documentation of the absence of sperm in the ejaculate; for female patients on the 
study, the vasectomized male partner should be the sole partner for that patient). 
• Established use of oral (except low-dose gestagens), implantable, injectable, or 
transdermal hormonal methods of contraception associated with the inhibition of 
ovulation. 
• True sexual abstinence, when in line with the preferred and usual lifestyle of the 
patient. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception. Abstinent 
patients must agree to use one of the above-mentioned contraceptive methods if they 
start heterosexual relationships during the study and through safety follow-up (if 
applicable; Section 3.1). 
Investigators should advise females of childbearing potential of the most appropriate birth 
control method available within their country taking into account local medical practice. 
Females of child-bearing potential include female patients who have experienced menarche (or 
begin menarche over the course of the study), and who are not postmenopausal or permanently 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
47 
sterilized (eg, bilateral tubal occlusion, hysterectomy, or bilateral salpingectomy). A 
postmenopausal state is defined as the absence of menses for 12 months without an alternative 
medical cause, confirmed by follicle stimulating hormone level within the postmenopausal 
range.  
For male patients, no contraception is required. However, use by males of contraception 
(condom) may be required in some countries, eg, France, in order to comply with local 
requirements as described in the corresponding patient ICFs.  
Compliance with contraception requirements will be assessed on a regular basis by the 
Investigator throughout the course of the study (see Section 6.5.5.3). Pregnancy testing will be 
performed before every dose for postmenarcheal females throughout the course of the study (see 
Section 6.5.5.3). 
5.7.2. 
Alcohol Restrictions 
Patients should limit alcohol consumption throughout the course of the study. Alcohol is limited 
to no more than 2 units per day (unit: 1 glass of wine [approximately 125 mL] =1 measure of 
spirits [approximately 1 fluid ounce] =½ pint of beer [approximately 284 mL]) for the duration 
of the study. Compliance with alcohol restrictions should be assessed on a regular basis by the 
Investigator throughout the course of the study. 
5.7.3. 
Tobacco and Nicotine Restrictions 
Use of nicotine or tobacco-containing products (including but not limited to snuff, chewing 
tobacco, cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) must be avoided within 30 
minutes prior to blood pressure measurements. 
5.7.4. 
Dietary Recommendations  
All patients will receive educational materials on diet with recommendations to limit sodium 
consumption to approximately 2.0 g per day from screening through the end of the Treatment 
period. This direction should be provided at the start of the Screening period, and treatment-
naïve patients should follow these recommendations for at least 1 week prior to screening 
assessments of blood pressure. Of note, this is the sodium intake recommended in the 2018 
European Society of Cardiology/European Society of Hypertension Guidelines for both 
hypertensive patients and for the general population.[Williams 2018]  
On days on which samples for fasting lipid panel and glycemic assessments are collected, 
patients are required to fast for ≥10 hours before sample collection (Section 6.5.5.1). 
5.7.5. 
Exercise 
Patients should abstain from strenuous exercise for 48 hours before each blood collection for 
clinical laboratory tests. 
6. 
STUDY ASSESSMENTS 
The Schedule of Assessments is provided in Table 1. Study visits should be scheduled for the 
morning. All assessments, except for postdose PK sample collection, are to be performed prior to 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
48 
dosing at dosing visits. Additional information on the collection of study assessments will be 
detailed in the Study Manual. 
Where applicable country and local regulations and infrastructure for home healthcare allow, 
home healthcare may take place at a location other than the clinical study site to perform study 
assessments, which may include collection of blood and urine samples and measurement of vital 
signs and weight (at the discretion of the Investigator). 
6.1. 
Screening Assessments 
An ICF that has been approved by the appropriate Institutional Review Board (IRB)/IEC must be 
signed by the patient or legal guardian before the screening procedures are initiated. All patients 
or their legal guardians will be given a copy of the signed and dated ICF. 
Patients will be screened to ensure that they meet all the inclusion criteria and none of the 
exclusion criteria. Rescreening of patients is permitted with consultation of the Medical Monitor 
(see Section 6.1.2). 
Patient demographic data and medical history/disease history will be obtained. Any changes to 
medical history occurring between the screening assessment and Day 1 will be updated prior to 
study drug administration. 
6.1.1. 
Retesting  
If in the Investigator’s judgement, the screening laboratory abnormalities are likely to be 
transient, then laboratory tests may be repeated. The Investigator’s rationale should be 
documented. Laboratory values can be retested once during screening provided that the patient 
can be evaluated for eligibility after at least 4 weeks of washout and randomized within the 
allowed Screening period. Retesting of screening ABPM is permitted once as described in 
Section 6.2.1, with eligibility assessed by the second ABPM result. 
6.1.2. 
Rescreening 
A patient who does not meet all study eligibility criteria due to a transient condition observed at 
screening (eg, prohibited medications that were subsequently discontinued) will be allowed to 
return once for rescreening. A patient will be re-consented if rescreening occurs outside of the 
60-day screening window. In this case, all screening procedures must be repeated. 
6.2. 
Efficacy Assessments 
All blood pressure measurements (ABPM, office, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in 
Section 10.1.  
In patients taking oral antihypertensives, a washout of at least 4 weeks must be completed prior 
to measurement of the baseline ABPM (for eligibility) and baseline office blood pressure. The 
baseline ABPM and office blood pressure must be measured within 2 weeks before 
randomization. An HBPM unit will be provided during the Screening period to facilitate 
monitoring during the washout of prior oral antihypertensives (if taking) and to establish the 
HBPM baseline prior to randomization. HBPM must be collected after at least 4 weeks of 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
49 
washout for at least 2 consecutive weeks (at least 3 recordings per week) prior to randomization 
to establish baseline. 
ABPM placement may be performed at home by appropriately trained individuals, as detailed in 
the Study Manual. If a patient is unable to report to the site for an office blood pressure 
assessment, a substitute “remote visit blood pressure measurement” may be obtained remotely 
using the methods described in Section 10.1. 
Recommendations for approach and monitoring of low blood pressure/hypotension and 
hypertensive escape are provided in Section 5.4.1 and Section 5.4.2, respectively. 
6.2.1. 
ABPM 
In patients taking oral antihypertensives (including those initiated as rescue medication), ABPM 
must be started prior to the morning dose of antihypertensive medication.  
Adequacy will be assessed for all ABPMs. If the ABPM recording is inadequate, the patient will 
be provided 1 opportunity to repeat the study. If the second ABPM recording is also inadequate 
during screening, the patient is a screen failure.  
See further details in Section 10.1 and the Study Manual. 
6.2.2. 
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor at trough (prior to taking oral antihypertensives) and at approximately the same time 
each day; therefore, visits should be scheduled at approximately the same time of day, whenever 
possible. Office blood pressure must include orthostatic measurements (seated and standing).  
Exercise, caffeine, alcohol consumption, and use of nicotine or tobacco-containing products 
(including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, nicotine patches, or 
e-cigarettes) must be avoided within 30 minutes prior to blood pressure measurements. The use 
of inhaled short-acting beta agonists should be avoided within 6 hours prior to measuring blood 
pressure and/or heart rate. The use of phosphodiesterase type 5 inhibitors (eg, sildenafil, 
tadalafil, vardenafil, avanafil) should be avoided within 48 hours prior to measuring blood 
pressure. 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the Study Manual.  
6.2.3. 
HBPM 
The HBPM should be measured in the morning upon waking, prior to breakfast/caffeine or 
taking morning oral medications. HBPM is not required at times when ABPM is being assessed. 
The patient should be seated comfortably with the back supported and the feet flat on the floor as 
detailed in Section 10.1 and the Study Manual. 
6.2.4. 
Exploratory Wearable Blood Pressure Assessment 
Approximately 100 patients at select sites will be given the option of using a wearable blood 
pressure sensor for 2 periods of 2 to 4 weeks each according to the Schedule of Assessments 
(Table 1). Wearable blood pressure assessments performed during screening should be obtained 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
50 
after at least 4 weeks of washout. Participation will be contingent upon individual patient 
consent. These noninvasive, cuffless devices are worn on the finger or wrist as described in the 
Study Manual, using the opposite arm as that used for ABPM. 
6.3. 
Pharmacodynamic Assessments 
Blood samples for determination of AGT and RAAS biomarkers (plasma renin concentration, 
AngI, AngII, and aldosterone) will be collected according to the Schedule of Assessments 
(Table 1). Blood samples collected for AngI and AngII require special processing and will be 
assessed at sites that have appropriate resources, equipment, and reagents. Blood samples for PD 
assessments must be collected before study drug administration (on days when study drug is to 
be dosed) or at a time point corresponding to the time of study drug dosing (on other days). 
Levels of aldosterone will also be analyzed in urine collections at the time points listed in the 
Schedule of Assessments (Table 1). Blood AGT levels will be analyzed at a central laboratory by 
enzyme-linked immunosorbent assay for measurement of PD effect. These biomarkers may be 
analyzed using qualified assays. Details regarding the collection, processing, shipping, and 
storage of the samples will be provided in the Laboratory Manual.  
Results will not be used to adjust dosing of ALN-AGT01 or guide other elements of study 
conduct or clinical management and will not be shared with sites until after study completion. If 
clinical circumstances arise for which such information is required to guide patient care, local 
laboratory assessments should be drawn. 
6.4. 
Pharmacokinetic Assessments 
Blood samples will be collected for the assessment of plasma concentrations of ALN-AGT01 
and its primary metabolite AS(N-1)3′ ALN-AGT01 at the time points indicated in the Schedule 
of Assessments (Table 1). A detailed schedule of time points for the collection of blood samples 
for PK analysis is in Table 2. 
Plasma concentrations of ALN-AGT01 and AS(N-1)3′ ALN-AGT01 will be determined using a 
validated assay. Details regarding sample volumes to be collected, and the processing, shipping, 
and analysis of the samples will be provided in the Laboratory Manual. 
6.5. 
Safety Assessments 
The assessment of safety during the study will consist of the surveillance and recording of AEs, 
including SAEs, recording of concomitant medication and measurements of vital signs, weight, 
electrocardiogram (ECG) findings, and laboratory tests. Clinically significant abnormalities 
observed during the physical examination are recorded. 
6.5.1. 
Vital Signs 
Vital signs will be measured as specified in the Schedule of Assessments (Table 1) and include 
blood pressure, heart rate, body temperature, and respiratory rate. When vital signs and blood 
sample collection occur at the same time, vital signs should be performed before blood samples 
are drawn, where possible. Vital signs should be measured predose in the seated position, after 
the patient has rested comfortably for 10 minutes. Body temperature in degrees Celsius will be 
obtained via oral, tympanic, or axillary methods. Heart rate will be counted for a full minute and 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
51 
recorded in beats per minute, and respiration rate will be counted for a full minute and recorded 
in breaths per minute. Blood pressure is described in Section 6.2.  
Additional vital sign assessments, as medially indicated, may be added at the discretion of the 
Investigator, or as per DMC advice. 
Vital signs results will be recorded in the eCRF. 
6.5.2. 
Weight, Height, and Morphometrics 
Height and body weight measurements will be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded in the eCRF. Height will be measured at screening 
only. Height will be measured in centimeters. Body weight should be measured in kilograms to 
the first decimal point in patients wearing light clothing and without shoes.  
Waist circumference and waist-to-hip-ratio will also be collected as specified in the Schedule of 
Assessments (Table 1) and will be recorded on the eCRF. For waist circumference and waist-to-
hip ratio, patients should wear minimal clothing to ensure that the measuring tape is correctly 
positioned. Patients should stand erect with the abdomen relaxed, arms at the sides, feet together 
and with their weight equally divided over both legs. To perform the waist measurement, the 
lowest rib margin is first located and marked with a pen. The iliac crest is then palpated in the 
midaxillary line, and also marked. It is recommended to apply an elastic tape horizontally 
midway between the lowest rib margin and the iliac crest, and tie firmly so that it stays in 
position around the abdomen about the level of the umbilicus. The elastic tape thus defines the 
level of the waist circumference, which can then be measured by positioning the measuring tape 
over the elastic tape. Hip circumference measurement should be taken around the widest portion 
of the buttocks.[Ma 2004] Patients are asked to breathe normally, and to breathe out gently at the 
time of the measurement to prevent them from contracting their muscles or from holding their 
breath. A stretch-resistant tape that provides a constant 100 g of tension is recommended. 
Measurements should be obtained with the tape positioned parallel to the floor and performed 
using the same procedure throughout the study. 
The reading is taken to the nearest centimeter and entered in the source document. Each 
measurement should be repeated twice; if the measurements are within 1 cm of each other, the 
average should be calculated. If the difference between the 2 measurements exceeds 1 cm, the 2 
measurements should be repeated.[Ma 2004] 
6.5.3. 
Physical Examination 
Full and symptom-directed physical examinations will be conducted according to the Schedule 
of Assessments (Table 1); if a physical examination is scheduled for a dosing visit, it should be 
conducted prior to dosing. Full physical examinations will include the examination of the 
following: general appearance; head, eyes, ears, nose and throat; respiratory, cardiovascular, 
gastrointestinal, musculoskeletal, and dermatological systems; thyroid; lymph nodes; and 
neurological status. 
Symptom-directed physical examinations will be guided by evaluation of changes in symptoms, 
or the onset of new symptoms, since the last visit. 
Clinically significant abnormalities observed during the physical examination are recorded on 
the medical history or AE eCRF. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
52 
6.5.4. 
Electrocardiogram 
The 12-lead ECGs reporting rhythm, ventricular rate, RR interval, PR interval, QRS duration, 
and QT interval and Fridericia-corrected QT interval will be obtained using a local machine, as 
specified in the Schedule of Assessments (Table 1). Patients should be supine for at least 10 
minutes before each ECG is obtained. The Investigator or qualified designee will review all 
single 12-lead ECGs to assess whether the results have changed since the Baseline visit and to 
determine the clinical significance of the results. These assessments will be recorded in the 
eCRF.  
When ECG and blood sample collection occur at the same visit, blood sample collection should 
occur first. ECGs should be performed at least 30 minutes after phlebotomy or other stressful 
assessments. 
The Investigator or qualified designee will review all ECGs to assess whether the results have 
changed since the baseline visit and to determine the clinical significance of the results. These 
assessments will be recorded in the eCRF. Additional ECGs may be collected at the discretion of 
the Investigator, or as per DMC advice. Recordings will be archived according to the Study 
Manual. 
6.5.5. 
Clinical Laboratory Assessments 
The following clinical laboratory tests will be evaluated by a central laboratory. Specific 
instructions for transaminase elevations are provided in Section 6.5.6.4. For any other 
unexplained clinically relevant abnormal laboratory test occurring after study drug 
administration, the test should be repeated and followed up at the discretion of the Investigator, 
or as per DMC advice, until it has returned to the normal range or stabilized, and/or a diagnosis 
is made to adequately explain the abnormality. Additional safety laboratories and assessments as 
indicated by the clinical situation may be requested. Clinical laboratory assessments are listed in 
Table 6 and will be assessed as specified in the Schedule of Assessments (Table 1).  
While local laboratory results may be used for urgent clinical decisions, on the day of the 
assessments all laboratory assessments specified in Table 6 which are performed at the clinic 
should also be sent in parallel to the central laboratory. In the case of discrepant local and central 
laboratory results on samples drawn on the same day, central laboratory results will be relied 
upon for clinical decisions. 
Clinical laboratory assessments may be collected at the clinical study center or at home by a 
trained healthcare professional. Blood samples collected for RAAS biomarkers should be 
collected in the morning and in the seated/upright position (after blood pressure measurements 
and before any assessments collected in the supine position). 
Spot urine collections for albumin and creatinine should be obtained in the morning. A 24-hour 
urine collection for aldosterone, sodium, and creatinine will be performed at time points listed in 
the Schedule of Assessments (Table 1). These 24-hour collections should be obtained within 2 
days before the ABPM associated with the same visit. 
For any safety event or laboratory abnormality, additional laboratory assessments, imaging, and 
consultation may be performed for clinical evaluation and/or in consultation with the Medical 
Monitor; results may be collected and should be included in the clinical database. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
53 
Table 6: 
Clinical Laboratory Assessments  
Hematology 
Complete blood count with differential 
 
Serum Chemistry 
Sodium 
Potassium 
BUN 
Phosphate 
Uric acid 
Albumin 
Total protein 
Calcium 
Glucose 
Bicarbonate 
Creatinine 
Chloride 
Liver Function Tests 
 
AST 
ALP 
ALT 
Bilirubin (total and direct) 
GGT 
 
Urinalysis 
Visual inspection for appearance and color 
Bilirubin 
pH (dipstick) 
Nitrite 
Specific gravity 
RBCs 
Ketones 
Urobilinogen 
Albumin 
Leukocytes 
Glucose 
Microscopy (if clinically indicated) 
Protein 
 
Coagulation  
Prothrombin time 
International normalized ratio 
Partial thromboplastin time  
 
Hepatitis Tests  
Hepatitis A, including: 
HAV antibody IgM and IgG 
Hepatitis B, including:  
HBsAg, HBc antibody IgM and IgG 
Hepatitis C, including:  
HCV antibody 
HCV RNA PCR – qualitative and quantitative 
assays 
Hepatitis E, including: 
HEV antibody IgM and IgG 
Fasting Lipid Panel and Glycemic Assessments (see Section 6.5.5.1) 
Lipid panel, including 
HDL-C, non-HDL-C, LDL-C, apolipoprotein A1, 
triglycerides, total cholesterol  
Insulin 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
54 
Fasting glucose 
HbA1c 
Immunogenicity (see Section 6.5.5.2) 
ADA 
 
Pregnancy Testing/FSH Screening (see Section 6.5.5.3) 
β-human chorionic gonadotropin (females of 
child-bearing potential only) 
Follicle-stimulating hormone (postmenopausal 
women only) 
Abbreviations: ADA=anti-drug antibodies; ALP=alkaline phosphatase; ALT=alanine aminotransferase; 
AST=aspartate aminotransferase; BUN=blood urea nitrogen; FSH=follicle-stimulating hormone; GGT=gamma 
glutamyl transferase; HAV=hepatitis A virus; HbA1c=hemoglobin A1c; HBc=hepatitis B virus core; 
HBsAg=hepatitis B virus surface antigen; HCV=hepatitis C virus; HDL-C=high-density lipoprotein; 
HEV=hepatitis E virus; IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; LDL-C=low-
density lipoprotein; PCR=polymerase chain reaction; RBCs=red blood cells; RNA=ribonucleic acid. 
6.5.5.1. 
Fasting Lipid Panel and Glycemic Assessments 
Blood samples for fasting glucose, insulin, lipid panel (including total cholesterol, high-density 
lipoprotein [HDL-C], non-HDL-C, low-density lipoprotein, apolipoprotein A1, and 
triglycerides), and HbA1c will be collected at the time points listed in the Schedule of 
Assessments (Table 1). Patients are required to fast for ≥10 hours before sample collection for 
fasting glucose, insulin, lipid panel, and HbA1c. Samples should be collected at approximately 
the same time of day (±2 hours). 
6.5.5.2. 
Immunogenicity 
Blood samples will be collected to evaluate anti-drug antibodies (ADA). Blood samples for ADA 
testing must be collected before study drug administration (on days when study drug is to be 
dosed) or at a time point corresponding to the time of study drug dosing (on other days) as 
specified in the Schedule of Assessments (Table 1). A blood sample to evaluate ADA will be 
collected at the ET visit, if applicable. Blood samples for ADA will be analyzed at a central 
laboratory. 
Details regarding the processing, shipping, and analysis of the samples will be provided in the 
Laboratory Manual. 
6.5.5.3. 
Pregnancy Testing 
A pregnancy test will be performed for females of child-bearing potential. A serum pregnancy 
test will be performed at screening, and urine pregnancy tests will be performed thereafter per 
the Schedule of Assessments and any time pregnancy is suspected. More frequent pregnancy 
testing may be performed where required per local requirements. The results of the pregnancy 
test must be known before study drug administration. Patients who are pregnant at screening are 
not eligible for study participation. Any woman with a positive urine pregnancy test, 
subsequently confirmed by a positive serum pregnancy test, during the study will be 
discontinued from study drug but will continue to be followed for safety. Patients determined to 
be pregnant while on study will be followed at least until the pregnancy outcome is known (see 
Section 6.5.6.7 for follow-up instructions). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
55 
A blood sample will be drawn at screening to measure the levels of follicle stimulating hormone 
in order to confirm postmenopausal status in all women suspected to be postmenopausal (see 
Section 5.7.1 for definition of postmenopausal state). 
6.5.5.4. 
Additional Liver Function Assessments 
Additional laboratory assessments will be performed in patients who experience any LFT 
abnormalities as outlined in Section 5.2.4. Following the occurrence of elevated liver 
transaminases or other LFT abnormalities per central laboratory, all assessments in Table 7 will 
be performed 1 time, as well as hematology, serum chemistry, LFT, and coagulation assessments 
from Table 6, and other assessments or evaluations per Investigator discretion, as appropriate.  
Monitoring, including criteria for dose modification or withholding the study drug, is described 
in Section 5.2.4.  
Table 7: 
Hepatic Assessments in Patients Who Experience Elevated Transaminases 
Extended Hepatic Panel 
HBsAg, HBc antibody IgM and IgG 
Parvovirus B19 
HAV antibody IgM 
HHV-6 
HCV antibody 
Anti-nuclear antibodies 
HCV RNA PCR – qualitative and quantitative 
Anti-smooth muscle antibodies 
HEV antibody IgM 
Anti-LKM1 antibody 
Herpes Simplex Virus 1 and 2 antibody IgM, IgG 
Anti-mitochondrial antibodies 
Herpes Zoster Virus IgM, IgG 
Anti-SLA 
Epstein-Barr Virus antibodies, IgM, and IgG 
Ferritin 
Cytomegalovirus antibodies, IgM, IgG 
Ceruloplasmin 
Imaging 
Abdominal ultrasound with Doppler flow (or CT or MRI) including right upper quadrant 
Focused Medical and Travel History 
Use of any potentially hepatotoxic concomitant 
medications, including over the counter medications 
and herbal remedies 
Alcohol consumption and drugs of abuse 
Other potentially hepatotoxic agents including any 
work-related exposures 
Recent travels to areas where hepatitis A or E 
is endemic 
Abbreviations: CT=computed tomography; HAV=hepatitis A virus; HBc=hepatitis B core; HBsAg=hepatitis B 
virus surface antigen; HCV=hepatitis C virus; HEV=hepatitis E virus; HHV-6=human herpesvirus 6; 
IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; LKM1=liver/kidney microsome-1 
antibody; MRI=magnetic resonance imagery; PCR=polymerase chain reaction; RNA=ribonucleic acid; 
SLA=soluble liver antigen 
Note: 
• 
All assessments will be measured in central laboratory. The full panel of assessments should only be 
performed once; individual assessments may be repeated, as needed. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
56 
6.5.6. 
Adverse Events 
6.5.6.1. 
Definitions 
Adverse Event 
According to the ICH E2A guideline Definitions and Standards for Expedited Reporting, and 21 
Code of Federal Regulations 312.32, Investigational New Drug Safety Reporting, an AE is any 
untoward medical occurrence in a patient or clinical investigational subject administered a 
medicinal product and which does not necessarily have a causal relationship with this treatment. 
Serious Adverse Event 
An SAE is any untoward medical occurrence that at any dose: 
• Results in death 
• Is life-threatening (an event which places the patient at immediate risk of death from 
the event as it occurred. It does not include an event that had it occurred in a more 
severe form might have caused death) 
• Requires inpatient hospitalization or prolongation of existing hospitalization 
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly or birth defect 
• Is an important medical event that may not be immediately life-threatening or result 
in death or hospitalization but may jeopardize the patient and may require 
intervention to prevent one of the other outcomes listed in the definition above (eg, 
events include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home, blood dyscrasias, convulsions, or the development of drug 
dependency or abuse). 
Adverse Events of Clinical Interest 
The following are considered to be AEs of clinical interest: 
• ALT or AST >3×ULN 
• Severe or serious ISRs; ISRs that are associated with a recall phenomenon (reaction 
at the site of a prior injection with subsequent injections), or those that lead to 
temporary dose interruption or permanent discontinuation of ALN-AGT01. 
An ISR is defined as a local reaction at or near the site of injection. “At or near” the injection site 
includes reactions at the injection site, adjacent to the injection site, or a reaction which may shift 
slightly away from the injection site due to gravity (eg, as may occur with swelling or 
hematoma). A systemic reaction which includes the injection site, eg, generalized urticaria, other 
distinct entities or conditions like lymphadenopathy that may be near the injection site is not 
considered an ISR. 
For information on recording and reporting of AEs of clinical interest, see Section 6.5.6.2 and 
Section 6.5.6.3, respectively. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
57 
Adverse Event Severity 
Adverse events are to be graded according to the categories detailed below: 
Mild: 
Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated. 
Moderate: 
Moderate; minimal, local, or noninvasive intervention indicated; 
limiting age appropriate instrumental activities of daily living (eg, 
preparing meals, shopping for groceries or clothes, using the telephone, 
managing money). 
Severe: 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self-care activities of daily living (ie, bathing, dressing and 
undressing, feeding self, using the toilet, taking medications, and not 
bedridden); OR life-threatening consequences; urgent intervention 
indicated; OR death related to an adverse event. 
Changes in severity should be documented in the medical record to allow assessment of the 
duration of the event at each level of severity. Adverse events characterized as intermittent 
require documentation of the start and stop of each incidence. When changes in the severity of an 
AE occur more frequently than once a day, the maximum severity for the experience that day 
should be noted. If the severity category changes over a number of days, then those changes 
should be recorded separately (with distinct onset dates). 
Adverse event severity and seriousness are assessed independently. ‘Severity’ characterizes the 
intensity of an AE. ‘Serious’ is a regulatory definition and serves as a guide to the Sponsor for 
defining regulatory reporting obligations (see definition for SAE). 
Relationship of the Adverse Event to Study Drug 
The relationship of each AE to study drug should be evaluated by the Investigator by a “yes” or 
“no” response to the question: “Is there a reasonable possibility that the event may have been 
caused by the study drug?” A “yes” response indicates that the event is considered as related to 
the study drug. 
6.5.6.2. 
Eliciting and Recording Adverse Events 
Eliciting Adverse Events 
The patient and legal guardian, if applicable, should be asked about medically relevant changes 
in the patient’s health since the last visit. The patient and legal guardian, if applicable, should 
also be asked if the patient has been hospitalized, had any accidents, used any new medications, 
or changed concomitant medication routines (both prescription and over-the-counter). In addition 
to patient observations, AEs will be documented from any clinically relevant laboratory findings, 
physical examination findings, ECG changes, or other findings that are relevant to patient safety. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
58 
Recording Adverse Events 
The Investigator is responsible for recording non-serious AEs that are observed or reported by 
the patient after administration of the first dose of study drug regardless of their relationship to 
study drug through the end of study. Non-serious AEs will be followed until the end of study. 
Events occurring after signing of the ICF and before study drug administration will be captured 
as medical history (see Section 6.1), while AEs that occur after study drug administration, and 
baseline events that worsen after study drug administration, must be recorded as AEs.  
The Investigator is responsible for recording SAEs that are observed or reported by the patient 
after the time when the informed consent is signed regardless of their relationship to study drug 
through the end of study. SAEs will be followed until satisfactory resolution, until baseline level 
is reached, or until the SAE is considered by the Investigator to be chronic or the patient is 
stable, as appropriate. 
All AEs must be recorded in the source records for the clinical study center and in the eCRF for 
the patient, whether or not they are considered to be drug-related. Each AE must be described in 
detail: onset time and date, description of event, severity, relationship to study drug, action taken, 
and outcome (including time and date of resolution, if applicable). 
For SAEs, record the event(s) in the eCRF and, as applicable, the SAE form. 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the supplemental AEs of 
Clinical Interest eCRF should be completed. Additional clinical and laboratory information may 
be collected. Refer to CRF completion guidelines for details on reporting events in the 
supplemental AEs of Clinical Interest eCRF. 
For all ISRs, the Investigator, or delegate, should submit an Injection Site Reaction Signs or 
Symptoms eCRF, recording additional information regarding each injection site reaction that is 
entered on the AE eCRF (eg, symptom(s), injection site location, follow-up actions taken, etc). 
6.5.6.3. 
Reporting Adverse Events of Clinical Interest to Sponsor/Designee 
For AEs that are considered AEs of clinical interest (Section 6.5.6.1), the Sponsor or its designee 
should be notified within 24 hours using the appropriate eCRF. 
6.5.6.4. 
Serious Adverse Events Require Immediate Reporting to Sponsor/Designee 
An assessment of the seriousness of each AE will be made by the Investigator. Any AE and 
laboratory abnormality that meets the SAE criteria in Section 6.5.6.1 must be reported to the 
Sponsor or designee within 24 hours from the time that clinical study center staff first learns of 
the event. All SAEs must be reported regardless of the relationship to study drug. 
The initial report should include at least the following information: 
• Patient’s study number 
• Description and date of onset of the event 
• Criterion for serious 
• Preliminary assignment of relationship to study drug, and 
• Investigator/site information 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
59 
To report the SAE, complete the eCRF and, as applicable, the SAE form. Within 24 hours of 
receipt of follow-up information, the Investigator must update the eCRF and, as applicable, the 
SAE form. Serious adverse events must be reported using the contact information provided in the 
Study Manual. 
Appropriate remedial measures should be taken by the Investigator using his/her best medical 
judgment to treat the SAE. These measures and the patient’s response to these measures should 
be recorded. All SAEs, regardless of relationship to study drug, will be followed by the 
Investigator until satisfactory resolution or the Investigator deems the SAE to be chronic or 
stable. Clinical, laboratory, and diagnostic measures should be employed by the Investigator as 
needed to adequately determine the etiology of the event. 
6.5.6.5. 
Sponsor Safety Reporting to Regulatory Authorities 
The Sponsor or its representative will report certain study events in an expedited manner to the 
Food and Drug Administration, the European Medicines Agency’s EudraVigilance electronic 
system according to Directive 2001/20/EC, and to all country Regulatory Authorities where the 
study is being conducted, according to local applicable regulations. 
6.5.6.6. 
Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee 
Suspected unexpected serious adverse reactions will be reported to the IRB/IEC per their 
institutional policy by the Investigator or Sponsor (or Sponsor designee) according to country 
requirements. Copies of each report and documentation of IRB/IEC notification and 
acknowledgement of receipt will be kept in the Investigator’s study file. 
6.5.6.7. 
Pregnancy Reporting 
If a female patient becomes pregnant during the study through safety follow-up (Section 3.1), the 
Investigator must report the pregnancy to the Sponsor or designee within 24 hours of being 
notified of the pregnancy. Details of the pregnancy will be recorded on the pregnancy reporting 
form. The patient should receive any necessary counseling regarding the risks of continuing the 
pregnancy, the possible effects on the fetus, and be counseled not to breastfeed for 90 days after 
the last dose of study drug. 
The pregnancy should be followed by the Investigator until completion. At the completion of the 
pregnancy, the Investigator will document the outcome of the pregnancy. If the outcome of the 
pregnancy results in a postpartum complication, spontaneous abortion, stillbirth, neonatal death, 
or congenital anomaly, then the Investigator should follow the procedures for reporting an SAE 
as outlined in Section 6.5.6.4. 
6.5.6.8. 
Overdose and Other Special Situations Reporting 
An overdose is defined as any dose of study drug administered to the participant or taken by the 
participant that is >2× the assigned dose during a single administration and/or ≥2 doses within ½ 
the intended dosing interval. 
The Sponsor does not recommend specific treatment for an overdose.  


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
60 
In an event of an overdose or other special situations (eg, medication error, abuse, misuse, CPC 
associated with an AE), the Investigator should: 
• Contact the Medical Monitor within 24 hours  
• Submit the special situations reporting form within 24 hours using the contact 
information in the Pharmacy Manual 
• Closely monitor the participant for any AE/SAE and laboratory abnormalities 
• Document the amount of study drug given  
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or 
a concomitant medication will be considered AEs/SAEs.  
Full details of overdose and other special situations reporting instructions will be outlined in the 
Pharmacy Manual. 
6.6. 
Biomarkers, DNA Genotyping, and Biospecimen Repository 
Alnylam’s RNAi therapeutics platform permits the highly specific targeting of investigational 
therapies based on genetic sequence. It is possible that variations in the target genetic sequence 
will result in variations in drug effect. More generally, genetic variations may account for the 
well-described heterogeneous manifestations of disease in patients with hypertension, as well as 
their responses to treatment. 
Where allowed per local regulations, ethics committee (IRB/IEC) approval, and patient consent, 
samples will be collected as part of this study to permit exploratory investigations and the 
application of novel approaches to bioanalyses that may further elucidate the outcomes of this 
study, or potentially advance understanding of the safety, mechanism of action, and/or efficacy 
of ALN-AGT01. 
Biological specimens will be collected at the intervals indicated in the Schedule of Assessments 
(Table 1). In addition to the dedicated collections for optional exploratory biomarkers (urine, 
plasma, serum), aliquots from each 24 hour urine collection will be archived for potential 
exploratory investigations. These specimens will be analyzed at a central laboratory. Potential 
exploratory investigations may include DNA, RNA, or biochemical metabolite assessments as 
they relate to disease progression, efficacy, or safety. 
The biospecimen repository will also include residual material from routine samples (safety 
laboratory samples, PK samples, etc) that are obtained during the study. 
These specimens will be securely stored in a central biorepository for up to 10 years following 
the completion of this clinical study (ie, last patient last visit), or as per local regulations. After 
10 years have elapsed, samples will be destroyed. 
Details regarding the collection, processing, storage, and shipping of the samples will be 
provided in the Laboratory Manual. 
Exploratory analysis of these biospecimens will be performed by Alnylam Pharmaceuticals or its 
designees. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
61 
When biobanking is permitted by local regulation, study participants will be advised during the 
informed consent process of these biobanking details and the potential for exploratory 
investigation of their samples. 
7. 
STATISTICS 
A Statistical Analysis Plan (SAP) will be finalized before database lock and unblinding for the 
primary analysis. The plan will detail the implementation of the statistical analyses in accordance 
with the principle features stated in the protocol. 
7.1. 
Determination of Sample Size 
Assuming a standard deviation in the range of 15 to 20 mmHg in change from baseline in 
24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size between 
ALN-AGT01 and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size of 375 
patients (75 per treatment group) provides at least 84% power to detect a dose response 
relationship in SBP reduction among all ALN-AGT01 doses and placebo at the 2-sided 
significance level of 0.05. In addition, this sample size provides at least 80% power to detect a 10 
mmHg difference between an individual ALN-AGT01 dose versus placebo with a 2-sided 
significance level of 0.05. Table 8 shows the statistical power with various standard deviation 
assumptions. 
Table 8: 
Statistical Power to Detect 10 mmHg Difference Between ALN-AGT01 and 
Placebo With Various Standard Deviation Assumptions 
Assumption of Standard 
Deviation (mmHg) 
Statistical Power to Detect 
Dose Response Trend (%) 
Statistical Power to Detect Difference 
Between an Individual ALN-AGT01 
Dose Versus Placebo (%) 
15 
97 
96 
18 
90 
88 
20 
84 
80 
7.2. 
Statistical Methodology 
The statistical and analytical plans presented below are brief summaries of planned analyses. 
More complete plans will be detailed in the SAP. Changes to the methods described in the final 
SAP will be described and justified as needed in the clinical study report. For information on 
study endpoints, see Section 2. 
7.2.1. 
Populations to be Analyzed 
The populations (analysis sets) are defined as follows: 
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
62 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• PK Analysis Set: All patients who received at least 1 full dose of study drug and 
have at least 1 evaluable postdose blood sample for the determination of plasma 
ALN-AGT01 concentrations. 
• PD Analysis Set: All patients who received any amount of study drug and who have 
baseline and at least 1 postdose blood sample for the determination of serum AGT 
will be included in the PD analyses. 
The primary population used to evaluate efficacy will be the FAS. For the efficacy endpoints of 
change from baseline to Month 3, ALN-AGT01 300 mg once every 3 months and once every 6 
months will be pooled together and analyzed. For all other efficacy endpoints, analysis will be 
performed according to the randomized treatment arm. 
Safety will be analyzed using the Safety Analysis Set. The PK and PD Analysis Sets will be used 
to conduct PK and PD analyses, respectively. 
7.2.2. 
Examination of Subgroups 
Subgroup analyses will be conducted for selected endpoints. Subgroup categories and detailed 
methodology will be provided in the SAP. 
7.2.3. 
Handling of Missing Data 
Handling of missing data will be described in the SAP. 
7.2.4. 
Baseline Evaluations 
Demographics and other disease-specific baseline characteristics will be summarized. 
In general, baseline will be defined as the average of all assessments, including unscheduled 
assessments, prior to the first dose of study drug. Details of the definition will be specified in the 
SAP. 
7.2.5. 
Efficacy Analyses 
The primary endpoint is the change in SBP from baseline at Month 3 assessed by ABPM. The 
primary hypothesis of the dose response relationship for the primary endpoint across 
ALN-AGT01 doses and placebo will be tested using a multiple comparison– modeling (MCP 
Mod) approach.[Bretz 2005] The presence of a dose-response trend will be initially tested 
against a set of prespecified dose-response models at a 2-sided significance level of 0.05, 
adjusted for multiplicity (the MCP step). Several candidate models will be prespecified in the 
SAP. Then, the dose-response curves will be further estimated (the modeling step) based on the 
‘best’ fitted dose response model. Furthermore, each ALN-AGT01 dose group will be compared 
against placebo using Dunnett’s Test.  
For the secondary endpoints of change in DBP assessed by ABPM at Month 3 and change in 
SBP and DBP assessed by ABPM at Month 6, each ALN-AGT01 dose group will be compared 
with placebo. For change in office SBP and DBP, each ALN-AGT01 dose group will be 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
63 
compared with placebo at Month 3 and Month 6 and also using the time-adjusted average from 
Month 1 to Month 3 and from Month 1 to Month 6. 
No multiplicity adjustment is applied across primary and secondary endpoints.  
Details of the analysis method for primary, secondary, and exploratory endpoints will be 
described in the SAP. 
7.2.6. 
Pharmacodynamic Analysis 
Pharmacodynamic analyses will include the evaluation of changes in levels of serum AGT and 
other exploratory biomarkers of the RAAS pathway. Descriptive statistics for observed levels 
and the relative change from baseline for all measured biomarkers will be presented for each of 
the postdose time points. 
Statistical comparison of the biomarker levels (absolute and/or change from baseline) across 
treatment groups may be explored. Details of the analysis will be specified in the SAP.  
Population PK/PD analysis may be conducted to evaluate the dose-response relationships for PD 
lowering after ALN-AGT01 treatment. Additionally, the relationship between lowering of serum 
AGT and blood pressure may be explored within a modeling framework. If conducted, these 
analyses will be described in a pharmacometrics analysis plan and results will be presented in a 
separate report. 
7.2.7. 
Pharmacokinetic Analysis 
Plasma concentrations of ALN-AGT01 and its metabolite AS(N-1)3′ ALN-AGT01 will be 
summarized using descriptive statistics. 
Population PK analysis may be conducted on the PK data from this study. If conducted, the 
analysis methods will be described in a pharmacometrics analysis plan and results will be 
presented in a separate report. 
7.2.8. 
Safety Analyses 
The primary parameter is the frequency of treatment-emergent AEs (hereafter referred to simply 
as AEs). Safety parameters also include vital signs, ECGs, clinical laboratory assessments and 
physical exams. Extent of exposure will be summarized.  
Prior and concomitant medications will be coded using the World Health Organization Drug 
Dictionary. Results will be tabulated by Anatomical Therapeutic Chemical Classification System 
and Preferred Term (PT). 
Adverse events will be classified according to the Medical Dictionary for Regulatory Activities 
(MedDRA) System Organ Class (SOC) and PT. Adverse events, SAEs, related AEs, AEs leading 
to discontinuation of study drug, and AEs leading to death will be summarized by SOC and PT 
for each treatment arm. By-patient listings will be provided for deaths, SAEs, and AEs leading to 
discontinuation of study drug.  
Descriptive statistics will be provided for clinical laboratory parameters, ECG, and vital signs 
summarizing the observed values and changes from baseline over time. Laboratory shift tables 
from baseline grade (or category) to worst post-baseline grade (or category) will be presented for 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
64 
laboratory parameters that are graded or categorized. Abnormal physical exam findings will be 
presented in listings. 
Other safety summaries will be presented as appropriate. Further details will be specified in the 
SAP. 
7.2.9. 
Immunogenicity Analyses 
The frequency and percentage of patients with confirmed positive ADA assay at any time during 
the study as well as at each scheduled visit will be summarized. The titer results for patients with 
confirmed positive ADA results will be summarized. 
7.2.10. 
Interim Analysis 
The primary analysis will be conducted after all patients complete the Month 6 visit or withdraw 
from the study prior to the Month 6 visit. No formal interim analysis is planned before the 
primary analysis.  
7.2.11. 
Optional Additional Research 
Optional additional research may be conducted in the future on the biological samples and/or 
data collected during the study in accordance with the strict terms of the ICF (see Section 4.3.2). 
8. 
STUDY ADMINISTRATION 
8.1. 
Ethical and Regulatory Considerations 
This study will be conducted in accordance with the protocol, all applicable regulatory 
requirements, and the current guidelines of Good Clinical Practice (GCP). Compliance with GCP 
provides public assurance that the rights, safety, and well-being of study patients are protected 
consistent with the principles that have their origin in the Declaration of Helsinki. 
8.1.1. 
Informed Consent 
The Investigator will ensure that the patient is given full and adequate oral and written 
information about the nature, purpose, possible risk, and benefit of the study. Patients must also 
be notified that they are free to discontinue from the study at any time. The patient should be 
given the opportunity to ask questions and allowed time to consider the information provided. 
The Investigator will inform the patient/legal guardian if new information becomes available that 
may be relevant to the patient’s/legal guardian’s willingness to continue participation in the 
study. Communication of this information should be documented. 
The patient’s signed and dated informed consent must be obtained before conducting any study 
tests or procedures that are not part of routine care. 
The Investigator must maintain the original, signed ICF. A copy of the signed ICF must be given 
to the patient or legal guardian. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
65 
8.1.2. 
Ethical Review 
The study protocol, including the ICF, must be approved or given a favorable opinion in writing 
by an IRB or IEC, as appropriate. The Investigator must submit written approval before he or she 
can enroll any patient into the study. 
The Investigator is responsible for informing the IRB or IEC of any amendment to the protocol 
in accordance with local requirements. In addition, the IRB or IEC must approve all patient 
materials for the study. The protocol must be reapproved by the IRB or IEC upon receipt of 
amendments and annually, as local regulations require. 
Initial IRB or IEC approval of the protocol, and all materials approved by the IRB or IEC for this 
study including the patient consent form and recruitment materials must be maintained by the 
Investigator and made available for inspection. 
The Investigator will submit reports of SAEs as outlined in Section 6.5.6. In addition, the 
Investigator agrees to submit progress reports to the IRB or IEC per their local reporting 
requirements, or at least annually and at the conclusion of the study. The reports will be made 
available to the Sponsor or designee. 
Any communications from regulatory agencies, IRBs, or IECs in regard to inspections, other 
studies that impact this protocol or the qualifications of study personnel should be promptly 
reported to the Sponsor or its designee. 
The Investigator is also responsible for providing the IRB or IEC with reports of any reportable 
serious adverse drug reactions from any other study conducted with the study drug. The Sponsor 
or designee will provide this information to the Investigator. 
Major changes in this research activity, except those to remove an apparent immediate hazard to 
the patient, must be reviewed and approved by the Sponsor and the IRB or IEC that approved the 
study. Amendments to the protocol must be submitted in writing to the Investigator’s IRB or IEC 
and the Regulatory Authority for approval before patients are enrolled under the amended 
protocol, and patients or their legal guardians must be re-consented to the most current version of 
the ICF.  
8.1.3. 
Serious Breach of Protocol 
Investigators must notify the Medical Monitor within 24 hours of becoming aware of a potential 
serious breach of the protocol. A serious breach is a breach that is likely to affect to a significant 
degree the safety and rights of a study participant or the reliability and robustness of the data 
generated in the clinical study. 
8.1.4. 
Study Documentation, Confidentiality, and Records Retention 
All documentation (including personal data) relating to the study should be retained for 2 years 
after the last approval in an ICH territory or as required by local laws and regulations, whichever 
is longer. 
If it becomes necessary for the Sponsor, the Sponsor’s designee, applicable IRB/IEC, or 
applicable regulatory authorities to review or audit any documentation relating to the study, the 
Investigator must permit direct access to all source documents/data. Records will not be 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
66 
destroyed without informing the Sponsor in writing and giving the Sponsor the opportunity to 
store the records for a longer period of time at the Sponsor’s expense. 
The Investigator must ensure that the patients’ confidentiality will be maintained. On the eCRFs 
or other documents submitted to the Sponsor or designees, patients should not be identified by 
their names, but by the assigned patient number or code. If patient names are included on copies 
of documents to be submitted to the Sponsor or designees, the names will be obliterated, and the 
assigned patient number added to the document, before sending to the Sponsor. Documents not 
for submission to the Sponsor (eg, signed ICFs) should be maintained by the Investigator in strict 
confidence. 
The Investigator must treat all of the information related to the study and the compiled data as 
confidential, whose use is for the purpose of conducting the study. The Sponsor must approve 
any transfer of information not directly involved in the study. 
To comply with local and/or regional regulations, this clinical study may be registered, and study 
results may be posted on public registries, such as ClinicalTrials.gov. 
8.1.5. 
End of Study 
The end of study is defined as the last patient last visit. 
8.1.6. 
Termination of the Clinical Study or Site Closure 
The Sponsor, or designee, reserves the right to terminate the study or a clinical study site at any 
time. Conditions that may warrant this action may include, but are not limited to: 
• The discovery of an unexpected, serious, or unacceptable risk to patients participating 
in the study 
• Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of participants by the Investigator 
• The decision on the part of the Sponsor to suspend or discontinue treatment with the 
study drug 
Should the study be terminated, and/or the site closed for whatever reason, all documentation and 
study drug pertaining to the study must be returned to the Sponsor or its representative, and the 
Investigators, IRB/IEC and Regulatory Authorities will be promptly informed of the termination 
and the reason for the decision. The Investigator should promptly inform the patients and assure 
appropriate therapy and follow-up. 
8.2. 
Data Quality Control and Quality Assurance 
8.2.1. 
Data Handling 
Study data must be recorded on CRFs (paper and/or electronic) provided by the Sponsor or 
designee on behalf of the Sponsor. Case report forms must be completed only by persons 
designated by the Investigator. If eCRFs are used, study data must be entered by trained site 
personnel with access to a valid and secure eCRF system. All data entered into the eCRF must 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
67 
also be available in the source documents. Corrections on paper CRFs must be made so as to not 
obliterate the original data and must be initialed and dated by the person who made the 
correction. 
8.2.2. 
Study Monitoring 
The Monitor, as a representative of the Sponsor, has an obligation to closely follow the study 
conduct at the site. The Monitor will visit the Investigator and clinical study center periodically 
and will maintain frequent telephone and written contact. The Monitor will maintain current 
personal knowledge of the study through observation, review of study records and source 
documentation, and discussion of the conduct of the study with the Investigator and staff. 
The Monitor will review source documents, systems and CRFs to ensure overall quality and 
completeness of the data and to confirm study procedures are complied with the requirements in 
the study protocol accurately. The Sponsor, or its designee, will be allowed to conduct site visits 
to the investigation facilities for the purpose of monitoring any aspect of the study. The 
Investigator agrees to allow the Monitor to inspect the drug storage area, study drug stocks, drug 
accountability records, patient charts and study source documents, site standard operating 
procedures and training records, and other records relative to study conduct. 
8.2.3. 
Audits and Inspections 
Periodically, the Sponsor or its authorized representatives audit clinical investigative sites as an 
independent review of core study processes and documents to determine whether these activities 
were conducted, and data were recorded, analyzed, and accurately reported according to the 
protocol, GCP guidelines of the ICH, and any applicable regulatory requirements. A regulatory 
authority, an IEC or an IRB may visit the site to perform audits or inspections, including source 
data verification. The Investigator should contact the Sponsor and designee immediately if 
contacted by a regulatory agency, an IEC, or an IRB about an inspection. 
8.3. 
Publication Policy 
It is intended that after completion of the study, the data are to be submitted for publication in a 
scientific journal and/or for reporting at a scientific meeting. A copy of any proposed publication 
(eg, manuscript, abstracts, oral/slide presentations, book chapters) based on this study, must be 
provided and confirmed received at the Sponsor at least 30 days before its submission. The 
Clinical Trial Agreement will detail the procedures for publications. 
Authorship of any publications resulting from this study will be determined on the basis of the 
Uniform Requirement for Manuscripts Submitted to Biomedical Journals (International 
Committee of Medical Journal Editors). 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
68 
9. 
LIST OF REFERENCES 
Angell SY, De Cock KM,Frieden TR. A public health approach to global management of 
hypertension. Lancet. 2015 Feb 28;385(9970):825-7. 
Beeftink MM, van der Sande NG, Bots ML, Doevendans PA, Blankestijn PJ, Visseren FL, et al. 
Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-
to-Control Hypertension. Hypertension. 2017 May;69(5):927-32. 
Bretz F, Pinheiro JC,Branson M. Combining multiple comparisons and modeling techniques in 
dose-response studies. Biometrics. 2005 Sep;61(3):738-48. 
Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to 
antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011 Mar;29(3):610-8. 
de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M, et al. Prevalence and 
factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension. 
2009 Mar;53(3):466-72. 
Dzau VJ,Balatbat CA. Future of Hypertension. Hypertension. 2019 Sep;74(3):450-7. 
Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of 
Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 
2017 Jan 10;317(2):165-82. 
Georgianos PI,Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding 
drugs. Kidney Int. 2018 Feb;93(2):325-34. 
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK,He J. Global burden of 
hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23. 
Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the 
Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-30. 
Ma KK, Ogawa T,de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the 
transcriptional and translational levels by pro-inflammatory cytokines and by conditioned 
medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol. 
2004 Apr;36(4):505-13. 
McClellan M, Brown N, Califf RM,Warner JJ. Call to Action: Urgent Challenges in 
Cardiovascular Disease: A Presidential Advisory From the American Heart Association. 
Circulation. 2019 Feb 26;139(9):e44-e54. 
McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, et al. Aliskiren, 
Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016 Apr 21;374(16):1521-
32. 
Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP,Crooke RM. Blood Pressure 
Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of 
Hypertension and Kidney Injury. Hypertension. 2017 Sep;70(3):566-76. 
Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, et al. Trends in Blood 
Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020 
Sep 22;324(12):1190-200. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
69 
NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a 
pooled analysis of 1479 population-based measurement studies with 19.1 million participants. 
Lancet. 2017 Jan 7;389(10064):37-55. 
Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and 
a lifecourse strategy to address the global burden of raised blood pressure on current and future 
generations: the Lancet Commission on hypertension. Lancet. 2016 Nov 26;388(10060):2665-
712. 
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. 
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 
6;367(23):2204-13. 
Peacock E,Krousel-Wood M. Adherence to Antihypertensive Therapy. Med Clin North Am. 
2017 Jan;101(1):229-45. 
Romero CA, Orias M,Weir MR. Novel RAAS agonists and antagonists: clinical applications and 
controversies. Nat Rev Endocrinol. 2015 Apr;11(4):242-52. 
Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE, et al. Medication 
adherence and persistence according to different antihypertensive drug classes: A retrospective 
cohort study of 255,500 patients. Int J Cardiol. 2016 Oct 1;220:668-76. 
Services UDoHaH. The Surgeon General's Call to Action to Control Hypertension. 2020 October 
2020:1-50. 
Uijl E, Mirabito Colafella KM, Sun Y, Ren L, van Veghel R, Garrelds IM, et al. Strong and 
Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen. 
Hypertension. 2019 Jun;73(6):1249-57. 
van der Laan DM, Elders PJM, Boons C, Beckeringh JJ, Nijpels G,Hugtenburg JG. Factors 
associated with antihypertensive medication non-adherence: a systematic review. J Hum 
Hypertens. 2017 Nov;31(11):687-94. 
Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients 
with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 
15;372(3):211-21. 
Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report 
of the American College of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115. 
White WB, Mansoor GA, Tendler BE,Anwar YA. Nocturnal blood pressure epidemiology, 
determinants, and effects of antihypertensive therapy. Blood Press Monit. 1998 Feb;3(1):43-51. 
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH 
Guidelines for the management of arterial hypertension: The Task Force for the management of 
arterial hypertension of the European Society of Cardiology and the European Society of 
Hypertension: The Task Force for the management of arterial hypertension of the European 
Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 
Oct;36(10):1953-2041. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
70 
10. 
APPENDICES 
10.1. 
Measurement of Blood Pressure 
All blood pressure measurements (office, ABPM, and HBPM) must be taken using the 
standardized equipment provided by the Sponsor, according to the methods described in the 
relevant user manuals.  
The appropriately sized cuff for each modality must be used for all assessments. The arm’s 
circumference at midpoint (halfway between the acromion and olecranon) should be determined 
at screening with a metric tape measure and used to select the appropriately sized blood pressure 
cuff/bladder for each instrument as described in the Study Manual. Unless significant weight loss 
or gain occurs between visits, the patient should use the same cuff/bladder size throughout the 
study. 
At the first Screening visit only, office blood pressure will be measured in both arms to select the 
appropriate arm to use for office blood pressure and HBPM measurements. Unless a concomitant 
condition favors the use of a specific arm, the arm with the higher office SBP should be used for 
all subsequent office blood pressure and HBPM readings. The ABPM should be measured using 
the patient’s nondominant arm. If the patient is ambidextrous, the same arm used for office blood 
pressure and HBPM readings should be used. 
ABPM 
The appropriately sized cuff should be placed on the correct arm following the instructions in the 
Study Manual. In patients taking oral antihypertensives (including those initiated as rescue 
medication), ABPM should be started prior to the morning dose of antihypertensive medication. 
All ABPM collections must be in the outpatient/ambulatory state. ABPM recordings that are 
associated with dosing visits must be obtained in advance of the visit (within 7 days before the 
corresponding dosing visit) and the results reviewed prior to dosing. 
During the 24 hour monitoring period, patients must avoid strenuous exercise but should 
otherwise maintain their usual level of physical activity. The ABPM is programmed to take 
readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the 
night (10 pm to 5:59 am). While awake, the patient should hold their arm still by their side while 
the device is inflating for a reading. Patients must record the timing of going to sleep, waking up, 
and any oral medications taken during the ABPM, and these responses must be entered into the 
eCRF. 
After the monitoring period is complete, upload the ABPM data to receive a report with 
adequacy assessment. An ABPM will be considered adequate if (1) the number of successful 
daytime readings is ≥33, (2) the number of successful nighttime readings is ≥11, and (3) no more 
than 3 hours are not represented (ie, 3 sections of 60 minutes where 0 valid readings were 
obtained). If the ABPM recording is inadequate, the patient will be provided 1 opportunity to 
repeat the study within 2 days. If the second ABPM recording is also inadequate during 
screening, the patient is a screen failure. 
Office Blood Pressure 
Office blood pressure must be measured using the automated blood pressure device provided by 
the Sponsor and the arm selected during screening. 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
71 
Office blood pressure should be measured early in the visit, before phlebotomy or other 
potentially stressful assessments. To minimize confounding by circadian changes, study visits 
should be scheduled for a consistent timeframe of the day. The use of inhaled short-acting beta 
agonists should be avoided within 6 hours prior to measuring blood pressure and/or heart rate. 
The use of phosphodiesterase type 5 inhibitors (eg, sildenafil, tadalafil, vardenafil, avanafil) 
should be avoided within 48 hours prior to measuring blood pressure. 
Before measuring blood pressure, confirm that there has been no exercise or use of caffeine or 
nicotine- or tobacco-containing products (including but not limited to snuff, chewing tobacco, 
cigars, cigarettes, pipes, nicotine patches, or e-cigarettes) within the last 30 minutes. If necessary, 
delay blood pressure assessment to meet these requirements. Because a full bladder can impact 
blood pressure measurements, ask the patient to use the bathroom before the assessment. 
All office blood pressure assessments will include both seated and standing measurements.  
Seated Office Blood Pressure Measurement: For seated measurements, the patient should be in a 
comfortable resting position in a chair with their back supported and their feet flat on the floor. 
• Place the appropriately sized cuff on the correct arm with no clothing between the 
patient’s arm and the cuff and with the midpoint of the bladder length positioned over 
the brachial artery (located by palpation). The arm should be supported on an armrest 
or table with mid-cuff at heart level and the palm facing the ceiling. 
• Follow the Study Manual to initiate the automated blood pressure device’s seated 
measurement protocol. This program includes a 5-minute period of rest, followed by 
4 sequential blood pressure measurements at 1-minute intervals. The seated blood 
pressure for the visit will be defined by the average of the last 3 individual 
measurements. 
• During the device’s seated measurement protocol, the staff member should leave the 
room and the patient should remain at rest without distraction (avoid mobile phones). 
The following script may be used: “The blood pressure device works best when you 
are at rest and without any distraction. If you agree, I would like to leave the room for 
the next 10 to 15 minutes while it is recording. This will include a 5-minute period of 
rest, followed by about 5 minutes of the device inflating to measure your blood 
pressure”. 
Standing Office Blood Pressure Measurement: A standing measurement should be obtained 
immediately after collection of the seated measurements. 
• Being careful to maintain the cuff’s position, ask the patient to stand with the cuffed 
arm bent slightly and the hand of the cuffed arm supported at heart level.  
• Using a stopwatch or watch, measure standing blood pressure 1 minute after standing 
by using the automated blood pressure device’s single measurement protocol.  
• After the standing measurement, ask the patient if they experienced dizziness or light-
headedness when standing and enter their response in the eCRF. 
If a patient is unable to report to the site for an office blood pressure assessment, a substitute 
“remote visit blood pressure measurement” may be obtained remotely by a visiting nurse or other 
appropriately trained personnel who will bring an office blood pressure instrument to the 


Clinical Study Protocol ALN-AGT01-002  
ALN-AGT01 
Original, 09 April 2021 
Alnylam Pharmaceuticals 
Confidential 
72 
patient’s location and follow the same procedure performed at the site. If a home visit is not 
possible, a “remote visit blood pressure measurement” should instead be obtained using the 
patient’s HBPM instrument under direct supervision (phone call or teleconferencing) by 
appropriately trained study staff, following the instructions detailed in the Study Manual. Results 
and the remote method used should be entered into the eCRF. 
HBPM 
Patients should measure HBPM every morning, prior to breakfast/caffeine or taking morning 
oral medications. HBPM is not required at times when ABPM is being assessed. The HBPM 
measurement should be obtained in a room without distractions, seated comfortably with the 
back supported and feet flat on the floor. The patient will initiate the automated blood pressure 
program on their HBPM device. This program includes a 5-minute period of rest, followed by 4 
sequential blood pressure measurements at 1-minute intervals. The seated blood pressure for the 
visit will be defined by the average of the last 3 individual measurements.  
To establish baseline, each patient must measure HBPM for at least 2 consecutive weeks (and 
with at least 3 successful readings per week) prior to randomization. Patients previously taking 
medication for hypertension must be without antihypertensives for ≥4 weeks prior to collecting 
these baseline HBPM measurements. If adequate baseline HBPM data (at least 3 successful 
readings per week for at least 2 consecutive weeks) are not collected within the Screening period, 
the patient is a screen failure. 
After Day 1, HBPM should be measured at least 3 times per week. Patients may select the 3 days 
of the week that are most convenient for their personal schedule. The frequency of HBPM 
monitoring should be increased to daily during the temporary hold of oral antihypertensives 
performed in some patients from Month 5 to Month 6. 

SAP_001.pdf: 
 
 
Official Title:  A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study 
to Evaluate the Efficacy and Safety of ALNAGT01 in Patients with Mild-to-Moderate Hypertension 
 
NCT Number:   
NCT04936035 
 
Document Date:   
Statistical Analysis Plan , Version 2.0, 14 July 2023  


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1) 
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
1 
STATISTICAL ANALYSIS PLAN 
ALN-AGT01-002 (KARDIA-1) 
Protocol Title: 
A Randomized, Double-blind, Placebo-
Controlled, Dose-Ranging Multicenter Study 
to Evaluate the Efficacy and Safety of ALN-
AGT01 in Patients with Mild-to-Moderate 
Hypertension 
Short Title: 
A Study to Evaluate Efficacy and Safety of 
ALN-AGT01 in Patients with Mild-to-
Moderate Hypertension (KARDIA-1) 
Study Drug: 
Zilebesiran (ALN-AGT01) 
Protocol Date: 
Original protocol, 09 April 2021 
Amendment 1, 20 April 2021 
Amendment 2, 09 June 2021 
Amendment 3, 09 December 2021 
Amendment 4, 22 March 2022 
Amendment 5, 04 November 2022 
SAP Date: 
Original SAP: 29 March 2022 
Amendment 1: 11 October 2022 
Amendment 2: 14 July 2023 
Sponsor: 
Alnylam Pharmaceuticals, Inc. 
300 Third Street 
Cambridge, MA 02142 USA 
Telephone: +1-617-551-8200 
The concepts and information contained in this document or generated during the study are 
considered proprietary and may not be disclosed in whole or in part without expressed written 
authorization of Alnylam Pharmaceuticals, Inc. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
2 
APPROVAL SIGNATURE PAGE 
 
 
 
 
 
 
This document has been authored, approved, and signed electronically on the final page by 
the following: 
 
 
 
Alnylam Pharmaceuticals, Inc. 
 
 
This document has been approved and signed electronically on the final page by the 
following: 
 
 
 
 
Alnylam Pharmaceuticals, Inc. 
 
 
 
 
Alnylam Pharmaceuticals, Inc. 
 
 
PPD
PPD
PPD
PPD
PPD
PPD


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
3 
TABLE OF CONTENTS 
APPROVAL SIGNATURE PAGE .................................................................................................2 
LIST OF ABBREVIATIONS ..........................................................................................................6 
1. 
INTRODUCTION ........................................................................................................8 
2. 
STUDY DESIGN .........................................................................................................8 
2.1. 
General Study Design ...................................................................................................8 
2.2. 
Objectives and Endpoints ...........................................................................................10 
2.3. 
Study Procedure ..........................................................................................................11 
2.4. 
Randomization Methodology .....................................................................................11 
2.5. 
Blinding ......................................................................................................................12 
2.6. 
Determination of Sample Size ....................................................................................13 
3. 
ANALYSIS POPULATIONS ....................................................................................13 
3.1. 
Randomization and Treatment Errors .........................................................................14 
4. 
GENERAL STATISTICAL CONSIDERATIONS ....................................................14 
4.1. 
General Considerations ...............................................................................................14 
4.2. 
Blood Pressure Collection and Handling ....................................................................15 
4.2.1. 
24-Hour Ambulatory Blood Pressure Monitoring ......................................................15 
4.2.2. 
Office Blood Pressure .................................................................................................15 
4.2.3. 
Home Blood Pressure Monitoring ..............................................................................15 
4.3. 
Multiple Comparisons/Multiplicity Procedure ...........................................................15 
4.4. 
Handling of Missing Data ...........................................................................................17 
4.5. 
Baseline Definitions ....................................................................................................17 
4.6. 
Randomization Stratification Factors .........................................................................17 
4.7. 
Planned Analyses and Data Cutoffs ...........................................................................17 
4.7.1. 
Primary Analysis ........................................................................................................17 
4.7.2. 
Final Analysis .............................................................................................................18 
5. 
STATISTICAL ANALYSES .....................................................................................18 
5.1. 
Patient Disposition ......................................................................................................18 
5.2. 
Demographics and Baseline Characteristics ...............................................................19 
5.3. 
Medical History ..........................................................................................................19 
5.4. 
Protocol Deviations ....................................................................................................19 
5.5. 
Study Drug Exposure and Compliance .......................................................................19 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
4 
5.6. 
Prior and Concomitant Medications ...........................................................................20 
5.7. 
Efficacy Analyses .......................................................................................................20 
5.7.1. 
Primary Endpoint ........................................................................................................20 
5.7.1.1. 
Definition of Estimand ...............................................................................................20 
5.7.1.2. 
Primary Analysis ........................................................................................................21 
5.7.1.3. 
Sensitivity Analyses ....................................................................................................21 
5.7.1.4. 
Other Analyses ............................................................................................................21 
5.7.2. 
Secondary Endpoints ..................................................................................................21 
5.7.2.1. 
Key Secondary Endpoints ...........................................................................................21 
5.7.2.2. 
Other Secondary Endpoints ........................................................................................22 
5.7.3. 
Exploratory Endpoints ................................................................................................23 
5.7.4. 
Evaluation of Subgroups .............................................................................................24 
5.8. 
Pharmacodynamic Analyses .......................................................................................24 
5.9. 
Pharmacokinetic Analyses ..........................................................................................25 
5.10. 
Anti-Drug Antibody ....................................................................................................25 
5.11. 
Safety Analyses ..........................................................................................................25 
5.11.1. 
Adverse Events ...........................................................................................................25 
5.11.2. 
Laboratory Data ..........................................................................................................27 
5.11.3. 
Electrocardiogram .......................................................................................................28 
5.11.4. 
Vital Signs ..................................................................................................................28 
5.11.5. 
Evaluation of Subgroups .............................................................................................29 
5.12. 
Interim Analysis ..........................................................................................................29 
5.13. 
COVID-19 ..................................................................................................................29 
5.13.1. 
General Impact ............................................................................................................29 
5.13.2. 
Impact on Adverse Events ..........................................................................................29 
6. 
CHANGES FROM PLANNED ANALYSES............................................................30 
7. 
APPENDICES ............................................................................................................31 
7.1. 
Protocol Schedule of Assessments .............................................................................31 
7.2. 
Time-Adjusted Change from Baseline .......................................................................36 
7.3. 
Missing or Partial Dates ..............................................................................................36 
7.3.1. 
Prior and Concomitant Medications ...........................................................................36 
7.3.2. 
Adverse Events ...........................................................................................................37 
7.3.3. 
Others ..........................................................................................................................37 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
5 
7.4. 
List of Rescue Antihypertensive Medication ATC Code ...........................................37 
7.5. 
Preferred Terms for Hyperkalemia and Potentially Related to Hypotension .............38 
 
LIST OF TABLES 
Table 1 
Multiplicity Procedure ................................................................................................16 
Table 2  
Schedule of Assessments ............................................................................................32 
Table 3  
Time-Adjusted Endpoints ...........................................................................................36 
 
LIST OF FIGURES 
Figure 1 
Study Design .................................................................................................................9 
 
 
 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
6 
LIST OF ABBREVIATIONS 
Abbreviation  
Definition 
ABPM 
Ambulatory blood pressure monitoring 
ADA 
Anti-drug antibody(ies) 
AE 
Adverse event 
AGT 
Angiotensinogen 
ALT 
Alanine aminotransferase 
AngI/II 
Angiotensin I/II 
AST 
Aspartate aminotransferase 
AUC 
Area under the curve 
DB 
Double-blind 
DBP 
Diastolic blood pressure 
ECG 
Electrocardiogram 
eGFR 
Estimated glomerular filtration rate 
eDISH 
Evaluation of drug-induced serious hepatotoxicity 
EOT 
End of treatment 
ET 
Early termination 
FAS 
Full analysis set 
HbA1c 
Hemoglobin A1c 
HBPM 
Home blood pressure monitoring 
HLT 
High level term 
ICF 
Informed consent form 
IEC 
Independent Ethics Committee 
IRB 
Institutional Review Board 
IRT 
Interactive Response Technology 
ISR 
Injection site reaction 
LFT 
Liver function test 
LLOQ 
Lower limit of quantification 
MedDRA 
Medical Dictionary for Regulatory Activities 
MMRM 
Mixed more for repeated measurement 
OLE 
Open-label extension 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
7 
Abbreviation  
Definition 
PD 
Pharmacodynamic(s) 
PK 
Pharmacokinetic(s) 
PT 
Preferred term 
Q3M 
Once every 3 months 
Q6M 
Once every 6 months 
RAAS 
Renin-angiotensin-aldosterone system 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SBP 
Systolic blood pressure 
SC 
Subcutaneous(ly) 
SD 
Standard deviation 
SOC 
System Organ Class 
ULN 
Upper limit of normal 
ULOQ 
Upper limit of quantification 
 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
8 
1. 
INTRODUCTION 
This statistical analysis plan (SAP) details comprehensive specifications of the efficacy, safety, 
pharmacokinetic (PK) and pharmacodynamic (PD) data summaries and statistical analyses in 
support of the clinical study report (CSR) for Study ALN-AGT01-002 (KARDIA-1). This SAP 
is finalized prior to treatment unblinding and conducting the primary analysis, which will occur 
after all patients complete the Month 6 visit or withdraw from the study prior to the Month 6 
visit. Changes to planned analyses specified in this SAP made after database lock will be 
documented in the CSR. 
Table, figure, and listing (TFL) mocked shells and specifications are contained in a separate 
document. 
2. 
STUDY DESIGN  
2.1. 
General Study Design  
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study 
designed to evaluate the safety, efficacy, and pharmacodynamics (PD) of zilebesiran (ALN-
AGT01), administered subcutaneously (SC), in patients with mild-to-moderate hypertension. A 
schematic of the study design is provided in Figure 1. Before randomization, patients will 
discontinue prior antihypertensive medications (if taking) for a Washout period of at least 2 
weeks (4 weeks of washout is required for long-acting antihypertensive medications, such as 
long-acting diuretics or calcium channel blockers).  
Patients who complete the Screening period and meet all inclusion/exclusion criteria for 
enrollment will receive zilebesiran or placebo for the first 6 months of the 12-month Double-
blind (DB) treatment period.  
Starting at Month 3, conventional oral antihypertensives may be added per Investigator 
judgement for elevated blood pressure. Oral antihypertensives (if taking) will be temporarily 
held from Month 5 to Month 6 to assess the effect of zilebesiran alone (vs placebo) at Month 6. 
During this 4-week period, blood pressure will be carefully monitored by home blood pressure 
monitoring and oral antihypertensive medications restarted if indicated. Patients may resume 
conventional oral antihypertensives at Month 6 per Investigator judgement. 
Patients randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial zilebesiran 
regimens until the end of the DB period. Patients randomized to zilebesiran regimens will remain 
on their originally assigned regimens through Month 12. 
After the 12-month DB treatment period, patients may be eligible to participate in a zilebesiran 
open-label extension (OLE) study. If an individual patient reaches Month 12 prior to availability 
of the OLE study, they may continue their current blinded dosing in the DB Extension period for 
up to 24 additional months until the OLE study is open and then transition. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
9 
Figure 1 
Study Design 
 
Abbreviations: aHTN=antihypertensive medications; DB=double-blind; M=month; OLE=open-label extension; 
PBO=placebo; PO=per os (oral); Q3M=once every 3 months; Q6M=once every 6 months; R=randomization; 
SC=subcutaneous; WO=washout. 
Note: Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the Month 12 
predose assessments. If an individual patient reaches Month 12 prior to availability of the OLE study, they may 
continue their current blinded dosing in the DB Extension period for up to 12 additional months until the OLE study 
is open and then transition. Once the OLE study is open for enrollment, eligible patients may rollover into the OLE 
study at Months 12, 18, 24, 30, or 36 (whichever visit occurs first). 
Note: Patients who were previously taking antihypertensives at screening should undergo a washout of these 
medications for at least 2 weeks during the Screening period (4 weeks of washout is required for long-acting 
antihypertensive medications, such as long-acting diuretics or calcium channel blockers).






Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
12 
• Placebo SC once every 3 months 
• 150 mg zilebesiran SC once every 6 months 
• 300 mg zilebesiran SC once every 6 months 
• 300 mg zilebesiran SC once every 3 months 
• 600 mg zilebesiran SC once every 6 months 
Patients initially randomized to placebo will be re-randomized 1:1:1:1 at Month 6 to 1 of the 4 
initial zilebesiran regimens. 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. 
Randomization will be stratified by race (black vs all other races) and by baseline blood pressure 
(mean 24-hour SBP < or ≥145 mmHg). 
Each patient will be uniquely identified in the study by a combination of the site number and 
patient identification number. Upon signing the informed consent form (ICF), the patient will be 
assigned a patient identification number by the IRT system. The Investigator or his/her designee 
will randomize the patient in IRT after confirming that the patient fulfills all the inclusion criteria 
and none of the exclusion criteria. The Investigator or his/her designee will re-randomize the 
patient in IRT at Month 6 to assign placebo patients to 1 of the 4 initial zilebesiran dose groups 
in a way that maintains the study blind for the patient. 
2.5. 
Blinding  
The Sponsor will be blinded to study drug treatment through Month 6 of the 12-month DB 
period. During the course of the study, serum AGT, plasma PK, and treatment assignment using 
dummy IDs will be made available to a small, independent pharmacometrics team at the Sponsor 
that will not be involved in the conduct or oversight of the study. After the last patient completes 
the Month 3 visit and prior to the last patient’s Month 6 visit, SBP data from a limited number of 
patients (about one-third) will be made available to this small, independent pharmacometrics 
team for preliminary PK/PD modeling. After the database lock to support the analysis of Month 
6 data is complete, all other Sponsor personnel will be unblinded to treatment assignment. 
Blinded doses of study drug will be administered under the supervision of the Investigator (refer 
to Protocol Section 5.2.2). All patients will receive the same volume and number of injections 
regardless of treatment assignment (patients receiving once every 6-month zilebesiran regimens 
will receive placebo SC at dosing visits at which they do not receive zilebesiran to maintain the 
blind). Because zilebesiran may be slightly visually distinguishable from placebo, all blinded 
study drug doses will be prepared, and the syringe(s) will be masked by a site pharmacist or 
delegate prior to administration by a blinded healthcare professional. See the Pharmacy Manual 
for additional details. 
Details about the specifics of the blinding aspects throughout the entire study are available in the 
Randomization and Blinding Plan.  
Any unplanned/emergency unblinding occurring during the DB Period will be documented and 
reported in the CSR. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
13 
Refer to the study Randomization and Blinding Plan for more details. 
2.6. 
Determination of Sample Size 
Assuming a standard deviation (SD) in the range of 15 to 20 mmHg in change from baseline at 
Month 3 in 24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size 
between zilebesiran and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size 
of 375 patients (75 per treatment group) provides at least 84% power to detect a dose response 
signal in SBP reduction among all zilebesiran doses and placebo at the 2-sided significance level 
of 0.05. In addition, this sample size provides at least 80% power to detect a 10 mmHg 
difference between an individual zilebesiran dose versus placebo with a 2-sided significance 
level of 0.05.  
3. 
ANALYSIS POPULATIONS 
During the study, 16 patients were randomized from Ukraine in January and February 2022 
before a geographic conflict started in February 2022. In response to this conflict, Regulatory 
Authorities advised Sponsors to refer to guidance documents issued during the COVID-19 
pandemic with respect to the handling of clinical trial sites in Ukraine. In line with these 
guidance documents, and due to challenges in data collection and cleaning and verification of 
such data, data from patients enrolled at sites in Ukraine will be excluded from the analysis sets 
defined below. Data from these patients will be provided in listings.  
The populations (analysis sets) are defined as follows: 
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• PK Analysis Set: All patients who received at least 1 full dose of ALN-AGT01 and 
have at least 1 nonmissing postdose PK assessment. 
• PD Analysis Set: All patients who received at least 1 full dose of study drug. All by-
treatment analyses based on the PD Analysis Set will be grouped according to the 
treatment actually received. 
• All Zilebesiran Treated Set: All patients who received any amount of 1 of the 4 ALN-
AGT01 dosing regimens, including patients who took ALN-AGT01 during the 6-
month placebo-controlled period and patients who initially took placebo and then 
switched to ALN-AGT01 after the Month 6 visit.  
 
For the primary analysis for 6-month placebo-controlled DB period, the primary population used 
to evaluate efficacy will be the FAS. Safety will be analyzed using the Safety Analysis Set. The 
PK and PD Analysis Sets will be used to conduct PK and PD analyses, respectively.  


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
14 
The All Zilebesiran Treated Set will be used to summarize the efficacy and safety of zilebesiran 
throughout the entire DB period (including DB extension period).  
3.1. 
Randomization and Treatment Errors 
For patients who were not treated, not randomized, or received incorrect treatment, the following 
rules will be used:  
• Randomized but not treated: they will be excluded from the FAS and Safety Analysis 
Set for efficacy and safety evaluations as actual treatment is missing.  
• Treated but not randomized: they will be excluded from the efficacy analyses since 
randomized treatment is missing but will be reported under the treatment actually 
received for all safety analyses.  
• Randomized but took incorrect treatment: they will be reported under their 
randomized treatment arm for all efficacy analyses. But for safety analyses, a patient 
will be included under the active treatment arm if the patient is randomized to placebo 
arm and received an active dose by mistake. 
4. 
GENERAL STATISTICAL CONSIDERATIONS 
4.1. 
General Considerations 
In general, data will be summarized for each planned analysis defined in Section 4.7 separately. 
For Month 3 endpoints, zilebesiran 300mg Q3M and 300mg Q6M will be pooled together.  
Categorical variables will be summarized using counts and percentages. Continuous variables 
will be summarized using the following descriptive summary statistics: number of patients (n), 
mean, standard deviation (SD), standard error of mean (SEM), median, first quartile (Q1), third 
quartile (Q3), minimum, and maximum. 
The day of the first dose of study drug administered is defined as Day 1. The Study Day of a 
time point of interest is calculated as follows: 
• If on or after Day 1, Study Day = date of interest – date of the first dose of study drug 
+ 1 
• If prior to Day 1, Study Day = date of interest – date of the first dose of study drug 
There is no Day 0. For example, the day before the first study drug dose is defined as Day -1. 
For laboratory parameters, assessments collected and recorded as lower than the lower limit of 
quantification/detection (LLOQ) will be replaced by the LLOQ. Any assessment collected and 
recorded as greater than the upper limit of quantification (ULOQ) will be replaced by the ULOQ. 
All descriptive summaries will be presented by treatment arm. 
Statistical analyses will be conducted using SAS software Version 9.4 or newer or R version 3.6 
or newer. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
15 
4.2. 
Blood Pressure Collection and Handling 
4.2.1. 
24-Hour Ambulatory Blood Pressure Monitoring 
24-hour ambulatory blood pressure monitoring (ABPM) is programmed to take readings every 
20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 
5:59 am). An ABPM will be considered adequate if (1) the number of successful daytime 
readings is ≥33, (2) the number of successful nighttime readings is ≥11, and (3) no more than 3 
hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). If 
the ABPM recording is inadequate, the patient will be provided 1 opportunity to repeat the 
recording within 7 days from the end time of the invalid ABPM.  
To summarize the 24-hour ABPM, hourly adjusted mean will be calculated. Hourly mean and 
24-hour mean will be calculated by two steps:  
1. Calculate the hourly mean: average of BP by each hour of the day (e.g., mean of BP 
measurements from 16:00 to 16:59). If there is no reading in a specific hour, this hour 
will not be included in calculation.   
2. Calculate the 24-hour mean: average of the hourly means.  
4.2.2. 
Office Blood Pressure 
The mean office BP in the sitting position and office BP in standing position will be used for the 
analysis. Office BP in the sitting position will be collected with a set of 4 replicates. The average 
of the last 3 replicates will be calculated and used for analysis. If there are multiple sets of 
assessments collected on the same day, the last set will be used for the analysis. Office BP 
collected in standing position will be used to derive orthostatic hypotension.   
4.2.3. 
Home Blood Pressure Monitoring 
Home blood pressure will be measured both pre and post randomization. To establish baseline, 
each patient should measure HBPM during the week (with at least 3 successful readings) 
immediately prior to randomization. After Day 1, HBPM will be measured at least once per 
week. Four sequential blood pressure measurements at 1-minute intervals will be recorded. The 
mean sitting blood pressure for the visit will be defined by the average of the last 3 individual 
measurements. HBPM will be summarized by weekly average.  
Details of the blood pressure collection are in Study Protocol Section 10. 
4.3. 
Multiple Comparisons/Multiplicity Procedure 
The overall familywise error rate will be controlled at α=0.05 for the primary and key secondary 
endpoints as shown in Table 1  


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
16 
Table 1 
Multiplicity Procedure 
Test 
Stepa 
Endpoint 
Comparison 
Success criteria 
1 
Change from baseline at Month 3 in 24-
hour mean SBP assessed by ABPM 
Dunnett’s 
Procedure 
If the global hypothesis is 
rejected at 0.05 alpha level, 
then at least one zilebesiran 
dose is superior to Placebo 
2 
Change from baseline at Month 3 in 24-
hour mean SBP assessed by ABPM 
300 mg Q3M 
vs placebo b 
Nominal p-value < 0.05 
3 
Change from baseline at Month 3 in 24-
hour mean SBP assessed by ABPM 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 
4 
Change from baseline at Month 3 in office 
SBP 
300 mg Q3M 
vs placebo b 
Nominal p-value < 0.05 
5 
Change from baseline at Month 3 in 
office SBP 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 
6 
Change from baseline at Month 6 in 24-
hour mean SBP assessed by ABPM 
300 mg Q3M 
vs placebo 
Nominal p-value < 0.05 
7 
Change from baseline at Month 6 in 24-
hour mean SBP assessed by ABPM 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 
8 
Change from baseline at Month 6 in 
office SBP 
300 mg Q3M 
vs placebo 
Nominal p-value < 0.05 
9 
Change from baseline at Month 6 in 
office SBP 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 
10 
Proportion of patients with 24-hour mean 
SBP assessed by ABPM <130 mmHg 
and/or reduction ≥20 mmHg without 
additional antihypertensive medications at 
Month 6 
300 mg Q3M 
vs placebo 
Nominal p-value < 0.05 
11 
Proportion of patients with 24-hour mean 
SBP assessed by ABPM <130 mmHg 
and/or reduction ≥20 mmHg without 
additional antihypertensive medications at 
Month 6 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
17 
a  If the MCP criterion is satisfied in a given step, the hypothesis test is deemed statistically significant, and the next 
step will be evaluated; otherwise all hypotheses in the given and subsequent steps are deemed not statistically 
significant 
b 300mg Q3M and 300mg Q6M will be pooled together for the test 
4.4. 
Handling of Missing Data 
No imputation will be done for missing values for the primary analysis of the primary endpoint. 
Results based on mixed model with repeated measurements (MMRM) are valid based on missing 
at random (MAR) assumption.  
4.5. 
Baseline Definitions 
For the primary analysis of 6-month placebo-controlled period, for office BP, the baseline is the 
average of the mean sitting office BP value on Day 1 prior to receiving the first dose of study 
drug and last non-missing value prior to Day 1 during screening visit. For HBPM, the baseline 
will be the average of all assessments during last week prior to receiving the first dose of study 
drug. For all other endpoints including ABPM, baseline is the last non-missing value (including 
unscheduled visit) prior to receiving the first dose of study drug. 
For final analyses, patients initially randomized to placebo and re-randomized at Month 6 will be 
summarized in two ways:  
From Day 1. Baseline definition is the same as for the primary analysis for the 6-month placebo-
controlled period. 
From the start of zilebesiran dosing at Month 6: Baseline is the last assessment prior to Month 6 
dosing.  
For patients initially randomized to zilebesiran dosing regimen, baseline remains the same as the 
one for the primary analysis.  
4.6. 
Randomization Stratification Factors 
Randomization will be stratified by race (black vs all other races) and by baseline blood pressure 
(24-hour mean SBP < or ≥145 mmHg). Stratification factors are recorded in the IRT database. 
Key data is integrated into the clinical database. In statistical analyses that use randomization 
stratification factors as covariates, the stratum assignment will reflect the values as recorded in 
the clinical database (EDC). In the presence of stratification errors, the stratification used in 
analysis may not match that in the IRT. A comparison of the number and percentage of patients 
in each randomization stratification factor in IRT versus the clinical database will be summarized 
by randomized treatment arm and overall. 
4.7. 
Planned Analyses and Data Cutoffs 
4.7.1. 
Primary Analysis 
The primary analysis will be performed after the last randomized patient has completed Month 6 
Visit or otherwise discontinued the study. For the primary analysis, as this study will be ongoing 
with some patients in the 12-month DB period, DB extension period or safety follow-up period, 
the study database will undergo an interim database lock with the last Month 6 visit date as the 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
18 
cutoff date (i.e., data in EDC will be cleaned, frozen and electronically signed by investigators; 
external laboratory data will be cleaned and will undergo quality assurance). Data will be 
summarized in the CSR. Additional details regarding the interim database locks will be 
documented in the study Data Management Plan. 
The primary analysis will include data on, or prior to, this prespecified cutoff date. For 
assessments with starting/ending dates (e.g., adverse events [AEs], medications), the starting date 
will be compared with the pre-specified cutoff date. Data records with starting dates after the 
specified data cutoff date will be excluded.  
Data collected during the 6-month double-blind period (i.e. up to Month 6 visit dates) will be 
analyzed based on the methodology described in this SAP, while the data after Month 6 visit 
dates will be mainly summarized by descriptive statistics.  
4.7.2. 
Final Analysis 
After all patients reach the end of the study, the database will undergo a final database lock, and 
the data will be summarized in the CSR. The analyses for the 6-Month DB period will not be 
repeated.   
A patient is considered to have reached the end of the study if the patient: 
• has completed at least the Month 12 visit and enrolled in the OLE study, or 
• has completed the Safety Follow-up visits for patients who discontinue study drug or 
do not enroll in the OLE study, or withdrawal from the study. 
5. 
STATISTICAL ANALYSES 
5.1. 
Patient Disposition 
The number and percentage of patients in the following categories will be summarized for all 
randomized patients and by randomized treatment arm and overall: 
• Randomized 
• Treated 
• Completed the placebo-controlled 6-month double-blind (DB) treatment period 
• Discontinuation and primary reason for discontinuation of treatment during 6-month 
DB period 
• Discontinuation of study and primary reason for discontinuation of study during the 
6-month DB period 
• Completed the 12-month double-blind (DB) treatment period 
• Completed the DB extension period 
• Completed the study 
• Discontinuation of treatment and primary reason for discontinuation of treatment after 
Month 6 during DB and DB extension period 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
19 
• Discontinuation of study and primary reason for discontinuation of study after Month 
6 during DB and DB extension period 
In addition to the primary reason for discontinuation of treatment and withdrawal from study, 
patients will also be categorized if discontinuation/withdrawal was due to COVID-19. 
5.2. 
Demographics and Baseline Characteristics 
Demographic and baseline disease characteristics will be summarized by treatment arm and 
overall for Full Analysis Set, and also presented in listings. 
Age at consent, height, weight, body mass index (BMI), 24-hour mean ABPM and office BP will 
be summarized using descriptive statistics. Sex, race, ethnicity, and country will be summarized 
by presenting the frequencies and percentages of patients in each category.   
5.3. 
Medical History 
Medical history and prior procedures reported will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA), Version 26.0 or newer. Unique patients who report medical 
history events will be summarized by MedDRA system organ class (SOC), high level term 
(HLT) and preferred term (PT). 
5.4. 
Protocol Deviations 
Protocol deviations will be classified by medical review prior to each planned analysis database 
lock, and major protocol deviations will be identified. A major protocol deviation is a deviation 
that may significantly impact the completeness, accuracy, and/or reliability of the trial data; that 
may significantly affect a subject's rights, safety, or well-being. (ICH E3 R1 Structure and 
Contents of Clinical Study Reports Guidance for Industry, 2013). 
The Sponsor or designee will be responsible for producing the protocol deviation file. This file 
will include a description of each protocol deviation and classification as major or minor. The 
protocol deviations will be reviewed and finalized prior to the planned analysis database lock. 
All protocol deviations and major protocol deviations will be summarized and listed. 
5.5. 
Study Drug Exposure and Compliance 
The following variables will be summarized by descriptive statistics and/or frequency tabulation: 
• Duration of exposure, defined as: date of last exposure – date of first dose +1. Date of 
last exposure is the earliest date of the following: 
− date of last dose + the length of dosing interval, i.e.,  
o date of last zilebesiran dose + 169 days for the following treatment arms: 
zilebesiran 150 mg Q6M, 300 mg Q6M and 600 mg Q6M,  
o date of last dose + 85 days for the following treatment arms: placebo and 
300 mg Q3M. 
− date of end of study 
− date of analysis data cutoff 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
20 
• Number of doses received; as continuous and/or categorical variable 
• Number of missed doses; as a categorical variable 
• Total exposure (patient years) 
5.6. 
Prior and Concomitant Medications 
Medications will be coded using the World Health Organization (WHO) Drug Dictionary, 
version WHO-DD Global B3, March 2021 or newer. Unique patients who reported medications 
will be summarized by Anatomical Therapeutic Chemical (ATC) level 3 class (or level 2 if not 
available) and PT. Summaries will be provided for prior and concomitant medications separately. 
Prior medications are those medications with start date prior to the first dose of study drug. 
Concomitant medications are medications, other than the study drug, administered at or after the 
first dose of study drug, as well as medications that started prior to the first dose of study drug 
and are ongoing after the first dose of study drug.  
If the medication start date is on or after the date of first dose of study drug, the medication will 
be summarized as a concomitant medication even if the medication end date is missing.  
If the end date of a medication is missing or incomplete, such that it cannot be determined 
whether it is after the first dose of study drug, it will be counted as a concomitant medication. 
For missing or partial dates for medications, the imputation of start and end dates is described in 
Section 7.2.  
5.7. 
Efficacy Analyses 
5.7.1. 
Primary Endpoint 
5.7.1.1. 
Definition of Estimand 
The primary objective of the study is to evaluate the effect of zilebesiran on SBP as assessed by 
ABPM at Month 3. Primary estimand is defined as: 
• Treatment condition: monotherapy including placebo, zilebesiran 150 mg Q6M, 300 
mg Q6M, 300 mg Q3M and 600 mg Q6M. (300 mg Q6M and Q3M will be pooled 
together) 
• Target population: patients with mild-to-moderate hypertension 
• Endpoint: Change from baseline at Month 3 in 24-hour mean SBP assessed by ABPM 
• Population-level summary: Least square mean difference between zilebesiran and 
placebo in change from baseline at Month 3 in 24-hour mean SBP assessed by ABPM 
• Intercurrent events strategy: Rescue medication taken before Month 3 visit will be 
considered as an intercurrent event. For patients who require rescue medication, given 
the expected number of such patients at Month 3 is low, hypothetical strategy will be 
used, i.e., ABPM assessed while patients are on and within 2 weeks after stopping 
any rescue medication will be censored. This will provide the estimated treatment 
effect of zilebesiran alone. List of rescue medication ATC code is in Section 7.4. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
21 
5.7.1.2. 
Primary Analysis  
The primary endpoint is the change from baseline at Month 3 in 24-hour mean SBP assessed by 
ABPM. The hypothesis of the dose response relationship for the primary endpoint will be tested 
as: 
• H0 : µ1 =µ2 =µ3 = µ0 (there is no dose response relationship)  
• Ha µ1 ≠ µ0 or µ2 ≠ µ0 or µ3 ≠ µ0  (at least one zilebesiran dose is different from 
placebo). 
Where µ0 is the mean change from baseline at Month 3 in 24-hour mean SBP assessed by ABPM 
in placebo arm; and µ1, µ2, and µ3 are the mean changes from baseline at Month 3 in 24-hour 
mean SBP in zilebesiran 150mg Q6M, 300mg Q3M and Q6M pooled, 600mg Q6M arms, 
respectively. 
The above hypothesis will be tested using the Dunnett’s procedure based on Mixed model for 
repeated measurements (MMRM). The MMRM model will include treatment, visit, treatment-
by-visit interaction, race (black; all other races) as fixed factors, baseline 24-hour mean SBP 
assessed by ABPM as a covariate. Unstructured covariance matrix will be used. Least square 
mean difference between zilebesiran and placebo, 95% confidence interval (CI) and p-values 
(both unadjusted and adjusted by Dunnett’s procedure) will be generated.    
5.7.1.3. 
Sensitivity Analyses  
For the sensitivity analysis, treatment policy strategy will be used for patients who require rescue 
medication. All collected blood pressure measurements will be analyzed by the same MMRM 
model as the primary analysis, regardless of the rescue medication. 
Due to the expected long-acting effect of zilebesiran, the commonly used control-based Pattern 
Mixture Model (PMM) will not be used to assess the missing not at random (MNAR) 
assumption. 
5.7.1.4. 
Other Analyses  
To demonstrate zilebesiran consistently controls blood pressure over the 24-hour period, hourly 
mean change from baseline at Month 3 in SBP assessed by ABPM will be plotted for each 
treatment group. 
5.7.2. 
Secondary Endpoints 
5.7.2.1. 
Key Secondary Endpoints 
Secondary objective of the study is to evaluate the effect of zilebesiran on blood pressure 
assessed by ABPM and office blood pressure through Month 6. The estimand is defined as:  
• Treatment condition: monotherapy including placebo, zilebesiran 150mg Q6M, 300mg 
Q6M, 300mg Q3M and 600mg Q6M 
• Target population: patients with mild-to-moderate hypertension 
• Endpoint:  
− Change from baseline at Month 3 in mean sitting office SBP 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
22 
− Change from baseline at Month 6 in 24-hour mean SBP assessed by ABPM 
− Change from baseline at Month 6 in mean sitting office SBP 
− Proportion of patients with 24-hour mean SBP assessed by ABPM <130 mmHg 
and/or reduction ≥20 mmHg without additional antihypertensive medication at 
Month 6 
• Population-level summary: Least square mean difference between zilebesiran and 
placebo in each of the change from baseline endpoints. Odds ratio for the binary 
endpoint. 
• Intercurrent events strategy: For patients who require rescue medication,  
− for change from baseline endpoints: given the expected number of such patients at 
Month 3 is low and the protocol requires washout of these medications between 
Month 5 and Month 6, the hypothetical strategy will be used, i.e, blood pressure 
assessed while patients are on and within 2 weeks after stopping any rescue 
medication will be censored. This will provide the estimated treatment effect of 
zilebesiran alone.  
− for binary endpoint, composite strategy will be used. Patients with rescue 
medication are considered as not meeting the BP control and response criteria. 
For change from baseline endpoints, MMRM model will be used as the primary analysis. The 
model will include treatment, visit, treatment-by-visit interaction, race (black, all other races) as 
fixed factors, corresponding baseline as a covariate. Least square (LS) mean difference of each 
zilebesiran dose group compared with placebo dose group, 95% CI and p-value will be 
generated. For change from baseline at Month 6 in office SBP, as a significant proportion of 
patients are expected to receive rescue medication, data collected at Month 4 and 5 visits will be 
excluded from MMRM model.   
These endpoints will also be analyzed by the same MMRM model using the treatment policy 
strategy. I.e., all collected data will be analyzed regardless of the rescue medication. For change 
from baseline at Month 6 in mean sitting office SBP, Data collected at Month 4 and 5 Visits will 
be included as well. 
For the proportion of patients with 24-hour mean SBP assessed by ABPM <130 mmHg and/or 
reduction ≥20 mmHg without rescue medication at Month 6, logistic regression will be used. The 
model will include treatment as a factor and baseline 24-hour mean SBP as a covariate. Patients 
without Month 6 ABPM data will be considered as not meeting the criteria.    
Multiplicity adjustment will be applied across primary and these secondary endpoints. Details of 
multiplicity control are in Section 4.3. 
5.7.2.2. 
Other Secondary Endpoints  
Other blood pressure related secondary endpoints are: 
• Change from baseline at Month 3 in 24-hour mean DBP assessed by ABPM 
• Change from baseline at Month 6 in 24-hour mean DBP assessed by ABPM 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
23 
• Change from baseline at Month 3 in mean sitting office DBP 
• Time adjusted change from baseline through Month 3 in mean sitting office 
SBP/DBP 
• Change from baseline at Month 6 in mean sitting office DBP  
• Time adjusted change from baseline through Month 6 in 24-hour mean SBP/DBP 
assessed by ABPM  
• Time adjusted change from baseline through Month 6 in mean sitting office 
SBP/DBP  
• Change from baseline in daytime/nighttime mean SBP/DBP by ABPM at each visit. 
Daytime is defined as 6 am to 9:59 pm and nighttime is defined as 10 pm to 5:59 am.  
Time-adjusted change is defined as the area under the curve (AUC) of BP change from baseline 
divided by the duration of the time period. It leads to the weighted average of change from 
baseline to each scheduled visit. Details of the definition and calculation are in Section 7.2. 
In general, these endpoints will be analyzed using two approaches, similar as primary endpoint 
and key secondary endpoints. Blood pressure collected while patients are on and within 2 weeks 
after stopping any rescue medication will be censored. All collected BP data will also be 
analyzed.   
Each endpoint will be analyzed by the MMRM model described in Section 5.7.1.2 with the 
corresponding baseline as a covariate.  
In addition, ABPM dipping pattern, defined as ratio of nighttime to daytime mean SBP will be 
calculated. The number and proportion of patients will be summarized by treatment and by visit 
into 3 categories: 1) <0.9; 2) ≥0.9 to <1; 3) ≥1. 
The secondary endpoint of percent change in serum AGT at each visit will be summarized by 
treatment using descriptive statistics. 
5.7.3. 
Exploratory Endpoints  
The blood pressure related exploratory endpoints through Month 12 are: 
• Change from baseline in 24-hour mean SBP/DBP assessed by ABPM by each visit 
• Change from baseline in mean sitting office SBP/DBP by each visit 
• Change in pulse pressure assessed by ABPM and office blood pressure 
• BP control and response rate by each visit, defined as 
− Office SBP < 140 mmHg and/or reduction from baseline ≥ 20 mmHg without 
additional antihypertensive medication 
− 24-hour mean DBP < 85 mmHg and/or reduction from baseline ≥ 10 mmHg 
assessed by ABPM without additional antihypertensive medication 
− Office DBP < 90 mmHg and/or reduction from baseline ≥ 10 mmHg without 
additional antihypertensive medication 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
24 
• Proportion of patients with rescue medication use by each visit 
• Change from baseline in SBP/DBP by HBPM 
To assess the long-term treatment effect of zilebesiran through Month 36, change from baseline 
in SBP/DBP assessed by ABPM, office BP and HBPM will be summarized. 
Body weight, metabolic related exploratory endpoints are: 
• Change from baseline in body weight/body mass index (BMI)/waist 
circumference/waist-to-hip ratio by each visit 
• Change from baseline in HbA1c/fasting glucose/insulin/serum lipids by each visit  
Exploratory endpoints will be summarized using descriptive statistics based on all observed data. 
Missing data will not be imputed.  
For BP control and response rate, data will be summarized based on observed data 
1. for all patients. 
2. for patients whose baseline BP is above the threshold.    
5.7.4. 
Evaluation of Subgroups 
Subgroup analyses will be conducted to assess the consistency of treatment effect within various 
subgroups defined by the following baseline characteristics: 
• Age (<65; >=65) 
• Sex 
• Race (black; all other races) 
• Baseline 24-hour mean SBP assessed by ABPM (<145 mmHg, >=145 mmHg) 
• eGFR (<60; >=60 mL/min/1.73m2) 
Subgroup analyses will be performed for the primary endpoint and key secondary endpoints 
using the MMRM within each subgroup. Model will include treatment, visit, treatment-by-visit 
interaction, race ([black, all other races], when race is not the subgroup to be analyzed) as fixed 
factors, baseline value as a covariate. Point estimate of treatment effect and 95% confidence 
interval are to be generated for each subgroup. If the number of patients in either treatment arm 
of a subgroup is less than 10, only descriptive statistics will be presented. A forest plot will be 
generated to illustrate the estimated treatment effect along with 95% CI within each subgroup. 
5.8. 
Pharmacodynamic Analyses 
In addition to serum AGT, the PD parameters include plasma renin concentration, aldosterone, 
AngI and AngII. Summary tables will be provided for observed values, changes and percentage 
changes from baseline for each scheduled time point by treatment group. In addition to serum 
AGT percent reduction analyses, the AGT maximum and mean percentage reductions over the 6-
month placebo-controlled DB period will be summarized using descriptive statistics.  


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
25 
5.9. 
Pharmacokinetic Analyses 
Plasma concentrations of zilebesiran and its metabolite will be summarized descriptively. 
Descriptive statistics for zilebesiran and its metabolite plasma concentrations will include the 
number of patients, mean, SD, coefficient of variation, geometric mean, geometric mean 
coefficient of variation, median, minimum, and maximum.  
Additional analysis may be done as needed.  
5.10. 
Anti-Drug Antibody 
The number and percentage of patients with confirmed positive anti-drug antibody (ADA) assay 
results at baseline and at any time during the 6-month placebo-controlled DB period, as well as 
treatment-emergent ADA during the 12-month DB period, will be summarized. Treatment-
emergent ADA consist of treatment-induced ADA and treatment-boosted ADA, as defined 
below: 
• Treatment-induced ADA: Confirmed positive ADA developed de novo after drug 
administration in patients without preexisting (baseline) confirmed positive ADA 
• Treatment-boosted ADA: Confirmed positive ADA after drug administration with 
ADA titer > 4x baseline ADA titer in patients with preexisting (baseline) confirmed 
positive ADA 
5.11. 
Safety Analyses 
5.11.1. 
Adverse Events 
Adverse events (AEs) will be classified by the MedDRA coding system (Version 26.0 or newer) 
and displayed in tables and data listings using SOC and PT. 
Treatment-emergent AEs (TEAEs) will be summarized for the 6-month placebo-controlled DB 
period and for the zilebesiran treatment period separately. For the 6-month DB period, TEAE is 
defined as any AE occurring or worsening on or after the first dose of study drug and through 
Month 6 Visit (prior to Month 6 dosing).  
For zilebesiran treatment period, TEAE is defined as any AE occurring or worsening after the 
first dose of zilebesiran through 169 days following the last dose of zilebesiran. TEAE will be 
summarized by zilebesiran dosing regimen.  
Treatment related AEs are counted as TEAE. 
AE occurred or worsening during safety follow-up period will be listed and may be summarized 
if needed. 
Because any worsening AE is reported as a new AE with higher severity, programmatical 
comparison of severity is not needed for the classification of TEAE. For missing or partial dates 
for AEs, the imputation of start and end date can be found in Section 7.3 . Events with a fully or 
partially missing onset date will be assumed to be treatment emergent unless it can be 
unequivocally determined (from the partial onset date and/or a partial or complete stop date) that 
the event occurred prior to the first dose of study drug. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
26 
AEs will be summarized by the numbers and percentages of patients and number of events 
reporting a given AE. An overall table of TEAEs will include: 
• any AE, 
• any AE related to study drug, 
• any serious AE (SAE), 
• any SAE related to study drug, 
• any AE leading to study drug discontinuation, 
• any drug-related AE leading to study drug discontinuation, 
• any AE leading to study drug interruption, 
• any drug-related AE leading to study drug interruption, 
• any AE leading to death.  
Tabulations by SOC and PT will be produced for the following:  
• AEs, 
• Treatment-related AEs, 
• AEs by maximum severity, 
• Treatment-related AEs by maximum severity, 
• Severe AEs, 
• SAEs, 
• AEs leading to treatment discontinuation. 
Tabulations by PT will be produced for the following: 
• AEs, 
• Treatment-related AEs, 
• SAEs. 
In addition, for the zilebesiran treatment period (includes the 12-month DB period and DB 
extension period) both exposure-adjusted event rate (EAER) and exposure-adjusted incidence 
rate (EAIR) will be calculated.  
EAER is defined as number of events/total duration of zilebesiran exposure * 100. 
EAIR is defined as number of patients with event/cumulative follow-up time * 100, where the 
follow-up time for each patient is defined as either: 
• the first dose of zilebesiran to the time of the first event occurrence for the patients 
with the event, or  
• the total duration of exposure for the patients without the event.  


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
27 
A patient contributes only once to the frequency  for a given AE (overall, by SOC, by preferred 
term). Patients who report multiple occurrences of the same AE (preferred term) will be 
classified according to the most severe occurrence. An AE with missing severity will be assumed 
to be severe. An AE with missing study drug relatedness will be assumed to be related. 
Listings of all deaths (if any), SAEs, and AEs leading to treatment discontinuation will be 
provided.  
AEs of Clinical Interest 
AEs of special interest or AEs mapping to certain standardized MedDRA queries (SMQs) will be 
summarized by SOC and PT. Other SMQs or AE groupings may be evaluated. 
Injection Site Reactions [ISRs]: AEs mapping to the High-Level Term (HLT)= “Injection Site 
Reactions” using MedDRA dictionary will be included in the summary. Frequency (percentages) 
of patients with ISRs by SOC and PT will be presented by treatment. A separate listing will be 
generated to display all patients who reported ISRs. In addition, a table of the number (%) of 
patients with signs and symptoms reported due to ISRs will be generated. 
Hepatic AEs, including Liver Function Test (LFT) abnormalities: Analysis of hepatic AEs 
will include AEs mapping to the Standardized MedDRA Query (SMQ) Drug-related hepatic 
disorders - comprehensive search (includes all narrow and broad terms).  
Acute renal failure/hyperkalemia/hypotension 
Acute renal failure AEs will include AEs mapping to the Standardized MedDRA Query (SMQ). 
The adjudicated renal events will be summarized or listed. 
Hyperkalemia AEs will be through Customized MedDRA Query (CMQ) search. PT terms are 
listed in Section 7.5 .  
Hypotension AEs include AEs mapping to the FDA Medical Queries (FMQ) hypotension search 
(includes narrow terms), and additional terms potentially related to hypotension. List of 
additional terms is in Section 7.5. Frequency (percentages) of these AEs will be summarized by 
SOC and PT.  Separate listings will be generated of all patients reporting these events. 
Additional summaries of AEs mapping to a COVID-19 custom query are described in Section 
5.13.2. 
5.11.2. 
Laboratory Data 
Clinical laboratory values will be expressed in SI units. Missing laboratory data will not be 
imputed. 
For each continuous clinical laboratory parameter (including hematology, serum chemistry, liver 
function tests and coagulation studies), descriptive statistics will be presented for the actual 
values, change from baseline, and percent change from baseline by visit. These by-visit tables 
will use central laboratory data only. 
Select clinical laboratory parameters may be graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 or above. Shift 
summary from baseline CTCAE grade to maximum (worst) post-baseline grade will be presented 
for all graded parameters with directionality specified (e.g., hyper or hypo). To determine the 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
28 
worst post-baseline value, all scheduled and unscheduled test results will be used. For 
hematology and serum chemistry, frequency tables of potentially clinically significant (PCS) 
abnormalities will be provided. 
All laboratory data (both central and local) will be provided in data listings.  Out-of-range 
laboratory results will be presented in a separate listing with proper flags. Local laboratory data, 
if available, will also be flagged. 
Liver Function Tests 
A frequency table and a shift table will be produced to summarize the number and percentage of 
patients in each of the below categories at any post-baseline time point.  
• ALT >1 & ≤3, >3 & ≤5, >5 & ≤10, >10 & ≤20, >20×ULN, 
• AST >1 & ≤3, >3 & ≤5, >5 & ≤10, >10 & ≤20, >20×ULN, 
• ALT or AST >1 & ≤3, >3 & ≤5, >5 & ≤10, >10 & ≤20, >20×ULN, 
• ALP > 1.5×ULN, 
• Total Bilirubin >1.5 & ≤2, >2 & ≤3, >3 & ≤5 and >5×ULN, 
• Total Bilirubin > 2×ULN concurrent with ALT or AST > 3×ULN 
In separate evaluation of drug-induced serious hepatotoxicity (eDISH) figures, the peak total 
bilirubin (as multiple of ULN) at any time post-baseline will be plotted against the peak ALT, 
AST, ALT or AST level and at any time post-baseline. 
A listing for all patients with abnormal liver function tests, defined as an ALT >3×ULN, AST 
>3×ULN, or total bilirubin >2×ULN at any time point, will also be provided. 
Renal function  
Estimated glomerular filtration rate (eGFR) will be calculated from serum creatinine (SCr) based 
on the Modification of Diet in Renal Disease (MDRD) Formula: 
• Conventional units – eGFR (mL/min/1.73 m2) = 175 × (SCr[mg/dL])-1.154 × (age)-0.203 
and (× 0.742, if female) and (× 1.212, if African American) 
• SI units – eGFR (mL/min/1.73 m2) = 175 × (SCr[µmol/L]/88.4)-1.154 × (age)-0.203 and 
(× 0.742, if female) and (× 1.212, if African American) 
5.11.3. 
Electrocardiogram 
Electrocardiogram (ECG) findings will include rhythm and overall interpretation.  
Post-baseline overall interpretation (normal vs. abnormal) will be summarized in frequency table 
by treatment and visit. 
All ECG data for each patient will be provided in a data listing. 
5.11.4. 
Vital Signs 
For vital signs except blood pressure, descriptive statistics for actual values and change from 
baseline will be provided by treatment and visit for each variable. Vital sign measurements will 
be presented for each patient in a data listing, with abnormal vital signs flagged. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
29 
Abnormal vital signs will be summarized by treatment arm. The abnormality is defined as:  
mean sitting office SBP > 160 mmHg; Increment from baseline > 40 mmHg; <90 mmHg; 
decrement from baseline >40 mmHg;  
mean sitting office DBP > 100 mmHg, increment from baseline >20 mmHg; < 50 mmHg; 
decrement from baseline > 20 mmHg. 
 
In addition, orthostatic hypotension will be summarized by treatment arm. Orthostatic 
hypotension is defined as office SBP drop at least 20mmHg or office DBP drop at least 10 
mmHg from sitting position to standing position. 
5.11.5. 
Evaluation of Subgroups  
AE summary tables will be separately generated for each of the subgroups as defined for the 
primary efficacy endpoint (see Section 5.7.4). 
5.12. 
Interim Analysis 
No interim analysis is planned for this study. 
5.13. 
COVID-19 
Additional data are collected to characterize the impact of the COVID-19 pandemic on general 
study conduct and disposition, and subsequently, additional analyses and summaries will be 
provided in acknowledgement of multiple regulatory guidance (including FDA Guidance on 
Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic: Guidance for 
Industry, Investigators, and Institutional Review Boards, US Food and Drug Administration, 
2020; Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) 
Pandemic, European Medicines Agency, 2020; Points to consider on implications of Coronavirus 
disease (COVID-19) on methodological aspects of ongoing clinical trials, European Medicines 
Agency, 2020; Statistical Considerations for Clinical Trials During the COVID-19 Public Health 
Emergency, US Food and Drug Administration, 2020). 
5.13.1. 
General Impact 
Patients who discontinue treatment or stop study participation due to COVID-19 will be included 
in patient disposition summaries as described in Section 5.1. 
Impact on study participation due to COVID-19, including missing visits, visit location changes, 
study drug dosing changes and missing doses, will be listed. 
Impact on study participation due to COVID-19 will be presented in data listings at patient and 
visit level. 
5.13.2. 
Impact on Adverse Events 
An overall summary of AEs mapping to a COVID-19 custom query will be presented. AEs 
mapping to the COVID-19 custom query will be summarized by SOC and PT. Due to the 
evolving nature of COVID-19-related MedDRA terminology, the COVID-19 custom query will 
be based on the latest information available at the specified analysis timepoint. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
30 
AEs mapping to the COVID-19 custom query will also be presented in a data listing.  
6. 
CHANGES FROM PLANNED ANALYSES 
Original SAP 
Section of the SAP 
Summary of change from 
protocol 
Rationale 
— 
—  
— 
Amendment 1 
Section of the SAP 
Summary of change from 
original SAP 
Rationale 
Section 3 
Ukraine patients handling  
During the study conduct, 16 patients were 
randomized from Ukraine in January/February 
2022 before geographic conflict started. Due 
to the challenge of data collection and 
cleaning, these patients will be excluded from 
the analysis sets defined below. Data from 
these patients will be listed only. 
Section 4.5 
ABPM baseline definition: 
 
Original SAP defines ABPM 
baseline as the one used for 
eligibility.  
In SAP Amendment 1, baseline 
ABPM definition is updated to 
use the last non-missing 
assessments prior to receiving 
study drug.  
Per schedule of assessment table, ABPM is 
only measured once during screening. It will 
be used for both enrollment eligibility and 
baseline for efficacy analysis. However, 
unscheduled ABPM assessments during 
screening were also performed in some 
patients. It is more appropriate to use the last 
one prior to randomization as the baseline for 
efficacy analyses.  
Section 4.7 
Remove Month 12 analysis as 
planned analysis  
There is no planned CSR when all patients 
complete 12-month DB period. Therefore, 
formal analysis is not needed.  
Section 5.7.2.2 
Add ABPM dipping definition 
ABPM dipping pattern was listed as a 
secondary endpoint. Details of the endpoint 
are specified. 
Section 5.11.2 
eGFR calculation 
eGFR will be derived for analysis. Formula is 
provided.  
Section 7.4 
Add list of rescue 
antihypertensive medication 
ATC code 
Rescue antihypertensive medication is 
important for the primary analyses of the 
primary endpoint and several key-secondary 
endpoints. The list of medication ATC code is 
added.  
Amendment 2 
Section of the SAP 
Summary of change from 
SAP Amendment 1 
Rationale 
Section 5.7.2 
Clarify for BP control and 
response endpoint, missing data 
is considered as non-responder. 
Clarification 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
31 
Section 5.7.3 
Remove the correlation 
between wearable device and 
other BP assessments 
During the study conduct, data collected by 
wearable device is very limited.  
Section 5.7.3 
Clarify BP control and 
response rate analysis 
Clarification 
Section 5.11.1 
Clarify both exposure adjusted 
event rate and incidence rate 
will be summarized for AEs 
during zilebesiran treatment 
period 
Clarification 
Section5.11.1 
Add additional safety analyses 
based on AE for: acute renal 
failure, hyperkalemia, and 
hypotension  
Acute renal failure, hyperkalemia and 
hypotension are potential risks for RAAS 
inhibitors.  
7. 
APPENDICES 
7.1. 
Protocol Schedule of Assessments 
Schedule of assessments are listed in Table 2. 








Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
35 
c Clinical laboratory assessments and blood pressure measurements taken for eligibility must be performed after at least 4 weeks of washout. 
d Office blood pressure must be measured before the patient takes oral antihypertensive medications.  
e ABPM recordings associated with dosing visits must be obtained within 7 days before the dosing visit and results reviewed before dosing. ABPM should only be collected at 
Months 18 and 24 for patients in the DB Extension period. 
f HBPM must be measured in the morning upon waking. HBPM should be measured daily between Months 5 and 6 if oral antihypertensives are temporarily held. HBPM is not 
required at times when ABPM is being assessed. 
g ABPM and collection of RAAS biomarkers should only be performed as part of ET assessments if the patient discontinues the study prior to Month 12, and ABPM should only 
be performed at ET if the patient and has not had an ABPM within the last 3 months. These assessments should not be performed at Month 36. 
h  Fasting plasma laboratory samples should only be collected at Month 18.i  The ADA sample should only be collected at the first Follow-Up visit during the Follow-up 
period.


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
36 
7.2. 
Time-Adjusted Change from Baseline 
Time-adjusted change from baseline is the area under the curve (AUC) divided by time interval. 
It leads to a weighted average of all scheduled change from baseline during that time interval.  
E.g., ABPM is assessed at Month 1, 3 and 6. Time-adjusted change from baseline through Month 
6 in 24-hour mean SBP assessed by ABPM is: 
1. AUC is calculated as:  ቂ
1
2 (𝑦𝑦1 + 𝑦𝑦3) ∗2 + 
1
2 (𝑦𝑦3 + 𝑦𝑦6) ∗3 ቃ 
2. Time interval is 5 months, from Month 1 to Month 6. AUC divided by time interval is  
𝐴𝐴𝐴𝐴𝐴𝐴5
⁄
= 0.2 ∗𝑦𝑦1 + 0.5 ∗𝑦𝑦3 + 0.3 ∗𝑦𝑦6 
Where 𝑦𝑦1, 𝑦𝑦3 and 𝑦𝑦6 are the 24-hour mean ABPM at Month 1, 3, and 6.   
Table 3  listed all time-adjusted endpoints and the weights of the assessments. 
Table 3  
Time-Adjusted Endpoints 
Time-adjusted Endpoint 
Weighted average 
Time-adjusted change from baseline 
through Month 3 in 24-hour mean 
SBP/DBP assessed by ABPM 
0.5 ∗𝑦𝑦1 + 0.5 ∗𝑦𝑦3 
Time-adjusted change from baseline 
through Month 3 in office SBP/DBP  
0.25 ∗𝑦𝑦1 + 05 ∗𝑦𝑦2 + 0.25 ∗𝑦𝑦3 
Time-adjusted change from baseline 
through Month 6 in 24-hour mean 
SBP/DBP assessed by ABPM 
0.2 ∗𝑦𝑦1 + 0.5 ∗𝑦𝑦3 + 0.3 ∗𝑦𝑦6 
Time-adjusted change from baseline 
through Month 6 in office SBP/DBP  
0.1 ∗𝑦𝑦1 + 0.2 ∗𝑦𝑦2 + 0.2 ∗𝑦𝑦3 + 0.2 ∗𝑦𝑦4 + 0.2 ∗𝑦𝑦5 + 0.1 ∗𝑦𝑦6 
7.3. 
Missing or Partial Dates 
7.3.1. 
Prior and Concomitant Medications 
For medications with partial start or end dates: the first day/month will be imputed for start date, 
and the last day/month will be imputed for end date. For medications with a completely missing 
start date, the medications will be considered as started one day prior to the first dose of study 
drug. If an imputed start date is after the collected end date, the end date will be used as the 
imputed start date. For medications with a completely missing end date or an imputed end date 
that is after the earliest date of: end of study date, data cutoff date or date of death, the latter (i.e., 
the earliest date of: end of study date, data cutoff date or date of death) will be used as the 
imputed end date. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
37 
7.3.2. 
Adverse Events 
For records with fully or partially missing AE onset date, conventions for the imputation is as 
below: 
• AE onset dates with missing day and non-missing month will be imputed to occur on 
the first day of the non-missing month, except for AEs occurring in the first month of 
dosing, in which case the date will be the first day of dosing. 
• AE onset dates with missing month will be imputed to occur on the first day of the 
non-missing year (i.e., January 1), except for AEs occurring in the first year of 
dosing, in which case the date will be the first day of dosing.  
• If year of the AE start date is missing, the onset date will be imputed as the first day 
of dosing, except if it can be unequivocally determined (from the partial or complete 
stop date) that the event occurred prior to the first dose of study drug, in which case 
the AE onset date will not be imputed.  
• If an imputed onset date is after the collected AE end date, the end date will be used 
as the imputed onset date.  
7.3.3. 
Others 
For other incomplete dates, unless otherwise specified, the following conventions will be used 
for the calculation of duration (e.g., time in years since diagnosis): 
• Missing day: the first day of the month will be used. 
• Missing month: the January 1 of the non-missing year will be used. 
• Missing year: no duration will be calculated. 
7.4. 
List of Rescue Antihypertensive Medication ATC Code 
The ATC codes for rescue medications are: 
• C02 - Antihypertensives 
• C03 - Diuretics 
• C07 - Beta blocking agents 
• C08 - Calcium channel blockers 
• C09 - Agents acting on the renin-angiotensin system 
 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 2, 14 July 2023 
Alnylam Pharmaceuticals 
Confidential 
38 
7.5. 
Preferred Terms for Hyperkalemia and Potentially Related to 
Hypotension 
Hyperkalemia: 
Hyperkalemia 
Blood potassium increased 
Blood potassium abnormal 
Potential Hypotension: 
Blood pressure fluctuation 
Labile blood pressure 
Orthostatic intolerance 
Circulatory collapse   
Distributive shock 
Dizziness 
Dizziness exertional 
Dizziness postural 
Hypoperfusion 
Peripheral circulatory failure 
Presyncope 
Procedural shock 
Shock 
Shock symptom 
Syncope 
Cardiovascular insufficiency 
Hypotensive crisis 
Hypotensive transfusion reaction 
Orthostatic hypotension 
Vasolplegia syndrome 
Blood pressure abnormal 
Blood pressure ambulatory abnormal 
Blood pressure ambulatory decreased 
Blood pressure diastolic abnormal 
Blood pressure immeasurable 
Blood pressure orthostatic abnormal 
Blood pressure orthostatic decreased 
Blood pressure systolic decreased 
Blood pressure systolic inspiratory decreased 
Mean arterial pressure decreased 
Loss of consciousness 
 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
1 
 
STATISTICAL ANALYSIS PLAN 
ALN-AGT01-002 (KARDIA-1) 
 
Protocol Title: 
A Randomized, Double-blind, Placebo-
Controlled, Dose-Ranging Multicenter Study 
to Evaluate the Efficacy and Safety of ALN-
AGT01 in Patients with Mild-to-Moderate 
Hypertension 
Short Title: 
A Study to Evaluate Efficacy and Safety of 
ALN-AGT01 in Patients with Mild-to-
Moderate Hypertension (KARDIA-1) 
Study Drug: 
Zilebesiran (ALN-AGT01) 
Protocol Date: 
Original protocol, 09 April 2021 
Amendment 1, 20 April 2021 
Amendment 2, 09 June 2021 
Amendment 3, 09 December 2021 
Amendment 4, 22 March 2022 
SAP Date: 
Original SAP: 29 March 2022 
 
Amendment 1: 11 October 2022 
Sponsor: 
Alnylam Pharmaceuticals, Inc. 
300 Third Street 
Cambridge, MA 02142 USA 
Telephone: +1-617-551-8200 
 
 
 
 
The concepts and information contained in this document or generated during the study are 
considered proprietary and may not be disclosed in whole or in part without expressed written 
authorization of Alnylam Pharmaceuticals, Inc. 
 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
2 
APPROVAL SIGNATURE PAGE 
 
 
 
 
 
 
This document has been authored, approved, and signed electronically on the final page by 
the following: 
 
 
 
Alnylam Pharmaceuticals, Inc. 
 
 
This document has been approved and signed electronically on the final page by the 
following: 
 
 
 
 
Alnylam Pharmaceuticals, Inc. 
 
 
 
 
Alnylam Pharmaceuticals, Inc. 
 
 
PPD
PPD
PPD
PPD
PPD
PPD


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
3 
TABLE OF CONTENTS 
APPROVAL SIGNATURE PAGE .................................................................................................2 
LIST OF ABBREVIATIONS ..........................................................................................................6 
1. 
INTRODUCTION ........................................................................................................8 
2. 
STUDY DESIGN .........................................................................................................8 
2.1. 
General Study Design ...................................................................................................8 
2.2. 
Objectives and Endpoints ...........................................................................................10 
2.3. 
Study Procedure ..........................................................................................................11 
2.4. 
Randomization Methodology .....................................................................................11 
2.5. 
Blinding ......................................................................................................................12 
2.6. 
Determination of Sample Size ....................................................................................13 
3. 
ANALYSIS POPULATIONS ....................................................................................13 
3.1. 
Randomization and Treatment Errors .........................................................................14 
4. 
GENERAL STATISTICAL CONSIDERATIONS ....................................................14 
4.1. 
General Considerations ...............................................................................................14 
4.2. 
Blood Pressure Collection and Handling ....................................................................15 
4.2.1. 
24-Hour Ambulatory Blood Pressure Monitoring ......................................................15 
4.2.2. 
Office Blood Pressure .................................................................................................15 
4.2.3. 
Home Blood Pressure Monitoring ..............................................................................15 
4.3. 
Multiple Comparisons/Multiplicity Procedure ...........................................................15 
4.4. 
Handling of Missing Data ...........................................................................................17 
4.5. 
Baseline Definitions ....................................................................................................17 
4.6. 
Randomization Stratification Factors .........................................................................17 
4.7. 
Planned Analyses and Data Cutoffs ...........................................................................17 
4.7.1. 
Primary Analysis ........................................................................................................17 
4.7.2. 
Final Analysis .............................................................................................................18 
5. 
STATISTICAL ANALYSES .....................................................................................18 
5.1. 
Patient Disposition ......................................................................................................18 
5.2. 
Demographics and Baseline Characteristics ...............................................................19 
5.3. 
Medical History ..........................................................................................................19 
5.4. 
Protocol Deviations ....................................................................................................19 
5.5. 
Study Drug Exposure and Compliance .......................................................................19 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
4 
5.6. 
Prior and Concomitant Medications ...........................................................................20 
5.7. 
Efficacy Analyses .......................................................................................................20 
5.7.1. 
Primary Endpoint ........................................................................................................20 
5.7.1.1. 
Definition of Estimand ...............................................................................................20 
5.7.1.2. 
Primary Analysis ........................................................................................................21 
5.7.1.3. 
Sensitivity Analyses ....................................................................................................21 
5.7.1.4. 
Other Analyses ............................................................................................................21 
5.7.2. 
Secondary Endpoints ..................................................................................................21 
5.7.2.1. 
Key Secondary Endpoints ...........................................................................................21 
5.7.2.2. 
Other Secondary Endpoints ........................................................................................22 
5.7.3. 
Exploratory Endpoints ................................................................................................23 
5.7.4. 
Evaluation of Subgroups .............................................................................................24 
5.8. 
Pharmacodynamic Analyses .......................................................................................24 
5.9. 
Pharmacokinetic Analyses ..........................................................................................24 
5.10. 
Anti-Drug Antibody ....................................................................................................25 
5.11. 
Safety Analyses ..........................................................................................................25 
5.11.1. 
Adverse Events ...........................................................................................................25 
5.11.2. 
Laboratory Data ..........................................................................................................27 
5.11.3. 
Electrocardiogram .......................................................................................................28 
5.11.4. 
Vital Signs ..................................................................................................................28 
5.11.5. 
Evaluation of Subgroups .............................................................................................28 
5.12. 
Interim Analysis ..........................................................................................................28 
5.13. 
COVID-19 ..................................................................................................................28 
5.13.1. 
General Impact ............................................................................................................28 
5.13.2. 
Impact on Adverse Events ..........................................................................................29 
6. 
CHANGES FROM PLANNED ANALYSES............................................................29 
7. 
APPENDICES ............................................................................................................30 
7.1. 
Protocol Schedule of Assessments .............................................................................30 
7.2. 
Time-Adjusted Change from Baseline .......................................................................35 
7.3. 
Missing or Partial Dates ..............................................................................................35 
7.3.1. 
Prior and Concomitant Medications ...........................................................................35 
7.3.2. 
Adverse Events ...........................................................................................................36 
7.3.3. 
Others ..........................................................................................................................36 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
5 
7.4. 
List of Rescue Antihypertensive Medication ATC Code ...........................................36 
 
LIST OF TABLES 
Table 1 
Multiplicity Procedure ................................................................................................16 
Table 2  
Schedule of Assessments ............................................................................................31 
Table 3  
Time-Adjusted Endpoints ...........................................................................................35 
 
LIST OF FIGURES 
Figure 1 
Study Design .................................................................................................................9 
 
 
 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
6 
LIST OF ABBREVIATIONS 
Abbreviation  
Definition 
ABPM 
Ambulatory blood pressure monitoring 
ADA 
Anti-drug antibody(ies) 
AE 
Adverse event 
AGT 
Angiotensinogen 
ALT 
Alanine aminotransferase 
AngI/II 
Angiotensin I/II 
AST 
Aspartate aminotransferase 
AUC 
Area under the curve 
DB 
Double-blind 
DBP 
Diastolic blood pressure 
ECG 
Electrocardiogram 
eGFR 
Estimated glomerular filtration rate 
eDISH 
Evaluation of drug-induced serious hepatotoxicity 
EOT 
End of treatment 
ET 
Early termination 
FAS 
Full analysis set 
HbA1c 
Hemoglobin A1c 
HBPM 
Home blood pressure monitoring 
HLT 
High level term 
ICF 
Informed consent form 
IEC 
Independent Ethics Committee 
IRB 
Institutional Review Board 
IRT 
Interactive Response Technology 
ISR 
Injection site reaction 
LFT 
Liver function test 
LLOQ 
Lower limit of quantification 
MedDRA 
Medical Dictionary for Regulatory Activities 
MMRM 
Mixed more for repeated measurement 
OLE 
Open-label extension 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
7 
Abbreviation  
Definition 
PD 
Pharmacodynamic(s) 
PK 
Pharmacokinetic(s) 
PT 
Preferred term 
Q3M 
Once every 3 months 
Q6M 
Once every 6 months 
RAAS 
Renin-angiotensin-aldosterone system 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SBP 
Systolic blood pressure 
SC 
Subcutaneous(ly) 
SD 
Standard deviation 
SOC 
System Organ Class 
ULN 
Upper limit of normal 
ULOQ 
Upper limit of quantification 
 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
8 
1. 
INTRODUCTION 
This statistical analysis plan (SAP) details comprehensive specifications of the efficacy, safety, 
pharmacokinetic (PK) and pharmacodynamic (PD) data summaries and statistical analyses in 
support of the clinical study report (CSR) for Study ALN-AGT01-002 (KARDIA-1). This SAP 
is finalized prior to treatment unblinding and conducting the primary analysis, which will occur 
after all patients complete the Month 6 visit or withdraw from the study prior to the Month 6 
visit. Changes to planned analyses specified in this SAP made after database lock will be 
documented in the CSR. 
Table, figure, and listing (TFL) mocked shells and specifications are contained in a separate 
document. 
2. 
STUDY DESIGN  
2.1. 
General Study Design  
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study 
designed to evaluate the safety, efficacy, and pharmacodynamics (PD) of zilebesiran (ALN-
AGT01), administered subcutaneously (SC), in patients with mild-to-moderate hypertension. A 
schematic of the study design is provided in Figure 1. Before randomization, patients will 
discontinue prior antihypertensive medications (if taking) for a Washout period of at least 2 
weeks (4 weeks of washout is required for long-acting antihypertensive medications, such as 
long-acting diuretics or calcium channel blockers). Patients who complete the Screening period 
and meet all inclusion/exclusion criteria for enrollment will receive zilebesiran or placebo for the 
first 6 months of the 12-month Double-blind (DB) treatment period.  
Starting at Month 3, conventional oral antihypertensives may be added per Investigator 
judgement for elevated blood pressure. Oral antihypertensives (if taking) will be temporarily 
held from Month 5 to Month 6 to assess the effect of zilebesiran alone (vs placebo) at Month 6. 
During this 4-week period, blood pressure will be carefully monitored by daily home blood 
pressure monitoring and medications restarted if indicated. Patients may resume conventional 
oral antihypertensives at Month 6 per Investigator judgement. 
Patients randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial zilebesiran 
regimens until the end of the DB period. Patients randomized to zilebesiran regimens will remain 
on their originally assigned regimens through Month 12. 
After the 12-month DB treatment period, patients may be eligible to participate in a zilebesiran 
open-label extension (OLE) study. If an individual patient reaches Month 12 prior to availability 
of the OLE study, they may continue their current blinded dosing in the DB Extension period for 
up to 12 additional months until the OLE study is open and then transition. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
9 
Figure 1 
Study Design 
 
Abbreviations: aHTN=antihypertensive medications; DB=double-blind; M=month; OLE=open-label extension; 
PBO=placebo; PO=per os (oral); Q3M=once every 3 months; Q6M=once every 6 months; R=randomization; 
SC=subcutaneous; WO=washout. 
Note: Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the Month 12 
predose assessments. If an individual patient reaches Month 12 prior to availability of the OLE study, they may 
continue their current blinded dosing in the DB Extension period for up to 12 additional months until the OLE study 
is open and then transition. Once the OLE study is open for enrollment, eligible patients may rollover into the OLE 
study at Months 12, 18, or 24 (whichever visit occurs first). 
Note: Patients who were previously taking antihypertensives at screening should undergo a washout of these 
medications for at least 2 weeks during the Screening period (4 weeks of washout is required for long-acting 
antihypertensive medications, such as long-acting diuretics or calcium channel blockers).






Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
12 
• Placebo SC once every 3 months 
• 150 mg zilebesiran SC once every 6 months 
• 300 mg zilebesiran SC once every 6 months 
• 300 mg zilebesiran SC once every 3 months 
• 600 mg zilebesiran SC once every 6 months 
Patients initially randomized to placebo will be re-randomized 1:1:1:1 at Month 6 to 1 of the 4 
initial zilebesiran regimens. 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. 
Randomization will be stratified by race (black vs all other races) and by baseline blood pressure 
(mean 24-hour SBP < or ≥145 mmHg). 
Each patient will be uniquely identified in the study by a combination of the site number and 
patient identification number. Upon signing the informed consent form (ICF), the patient will be 
assigned a patient identification number by the IRT system. The Investigator or his/her designee 
will randomize the patient in IRT after confirming that the patient fulfills all the inclusion criteria 
and none of the exclusion criteria. The Investigator or his/her designee will re-randomize the 
patient in IRT at Month 6 to assign placebo patients to 1 of the 4 initial zilebesiran dose groups 
in a way that maintains the study blind for the patient. 
2.5. 
Blinding  
The Sponsor, all site personnel (except for the site pharmacist or delegate), and patients will be 
blinded to study drug treatment through Month 6 of the 12-month DB period. During the course 
of the study, serum AGT, plasma PK, and treatment assignment using dummy IDs will be made 
available to a small, independent pharmacometrics team at the Sponsor that will not be involved 
in the conduct or oversight of the study. After the last patient completes the Month 3 visit and 
prior to the last patient’s Month 6 visit, SBP data from a limited number of patients (about on-
third) will be made available to this small, independent pharmacometrics team for preliminary 
PK/PD modeling. After the database lock to support the analysis of Month 6 data is complete, all 
other Sponsor personnel will be unblinded to treatment assignment, but the site personnel (except 
for the site pharmacist) and patients will remain blinded to treatment assignment until after the 
analysis of Month 12 data is complete. The Sponsor and all site personnel will be blinded to 
serum AGT results until their respective unblinding. Serum AGT results will not be reported to 
site personnel until the last patient completes the assessments at the Month 12 visit. 
Blinded doses of study drug will be administered under the supervision of the Investigator (refer 
to Protocol Section 5.2.2). All patients will receive the same volume and number of injections 
regardless of treatment assignment (patients receiving once every 6-month zilebesiran regimens 
will receive placebo SC at dosing visits at which they do not receive zilebesiran to maintain the 
blind). Because zilebesiran may be slightly visually distinguishable from placebo, all blinded 
study drug doses will be prepared, and the syringe(s) will be masked by a site pharmacist or 
delegate prior to administration by a blinded healthcare professional. See the Pharmacy Manual 
for additional details. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
13 
Details about the specifics of the blinding aspects throughout the entire study are available in the 
Randomization and Blinding Plan.  
Any unplanned/emergency unblinding occurring during the DB Period will be documented and 
reported in the CSR. 
Refer to the study Randomization and Blinding Plan for more details. 
2.6. 
Determination of Sample Size 
Assuming a standard deviation (SD) in the range of 15 to 20 mmHg in change from baseline at 
Month 3 in 24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size 
between zilebesiran and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size 
of 375 patients (75 per treatment group) provides at least 84% power to detect a dose response 
signal in SBP reduction among all zilebesiran doses and placebo at the 2-sided significance level 
of 0.05. In addition, this sample size provides at least 80% power to detect a 10 mmHg 
difference between an individual zilebesiran dose versus placebo with a 2-sided significance 
level of 0.05.  
3. 
ANALYSIS POPULATIONS 
During the study, 16 patients were randomized from Ukraine in January and February 2022 
before a geographic conflict started in February 2022. In response to this conflict, Regulatory 
Authorities advised Sponsors to refer to guidance documents issued during the COVID-19 
pandemic with respect to the handling of clinical trial sites in Ukraine. In line with these 
guidance documents, and due to challenges in data collection and cleaning and verification of 
such data, data from patients enrolled at sites in Ukraine will be excluded from the analysis sets 
defined below. Data from these patients will be provided in listings.  
The populations (analysis sets) are defined as follows: 
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• PK Analysis Set: All patients who received at least 1 full dose of ALN-AGT01 and 
have at least 1 nonmissing postdose PK assessment. 
• PD Analysis Set: All patients who received at least 1 full dose of study drug. All by-
treatment analyses based on the PD Analysis Set will be grouped according to the 
treatment actually received. 
• All Zilebesiran Treated Set: All patients who received any amount of 1 of the 4 ALN-
AGT01 dosing regimens, including patients who took ALN-AGT01 during the 6-
month placebo-controlled period and patients who initially took placebo and then 
switched to ALN-AGT01 after the Month 6 visit.  
 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
14 
For the primary analysis for 6-month placebo-controlled DB period, the primary population used 
to evaluate efficacy will be the FAS. Safety will be analyzed using the Safety Analysis Set. The 
PK and PD Analysis Sets will be used to conduct PK and PD analyses, respectively.  
The All Zilebesiran Treated Set will be used to summarize the efficacy and safety of zilebesiran 
throughout the entire DB period (including DB extension period).  
3.1. 
Randomization and Treatment Errors 
For patients who were not treated, not randomized, or received incorrect treatment, the following 
rules will be used:  
• Randomized but not treated: they will be excluded from the FAS and Safety Analysis 
Set for efficacy and safety evaluations as actual treatment is missing.  
• Treated but not randomized: they will be excluded from the efficacy analyses since 
randomized treatment is missing but will be reported under the treatment actually 
received for all safety analyses.  
• Randomized but took incorrect treatment: they will be reported under their 
randomized treatment arm for all efficacy analyses. But for safety analyses, a patient 
will be included under the active treatment arm if the patient is randomized to placebo 
arm and received an active dose by mistake. 
4. 
GENERAL STATISTICAL CONSIDERATIONS 
4.1. 
General Considerations 
In general, data will be summarized for each planned analysis defined in Section 4.7 separately. 
For Month 3 endpoints, zilebesiran 300mg Q3M and 300mg Q6M will be pooled together.  
Categorical variables will be summarized using counts and percentages. Continuous variables 
will be summarized using the following descriptive summary statistics: number of patients (n), 
mean, standard deviation (SD), median, first quartile (Q1), third quartile (Q3), minimum, and 
maximum. 
The day of the first dose of study drug administered is defined as Day 1. The Study Day of a 
time point of interest is calculated as follows: 
• If on or after Day 1, Study Day = date of interest – date of the first dose of study drug 
+ 1 
• If prior to Day 1, Study Day = date of interest – date of the first dose of study drug 
There is no Day 0. For example, the day before the first study drug dose is defined as Day -1. 
For laboratory parameters, assessments collected and recorded as lower than the lower limit of 
quantification/detection (LLOQ) will be replaced by the LLOQ. Any assessment collected and 
recorded as greater than the upper limit of quantification (ULOQ) will be replaced by the ULOQ. 
All descriptive summaries will be presented by treatment arm. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
15 
Statistical analyses will be conducted using SAS software Version 9.4 or newer or R version 3.6 
or newer. 
4.2. 
Blood Pressure Collection and Handling 
4.2.1. 
24-Hour Ambulatory Blood Pressure Monitoring 
24-hour ambulatory blood pressure monitoring (ABPM) is programmed to take readings every 
20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 
5:59 am). An ABPM will be considered adequate if (1) recording time is at least 22 hours (2) the 
number of successful daytime readings is ≥33, (3) the number of successful nighttime readings is 
≥11, and (4) no more than 3 hours are not represented (ie, 3 sections of 60 minutes where 0 valid 
readings were obtained). If the ABPM recording is inadequate, the patient will be provided 1 
opportunity to repeat the study within 4 days.  
To summarize the 24-hour ABPM, hourly adjusted mean will be calculated. Hourly adjusted 
mean will be calculated by two steps:  
1. Calculate the hourly mean: average of BP by each hour of the day (e.g., mean of BP 
measurements from 16:00 to 16:59). If there is no reading in a specific hour, this hour 
will not be included in calculation.   
2. Calculate the 24-hour mean: average of the hourly means.  
4.2.2. 
Office Blood Pressure 
The office BP in the sitting position will be used for the analysis. Office BP will be collected 
with a set of 4 replicates. The average of the last 3 replicates will be calculated and used for 
analysis. Office BP collected in standing position will be listed.   
4.2.3. 
Home Blood Pressure Monitoring 
Home blood pressure will be measured both pre and post randomization. To establish baseline, 
each patient should measure HBPM during the week (with at least 3 successful readings) 
immediately prior to randomization. After Day 1, HBPM will be measured at least once per 
week. Four sequential blood pressure measurements at 1-minute intervals will be recorded. The 
seated blood pressure for the visit will be defined by the average of the last 3 individual 
measurements. HBPM will be summarized by weekly average.  
Details of the blood pressure collection are in Study Protocol Section 10. 
4.3. 
Multiple Comparisons/Multiplicity Procedure 
The overall familywise error rate will be controlled at α=0.05 for the primary and key secondary 
endpoints as shown in Table 1  


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
16 
Table 1 
Multiplicity Procedure 
Test 
Stepa 
Endpoint 
Comparison 
Success criteria 
1 
Change from baseline at Month 3 in 24-
hour mean SBP assessed by ABPM 
Dunnett’s 
Procedure 
If the global hypothesis is 
rejected at 0.05 alpha level, 
then at least one zilebesiran 
dose is superior to Placebo 
2 
Change from baseline at Month 3 in 24-
hour mean SBP assessed by ABPM 
300 mg Q3M 
vs placebo b 
Nominal p-value < 0.05 
3 
Change from baseline at Month 3 in 24-
hour mean SBP assessed by ABPM 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 
4 
Change from baseline at Month 3 in office 
SBP 
300 mg Q3M 
vs placebo b 
Nominal p-value < 0.05 
5 
Change from baseline at Month 3 in 
office SBP 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 
6 
Change from baseline at Month 6 in 24-
hour mean SBP assessed by ABPM 
300 mg Q3M 
vs placebo 
Nominal p-value < 0.05 
7 
Change from baseline at Month 6 in 24-
hour mean SBP assessed by ABPM 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 
8 
Change from baseline at Month 6 in 
office SBP 
300 mg Q3M 
vs placebo 
Nominal p-value < 0.05 
9 
Change from baseline at Month 6 in 
office SBP 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 
10 
Proportion of patients with 24-hour mean 
SBP assessed by ABPM <130 mmHg 
and/or reduction ≥20 mmHg without 
additional antihypertensive medications at 
Month 6 
300 mg Q3M 
vs placebo 
Nominal p-value < 0.05 
11 
Proportion of patients with 24-hour mean 
SBP assessed by ABPM <130 mmHg 
and/or reduction ≥20 mmHg without 
additional antihypertensive medications at 
Month 6 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
17 
a  If the MCP criterion is satisfied in a given step, the hypothesis test is deemed statistically significant and the next 
step will be evaluated; otherwise all hypotheses in the given and subsequent steps are deemed not statistically 
significant 
b 300mg Q3M and 300mg Q6M will be pooled together for the test 
4.4. 
Handling of Missing Data 
No imputation will be done for missing values for the primary analysis of the primary endpoint. 
Results based on mixed model with repeated measurements (MMRM) are valid based on missing 
at random (MAR) assumption. A sensitivity analysis of the primary endpoint using an imputation 
method will be performed (details described in Section 5.7.1.3). For all analyses using MMRM, 
no explicit imputation of missing values will be done. 
4.5. 
Baseline Definitions 
For the primary analysis of 6-month placebo-controlled period, for office BP, baseline is the 
average of the office BP value on Day 1 prior to receive the first dose of study drug and last non-
missing value prior to Day 1 during screening visit. For HBPM, baseline will be the average of 
all assessments during last week prior to receive the first dose of study drug. For all other 
endpoints including ABPM, baseline is the last non-missing value (including unscheduled visit) 
prior to receive the first dose of study drug. 
For final analyses, patients initially randomized to placebo and re-randomized at Month 6 will be 
summarized in two ways:  
From Day 1. Baseline is the same as the one for the primary analysis. 
From the start of zilebesiran dosing at Month 6. Baseline will be the last assessment prior to 
Month 6 dosing.  
For patients initially randomized to zilebesiran dosing regimen, baseline remains the same as the 
one for the primary analysis.  
4.6. 
Randomization Stratification Factors 
Randomization will be stratified by race (black vs all other races) and by baseline blood pressure 
(mean 24-hour SBP < or ≥145 mmHg). Stratification factors are recorded in the IRT database. 
Key data is integrated into the clinical database. In statistical analyses that use randomization 
stratification factors as covariates, the stratum assignment will reflect the values as recorded in 
the clinical database (EDC). In the presence of stratification errors, the stratification used in 
analysis may not match that in the IRT. A comparison of the number and percentage of patients 
in each randomization stratification factor in IRT versus the clinical database will be summarized 
by randomized treatment arm and overall. 
4.7. 
Planned Analyses and Data Cutoffs 
4.7.1. 
Primary Analysis 
The primary analysis will be performed after the last randomized patient has completed Month 6 
Visit or otherwise discontinued the study. For the primary analysis, as this study will be ongoing 
with some patients in the 12-month DB period, DB extension period or safety follow-up period, 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
18 
the study database will undergo an interim database lock at the Month 6 cutoff dates (i.e., data in 
EDC will be cleaned, frozen and electronically signed by investigators; external laboratory data 
will be cleaned and will undergo quality assurance). Data will be summarized in the CSR. 
Additional details regarding the interim database locks will be documented in the study Data 
Management Plan. 
The primary analysis will include data on, or prior to, this prespecified cutoff date. For 
assessments with starting/ending dates (e.g., adverse events [AEs], medications), the starting date 
will be compared with the pre-specified cutoff date. Data records with starting dates after the 
specified data cutoff date will be excluded.  
4.7.2. 
Final Analysis 
After all patients reach the end of the study, the database will undergo a final database lock, and 
the data will be summarized in the CSR.  
A patient is considered to have reached the end of the study if the patient: 
• has completed at least the Month 12 visit and enrolled in the OLE study, or 
• has completed the Safety Follow-up visits for patients who discontinue study drug or 
do not enroll in the OLE study, or withdrawal from the study. 
5. 
STATISTICAL ANALYSES 
5.1. 
Patient Disposition 
The number and percentage of patients in the following categories will be summarized by 
randomized treatment arm and overall: 
• Randomized 
• Treated 
• Completed the placebo-controlled 6-month double-blind (DB) treatment period 
− Primary reason for discontinuation of treatment during 6-month DB period. 
• Completed the 12-month double-blind (DB) treatment period 
• Discontinuation of treatment and primary reason for discontinuation of treatment 
• Withdrawal from study and primary reason for withdrawal from study 
• Completed the DB extension period 
• Completed the study 
• Rollover to the separate OLE study 
In addition to the primary reason for discontinuation of treatment and withdrawal from study, 
patients will also be categorized if discontinuation/withdrawal was due to COVID-19. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
19 
5.2. 
Demographics and Baseline Characteristics 
Demographic and baseline disease characteristics will be summarized by treatment arm and 
overall for Full Analysis Set, and also presented in listings. 
Age at consent, height, weight, body mass index (BMI), 24-hour mean ABPM and office BP will 
be summarized using descriptive statistics. Sex, race, ethnicity, and country will be summarized 
by presenting the frequencies and percentages of patients in each category.   
5.3. 
Medical History 
Medical history and prior procedures reported will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA), Version 23.1 or newer. Unique patients who report medical 
history events will be summarized by MedDRA system organ class (SOC), high level term 
(HLT) and preferred term (PT). 
5.4. 
Protocol Deviations 
Protocol deviations will be classified by medical review prior to each planned analysis database 
lock, and major protocol deviations will be identified. A major protocol deviation is a deviation 
that may significantly impact the completeness, accuracy, and/or reliability of the trial data; that 
may significantly affect a subject's rights, safety, or well-being. (ICH E3 R1 Structure and 
Contents of Clinical Study Reports Guidance for Industry, 2013). 
The Sponsor or designee will be responsible for producing the protocol deviation file. This file 
will include a description of each protocol deviation and classification as major or minor. The 
protocol deviations will be reviewed and finalized prior to the planned analysis database lock. 
All protocol deviations and major protocol deviations will be summarized and listed. 
5.5. 
Study Drug Exposure and Compliance 
The following variables will be summarized by descriptive statistics and/or frequency tabulation: 
• Duration of exposure, defined as: date of last exposure – date of first dose +1. Date of 
last exposure is the earliest date of the following: 
− date of last dose + the length of dosing interval, i.e.,  
o date of last dose + 169 days for zilebesiran 150 mg Q6M, 300 mg Q6M 
and 600 mg Q6M,  
o date of last dose + 85 days for placebo and 300 mg Q3M. 
− date of end of study 
− date of analysis data cutoff 
• Number of doses received; as continuous and/or categorical variable 
• Number of missed doses; as a categorical variable 
• Total exposure (patient years) 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
20 
5.6. 
Prior and Concomitant Medications 
Medications will be coded using the World Health Organization (WHO) Drug Dictionary, 
version WHO-DD Global B3, March 2021 or newer. Unique patients who reported medications 
will be summarized by Anatomical Therapeutic Chemical (ATC) level 3 class (or level 2 if not 
available) and PT. Summaries will be provided for prior and concomitant medications separately. 
Prior medications are those medications with start date prior to the first dose of study drug. 
Concomitant medications are medications, other than the study drug, administered at or after the 
first dose of study drug, as well as medications that started prior to the first dose of study drug 
and are ongoing after the first dose of study drug.  
If the medication start date is on or after the date of first dose of study drug, the medication will 
be summarized as a concomitant medication even if the medication end date is missing.  
If the end date of a medication is missing or incomplete, such that it cannot be determined 
whether it is after the first dose of study drug, it will be counted as a concomitant medication. 
For missing or partial dates for medications, the imputation of start and end dates is described in 
Section 7.2  
5.7. 
Efficacy Analyses 
5.7.1. 
Primary Endpoint 
5.7.1.1. 
Definition of Estimand 
The primary objective of the study is to evaluate the effect of zilebesiran on SBP as assessed by 
ABPM at Month 3. Primary estimand is defined as: 
• Treatment condition: monotherapy including placebo, zilebesiran 150 mg Q6M, 300 
mg Q6M, 300 mg Q3M and 600 mg Q6M. (300 mg Q6M and Q3M will be pooled 
together) 
• Target population: patients with mild-to-moderate hypertension 
• Endpoint: Change from baseline at Month 3 in 24-hour mean SBP assessed by ABPM 
• Population-level summary: Least square mean difference between zilebesiran and 
placebo in change from baseline at Month 3 in 24-hour mean SBP assessed by ABPM 
• Intercurrent events strategy: Rescue medication taken before Month 3 visit will be 
considered as an intercurrent event. For patients who require rescue medication, given 
the expected number of such patients at Month 3 is low, hypothetical strategy will be 
used, i.e., ABPM assessed while patients are on and within 2 weeks after stopping 
any rescue medication will be censored. This will provide the estimated treatment 
effect of zilebesiran alone. List of rescue medication ATC code is in Section 7.4. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
21 
5.7.1.2. 
Primary Analysis  
The primary endpoint is the change from baseline at Month 3 in 24-hour mean SBP assessed by 
ABPM. The hypothesis of the dose response relationship for the primary endpoint will be tested 
as: 
• H0 : µ1 =µ2 =µ3 = µ0 (there is no dose response relationship)  
• Ha µ1 ≠ µ0 or µ2 ≠ µ0 or µ3 ≠ µ0  (at least one zilebesiran dose is different from 
placebo). 
Where µ0 is the mean change from baseline at Month 3 in 24-hour mean SBP assessed by ABPM 
in placebo arm; and µ1, µ2, and µ3 are the mean changes from baseline at Month 3 in 24-hour 
mean SBP in zilebesiran 150mg Q6M, 300mg Q3M and Q6M pooled, 600mg Q6M arms, 
respectively. 
The above hypothesis will be tested using the Dunnett’s procedure based on Mixed model for 
repeated measurements (MMRM). The MMRM model will include treatment, visit, treatment-
by-visit interaction, race (black; all other races) as fixed factors, baseline 24-hour mean SBP 
assessed by ABPM as a covariate. Unstructured covariance matrix will be used. Least square 
mean difference between zilebesiran and placebo, 95% confidence interval (CI) and adjusted p-
values will be generated.    
5.7.1.3. 
Sensitivity Analyses  
For the sensitivity analysis, treatment policy strategy will be used for patients who require rescue 
medication. All collected blood pressure measurements will be analyzed by the same MMRM 
model as the primary analysis, regardless of the rescue medication. 
Due to the expected long-acting effect of zilebesiran, the commonly used control-based Pattern 
Mixture Model (PMM) will not be used to assess the missing not at random (MNAR) 
assumption. 
5.7.1.4. 
Other Analyses  
To demonstrate zilebesiran consistently controls blood pressure over the 24-hour period, hourly 
mean change from baseline at Month 3 in SBP assessed by ABPM will be plotted for each 
treatment group. 
5.7.2. 
Secondary Endpoints 
5.7.2.1. 
Key Secondary Endpoints 
Secondary objective of the study is to evaluate the effect of zilebesiran on blood pressure 
assessed by ABPM and office blood pressure through Month 6. The estimand is defined as:  
• Treatment condition: monotherapy including placebo, zilebesiran 150mg Q6M, 300mg 
Q6M, 300mg Q3M and 600mg Q6M 
• Target population: patients with mild-to-moderate hypertension 
• Endpoint:  
− Change from baseline at Month 3 in office SBP 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
22 
− Change from baseline at Month 6 in 24-hour mean SBP assessed by ABPM 
− Change from baseline at Month 6 in office SBP 
− Proportion of patients with 24-hour mean SBP assessed by ABPM <130 mmHg 
and/or reduction ≥20 mmHg without additional antihypertensive medication at 
Month 6 
• Population-level summary: Least square mean difference between zilebesiran and 
placebo in each of the endpoints 
• Intercurrent events strategy: For patients who require rescue medication, given the 
expected number of such patients at Month 3 is low and the protocol requires washout 
of these medications between Month 5 and Month 6, the hypothetical strategy will be 
used, i.e, blood pressure assessed while patients are on and within 2 weeks after 
stopping any rescue medication will be censored. This will provide the estimated 
treatment effect of zilebesiran alone. 
MMRM model will be used as the primary analysis. The model will include treatment, visit, 
treatment-by-visit interaction, race (black, all other races) as fixed factors, corresponding 
baseline as a covariate. Least square (LS) mean difference of each zilebesiran dose group 
compared with placebo dose group, 95% CI and p-value will be generated. In addition, LS mean 
difference between 300 Q3M and 600 Q6M groups and the 95% CI will be calculated. For 
change from baseline at Month 6 in office SBP, as a significant proportion of patients are 
expected to receive rescue medication, data collected at Month 4 and 5 visits will be excluded 
from MMRM model.   
For the proportion of patients with 24-hour mean SBP assessed by ABPM <130 mmHg and/or 
reduction ≥20 mmHg without rescue medication at Month 6, logistic regression will be used. The 
model will include treatment as a factor and baseline 24-hour mean SBP as a covariate.   
Multiplicity adjustment will be applied across primary and these secondary endpoints. Details of 
multiplicity control are in Section 4.3. 
These endpoints will also be analyzed by the same MMRM model using the treatment policy 
strategy. I.e., all collected data will be analyzed regardless of the rescue medication. For change 
from baseline at Month 6 in office SBP, Data collected at Month 4 and 5 Visits will be included 
as well.  
5.7.2.2. 
Other Secondary Endpoints  
Other blood pressure related secondary endpoints are: 
• Change from baseline at Month 3 in 24-hour mean DBP assessed by ABPM 
• Change from baseline at Month 6 in 24-hour mean DBP assessed by ABPM 
• Change from baseline at Month 3 in office DBP 
• Time adjusted change from baseline through Month 3 in office SBP/DBP 
• Change from baseline at Month 6 in office DBP  


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
23 
• Time adjusted change from baseline through Month 6 in 24-hour mean SBP/DBP 
assessed by ABPM  
• Time adjusted change from baseline through Month 6 in office SBP/DBP  
• Change from baseline in daytime/nighttime SBP/DBP by ABPM at each visit. 
Daytime is defined as 6 am to 9:59 pm and nighttime is defined as 10 pm to 5:59 am.  
Time-adjusted change is defined as the area under the curve (AUC) of BP change from baseline 
divided by the duration of the time period. It leads to the weighted average of change from 
baseline to each scheduled visit. Details of the definition and calculation are in Section 7.2. 
In general, these endpoints will be analyzed using two approaches, similar as primary endpoint 
and key secondary endpoints. Blood pressure collected while patients are on and within 2 weeks 
after stopping any rescue medication will be censored. All collected BP data will also be 
analyzed.   
Each endpoint will be analyzed by the MMRM model described in Section 5.7.1.2 with the 
corresponding baseline as a covariate.  
In addition, ABPM dipping pattern, defined as ratio of nighttime to daytime SBP will be 
calculated. The number and proportion of patients will be summarized by treatment and by visit 
into 3 categories: 1) <0.9; 2) ≥0.9 to <1; 3) ≥1. 
The secondary endpoint of percent change in serum AGT at each visit will be summarized by 
treatment using descriptive statistics. 
5.7.3. 
Exploratory Endpoints  
The blood pressure related exploratory endpoints through Month 12 are: 
• Change from baseline in 24-hour mean SBP/DBP assessed by ABPM by each visit 
• Change from baseline in office SBP/DBP by each visit 
• Change in pulse pressure assessed by ABPM and office blood pressure 
• BP response rate by each visit, defined as 
− Office SBP < 140 mmHg and/or reduction from baseline ≥ 20 mmHg without 
additional antihypertensive medication 
− 24-hour mean DBP < 85 mmHg and/or reduction from baseline ≥ 10 mmHg 
assessed by ABPM without additional antihypertensive medication 
− Office DBP < 90 mmHg and/or reduction from baseline ≥ 10 mmHg without 
additional antihypertensive medication 
• Proportion of patients with rescue medication use by each visit 
• Change from baseline in SBP/DBP by HBPM 
• Correlation of blood pressure obtained by wearable device versus ABPM, office BP 
and HBPM.   


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
24 
To assess the long-term treatment effect of zilebesiran through Month 24, change from baseline 
in SBP/DBP assessed by ABPM, office BP and HBPM will be summarized. 
Body weight, metabolic related exploratory endpoints are: 
• Change from baseline in body weight/body mass index (BMI)/waist 
circumference/waist-to-hip ratio by each visit 
• Change from baseline in HbA1c/fasting glucose/insulin/serum lipids by each visit  
Exploratory endpoints will be summarized using descriptive statistics based on all observed data. 
Missing data will not be imputed.    
5.7.4. 
Evaluation of Subgroups 
Subgroup analyses will be conducted to assess the consistency of treatment effect within various 
subgroups defined by the following baseline characteristics: 
• Age (<65; >=65) 
• Sex 
• Race (black; all other races) 
• Baseline 24-hour mean SBP assessed by ABPM (<145 mmHg, >=145 mmHg) 
• eGFR (<60; >=60 mL/min/1.73m2) 
Subgroup analyses will be performed for the primary endpoint using the MMRM within each 
subgroup. Model will include treatment, visit, treatment-by-visit interaction, race ([black, all 
other races], when race is not the subgroup to be analyzed) as fixed factors, baseline 24-hour 
mean SBP assessed by ABPM as a covariate. Point estimate of treatment effect and 95% 
confidence interval are to be generated for each subgroup. If the number of patients in either 
treatment arm of a subgroup is less than 10, only descriptive statistics will be presented. A forest 
plot will be generated to illustrate the estimated treatment effect along with 95% CI within each 
subgroup. 
5.8. 
Pharmacodynamic Analyses 
In addition to serum AGT, the PD parameters include plasma renin concentration, aldosterone, 
AngI and AngII. Summary tables will be provided for observed values, changes and percentage 
changes from baseline for each scheduled time point by treatment group. In addition to serum 
AGT percent reduction analyses, the AGT maximum and mean percentage reductions over the 6-
month placebo-controlled DB period will be summarized using descriptive statistics.  
5.9. 
Pharmacokinetic Analyses 
Plasma concentrations of zilebesiran and its metabolite will be summarized descriptively. 
Descriptive statistics for zilebesiran and its metabolite plasma concentrations will include the 
number of patients, mean, SD, coefficient of variation, geometric mean, geometric mean 
coefficient of variation, median, minimum, and maximum.  
Additional analysis may be done as needed.  


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
25 
5.10. 
Anti-Drug Antibody 
The number and percentage of patients with confirmed positive anti-drug antibody (ADA) assay 
results at baseline and at any time during the 6-month placebo-controlled DB period, as well as 
treatment-emergent ADA during the 12-month DB period, will be summarized. Treatment-
emergent ADA consist of treatment-induced ADA and treatment-boosted ADA, as defined 
below: 
• Treatment-induced ADA: Confirmed positive ADA developed de novo after drug 
administration in patients without preexisting (baseline) confirmed positive ADA 
• Treatment-boosted ADA: Confirmed positive ADA after drug administration with 
ADA titer > 4x baseline ADA titer in patients with preexisting (baseline) confirmed 
positive ADA 
5.11. 
Safety Analyses 
5.11.1. 
Adverse Events 
Adverse events (AEs) will be classified by the MedDRA coding system (Version 23.1 or newer) 
and displayed in tables and data listings using SOC and PT. 
Treatment-emergent AEs (TEAEs) will be summarized for the 6-month placebo-controlled DB 
period and for the zilebesiran treatment period separately. For the 6-month DB period, TEAE is 
defined as any AE occurring or worsening on or after the first dose of study drug and through 
Month 6 Visit (prior to Month 6 dosing).  
For zilebesiran treatment period, TEAE is defined as any AE occurring or worsening after the 
first dose of zilebesiran through 169 days following the last dose of zilebesiran. TEAE will be 
summarized by zilebesiran dosing regimen.  
AE occurred or worsening during safety follow-up period will be listed and may be summarized 
if needed. 
Because any worsening AE is reported as a new AE with higher severity, programmatical 
comparison of severity is not needed for the classification of TEAE. For missing or partial dates 
for AEs, the imputation of start and end date can be found in Section 7.2. Events with a fully or 
partially missing onset date will be assumed to be treatment emergent unless it can be 
unequivocally determined (from the partial onset date and/or a partial or complete stop date) that 
the event occurred prior to the first dose of study drug. 
AEs will be summarized by the numbers and percentages of patients reporting a given AE. An 
overall table of TEAEs will include: 
• any AE, 
• any AE related to study drug, 
• any serious AE (SAE), 
• any SAE related to study drug, 
• any AE leading to study drug discontinuation, 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
26 
• any drug-related AE leading to study drug discontinuation, 
• any AE leading to death.  
Tabulations by SOC and PT will be produced for the following:  
• AEs, 
• Treatment-related AEs, 
• AEs by maximum severity, 
• Treatment-related AEs by maximum severity, 
• Severe AEs, 
• SAEs, 
• AEs leading to treatment discontinuation. 
Tabulations by PT will be produced for the following: 
• AEs, 
• Treatment-related AEs, 
• SAEs. 
A patient contributes only once to the count for a given AE (overall, by SOC, by preferred term). 
Patients who report multiple occurrences of the same AE (preferred term) will be classified 
according to the most severe occurrence. An AE with missing severity will be assumed to be 
severe. An AE with missing study drug relatedness will be assumed to be related. 
Listings of all deaths (if any), SAEs, and AEs leading to treatment discontinuation will be 
provided.  
AEs of Clinical Interest 
AEs of special interest or AEs mapping to certain standardized MedDRA queries (SMQs) will be 
summarized by SOC and PT. Other SMQs or AE groupings may be evaluated. 
Injection Site Reactions [ISRs]: AEs mapping to the High-Level Term (HLT)= “Injection Site 
Reactions” using MedDRA dictionary will be included in the summary. Frequency (percentages) 
of patients with ISRs by SOC and PT will be presented by treatment. A separate listing will be 
generated to display all patients who reported ISRs. In addition, a table of the number (%) of 
patients with signs and symptoms reported due to ISRs will be generated. 
Hepatic AEs, including Liver Function Test (LFT) abnormalities: Analysis of hepatic AEs 
will include AEs mapping to the Standardized MedDRA Query (SMQ) Drug-related hepatic 
disorders - comprehensive search (includes all narrow and broad terms). Frequency (percentages) 
of hepatic AEs will be summarized by SOC and PT.  A separate listing will be generated of all 
patients reporting these events. 
All AEs will be presented in patient data listings. AEs mapping to the SMQs as described above 
will also be listed. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
27 
Additional summaries of AEs mapping to a COVID-19 custom query are described in Section 
5.13.2. 
5.11.2. 
Laboratory Data 
Clinical laboratory values will be expressed in SI units. Missing laboratory data will not be 
imputed. 
For each continuous clinical laboratory parameter (including hematology, serum chemistry, liver 
function tests and coagulation studies), descriptive statistics will be presented for the actual 
values, change from baseline, and percent change from baseline by visit. These by-visit tables 
will use central laboratory data only. 
Select clinical laboratory parameters may be graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 or above. Shift 
summary from baseline CTCAE grade to maximum (worst) post-baseline grade will be presented 
for all graded parameters with directionality specified (e.g., hyper or hypo). To determine the 
worst post-baseline value, all scheduled and unscheduled test results will be used. For 
hematology and serum chemistry, frequency tables of potentially clinically significant (PCS) 
abnormalities will be provided. 
All laboratory data (both central and local) will be provided in data listings.  Out-of-range 
laboratory results will be presented in a separate listing with proper flags. Local laboratory data, 
if available, will also be flagged. 
Liver Function Tests 
A frequency table and a shift table will be produced to summarize the number and percentage of 
patients in each of the below categories at any post-baseline time point.  
• ALT >1 & ≤3, >3 & ≤5, >5 & ≤10, >10 & ≤20, >20×ULN, 
• AST >1 & ≤3, >3 & ≤5, >5 & ≤10, >10 & ≤20, >20×ULN, 
• ALT or AST >1 & ≤3, >3 & ≤5, >5 & ≤10, >10 & ≤20, >20×ULN, 
• ALP > 1.5×ULN, 
• Total Bilirubin >1.5 & ≤2, >2 & ≤3, >3 & ≤5 and >5×ULN, 
• Total Bilirubin > 2×ULN concurrent with ALT or AST > 3×ULN 
In separate evaluation of drug-induced serious hepatotoxicity (eDISH) figures, the peak total 
bilirubin (as multiple of ULN) at any time post-baseline will be plotted against the peak ALT, 
AST, ALT or AST level and at any time post-baseline. 
A listing for all patients with abnormal liver function tests, defined as an ALT >3×ULN, AST 
>3×ULN, or total bilirubin >2×ULN at any time point, will also be provided. 
Estimated glomerular filtration rate (eGFR) will be calculated from serum creatinine (SCr) based 
on the Modification of Diet in Renal Disease (MDRD) Formula: 
• Conventional units – eGFR (mL/min/1.73 m2) = 175 × (SCr[mg/dL])-1.154 × (age)-0.203 
and (× 0.742, if female) and (× 1.212, if African American) 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
28 
• SI units – eGFR (mL/min/1.73 m2) = 175 × (SCr[µmol/L]/88.4)-1.154 × (age)-0.203 and 
(× 0.742, if female) and (× 1.212, if African American) 
5.11.3. 
Electrocardiogram 
Electrocardiogram (ECG) findings will include rhythm and overall interpretation.  
Post-baseline overall interpretation (normal vs. abnormal) will be summarized in frequency table 
by treatment and visit. 
All ECG data for each patient will be provided in a data listing. 
5.11.4. 
Vital Signs 
For vital signs except blood pressure, descriptive statistics for actual values and change from 
baseline will be provided by treatment and visit for each variable. Vital sign measurements will 
be presented for each patient in a data listing, with abnormal vital signs flagged. 
5.11.5. 
Evaluation of Subgroups  
AE summary tables will be separately generated for each of the subgroups as defined for the 
primary efficacy endpoint (see Section 5.7.4). 
5.12. 
Interim Analysis 
No interim analysis is planned for this study. 
5.13. 
COVID-19 
Additional data are collected to characterize the impact of the COVID-19 pandemic on general 
study conduct and disposition, and subsequently, additional analyses and summaries will be 
provided in acknowledgement of multiple regulatory guidance (including FDA Guidance on 
Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic: Guidance for 
Industry, Investigators, and Institutional Review Boards, US Food and Drug Administration, 
2020; Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) 
Pandemic, European Medicines Agency, 2020; Points to consider on implications of Coronavirus 
disease (COVID-19) on methodological aspects of ongoing clinical trials, European Medicines 
Agency, 2020; Statistical Considerations for Clinical Trials During the COVID-19 Public Health 
Emergency, US Food and Drug Administration, 2020). 
5.13.1. 
General Impact 
Patients who discontinue treatment or stop study participation due to COVID-19 will be included 
in patient disposition summaries as described in Section 5.1. 
Impact on study participation due to COVID-19, including missing visits, visit location changes, 
study drug dosing changes and missing doses, will be summarized descriptively overall and by 
visit on the patient level, and overall on the event level. Patient- and event-level summaries of 
the impact on study participation due to COVID-19 may also be generated by site and/or region. 
Impact on study participation due to COVID-19 will be presented in data listings at patient and 
visit level. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
29 
5.13.2. 
Impact on Adverse Events 
An overall summary of AEs mapping to a COVID-19 custom query will be presented. AEs 
mapping to the COVID-19 custom query will be summarized by HLT and PT. Due to the 
evolving nature of COVID-19-related MedDRA terminology, the COVID-19 custom query will 
be based on the latest information available at the specified analysis timepoint. 
AEs mapping to the COVID-19 custom query will also be presented in a data listing.  
6. 
CHANGES FROM PLANNED ANALYSES 
Original SAP 
Section of the SAP 
Summary of change from 
protocol 
Rationale 
— 
—  
— 
Amendment 1 
Section of the SAP 
Summary of change from 
protocol 
Rationale 
Section 3 
Ukraine patients handling  
During the study conduct, 16 patients were 
randomized from Ukraine in January/February 
2022 before geographic conflict started. Due 
to the challenge of data collection and 
cleaning, these patients will be excluded from 
the analysis sets defined below. Data from 
these patients will be listed only. 
Section 4.5 
ABPM baseline definition: 
 
Original SAP defines ABPM 
baseline as the one used for 
eligibility.  
In SAP Amendment 1, baseline 
ABPM definition is updated to 
use the last non-missing 
assessments prior to receive 
study drug.  
Per schedule of assessment table, ABPM is 
only measured once during screening. It will 
be used for both enrollment eligibility and 
baseline for efficacy analysis. However, 
unscheduled ABPM assessments during 
screening were also performed in some 
patients. It is more appropriate to use the last 
one prior to randomization as the baseline for 
efficacy analyses.  
Section 4.7 
Remove Month 12 analysis as 
planned analysis  
There is no planned CSR when all patients 
complete 12-month DB period. Therefore, 
formal analysis is not needed.  
Section 5.7.2.2 
Add ABPM dipping definition 
ABPM dipping pattern was listed as a 
secondary endpoint. Details of the endpoint 
are specified. 
Section 5.11.2 
eGFR calculation 
eGFR will be derived for analysis. Formula is 
provided.  
Section 7.4 
Add list of rescue 
antihypertensive medication 
ATC code 
Rescue antihypertensive medication is 
important for the primary analyses of the 
primary endpoint and several key-secondary 
endpoints. The list of medication ATC code is 
added.  


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
30 
7. 
APPENDICES 
7.1. 
Protocol Schedule of Assessments 
Schedule of assessments are listed in Table 2. 








Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
34 
d Office blood pressure must be measured before the patient takes oral antihypertensive medications.  
e ABPM recordings associated with dosing visits should be obtained within 7 days before the dosing visit and results reviewed before dosing. ABPM should only be collected at 
Months 18 and 24 for patients in the DB Extension period. 
f HBPM must be measured in the morning upon waking. HBPM should be measured daily between Months 5 and 6 if oral antihypertensives are temporarily held. HBPM is not 
required at times when ABPM is being assessed. 
g ABPM and collection of RAAS biomarkers should only be performed as part of ET assessments if the patient discontinues the study prior to Month 12, and ABPM should only 
be performed at ET if the patient and has not had an ABPM within the last 3 months. These assessments should not be performed at Month 24. 
h  Fasting plasma laboratory samples should only be collected at Month 18. 
 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
35 
7.2. 
Time-Adjusted Change from Baseline 
Time-adjusted change from baseline is the area under the curve (AUC) divided by time interval. 
It leads to a weighted average of all scheduled change from baseline during that time interval.  
E.g., ABPM is assessed at Month 1, 3 and 6. Time-adjusted change from baseline through Month 
6 in 24-hour mean SBP assessed by ABPM is: 
1. AUC is calculated as:  ቂ
1
2 (𝑦𝑦1 + 𝑦𝑦3) ∗2 + 
1
2 (𝑦𝑦3 + 𝑦𝑦6) ∗3 ቃ 
2. Time interval is 5 months, from Month 1 to Month 6. AUC divided by time interval is  
𝐴𝐴𝐴𝐴𝐴𝐴5
⁄
= 0.2 ∗𝑦𝑦1 + 0.5 ∗𝑦𝑦3 + 0.3 ∗𝑦𝑦6 
Where 𝑦𝑦1, 𝑦𝑦3 and 𝑦𝑦6 are the 24-hour mean ABPM at Month 1, 3, and 6.   
Table 3  listed all time-adjusted endpoints and the weights of the assessments. 
Table 3  
Time-Adjusted Endpoints 
Time-adjusted Endpoint 
Weighted average 
Time-adjusted change from baseline 
through Month 3 in 24-hour mean 
SBP/DBP assessed by ABPM 
0.5 ∗𝑦𝑦1 + 0.5 ∗𝑦𝑦3 
Time-adjusted change from baseline 
through Month 3 in office SBP/DBP  
0.25 ∗𝑦𝑦1 + 05 ∗𝑦𝑦2 + 0.25 ∗𝑦𝑦3 
Time-adjusted change from baseline 
through Month 6 in 24-hour mean 
SBP/DBP assessed by ABPM 
0.2 ∗𝑦𝑦1 + 0.5 ∗𝑦𝑦3 + 0.3 ∗𝑦𝑦6 
Time-adjusted change from baseline 
through Month 6 in office SBP/DBP  
0.1 ∗𝑦𝑦1 + 0.2 ∗𝑦𝑦2 + 0.2 ∗𝑦𝑦3 + 0.2 ∗𝑦𝑦4 + 0.2 ∗𝑦𝑦5 + 0.1 ∗𝑦𝑦6 
7.3. 
Missing or Partial Dates 
7.3.1. 
Prior and Concomitant Medications 
For medications with partial start or end dates: the first day/month will be imputed for start date, 
and the last day/month will be imputed for end date. For medications with a completely missing 
start date, the medications will be considered as started one day prior to the first dose of study 
drug. If an imputed start date is after the collected end date, the end date will be used as the 
imputed start date. For medications with a completely missing end date or an imputed end date 
that is after the earliest date of: end of study date, data cutoff date or date of death, the latter (i.e., 
the earliest date of: end of study date, data cutoff date or date of death) will be used as the 
imputed end date. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Amendment 1, 11 October 2022 
Alnylam Pharmaceuticals 
Confidential 
36 
7.3.2. 
Adverse Events 
For records with fully or partially missing AE onset date, conventions for the imputation is as 
below: 
• AE onset dates with missing day and non-missing month will be imputed to occur on 
the first day of the non-missing month, except for AEs occurring in the first month of 
dosing, in which case the date will be the first day of dosing. 
• AE onset dates with missing month will be imputed to occur on the first day of the 
non-missing year (i.e., January 1), except for AEs occurring in the first year of 
dosing, in which case the date will be the first day of dosing.  
• If year of the AE start date is missing, the onset date will be imputed as the first day 
of dosing, except if it can be unequivocally determined (from the partial or complete 
stop date) that the event occurred prior to the first dose of study drug, in which case 
the AE onset date will not be imputed.  
• If an imputed onset date is after the collected AE end date, the end date will be used 
as the imputed onset date.  
7.3.3. 
Others 
For other incomplete dates, unless otherwise specified, the following conventions will be used 
for the calculation of duration (e.g., time in years since diagnosis): 
• Missing day: the first day of the month will be used. 
• Missing month: the January 1 of the non-missing year will be used. 
• Missing year: no duration will be calculated. 
7.4. 
List of Rescue Antihypertensive Medication ATC Code 
The ATC codes for rescue medications are: 
• C02 - Antihypertensives 
• C03 - Diuretics 
• C07 - Beta blocking agents 
• C08 - Calcium channel blockers 
• C09 - Agents acting on the renin-angiotensin system 
 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
1 
 
STATISTICAL ANALYSIS PLAN 
ALN-AGT01-002 (KARDIA-1) 
 
Protocol Title: 
A Randomized, Double-blind, Placebo-
Controlled, Dose-Ranging Multicenter Study 
to Evaluate the Efficacy and Safety of ALN-
AGT01 in Patients with Mild-to-Moderate 
Hypertension 
Short Title: 
A Study to Evaluate Efficacy and Safety of 
ALN-AGT01 in Patients with Mild-to-
Moderate Hypertension (KARDIA-1) 
Study Drug: 
Zilebesiran (ALN-AGT01) 
Protocol Date: 
Original protocol, 09 April 2021 
Amendment 1, 20 April 2021 
Amendment 2, 09 June 2021 
Amendment 3, 09 December 2021 
Amendment 4, 22 March 2022 
SAP Date: 
Original SAP: 29 March 2022 
Sponsor: 
Alnylam Pharmaceuticals, Inc. 
300 Third Street 
Cambridge, MA 02142 USA 
Telephone: +1-617-551-8200 
 
 
 
 
The concepts and information contained in this document or generated during the study are 
considered proprietary and may not be disclosed in whole or in part without expressed written 
authorization of Alnylam Pharmaceuticals, Inc. 
 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
2 
APPROVAL SIGNATURE PAGE 
 
 
 
 
 
 
This document has been authored, approved, and signed electronically on the final page by 
the following: 
 
 
 
Alnylam Pharmaceuticals, Inc. 
 
 
This document has been approved and signed electronically on the final page by the 
following: 
 
 
 
 
Alnylam Pharmaceuticals, Inc. 
 
 
 
 
Alnylam Pharmaceuticals, Inc. 
 
 
PPD
PPD
PPD
PPD
PPD
PPD


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
3 
TABLE OF CONTENTS 
APPROVAL SIGNATURE PAGE .................................................................................................2 
LIST OF ABBREVIATIONS ..........................................................................................................6 
1. 
INTRODUCTION ........................................................................................................8 
2. 
STUDY DESIGN .........................................................................................................8 
2.1. 
General Study Design ...................................................................................................8 
2.2. 
Objectives and Endpoints ...........................................................................................10 
2.3. 
Study Procedure ..........................................................................................................11 
2.4. 
Randomization Methodology .....................................................................................11 
2.5. 
Blinding ......................................................................................................................12 
2.6. 
Determination of Sample Size ....................................................................................13 
3. 
ANALYSIS POPULATIONS ....................................................................................13 
3.1. 
Randomization and Treatment Errors .........................................................................13 
4. 
GENERAL STATISTICAL CONSIDERATIONS ....................................................14 
4.1. 
General Considerations ...............................................................................................14 
4.2. 
Blood Pressure Collection and Handling ....................................................................14 
4.2.1. 
24-Hour Ambulatory Blood Pressure Monitoring ......................................................14 
4.2.2. 
Office Blood Pressure .................................................................................................15 
4.2.3. 
Home Blood Pressure Monitoring ..............................................................................15 
4.3. 
Multiple Comparisons/Multiplicity Procedure ...........................................................15 
4.4. 
Handling of Missing Data ...........................................................................................16 
4.5. 
Baseline Definitions ....................................................................................................16 
4.6. 
Randomization Stratification Factors .........................................................................17 
4.7. 
Planned Analyses and Data Cutoffs ...........................................................................17 
4.7.1. 
Primary Analysis ........................................................................................................17 
4.7.2. 
Month 12 Analysis ......................................................................................................17 
4.7.3. 
Final Analysis .............................................................................................................18 
5. 
STATISTICAL ANALYSES .....................................................................................18 
5.1. 
Patient Disposition ......................................................................................................18 
5.2. 
Demographics and Baseline Characteristics ...............................................................18 
5.3. 
Medical History ..........................................................................................................18 
5.4. 
Protocol Deviations ....................................................................................................19 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
4 
5.5. 
Study Drug Exposure and Compliance .......................................................................19 
5.6. 
Prior and Concomitant Medications ...........................................................................19 
5.7. 
Efficacy Analyses .......................................................................................................20 
5.7.1. 
Primary Endpoint ........................................................................................................20 
5.7.1.1. 
Definition of Estimand ...............................................................................................20 
5.7.1.2. 
Primary Analysis ........................................................................................................20 
5.7.1.3. 
Sensitivity Analyses ....................................................................................................21 
5.7.1.4. 
Other Analyses ............................................................................................................21 
5.7.2. 
Secondary Endpoints ..................................................................................................21 
5.7.2.1. 
Key Secondary Endpoints ...........................................................................................21 
5.7.2.2. 
Other Secondary Endpoints ........................................................................................22 
5.7.3. 
Exploratory Endpoints ................................................................................................23 
5.7.4. 
Evaluation of Subgroups .............................................................................................24 
5.8. 
Pharmacodynamic Analyses .......................................................................................24 
5.9. 
Pharmacokinetic Analyses ..........................................................................................24 
5.10. 
Anti-Drug Antibody ....................................................................................................24 
5.11. 
Safety Analyses ..........................................................................................................25 
5.11.1. 
Adverse Events ...........................................................................................................25 
5.11.2. 
Laboratory Data ..........................................................................................................26 
5.11.3. 
Electrocardiogram .......................................................................................................27 
5.11.4. 
Vital Signs ..................................................................................................................27 
5.11.5. 
Evaluation of Subgroups .............................................................................................28 
5.12. 
Interim Analysis ..........................................................................................................28 
5.13. 
COVID-19 ..................................................................................................................28 
5.13.1. 
General Impact ............................................................................................................28 
5.13.2. 
Impact on Adverse Events ..........................................................................................28 
6. 
CHANGES FROM PLANNED ANALYSES............................................................28 
7. 
APPENDICES ............................................................................................................29 
7.1. 
Protocol Schedule of Assessments .............................................................................29 
7.2. 
Time-Adjusted Change from Baseline .......................................................................34 
7.3. 
Missing or Partial Dates ..............................................................................................34 
7.3.1. 
Prior and Concomitant Medications ...........................................................................34 
7.3.2. 
Adverse Events ...........................................................................................................35 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
5 
7.3.3. 
Others ..........................................................................................................................35 
 
LIST OF TABLES 
Table 1 
Multiplicity Procedure ................................................................................................15 
Table 2  
Schedule of Assessments ............................................................................................30 
Table 3  
Time-Adjusted Endpoints ...........................................................................................34 
 
LIST OF FIGURES 
Figure 1 
Study Design .................................................................................................................9 
 
 
 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
6 
LIST OF ABBREVIATIONS 
Abbreviation  
Definition 
ABPM 
Ambulatory blood pressure monitoring 
ADA 
Anti-drug antibody(ies) 
AE 
Adverse event 
AGT 
Angiotensinogen 
ALT 
Alanine aminotransferase 
AngI/II 
Angiotensin I/II 
AST 
Aspartate aminotransferase 
AUC 
Area under the curve 
DB 
Double-blind 
DBP 
Diastolic blood pressure 
ECG 
Electrocardiogram 
eGFR 
Estimated glomerular filtration rate 
eDISH 
Evaluation of drug-induced serious hepatotoxicity 
EOT 
End of treatment 
ET 
Early termination 
FAS 
Full analysis set 
HbA1c 
Hemoglobin A1c 
HBPM 
Home blood pressure monitoring 
HLT 
High level term 
ICF 
Informed consent form 
IEC 
Independent Ethics Committee 
IRB 
Institutional Review Board 
IRT 
Interactive Response Technology 
ISR 
Injection site reaction 
LFT 
Liver function test 
LLOQ 
Lower limit of quantification 
MedDRA 
Medical Dictionary for Regulatory Activities 
MMRM 
Mixed more for repeated measurement 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
7 
Abbreviation  
Definition 
OLE 
Open-label extension 
PD 
Pharmacodynamic(s) 
PK 
Pharmacokinetic(s) 
PT 
Preferred term 
Q3M 
Once every 3 months 
Q6M 
Once every 6 months 
RAAS 
Renin-angiotensin-aldosterone system 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SBP 
Systolic blood pressure 
SC 
Subcutaneous(ly) 
SD 
Standard deviation 
SOC 
System Organ Class 
ULN 
Upper limit of normal 
ULOQ 
Upper limit of quantification 
 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
8 
1. 
INTRODUCTION 
This statistical analysis plan (SAP) details comprehensive specifications of the efficacy, safety, 
pharmacokinetic (PK) and pharmacodynamic (PD) data summaries and statistical analyses in 
support of the clinical study report (CSR) for Study ALN-AGT01-002 (KARDIA-1). This SAP 
is finalized prior to treatment unblinding and conducting the primary analysis, which will occur 
after all patients complete the Month 6 visit or withdraw from the study prior to the Month 6 
visit. Changes to planned analyses specified in this SAP made after database lock will be 
documented in the CSR. 
Table, figure, and listing (TFL) mocked shells and specifications are contained in a separate 
document. 
2. 
STUDY DESIGN  
2.1. 
General Study Design  
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study 
designed to evaluate the safety, efficacy, and pharmacodynamics (PD) of zilebesiran (ALN-
AGT01), administered subcutaneously (SC), in patients with mild-to-moderate hypertension. A 
schematic of the study design is provided in Figure 1. Before randomization, patients will 
discontinue prior antihypertensive medications (if taking) for a Washout period of at least 2 
weeks (4 weeks of washout is required for long-acting antihypertensive medications, such as 
long-acting diuretics or calcium channel blockers). Patients who complete the Screening period 
and meet all inclusion/exclusion criteria for enrollment will receive zilebesiran or placebo for the 
first 6 months of the 12-month Double-blind (DB) treatment period.  
Starting at Month 3, conventional oral antihypertensives may be added per Investigator 
judgement for elevated blood pressure. Oral antihypertensives (if taking) will be temporarily 
held from Month 5 to Month 6 to assess the effect of zilebesiran alone (vs placebo) at Month 6. 
During this 4-week period, blood pressure will be carefully monitored by daily home blood 
pressure monitoring and medications restarted if indicated. Patients may resume conventional 
oral antihypertensives at Month 6 per Investigator judgement. 
Patients randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial zilebesiran 
regimens until the end of the DB period. Patients randomized to zilebesiran regimens will remain 
on their originally assigned regimens through Month 12. 
After the 12-month DB treatment period, patients may be eligible to participate in a zilebesiran 
open-label extension (OLE) study. If an individual patient reaches Month 12 prior to availability 
of the OLE study, they may continue their current blinded dosing in the DB Extension period for 
up to 12 additional months until the OLE study is open and then transition. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
9 
Figure 1 
Study Design 
 
Abbreviations: aHTN=antihypertensive medications; DB=double-blind; M=month; OLE=open-label extension; 
PBO=placebo; PO=per os (oral); Q3M=once every 3 months; Q6M=once every 6 months; R=randomization; 
SC=subcutaneous; WO=washout. 
Note: Patients may be eligible to participate in an ALN-AGT01 OLE study upon completion of the Month 12 
predose assessments. If an individual patient reaches Month 12 prior to availability of the OLE study, they may 
continue their current blinded dosing in the DB Extension period for up to 12 additional months until the OLE study 
is open and then transition. Once the OLE study is open for enrollment, eligible patients may rollover into the OLE 
study at Months 12, 18, or 24 (whichever visit occurs first). 
Note: Patients who were previously taking antihypertensives at screening should undergo a washout of these 
medications for at least 2 weeks during the Screening period (4 weeks of washout is required for long-acting 
antihypertensive medications, such as long-acting diuretics or calcium channel blockers).






Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
12 
• 300 mg zilebesiran SC once every 6 months 
• 300 mg zilebesiran SC once every 3 months 
• 600 mg zilebesiran SC once every 6 months 
Patients initially randomized to placebo will be re-randomized 1:1:1:1 at Month 6 to 1 of the 4 
initial zilebesiran regimens. 
Patients who enter the DB Extension period will continue their current blinded dosing regimen 
from the DB period. 
Randomization will be stratified by race (black vs all other races) and by baseline blood pressure 
(mean 24-hour SBP < or ≥145 mmHg). 
Each patient will be uniquely identified in the study by a combination of the site number and 
patient identification number. Upon signing the informed consent form (ICF), the patient will be 
assigned a patient identification number by the IRT system. The Investigator or his/her designee 
will randomize the patient in IRT after confirming that the patient fulfills all the inclusion criteria 
and none of the exclusion criteria. The Investigator or his/her designee will re-randomize the 
patient in IRT at Month 6 to assign placebo patients to 1 of the 4 initial zilebesiran dose groups 
in a way that maintains the study blind for the patient. 
2.5. 
Blinding  
The Sponsor, all site personnel (except for the site pharmacist or delegate), and patients will be 
blinded to study drug treatment through Month 6 of the 12-month DB period. During the course 
of the study, serum AGT, plasma PK, and treatment assignment using dummy IDs will be made 
available to a small, independent pharmacometrics team at the Sponsor that will not be involved 
in the conduct or oversight of the study. After the last patient completes the Month 3 visit and 
prior to the last patient’s Month 6 visit, a limited amount (ie, one-third) of SBP data will be made 
available to this small, independent pharmacometrics team for preliminary PK/PD modeling. 
After the database lock to support the analysis of Month 6 data is complete, all other Sponsor 
personnel will be unblinded to treatment assignment, but the site personnel (except for the site 
pharmacist) and patients will remain blinded to treatment assignment until after the analysis of 
Month 12 data is complete. The Sponsor and all site personnel will be blinded to serum AGT 
results until their respective unblinding. Serum AGT results will not be reported to site personnel 
until the last patient completes the assessments at the Month 12 visit. 
Blinded doses of study drug will be administered under the supervision of the Investigator (see 
Protocol Section 5.2.2). All patients will receive the same volume and number of injections 
regardless of treatment assignment (patients receiving once every 6-month zilebesiran regimens 
will receive placebo SC at dosing visits at which they do not receive zilebesiran to maintain the 
blind). Because zilebesiran may be slightly visually distinguishable from placebo, all blinded 
study drug doses will be prepared, and the syringe(s) will be masked by a site pharmacist or 
delegate prior to administration by a blinded healthcare professional. See the Pharmacy Manual 
for additional details. 
Details about the specifics of the blinding aspects throughout the entire study are available in the 
Randomization and Blinding Plan.  


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
13 
Any unplanned/emergency unblinding occurring during the DB Period will be documented and 
reported in the CSR. 
Refer to the study Randomization and Blinding Plan for more details. 
2.6. 
Determination of Sample Size 
Assuming a standard deviation (SD) in the range of 15 to 20 mmHg in change from baseline at 
Month 3 in 24-hour mean SBP assessed by ABPM, a maximum mean difference in effect size 
between zilebesiran and placebo of 10 mmHg, and a 15% dropout rate at Month 3, a sample size 
of 375 patients (75 per treatment group) provides at least 84% power to detect a dose response 
signal in SBP reduction among all zilebesiran doses and placebo at the 2-sided significance level 
of 0.05. In addition, this sample size provides at least 80% power to detect a 10 mmHg 
difference between an individual zilebesiran dose versus placebo with a 2-sided significance 
level of 0.05.  
3. 
ANALYSIS POPULATIONS 
The populations (analysis sets) are defined as follows: 
• Full Analysis Set (FAS): All randomized patients who received any amount of study 
drug. All by-treatment analyses based on the FAS will be according to the 
randomized treatment arm. 
• Safety Analysis Set: All patients who received any amount of study drug, grouped 
according to the treatment actually received. 
• PK Analysis Set: All patients who received at least 1 full dose of ALN-AGT01 and 
have at least 1 nonmissing postdose PK assessment. 
• PD Analysis Set: All patients who received at least 1 full dose of study drug. All by-
treatment analyses based on the PD Analysis Set will be grouped according to the 
treatment actually received. 
• All Zilebesiran Treated Set: All patients who received any amount of 1 of the 4 ALN-
AGT01 dosing regimens, including patients who took ALN-AGT01 during the 6-
month placebo-controlled period and patients who initially took placebo and then 
switched to ALN-AGT01 after the Month 6 visit.  
For the primary analysis for 6-month placebo-controlled DB period, the primary population used 
to evaluate efficacy will be the FAS. Safety will be analyzed using the Safety Analysis Set. The 
PK and PD Analysis Sets will be used to conduct PK and PD analyses, respectively.  
The All Zilebesiran Treated Set will be used to summarize the efficacy and safety of zilebesiran 
throughout the entire DB period (including DB extension period).  
3.1. 
Randomization and Treatment Errors 
For patients who were not treated, not randomized, or received incorrect treatment, the following 
rules will be used:  


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
14 
• Randomized but not treated: they will be excluded from the FAS and Safety Analysis 
Set for efficacy and safety evaluations as actual treatment is missing.  
• Treated but not randomized: they will be excluded from the efficacy analyses since 
randomized treatment is missing but will be reported under the treatment actually 
received for all safety analyses.  
• Randomized but took incorrect treatment: they will be reported under their 
randomized treatment arm for all efficacy analyses. But for safety analyses, a patient 
will be included under the active treatment arm if the patient is randomized to placebo 
arm and received an active dose by mistake. 
4. 
GENERAL STATISTICAL CONSIDERATIONS 
4.1. 
General Considerations 
In general, data will be summarized for each planned analysis defined in Section 4.7 separately. 
For Month 3 endpoints, zilebesiran 300mg Q3M and 300mg Q6M will be pooled together.  
Categorical variables will be summarized using counts and percentages. Continuous variables 
will be summarized using the following descriptive summary statistics: number of patients (n), 
mean, standard deviation (SD), median, first quartile (Q1), third quartile (Q3), minimum, and 
maximum. 
The day of the first dose of study drug administered is defined as Day 1. The Study Day of a 
time point of interest is calculated as follows: 
• If on or after Day 1, Study Day = date of interest – date of the first dose of study drug 
+ 1 
• If prior to Day 1, Study Day = date of interest – date of the first dose of study drug 
There is no Day 0. For example, the day before the first study drug dose is defined as Day -1. 
For laboratory parameters, assessments collected and recorded as lower than the lower limit of 
quantification/detection (LLOQ) will be replaced by the LLOQ. Any assessment collected and 
recorded as greater than the upper limit of quantification (ULOQ) will be replaced by the ULOQ. 
All descriptive summaries will be presented by treatment arm. 
Statistical analyses will be conducted using SAS software Version 9.4 or newer or R version 3.6 
or newer. 
4.2. 
Blood Pressure Collection and Handling 
4.2.1. 
24-Hour Ambulatory Blood Pressure Monitoring 
24-hour ambulatory blood pressure monitoring (ABPM) is programmed to take readings every 
20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 
5:59 am). An ABPM will be considered adequate if (1) recording time is at least 22 hours (2) the 
number of successful daytime readings is ≥33, (3) the number of successful nighttime readings is 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
15 
≥11, and (4) no more than 3 hours are not represented (ie, 3 sections of 60 minutes where 0 valid 
readings were obtained). If the ABPM recording is inadequate, the patient will be provided 1 
opportunity to repeat the study within 4 days.  
To summarize the 24-hour ABPM, hourly adjusted mean will be calculated. Hourly adjusted 
mean will be calculated by two steps:  
1. Calculate the hourly mean: average of BP by each hour of the day (e.g., mean of BP 
measurements from 16:00 to 16:59). If there is no reading in a specific hour, this hour 
will not be included in calculation.   
2. Calculate the 24-hour mean: average of the hourly means.  
4.2.2. 
Office Blood Pressure 
The office BP in the sitting position will be used for the analysis. Office BP will be collected 
with a set of 4 replicates. The average of the last 3 replicates will be calculated and used for 
analysis. Office BP collected in standing position will be listed.   
4.2.3. 
Home Blood Pressure Monitoring 
Home blood pressure will be measured both pre and post randomization. To establish baseline, 
each patient should measure HBPM during the week (with at least 3 successful readings) 
immediately prior to randomization. After Day 1, HBPM will be measured at least once per 
week. Four sequential blood pressure measurements at 1-minute intervals will be recorded. The 
seated blood pressure for the visit will be defined by the average of the last 3 individual 
measurements. HBPM will be summarized by weekly average.  
Details of the blood pressure collection are in Study Protocol Section 10. 
4.3. 
Multiple Comparisons/Multiplicity Procedure 
The overall familywise error rate will be controlled at α=0.05 for the primary and key secondary 
endpoints as shown in Table 1  
Table 1 
Multiplicity Procedure 
Test 
Step a 
Endpoint 
Comparison 
Success criteria 
1 
Change from baseline at Month 3 in 24-hour 
mean SBP assessed by ABPM 
Dunnett’s 
Procedure 
If the global hypothesis is 
rejected at 0.05 alpha level, 
then at least one zilebesiran 
dose is superior to Placebo 
2 
Change from baseline at Month 3 in 24-hour 
mean SBP assessed by ABPM 
300 mg Q3M 
vs placebo b 
Nominal p-value < 0.05 
3 
Change from baseline at Month 3 in 24-hour 
mean SBP assessed by ABPM 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
16 
Test 
Step a 
Endpoint 
Comparison 
Success criteria 
4 
Change from baseline at Month 3 in office 
SBP 
300 mg Q3M 
vs placebo b 
Nominal p-value < 0.05 
5 
Change from baseline at Month 3 in 
office SBP 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 
6 
Change from baseline at Month 6 in 24-hour 
mean SBP assessed by ABPM 
300 mg Q3M 
vs placebo 
Nominal p-value < 0.05 
7 
Change from baseline at Month 6 in 24-hour 
mean SBP assessed by ABPM 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 
8 
Change from baseline at Month 6 in 
office SBP 
300 mg Q3M 
vs placebo 
Nominal p-value < 0.05 
9 
Change from baseline at Month 6 in 
office SBP 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 
10 
Proportion of patients with 24-hour mean 
SBP assessed by ABPM <130 mmHg and/or 
reduction ≥20 mmHg without additional 
antihypertensive medications at Month 6 
300 mg Q3M 
vs placebo 
Nominal p-value < 0.05 
11 
Proportion of patients with 24-hour mean 
SBP assessed by ABPM <130 mmHg and/or 
reduction ≥20 mmHg without additional 
antihypertensive medications at Month 6 
600 mg Q6M 
vs placebo 
Nominal p-value < 0.05 
a  If the MCP criterion is satisfied in a given step, the hypothesis test is deemed statistically significant and the next 
step will be evaluated; otherwise all hypotheses in the given and subsequent steps are deemed not statistically 
significant 
b 300mg Q3M and 300mg Q6M will be pooled together for the test 
4.4. 
Handling of Missing Data 
No imputation will be done for missing values for the primary analysis of the primary endpoint. 
Results based on mixed model with repeated measurements (MMRM) are valid based on missing 
at random (MAR) assumption. A sensitivity analysis of the primary endpoint using an imputation 
method will be performed (details described in Section 5.7.1.3). For all analyses using MMRM, 
no explicit imputation of missing values will be done. 
4.5. 
Baseline Definitions 
For the primary analysis of 6-month placebo-controlled period, for office BP, baseline is the 
average of the office BP value on Day 1 prior to receive the first dose of study drug and last non-
missing value prior to Day 1 during screening visit. For 24-hour ABPM, baseline is the 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
17 
measurement used for eligibility. For HBPM, baseline will be the average of all assessments 
during last week prior to receive the first dose of study drug. For all other endpoints, baseline is 
the last non-missing value (including unscheduled visit) prior to receive the first dose of study 
drug. 
For Month 12 and final analyses, patients initially randomized to placebo and re-randomized at 
Month 6 will be summarized in two ways:  
• From Day 1. Baseline is the same as the one for the primary analysis 
• From the start of zilebesiran dosing at Month 6. Baseline will be the last assessment 
prior to Month 6 dosing.  
For patients initially randomized to zilebesiran dosing regimen, baseline remains the same as the 
one for the primary analysis.  
4.6. 
Randomization Stratification Factors 
Randomization will be stratified by race (black vs all other races) and by baseline blood pressure 
(mean 24-hour SBP < or ≥145 mmHg). Stratification factors are recorded in the IRT database. 
Key data is integrated into the clinical database. In statistical analyses that use randomization 
stratification factors as covariates, the stratum assignment will reflect the values as recorded in 
the clinical database (EDC). In the presence of stratification errors, the stratification used in 
analysis may not match that in the IRT. A comparison of the number and percentage of patients 
in each randomization stratification factor in IRT versus the clinical database will be summarized 
by randomized treatment arm and overall. 
4.7. 
Planned Analyses and Data Cutoffs 
4.7.1. 
Primary Analysis 
The primary analysis will be performed after the last randomized patient has completed Month 6 
Visit or otherwise discontinued the study. For the primary analysis, as this study will be ongoing 
with some patients in the 12-month DB period, DB extension period or safety follow-up period, 
the study database will undergo an interim database lock at the Month 6 cutoff dates (ie, data in 
EDC will be cleaned, frozen and electronically signed by investigators; external laboratory data 
will be cleaned and will undergo quality assurance). Additional details regarding the interim 
database locks will be documented in the study Data Management Plan. 
The primary analysis will include data on, or prior to, this prespecified cutoff date. For 
assessments with starting/ending dates (e.g., adverse events [AEs], medications), the starting date 
will be compared with the pre-specified cutoff date. Data records with starting dates after the 
specified data cutoff date will be excluded. 
4.7.2. 
Month 12 Analysis 
The analysis after the end of double-blind period is the Month 12 analysis. The analysis will be 
performed after all randomized patients have completed the Month 12 Visit or otherwise 
withdrawn from the study.  
The database will undergo an interim database lock, and the data will be summarized in the CSR. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
18 
4.7.3. 
Final Analysis 
After all patients reach the end of the study, the database will undergo a final database lock, and 
the data will be summarized in the CSR.  
A patient is considered to have reached the end of the study if the patient: 
• has completed at least the Month 12 visit and enrolled in the OLE study, or 
• has completed the Safety Follow-up visits for patients who discontinue study drug or 
do not enroll in the OLE study, or withdrawal from the study. 
5. 
STATISTICAL ANALYSES 
5.1. 
Patient Disposition 
The number and percentage of patients in the following categories will be summarized by 
randomized treatment arm and overall: 
• Randomized 
• Treated 
• Completed the placebo-controlled 6-month double-blind (DB) treatment period 
− Primary reason for discontinuation of treatment during 6-month DB period. 
• Completed the 12-month double-blind (DB) treatment period 
• Discontinuation of treatment and primary reason for discontinuation of treatment 
• Withdrawal from study and primary reason for withdrawal from study 
• Completed the DB extension period 
• Completed the study 
• Rollover to the separate OLE study 
In addition to the primary reason for discontinuation of treatment and withdrawal from study, 
patients will also be categorized if discontinuation/withdrawal was due to COVID-19. 
5.2. 
Demographics and Baseline Characteristics 
Demographic and baseline disease characteristics will be summarized by treatment arm and 
overall for Full Analysis Set, and also presented in listings. 
Age at consent, height, weight, body mass index (BMI), 24-hour mean ABPM and office BP will 
be summarized using descriptive statistics. Sex, race, ethnicity, and country will be summarized 
by presenting the frequencies and percentages of patients in each category.   
5.3. 
Medical History 
Medical history and prior procedures reported will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA), Version 23.1 or newer. Unique patients who report medical 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
19 
history events will be summarized by MedDRA system organ class (SOC), high level term 
(HLT) and preferred term (PT). 
5.4. 
Protocol Deviations 
Protocol deviations will be classified by medical review prior to each planned analysis database 
lock, and major protocol deviations will be identified. A major protocol deviation is a deviation 
that may significantly impact the completeness, accuracy, and/or reliability of the trial data; that 
may significantly affect a subject's rights, safety, or well-being. (ICH E3 R1 Structure and 
Contents of Clinical Study Reports Guidance for Industry, 2013). 
The Sponsor or designee will be responsible for producing the protocol deviation file. This file 
will include a description of each protocol deviation and classification as major or minor. The 
protocol deviations will be reviewed and finalized prior to the planned analysis database lock. 
All protocol deviations and major protocol deviations will be summarized and listed. 
5.5. 
Study Drug Exposure and Compliance 
The following variables will be summarized by descriptive statistics and/or frequency tabulation: 
• Duration of exposure, defined as: date of last exposure – date of first dose +1. Date of 
last exposure is the earliest date of the following: 
− date of last dose + the length of dosing interval, i.e.,  
o date of last dose + 169 days for zilebesiran 150 mg Q6M, 300 mg Q6M 
and 600 mg Q6M,  
o date of last dose + 85 days for placebo and 300 mg Q3M. 
− date of end of study 
− date of analysis data cutoff 
• Number of doses received; as continuous and/or categorical variable 
• Number of missed doses; as a categorical variable 
• Total exposure (patient years) 
5.6. 
Prior and Concomitant Medications 
Medications will be coded using the World Health Organization (WHO) Drug Dictionary, 
version WHO-DD Global B3, March 2021 or newer. Unique patients who reported medications 
will be summarized by Anatomical Therapeutic Chemical (ATC) level 3 class (or level 2 if not 
available) and PT. Summaries will be provided for prior and concomitant medications separately. 
Prior medications are those medications with start date prior to the first dose of study drug. 
Concomitant medications are medications, other than the study drug, administered at or after the 
first dose of study drug, as well as medications that started prior to the first dose of study drug 
and are ongoing after the first dose of study drug.  


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
20 
If the medication start date is on or after the date of first dose of study drug, the medication will 
be summarized as a concomitant medication even if the medication end date is missing.  
If the end date of a medication is missing or incomplete, such that it cannot be determined 
whether it is after the first dose of study drug, it will be counted as a concomitant medication. 
For missing or partial dates for medications, the imputation of start and end dates is described in 
Section 7.2  
5.7. 
Efficacy Analyses 
5.7.1. 
Primary Endpoint 
5.7.1.1. 
Definition of Estimand 
The primary objective of the study is to evaluate the effect of zilebesiran on SBP as assessed by 
ABPM at Month 3. Primary estimand is defined as: 
• Treatment condition: monotherapy including placebo, zilebesiran 150 mg Q6M, 300 
mg Q6M, 300 mg Q3M and 600 mg Q6M. (300 mg Q6M and Q3M will be pooled 
together) 
• Target population: patients with mild-to-moderate hypertension 
• Endpoint: Change from baseline at Month 3 in 24-hour mean SBP assessed by ABPM 
• Population-level summary: Least square mean difference between zilebesiran and 
placebo in change from baseline at Month 3 in 24-hour mean SBP assessed by ABPM 
• Intercurrent events strategy: Rescue medication taken before Month 3 visit will be 
considered as an intercurrent event. For patients who require rescue medication, given 
the expected number of such patients at Month 3 is low, hypothetical strategy will be 
used, i.e., ABPM assessed while patients are on and within 2 weeks after stopping 
any rescue medication will be censored. This will provide the estimated treatment 
effect of zilebesiran alone. 
5.7.1.2. 
Primary Analysis  
The primary endpoint is the change from baseline at Month 3 in 24-hour mean SBP assessed by 
ABPM. The hypothesis of the dose response relationship for the primary endpoint will be tested 
as: 
• H0 : µ1 =µ2 =µ3 = µ0 (there is no dose response relationship)  
• Ha µ1 ≠ µ0 or µ2 ≠ µ0 or µ3 ≠ µ0  (at least one zilebesiran dose is different from 
placebo). 
Where µ0 is the mean change from baseline at Month 3 in 24-hour mean SBP assessed by ABPM 
in placebo arm; and µ1, µ2, and µ3 are the mean changes from baseline at Month 3 in 24-hour 
mean SBP in zilebesiran 150mg Q6M, 300mg Q3M and Q6M pooled, 600mg Q6M arms, 
respectively. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
21 
The above hypothesis will be tested using the Dunnett’s procedure based on Mixed model for 
repeated measurements (MMRM). The MMRM model will include treatment, visit, treatment-
by-visit interaction, race (black; all other races) as fixed factors, baseline 24-hour mean SBP 
assessed by ABPM as a covariate. Unstructured covariance matrix will be used. Least square 
mean difference between zilebesiran and placebo, 95% confidence interval (CI) and adjusted p-
values will be generated.    
5.7.1.3. 
Sensitivity Analyses  
For the sensitivity analysis, treatment policy strategy will be used for patients who require rescue 
medication. All collected blood pressure measurements will be analyzed by the same MMRM 
model as the primary analysis, regardless of the rescue medication. 
Due to the expected long-acting effect of zilebesiran, the commonly used control-based Pattern 
Mixture Model (PMM) will not be used to assess the missing not at random (MNAR) 
assumption. 
5.7.1.4. 
Other Analyses  
In addition to analyses for the primary estimand, treatment policy strategy will also be used for 
patients who require rescue medication. All collected primary endpoint assessments will be 
analyzed by the same MMRM model as the primary analysis, regardless of use of rescue 
medication.   
To demonstrate zilebesiran consistently controls blood pressure over the 24-hour period, hourly 
mean change from baseline at Month 3 in SBP assessed by ABPM will be plotted for each 
treatment group. 
5.7.2. 
Secondary Endpoints 
5.7.2.1. 
Key Secondary Endpoints 
Secondary objective of the study is to evaluate the effect of zilebesiran on blood pressure 
assessed by ABPM and office blood pressure through Month 6. The estimand is defined as:  
• Treatment condition: monotherapy including placebo, zilebesiran 150mg Q6M, 300mg 
Q6M, 300mg Q3M and 600mg Q6M 
• Target population: patients with mild-to-moderate hypertension 
• Endpoint:  
− Change from baseline at Month 3 in office SBP 
− Change from baseline at Month 6 in 24-hour mean SBP assessed by ABPM 
− Change from baseline at Month 6 in office SBP 
− Proportion of patients with 24-hour mean SBP assessed by ABPM <130 mmHg 
and/or reduction ≥20 mmHg without additional antihypertensive medication at 
Month 6 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
22 
• Population-level summary: Least square mean difference between zilebesiran and 
placebo in each of the endpoints 
• Intercurrent events strategy: For patients who require rescue medication, given the 
expected number of such patients at Month 3 is low and the protocol requires washout 
of these medications between Month 5 and Month 6, the hypothetical strategy will be 
used, i.e, blood pressure assessed while patients are on and within 2 weeks after 
stopping any rescue medication will be censored. This will provide the estimated 
treatment effect of zilebesiran alone. 
MMRM model will be used as the primary analysis. The model will include treatment, visit, 
treatment-by-visit interaction, race (black, all other races) as fixed factors, corresponding 
baseline as a covariate. Least square (LS) mean difference of each zilebesiran dose group 
compared with placebo dose group, 95% CI and p-value will be generated. In addition, LS mean 
difference between 300 Q3M and 600 Q6M groups and the 95% CI will be calculated. For 
change from baseline at Month 6 in office SBP, as a significant proportion of patients are 
expected to receive rescue medication, data collected at Month 4 and 5 visits will be excluded 
from MMRM model.   
For the proportion of patients with 24-hour mean SBP assessed by ABPM <130 mmHg and/or 
reduction ≥20 mmHg without rescue medication at Month 6, logisitic regression will be used. 
The model will include treatment as a factor and baseline 24-hour mean SBP as a covariate.   
Multiplicity adjustment will be applied across primary and these secondary endpoints. Details of 
multiplicity control are in Section 4.3. 
These endpoints will also be analyzed by the same MMRM model using the treatment policy 
strategy. I.e., all collected data will be analyzed regardless of the rescue medication. For change 
from baseline at Month 6 in office SBP, Data collected at Month 4 and 5 Visits will be included 
as well.  
5.7.2.2. 
Other Secondary Endpoints  
Other blood pressure related secondary endpoints are: 
• Change from baseline at Month 3 in 24-hour mean DBP assessed by ABPM 
• Change from baseline at Month 6 in 24-hour mean DBP assessed by ABPM 
• Change from baseline at Month 3 in office DBP 
• Time adjusted change from baseline through Month 3 in office SBP/DBP 
• Change from baseline at Month 6 in office DBP  
• Time adjusted change from baseline through Month 6 in 24-hour mean SBP/DBP 
assessed by ABPM  
• Time adjusted change from baseline through Month 6 in office SBP/DBP  
• Change from baseline in daytime/nighttime SBP/DBP by ABPM at each visit. 
Daytime is defined as 6 am to 9:59 pm and nighttime is defined as 10 pm to 5:59 am.  


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
23 
Time-adjusted change is defined as the area under the curve (AUC) of BP change from baseline 
divided by the duration of the time period. It leads to the weighted average of change from 
baseline to each scheduled visit. Details of the definition and calculation are in Section 7.2. 
In general, these endpoints will be analyzed using two approaches, similar as primary endpoint 
and key secondary endpoints. Blood pressure collected while patients are on and within 2 weeks 
after stopping any rescue medication will be censored. All collected BP data will also be 
analyzed.   
Each endpoint will be analyzed by the MMRM model described in Section 5.7.1.2 with the 
corresponding baseline as a covariate.  
The secondary endpoint of percent change in serum AGT at each visit will be summarized by 
treatment using descriptive statistics. 
5.7.3. 
Exploratory Endpoints  
The blood pressure related exploratory endpoints through Month 12 are: 
• Change from baseline in 24-hour mean SBP/DBP assessed by ABPM by each visit 
• Change from baseline in office SBP/DBP by each visit 
• Change in pulse pressure assessed by ABPM and office blood pressure 
• BP response rate by each visit, defined as 
− Office SBP < 140 mmHg and/or reduction from baseline ≥ 20 mmHg without 
escape antihypertensive medication 
− 24-hour mean DBP < 85 mmHg and/or reduction from baseline ≥ 10 mmHg 
assessed by ABPM without escape antihypertensive medication 
− Office DBP < 90 mmHg and/or reduction from baseline ≥ 10 mmHg without 
escape antihypertensive medication 
• Proportion of patients with rescue medication use by each visit 
• Change from baseline in SBP/DBP by HBPM 
• Correlation of blood pressure obtained by wearable device versus ABPM, office BP 
and HBPM.   
To assess the long-term treatment effect of zilebesiran through Month 24, change from baseline 
in SBP/DBP assessed by ABPM, office BP and HBPM will be summarized. 
Body weight, metabolic related exploratory endpoints are: 
• Change from baseline in body weight/body mass index (BMI)/waist 
circumference/waist-to-hip ratio by each visit 
• Change from baseline in HbA1c/fasting glucose/insulin/serum lipids by each visit  
Exploratory endpoints will be summarized using descriptive statistics based on all observed data. 
Missing data will not be imputed.    


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
24 
5.7.4. 
Evaluation of Subgroups 
Subgroup analyses will be conducted to assess the consistency of treatment effect within various 
subgroups defined by the following baseline characteristics: 
• Age (<65; >=65) 
• Sex 
• Race (black; all other races) 
• Baseline 24-hour mean SBP assessed by ABPM (<145 mmHg, >=145 mmHg) 
• eGFR (<60; >=60 mL/min) 
Subgroup analyses will be performed for the primary endpoint using the MMRM within each 
subgroup. Model will include treatment, visit, treatment-by-visit interaction, race ([black, all 
other races], when race is not the subgroup to be analyzed) as fixed factors, baseline 24-hour 
mean SBP assessed by ABPM as a covariate. Point estimate of treatment effect and 95% 
confidence interval are to be generated for each subgroup. If the number of patients in either 
treatment arm of a subgroup is less than 10, only descriptive statistics will be presented. A forest 
plot will be generated to illustrate the estimated treatment effect along with 95% CI within each 
subgroup. 
5.8. 
Pharmacodynamic Analyses 
In addition to serum AGT, the PD parameters include plasma renin concentration, aldosterone, 
AngI and AngII. Summary tables will be provided for observed values, changes and percentage 
changes from baseline for each scheduled time point by treatment group. In addition to serum 
AGT percent reduction analyses, the AGT maximum and mean percentage reductions over the 6-
month placebo-controlled DB period will be summarized using descriptive statistics.  
5.9. 
Pharmacokinetic Analyses 
Plasma concentrations of zilebesiran and its metabolite will be summarized descriptively. 
Descriptive statistics for zilebesiran and its metabolite plasma concentrations will include the 
number of patients, mean, SD, coefficient of variation, geometric mean, geometric mean 
coefficient of variation, median, minimum, and maximum.  
Additional analysis may be done as needed.  
5.10. 
Anti-Drug Antibody 
The number and percentage of patients with confirmed positive anti-drug antibody (ADA) assay 
results at baseline and at any time during the 6-month placebo-controlled DB period, as well as 
treatment-emergent ADA during the 12-month DB period, will be summarized. Treatment-
emergent ADA consist of treatment-induced ADA and treatment-boosted ADA, as defined 
below: 
• Treatment-induced ADA: Confirmed positive ADA developed de novo after drug 
administration in patients without preexisting (baseline) confirmed positive ADA 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
25 
• Treatment-boosted ADA: Confirmed positive ADA after drug administration with 
ADA titer > 4x baseline ADA titer in patients with preexisting (baseline) confirmed 
positive ADA 
5.11. 
Safety Analyses 
5.11.1. 
Adverse Events 
Adverse events (AEs) will be classified by the MedDRA coding system (Version 23.1 or newer) 
and displayed in tables and data listings using SOC and PT. 
Treatment-emergent AEs (TEAEs) will be summarized for the 6-month placebo-controlled DB 
period and for the zilebesiran treatment period separately. For the 6-month DB period, TEAE is 
defined as any AE occurring or worsening on or after the first dose of study drug and through 
Month 6 Visit (prior to Month 6 dosing).  
For zilebesiran treatment period, TEAE is defined as any AE occurring or worsening after the 
first dose of zilebesiran. TEAE will be summarized by zilebesiran dosing regimen.  
AE occurred or worsening during DB extension period and safety follow-up period will be listed 
and maybe summarized if needed. 
Because any worsening AE is reported as a new AE with higher severity, programmatical 
comparison of severity is not needed for the classification of TEAE. For missing or partial dates 
for AEs, the imputation of start and end date can be found in Section 7.2. Events with a fully or 
partially missing onset date will be assumed to be treatment emergent unless it can be 
unequivocally determined (from the partial onset date and/or a partial or complete stop date) that 
the event occurred prior to the first dose of study drug. 
AEs will be summarized by the numbers and percentages of patients reporting a given AE. An 
overall table of TEAEs will include: 
• any AE, 
• any AE related to study drug, 
• any serious AE (SAE), 
• any SAE related to study drug, 
• any AE leading to study drug discontinuation, 
• any drug-related AE leading to study drug discontinuation, 
• any AE leading to death.  
Tabulations by SOC and PT will be produced for the following:  
• AEs, 
• Treatment-related AEs, 
• AEs by maximum severity, 
• Treatment-related AEs by maximum severity, 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
26 
• Severe AEs, 
• SAEs, 
• AEs leading to treatment discontinuation. 
Tabulations by PT will be produced for the following: 
• AEs, 
• Treatment-related AEs, 
• SAEs. 
A patient contributes only once to the count for a given AE (overall, by SOC, by preferred term). 
Patients who report multiple occurrences of the same AE (preferred term) will be classified 
according to the most severe occurrence. An AE with missing severity will be assumed to be 
severe. An AE with missing study drug relatedness will be assumed to be related. 
Listings of all deaths (if any), SAEs, and AEs leading to treatment discontinuation will be 
provided.  
AEs of Clinical Interest 
AEs of special interest or AEs mapping to certain standardized MedDRA queries (SMQs) will be 
summarized by SOC and PT. Other SMQs or AE groupings may be evaluated. 
Injection Site Reactions [ISRs]: AEs mapping to the High-Level Term (HLT)= “Injection Site 
Reactions” using MedDRA dictionary will be included in the summary. Frequency (percentages) 
of patients with ISRs by SOC and PT will be presented by treatment. A separate listing will be 
generated to display all patients who reported ISRs. In addition, a table of the number of patients 
with at least 1 ISR, total number of doses (any dose split into multiple injections will be 
considered 1 dose), total number of doses with ISRs and corresponding % of injections with ISR 
with the most common signs and symptoms reported due to ISRs will be generated. 
 
Hepatic AEs, including Liver Function Test (LFT) abnormalities: Analysis of hepatic AEs 
will include AEs mapping to the Standardized MedDRA Query (SMQ) Drug-related hepatic 
disorders - comprehensive search (includes all narrow and broad terms). Frequency (percentages) 
of hepatic AEs will be summarized by SOC and PT.  A separate listing will be generated of all 
patients reporting these events. 
All AEs will be presented in patient data listings. AEs mapping to the SMQs as described above 
will also be listed. 
Additional summaries of AEs mapping to a COVID-19 custom query are described in Section 
5.13.2. 
5.11.2. 
Laboratory Data 
Clinical laboratory values will be expressed in SI units. Missing laboratory data will not be 
imputed. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
27 
For each continuous clinical laboratory parameter (including hematology, serum chemistry, liver 
function tests and coagulation studies), descriptive statistics will be presented for the actual 
values, change from baseline, and percent change from baseline by visit. These by-visit tables 
will use central laboratory data only. 
Select clinical laboratory parameters may be graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 or above. Shift 
summary from baseline CTCAE grade to maximum (worst) post-baseline grade will be presented 
for all graded parameters with directionality specified (e.g., hyper or hypo). To determine the 
worst post-baseline value, all scheduled and unscheduled test results will be used. For 
hematology and serum chemistry, frequency tables of potentially clinically significant (PCS) 
abnormalities will be provided. 
All laboratory data (both central and local) will be provided in data listings.  Out-of-range 
laboratory results will be presented in a separate listing with proper flags. Local laboratory data, 
if available, will also be flagged. 
Liver Function Tests 
A frequency table and a shift table will be produced to summarize the number and percentage of 
patients in each of the below categories at any post-baseline time point.  
• ALT >1 & ≤3, >3 & ≤5, >5 & ≤10, >10 & ≤20, >20×ULN, 
• AST >1 & ≤3, >3 & ≤5, >5 & ≤10, >10 & ≤20, >20×ULN, 
• ALT or AST >1 & ≤3, >3 & ≤5, >5 & ≤10, >10 & ≤20, >20×ULN, 
• ALP > 1.5×ULN, 
• Total Bilirubin >1.5 & ≤2, >2 & ≤3, >3 & ≤5 and >5×ULN, 
• Total Bilirubin > 2×ULN concurrent with ALT or AST > 3×ULN 
In separate evaluation of drug-induced serious hepatotoxicity (eDISH) figures, the peak total 
bilirubin (as multiple of ULN) at any time post-baseline will be plotted against the peak ALT, 
AST, ALT or AST level and at any time post-baseline. 
A listing for all patients with abnormal liver function tests, defined as an ALT >3×ULN, AST 
>3×ULN, or total bilirubin >2×ULN at any time point, will also be provided. 
5.11.3. 
Electrocardiogram 
Electrocardiogram (ECG) findings will include rhythm and overall interpretation.  
Post-baseline overall interpretation (normal vs. abnormal) will be summarized in frequency table 
by treatment and visit. 
All ECG data for each patient will be provided in a data listing. 
5.11.4. 
Vital Signs 
For vital signs except blood pressure, descriptive statistics for actual values and change from 
baseline will be provided by treatment and visit for each variable. Vital sign measurements will 
be presented for each patient in a data listing, with abnormal vital signs flagged. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
28 
5.11.5. 
Evaluation of Subgroups  
AE summary tables will be separately generated for each of the subgroups as defined for the 
primary efficacy endpoint (see Section 5.7.4). 
5.12. 
Interim Analysis 
No interim analysis is planned for this study. 
5.13. 
COVID-19 
Additional data are collected to characterize the impact of the COVID-19 pandemic on general 
study conduct and disposition, and subsequently, additional analyses and summaries will be 
provided in acknowledgement of multiple regulatory guidance (including FDA Guidance on 
Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic: Guidance for 
Industry, Investigators, and Institutional Review Boards, US Food and Drug Administration, 
2020; Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) 
Pandemic, European Medicines Agency, 2020; Points to consider on implications of Coronavirus 
disease (COVID-19) on methodological aspects of ongoing clinical trials, European Medicines 
Agency, 2020; Statistical Considerations for Clinical Trials During the COVID-19 Public Health 
Emergency, US Food and Drug Administration, 2020). 
5.13.1. 
General Impact 
Patients who discontinue treatment or stop study participation due to COVID-19 will be included 
in patient disposition summaries as described in Section 5.1. 
Impact on study participation due to COVID-19, including missing visits, visit location changes, 
study drug dosing changes and missing doses, will be summarized descriptively overall and by 
visit on the patient level, and overall on the event level. Patient- and event-level summaries of 
the impact on study participation due to COVID-19 may also be generated by site and/or region. 
Impact on study participation due to COVID-19 will be presented in data listings at patient and 
visit level. 
5.13.2. 
Impact on Adverse Events 
An overall summary of AEs mapping to a COVID-19 custom query will be presented. AEs 
mapping to the COVID-19 custom query will be summarized by HLT and PT. Due to the 
evolving nature of COVID-19-related MedDRA terminology, the COVID-19 custom query will 
be based on the latest information available at the specified analysis timepoint. 
AEs mapping to the COVID-19 custom query will also be presented in a data listing.  
6. 
CHANGES FROM PLANNED ANALYSES 
Original SAP 
Section of the SAP Summary of change from protocol 
Rationale 
— 
—  
— 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
29 
7. 
APPENDICES 
7.1. 
Protocol Schedule of Assessments 
Schedule of assessments are listed in Table 2. 










Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
34 
7.2. 
Time-Adjusted Change from Baseline 
Time-adjusted change from baseline is the area under the curve (AUC) divided by time interval. 
It leads to a weighted average of all scheduled change from baseline during that time interval.  
E.g., ABPM is assessed at Month 1, 3 and 6. Time-adjusted change from baseline through Month 
6 in 24-hour mean SBP assessed by ABPM is: 
1. AUC is calculated as:  ቂ
1
2 (𝑦𝑦1 + 𝑦𝑦3) ∗2 + 
1
2 (𝑦𝑦3 + 𝑦𝑦6) ∗3 ቃ 
2. Time interval is 5 months, from Month 1 to Month 6. AUC divided by time interval is  
𝐴𝐴𝐴𝐴𝐴𝐴5
⁄
= 0.2 ∗𝑦𝑦1 + 0.5 ∗𝑦𝑦3 + 0.3 ∗𝑦𝑦6 
Where 𝑦𝑦1, 𝑦𝑦3 and 𝑦𝑦6 are the 24-hour mean ABPM at Month 1, 3, and 6.   
Table 3  listed all time-adjusted endpoints and the weights of the assessments. 
Table 3  
Time-Adjusted Endpoints 
Time-adjusted Endpoint 
Weighted average 
Time-adjusted change from baseline 
through Month 3 in 24-hour mean 
SBP/DBP assessed by ABPM 
0.5 ∗𝑦𝑦1 + 0.5 ∗𝑦𝑦3 
Time-adjusted change from baseline 
through Month 3 in office SBP/DBP  
0.25 ∗𝑦𝑦1 + 05 ∗𝑦𝑦2 + 0.25 ∗𝑦𝑦3 
Time-adjusted change from baseline 
through Month 6 in 24-hour mean 
SBP/DBP assessed by ABPM 
0.2 ∗𝑦𝑦1 + 0.5 ∗𝑦𝑦3 + 0.3 ∗𝑦𝑦6 
Time-adjusted change from baseline 
through Month 6 in office SBP/DBP  
0.1 ∗𝑦𝑦1 + 0.2 ∗𝑦𝑦2 + 0.2 ∗𝑦𝑦3 + 0.2 ∗𝑦𝑦4 + 0.2 ∗𝑦𝑦5 + 0.1 ∗𝑦𝑦6 
7.3. 
Missing or Partial Dates 
7.3.1. 
Prior and Concomitant Medications 
For medications with partial start or end dates: the first day/month will be imputed for start date, 
and the last day/month will be imputed for end date. For medications with a completely missing 
start date, the medications will be considered as started one day prior to the first dose of study 
drug. If an imputed start date is after the collected end date, the end date will be used as the 
imputed start date. For medications with a completely missing end date or an imputed end date 
that is after the earliest date of: end of study date, data cutoff date or date of death, the latter (i.e., 
the earliest date of: end of study date, data cutoff date or date of death) will be used as the 
imputed end date. 


Statistical Analysis Plan, ALN-AGT01-002 (KARDIA-1)  
 zilebesiran (ALN-AGT01) 
Original, 29 March 2022 
Alnylam Pharmaceuticals 
Confidential 
35 
7.3.2. 
Adverse Events 
For records with fully or partially missing AE onset date, conventions for the imputation is as 
below: 
• AE onset dates with missing day and non-missing month will be imputed to occur on 
the first day of the non-missing month, except for AEs occurring in the first month of 
dosing, in which case the date will be the first day of dosing. 
• AE onset dates with missing month will be imputed to occur on the first day of the 
non-missing year (i.e., January 1), except for AEs occurring in the first year of 
dosing, in which case the date will be the first day of dosing.  
• If year of the AE start date is missing, the onset date will be imputed as the first day 
of dosing, except if it can be unequivocally determined (from the partial or complete 
stop date) that the event occurred prior to the first dose of study drug, in which case 
the AE onset date will not be imputed.  
• If an imputed onset date is after the collected AE end date, the end date will be used 
as the imputed onset date.  
7.3.3. 
Others 
For other incomplete dates, unless otherwise specified, the following conventions will be used 
for the calculation of duration (e.g., time in years since diagnosis): 
• Missing day: the first day of the month will be used. 
• Missing month: the January 1 of the non-missing year will be used. 
• Missing year: no duration will be calculated.